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Foreword
The Proceedings of each Annual Scientific Meeting of the Committee
on Problems of Drug Dependence (CPDD) comprise a kind of contour
map of one year’s explorations and advances along the frontiers of
our knowledge about drug abuse. The remarkably broad range of
research interests among the membership of the CPDD is reflected
in the record of its meetings and the expertise of its membership,
which includes biochemists and pharmacologists, physicians,
sociologists, psychologists and other public health
professionals. The proceedings of its annual meeting enable the
reader to consider the vast scientific territory of recent
research advances in substance abuse in a single volume. For that
reason, the National Institute on Drug Abuse is once again pleased
to publish the CPDD proceedings in its Research Monograph series.
As in past years this volume contains a variety of timely papers
and progress reports on ongoing investigations in the field as
well as the annual report of the CPDD Drug Testing Program which
evaluates the efficacy and dependence liability of new compounds.
Several of the papers from the 44th Annual Scientific Meeting,
held in Toronto on June 27-30, 1982, present Canadian perspectives
on issues of common concern.
Approximately half of the projects discussed are fully or
partially supported by NIDA but much work is also underwritten by
our sister Institutes in ADAMHA, by other Federal agencies, by
State governments, by the governments of other countries, and by
private industry. A most important contribution of the CPDD is
its linking of the efforts of all of these groups to enlarge our
understanding of psychoactive substances and their effects on
human health and behaviors. This should help lead toward more
effective prevention and treatment of the serious public health
consequences of drug abuse.
William Pollin, M.D.
Director
National Institute on Drug Abuse
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The J. Michael Morrison
Award, 1982
Robert C. Petersen
One rarely gets ten minutes to say just about anything one wishes,
to as distinguished an audience as this. But, since Joe Cochin
assures me I can, I mean to take full advantage of it.
To say that I feel honored and grateful to be the first recipient
of the J. Michael Morrison Award is to belabor the obvious.
When I first joined Roger Meyer, then Acting Chief of the newly
formed Center for Studies of Narcotics and Drug Abuse, I had no
idea that so much of my professional life would become involved
in drug abuse. Actually, I was more interested in mind alteration
more generally, with drug use as only one aspect. But the Center,
with Roger as its energetic chief, seemed like an interesting
place to pursue my interests. What a small handful of professionals
supported by a committed staff we were -- and with responsibility
for prevention, treatment and research all in a highly visible
area. Fortunately, the sheer magnitude of the newly passed NARA*
program was so obviously overwhelming that NIMH, of which we were
a part, created a Division of Narcotics and Drug Abuse. That
relieved us of the treatment aspects, freeing us to focus on
research which was of more primary interest. Nevertheless, I
remember Roger Meyer, who was surely dynamic, eagerly awaiting his
discharge from the public Health Service while muttering darkly
that if he had to remain Chief much longer he would climb the
walls! Unfortunately, the plane from California was slow, the
Washington scene dynamic, and by the time Sid arrived he dis-
covered he was slated to become Division Director. More or less
by default -- there being no more obvious contenders -- I
inherited Sid's mantle. How often I wished in succeeding months
I could return it!
It was a hectic time -- to say the least, a challenging time.
Marijuana, LSD and amphetamine use were all burgeoning. Public
concern approached hysteria and our program had high priority.
That does not, of course, mean that we had anything but the most
general ideas of just how to set up such a program. While there
were distinguished researchers in a few places, such as the
Addiction Research Center in Lexington, it's safe to say that
more traditional research settings, such as universities, were not
overly eager to become involved in drug research that might bring
them notoriety. Moreover, the Federal Bureau of Narcotics and
*Narcotic Addict Rehabilitation Act
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Dangerous Drugs was a mite suspicious of the motives of those eager
to become involved, especially in marijuana research. Even the
well specified natural and synthetic materials needed for orderly
pharmacological research were largely unavailable. Development of
such resources was viewed with restrained enthusiasm by the gen-
eral public. Creation of a marijuana "plantation" at the University
of Mississippi, thought humorous by some, was greeted with down-
right irdignation by others. I remember a long distance call from
a lady representing the Garden Clubs of America. She demanded to
know why we Were "wasting" $60,000 of the taxpayer's money when
the ladies of her garden clubs would be happy to grow the needed
material as a public service. My explanation of the need for
uniform growing conditions and adequate security left her unimpressed
She assured me that the good ladies would not dream of diverting
the pot to their personal use. It was only when I explained that
the ladies were not the problem, but unspecified others who might
steal the plants, that she was somewhat modified. And, of course,
there were the inevitable letters from farmers who wanted to get
in on the ground floor of the government's new "supports program.
Letters from the general public ranged from the sensible to the
sometimes bizarre and unconsciously humorous. I regret that we
didn't keep a scrapbook of some of them. But all had to be
answered -- together with congressional inquiries -- while plan-
ning an overall program. We certainly had our hands full on many
fronts. Thinking back to our beginnings, therewere those who
richly deserved to be honored, but only rarely were. one of them
was certainly Eleanor Carroll whom some of you remember as vividly
as I. I doubt that anyone who ever encountered her failed to
remember her very vividly. Ellie, while technically a sociologist,
was very widely read, formidably bright, immensely dedicated,
and not a little intolerant of bureaucratic absurdity. She surely
did not "suffer fools gladly."
In her uncompromising pursuit of excellence she shaped our over-
seas program, most of our psychosocial research program, and her
colleagues as well! Although she could be as kind as she could be
critical, few -- including those on the highest echelons -- were
eager to be confronted by her. They would often go out of their
way to avoid having to explain a bureaucratic decision they knew
she viewed with a jaundiced eye. Ellie could chill the soul of
the hardiest administrator, were she ton make her dismay visibly
apparent in a meeting, by rolling her eyes or striking her fore-
head in evident distress at the administrator's remarks. I'll only
tell one Ellie story, although they are many. During a research
review committee or IRG meeting, Ellie became increasingly irritated
with a reviewer who alluded to the physical attributes of a women
P.I. Unable to contain herself any longer, Ellie roared -- in
Spanish -- that the next time she went on a site visit to a male
P.I., she intended to include in her review that he had "testicles
the size of a cathedral." Following her Spanish version, she of-
fered her own inimitable translation for the uninitiated. Needless
to say, the frequency of remarks alluding to the physical attributes
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of our principal investigators dramatically decreased. There were
many impressive members of our initial review groups as wall, some
of whom here today. I hesitate to single any out for surely
I would omit others no less impressive. But, I would especially
like to mention Jack O'Donnell of the Addiction Research Center.
To the very end of his very productive life Jack gave generously
of his time, his energy, and his wisdom in shaping our program.
Whatever the request -- to consult, make a site visit or to write
a report -- Jack rarely refused and always gave in full measure.
Then, as now, review committee members were overworked, underpaid,
and their contribution largely unrecognized. While peer review
has its problems, in my opinion, it is like democratic government
itself, the best system so far devised.
I would, most especially, like to thank all those who served on
review committees during my tenure who gave so freely of their
wisdom and time to help make our programs work.
During my years as Center Chief at NIMH, I increasingly chafed at
the role of being an administrator. As the organization grew
inevitably larger and the bureacratic restrictions multiplied,
more and more energy seemed to be consumed overcoming the inertia
of the cumbersome bureaucracy. The yeasty initial excitement of
innovative programming because increasingly an ordeal of meeting
a myriad of requirements that often seemed extraordinarily remote
from accomplishing our objectives. I had long cherished the idea
of developing a Research Monograph Series of high guality to
provide integrative reviews of our scientific knowledge concerning
drug abuse. I also yearned for the opportunity to once again play
a planning role, to supplant the "go, go, go" demands with which
we were contending daily with n-ore thinking. Our reorganization
as part of NIDA provided an obvious opportunity to realize these
long dormant objectives. Fortunately, NIDA's new research director,
Bill Pollin, shared the vision. "Thank you, Bill, for your support."
Once again, a formidable woman entered my life. Her name was
Eunice Corfman. I had talked with a number of people who might
assist in editing the new Research Monograph Series without much
conviction that any of them really suited. Bill Pollin suggested
I might want to talk with Eunice. Within the first ten minutes I
was convinced she was the person for the job. While her back-
ground in science was modest, her commitment to learning about it
was not -- and she was impressively bright. Whether the question
was one of readability of possible format or actual content, Eunice
was soon knowledgeable. Not easily daunted, her energies seemed
limitless and through our combined efforts the new monograph series
was launched. Alas, as was true of others hired, one hazard of
hiring very able people is that they are soon offered still more
demanding opportunities elsewhere. It was, however, a shock to
us all when shortly after becoming publications chief at NIMH
Eunice died quite suddenly. I'd like to take this opportunity to
publicly thank her for her profound contribution to my life,
both professionally and personally.
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Looking back -- as well as looking forward -- is especially reward-
ing after having retired from government service at a relatively
young age. I did not start out to be a bureaucrat, but I soon
discovered that without bright, committed bureaucrats, the pursuit
of excellence in the larger scientific community is far more
difficult, and sometimes impossible. Michael Morrison typified the
best in that type of commitment. Unlike the stereotyped government
worker more interested in his paycheck than his performance,
Michael pursued his task with impressive courage and dedication to
the end of his tragically short life. I am very proud to be
chosen as exemplifying the tradition of scientific administration
and service that Michael Morrison represented.
This is a difficult time for my in government service. Too often
their contribution is minimized and there has been the indication
that their jobs are sinecures. Any of us who have navigated the
bureaucratic straits in pursuit of excellence know just how false
that characterization is. It has been my privilege to have worked
with some of the ablest and the best. Without their collective
dedication, an innovative program of the properties that has
resulted would not have been possible. To have been involved
from a program's inception to its initial fruition --and to have
that role recognized -- is gratifying, indeed. There have certainly
been times of profound self doubt in which I wondered whether my
choice of government service was a worthwhile career choice. This
is not one of them.
Thank you all.
Author
Robert C. Petersen, Ph.D.
Fomrly Assistant Director
Division of Research
National Institute on Drug Abuse
Rockville, Maryland 20857
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Pharmacological Treatment of
Narcotic Addiction
(The Eighth Nathan B. Eddy
Memorial Award Lecture)
Vincent P. Dole and Marie E. Nyswander
Marie and I are privileged to join with you in honoring the memory
of Nathan B. Eddy. We owe much to him. On two critical occasions,
he endorsed our efforts when it appeared that the work might be
stopped by unfriendly authorities.
In 1955, eight years before I knew her, Marie Nyswander presented a
paper before this Committee suggesting that narcotic addicts could
be treated on a voluntary basis as ambulatory drug-free patients by
psychotherapists in New York City. Although this approach was total-
ly at odds with the accepted practice of incarceration and compulsory
treatment and had been condemned by the Federal Bureau of Narcotics,
the Committee listened sympathetically and encouraged her to go for-
ward with the trial. She recruited physicians, psychologists and
social workers to work as unpaid volunteers in this project, and
carried it through to a conclusion.
Three important findings came from this pilot study: chronic users
of heroin were found to be sufficiently motivated to volunteer for
treatment; they did not present any exceptional problems in manage-
ment as medical patients; and psychotherapy with social support was
not an adequate treatment for persons with longstanding habits of
daily heroin use. In short, she established that heroin addicts
could be considered as persons with a chronic disease for which an
effective medical treatment remained to be discovered. This pointed
to the next step when I joined her in 1964. We decided to look more
closely at the functional state of long term addicts given controlled
doses of various narcotic drugs under non-punitive conditions. After
much preliminary planning and with support from various authorities
including Or. Eddy, we began the research on a metabolic ward of
Rockefeller University Hospital.
It soon became apparent that methadone, when given in a constant
daily dose, had functional effects quite different from those of in-
jected heroin, morphine, and other usual narcotics. Patients on
stabilized doses of methadone lost their craving for narcotics and
appeared functionally normal in all important respects. They were
able to return to their old neighborhoods without being drawn back
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to heroin. They, re-established family structures, attended school,
obtained jobs and desisted from criminal activities. At the time
we were unable to explain the marked difference. between methadone
and heroin, but accepted it empirically as a basis for a rehabili-
tation program.
Not long after this study had begun we were asked by Dr. Eddy to
summarize our findings before this Committee, which we did in the
annual meeting of 1966. Fortunately we had documented the work in
great detail. To provide an objective measure of drug taking, we
introduced a routine of daily urine testing after adapting a chroma-
tographic method of Joseph Cochin for large scale use. We estab-
lished a computerized data system to record the intake and discharge
of every patient who entered treatment, including even those who re-
mained for no more than one day. We initiated systematic studies
of coordination, intellectual function and vigilance. We established
job placement services and legal supports to help in rehabilitation
and to record the shift from criminality to normal social function-
ing. We invited experts in pharmacology and social services to visit
our clinic and interview our patients.
The Committee appeared to be favorably impressed by these results.
It encouraged us to continue, while emphasizing that the treatment
was still in a research stage needing further systematic study. At
the time we did not fully realize how fortunate we were in receiving
this endorsement. Some years later, when reading Eddy's monograph
in the work of this Committee, we learned that the Bureau of Narcot-
ics had been looking for scientific justification to extinguish the
study. Without the endorsement given to us at this critical time by
the leading scientific authorities in the field, our work probably
would have been terminated and the effort recorded in history as an-
other failure of maintenance treatment. My admiration for Dr. Eddy's
scientific integrity was heightened by his frank comment that he per-
sonally disliked the idea of giving any narcotic drug to addicts,
and felt that it should be possible to discover a better way of
treatment - but that, nevertheless, he supported the work as scien-
tifically competent research. During the subsequent sixteen years,
mindful of his rigorous standards, we have been reaching for a bio-
chemical understanding of maintenance treatment. We wish that he
were here with us today to discuss the matter, taking into account
modern discoveries of endogenous opioid peptides and further evidence
supporting the metabolic disease concept of narcotic addiction. In
default of this opportunity, we address our report to his successors,
as surely he would have wanted us to do.
Our hypothesis of narcotic addiction as a metabolic disease stemmed
from the consistent therapeutic response of chronic, previously in-
tractable, addicts to adequate doses of methadone. Normalization of
function occurred independently'of social status, age, ethnic classi-
fication and. personality type. It suggested to us that the medica-
tion was somehow correcting (or compensating for) a biochemical de-
fect which was expressed in an abnormal appetite for narcotic drugs.
In 1967, we therefore launched a search for stereospecific binding
sites in the brain of rats, using radio-labeled l- and d- methadone.
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The study failed to disclose any, but in analyzing the reasons for
our failure it became obvious to us that the discovery of specific
narcotic binding sites would require narcotic ligands of higher spe-
cific activity and higher radiochemical purity than any available
at that time. This finding was reported in 1970. Subsequent work
in other laboratories substantiated this interpretation and carried
the work far beyond our simple expectations.
Meanwhile in pursuing the difference between chronic administration
of heroin and methadone we obtained an explanation of why methadone,
but not heroin, can sustain patients in normal function. Reversible
binding of methadone by tissues in the liver and elsewhere estab-
lishes a huge buffer of inactive drug that stabilizes the blood
level. As circulating methadone is removed by metabolism, it is re-
placed by dissociation of molecules from non-specific binding sites
in the tissue. The difference in clinical effects of methadone and
other narcotics therefore does not reflect differences in action at
the stereo-specific binding sites; it is simply a reflection of the
much slower clearance of methadone from the blood.
When one compares the clinical phenomena of euphoria and abstinence
in addicts with the blood levels of narcotic drug, the quantitative
association between biochemistry and behavior becomes quite clear.
Figures 1 and 2 show (schematically) the disparate effects of heroin
and methadone in a narcotic addict and a maintenance patient, re-
spectively. Both individuals have been made physically dependent
by repeated administration of a narcotic drug, and therefore will ex-
perience withdrawal symptoms if the concentration of circulating drug
falls below a critical level. At the upper limit, both are pharma-
cologically tolerant and thus are-protected from disabling narcotic
effects until the circulating concentration is quite high. Here the
similarity ends, because blood morphine (the active metabolite of
heroin) fluctuates rapidly between the extremes of narcosis and ab-,
stinence, while methadone remains relatively constant if the medi-
cine is given in proper dose on a fixed schedule. The reservoir of
bound methadone stabilizes the concentration of blood in circulation,
and possibly releases extra drug under conditions of stress.
What we are witnessing in clinical symptomology is a titration of
narcotic receptors in the intact organism using the clinical state
as an end point. From this perspective it is interesting to note.
that the apparent binding affinity of these receptors in vivo is 1
or 2 orders of magnitude lower than the µ receptors that have been
studied in vitro: Either the functionally significant receptors are
of a category still undiscovered, or more likely the affinity of
receptors in vivo is modulated downward by local conditions of temp-
erature, salt concentration and competitive ligands. Since the ad-
dict can be normalized by exogenous narcotic, it seems unlikely that
the defect in addiction is a failure of transducer function of the
narcotic receptors. As a speculation, we suggest that the link be-
tween biochemistry and addiction will be found in deficient produc-
tion of endogenous opioids, impaired release of these ligands in
stress, or in abnormally low affinity of receptors. These variables
are open to study with modifications of existing methods. If our
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speculation is correct, the deficiency in endogenous opioid function
will provide a rationale for maintenance treatment that would meet
even the rigorous criteria of Nathan Eddy. Incidentally, according
to this interpretation naltrexone and other narcotic antagonists are
precisely the wrong agents to use in treatment of narcotic addiction.
If endogenous opioids are deficient, antagonists would add to the
biochemical disability. Their therapeutic efficacy, in comparison
to that of agonists, thus provides another test of the metabolic
theory of addiction.
Before closing, let us leave no doubt that this award reflects the
efforts of many hundreds of quietly dedicated people. We have been
fortunate in our associates. While it is impossible to list all of
them, at least we must note those who contributed in the early, form-
ative stage of the work: Beatrice Berle pioneered in the delivery
of medical services in Harlem and introduced Marie Nyswander to work
in this area. Mary Jeanne Kreek participated in the studies of nar-
cotic pharmacology, and has emerged as a leading authority in this
field. Joyce Lowinson, Harold Trigg, and Robert Newman participated
in the clinical application, and showed the feasibility of large-
scale treatment programs. Norman Gordon and Ann Ho demonstrated the
functional normality of stabilized patients using sophisticated tests
of coordination and reaction time. Ray Trussell, as an administra-
tive leader in public health, lifted us out of the sheltered world
of metabolic research and enabled us to develop maintenance programs
in the context of a general hospital. The Trustees of Beth Israel
Medical Center were courageous in their firm support of this program
at a time when it was surrounded with controversy. And, above all,
the addicts themselves, with the sad wisdom of their experience,
guided our efforts. We proudly accept this distinguished award on
behalf of these contributors.
AUTHORS
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FIGURES 1 and 2. The essential difference between methadone
maintenance and chronic use of heroin is illustrated in these
schematic diagrams. A maintenance patient can be stabilized
on a constant dose of methadone, which holds the blood level
in the range of normal function. The heroin user is repeat-
edly disabled by alternating periods of narcotic effect
("HIGH") and abstinence ("SICK"), even with multiple injec-
tions during a 24-hour period. Because of instability of the
blood level of morphine (the metabolite of heroin) and the
need for progressively increasing doses, "heroin maintenance"
fails as a treatment program. In contrast, patients remain
in good health and normal function for years when maintained
on a constant daily dose of methadone.
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Chemical Dependence in Canada:
A View From the Hill
Ian W. D. Henderson
While Canada has not been immune for many years to substance
abuse, it is recently that the social as well as the health as-
pects of the non-medical use of drugs have been recognized as
causative of a multiplicity of problems. It is generally agreed
that the largest component of substance abuse in Canada still
rests with the simple chemical ethanol. We are all aware, how-
ever, that the social and addictive of psychotropic drugs
cannot be ignored from the public health viewpoint, and that
many adverse social effects are engendered as a result of abuse
of a wide variety of chemical agents.
It was well stated in A New Perspective on the Health of
canadians, issued by Marc Lalonde, Minister of National Health
and Welfare in 1974, that there are risks of all sorts inherent
in drug use, and that for the most part, all of these are self-
imposed. The effect of drug-related risk-taking on the levels
of sickness and mortality in Canada is well reflected in a
delineation of destructive lifestyle habits and their
consequences.
(a) alcohol addiction leads to cirrhosis of the liver,
encephalopathy and various forms of malnutrition;
(b) social excess of alcohol leads to a very high
incidence of motor vehicle accidents, which account
for a very high proportion of premature deaths among
young people of both sexes in Canada;
(c) cigarette smoking causes chronic bronchitis, emphysema
and cancer of the lung; at the same time, it
aggravates coronary artery disease;
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(d) the abuse of  pharmaceutica1 agents of legal origin not
infrequently results in states of drug dependence, and
occasions a variety of drug adverse reactions and
interactions. It was for this reason that Canada in
1972 chose to restrict drastically the conditions for
which amphetamines could legally be prescribed; it is
also this which expedites our examination on a regular
basis of the scheduling of drugs to groups that
require appropriate degrees of social and professional
control in terms of general availability:
(e) other psychotropic drugs lead to suicide, homicide,
and to many forms of accidents;
(f) the continuedand regular social use of a variety of
mind-altering drugs leads to social withdrawal,
"anomie" , alienation, nonprcductivity, and to acute
panic and anxiety states that commonly require expert
treatment.
Notwithstanding this holistic approach, one can readily contend
that in terms of drug-related crime, and the cost to society,
opiate abuse is unique. Although is difficult to provide
definite figures concerning the prevalence of addictive states
when the substances involved are legally prohibited, it appears
that within Canada's presumed 15,000 heroin-dependent persons,
the number of convictions for possession or trafficking repre-
sents only 5%; in terms of the total number of heroin users,
both dependent and nondependent, the conviction figure repre-
sents under l% of the the numbers involved. The conviction
rate, therefore, is little more than the tip of an iceberg which
warns us of the vast nature of this drug problem in our country
- a problem which is relatively hidden from view of the general
public.
The policy of government against heroin addicts in Canada has
been one of containment. Our police forces have had to attempt
to apprehend the opiate user when he has prepared the substance
for use, and when he is just about to use it. This apprehension
has been predicated by the need to possess a sample of the sub-
stance before it is placed beyond physical reach. In this
sense, possession "in the hand" and possession in some physio-
logical compartment of the body are not regarded by the law as
entirely equivalent. A high proportion of persons convicted of
possession of opiate narcotics have previous criminal records.
Federal penetentiaries demonstrate an average of over 8
convictions per person. These previous offences usually include
breaking and entering, theft, forgery, counterfeiting,
possession of stolen property, vagrancy and prostitution. There
are also many kinds of violence.
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The situation in terms of alcohol is entirely different. While
it is true that alcohol is associated with a number of types of
crime, including personal assault and rape, impaired driving,
theft, brawling, wife and child abuse, and homicide, it is
relatively ingrequent that people who are alcohol dependent are
in deliberate contravention of the law. This is due to the fact
that ethanol is entirely legal and is usually bought in a legal
manner, rather than obtained by theft. The vast majority of
alcohol-dependent persons in need of treatment are not skid-row
alcoholics, but persons whose only transgressions are those of
social disintegration and personal health deterioration.
If substance dependence states, whether these be opiate, bar-
biturate, or alcohol related, are to continue to be regarded
in Canada as "treatable conditions," then individuals with any
of them must be included under the heading of persons whose
drug-induced states warrant subsidized care, treatment and
rehabilitation. Apart from actual medical treatment of the
many conditions that can result from substance abuse, there are
social forms of treatment including retraining, job placement,
sheltered workshops, and a slow build-up of self-esteem and
feelings of personal social responsibility.
You realize that there are many basic issues with respect to
control of drug abusers. These include relevant and pertinent
questions regarding: the appropriateness of offences for simple
possession; offences for non-medical use, both intermittent and
regular; what the penalties for such offences ought to be; and
whether there should be coercion or compulsion for treatment
with respect to the users.
Despite continuing concern over the social limitations and the
social consequences of employing a form of criminal justice in
the field of non-medical drug use, the majority of law-abiding
citizens in Canada are greatly concerned with crime in our
society, and they are constantly asking about the relationship
of this crime rate to the abuse of drugs. There is moreover a
growing public concern over wasted lives and the societal
problems that are created by chronically dependent persons.
This is particularly relevant for the heroin addict who must
commit criminal acts to survive in his dependent state. It is
perhaps less an issue with regard to the cocaine user, who is
not uncommonly a relatively affluent, if not wholly respectable,
member of the social community. The LeDain Commissioners in
their final report discussed the controversy that underlines the
case for coercion or mandatory treatment of the drug addict.
Some Canadian experts have argued against the assumption that
persons can be motivated for treatment by any form of coercion;
indeed some contend that any person who is compelled to submit
to any form of treatment will almost invariably lack the
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motivation which is essential to a successful outcome. There is
almost certainly some merit to this argument, but I am not sure
that it is universally the case.
Even although actual apprehension has been caused by drug-
related criminal behaviour such as theft, it is probably not
essential that all offenders have to be subjected to con-
finement. For some, adequate control can be exercised within
the community by means of surveillance in the form of parole or
probation, or within community programs. However, non-confine-
ment treatment is very difficult to accomplish in view of the
small number of probationary officers, their very large work
loads, and their general lack of enthusiasm for this type of
work. It is difficult to launch and maintain non-residential
programs unless adequate training facilities for professionals
and para-professionals are available, and unless continuing
community support is forthcoming. Again, any form of community
control of the drug abuser has to be backed up by some sanctions
for violations of the conditions of the probationary form of
"court-diversion" from a confinement in prison. Probably the
only effective sanction is the deprivation of liberty. If we in
Canada choose a system of control of the drug user, it will be
necessary to prepare ourselves for the use of some forms of
confinement. If this is so, then it is obvious that we must
possess both the facilities and the will to make the threat of
confinement a credible back-up position. Confinement as such
however is unlikely to accomplish any therapeutic goal.
Treatment, therefore, in a residential setting has to be regarded
in a totally different light from programs for non-motivated
incarcerated addicts. The therapeutic community has obviously
been developed to fill this gap. What has still to be
established in Canada is a formalisation of court diversion from
punition to treatment - be that residential or not.
JURISDICTION IN CANADA WITH RESPECT TO HEALTH
There have been expressions of opinion that the general or
residuary jurisdiction with respect to health rests with the
Parliament of Canada on the basis of its general power; but the
weight of opinion and the assumption on which governments have
been acting, is that the provision of health care rests with the
provinces. Parliament, of course, can invoke its general power
to cope with emergencies. Two important functions in respect to
health are treatment and quarantine. In each case, the general
jurisdiction appears to be provincial. The primary jurisdiction
with respect to medical treatment lay with the provinces by
virtue of Section 92(7) of the British North American Act, which
conferred upon provincial legislatures exclusive jurisdiction
with respect to "the establishment, maintenance and the
management of hospitals, asylums, charities and eleemosynary
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(sic) institutions in and for the province, other than marine
hospitals." The federal jurisdiction with respect to the estab-
lishment of treatment facilities was also restricted. The only
expressed power was in Section 91(11), which gave Parliament
jurisdiction with respect to "quarantine and the establishment
and maintenance of marine hospitals." In addition, Parliament
may establish and manage treatment facilities in other areas of
Federal concern such as the Armed Forces, the Indian population
on reservations, the population in federal institutions, and in
matters of health related to immigration.
It is necessary to distinguish between the regulatory jurisdic-
tion with respect to hospitals and other treatment facilities
which lies with the provinces, andcapacity of the Federal
Government through the exercise of its spending per to provide
financial assistance for the establishment of facilities within
provinces. The use of the Federal spending power in areas
beyond Federal legislative jurisdiction remains a controversial
issue as a matter of policy, but it has not ever been ruled to
be constitutionally invalid. By this device, the Federal
Government may impose conditions upon grants of financial
assistance, which will assure the implementation of certain
Federal policies and standards.
Whether the Federal Government has a true general power in
relation to non-medical drug use, and the scope of that federal
power with respect to matters of health are particularly
relevant in view of the non-penal dispositional alternatives
suggested by Article 22 of the Convention on Psychotropic
Substances (1971), which provides
. . . when abusers of psychotropic substances have
committed such offences, the parties may provide, either as
an alternative to conviction or punishment, or in addition
to punishment, that such abusers undergo measures of
treatment, education, after-care, rehabilitation and social
re-integration in conformity with Paragraph 1 of Article
2 0 . . .
I should, of course, point out that Canada is not yet a
signatory to this Treaty but probably will be in the not too
distant future.
In the absence of a true general power with respect to non-
medical drug use, or a general jurisdiction with respect to
health, federal powers to provide for treatment have to be
grounded on the Criminal Law. On this issue, the special
committee of the Senate on the traffic in narcotic drugs which
reported in 1955, contended:
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. . . that it is not within the constitutional authority of
the Federal Government to assume responsibility for treat-
ment of drug addicts, nor to enact the kind of legislation
necessary in that connection. This legislation would need
to include the compulsory treatment of addiction, the legal
supervision of control over the individual during
treatment, and the right of control of the individual
following treatment to prevent his return to the use of
drugs, former associations or habits. These are considered
to be matters beyond the competence of the Federal
Government.
Notwithstanding, Parliament has provided for the compulsory
treatment of drug offenders in Part II of the Narcotic Control
Act (1961). However, this part of the Act has not yet been put
into force by proclamation. This my be so because of doubts
about the constitutional validity of these provisions, or the
failure to develop suitable treatment methods and facilities,
or, in fact, the continuing reservations of the Federal
Government as to the advisability of compulsory treatment in
principle, or a combination of all these.
For this reason, facilities necessary for the acceptance from the
courts of drug offenders, whose offence has been occasioned by
their state of dependence or addiction, have been very few in
number. This is in contrast with the United. States, where
residential facilities, including therapeutic communities,
receive a considerable proportion of their clientele from the
law courts as a form of diversion to treatment in lieu of
punishment. In France since 1970, the illicit use of drugs has
been an offence. Provided that persons are charged and con-
victed of the offence, they may be ordered by law enforcement
authorities to submit to detoxification, following which they
can be kept under medical surveillance for indefinite periods of
time.
Canadian experience, however, with the deprivation of liberty as
a means of facilitating treatment and rehabilitation has so far
not been encouraging. Treatment within prison settings has been
unsatisfactory. Indeed, bringing addicts together for long
periods of confinement without a restructuring of lifestyle
accomplishes little or nothing. It may indeed have a negative
effect.
TREATMENT NEEDS OF DRUG ABUSERS
While there are many physical needs of many drug abusers, there
is a proportion within any sample of narcotic-addicted persons
who heed some form of what is generically referred to as
psychotherapy. Often it is this group that voluntarily seeks
aid for their problems that are commonly long-standing in
nature.
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The therapeutic community, the history of which is well
documented, was predicated on the concept that a controlled
environment could be utilized as an effective instrument of
therapy. The idea is not a new one; indeed nearly all theories
of personality development have emphasized the fundamental
importance of inter-personal relationships, group experiences
and social interactions. Nevertheless, in spite of this
awareness and notwithstanding its historical and basic
importance for all behavioural sciences, the therapeutic
community has been poorly appreciated in the treatment and the
rehabilitation of both drug and alcohol abusers.
This might be due to the relative newness of the term, which
originated with Maxwell Jones about 25 years ago. Another
factor may be the wide disparity of standards that have existed.
in North America among various therapeutic communities. Some
have been based in schools, others in prisons, and others within
community or half-way houses. They have ranged from crisis
intervention centers to long-term residential facilities. Some
have tolerated a code of behaviour that has been generally
unacceptable to the community at large, while others have
enforced strict, demanding codes of conduct. Starting patterns
have varied from purely professional to entirely non-pro-
fessional. Some programs have maintained liaison with the
establishment, the law enforcement agencies, and the courts,
while others have eschewed this entirely. There are programs,
the orientation of which is to return persons to society as
constructive, productive citizens, while others have held that
society itself is the villain,, and it may be counterproductive
for residents ever to consider leaving the umbrella of group
support.
Approximately six years ago, I was privileged to receive a
special award from the National Institute of Drug Abuse of the
United States to join a group of drug dependence administrators
from overseas countries in examining American programs in a
number of large U.S. cities. During that month-long stay, I saw
for myself how many differences exist within various modifi-
cations of the models of treatment.
There is, however, a general sense of agreement for an
existential approach on the basis of three principles:
1. addicts are curable until proven otherwise;
2. that they are, and should be treated as though they
are responsible for their own conduct and treatment;
3. that the treatments must be aimed at profound
character reconstruction, rather than just physical
detoxification and social adjustment.
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In virtually all the programs that I was privileged to visit,
there was the belief that underlying all severe chronic d-rug
use, there are serious maladaptive patterns of response to
emotional states which are induced by biological needs and
psychological conflicts, as well as by outer stress, familial,
social and situational in nature. It appears to be generally
accepted that such emotional response patterns predispose
individuals to drug use. At the same time, there continues to
be an optimism that these patients can be altered. The primary
objective, therefore, has to be the effective alteration of in-
effective emotional and response pattern behaviours, to more
effective ones.
I believe, personally, that there is still a place for the
professional worker and the physician within most treatment
programs, especially to identify possible psychopathology within
the residential body. Serious and even irreparable damage can
occur as a result of say, encounter technology when the fund-
amental distinction between the sociopath and the pre-psychotic
is not wholly appreciated. While the sociopath improves as a
result of healthy guilt feelings and stressful anxiety, these
very techniques can be wholly destructive of the individual who
has an underlying mental illness, such as undiagnosed
depression.
I was especially interested to note that in some programs of the
United States, there are special provisions for women. It seems
clear that the needs of the pregnant addict, the older female
and the addicted mother are often beyond what the average "co-
educational" program can provide. It is even possible to
contend that in addition to the emotional problems found in male
addicts, females have additional problems of hostility, and a
confused sexual identity, not uncommonly manifested with a
degree of brutality. Most of them seem to have grown up in a
sterile, unemotional milieu. Most seem never to have known what
it is like to be loved, nor have they ever experienced any warm,
meaningful relationships. Most have not been prepared to become
adequates mothers. All this can lead to the birth of a child by
a mother whose main motive in the pregnancy seems to be a re-
assertion of her female ego. What is disturbing about this is
the reported high incidence of child abuse and child neglect,
directly attributable to drugs, or alcohol-addicted parents.
From a community perspective, it is becoming increasingly clear
that for the highly complex field of treatment of addicted
states, a multi-modality approach is required. Psychotherapy
still has a place, albeit a small one; for others, some form of
behaviour modification may be appropriate. Chemical aversion
has its advocates, while contingent reinforcement is a batter
approach for others. Even acupuncture may be indicated for
some!
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If the Department of National Health and Welfare has any
concern, it seems to rest on the tendency of many forms of
treatment to substitute one kind of dependence for another.
While this is not done in terms of one drug for another within
therapeutic community programs, there is even the potential for
dependence on the program and its specific principles. It is a
feature of nearly all forms of chronic treatment, and even
therapeutic communities cannot escape from it. it is a seductive
tread which is easy to ignore, especially when one is intimately
concerned with treatment, and may, in fact, be more obvious to an
outsider than those involved with the program itself.
METHADONE PROGRAMS
While Canada has established both methadone slow withdrawal and
methadone maintenance programs in all geographic areas that have
a significant opiate problem, there has not been the enthusiasm
for Maintenance that has been reported from the U.S.A.
A publication from the Addiction Research Foundation of Toronto
in 1972* analysed the outcomes of the first 90 patients treated
within the methadone maintenance program. They reported that
half of the male patients left the program voluntarily either by
quitting without notice (28.1%) or by requesting a planned
withdrawal (21.9%). A further major cause for dismissal from
the program was legal arrest (37.5%) of the men and (31.6%) of
the women. The most prominent cause of discharge among won-en
was excessive drug use other than narcotics, involving most
often barbiturates. About 16 months after the last patient
intake it was found that over 50% of the group discharged
voluntarily or by dismissal were readdicted to heroin or other
narcotics. One in four was in prison.
In a study of employment rates the authors found that after one
year on methadone maintenance 66.7% of their patients were
working or participating in a vocational rehabilitation program.
At the time that they entered the program 43.6% of the group was
employed. This was considered a limited success.
With regard to employability of methadone-maintained persons it
is generally accepted that one legitimate excuse which can be
made by methadone program directors for limited success in this
area is that they are being asked to attain levels of employment
and productivity for people who, prior to their use of heroin,
were chronically unemployable. Indeed, a high percentage of
heroin users in their early 20's have little or no skills, a
* M. Krakowski; R.G. Smart: "The Outpatient Treatment of Heroin
Addicts with Methadone." Can. J. Public Health, 63 (1972)
397-404.
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limited education, and usually no established work pattern. A
high proportion has never worked at all. It may be somewhat
unfair therefore to expect methadone programs to accomplish a
vocational reintegration process into society when the limited
capabilities antedated, and were not the result of, heroin use.
In the year 1975 the Government carried out an investigation
into the reasons for a decline in a number of Canadian addicts
receiving methadone as part of their treatment of opiate addict-
ion. Specifically program controls were examined with a view to
establishing whether or not they were so stringent that they
were discouraging new addict clients; and whether or not our
controls, if lessened, would lead to increased diversion of
methadone to the streets.
The study committee contacted and received reports from medical
practitioners who have been licensed to use methadone to treat
drug addicts; from the treatment agencies where methadone is
regularly used; from drug free treatment programs; and from
social workers and counsellors in the field of correction
treatment and rehabilitation who are in daily contact with
addiction problem. There appear to be four main reasons in
Canada for the decrease in the total number of narcotic addicts
being treated with methadone.
1. Changed attitudes on the part of physicians and
concomitant loss of interest in methadone on the part
of addicts.
It would appear that at least some physicians who once used
methadone have become disillusioned with obtained results. In
addition, there seems to be evidence that addicts, in general,
are disenchanted. Reasons for this include the fact that oral
methadone is not perceived by many addicts as an adequate
substitute for intravenous heroin. Addicts are aware that
methadone is just as addictive as heroin, and indeed withdrawal
from it my be more difficult and prolonged. Many complain of
the side effects of methadone such as constipation and loss of
sexual drive. Addicts also seem to be worried about the dangers
of methadone overdose.
2. Addict dissatisfaction with conditions imposed by some
clinics.
The examples here include inflexibility in handling patients,
and some degree of insensitivity to their daily needs. Addicts
will not put up long with what they term a daily "hassle" in
dealing with clinics. The necessity for daily visits to obtain
methadone restricts their activities such as going away for a
weekend. This is despite the fact that the lifestyle of the
average junkie has long necessitated a daily contact with a
pusher on the street, including the weekend days.
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3. Changing trends in drug use.
Tnis seems to be an important factor in Canada. There is a
trend towards multiple drug use, and this is lessening the number
of hard core addicts to opiates. Better enforcement activities
by the police have reduced supplies of heroin, and at the sane
time have produced a lower grade of heroin available for sale.
Individuals using this are not as heavily addicted as far as
physical dependence is concerned. Most addicts use drugs such
as tranquilizers, barbiturates, and alcohol to help them over
periods of heroin non-availability. Lastly, there seems to be
little doubt that a rapid increase in the use of cocaine is a
factor in the decrease in heroin addiction. While some addicts
use both heroin and cocaine the cost militates against heavy
use; this again lessens the degree of physical dependency.
4. There is a tendency in Canada for programs to orient
addicts towards a drug free state as a preferred
future.
For this reason n-any clinics are moving to slow detoxification
with methadone, rather than maintenance with it. There is
generally more interest in drug free programs.
I have chosen to present this overview of arrests, deaths, drug
seizures, of details of Canadian programs and success/failure
rates. I trust that it has ken of use as an introduction to
this conference on continuation of international approaches to
the prevention and treatment of the unfortunate victims of
chemical dependence.
Thank you.
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Cultural Aspects of Alcohol and
Drug Problems in Canada
Juan Carlos Negrete
This analysis of cultural trends in drug and alcohol abuse in
Canada is based on a comparison with the U.S.A. and on differ-
ences observed between separate regions of the country. The
subject is approached from an epidemiological standpoint in the
hope that speculation on cultural influences would result from
the study of quantitative evidence rather than from subjective
impressions. This approach is, of course, not without its
shortcomings and serious limitations: national statistics are
scarce and tend to cover mostly items whose nature is perhaps
too general to accurately reflect cultural variance. In add-
ition, the comparability to data from separate countries or reg-
ions is frequently rendered difficult by differences in sources
of information and in the methods utilized to gather them.
In comparing the sociocultural basis of drug and alcohol use in
Canada and the United States, it is warranted to begin by adopt-
ing the null hypothesis, not simply as a matter of standard
scientific procedure, but also because one can truly expect to
find no major differences in cultural phenomena occurring in two
societies which have so much in common. There are few countries
in the world as much in contact with one another, sharing life-
styles to the same extent. Both populations are exposed to com-
mon mass media messages; they tune in to the same television
stations on a daily basis. Canadians are frequently more aware
of what is current in the United States than in other parts of
Canada. The same consumer products are marketed simultaneously
in both countries, often using identical commercial advertising.
The mobility of persons across the border is practically unre-
strained. These factors greatly facilitate cultural trans-
mission and contribute to the development of similar habits and
social attitudes in both countries.
In spite of these similarities and of the many historical, soci-
oeconomic and political ties which unite these two societies,
there are certain divergences which may be expected to differen-
tially influence patterns of alcohol and drug use in them. An
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important one is the ethnic and subcultural breakdown of their
populations. The 1981 census data just released on the popula-
tion of Canada (1) shows that the largest group (61.3 percent)
is that of persons indicating English as their mother tongue.
As in the United States, this group is composed mainly of the
original British settlers plus descendants of earlier immigrant
groups (Irish, German, Dutch, Scandinavian) who have been large-
ly assimilated by them. But it also includes second and third
generation descendants of other immigrant groups such as Ital-
ians, Greeks, Asians and Eastern Europeans who, on being quest-
ioned, would declare English as their mother tongue. The
French-speaking group is the second largest (25.7 percent); with
the exception of some very recent and as yet not significant
additions (Haitians, North Africans), French mother tongue per-
sons represent the original French Canadians.
Notable differences with the American population are, in the
first place, this very large French minority. People of French
origin in the United States represent 1.5 percent of the total
population. Secondly, the important southern European minor-
ities - Italians, Portuguese, and Greeks - in Ontario and Quebec
(6 percent and 3.1 percent, respectively), and the Ukrainians in
the Prairies (4.0 percent). Thirdly, the existence in the
United States of two major ethnic groups not yet significant in
Canada: blacks and Hispanics (11 percent and eight percent,
respectively). This difference is important in relation to the
problems of drug abuse, as these two groups appear to be part-
icularly vulnerable.
Another important feature is the regional distribution of ethnic
groups in Canadian society. A solid French majority in Quebec
(82.4 percent) has created a veritable separation of cultures
which appears to influence some aspects of the alcohol and drug
abuse problem. There are in Canada some 370,000 natives who
account for 1.5 percent of the total population. In the United
States, on the other hand, a total of 800,000 native Americans
represents less than 0.5 percent. Although in both countries
natives tend to concentrate in certain regions, their numbers in
the Canadian Prairies (5 percent) and the Northern Territories
(34.5 percent) are a major influence in the regional picture of
alcohol abuse.
Canadians are rather proud of the fact that different ethnic
groups tend to keep their own traditions and retain their sep-
arate identities. This cultural trait makes Canadian society
somewhat different from the American one where the homogeniz-
ation of lifestyle is encouraged.
ALCOHOL USE
National per capita consumption figures demonstrate that
Canada's pattern is closer to that of the United States than to
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the ones in other related countries. Canada and the United
States present medium overall levels which have increased at a
similar pace over the years. (Table 1)
The similarity extends to beverage class preferences: both Can-
adians and Americans are heavy beer and light wine drinkers, a
tendency observed in Britain and Australia as well. However,
unlike those two culturally related societies, the consumption
of spirits is much higher in North America. The picture in
France is so markedly different, with 70 percent of the total
alcohol intake in the form of wine, that French influence on
Canadian drinking patterns may be considered as minimal. (Table
2)
The regional variance within Canada shows the highest total con-
sumption levels in the Yukon and Northwest Territories. There
is also a clear trend towards higher consumption in the western
provinces: Alberta and British Columbia yield figures well a-
bove the national average. The higher overall levels in the
West and the Northern Territories are accounted for almost en-
tirely by high rates of spirits drinking; beer and wine figures
appear to follow this asymmetric regional distribution. British
Columbians drink the highest average amounts of wine in the
country; this finding not only reflects the existence of a local
wine industry, but also a tendency among west coast Canadians to
follow closely social habits prevailing on the American west
coast. As British Columbia, California presents the highest
level of wine drinking in the country. The highest per capita
total consumption levels in the United States are also found in
the Pacific region.
Quebec shows the second highest figure for wine use in Canada,
but it must be noted that sales statistics do not include
homemade products. It has been well established that the
majority of Italians, Portuguese and Spanish living in Montreal
produce their own wine each year in amounts frequently beyond
the allowed quota of 200 gallons per household (2). Since these
ethnic groups constitute a sizeable minority in the province,
consumption figures could be significantly influenced by this
omission. (Figure 1)
The regional tendencies identified through beverage sales fig-
ures are supported by findings of general population self-
report surveys on drinking. There are more drinkers in the
western provinces and, more importantly, a considerably higher
percentage of heavy drinkers. The tendency is particularly
clear for females: the percentage of heavy drinking women in
British Columbia and the Prairies is three times that in Quebec
and the Atlantic provinces. One clear difference in alcohol use
practices between Canada and the United States is the number of
abstainers in the population of drinking age: 33 of 100 Amer-
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icans as opposed to 25 percent of Canadians fall in this cat-
egory. The percentage of heavy drinkers, however, is remarkably
similar in both countries; an average of 6 surveys conducted in
the United States during the period 1971-1976 indicates that 18
percent of males and 4 percent of females consume 14 or more
drinks per week (3). (Table 3)
ALCOHOL-RELATED MORTALITY
Mortality due to cirrhosis of the liver is clearly higher in the
U.S. than in Canada, both for males and females. Yet Canadian
rates are closer to American ones than to those in the United
Kingdom or France. Also, the male-female ratio of 2:l is rough-
ly the same in both countries, whereas it is considerably lower
in Britain and slightly higher in France.
Regional liver cirrhosis mortality figures within Canada do not
appear to correlate with local per capita consumption levels, as
could be expected. Quebec, for instance, with much lower aver-
age consumption than Alberta, Ontario and Prince Edward Island,
presents a higher rate than those provinces. Factors such as
beverage class preference - beer vs. spirits - and alcohol use
patterns - daily drinking vs. intermittent bouts - may be more
responsible for differences in cirrhosis rates than the varying
consumption levels. On the other hand, the regional variance in
male-female ratios of alcohol-related deaths (alcoholism, alco-
holic psychosis, liver cirrhosis, alcohol poisoning and suicide)
does follow closely that of consumption patterns: it is 1:l in
the Yukon, while in New Brunswick and Quebec, where the percent-
ages of heavy-drinking women are the lowest, the relation is 4
males for each female (4).
ALCOHOL-RELATED SOCIAL PROBLEMS
There are very few quantitative indicators of social behaviour
which are suitable for cross-cultural comparisons. However,
some alcohol-related social problems can be tallied and rates
may be calculated. These indicators are more related to acute
alcohol intoxication than chronic alcohol abuse and tend to de-
pict alcohol-related public disorder rather than disturbances
which occur in private. (Table 4)
The number of DWI offences in a given year varies widely across
the different regions of Canada. The average rate for Canada is
slightly higher than that for the United States, with the west-
ern provinces and the northern territories showing highly sign-
ificant increases. It has been established that these areas
present larger consumption volumes as well, but there are some
environmental factors which may also contribute to the regional
disparity in rates. For example, drinkers are more likely to be
on the roads in sparsely populated rural areas where they must
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travel some distance to and from public drinking places. This
factor is particularly important where local attitudes do not
favour drinking at home. An additional influence may be a cul-
tural preference for distilled beverages and a pattern of heavy
weekend intoxication. This is no doubt the case in the prair-
ies, the northern territories and Prince Edward Island. (Table
5)
Rates for aggressive behaviour incidents also vary across diff-
erent provinces. The number of violent crimes recorded by the
police tends to follow the same direction observed with alcohol
traffic offences, and the highest figures are found in the west-
ern region of the country. Admittedly, this type of offence is
not as reliable an indicator of alcohol abuse as DWI reports,
but the major role played by alcohol intoxication in violent
behaviour cannot be ignored. Disorderly and aggressive behav-
iour under the influence of alcohol is one of the features of
alcoholism more strongly linked to sociocultural factors and
some of these could explain the regional variance in Canada.
Jellinek, for instance, reported crosscultural differences in
the social behaviour of heavy drinkers. He noted that in count-
ries such as Switzerland, France, Italy and Portugal, middle-
aged individuals were observed who appeared with physical com-
plications of chronic alcohol abuse, such as cirrhosis of the
liver, without having been identified as alcoholics earlier in
their lives (5). They would apparently neither seek treatment
nor be perceived as needing assistance for this problem in their
milieu. The fact that their chronic abuse could go unremarked
for so many years may reflect a high degree of cultural toler-
ance for heavy alcohol consumption, but it also shows that these
heavy drinkers do not behave in a way that would precipitate an
earlier intervention. These examples are societies where the
prevailing pattern is one of regular daily use, mostly at home,
and where alcohol is not philosophically perceived as evil.
Alcoholic behaviour tends to be more disturbed in those commun-
ities whose value systems include strongly critical views on
drinking (6). A possible sociodynamic mechanism is that of the
self-fulfilling prophecy. Individuals whose social milieu
strongly cautions against the disinhibitory effects of alcohol
are likely to act up the apprehended behaviour when intoxicated.
They may, in fact, tend to drink with the purpose of releasing
repressed impulses. A classic study by Skolnick on the social
consequences of drinking experiences among American students
found that those individuals belonging to religious groups with
the strongest temperance views were the ones who became involved
in more incidents after drinking (7). Prohibition was introduc-
ed mostly in countries where stronger puritanical religious
beliefs prevailed. In Canada, a law was enacted which permitted
each local government to impose prohibition in accordance with
the results of a local plebiscite. The only province never to
25
introduce it is Quebec which, coincidentally, shows the lowest
DWI rate and the second lowest violent crime figures.
Another factor that may account for the variance in rates of
reported crime is differential police action. That is, police
could be more inclined to intervene or to report in one region
than in another. There are, unfortunately, no elements which
could satisfactorily clear this question. However, it may be
relevant to look at data gathered some years ago in a compara-
tive study of alcoholics in treatment at a Montreal facility.
These were all local residents and consequently subject to con-
trol by the same police force. (Table 6)
Even after allowing for age and years of drinking, alcoholics of
Anglo-Protestant cultural identity were significantly more like-
ly than French Catholics to be arrested for public drunkenness
offences. Other parameters, such as permanence of marriage, also
indicate that the former faced a higher degree of social diffi-
culties and rejection. These findings are supported by those of
a recent study by Babor et al. (8) who found French-Canadian al-
coholics in the United States to show the second lowest rate of
public drunkenness and disorderly conduct arrests among seven
subcultural groups surveyed. The uneven distribution of these
cultural groups in Canada may be a factor in regional rates of
alcohol-related behavioural problems.
Differential police action, however, may be a real factor in the
higher rates of alcohol offences registered in the Northwest
Territories, the Yukon and the prairies, where the proportion of
native population is the largest. In Canada, as in the United
States, Indians and Inuit are particularly vulnerable to alcohol
abuse problems; society at large, as well as its law enforcing
agents, have come to expect natives to exhibit disorderly
behaviour under the effects of alcohol. A vicious circle situ-
ation may have been created as natives tend to fulfill the
prophecy. In British Columbia, for example, natives make up
less than 2 percent of the general population but constitute 30
percent of jail inmates. The white-native ratio of referrals to
psychiatric centres in that province, however, is 10:l. This
evidence would suggest that behaviour problems normally handled
by health services in the case of non-natives, tend to be pro-
cessed through the justice system when presented by natives.
Studies of patient populations in Alberta and Saskatchewan found
that natives receive the "personality disorder" diagnosis sign-
ificantly more often than non-natives. It was also observed
that Indian and Metis patients were more likely than non-natives
to have entered hospitals on an involuntary basis. Rates of ad-
mission for alcoholism are also higher among natives but this
difference is accounted for by the number of females entering
hospitals with that diagnosis since the percentage of male nat-
ives so labelled is actually lower than that of non-natives. It
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would appear that there is a tendency to refer native female al-
cohol abusers to hospitals and male ones to jail (9) (10) (11).
In the United States, natives are twenty times more likely than
whites to be arrested for public drunkenness and the ratio for
violent crime convictions is 3:l; but these problems are not
evenly distributed across the different sectors of the native
population. French and Hornbuckle (12) have identified three
separate sociocultural categories among them with respect to
drinking behaviour: a) the traditional native Americans, repre-
senting no more than 20 percent of the total aboriginal popula-
tion, and living isolated from mainstream culture, among whom
alcohol intoxication is one within a set of ritual practices and
appears to cause less social damage; b) the middle class nat-
ives, also called "white Indians," a selected minority repre-
senting the establishment-supported native spokespersons. They
are in active Indian affairs bodies. Their pattern of drinking
differs little from that of the non-native society; c) the mar-
ginal native Americans who form the largest group, accounting
for some 65 percent of the total native population. They are
neither traditional nor totally acculturated and display the
highest rates of alcohol-related social problems.
In Canada there is an equivalent of these distinctions: the
marginal natives are represented mostly by the Metis and the
non-status Indians, also called non-treaty Indians. As the
denominations indicate, these are people whose identity is most
conflictive, finding themselves at a crosspoint between native
and non-native cultures. They cannot fully identify themselves
with either and have insufficient elements for developing their
own. Surveys in Alberta and Saskatchewan have demonstrated that
the Metis when compared with treaty Indians and Eskimo are the
group with the highest rates of alcohol pathology (10).
PROBLEMS OF DRUG ABUSE IN CANADA
The United States has developed a multivariate monitoring system
which has no equivalent in Canada. The DAWN and CODAP pro-
grammes, and the periodic national surveys, for example, have
not yet been introduced in this country. An important exception
is the province of Ontario where the Addiction Research Found-
ation has been systematically recording general population drug
use trends since 1977. Currently available national drug use
data originates mainly from two sources: one is the Federal
Bureau of Dangerous Drugs which receives police reports of
arrests and pharmacy thefts, compiles conviction statistics and
keeps methadone treatment and "known user" files; the other is
the federal police force (R.C.M.P.) which has information on
crime reports, arrests and charges, drug exhibits submitted for
analysis, street drug purity control tests, street drug avail-
ability and cost; and keeps a file on narcotic users.
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The evidence thus collected points to some marked differences in
the drug abuse pictures of Canada and the United States. The
use of heroin, for instance, although a major drug problem south
of the border, would appear comparatively insignificant in
Canada, with the exception of the province of British Columbia
where reside close to 10 percent of all known opiate users in
the country. Vancouver is the port of entry for traffic coming
from the Orient and it has the largest concentration of Asian
immigrants who maintain active contact with Hong Kong and Indo-
china; consequently, greater availability of the drug in that
city is a likely explanation for this regional disparity. It is
also possible that many heroin users from other regions have
gone to British Columbia following the closure of drug main-
tenance treatment programs in their home provinces. Methadone
clinics which operated during the 60's in Montreal, for example,
were discontinued a few years later, mostly due to little sup-
port from the public and the health profession community. An
attitude of disapproval towards drug maintenance appears to
prevail elsewhere in the country as well. In places where
methadone is still used, it is given mostly within the context
of shortterm detoxification protocols. It would appear that
cultural support for continuing drug supply programs is more
readily accorded in the United States than in Canada. The ab-
sence of high risk ethnic ghettos in the latter, and a relat-
ively small number of addicts, markedly reduces the degree of
local concern about this problem. The use of cocaine, on the
other hand, seems to be equally prevalent in both countries; in
Canada it is concentrated mostly within the larger urban centres
(Montreal, Toronto, Vancouver).
Leaving tobacco aside, cannabis is the psychoactive agent most
widely used for non-medical purposes across the country. Sur-
veys conducted by Health and Welfare Canada in 1980 show that
levels of use for respondents aged 18 years or younger are
higher in Ontario and the western provinces than in the east.
However, samples of adults yield a remarkably stable rate of 10
percent in all regions (13). When compared with the surveys
conducted by Johnston et al. (14) in the United States, it would
appear that the Cannabis-using population in Canada is smaller
by a factor of 10 to 20 percent. Contrary to what climatic con-
ditions might suggest, cannabis is also available in Canada
through local production; the largest cultivation is concentrat-
ed in British Columbia where cannabis patches hidden in remote
public forest are constantly being detected by the police
through helicopter surveys. This illegal supply is reported to
have increased considerably since the recent introduction of the
sinsemilla variety, a high yield, shorter plant more difficult
to detect from the air (15). (Table 7)
Findings from a 1981 survey of high school students in Ontario
demonstrate the extent of prescription drug abuse in Canada. In
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this sample, ranging in age from 13 to 18 years, the use of
pharmaceutical psychotropics is particularly prevalent among the
younger ones, and has grown since 1977 when a similar population
was surveyed. The use of alcohol and cannabis, on the other
hand, appears to have peaked in 1979 and shows a declining tend-
ency in 1981. The latter finding correlates with cannabis use
trends in the United States, but the abuse of psychotropic medi-
cations is definitely a greater problem in Canada. (Table 8)
This assumption is further supported by data from client popula-
tions in the United States and Quebec. There are marked differ-
ences in the primary drugs of abuse reported by individuals
seeking help at publicly funded treatment centres in both loca-
tions. Whereas, in the United States, heroin abuse is by far
the most prevalent problem; in Quebec, the largest percentage
corresponds to the sedatives/hypnotics group of substances. It
is difficult to speculate on "cultural" reasons for these diver-
gences. A relevant factor may be the different degree of access
to medical care in these two societies: Canadian health insur-
ance programs allow for unrestricted contact with medical prac-
titioners, and prescription drugs are likely to be more often
reported; American drug rehabilitation centres are geared to-
wards narcotics addicts - perceived as the major local problem -
and have tended to neglect the care of other substance abusers.
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TABLE 1
APPARENT PER CAPITA CONSUMPTION OF ALCOHOLIC BEVERAGES IN LITERS OF
ABSOLUTE ALCOHOL IN PERSONS 15 YEARS AND OVER
TOTAL
FRANCE
AUSTRALIA
CANADA
U.S.A. *
U.K.
YEAR
1972
1972-73
1974
1975
1974
SPIRITS
3.2
1.8
4.0
4.5
2.1
WINE
16.2 3.9
1.8 9.6
1.2 6.0
1.3 5.2
1.1 7.7
BEER
23.4
13.2
11.3
11.1
11.0
* 14 YEARS AND OVER
Source: ADAPTED FROM MARK KELLER AND CAROL GURIOLI, STATISTICS ON
CONSUMPTION OF ALCOHOL AND ON ALCOHOLISM. NEW BRUNSWICK,
N.J., RUTGERS CENTER OF ALCOHOL STUDIES, 1976 ED. Reprinted
by permission from Journal of Studies on Alcohol, Inc.
TABLE 2
PER CAPITA CONSUMPTION (LITERS ETHANOL) BEER, SPIRITS AND WINE.
CANADA AND PROVINCES. TOTAL POPULATION. 1979.
REGION
NEWFOUNDLAND
PRINCE EDWARD ISLAND
NOVA SCOTIA
NEW BRUNSWICK
QUEBEC
ONTARIO
MANITOBA
SASKATCHEWAN
ALBERTA
BRITISH COLUMBIA
NORTHWEST TERRITORIES
YUKON
CANADA
BEER
6.20
5.16
4.89
5.05
6.05
5.61
4.50
4.70
4.95
4.65
5.53
8.61
5.45
SPIRITS
3.92
5.08
4.44
3.44
2.80
4.44
5.08
4.56
6.28
5.88
7.20
9.72
4.32
WINE TOTAL
0.51 10.63
0.79 11.03
0.97 10.30
0.73 9.22
1.71 10.62
1.51 11.56
1.21 10.79
0.85 10.11
1.71 12.94
2.44 12.97
1.38 14.11
2.77 21.10
1.60 11.37
Source: STATISTICS CANADA, CONTROL AND SALES OF ALCOHOLIC BEVERAGES IN
CANADA. CATALOGUE 63-202, 1979
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TABLE 3
MORTALITY FROM CIRRHOSIS OF THE LIVER,
RATE PER 100,000 POPULATION, 974
TOTAL MALES FEMALES
AUSTRALIA 8.3 11.6 4.9
CANADA 11.6 16.0 7.3
FRANCE 32.8 47.6 18.6
ENGLAND
& WALES 3.6 3.8 3.4
SCOTLAND 6.3 7.2 5.4
U.S.A. 15.8 21.4 10.6
Source: W.H.O. (1977) Wld Hlth Stat Ann 1
TABLE 4
DRIVING WHILE IMPAIRED, OFFENCES REPORTED BY POLICE,
BY PROVINCE, RATES PER 100,000 PERSONS, 1977
NEWFOUNDLAND 650.1
PRINCE EDWARD
ISLAND 674.9
NOVA SCOTIA 490.6
NEW BRUNSWICK 500.2
QUEBEC 433.8
ONTARIO 511.1
MANITOBA 728.4
SASKATCHEWAN 906.9
ALBERTA 997.7
BRITISH
COLUMBIA 900.9
YUKON 2,018.6
NORTHWEST
TERRITORIES 1,794.4
CANADA 604.2
Source: STATISTICS CANADA. CRIME AND TRAFFIC
ENFORCEMENT STATISTICS, CATALOCUE 85-205,
1977
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TABLE 5
VIOLENT OFFENCE RATES PER 100,000 PERSONS, 1978
NEWFOUNDLAND
PRINCE EDWARD ISLAND
458.6
344.2
NOVA SCOTIA 523.1
NEW BRUNSWICK 433.6
QUEBEC 400.9
ONTARIO 621.1
MANITOBA
SASKATCHEWAN
567.4
ALBERTA
593.1
778.4
BRITISH COLUMBIA 871.0
Source: STATISTICS CANADA. CRIME AND TRAFFIC
ENFORCEMENT STATISTICS, CATALOGUE 85-205,
1978
TABLE 6
PERCENTAGE OF SUBJECTS EXPERIENCING SOCIAL
DIFFICULTIES, BY CULTURAL IDENTITY
PUBLIC DRUNKENNESS MARITAL EARLY LIVING
ARRESTS BREAKDOWN UNEMPLOYMENT ALONE
F.C. 17 50 14 51
A.P. 48 85 44 80
Source: NEGRETE, J.C., CULTURAL INFLUENCES ON SOCIAL
PERFORMANCE OF CHRONIC ALCOHOLICS. QUART. J.
STUD. AK. 34: 905-916, 1973. Reprinted by
permission from copyright holder. Journal of
Studies on Alcohol, Inc., New Brunswick, NJ
08903.
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TABLE 7
DRUG USE* AMONG HIGH SCHOOL STUDENTS, ONTARIO. 1981
DRUG PERCENT
TOBACCO
ALCOHOL
CANNABIS
STIMULANTS
BARBITURATES
HALLUCINOGENS
SEDATIVES
GLUE & SOLVENTS
COCAINE
HEROIN
30.3
75.3
29.9
21.2
20.6
14.9
12.4
5.5
4.8
1.5
*
AT LEAST ONCE IN PRIOR 12 MONTHS.
ADAPTED FROM SMART ET AL., ADDICTION RESEARCH FOUNDATION,
TORONTO, 1981
TABLE 8
PERCENT DISTRIBUTION CLIENTS, 1978
PRIMARY DRUG U.S.A. QUEBEC
HEROIN 51,7 8.0
SYNTHETIC NARCOTICS 6.7 4,6
MARIJUANA 3.5 14.5
AMPHETAMINES 600 10.6
BARBITURATES 4.6 8.0
ALCOHOL 9.2 12.4
COCAINE 2.7 9.0
HALLUCINOGENS 5.2 l3.0
SEDATIVES/HYPNOTICS 4.3 16.6
INHALANTS 1.5 3.3
Sources: CODAP DATA, U.S.A.
ALTERNATIVES, QUE.
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FIGURE 1
SOURCE: CANADA HEALTH SURVEY, STATISTICS CANADA CATALOGUE 82-538E
The Addiction Research
Foundation—Mandate, Role,
and Directions
Joan A. Marshman
INTRODUCTION
Mr. Chairman, I am delighted that the Committee on Problem of
Drug Dependence elected to hold its 44 Annual Scientific
Meeting in Toronto. Not only does this venue ensure an oppor-
tunity for those of us in the Addiction Research Foundation
(A.R.F.) to "show off" our city while exchanging views with our
international colleagues, but it represents the salvation of our
travel budget which is currently reeling from the widening gap
between the Canadian and U.S. dollars.
I see my task for today as sharing with you the "flavour" of the
Addiction Research Foundation in the context of the Canadian
approach to problems of drug dependence. My perspective will be
managerial rather than scientific in character, and I will
attempt to shed some light on the Foundation's mandate and
organization, its program areas and goals areas, and its
approaches to future effort.
MANDATE AND ORGANIZATION
The Addiction Research Foundation was established by the
Government of Ontario in 1949. This initiative of the
Provincial Government reflected several factors, among them:
the constitutional responsibility of the Provinces
(rather than of the Federal Government) to provide
health care services;
the Provincial Government's decision to permit the
opening of Ontario's first cocktail lounges, and the
vocal negative response from several sectors of the
community, including the Temperance movement and the
churches: and
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the efforts of H. David Archibald, who was actively
involved in the mental health field, both provincially
and nationally, and became the Foundation's first
Executive Director.
This Foundation, established by Provincial statute, with respon-
sibility for research directed to a single type of health
problem, and reporting annually to the Legislature via the
Minister of Health, constituted a model in the Province for the
subsequently established research foundations in the areas of
cancer and mental health.
The initial legislation gave the Foundation responsibility in
the area of alcoholism. Not until 1961-62 was the mandate
broadened to include "drug addiction," and the name changed to
the Alcoholism and Drug Addiction Research Foundation. By
statute the mandate of the Foundation has three dimensions:
research, treatment, and information dissemination (which is
more commonly referred to, internally, as "education"). It is
noteworthy that the Foundation's responsibilities for inform-
ation dissemination include specifically the dimension of
"prevention," and in this respect this Foundation is unique
among the Province's statutory foundations.
The initial research efforts were effected through a program of
extramural grants to university scientists, but more recently
the program has been focussed intramurally and is located
largely in Toronto. Although the Foundation's treatment
services were established initially in Toronto, its outpatient
services (along with education services) were subsequently
diffused to many Ontario cities. However, in 1969, the
Foundation, with the Minister of Health's agreement, clarified
and focussed its role with respect to treatment. Specifically,
it undertook to concentrate its treatment efforts within the
framework of treatment research, demonstration treatment models,
and education and training for health and social service
personnel, rather than in widespread direct treatment service
delivery; thus, the Foundation currently provides treatment
services only in its headquarters building in Toronto.
Today the Foundation has a total (1982-83) budget of $26.4
million and a full time staff of 694, located in its Toronto
head quarters and in offices in Ontario cities. Administratively
it is organized into six Divisions: the Clinical Institute,
Social and Biological Studies, Education Resources, School for
Addiction Studies, Regional Programs, and Administration and
Support Services. In terms of the mandated responsibilities, the
allocation of functions to these Divisions is indicated in
Figure 1 (on the following page).
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Figure 1
Divisional Allocation of the Foundation's Mandated
Responsibilities
Research Social and Biological Studies Division
Clinical Institute Division
Regional Research Centre
(Regional Programs Division)
Treatment Clinical Institute Division
Regional Program Division
Information Education Resources Division
Dissemination School for Addiction Studies
Clinical Institute Division
Regional Programs Division
THE FOUNDATION'S PROGRAM AREAS AND GOALS
Perhaps a more useful perspective on the Foundation's programs
ing is that developed along the functional lines identified in
Figure 2. As indicated in the Figure, these programareas are
not discrete and isolated; rather, the current management thrust
is directed to ensuring that they are appropriately interactive.
Some of the implications of such an interactive approach to
programming are clear, for example:
a "building" process from research to education
(including policy advice), so that the Foundation's
information, training, and advice has largely a
research base, rather than a moralistic or legal base;
this tends to alienate some other organizations whose
"causes" the Foundation cannot support;
a need for not only information dissemination to the
community but also feedback loops from the community-
based staff to the researchprograms; and
the opportunity and challenge to the Foundation of
effectively mobilizing its information so as to "sell"
its efforts to the community and government as being
relevent and cost-effective, on the basis of their
impact on prevention, treatment services, and policy
advice.
Other consequences of this interactive system may be less
readily apparent, and include:
38

the need to nurture effective dialogue between
research staff and community-based staff, and particu-
larly the need to ensure that the implications of
research findings for community programs are effect-
ively communicated; and
the fact that the Foundation's position or advice on
any question is continuously subject to change over
tine as a function of new information, with the result
that the Foundation is periodically subject to some
criticism about the inconsistency of its position.
But to what ends are these program efforts directed? The goals
of the Foundation have recently been reviewed and reformulated,
and the goal areas are identified in Figure 2. They include:
increased public knowledge and awareness;
alcohol and drug control policies and strategies which
take into account public health aims;
increased (addictions-i-elated) knowledge and skills of
(health and social service) professionals;
effective and efficient treatment methods and systems
(for individuals with alcohol- and drug-related
problem);
improved traffic safety programs;
effective employee assistance programs.
This representation of the goal areas clearly has a "community
impact" flavour, consistent with the interactive system
described above which suggests that "the job is not done until
the Foundation's work has had an impact on the community."
However, the detailed goal statements are actually formulated in
a manner which emphasizes the research base for the efforts
which will be directed to achieving-the goals.
FOUNDATION DIRECTIONS
Any attempt to enumerate research directions for the future is
fraught with risk. Therefore, it seems more appropriate to share
with you a sense of the factors which bear on the Foundation's
decisions concerning research priorities.
Traditionally,Foundation priorities have been determined by
assessment of "need" which might be defined hypothetically by
both the frequency of the problematic alcohol or drug use in
this Province and this Country and the severity of its
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consequences. (In this context assessment of consequences must
take into account not only the risk of morbidity and mortality
for the individual user, but also the costs to the community in
lost productivity, family and social problems, and law
enforcement costs.) On this basis, research into alcoholism and
tobacco dependence are seen by the Foundation as having higher
priority than research focussing on opiate/opioid dependence.
(Clearly this is an oversimplification, for it ignores the
potential of narcotic research to illuminate mechanisms which
represent common pathways or models for other drugs; however,
while such research is, in fact, carried on within the
Foundation, it has a somewhat lower overall priority.)
Coupled with "need" there must, of course, be opportunity -- a
knowledge base adequate to permit identification of productive
"next steps" which have a high probability of contributing to
the appropriate types of human and material resources.
In the context of this approach to priority setting, the area of
benzodiazepine research has been particularly problematic.
Certainly this class of drugs is widely used in Ontario, but
assessment of the benefits versus risks associated with their
use has been a complex task.
Finally, with respect to research, resource limitations require
careful decision-making with respect to the balance of basic vs.
pre-clinical vs. clinical studies. This has been a serious
consideration for the Foundation in the area of cannabis
research, for which long term clinical studies would seem to
have particular importance; at present the Foundation is not
engaged in such research, at least partially because of the
demand that such studies would place on its available resources.
In the case of treatment services the Foundation's priorities
are two-fold: to provide a treatment system and treatment
programs in its Clinical Institute Division in Toronto which, in
addition to serving as the locus of treatment research efforts,
and of some professional training programs, represent models for
the community; and, through community development efforts, to
promote and facilitate the development of appropriate treatment
services in all areas of the Province.
The Foundation's gradual withdrawal from Province-wide direct
delivery of treatment services, beginning in 1969, was not
complemented by the systematic integration of alcohol and drug
treatment services into the existing health care system, as had
been envisaged. Instead, treatment services development has
been quite uneven across the Province. However, within the last
decade the Ministry of Health has established District Health
Councils (D.H.C.'s) throughout the province as local advisory
bodies to coordinate the development of appropriate health
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services in each district; some 26 D.H.C.'s have now been
established and the Foundation's Regional Programs Division
staff is actively involved with 19 of these D.H.C.'s working
towards the development of a rational plan for treatment
services delivery to individuals with alcohol and drug problems,
in the context of the general health and social services
systems.
Consistent with the Ministry of Health's position on health care
services delivery, the Foundation is advising:
a community-based system of alcohol and drug treatment
services which will optimally involve existing health
care and social services resources:
the establishment of patient assessment and primary
care capacities as integral parts of the system;
an emphasis on outpatient treatment services, with
access to living accommodation where specifically
justified on the basis of assessment findings, rather
than a view that inpatient treatment facilities
represent the cornerstone of the system.
Further, through programs directed. to business, industry and
labour, the Foundation is providing consultative services for
development of employee assistance programs.
It is important to remember, however, that the Foundation
neither funds nor operates the treatment services system in the
Province, with the result that its achievements in this area are
a function of its proselytizing for its proposals, and its
function as a catalyst or facilitator within communities.
The Foundation's professional education and training programs
reside in two Divisions -- the Clinical Institute (a teaching
hospital of the University of Toronto) and the School for
Addiction Studies. To date, the programs of the School for
Addiction Studies have been directed primarily to training of
A.R.F. staff. However, the top priority for the forseeable
future rests in treatment-related training of health care and
social services staff from community agencies. Clearly this
direction is complementary to the thrust towards a community-
based system of treatment services.
Finally the Foundation has recently formulated a plan for its
public education activities for the '80's which is characterized
by:
an emphasis on alcohol, tobacco, and cannabis;
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a focus on pre-adolescents, adolescents and young
adults (together with persons who influence young
people, including teachers and parents);
a focus on opinion-makers, gatekeepers, and
influencers in professional and other community
groups;
efforts directed to the mass media, to provide maximum
access to relevant scientific data available from the
Foundation (rather than the development of large paid
media campaigns).
As a government agency established in a Province which has been
governed by a single political party for more than 30 years,
A.R.F. has not been subject to the type of political turbulence
experienced by alcohol and drug programs in some other
jurisdictions. However, as the Government of Ontario has sought
to reduce its deficits and to achieve a balanced budget, the
Foundation has experienced some significant erosion of its
grant, over the past 5 or 6 years. Further, as the Province
faces the prospect of decreased federal transfers to health
care, it is giving increased attention to the cost effectiveness
of all of its health efforts. Clearly "accountability" is
today's password!
Author
Joan A. Marshman
Addiction Research Foundation
Toronto, Canada
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Recent Advances in Opiate
Detoxification: Clonidine
and Lofexidine
Arnold M. Washton and Richard B. Resnick
INTRODUCTION
Recent. studies (Cold et 61.1978; Washton et al. 1980) showing that
the nonopiate antihypertensive agent, clonidine hydrochloride,
suppresses signs and symptoms of opiate withdrawal have suggested
that clonidine and similar drugs might be useful in the clinical
management of opiate detoxification. The fact that clonidine is
not an opiate drug and does not itself produce addiction or euph-
oria suggests some unique and potentially useful applications of
this medication in the treatment of opiate-dependent persons. For
example, clonidine might be used to block the emergence of abstin-
ence symptoms during a gradual methadone detoxification, Clonidine
might also serve as a transitional treatment between opiate depend-
ence and induction onto the long-acting opiate antagonist, naltrex-
one (Resnick et a1. 1979). If withdrawal symptoms were controlled
by clonidine, patients might be able to abruptly discontinue chronic
opiate use and remain abstinent during the minimum 10-day opiate-
free period that is required before starting naltrexone aftercare
treatment. In general, clonidine might increase the chances of
detoxification success and allow patients greater access to naltrex-
one and drug-free modalities.
Since the initial reports of clonidine's withdrawal-suppressing
effects in opiate addicts, a variety of clinical studies have ex-
plored the usefulness of this medication in opiate detoxification,
as reviewed recently by Washton and Resnick (1981). The present
paper will summarize the outpatient studies conducted at New York
Medical College with patients addicted to heroin and/or methadone.
It will also describe our recent studies of lofexidine, an analogue
of clonidine that appears to be a safer and more effective nonopiate
treatment for opiate withdrawal.
CLONIDINE
Our first study (Washton et al. 1980) sought to replicate the single-
dose findings of Cold et al. (1978) in order to gather additional
information on the physiological and subjective effects of clonidine
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in opiate-dependent humans. A single oral dose of 0.2 or 0.3 mg
clonidine was administered to 12 opiate-dependent outpatients exper-
iencing acute withdrawal from heroin and/or methadone. Blood
pressure and ratings for the presence and severity of withdrawal
symptoms were taken immediately before clonidine administration
and at 2 hours postclonidine. The data showed that clonidine
produced a marked and significant reduction in subjective with-
drawal severity. The particular symptoms reduced most effectively
by clonidine were chills, lacrimation, rhinorrhea, yawning, stomach
cramps, sweating, and muscle and joint aches. Marked reductions
in anxiety and restlessness were also reported. Side effects were
dry mouth, drowsiness, and a decrease of 10-15 mm Hg in systolic
and diastolic blood pressure. None of the 12 subjects experienced
euphoria or any other opiate-like effects from clonidine, and none
reported unpleasant side effects.
We subsequently explored clonidine's usefulness as an adjunct to
methadone dose reductions and also as a transitional treatment
during the 10-day period between opiate dependence and naltrexone.
In an initial outpatient trial (Washton and Resnick 1980a) with
20 methadone-dependent volunteers, an attempt was made to determine
whether clonidine could be used to prevent emergence of abstinence
symptoms during the course of gradual methadone dose reductions.
This study addressed the issue of prophylactic blockade of the
abstinence syndrome in contrast to the previous studies that used
clonidine to reduce ongoing withdrawal symptoms. Patients taking
10-50 mg methadone daily were inducted onto clonidine doses of
0.5-0.9 mg per day before initiating methadone dose reductions of
5 or 10 mg per week. All patients had been taking clonidine for at
least 2 weeks before the methadone detoxification was begun. Ten
of the 20 patients (50 percent) reached a zero methadone dose and
remained opiate-free on clonidine for 10 days before starting
naltrexone. Although the patients who successfully completed the
detoxification generally complained of less severe and fewer symp-
toms than the patients who failed, it was evident that clonidine
did not totally prevent the emergence of withdrawal symptoms.
Patients who complained of intense withdrawal discomfort tended
to be those who had been taking clonidine for more than 3 weeks,
suggesting the development of tolerance to clonidine's antiwith-
drawal effects.
In another outpatient trial (Washton et al. 1980) clonidine was
administered to 88 opiate-dependent volunteers following abrupt
discontinuation of methadone or heroin, Forty-three patients had
received methadone 5-40 mg daily (mean 15 mg), and the other 45
patients had been taking illicit methadone or heroin in varying
doses. On day 1, all patients received placebo methadone and
started a self-administered clonidine dose regimen of 0.1 mg qid
with gradual increases as needed over succeeding days. The maximum
daily clonidine dose averaged 0.8 mg (range 0.3-1.2 mg). On day 10,
patients who showed opiate-free urines and denied using any illicit
opiates while on clonidine were given a naloxone challenge of 2.0
mg IV to assess their readiness to begin treatment with naltrexone.
Seventy-two percent of the 43 methadone maintenance patients and
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50 percent of illicit opiate users completed detoxification and
started naltrexone treatment. Those who were on the higher doses
of heroin and/or methadone had the greatest difficulty in completing
detoxification. All patients reported that clonidine reduced, but
did not eliminate, their withdrawal discomfort. Lethargy and insom-
nia were the most frequent and persistent residual complaints. Most
patients experienced some mild dizziness or lightheadedness upon
standing, but these side effects were unacceptably severe in only
six cases. No single clonidine dose regimen was best for all
patients, because sensitivity to clonidine's effects varied widely
among individuals. To achieve effective control of withdrawal
symptoms without untoward side effects, it was necessary to individ-
ualize the clonidine dose regimen according to each patient's blood
pressure and symptomatology.
Rawson et al. (1981) provided additional evidence of clonidine's
effectiveness in outpatient opiate withdrawal and found that the
availability of naltrexone aftercare treatment significantly
increased detoxification success rates. Among patients offered
clonidine as a transitional treatment between methadone and naltrex-
one, 9 of 12 (75 percent) achieved 10 days of opiate abstinence and
started naltrexone, whereas only 3 of 12 (25 percent) in a group
offered clonidine but no naltrexone achieved 10 days abstinence.
The differential efficacy of the clonidine detoxification procedure
between the two groups of subjects did not appear to result from
differences in the degree to symptom relief, but rather from differ-
ent subject attitudes toward their detoxification. Subjects in the
clonidine/naltrexone group perceived the clonidine detoxification
as a transitional treatment with a specific goal. Naltrexone
induction on day 10 postmethadone was perceived as a clear endpoint
to the detoxification. Subjects in this group frequently expressed
the feeling that they had "made it" when they started naltrexone
and many reported feeling relief that once on naltrexone they no
longer had to struggle with the urges and cravings to use opiates.
It appeared that if the clonidine procedure was perceived by subjects
as being for a specific number of days with a clear goal and end-
point such as starting naltrexone, most of them could exert suffi-
cient control to abstain from opiate use for the 10 days of post-
methadone. Subjects in the clonidine-only group did not view the
detoxification process as having a clear endpoint or goal and this
seemed to contribute to their inability to resist opiate cravings.
Although the clinical studies summarized above were encouraging,
none compared clonidine against other detoxification methods. We
recently reported a double-blind outpatient study (Washton and
Resnick 1980b) in which 26 volunteers dependent on methadone (15-30
mg daily) were randomly assigned to a clonidine or methadone detox-
ification procedure. The clonidine procedure (N=13) consisted of
abrupt substitution of clonidine for methadone on day 1 of the study.
The methadone procedure (N=13) consisted of methadone dose reductions
of 1 mg per day until a zero dose was reached. Both procedures
were placebo controlled with daily regimens of active or placebo
clonidine tablets individualized by a physician who was not aware
of the patient's assigned treatment group. No significant difference
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was found between the clonidine and methadone procedures in terms
of the numbers of patients who completed a 10-day opiate-abstinence
period after the last dose of active methadone. Four of 13 subjects
(38 Percent) were successful with clonidine, and 6 of 13 (46 Percent)
were successful with methadone (P<0.05, chi-square test). Major
withdrawal symptoms were nearly identical for both groups and
consisted mainly of lethargy, restlessness, and insomnia. The
clinical course of subjects was distinctly different for the clon-
idine and methadone procedures, making it impossible to maintain
truly double-blind conditions. Subjects taking clonidine reported
sedation, dry mouth, occasional dizziness, and onset of withdrawal
symptoms within the first 2-3 days of the study. By contrast,
subjects taking methadone reported no sedation, dry mouth, or
dizziness, and no major withdrawal symptoms until the final week
of the procedure when methadone doses were approaching zero milli-
grams.
LOFEXIDINE
Clonidine's efficacy in suppressing opiate withdrawal has suggested
that other alpha-2 noradrenergic agonists might also be effective
in opiate withdrawal but without untoward side effects. Lofexidine
is an investigational analogue of clonidine that has been shown to
suppress opiate withdrawal in morphine-dependent rats (Shearman
et al. 1980). Clinical testing in human hypertensive patients
(Wilkin et al. 1981) has suggested that lofexidine's sedative and
hypotensive effects are less potent than those of clonidine.
We have recently completed an open clinical trial of lofexidine
in opiate detoxification (Washton et al. 1981). As in our earlier
studies with clonidine, the clinical test of lofexidine's usefulness
was conducted in an outpatient setting with the measure of detoxi-
fication success defined by induction onto naltrexone. Our subjects
were 15 methadone-dependent male outpatient volunteers who showed
no evidence of medical or psychiatric illness and gave informed
consent to the study which involved an abrupt switch from methadone
to lofexidine. On day 1, subjects received their usual methadone
dose (10-25 mg) and began a self-administered lofexidine dose reg-
imen of 0.1 mg two or three times daily. On day 2, methadone was
abruptly discontinued with subjects receiving a matched placebo
methadone solution and the lofexidine dosage was increased to 0.1
mg four times daily. Subsequently, the lofexidine dose was increased
as needed to no more than 0.4 mg four times daily according to
symptoms and side effects. All subjects were told that the detox-
ification procedure would take 11 days and that naltrexone could be
started on day 11 (10 days postmethadone) provided that they used
no illicit opiates during the study as confirmed by the absence
of a precipitated withdrawal reaction to intravenous naloxone
challenge (2.0 mg) on day 11. Subjects who did use illicit opiates
during the first 10 days postmethadone were allowed to continue on
lofexidine and the naloxone challenge was postponed to the first
opportunity where it posed minimal risk of precipitating a with-
drawal reaction (i.e., to at least 5 days after the last opiate
use) but no later than day 21 of the study. Subjects who passed
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the naloxone challenge and started naltrexone on days 11-21 were
considered successful detoxifications. Those who returned to using
opiates and failed to begin naltrexone by day 21 were considered
unsuccessful.
Successful detoxification and induction onto naltrexone was accomp-
lished with 10 of the 15 subjects. All patients rated lofexidine
as moderately to extremely effective in reducing most of the
commonly experienced withdrawal symptoms: insomnia, lethargy, and
muscle/bone pain were the most frequent residual complaints. None
of the 10 subjects reported unacceptable withdrawal symptoms while
taking lofexidine. Those who failed to complete the detoxification
procedure cited opiate craving rather than withdrawal discomfort
as the major reason for returning to opiate use. None of the sub-
jects reported oversedation, dizziness, or lightheadedness from
lofexidine, despite rapid increases in the dose to as much as 1.6
mg per day within the first 5 days. The maximum daily lofexidine
dose ranged from 0.6 mg to 1.6 mg across the 10 subjects with an
average of 1.2 mg. There was no significant lowering of blood
pressure even at the maximum lofexidine dose (mean prelofexidine
BP; 115/74 mm Hg: mean BP at maximum lofexidine dose; 115/76 mm
Hg). Dry mouth and mild drowsiness were the most commonly reported
side effects. Reductions in the daily lofexidine dose by 0.2 to
0.6 mg per day at the end of the study produced no symptanatic
complaints or significant changes in blood pressure.
DISCUSSION
While our studies of clonidine suggest the usefulness of this
nonopiate agent in outpatient opiate detoxification, it has also
become clear that clonidine is not without clinical risks and
potential drawbacks and thus is not an ideal agent for treating
withdrawal symptoms. Some patients are extremely sensitive to
clonidine's hypotensive and sedative effects and cannot tolerate
the doses needed to relieve withdrawal discomfort. This has led
patients to discontinue their detoxification before canpletion
and has seriously restricted the usefulness of clonidine in out-
patient withdrawal to patients whose level of opiate dependence
is below 30 mg/day of methadone. Additionally, the close monitoring
of patients that is required because of potentially trouble-
side effects during clonidine treatment can be inordinately time-
consuming and inconvenient for both patient and physician. These
factors tend to decrease the efficacy and acceptability of clonidine
detoxification especially in an outpatient setting where side
effects can interfere with the patient's daily functioning.
Cur results with lofexidine suggest that this medication is compar-
able to clonidine in terms of antiwithdrawal efficacy but without
the adverse sedative and hypotensive side effects that limit cloni-
dine's usefulness. It appears, therefore, that lofexidine might
be a more clinically useful and viable treatment than clonidine
in opiate detoxification, especially with ambulatory outpatients
where safety and ability to maintain normal functioning are impor-
tant concerns. Additionally, because lofexidine can be administered
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in higher doses than clonidine without unacceptable side effects,
it might be possible to detoxify outpatients from higher levels of
opiate dependence than has been the case with clonidine.
Nonopiate treatment with clonidine or lofexidine may be specifically
indicated and preferable to detoxification using methadone in some
cases. For example, these agents may be the treatment of choice
for addicts with low levels of opiate dependence whose addiction
might be increased by the use of methadone. Clonidine or lofexidine
may be especially useful in treating iatrogenic addiction to pre-
scription opiates and treating addicted physicians or others having
no prior involvement with illicit opiates where exposure to methadone
or methadone treatment facilities might be undesirable or contra-
indicated. In general, clonidine and lofexidine may provide
potentially useful and desirable treatment options whenever detox-
ification using methadone is inappropriate, unsuccessful, or simply
unavailable.
Clonidine and lofexidine seem best suited for clinical use as tran-
sitional treatments between opiate dependence and naltrexone.
Nonopiate medications with significant withdrawal-suppressing
effects can provide symptomatic relief following rapid discontinu-
ation of opiates without postponing the introduction of naltrexone
at the earliest possible time to foster continued abstinence. The
treatment sequence of clonidine or lofexidine followed as soon as
possible by naltrexone induction is highly attractive to outpatients
because it offers the opportunity for rapid detoxification with
minimal discomfort and a clearly defined endpoint to the detoxi-
fication process.
The role of detoxification treatment alone as a therapeutic modality
has long been overemphasized in addiction treatment. Attempts to
detoxify large numbers of opiate addicts using clonidine or lofex-
idine, based on expectations that these patients will remain absti-
nent without some form of intensive aftercare treatment, are highly
unrealistic. In most cases, readdiction will rapidly ensue. Addicts
are extremely vulnerable to relapse, particularly during the first
week or two following cessation of opiate use. Although clonidine
and lofexidine might be extremely useful in helping addicts achieve
initial abstinence, a more comprehensive multimodality aftercare
treatment approach including naltrexone and psychotherapy is usually
necessary in enabling detoxified addicts to maintain an abstinent
state (Resnick et al. 1981).
REFERENCES
Gold, M.S., Redmond, D.E., and Kleber, H.D. Clonidine blocks acute
opiate-withdrawal symptoms. Lancet, 1:599-801, 1978.
Rawson, R.A., Washton, A.M., Resnick, R.B., and Tennant, F.S,
Clonidine hydrochloride detoxification from methadone treatment:
The value of naltrexone aftercare. In Harris, L.S., ed, Problems
of Drug Dependence, 1980. National Institute on Drug Abuse Research
Monograph 34. DHHS Pub. No. (ADM)81-1058. Washington, D.C.: Supt.
of Docs., U.S. Govt. Print. Off., 1981. pp. 101-108.
49
Resnick, R.B., Schuyten-Resnick, E., Washton, A.M. Narcotic
antagonists in the treatment of opioid dependence: Review and
commentary. Comp Psychiatry, 20:116-125, 1979.
Resnick, R.B., Washton, A.M., Stone-Washton, N., and Rawson, R.A.
Psychotherapy and naltrexone in opioid dependence. In Harris, L.S.,
ed. Problems of Drug Dependence, 1980. National Institute on Drug
Abuse Research Monograph 34. DHHS Pub. No. (ADM)81-1058. Washing-
ton, D.C.: Supt. of Docs., U.S. Govt. Print. Off., 1981. pp. 109-
115.
Shearman, G.T., Lal, H., and Ursillo, R.C. Effectiveness of lofex-
idine in blocking morphine-withdrawal signs in the rat. Pharmacol
Biochem Behav, 12:573-575, 1980.
Washton, A.M., and Resnick, R.B. Clonidine for opiate detoxifica-
tion: Outpatient clinical trials. Am J Psychiatry, 137:1121-1122,
198Oa.
Washton, A.M., and Resnick, R.B. Clonidine versus methadone for
opiate detoxification, Lancet, 2:1297, 1980b.
Review and appraisal of clinical findings. Pharmacotherapy, 1(2):
Washton, A.M., and Resnick, R.B. Clonidine in opiate withdrawal:
140-146, 1981.
Washton, A.M., Resnick, R.B., and LaPlaca, R. Clonidine hydro-
chloride: A nonopiate treatment for opiate withdrawal. Psycho-
pharm Bull, 2:50-52, 1980.
Washton, A.M., Resnick, R.B., Perzel, J.F., and Garwood, J. Lofex-
idine, a clonidine analogue effective in opiate withdrawal. Lancet
1:991-992, 1981.
Washton, A.M., Resnick, R.B. and Rawson, R.A. Clonidine for out-
patient opiate detoxification. Lancet, 1:1078-1079, 1980.
Wilkins, L.H., Winternitz, S.R., Oparil, S., Smith, L.R., and Dustan,
H.P. Jofexidine and clonidine in moderate essential hypertension.
Clin Pharmacol Ther, 20(6):752-757, 1981.
ACKNOWLEDGEMENTS
The studies at New York Medical College were conducted within
a treatment program sponsored by the New York State Office of
Alcholism and Substance Abuse Services. Research funds and
supplies of lofexidine were provided by Merrell-Dow
Pharmaceuticals, Inc.
AUTHORS
Arnold M. Washton, Ph.D., end Richard B. Resnick, M.D.,
New York Medical College, Department of Psychiatry, Division of
Drug Abuse Research and Treatmant, Five East l02nd Street,
New York, New York 10029
50
Methadone Maintenance:
An Update
Edward C. Senay
It is only in the last two decades that we have acquired an exten-
sive experience with the use of legal opioids in the treatment of
opioid dependence. While our experience is modem the concept of
providing legal opioids to the opioid dependent is distinctly not
modem. In history the earliest mention of such a concept appears
to be in Siam in the 1850’s when the King of Siam decreed that
the state would give opium to persons addicted to opium. The
first direct American experience with the concept of narcotic
substitution was at the turn of the century when we took over the
Philippines and inherited a state-administered narcotic distribu-
tion system.
For a time we utilized morphine for maintenance in some of our
major cities but in the 1920’s court interpretations ended our
brief experience with this notion. In the 1950’s a joint commit-
tee of the New York State Medical Society and the American Bar
Association called for exploration of the concept and, as every-
one in this room knows, Drs. Dole and Nyswander carried out a
series of studies on the potential of methadone. These studies
formed the base for an enormous expansion of this treatment in
America in the last two decades. In the brief time available, I
want to comment on our experience with methadone treatment.
Drs. Dole and Nyswander reported on the success of their experi-
ments in the middle 1960’s and some one hundred and fifteen
studies later one can say that their findings have held up, per-
haps not to the same degree of initial success because their
studies quite rightly excluded the more complicated cases which
had to be treated when the method gained approval for widespread
use.
To say that their findings have held up is not a casual statement.
Methadone maintenance has been evaluated more than any other
human service modality with the possible exception of psycho-
therapy. The public is not aware that this is the case, and there
is virtually no public recognition that the evaluations of
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methadone maintenance are almost uniformly favorable. Surpris-
ingly, many workers in the field of substance abuse share with the
public lack of awareness of the extent of the outcome research
which has been carried out on methadone and many also appear to be
unaware of the favorable findings of this research.
It is important to stress that the studies which have been carried
out have encompassed years of observation, thousands of patients,
and that independent groups have been involved. The General Ac-
counting Office of Congress (GAO), for example, reviewed the re-
views of the effectiveness of methadone maintenance and reported
to the U.S. Congress that it was an effective treatment modality.
But, persistently, a common critique of the outcome research on
methadone maintenance repeats what Dr. William Martin said at the
Second National Methadone Conference in 1969 to the effect that
we don’t have double-blind studies which would permit us to evalu-
ate this modality scientifically. This critique is no longer
valid because we do have one double-blind study with random as-
signment reported in the Lancet in 1979. Newman and Whitehead
recruited 100 heroin addicts in Hong Kong for a double-blind study
which lasted for 36 weeks. The study actually was biased against
the hypothesis that methadone is superior to placebo because both
groups received methadone in the induction phase of the study.
The experimental group was maintained for the 36 weeks of the
study while the control group was withdrawn from the daily induc-
tion dose of 60 mg. of methadone during the first 60 days. This
study was, in effect, a study of methadone maintenance versus
methadone detoxification. Large differences were observed be-
tween experimental and control groups, the differences being fa-
vorable for methadone maintenance.
In the face of data accumulation almost unparalleled in history,
complete with one double-blind study with satisfactory methodology,
the message that methadone works hasn’t gotten through. How can
we account for the public and, in large measure, those who work
in the field being unaware of or unaffected by the data? Part of
the reason stems, no doubt, from the factionalism so prominent in
the field of substance abuse. For example, workers in the alcohol
treatment community tend to be biased against the basic concept of
legal substitution. “It’s like giving an alcoholic bourbon”.
The Therapeutic Community groups have long been hostile to the
notion of substitute therapy and a host of workers, unfamiliar
with the clinical realities of opioid dependence, find the substi-
tution concept difficult.
Part of the reason also appears to be the cautious way in which
evaluators worded their findings. If one reviews the evaluations,
one does not find simple statements to the effect that the data
indicates that the treatment works. Why evaluators have been so
hesitant is a matter of conjecture; a good guess is that the tur-
bulence and politicalization of the field gave them pause.
Some may be ambivalent about methadone substitution because we
have not carried out replicated, and I underline replicated, double-
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blind studies of the effectiveness of maintenance treatment.
Given the current climate of anti-intellectualism and public sus-
picion of research it is doubtful that further double-blind stud-
ies can be carried out. In the event that they are, let us hope
that we institute control for factors such as degree of dependence.
We have many studies now indicating that applicants for methadone
treatment vary from no dependence on opioids to severe dependence
on opioids. Studies by Blachly, Resnick, Goldstein, O’Brien and
Senay indicate that this is the case. Improving diagnosis along
the lines suggested by Dr. Sellers’ work at the Addiction Research
Foundation here in Toronto is urgently needed. If we could mea-
sure psychological dependence it would be desirable to control for
level of psychological dependence occurring at any given level of
biologic dependence. Control for these factors would delineate
more precisely what methadone contributes.
Recent work by the Philadelphia group suggests that psychiatric
status is another factor which contributes substantially to vari-
ance. The most serious methodologic obstacle in studying legal
maintenance relates to the fact that we are studying a problem
that tends to take the form of a career, lasting at least ten and,
frequently, many more years. Obviously, we need to design studies
which cover long periods of time.
Another factor possibly explaining the discrepancy between data
and awareness is the large impact of a few poorly administered
programs; the bad press associated with these programs has im-
peded progress in recognizing the usefulness of methadone and has
in some communities, in Oklahoma and California for example, led
to abandonment of this modality.
The verdict of clinicians is almost uniformly favorable; that is,
those most in touch with the day-to-day realities of treatment of
opioid dependence with methadone are impressed with what it has
to offer. Part of the problem with public recognition of this
treatment stems from the fact that only a relative handful of
professionals have experience with methadone maintenance and until
recently their interest had little visibility in so-called “main
stream medicine” and no visibility in the public sector. Since
their interests were and are professional, they simply didn’t write
for the public. Those writing for the public tended to be jour-
nalists whose tenure in the field tended to be brief. I’m think-
ing of people like Edward Jay Epstein whose exposure to the field
was at most one to two years. Epstein wrote a review of methadone
and damned it for its purportedly evil political utilization.
His article, in the journal Public Interest, was widely read
and had an impact on the attitudes important people in
government. The Public Interest refused to print my letter
reviewing the many errors of omission and commission in the
Epstein paper. So we haven’t done a good job with public
relations.
A recent NIDA Treatment Research Report presents evaluation re-
sults from therapeutic community as well as methadone maintenance
and drug free treatment. We, who work in the field, need to
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review and to know these data. For too many years people who
work in substance abuse have been either blind proponents of one
modality or apologetic about what we do. If the people in the
field won’t read the outcome studies they should not be surprised
that the public has attitudes based on a lack of awareness of the
data. Again, I would call your attention to the number of sub-
jects involved in these studies. It is in the tens of thousands.
Although the study does not display Sells latest writing, the time
periods included in these most recent outcome studies are now
close to two to three years and the results remain favorable.
A causal relationship between treatment and the favorable out-
comes observed is, in my opinion, is not definitively established
by these studies either individually or in the aggregate; matura-
tion, regression toward the mean, reduction of symptoms following
the crises in which patients usually seek treatment, lack of rep-
lication, random assignment and lack of adequate control groups,
the use of remaining samples and other problems with methodology
mean that we can only say that treatment is associated with de-
sirable outcomes and probably produces the results we see. The
NIDA monograph from which these slides were made does not mention
other large scale studies of outcome such as those published by
Newman et al. in New York, Goldstein et al. in Palo Alto and
Senay et al. in Chicago. These three reports document additional
thousands of patients studied for extended periods of time and in
concert with the studies mentioned in the NIDA monograph demon-
strate that desirable changes are associated with treatment.
In passing one should also note that, although this is less true
now than it was in 1970, methadone maintenance is a treatment
which is attractive to consumers. Over the past decade and one
half, addicts numbering in the 100,000’s have utilized this treat-
ment . This is no small point. Ideally one would wish that all
these addicts could have been persuaded to accept treatment with
narcotic blocking agents such as cyclazocine or naltrexone. But
the fact is that the consumers of addiction services will not
accept such treatment in numbers which are significant from a
public health point of view.
Length of stay in maintenance has declined sharply in the past de-
cade . In 1970 more than one half stayed in treatment over a year
but in 1980 the figure was close to 25%. I believe that there
are at least three factors involved in the change of consumer at-
titudes. One, the most powerful in its impact, is the change in
the nature of our drug problems; to illustrate, in 1968, in Illi-
nois, 80% of those seeking maintenance treatment used heroin as a
sole drug or the main drug of abuse. That is, these patients used
heroin with occasional use of another drug such as marijuana or
alcohol: In 1978, in Chicago, this figure was down to 18%. So the
consumer has changing needs. The second factor relates to our poor
public relations record. Again many, perhaps most, of the workers
in the field have ambivalent attitudes at best toward opioid sub-
stitution therapy. Another factor was the impact of regulation
on progress. The adversarial approach used by regulatory agencies
54
in the United States helped to worsen the natural divisions among
workers in the field and generated the kind of low morale which
was reflected in Dr. Dole’s paper on the subject in the Journal
of the American Medical Association.
With the sharp reduction in resources experienced in the last few
years, the question of long term goals of maintenance has assumed
renewed importance. Currently we see administrators asking if we
can’t get successful patients on chronic maintenance detoxified
so we can use their slots to treat new patients. But our
collective experience is not encouraging in this regard. With-
drawal from legitimate narcotics is as problem-ridden as with-
drawal from illicit narcotics and the logic of exchanging a
proven success for an uncertain success is shaky. Ideally one
would wish for a drug free state but for many thousands of
addicts that is, as yet, an unreachable goal. Some can reach
this goal and we should continue to try, but we know the odds
are against successful detoxification of successful chronic
methadone maintenance patients.
The safety of chronic administration of methadone under medical
auspices is impressive. In some instances, patients have been
taking daily methadone for a decade or more and are suffering no
medical consequences. Indeed the clinical impression one has is
that the health of addicts improves dramatically when addicts use
the treatment to stop intravenous drug use. Hepatitis, endocar-
ditis, systemic infection and soft tissue infections certainly
seem to be greatly diminished during chronic methadone, as would
be predicted from cessation of the use of unsterile needles.
A number of recent large-scale studies suggest that treatment for
drug and alcohol problems greatly reduces further utilization of
the standard medical care system in the years following substance
abuse treatment. Roughly speaking, a dollar spent on treatment
for substance abuse appears to prevent two to three dollars of
future expenditures on visits to hospitals and outpatient offices
and clinics. In Illinois, a current study is under way attempting
to document further this relationship. Again workers in our field
ought to know and should be able to acquaint legislators and com-
munity leaders with the relevant data.
The dilemma of the pregnant active opioid addict seems to have
been at least partially solved by the utilization of low dose
methadone maintenance throughout the pregnancy and delivery.
Prior to the past decade clinicians attempted to withdraw pregnant
addicts and did not realize that the human fetus frequently will
die in narcotic withdrawal. This is in contrast to the adult ad-
dict who dies so rarely in narcotic withdrawal that there is real
question if some complicating factor must not be present to pro-
duce death. Early attempts at high dose maintenance of the mother
were associated with severe post-natal problems for the neonates.
Finally, low dose maintenance evolved and appears to be the best
solution to a difficult problem. Use of any opioid, licit or
illicit, may be associated with an increase in the occurrence of
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the Sudden Infant Death Syndrome (S.I.D.S.). The data, at this
time, is suggestive but not conclusive of such a relationship.
The attribution of causality is usually not possible because of
the use of multiple substances by most opioid-dependent pregnant
women.
When the decade started there was serious doubt by many that
there was an association between heroin dependence and crime.
There was also little data concerning the effects, if any, of
treatment on criminal behavior. The data base bearing on this
question has grown enormously. The preponderance of evidence
now strongly supports the notion that active phases of heroin
dependence are associated with a substantial increase in the
crime rate and that treatment, including but not limited to metha-
done maintenance, is associated with a substantial reduction in
the rate of commission of crime. The relationship appears to
hold in different ethnic groups in the United States. On this
ground alone Drs. Dole and Nyswander deserve our highest awards.
The question of high-dose versus low-dose maintenance was raised
by a number of studies in the early seventies with the general
conclusion that retention rates and outcome in treatment were as
favorable at low doses as they were at high doses. I don’t re-
gard the issue of dose as closed, however, because of my belief
that the opioid-dependent population of 1982 is bi-modal with
respect to degree of dependence. In my opinion, there are large
numbers of addicts probably not needing strong opioid agonists
such as methadone. It is time that we carried out maintenance
studies comparing weak with strong opioid agonists under double-
blind conditions.
The question of staffing of methadone maintenance programs is
still not settled. Although the para-professional, or community
worker, has succeeded in contributing to progress by creating for
the consumer a sense of familiarity, commonality of language and
custom and a role model, the training of such counselors has not
provided them with the skills they need to compete with standard
professional groups. Licensure and certification for this group
of workers, however distasteful, is necessary for their survival.
It is surprising that, in 1982, we have no substantial body of
data which would permit us to judge what contributions various
staff members make, if any. For some patients the mere provision
of methadone appears to be clinically potent while for other pa-
tients, many other patients in my view, the provision of metha-
done alone has little or no payoff. We tried to study this in
Illinois but resources did not permit us to study the matter
properly. Obviously it is a matter, in these times of diminished
funding, that we should examine in rigorous clinical studies.
The idea that methadone would work by exposing people to treatment
has not been resolved satisfactorily. We don’t know why we get
the results we get, and it is obviously something we need to exam-
ine critically in the future.
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In putting this program together we agreed to review the recent
advances in the particular area each of us was to review. In pre-
paring this paper I asked myself repeatedly the question, What
have been the advances in methadone maintenance over the past fif-
teen years? In thinking about these years, the events that came
to memory most immediately and forcefully are those in which we
reacted to attack from the media, from auditors, regulators, re-
viewers, inspectors, commissioners and interrogators in a line
which would have given Kafka material for two or three more ca-
reers. There was threat of assult from ideologues of every per-
suasion ranging from the National Caucus of Labor Committees
(members of this group threatened my life repeatedly) to the mind-
less libertarians who appear to want free access for all people,
including children, to any and all psychoactive substances. The
basis of the fundamental assault was that they viewed us not as
physicians working in communities with few resources, with
difficult clinical populations, often under dangerous conditions,
but rather as adversaries, often viewed as members of the “Drug
Abuse Industrial Complex” with the implication of a sybaritic,
criminal lifestyle based on stealing from the government. NIDA, to
its everlasting credit, did see to it that we were evaluated and
the evaluations speak for themselves. So, although we’ve spent
most of our energy on defense we have made one advance of great
importance. We’ve shown that treatment is associated with
desirable outcomes and the burden is now on those who say that
it isn’t.
We have not improved narcotic substitution therapy as we might
have if we had lived in less troubled times. The failure to get
LAAM through the bureaucracy is distressing. I regard LAAM as a
form of methadone maintenance and know this drug in clinical set-
tings. LAAM clinics especially in cities like Chicago where pub-
lic transportation for our patients is expensive and extremely
time consuming would represent a major advance which would permit
us to improve our services and to focus more energy on new and/or
difficult cases, I hope the CPDD will interest itself most vigor-
ously in the LAAM matter.
At the beginning of the decade, I hoped that we would come to re-
quire licensing and certification for physicians working in metha-
done programs. Methadone prescribing for maintenance and detoxi-
fication is not within the competence of every physician. Sub-
stance abuse is a specialty -- not a specialty with highly develop-
ed techniques like cardiac surgery or burn care but it is nonethe-
less a specialty. We have paid a high price by not recognizing
this fact. We could improve the entire field by requiring train-
ing for physicians and all other workers before they work in
methadone programs.
No review of narcotic substitution therapy would be complete with-
out examining the effects of sponsorship; that is, who is adminis-
tering the substitute narcotic and for what purpose. Drs. Newman
and Dole cautioned us early in our national experience of the dan-
gers of merging medical treatment with the criminal justice system
Their concerns were echoed by members of President Carter’s
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Commission on Mental Health who called our attention to the
“insidious” possibilities in such a relationship. If a court
orders treatment and the treatment of choice on the part of the
patient and physician is methadone, has an “insidious” merger
occurred? What is our experience in this regard? First we should
note that in most of the major cities of America substantial num-
bers of applicants for any treatment of narcotic dependence have
an active relationship with a criminal justice system. In my
experience an “insidious” merger has not occurred. Treatment
diversion programs have served well the individual, families and
communities involved. Court decisions influenced by communica-
tion from workers in treatment programs like myself have been a
near daily experience of mine for over a decade. This experience
does not lead me to want to change the relationship or to fear
that somehow, because in the abstract it could be bad, we
should avoid the relationship. Given the crowded situation in the
nation’s jails and prisons I predict a large expansion of diver-
sion programs in the 1980’s and believe that it would be criminal
not to include opioid substitution therapy as one of the possi-
bilities for diversion.
In 1982, as never before, the multi-modality concept developed by
Jaffe is most relevant. Methadone, for maximum public health
effectiveness should be part of a treatment system and it should
not stand alone. The continued use of alcohol and opioids is now
the rule, not an exception. The changes in the nature of our sub-
stance abuse problem argue strongly for this position. Chicago,
for example, has changed dramatically since 1967; the abuse of
weak agonists such as pentazocine has come to occupy a large part
of the sector of clinical demand. Methadone is, therefore, not
as central as it once was in our clinical efforts. The drug ex-
perimentation and use patterns identified by Dr. Lloyd Johnston
in the nation’s high schools suggest strongly that we will need
multi-modality programming for the foreseeable future. Dr. John-
ston’s data indicates that the use of multiple substances appears
to be the dominant mode among those who will come to our
attention in the future.
We have made some progress on the problem of detoxification from
chronic methadone maintenance in that we have learned to go slower.
In some instances, we can get patients drug free after some years
of successful maintenance but these patients, as I noted above,
are more of an exception than a rule. When this decade started,
I had high hopes that we would find a path back to drug free
living but this clinical dream has not been realized.
In summary, then, we have not changed clinical use of methadone
significantly in the past decade but we have proven that its use
is associated with desirable outcomes. I think that we know more
now about what needs to be studied and we know that we have to im-
prove training and staffing. Opioid substitution therapy has con-
tributed substantially to public welfare and, in the future, we
should be able to increase its contribution based on our experience
of the last two decades.
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SUMMARY
An opportunity to receive a six-month course of professional
psychotherapy in addition to paraprofessional counseling was
offered to opiate addicts who were beginning a new treatment
episode on a methadone maintenance program. The treatments
offered were drug counseling alone (DC), counseling plus
supportive-expressive psychotherapy (SE), or counseling plus
cognitive-behavioral psychotherapy (CR). Sixty percent of
patients meeting the study criteria expressed an interest in
the psychotherapy program and 60% of these actually became
engaged. One hundred and ten subjects completed the study
intake procedure, were randomly assigned to one of the three
treatment conditions and kept three or more appointments within
the first six weeks of the project.
A variety of outcome measures showed that patients in all three
treatment groups improved. Patients receiving the additional
psychotherapies improved in more areas and to a greater degree
than those who received counseling alone. The specific
improvements seen appear to be related to the focus of the
therapy used. Patients with antisocial personality disorder,
as defined by Research Diagnostic Criteria, did not benefit
significantly from therapy, but those with depression did.
Patients with high levels of psychiatric symptoms made many
significant gains if they received additional therapy, but
improved only in drug use if they received counseling alone.
Patients in all three treatment groups having low levels of
psychiatric symptoms improved significantly in many areas.
We conclude that more than a third of opiate addicts in our
treatment program are interested in psychotherapy and many of
these can benefit from it. Certain administrative procedures
appear necessary to maximize the chances that psychotherapy can
be used effectively with drug addicted patients.
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INTRODUCTION
There is sane evidence to suggest that psychotherapy may be
both practical and helpful with addicts if given under certain
conditions. The development of methadone maintenance treatment
programs has provided a means to reduce much of the intense,
impulsive and daily search for illicit substances that is
observed in private practice. Stabilization with methadone has
permitted the development of therapeutic, long term relation-
ships and this, in theory at least, methadone programs might
provide a medium in which psychotherapy could be employed
effectively. In addition, the most recent study on psycho-
pathology in methadone - maintained patients showed that
depression and not sociopathy is the most commonly diagnosed
psychiatric disorder, though sociopathy is certainly well
represented (Rounsaville et al. 1982). Further, about half of
those patients with a diagnosis of sociopathy also have other
psychiatric problems. Thus, there is reason to believe that
psychotherapy may be capable of providing benefits to addicts,
especially if it is delivered in a methadone treatment program.
Background Work
No published studies on the effectiveness of psychotherapy with
this population appear to have been done prior to 1970. The
one exception was the early work of Nyswander et al. (1958)
which was completed before the development of methadone
treatment. The overall conclusion reached from a review of the
few studies done is that there is evidence to indicate that
psychotherapy can be helpful for opiate-dependent patients.
This type of review and conclusion is similar to that reached
by Luborsky et al. and others in their overviews of many
diverse psychotherapy studies of treatment efficacy for
psychiatric patients in general (Luborsky et al. 1975; Smith et
al. 1980; Andrews and Harvey 1981). These reviews found that
65 percent of the patients in the psychotherapy outcome studies
showed a treatment effect.
PFESENT WORK: THE PENN-VA PSYCHOTHERAPY STUDY
This paper reports the results of a controlled study done to
test whether professional psychotherapy can provide additional
benefits when combined with standard drug counseling services
in a methadone treatment program. The study was done in the
methadone treatment unit of the Philadelphia VA Medical Center.
This treatment unit is one of eight methadone programs in the
Philadelphia area and has an active census of about 350
patients. It is a full service program which is mandated to
treat all veterans who apply. The program's administration has
always conceived of drug dependence as being related to life
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events such as social or psychiatric problems. Therefore,
services provided include, where appropriate, drug and social
work counseling, vocational rehabilitation, and medical
consultation. Psychotropic medications are also used along
with methadone and drug counseling to treat psychiatric
problems that accompany the addiction.
Administrative Procedures
Prior to beginning the study we gave considerable thought to
the administrative procedures that might be used in a psycho-
therapy program with this special population. We had completed
a previous study of family therapy with addicts in 1976 and
that experience was of considerable help because we learned
that there are special conditions under which therapy has the
best chance to work (Woody et al. 1981). Based on this
experience we expected three problems to occur: 1) missed
appointments by patients; 2) competition between counselors and
therapists; and 3) loss of morale by therapists in response to
the nature of the addicts' problems.
We implemented a series of procedures from the start of the
study, in a largely successful attempt to combat these
anticipated problems. These are described in detail elsewhere,
as are the treatments used (Woody et al. 1983).
Subjects and Methods of Recruitment
Patients selected were all males, between 18 and 55 years of
age, were nonpsychotic, did not have a persistent or clinically
significant organic brain syndrome, and met FDA requirements
for methadone maintenance treatment. They had teen on methadone
for at least two weeks but not more than six months during their
current treatment episode and were screened to exclude those who
appeared to have serious medical, legal, or personal problems
that would require their moving from the Philadelphia area
within one year.
Design - Patients were randomly assigned to three treatment
conditions upon completing intake: Drug Counseling alone (DC),
Supportive-Expressive psychotherapy plus counseling (SE), and
Cognitive-Behavioral psychotherapy plus counseling (CB).
Patients who completed the intake procedure were required to
keep three appointments with their counselor and therapist in
the first six weelks (total of six appointments), or with their
counselor if they were assigned to DC alone (total of three
appointments). If they failed to keep these three appointments,
they were considered nonengaged and dropped from the study.
About 80 percent of the patients who completed intake kept
these initial appointments.
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Measures - A schedule of a sample of the measures used is given
in table 1.
Another highly objective set of measures were the records of
drugs used by patients during the six-mnth study period. The
drugs of particular interest were methadone prescribed for
maintenance treatment; ancillary psychotropic medicines
prescribed for treatment of psychiatric symptoms; and urine
test results for illicit drugs.
RESULTS
(1) Interest and Participation of Patients
It is a common opinion of booth professionals and non-
professionals that drug-addicted patients are not interested in
psychotherapy. Our results show this is not so. Most patients
who fit the intake criteria were asked if they wished to
participate. Approximately 60 percent of the patients Who were
asked said they were interested in the project, and about 60
percent of these completed the intake procedure plus the three
initial appointments. Patients who were interested appeared to
be no different from those who declined. Some who declined
appeared to do so out of practical considerations such as
extended job hours. Thus, while participation was by no means
universal, there was a substantial number of patients who
demonstrated interest in the psychotherapy as an addition to
their drug counseling:
(2) Benefits Achieved by the Patients
The data to be presented in this section represent the seven
month ASI evaluations, the psychological test results, and the
methadone doses, ancillary psychotropic medications prescribed,
and urine test results for opiates and other abused drugs.
Specifically, data are presented for all patients in each group
who completed their intake evaluation plus the initial three
appointments. Composite scores and single items from the ASI
as well as psychological test scores for each treatment group
can be seen in table 2.
The clear overall result was that patients in all three groups
improved in many outcome measures, including lessened drug use,
crime days, illegal income, and improved psychological function.
The data also indicate that patients who received psychotherapy
in addition to drug counseling made more and larger gains than
those who received drug counseling alone. The SE group showed
twelve, significant changes; the CB group slowed nine, and the DC
group showed seven significant changes from intake to seven-
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month follow-up. The SE patients' gains were especially
prominent in the areas of psychiatric symptoms and employment.
All patients improved significantly in the drug use factor,
with DC and SE patients improving more than CB patients.
Some very significant group differences are also seen when one
compares the medications used by patients in the three treatment
groups. There are significant differences in the average
methadone dose required for the three groups. The average dose
for DC patients increased significantly (p<.01) up to week
eight where it leveled off at about 43 mg/day, which is approxi-
mately the average dose used in the clinic. CB patients doses
also rose and leveled off but then gradually but significantly
(p<.01) decreased. SE patients' doses were approximately level
for about 15 weeks and than decreased. The mean methadone dose
prescribed over the course of the study was significantly higher
for the DC group than for the two therapy groups, which did not
differ from each other.
It is important to mention that decisions for methadone dose
changes were not made by the therapists. Patients usually
initiated the discussion about the question of a medication
change and the counselor formed an opinion. The situation was
then presented to a clinic physician if the counselor felt that
a change was necessary. The physician sometimes met with the
counselor and patient and other times acted on the counselor's
recommendation without seeing the patient. All these procedures
are standard clinic practice and were not initiated simply for
the study. Five physicians were working in the clinic during
the study and only one of these physicians was a therapist.
This plysician saw eight therapy patients, and decisions about
medication changes for his patients were made by one of the
other M.D.'s.
The mean percentage of patients prescribed an ancillary psycho-
tropic medication was significantly higher in the DC group
(F=52.31, p<.01) than the psychotherapy groups which did not
differ from each other (p>.10). Further, there was a
significant increase in the proportion of DC subjects who were
prescribed ancilliary medication (p<.01), while the two therapy
groups showed significant decreases (p<.01) over the course of
the study.
One to three urines were collected weekly for each patient on
days that were chosen at random. All groups showed a
significant decrease in positive urines over the course of the
study (F=8.41, p<.05) but there were no differences among the
three groups (p>.10). There was significantly more variability
in the urine test results for the DC group than for either of
the therapy groups. We also examined opiate-positive
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urines separately from any other illicit substances. Again all
the groups showed a significant decrease over the course of
the study (F=11.81, p<.01).
patients receiving the additional psychotherapy showed a
However, in this analysis the
significantly less use of opiates than the patients Who received
counseling alone (F= p<.05).
The last analyses presented hare were done to see if there were
subgroups of patients who responded differentially to therapy
or to counseling. These analyses are seen in table 3 which
shows results of treatment outcome in therapy or counseling for
patients in each treatment group with either high or low levels
of psychiatric symptoms, as measured at study intake. The upper
and lower thirds of the composite scores were used to produce
this table, with the middle group (mid-severity patients) being
excluded.
As seen, low-severity patients achieved many significant gains
under each of the three treatment conditions. High-severity
patients assigned to the additional therapy groups showed many
significant improvements, but those high-severity patients who
received only counseling showed progress only in reducing their
drug use. These results suggest that the supplemental psycho-
therapies made a significant difference in outcome for the high
severity patients and produced a level of improvement that did
not occur if they received drug counseling alone.
Finally, we analyzed the data to see if psychiatric diagnosis
was a predictor of outcome. To accomplish this end we looked
at treatment outcome in patients who received therapy Who had
RDC diagnoses of opiate abuse only, those who had opiate abuse
and depression, and those who had only opiate abuse and
antisocial personality disorder. Both therapy groups were
combined in this analysis in order to achieve a sufficient
number of subjects in each category.
The largest therapy effect was observed in those patients with
depression and there was no significant effect in patients with
only antisocial personality disorder except that drug use was
reduced. These findings are supportive of the idea that
psychotherapy is not helpful for people with sociopathy.
Preliminary analyses of outcome according to individual
therapists or counselors show that there are significant
differences in the treatment effect achieved by specific
individuals. Several therapists produced much better results
than others, and the same was true for counselors.
64
Comments
It is necessary to comment on a limitation in this project,
which is the unbalanced design. Patients treated in the
therapy groups saw a helping person (therapist or counselor),
an average of 23 times whereas those in the DC alone group saw
their counselors an average of 17 times. Thus, the patients in
the therapy groups spent about 35 percent more time with a
helping person than the IX alone patients. This design was
deliberate since our aim was to see if the addition of
professional-therapy to counseling services would provide extra
benefits. This question was the major practical issue addressed
by the project. We never considered it reasonable that
therapists could be used to replace counselors. However, we do
think it is practical and advantageous for psychotherapy to
supplement the important role of counselors with certain
patients. We are also interested in the question of total time
spent with a helping person vs outcome and have begun to study
this issue.
We find it interesting to speculate about why the psychotherapy
provided the ingredients necessary to permit a reduction in
drug use without the necessity to elevate the methadone. One
central factor in this regard was the development of a
supportive relationship between the patient and the therapist.
Some authors in the field have theorized that drug dependence
is a substitute for certain aspects of important personal
relationships (Fenichel 1945) such as in the case of an
alcoholic who brings out three bottles of his favorite liqors
and greets them as reliable old friends. Under this view it is
possible that the personal therapeutic relationship formed in
psychotherapy became a direct substitute for drug use. However,
we think that the benefits of psychotherapy are more than simply
the results of a relationship. Observations that we made during
this study and in other therapy situations suggest that the
benefits of therapy are a result of the therapists' ability to
form a relationship combined with special knowledge and skill
about how to use it. We have noticed that many of the
counselors form good patient relationships but have trouble
managing them, especially with the very disturbed patients. It
should also be remembered that, like other patients who have
been treated with psychotherapy, opiate addicts often have
significant psychiatric problems, especially in the areas of
depression and anxiety. To the extent that drug use is an
attempt to medicate these problems and to the degree that
psychotherapy can reduce them, psychotherapy can reduce drug
use indirectly.
It is important to mention in closing that there are
substantial predictors of the benefits received by adding
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psychotherapy to counseling. These predictors are related to
the severity of psychiatric symptoms and psychiatric diagnoses,
especially depression and antisocial personality. These
predictors and the effect of therapy plus counseling vs.
counseling alone speak to potential areas where additional
psychotherapy might be used to improve ongoing treatment
services.
REFERENCES (Available upon request)
A C K N O W L E D G E M E N T S
This work was supported by NIDA Contract #271-81-4921.
Rebecca Ashery, DSW, and Barry Brown, Ph.D., served as project
officers for this study.
and Jim Mintz, Ph.D.,
Mrs. Beverly Pomerantz, Mrs. Diane Hery,
provided useful scientific input at various
stages of the study.
Finally, we appreciate the contributions of the therapists and
counselors who participated on this project: Robert Behney,
B.A.; Marsia Canto, B.A.; Maureen Dubyak, B.S.; Sonja Fox,
Arthur Freeman, Ph.D.; Elton Hargrove, B.A.; Clarence Harris,
Pay Harrison, Ph.D., Larry Hart, Ph.D., Pamela Moore, M.S.W.;
Sam Okpaku, M.D., Ph.D., Steve Perry, Dennis Sacks, B.S.W.;
Marshall Schechter, M.D., Louis Umansky, B.A.; and Tony
Villeco, M.A.
A U T H O R S
George E. Woody, M.D., Chief, Drug Dependence Treatment Unit,
VA Medical Center, Philadelphia, PA 19104 and Clinical
Associate Professor of Psychiatry, University of Pennsylvania,
Philadelphia, PA 19104
Lester Luborsky, Ph.D., Professor of Psychology in Psychiatry,
University of Pennsylvania, Philadelphia, PA 19104
A. Thomas McLellan, Ph.D., Director, Clinical Research, Drug
Dependence Treatment Unit, VA Medical Center, Philadelphia, PA
19104 and Assistant Professor of Psychiatry, University of
Pennsylvania, Philadelphia, PA 19104
Charles P. O'Brien, M.D., Ph.D., Chief, Psychiatry Service, VA
Medical Center, Philadelphia, PA 19104 and Professor of
Psychiatry, University of Pennsylvania, Philadelphia, PA 19104
Aaron T. Beck, M.D., Professor of Psychiatry, University of
Pennsylvania, Philadelphia, PA 19104
66
Jack Blaine, M.D., Staff Psychiatrist, Pharmacological and
Somatic Treatments Research Branch, Department of Health and
Human Services, Rockville, Maryland, 20857
Ira Herman, M.D., Clinical Associate in Psychiatry, University
of Pennsylvania, Philadelphia, PA 19104
Anita Hole, Ph.D., Lecturer of Psychology in Psychiatry,
University of Pennsylvania, Philadelphia, PA 19104
67
TABLE 1
SAMPLE OF MEASURES USED
INTAKE 1-MO. 7-MO. 12-MO.
CONSENT FORM X
SCHEDULE FOR AFFECTIVE DISORDEPS AND
SCHIZOPHRENIA - LIFE TIME VERSION
(SADS-L) (26) X
MAUDSLEY PEPSONALITY INVENTORY (27) X X X X
BECK DEPRESSION INVENTORY (28) X X X X
SOCIAL ADJUSTMENT SCALE (29) X X X X
SCL-90 (30) X X X X
SHIPLEY (31) X
REIATIONSHIP INVENTORIES (32,33) X
SCHEDULE FOR AFFECTIVE DISORDERS-
CHANGE VERSION (SADS-C) (26) X X X X
ADDICTION SEVERITY INDEX (ASI) (34) X X X X
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TABLE 2
* = p < .05
** = p < .01
Range of appointments: 3-24
SE average - 12 sessions
CB average - 9.3 sessions
DC average - 17 sessions
TABLE 3
START TO SEVEN MONTH IMPROVEMENT
* = p < .O1
+  = p < .05
Opioid Antagonists: Do They Have
a Role in Treatment Programs?
Charles P. O’Brien, Robert A. Greenstein, Bradley Evans,
George E. Woody, and Robin Arndt
The rationale for using opioid antagonists is based on the
provision of a nondependence-producing drug to protect the
detoxified addict from readdiction despite his returning to
areas of high drug availability.
This paper will concentrate on naltrexone and only briefly
mention buprenorphine. We will not discuss the history of
opioid antagonists although this is a fascinating story in
itself. These drugs have helped to define concepts like
physical dependence, and they have been instrumental in the
discovery of opiate receptors and endogenous opiates. Drugs
like nalorphine, naloxone and cyclazocine have been used for
treating dependence clinically and discarded for various
reasons over the past 15 years.
Naltrexone has been used in clinics since 1973. It is still an
investigational drug and its prospects for approval for general
use remain uncertain. Let us examine the important issues of
safety and efficacy.
S A F E T Y
Animal toxicity data indicate that naltrexone has a wide margin
of safety. LD 50's in several species are quite high and
chronic administration studies also indicate lack of toxicity.
Several years ago there were rumors in the treatment community
that naltrexone may be carcinogenic. That notion was based on
the misinterpretation of son-e interim data in a rat chronic
toxicity model. In fact, a full range of testing has found
naltrexone to be noncarcinogenic and one model even suggests
sane anti-tumor activity (Braude 1980).
Over 2,000 human subjects have teen treated with naltrexone,
most for a few weeks but sane for as long as two years. Toxic
effects have been few. The usual dose is 50 mg per day or 350
mg per week in two or three doses. However, up to 800 mg per
day have been given without apparent toxicity (Verebey 1980).
There have been several cases of skin rash and one case of
idiopathic thrombocytopenic purpura which cleared on cessation
of the drug and these may have represented immune reactions.
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The most commonly reported naltrexone side-effect has been
gastrointestinal distress. This usually occurs early in
treatment, and in sane cases, it may represent a mild
precipitated opioid withdrawal reaction rather than a
side-effect in the usual sense.
There are other naltrexone effects which relate to its
pharmacological actions separate from blocking re-addiction to
opioids. A wide spectrum of opioid receptors are affected by
naltrexone and this can be expected to influence the role of
these receptors in normal physiology. The hypothalamic-
pituitary-gonadal axis is a good case in point. Mendelson and
colleagues (Mendelson et al. 1979, Ellingboe et al. 1982) have
reported that naltrexone produces a prompt rise in luteinizing
hormone (IH) in both normals and recently detoxified addicts.
Cicero and co-workers (1979) have reported similar findings in
rodents leading to theories about the mechanisms of the
pulsatile release of LH. Normal human males given an acute
dose of 50 mg of naltrexone reported irritability, dysphoria,
sexual ideation and penile erections (Mendelson et al. 1979).
Such subjective complaints were not reported by normals given
10 mg of naltrexone increasing gradually to 50 mg over a period
of days (O'Brien et al. 1978). These complaints generally have
not been reported by thoroughly detoxified postaddicts given
gradually increasing doses of naltrexone.
Tolerance appears to develop to these endocrine effects;.
although, thus far, human subjects on long-term naltrexone have
not been adequately examined for chronic endocrine effects.
Most of the speculation concerning chronic disruption of the
endorphin system in human subjects is supported by anecedotal
evidence only. For example, one might expect pain systems to
be affected in the direction of a lowered threshold. However,
we have been impressed by the reactions of two long-term
naltrexone patients who sustained trauma and demonstrated a
higher than normal tolerance for pain. There is also reason to
suspect from animal studies that feeding behavior may be
affected (Morley 1980). A few clinicians have also reported
cases of apparent naltrexone - related appetite suppression.
However, a review of the large NAS/NIDA series of naltrexone
patients reveals about an equal number of those who gain and
lose weight (Bradford and Kaim 1977).
One might also expect some direct effects of naltrexone on the
homeostatic equilibrium of the endorphin system. Zukin and
colleagues (1981) have reported increased sensitivity of rat
brain opioid receptors beginning within the first two days of
naltrexone treatment and increasing for eight days thereafter.
In postaddict humans treated for two to eight weeks with
naltrexone, we have reported increased endorphin activity as
measured by radioreceptor assay (O'Brien et al. 1981). However,
this can only be considered a preliminary report because the
magnitude of this increase is uncertain due to difficulties in
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extracting all of the naltrexone metatolites which themselves
were active in the receptor assay.
Several studies have reported a possible effect on "craving,"
but this has not been satisfactorily separated from the setting
variable, that is, the presence or absence of drug availability.
The bottom line on safety is that this is a powerful drug with
widespread effects; yet, by all of the usual criteria, it appears
remarkably safe.
EFFICACY
Pharmacological efficacy is a straightforward question and the
answer is equally straightforward. Naltrexone clearly acts as
a competitive antagonist of opioid drugs (Martin et al. 1976).
When a subject is "protected' by naltrexone, the effects of
opioids are blocked or attenuated in a dose-related fashion.
Significant antagonism can persist for 72 hours after a 150 or
200 mg dose of naltrexone (Resnick et al. 1974, O'Brien et al.
1975) . The degree of antagonism is related to the plasma
levels of naltrexone and its active metabolites,and thus it is
less in patients why are rapid metabolizers (Verebey 1980).
Under controlled laboratory conditions sane opiate effects can
be perceived by subjects injecting opioids while receiving
naltrexone, and these have hen confirmed by physiological
monitoring devices in two laboratories (O'Brien et al. 1975,
Verebey 1980). However, the attenuation is such that even
fairly large street doses of heroin are relatively non-
rewarding. Thus, it is practical to give naltrexone two or
three times per week and assume that the patient will be
wasting money if he uses street heroin. For perhaps the first
time in many years, a detoxified former addict is free to walk
the streets of his neighborhood without fear of becoming
re-addicted.
So, the pharmacological efficacy of naltrexone is unquestioned.
What about clinical efficacy? This is a complex question which
involves hard-to-define issues such as readiness for
opioid-free treatment, patient goals vs. therapist goals, and
availability of other reinforcers such as employment. Perhaps
the most difficult question involves the technology to test the
clinical efficacy of an antagonist drug.
We are accustomed to using a double-blind trial of test drug vs.
placebo. Such trials have already demonstrated the clear
pharmacological efficacy of naltrexone in short-term inpatient
studies (Meyer et al. 1976). Clinical efficacy in a placebo
controlled trial is a different matter. The structure of such
a trial
activity.
is based on naltrexone's known pharmacological
Patients are told that they will receive either an
antagonist or placebo.
"break!" the blind.
If they test by using opioids, they can
If they fail to test, then placebo has, in
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a sense, "borrowed" naltrexone's pharmacological activity and
there is no advantage to being on naltrexone. In fact there is
an advantage to being on placebo because placetos have no
possible pharmacological side-effects.
The results of the one large placeto-controlled trial of
naltrexone follow this pattern (Hollister et al. 1978).
Overall there were no differences between placebo and
naltrexone. Among the small sub-sample who tested the
blockade, there was a significant advantage for naltrexone.
Those on naltrexone tested once or twice at the beginning and
then stopped illicit drug use. Those on placebo continued to
test intermittently throughout the trial.
What then is the clinical role of naltrexone? Cur review of
the literature and nine years of clinical experience with
naltrexone indicate that it is an important option for perhaps
5-10% of opioid addicts at a given time in a large multi-
modality treatment program. Patients who have done well on
methadone maintenance and who have undergone a planned slow
detoxification are good candidates. Retrospective analyses
have shown that these who have stable relationships and
employment are more likely to do well (Resnick et al. 1979).
Former addicts who have served a prison term, particularly
those in a work-release program have done well (Brahen et al.
1977). Physician addicts have done exceptionally well on
naltrexone. Patients receiving psychotherapy, family therapy
or behavior therapy have generally done better than naltrexone
patients not getting these treatments (Grabowski et al. 1979,
Anton et al. 1981, Resnick et al. 1981). Long term follow-ups
have generally shown that the longer the patient remains on
naltrexone in the community the greater the likelihood of
finding that patient opioid-free at one year follw-up. While
naltrexone blocks only opioid effects, only a few patients show
increased use of alcohol and other drugs.
Of course, skeptics can appropriately point out that those who
continue on naltrexone are relatively good prognosis patients
anyway and that you may get equally good results by giving
placebo naltrexone. This is probably true, at least as long as
some patients in the population were receiving active
naltrexone so that the antagonist treatment structure and
reputation would be maintained. If naltrexone were made
totally unavailable, so that all patients received placebo, the
word would eventually get out. The results then would be no
different from drug-free outpatient therapy, which has even less
compliance than antagonist programs.
In our opinion, the release of naltrexone for general use is
long overdue. We realize that there are certain problems with
drugs used in a small specialized population, the so-called
"orphan" drugs. Unless new indications are found for
naltrexone, such as the treatment of certain types of obesity,
74
there is unlikely to be much financial profit in this drug.
However, there will be a great loss to the addiction treatment
field if it is not approved.
Another promising agent in the antagonist category is
buprenorphine. This is a mixed agonist/antagonist with maximum
agonist effects equivalent to about 20 mg of parenteral
morphine (Jasinski et al. 1978). Although it has not yet been
tested in an outpatient addiction treatment program,
preliminary inpatient studies are promising. Buprenorphine may
overcome the major problem with naltrexone, which is the lack
of compliance. Patients generally like buprenorphine, although
they do not report withdrawal effects if they stop it. Perhaps
buprenorphine could play a transitional role in a gradual
progression from street heroin to methadone to buprenorphine to
naltrexone and finally the drug-free state. Of course
buprenorphine has its own set of potential problems. It must
be given parenterally or sublingually. Its agonist effects
give it a certain abuse potential reminiscent of pentazocine.
Potential abuse is further influenced by its expected
widespread usefulness as an analgesic. The seriousness of the
current pentazocine problem ("T's and Blues") makes it
mandatory that all agonist/antagonists be carefully considered
from this perspective.
In conclusion, the increased sophistication of treatment in the
area of substance abuse is reflected in the complexity of the
opioid antagonist issue. No longer is it meaningful to say
that a treatment was tested in a group of "addicts" or
"alcoholics." All addicts are not alike. We must specify the
relevant characteristics of the population and the setting.
Some patients do well in a particular type of treatment
(McLellan et al. 1982). others get no benefit or may even be
made worse by a specific treatment. Data on this concept of
matching patients are contained in a paper presented at this
meeting by McLellan and colleagues (1982).
Clearly, we have progressed far from the stage mentioned by Dr.
Dole in his 1982 Eddy acceptance address when he referred to
the time when the only treatment available for addiction was
incarceration. We now have many active treatments and although
we have a lot further to go in developing better treatments, we
have an even further way to go in making these treatments
available to the appropriate patients.
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Progress Report: Medical College
of Virginia—Sigma Agonists
L. S. Harris, M. D. Aceto, R. L. Balster, and B. R. Martin
Based on an immense amount of chemical and pharmacologic inform-
ation both in animals and man, Martin and his colleagues (Martin
et al., 1976) proposed a concept of multiple opiate receptors.
From their own work, they described three receptor types. These
were: mu, for morphine-like; kappa, for ketocyclazocine-like;
and sigma, for SKF l0,047(N-allylnormetazocine). Since then, the
concept of a mu receptor has been extensively investigated
(Goldstein et al., 1971). The discovery of stereospecific bind-
ing sites in the brain and other tissues led to the identifica-
tion of endogenous ligands subserving pain and other mechanisms
(Hughes, 1975; Chau, 1982).
More recently, attention has focused on possible kappa-type re-
ceptors and some progress in this area appears to be forthcoming.
In addition, attention is turning to investigations of sigma-type
activity. SKF 10,047, the prototypic drug of this type, has a
pharmacology quite similar to nalorphine. Thus, it is a mixed
agonist-antagonist analgesic which is associated at elevated
doses, with a high incidence of nalorphine-like psychotomimetic
activity in man. This type of side effect has been one of the
limiting factors in the development of better therapeutic agents
from this class of compound. Our interest in sigma-like activity
was rekindled from a body of work appearing from our laboratory
and others which showed a relationship between the pharmacolog-
ical properties of the sigma agonists and phencyclidine (PCP).
This information is summarized in Table 1.
Of particular interest was our finding (Brady et al., 1982) that
there may be some stereoselectivity to sigma-like activity.
Thus, in drug discrimination studies, (±)-SKF 10,047 generalized
to PCP while the (-)-isomer did not at doses below those which
produced behavioral disruption. We have later shown that animals
can be trained to discriminate (+)-SKF 10,047 from vehicle, and
that PCP is generalized to this discriminate cue while the (-)-
isomer does not at doses below those which produce behavioral
disruption (Balster and Brady, In press). Thus (+)-isomer of SKF
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10,047 is more specific for PCP-like effects. The (-)-isomer,
and therefore, the racemate, have prominent non-PCP-like effects
probably mediated by mu or kappa receptors which may mask sigma
activity.
Table 1
REPORTED SIMILARITIES BETWEEN PCP AND THE SIGMA-
AGONIST (+)-N-ALLYLNORMETAZOCINE (SKF 10,047)
1.
2.
3.
4.
Similar Effects in the Chronic Spinal Dog
Jasinsky et al., 1981
Martin et al., 1976
Receptor Binding Studies - Displacement of Bound PCP or SKF
10,047 by SKF or PCP, Respectively
Palmur et al., 1980
Quirion et al., 1981
Zukin and Zukin, 1979, 1981
Discrimination Studies - Generalization Between Phencycli-
dine or Ketamine and (+)-N-Allylnormetazocine
Brady et al., 1982
Holtzman, 1980
Shannon, 1981
Young, et al., 1981
Reported Psychotomimetic Effects in Humans
Davies and Beech, 1960
Domino and Luby, 1981
Keats and Telford, 1964
Martin et al., 1965
########
The findings from the discrimination studies prompted us to
undertake binding studies. We hypothesized that binding of (+)-
SKF 10,047 would be a more homogeneous sigma-like class of recep-
tors than would the binding of the (-)-SKF 10,047. Binding of
the latter should be more readily displaced by mu and kappa
agonists or antagonists. It is preliminary results with binding
of the isomers of SKF 10,047 that are described here. First,
radiolabeled (+)-SKF 10,047 with high specific activity had to be
prepared. This was done by preparing the pure isomers of N-pro-
parylnormetazocine and reducing them with 3H (Figure 1). The 3H
reduction was carried out by Dr. F. I. Carroll at the Research
Triangle Institute. This gave the (+)- and (-)-isomers with a
specific activity of 54Ci/mmole and 65Ci/mmole, respectively.
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Figure 1
Binding studies using rat brain homogenates with labeled dehydro-
morphine as the ligand, showed that (-)-SKF 10,047 displaced with
a K1 = 1x10
-10 M, while the (+)-isomer produced only a 67% dis-
placement at 10-5M. Using the labeled SKF 10,047 isomers and rat
brain homogenates,
isomers.
linear Scatchard plots were obtained for both
The (-)-isomers had an estimated KD = 1.2 x 10
-8 M.
Using other ligands, we found that (-)-morphine displaced the (-)
-SKF 10,047 but not the (+)-isomers while (+)-morphine displaced
(+)-SKF 10,047 25 times more effectively than (-)-SKF 10,047.
Displacement studies with a wide variety of other ligands are now
in progress. Sodium chloride did not effect the KD of either
(+)- or (-)-SKF 10,047. However, the number of binding sites of
(-)-SKF 10,047 was markedly reduced by the addition of NaCl.
We also took the opportunity to reexamine the agonist and antag-
onist activity of (+)-, (+)-, and (-)-SKF 10,047 in a variety of
antinociceptive test procedures. Neither (+)-SKF 10,047 nor its
isomers were active as antinociceptive agents in the tail-flick
test. In the phenylquinone abdominal stretching (PPQ) test, the
racemate was about 50 times less potent than morphine (see Table
2).
Table 2
AGONIST ACTIVITY OF SKF 10,047 AND ITS ISOMERS
Tail-Flick Agonist PPQ Abdominal Stretching Test
Compound ED50 mg/kg ED50 mg/kg
Morphine 5.8 0.23
(+)-SKF 10,047 Inactive to 30 10.4
(+)-SKF 10,047 Inactive to 30 Inactive to 40
(-)-SKF 10,047 Inactive to 40 1.3
########
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The (-)-isomer gave an ED50 = 1.3 mg/kg while the (+)-isomer was
inactive in doses up to 40 mg/kg. Thus, there was a separation
of greater than 40 to one between the (-)- and (+)-isomers as
agonists. As antagonists, the racemate was active against mor-
phine in both the tail-flick and PPQ tests (see Table 3).
Table 3
ANTAGONIST ACTIVITY OF SKF-10,047
AND ITS ISOMERS
Compound
Tail-Flick Antagonist PPQ Test Antagonist
ED50 mg/kg ED50 mg/kg
Morphine
(±)-SKF 10,047
(+)-SKF 10,047
(-)-SKF 10,047
N/A N/A
1.9 3.3
13.2 Inactive to 30.0
0.2 1.2
########
The antagonist activity lies essentially in the (-)-isomer. The
separation in the tail-flick test was greater than 60 to one;
while in the PPQ test, the (+)-isomer was inactive in doses up to
30.0 mg/kg, giving a ratio of at least 30 to one. Thus, except
for some very weak antagonist activity in the tail-flick test,
(+)-SKF 10,047 appears to have little narcotic agonist or antag-
onist activity. In other experiments we found that naloxone was
able to antagonize the antinociceptive activity of (±)- and (-)-
SKF 10,047 in the PPQ test. However, it takes 30 times more
naloxone to antagonize the racemate than the (-)-isomer.
In summary, we have found many pharmacological commonalities
between the sigma agonists SKF 10,047 and PCP with evidence that
the (+)-isomers has more selectivity for PCP-like effects.
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First, a brief administrative update. In this transition period
(during which the ARC is in process of relocating from Lexington,
Ky. to Baltimore, Md.) a unit of the ARC remains active in Lexing-
ton, engaging primarily in animal and chemical research, but also
working coordinately and collaboratively with our colleagues in
Baltimore. We are anticipating at this time that final reloca-
tion will be accomplished in the summer of 1984. In my progress
report I will highlight briefly the results of several ongoing
studies in our laboratory.
METABOLISM OF OXYMORPHONE
This study is being performed in the Chemistry Section and
describes the metabolism and urinary excretion of oxymorphone
in man and several laboratory animals. This is part of a study
which was undertaken several years ago to study the comparative
metabolism of six compounds which had in common a ketone at the
no. 6 position. Naloxone and naltrexone are narcotic antagonists.
Oxycodone (in Percodan), hydromorphine (or Dilaudid), and oxy-
morphone (or Numorphan) are strong analgesics; and hydrocodone
(in Hycodid) is used primarily as an antitussive. Although these
drugs have been used for many years, there was little known of
their metabolism or urinary excretion profiles.
In the human study, single 10 mg. oral doses of oxymorphone hydro-
chloride were administered to six healthy, adult male, Federal
prisoners from whom informed consent had been obtained. All were
former addicts who were drug free at the time of the study. Con-
trol urines were collected for 24 hr. prior to drug administration;
and following drug, all urine was collected for 144 hr., with
collection periods ending at 2, 4, 8, 12, 24, 48, 72, 96, 120 and
144 hr.
In the animal studies, the following species were used: Male
albino Wistar rats (N = 6); male albino New Zealand rabbits
(N = 4); male albino Hartley guinea pigs (N = 4); and one male
and one female mongrel Beagle dog. Each subject received a single
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2.5 mg./kg. dose of oxymorphone hydrochloride, administered subcu-
taneously. Urine was collected for 24 hr. predrug and 24 hr.
following drug administration. Urine samples were frozen until
the time of analysis.
Standard extraction and acid-hydrolysis procedures were used for
isolation of oxymorphone and metabolites. Briefly, samples were
extracted for free or total drug at pH 10 with chloroform/isopro-
panol (9:1 v/v), back-extracted into acid, and basified and
reextracted with chloroform/isopropanol. Following evaporation,
samples were converted into silyl derivatives for GC and GC/MS
analysis. Recovery of oxymorphone by this procedure was 73.4
percent.
Oxymorphone was found to be excreted in small amounts in the intact
form, as well as being extensively conjugated at the 3-phenolic
position. In addition, metabolites of oxymorphone were isolated
which were identified by comparison with authentic standards as
6-ketone reduction products, i.e., 6 -oxymorphol and 6 -oxymorphol.
No noroxymorphone was detected.
A quantitative assay for oxymorphone and its 6-keto reduced metabo-
lites was developed with GC/MS-mass fragmentography, using methane
chemical ionization mode, with 6 -hydrocodol as internal standard.
Linear standard curves were obtained from 0.1-2.0 µg./ml. for
oxymorphone and from 0.05-1.0 µg./ml. for the metabolites. Samples
were analyzed in triplicate.
In the six human subjects, total oxymorphone excretion over the
6-day collection period ranged from 28 to 57 percent of the
administered dose, with a mean of 41 percent. Small amounts of
6 -oxymorphol were found (about 3 percent of the administered
dose) , together with traces of 6 -oxymorphol. This pattern of
6-keto reduction (i.e., selectivity for the 6 configuration) is
consistent with that found for other 6-keto opioids possessing a
3-phenolic group (i.e., naltrexone, naloxone, and hydromorphone).
Both oxymorphone and its metabolites were extensively conjugated
(i.e., greater than 90 percent). Overall urinary recovery of the
administered dose ranged from 30 to 60 percent.
Results of the animal studies from this and previously presented
data from this study allow several cross-species generalizations.
There was very little 6-keto reduction in the rat and dog, while
guinea pig and rabbit produced about the same amounts as did man.
This is consistent with previous studies. With regard to stereo-
selectivity, man and rabbit produced predominantly the 6 form,
while guinea pig showed predominantly 6 . Again, this is a con-
sistent pattern; the guinea pig generally shows the lowest
ratio, but this is the first compound where it has been less than
1 in these in vivo studies. All species but the rabbit showed a
heavy preponderance of conjugated urinary metabolites. Generally,
the dog has always shown strong conjugation, with man strong to
intermediate. The rat and guinea pig have varied somewhat from
drug to drug; and the rabbit has been a consistently poor
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conjugator. Overall drug recovery ranged from about 15 to 90 per-
cent. In these studies, recovery has been consistently low in
the rat, moderate to high in man and guinea pig, and somewhat
variable in dog and rabbit.
The data from this study should prove useful in further defining
cross-species differences and similarities and for predicting
likely oxymorphone metabolites and amounts detectable in human
urine following use or possibly abuse of this compound.
SKF-10,047 EVALUATION IN THE DOG
This study is from the Whole Animal Pharmacology Section and con-
cerns our continued interest in the relationship of -opioid
receptor agonists and PCP. The similarity between PCP and N-allyl-
normetazocine (SKF-10,047, NANM) has been reported in several
animal species including rat, dog, and squirrel and rhesus monkey.
Although initial studies evaluated primarily racemic SKF, more
recent studies (and those reported here) have focused on the phar-
macology of the stereoisomers. Specifically, this study was aimed
at determining if the PCP-like activity of SKF resided in one of
the two stereoisomers, thereby demonstrating a pharmacologic selec-
tivity of action. For this purpose, the spectrum of action and
relative potencies of the d- and l-isomers of SKF, the racemate,
PCP, and saline were determined in two groups of three chronic
spinal dogs using an incompletely randomized crossover design,
with geometrically spaced doses. Subjects were adult, female
Beagle dogs, with chronic spinal section at T-10, who had been off
all chronic drugs for at least 6 months prior to initiation of the
study. The study is now half completed and the results obtained
in the first three dogs are presented. The experimental paradigm
utilized a 30-min. control period, followed by the intravenous
administration of the drug over 4 min., and a 60-min. postdrug
observation period. Parallel line bioassay analyses of variance
were employed to evaluate physiologic effects measured as 60-min.
areas of the time-action curves and behavioral effects reported
as total 1-hr. scores.
Profilesofaction for PCP and racemic SKF have been established
previously in the dog. Common effects of these two compounds were
depression of the flexor reflex, tachycardia, mydriasis, retrac-
tion of the nictitating membrane, analgesia (as indicated by
increased onset latency of the skin twitch reflex), hyperthermia,
and the combination of nystagmus and stereotypy.
Comparison of d- and 1-SKF in the present study showed that both
isomers produced dose-related depression of the flexor reflex,
augmentation of the pulse rate and of skin twitch reflex latency,
dilatation of the pupils, increases in the incidence of concurrent
nystagmus and stereotyped head movements, and increase in whining.
Also, increases were seen in respiration, temperature, and inci-
dence of staring. At the highest dose tested, all of the dogs
at one time or another failed to attend to external stimuli.
Among the potency estimates, only the mydriatic response produced
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confidence limits that did not include 1; for this measure the
d-isomer appeared somewhat more potent than the l-isomer. Also,
it appeared that the l-isomer more effectively depressed the flexor
reflex than did the d-isomer, but confidence limits could not be
calculated because of preparation differences. A lower dose of
the l-isomer is being added to the study. The effects of the
racemate and PCP were identical to those observed for the individ-
ual SKF isomers. The dose-response curves of the racemate were
located in close proximity to or between those of the isomers.
With one exception, the PCP curves were positioned to the left of
the three SKF curves by 0.5 to 1 log unit, indicating a greater
potency of PCP than racemic SKF or its individual isomers. For
the flexor reflex, the PCP curve was partially superimposable on
the curve for 1-SKF.
In summary, it is tentatively concluded that both the d- and l-
isomers show pharmacologic activity of the type, indicating no
selectivity of action, with both profiles similar to that of PCP.
In addition, the isomers are generally equal in potency; although
the l-isomer was less effective as a mydriatic and possibly
depressed the flexor reflex more than the d-form. These two
exceptions could suggest aslightlyhigher degree of activity
associated with the l-isomer of SKF.
NICOTINE AND COCAINE SELF-ADMINISTRATION IN THE DOG
This study, from the Behavioral Pharmacology Section, is a follow-
up on the continuing exploration of the reinforcing properties of
nicotine in comparison with cocaine in the dog. Subjects of this
study were four Beagle dogs surgically fitted with venous cathe-
ters, then given access to response-contingent drug infusions
under a fixed-ratio with limited hold schedule of reinforcement.
Daily sessions, conducted Monday through Friday, consisted of
16 trials, each trial lasting a maximum of 10 min. During each
trial, the 15th lever-pressing response produced a 15-sec. i.v.
infusion of drug (i.e., an FR-15 schedule). Successive trials
were separated by a time-out period, lasting at least 240 sec.
Following acquisition of stable responding (with cocaine as the
reinforcer). the does were tested with five doses of nicotine
(3-300 µg.]kg./infuEion), five doses of cocaine (3-300 µg./kg./
infusion), and saline. Each dose was tested for five to seven
consecutive sessions, with treatment order randomly determined
for each dog.
Results of the first study showed that both nicotine and cocaine
were self-administered above saline levels, with the maximum num-
ber of infusions occurring at doses of 30 and 100 µg./kg./infusion.
For both drugs, overall response rates varied systematically as a
function of dose per infusion, with nicotine reaching a maximum of
0.3 responses/sec. at 30 µg./kg./infusion and cocaine with a maxi-
mum of 0.7 responses/sec. at 10 µg./kg./infusion. The running
rate also showed systematic variation with dose with maximum
rates at 10 µg./kg./infusion for both drugs.
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Upon completion of the dose-response curves, the effects of pre-
session treatment with the nicotinic antagonist mecamylamine on
nicotine and cocaine self-administration behavior were assessed
in the same four dogs. Mecamylamine, at a dose of 1 mg./kg., i.v.,
was given 30 min. before the start of each session for seven con-
secutive sessions; both nicotine and cocaine were administered at
a dose of 30 µg./kg./infusion. For both infusions per session and
overall response rate, presession treatment with mecamylamine
altered the behavior maintained by nicotine, but not the behavior
maintained by cocaine. The number of nicotine infusions per
session dropped from 13.9 during the control period to 11 on the
first session of mecamylamine treatment and continued to decline
over the 7-day period to 4.7 infusions. Similarly, the overall
response rate dropped to 34.5 percent of control in the first
mecamylamine pretreatment session and continued to decline to
7 percent of control after 7 days of mecamylamine. When respond-
ing was maintained by cocaine infusions, presession treatment with
mecamylamine had little effect on the response rate and no effect
on the number of infusions self-administered each session. The
temporal pattern of nicotine self-administered during mecamylamine
treatment was much like that seen when saline was substituted for
drug. The first two or three fixed-ratio trials in each session
were rapidly completed, resulting in two to three infusions sepa-
rated by the shortest possible time-out period. If any subsequent
infusions occurred, they were separated by long periods of minimal,
if any, responding. During mecamylamine treatment, the temporal
pattern of cocaine self-administration was unchanged.
In summary, it is concluded that nicotine does have reinforcing
properties demonstrable in the laboratory; and they appear to be
due to a mechanism involving nicotinic receptors and different
from that of cocaine.
BENZODIAZEPINE ANTAGONISTS
This study, also from the Behavioral Pharmacology Section, concerns
benzodiazepine antagonists. As the sedative-hypnotics have become
of greater concern as drugs of abuse, emphasis on these compounds
has increased in studies at the ARC and major studies have been
initiated in this area. This paper summarizes initial results of
studies on two benzodiazepine antagonists: Ro 15-1788, an imidazo-
diazepine derivative which has been reported to selectively
antagonize the effects of benzodiazepines in humans and animals;
and CGS 8216, a pyrazoloquinoline derivative reported to antagonize
the anticonvulsant effects of diazepam (although CGS may also
antagonize nonbenzodiazepine sedative-hypnotics). In these studies,
the discriminative stimulus paradigm in the rat was used. Male,
Fisher-derived rats were trained to discriminate between saline
and either 1.0 or 3.0 mg./kg. of diazepam s.c. in a two-choice,
discrete-trial, shock avoidance or escape procedure by responding
on one lever after receiving saline and on a second lever after
receiving diazepam. Each session consisted of 20 trials or
30 min.; data are presented as percent of responses completed on
the diazepam appropriate lever. Animals were trained and main-
tained at a 90 percent correct response criterion.
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The effects of CGS and Ro on the discriminative stimulus proper-
ties of diazepam and pentobarbital in rats trained to discriminate
1.0 mg./kg. diazepam were evaluated. The antagonists were adminis-
tered 40 min. before the start of the session (Ro as an oral
suspension and CGS i.p.) and diazepam or pentobarbital was adminis-
tered subcutaneously 30 min. presession. Diazepam and pentobarbital
alone produced greater than 85 percent diazepam appropriate respond-
ing. Both CGS and Ro produced a dose-related antagonism of diazepam
discriminative effects but did not alter the effects of pentobar-
bital. CGS was approximately ten times more potent than Ro on a
mg. for mg. basis. Both antagonists administered alone produced
almost exclusively saline appropriate responding. Similar results
were obtained in rats trained to discriminate pentobarbital from
saline.
The effects of varying doses of Ro on the diazepam dose response
curve in animals trained to discriminate 1 mg./kg. diazepam were
determined. Ro and diazepam were administered by the same routes
in the same time course as described above. Diazepam dose effect
curves were shifted approximately three- and 18-fold to the right
in a parallel fashion by 10 and 32 mg./kg. of Ro. Preliminary
data indicate that CGS produces similar parallel shifts in the
diazepam dose effect curve.
In another set of experiments, interactions between diazepam,
ethanol, and CGS were evaluated. In this study, cumulative dose
response curves were generated in a single session in each subject.
Ethanol or tap water was administered 30 min. presession. The
session consisted of consecutive 15-min. periods, the first 10 min.
of which was a black-out period, followed by a 5-min. period during
which a maximum of ten discriminative stimulus trials were run.
Diazepam was administered at the beginning of the black-out period
in amounts resulting in the cumulative doses of 0.1 to 10 mg./kg.
Animals were trained to discriminate 3.0 mg./kg. diazepam. The
cumulative latency was also determined, that is, the time from the
beginning to the end of each trial summed over ten trials for
each point. Ethanol alone at a dose of 1.8 g./kg. administered
orally caused no diazepam appropriate responding, but produced
an approximately three-fold shift to the left in the diazepam
dose response curve; about a ten-fold shift was seen in the cumu-
lative latency dose response curve. That is, ethanol potentiated
the discriminative stimulus and latency increasing effects of
diazepam. In CGS interaction studies, CGS was administered con-
currently with the first dose of diazepam in a dose of 3.0 mg./kg.
i.p. CGS produced a greater than 40-fold shift to the right in
the dose response curves for diazepam both alone and in the
presence of ethanol. These results indicate the potentiating
effects of diazepam by ethanol and the effectiveness of CGS in
antagonizing diazepam even in the presence of ethanol.
In summary, these initial data seem consistent with the conclu-
sions that Ro and CGS appear to be specific benzodiazepine
antagonists, working via a competitive antagonistic mechanism,
and they may have potential clinical utility. Studies are presently
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underway to further define their specificity and mechanism of
action.
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As reported last year, the Clinical Research Program of the
Addiction Research Center (ARC) has been successfully relocated
to Baltimore City Hospitals. The first subject was admitted in
February 1980. From February 20, 1980 to December 31, 1981 there
were a total of 179 volunteer admissions into the ARC clinical
unit for research studies. Of these admissions, 108 subjects
completed their study, 40 voluntarily withdrew, 24 were
discharged for medical reasons, 5 were discharged for adverse
behavior and 2 were discharged because of inability to give
informed consent.
Review of subject drug histories revealed a wide range of
patterns of abuse, from cigarette smoking to poly-drug abuse.
Comparison of selected psycho-social characteristics with those
obtained in the CODAP survey for corresponding periods,
nationally and in Baltimore, indicated that the ARC subject
population is similar to that in treatment. These observations
suggest that the subject population is appropriate to the type of
drug abuse/liability research studies conducted at the ARC.
STUDY I - EVALUATION OF CHLORDIAZEPOXIDE FOR PENTOBARBITAL-LIKE
EFFECTS
In the last annual report (Jasinski et al. 1981), we reported
that diazepam given in single doses produced typical
pentobarbital-like effects including euphoria. The onset, peak
and duration were similar for both diazepam and pentobarbital.
Relative potencies were similar across subjective and behavioral
measures indicating diazepam is 10 times more potent than
pentobarbital in producing euphoria and subjective effects. A
preliminary study comparing chlordiazepoxide 50, 100 and 200 mg,
pentobarbital 120 and 240 mg and placebo was conducted.
Chlordiazepoxide produced dose-related pentobarbital-like effects
and euphoria; however, the response to the 200 mg dose was less
than that of the 240 mg dose of pentobarbital. Consequently,
valid bioassays were not obtained; therefore, the study was
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repeated with a larger dose of chlordiazepoxide. In this second
study chlordiazepoxide 100, 200 and 400 mg pentobarbital 120 and
240 mg and placebo were all given orally and compared in six
subjects. The experimental design and procedures were similar to
those for the first chlordiazepoxide study and the diazepam study
as reported in last year's annual report. It was found that the
onset, peak and duration of response of chlordiazepoxide and
pentobarbital were similar. Valid relative potencies were
obtained on all measures except that for the euphoria scale in
which there was a flat dose response curve for chlordiazepoxide.
On the basis of the studies conducted to date with both
chlordiazepoxide and diazepam, it is concluded that (in the doses
studied) diazepam and chlordiazepoxide produced
pentobarbital-like effects including euphoria. Diazepam is 10
times as potent as pentobarbital while chlordiazepoxide is 1/2 as
potent as pentobarbital. Therefore, by extrapolation
chlordiazepoxide is approximately 1/20 as potent as diazepam in
producing subjective effects and euphoria. The flat dose
response curve for the euphoria scale scores with
chlordiazepoxide indicates the possibility of qualitative
differences between diazepam and chlordiazepoxide.
STUDY II - ASSESSMENT OF NABILONE AND
DELTA-9-TETETRAHYDROCANNABINOL (THC) FOR ABUSE POTENTIAL
The cannabinoids nabilone and THC are proposed for introduction
into therapeutics as treatment modalities for the nausea and
vomiting associated with certain forms of cancer chemotherapy.
Although THC has been shown to produce marijuana-like effects,
there is no epidemologic evidence to indicate that THC will have
an abuse potential equivalent to marijuana smoking. Further,
studies by others have indicated that nabilone may produce
effects which are distinct from that of 'IHC. A single dose study
has been initiated in which ten subjects are being given,
according to a latin square design, the following treatment
conditions: 1) placebo, 2) morphine, 15 and 30 mg subcutaneously,
3) THC 5, 10 and 20 mg orally, 4) nabilone, 2, 4 and 8 mg orally
and 5) on one occassion the smoking of a standard 1-1.5% NIDA
marijuana cigarette. Except for the cigarette smoking condition,
the studies are conducted under "double-blind" and "double-dummy"
conditions. The purposes of the study are to learn if marijuana
and THC produce similar subjective, physiologic and behavioral
effects and to learn if both are euphoriants compared to the
euphoric responses to standard doses of morphine and the standard
1-1.5% marijuana cigarette. The study is not completed; however,
a preliminary analysis of the data indicates that when given
orally, THC and nabilone produce similar effects. Both are
euphoriants as measured by responses on the ARCI MBG and liking
scales. It should be noted that oral THC and inhaled marijuana
have a more rapid onset of action than nabilone; however, the
effects of nabilone last longer than those of THC.
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STUDY III - CONTINUATION OF STUDIES OF INTRAVENOUS NICOTINE AND
TOBACCO SMOKE
In last year's annual report, we reported that nicotine is a
euphoriant when given to addicts either intravenously or in
cigarette smoke. Methods had been dweloped to quantify the
subjective, physiologic and behavioral changes produced by
nicotine, and a self-administration procedure was developed to
conduct behavioral pharmacologic studies of intravenous nicotine
in humans. In the past year these studies have continued and
have been extended. One major group of studies has been to
investigate mecamylamine as a competitive antagonist to the
physiologic, subjective and behavioral effects of nicotine.
These studies will be reported in greater detail in another
chapter in this volume (Henningfield, Miyasato and Jasinski). In
addition, we have continued self-administration studies for the
purpose of comparing and integrating the findings in man with
those of animal studies concerned with the reinforcing effects of
nicotine, predominantly those of Dr. Steven Goldberg in our
laboratory. Further, we have been interested in investigating
the relation of nicotine-induced euphoric and dysphoric responses
to the self-administration behavior and in investigating the role
of tolerance development in nicotine. When given access to two
levers, one resulting in the injection of saline and the other
resulting in injection of nicotine over a range of dosages,
subjects self-administer nicotine in preference to saline.
Studies of the euphoric responses to programmed injections of
nicotine indicate that tolerance develops rapidly to nicotine.
This suggests that in self-administration studies involving
repeated administration of nicotine (and by extrapolation
cigarette smoking) the positive effects of the nicotine are
rapidly lost through tolerance. It's probable that with short
periods of abstinence, the reinforcing effects are rapidly
recovered. In series of self-administration studies, subjects
rated the degree of positive responses to nicotine in an analogue
scale after each self-administration of nicotine. In addition,
after the three-hour self-administration session they were
required to give their overall liking for the drug effect in the
session. Increasing doses of mecamylamine reduced the liking
score, the self-administration and positive analog scale
responses in direct proportion to the dose of mecamylamine.
Our studies to date with nicotine delivered either intravenously
or in tobacco smoke have led us to conclude that 1) nicotine can
act as a reinforcer in humans relative to placebo, 2) that
tolerance to nicotine is rapidly developed and lost, 3) that
self-administration behavior is related to the perceived positive
and negative effects of nicotine. The relation between
self-administration and perceived positive and negative stimulus
strength is complex but orderly. Finally, the biomedical and
behavioral data generated to date justifies the investigation of
chemotherapy as an approach to treating tobacco addiction.
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STUDY IV - STUDIES OF BUPRENORPHINE AS A TREATMENT AGENT IN
NARCOTIC ADDICTION
In previous meetings we reported that the long-acting partial
agonist of morphine, buprenorphine, produced little or no
physical dependence and had proposed that buprenorphine might
have utility as a treatment drug in narcotic addiction. At last
year's meeting we reported on a series of single dose studies
evaluating the sublingual and oral route and had concluded that
given orally in doses of 10 to 40 mg, sublingually in doses of
24 mg, and subcutaneously in doses 1 to 2 mg, buprenorphine
could act as a maintenance/detoxification agent. In the past
year we have conducted studies by both the subcutaneous and
sublingual routes of administration on the use of buprenorphine
as a detoxification maintenance agent. At this meeting we will
report on only our experience evaluating buprenorphine as a
detoxification agent for methadone maintenance patients. Our
studies have emphasized detoxification in methadone maintenance
patients primarily because this has allowed us to use volunteers
with known levels of physical dependence. It is also felt that
the most difficult narcotic detoxification is that of methadone
and because of its long-Lasting withdrawal syndrome, it could
serve as the prototype for other detoxifications. Finally, a
major therapeutic problem in treating narcotic addiction is the
disruption caused by the discontinuation of methadone in a
patient who has exhibited psychosocial rehabilitation with
maintenance, and as such buprenorphine may have an immediate
utility.
As a partial agonist, under certain conditions buprenorphine was
shown to be able to precipitate abstinence. To determine if in
doses proposed for maintenance/detoxification buprenorphine would
precipitate abstinence, a series of studies were done in six
subjects dependent upon methadone. Maintenance levels of
methadone were 25 mg, 30 mg, 2 subjects at 40 mg and 2 subjects
at 45 mg for a mean methadone maintenance dose of 38 mg. Using
our standard precipitated abstinence procedure, under
"double-blind", "double-dummy" conditions, subjects were tested
twice weekly with test doses being given three hours following
the subject's methadone maintenance dose. Test doses of placebo,
naloxone 0.5 mg subcutaneously, and buprenorphine 2 and 4 mg
sublingually, were given in randomized order.
When compared to placebo, naloxone produced physiologic signs of
withdrawal that include pupil dilation, increased blood pressure,
lacrimation, rhinorhea, perspiration and subjective reports of
withdrawal sickness. Buprenorphine, on the other hand, produced
mydriasis and hypertension; however, there were no subjective
reports of withdrawal sickness. Subjects did report with two
doses of buprenorphine feelings of relaxation, coasting and
typical opiate-like subjective effects in contrast to naloxone in
which the primary symptoms were nervousness and upset stomach.
These observations suggest that there is lack of cross tolerance
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in methadone maintenance patients to some of the effects of
buprenorphine. In addition, there is no evidence that, in
methadone maintenance patients (up to 45 mg), buprenorphine will
precipitate clinically significant withdrawal.
A series of studies was conducted to determine if buprenorphine
would substitute for methadone such that the withdrawal from the
substituted buprenorphine would be less than that expected from
the methadone. The first set of experiments were concerned with
the transition from methadone to buprenorphine and the second set
with abrupt withdrawal of substituted buprenorphine. Both sets
of experiments were conducted under double-blind conditions with
subjects residing on the ARC ward with daily monitoring of signs
of abstinence, signs of intoxication and subject's and observer's
chronic opiate questionnaires and the items from the weak and
strong opiate withdrawal scale of the Addiction Research Center.
In the first set of transition experiments eight subjects on
methadone (25 mg in two subjects, 30 mg in one subject, 40 mg in
three subjects and 45 mg in two subjects for a mean of 36 mg)
were abruptly transferred from methadone to a 2 mg daily
sublingual dose of buprenorphine given under double-blind,
double-dummy circumstances. Subjects perceived the change,
reported mild discomfort, which reached its maximum following the
third day of substitution; however, by the fourth and fifth day
the subjects were stabilized.
A second group of four subjects were transferred from methadone
to 2 mg of sublingual buprenorphine under identical circumstances
except that after the administration of the daily sublingual
buprenorphine, methadone administration was continued in an
attempt to attenuate even the mild withdrawal symptoms.
In these subjects on methadone (25 mg, 50 mg in two subjects, and
60 mg in one subject for a mean of 46 mg) the methadone was
decreased 50% on the first day of substitution of buprenorphine
and 50% every third day until the final dose of methadone was
12.5 or 7.5 mg. When the subject reached this level, methadone
was discontinued. It was observed that the continuation of
methadone did not attentuate the mild opiate withdrawal signs and
symptoms seen during the abrupt transition. It was observed that
the symptoms and signs of withdrawal were equal or slightly
greater than those seen in the gradual and abrupt transition.
This suggests that certain actions of methadone are unrelated to
the effects of buprenorphine.
Once stabilized on buprenorphine, subjects reported little or no
subjective effects and in general were less sedated than on
methadone. Six subjects completed the double-blind study which
included 28 days of buprenorphine administration (2 mg
sublingually q. day) and the abrupt substitution of placebo under
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"double-blind" "double-dummy" conditions. These six subjects
originally had been methadone dependent on 40 mg and 45 mg (two
subjects each), 25 mg and 30 mg (one subject each) for a mean
daily dose of 35 mg. When the substituted burprenorphine was
abruptly discontinued, a mild abstinence syndrome was observed on
the first day of substitution reaching its peak on the second and
third day and then subsiding such that by the fourth day after
abrupt discontinuation there were little or no signs of symptoms
of withdrawal. The withdrawal after termination of the
substituted buprenorphine was different than that of abrupt
withdrawal of methadone since methadone withdrawal becomes
maximum the third day and persists for weeks. It was
hypothesized that the buprenorphine when substituted for
methadone would suppress the signs and symptoms of methadone
withdrawal but that the basic process of methadone withdrawal was
ongoing. Consequently, it was felt that the termination of the
substituted buprenorphine led to a re-emergence of the methadone
abstinence syndrome. To evaluate this hypothesis, the withdrawal
seen from day 29 through 38 following abrupt withdrawal from
buprenorphine was compared with previous data for days 29 through
38 following abrupt withdrawal form methadone. Comparison of the
abstinence scores and withdrawal signs and symptoms showed that
the two syndromes were similar in both degree and intensity,
supporting the concept that the abstinence after abrupt
discontinuation of the substituted buprenorphine was due to a
re-emergence of the methadone withdrawal syndrome. If this
hypothesis is true, then it was felt that a Longer time of
substitution of buprenorphine for methadone should be accompanied
by less intense withdrawal or "reversed dependence." A study was
conducted in which one subject dependent upon 45 mg methadone
daily was placed on "double-blind " "double-dummy" condition on 2
mg of buprenorphine subcutaneously. After fifteen days of
buprenorphine administration, placebo was substituted and an
abstinence syndrome of increasing intensity developed wer the
next ten days such that the subject was reporting moderate to
severe withdrawal. Administration of buprenorphine 2 mg
subcutaneously daily was reinstituted on day eleven and continued
for an additional fourteen days such that the second abrupt
discontinuation of buprenorphine took place 40 days after the
Last dose of methadone. Again, abstinence emerged but it was
mild and low in intensity lasting for about three or four days
and the subject was reporting no withdrawal symptoms ten days
later.
On the basis of these studies it is concluded that buprenorphine
will partially substitute for methadone. Buprenorphine treatment
attenuates the methadone withdrawal syndrome. As a result,
buprenorphine can be used to detoxify methadone-dependent
patients with minimal discomfort or behavioral disruption. It is
possible that buprenorphine and methadone act through separate
subpopulations of mu receptors. Finally, the time course of
methadone withdrawal appears to be independent of the presence of
buprenorphine.
97
R E F E R E N C E S
Jasinski, D.R., Haertzen, C.A., Henningfield, J.E., Johnson,
R.E., Makhzoumi, H.M. and Miyasato, K.: Progress report from the
NIDA Addiction Research Center in Baltimore. Presented at the
43rd Annual Scientific Meeting, the Committee on Problems of Drug
Dependence, Inc., San Francisco, CA, NIDA Research Monograph
Series, No. 41, pp. 45-52, 1981.
Henningfield, J.E., Goldberg, S.R., Miyasato, K., Spealman, R.D.
and Jasinski, D.R. Functional properties of nicotine in monkeys
and humans. Presented at the Federation of American Societies
for Experimental Biology (FASAB) meeting, New Orleans, April,
1982.
Donald R. Jasinski, M.D.,
Jack E. Henningfield, Ph.D.,
John E. Hickey, L.C.S.W., and
Rolley E. Johnson, Pharm.D.
U. S. Department of Health and Human Services
Public Health Service
Alcohol, Drug Abuse, and Mental Health Administration
National Institute on Drug Abuse
Addiction Research Center
P. O. Box 5180
Baltimore, Maryland 21224
98
Testing Drugs for Abuse Liability
and Behavioral Toxicity: Progress
Report From the Laboratories at
the Johns Hopkins University
School of Medicine
J. V. Brady and R. R. Griffiths
A. Introduction
Although this is the first formally constituted progress report
from the drug abuse liability assessment laboratories at The Johns
Hopkins University School of Medicine to be included in the published
proceedings of the Committee on Problems of Drug Dependence Annual
Scientific Meeting, the programs supporting this work have been in
existence for well over a decade. The animal behavioral pharmacology
laboratories at the Johns Hopkins University School of Medicine were
established in the early 1970's with funds provided by the Drug
Enforcement Agency (DEA) and the National Institute on Drug Abuse
(NIDA). Continuing support from NIDA has provided for a vigorous
ongoing research program with laboratory baboons focused upon both
drug self-administration procedures and senory-motor psychophysical
methodologies to evaluate the reinforcing properties and behavioral
toxicology of drugs with abuse potential.
B. Progress Report from The Johns Hopkins University School of
Medicine Behavioral Pharmacology Laboratories
Research over the past decade or more in the behavioral
pharmacology laboratories at the Johns Hopkins University School of
Medicine has convincingly demonstrated that there is a good
correspodence between the range of chemical compounds self-injected
by experimental animals and those abused by humans (Brady et al.,
1975; 1976; 1977a; 1977b; Griffiths et al., 1976; 1978; 1981).
Moreover, the variables of which such drug self-administration are a
function (e.g., dose, response requirement, schedule of availability,
environmental conditions, past history, etc.) have been found to
exert their influence in a similar fashion independently of the type
of substance maintaining the performance or the species of organism
involved (Griffiths et al., 1980). The recognition of these
cross-species and cross-drug generalities has radically changed
conceptualizations of drug-related problems and focused attention
upon the need to distinguish between two terms which have continued
to be used interchangeably with reference to drug action --
"dependence" and "abuse". Drug dependence has been identified
traditionally with the biochemical, physiological, and behavioral
99
changes which occur acutely and become increasingly manifest
following repeated exposure to a pharmacoloqic agent (e.g., tolerance
and withdrawal). Drug abuse, in contrast, defined in the more
contemporary context of an extensive self-administration literature,
is clearly identified with the characteristically strong drug-seeking
and drug-taking behaviors which precede the pharmacological action of
abused drugs.
Within the context of these distinctions, the proper preclinical
evaluation of a given drug's abuse liability has been considered to
require an assessment which takes account not only of the reinforcing
properties of the compound in maintaining self-administration, but of
its toxic effects as well, in terms of disruptive
physiological/behavioral changes. An experimental model has been
developed (Brady et al. 1982) for comparing the relative potency of a
drug as a reinforcer maintaining self-administration, on the one
hand, with its relative potency in eliciting disruptive toxic effects
upon sensory and motor functions, on the other, thus providing a
potentially useful preclinical assessment of the extent to which
self-administration of a drug may involve exposure to the disruptive
sensory/motor effects of the compound as a basis for determining its
abuse liability.
1. Methods and Results with Animal Drug Self-Administration
Procedures
The procedure for determining reinforcing properties with a
range of drugs has been previously described in detail (Brady and
Griffiths, 1976; 1977a & b; Griffiths, Brady, and Snell, 1978;
Griffiths, Brady and Bradford, 1979): Briefly, male baboons (Papio
anubis or Papio hamadryas) weighing from 12-30 kg, were adapted to a
standard restraint cart, or a harness/tether system (Lukas et al.,
1982) and individually housed in a sound-attenuated chamber
approximately 0.8 x 0.8 x 1.2 m. Water via a drinking tube and the
opportunity to respond for food (1 gram Purina monkey pellets) were
continuously available. The food lever was located on the lower
right side of a work panel facing the animal, and food pellets were
available on a fixed-ratio 30 schedule of reinforcement.
After initial behavioral training on a progressive-ratio
paradigm with food reinforcement, each subject was surgically
prepared with a chronic silastic catheter in either the internal
jugular, femoral, or axillary vein. The catheter was passed
subcutaneously, exited at the middle of the back, and was attached to
a valve system which allowed for the slow continuous administration
(approximately 100 ml/24 hours) of heparinized saline via a
peristaltic pump to maintain catheter patency. Drug was injected
into the valve system near the animal by means of a second
peristaltic pump and then flushed into the animal with saline from a
third pump. This system necessitated a delay of approximately 20 sec
between onset of drug delivery and actual injection into the vein.
All drugs were delivered within a 2-min period. In experiments
involving manipulation of drug dose, the volume of drug solution per
injection and the injection duration remained constant throughout the
experiment.
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The availability of a trial occurred at a minimum interval of
three hours since the completion of the preceding trial. The
availability of a trial was indicated by the illumination of a jewel
light directly over the initiate lever located slightly to the left
of center at the bottom of the subject's work panel. In the presence
of an illuminated jewel light, each response on a standard Lindsley
lever produced a brief feedback tone (approximately 0.2 sec). The
light remained illuminated until completion of the fixed-ratio
requirement (FR 160). At this time, the light over the lever was
extinguished, the drug injection began, and a 5 x 5 cm light was
illuminated in the upper left hand corner of the intelligence panel
for a one-hour period. A time-out period of three hours followed
each injection. Thus, a maximum of eight injections was possible
each day.
unknown
Self-injection performance was first established with cocaine at a
A substitution procedure was utilized to determine whether an
compound would maintain self-injection behavior.
dose of 0.32 mg/kg/inj. After three consecutive days of cocaine
availability, during which six or more injections were taken each
day, a specified dose of the test drug or saline was substituted for
the cocaine. At least twelve days access to each dose of drug or
saline was permitted. Cocaine was then reinstated, and when the
criterion of three consecutive days of six or more injections per day
had been met, another dose or drug was again substituted. The order
of exposure to drugs, saline and different doses was mixed; all
animals were given twelve days of access to saline several times
during the examination of different drugs at different doses. This
basic approach thus provided a standardized procedure for evaluating
the reinforcing properties of drugs.
A progressive-ratio procedure provided a measure of relative
reinforcing strength of a drug by determining the maximum amount of
responding (i.e., work) that can be maintained by the compound.
Progressive-ratio experiments involved first introducing a drug on
the progressive ratio procedure with a low ratio requirement on the
initiate lever (usually FR 160) and obtaining a baseline performance
of a high and stable frequency of trial completion. Once this
performance was established, the ratio requirement on the Lindsley
lever was systematically increased until the rate of completing
trials fell below a criterion level. A breaking point was defined as
the ratio value at which criterion performance disruption occurred.
The sequence of ratio values typically included: 160, 320, 640,
1280, 2400, 3600, 4800, 6000 and 7200. Following disruption of
performance, the ratio requirement on the Lindsley lever was
lowered, and the original performance recovered prior to replication
of the experiment or substitution of another dose or drug. The
sequence of exposure to different doses of a drug and the order of
exposure to different drugs was mixed.
Figure 1 presents illustrative data obtained with the
substitution procedure in examining a range of doses of the
substituted phenylethyramine, diethylpropion, in one baboon. The
figure shows that when saline or a low dose (0.1 mg/kg) of
diethylpropion was substituted for cocaine, the self-injection
performance decreased during the 12-day substitution period until the
101
Figure 1. Daily pattern of self-injection maintained by
various doses of diethylpropion, HCl and saline in the same
subject. The initial three-day period of each determination
shows the self-injection performance maintained by cocaine
HCl (0.4 mg/kg) prior to substitution of saline or the
indicated dose of diethylpropion.
subject self-administered only two or three injections per day. At a
dose of 0.5 mg/kg diethylpropion, self-administration performance was
maintained at an average rate of about five injections per day, which
was higher than saline but lower than the preceding cocaine control
periods. Finally, at the highest doses tested of 1.0 and 2.0 mg/kg,
the figure shows that relatively stable rates of self-administration
were maintained at overall rates comparable to cocaine control
periods (seven or eight injections per day).
Figure 2 also
procedure showing
presents illustrative data from the substitution
daily patterns of self-injection performance
maintained by saline and several doses of phentermine in three
baboons. The figure shows that when saline was substituted for
cocaine, the number of injections per day progressively decreased.
At a dose of 0.5 mg/kg, phentermine self-injection performance was
maintained at levels similar to cocaine control levels. At a dose of
1.0 mg/kg, self-injection performance was also maintained in all
three animals, however, drug intake was characterized by a cyclic
pattern in which a number of consecutive days of self-injection at a
high rate (6 or more injections per day) was followed by several
consecutive days at a lower rate and then a return to the higher
rate. Previous experiments (Griffiths et al., 1976; Pickens and
Thompson, 1971) have documented a virtually identical cyclic pattern
of self-injection performance with d-amphetamine.
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Figure 2. Daily pattern of self-injection maintained
by saline or phentermine in three baboons. Ordinates:
number of injections. Abscissae: experimental days.
Intravenous injections were delivered upon completion
of 160 lever presses; a 3-hr timeout followed each
injection, permitting a maximum of eight injections per
day. The initial three-day period of each determina-
tion shows the number of injections maintained by
cocaine prior to substitution of saline or indicated
dose (mg/kg/inj.) of phentermine.
Figure 3 presents the chemical structure, and Figure 4 the mean
levels of self-injection for fourteen phenylethylamlnes evaluated.
As shown in Figure 4 of all the drugs examined d-amphetamine was
the most potent, maintaining levels of self-administration above
saline at doses of 0.05 and 1.0 mg/kg. Phentermine, diethylpropion,
phenmetrazine, phendimetrazine, benzphetamine, and MDA all maintained
levels of self-administration above saline at doses of 0.5 and 1.0
mg/kg. l-Ephedrine, clortermine, and chlorphentermine were the least
potent of the drugs which maintained performance, supporting
self-injection rates above saline control levels at doses of 3.0 and
10.0 mg/kg (l-ephedrine), 3.0 and 5.0 mg/kg (clortermine), and 2.5
and 5.0 mg/kg-(chlorphentermine). In contrast to most of the other
phenylethylamines which maintained self-administration behavior, the
pattern of self-administration with l-ephedrine was particularly
unstable, characterized by either an erratic or cyclic pattern over
days. Finally, fenfluramine, PMA, DOM, and DOET were not
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self-administered at a rate greater than saline at any of the doses
studied (means of the determinations at each dose did not exceed the
range of saline values).
A comparison of Figures 3 and 4 provides some information about
structure-activity relationships of phenylethylamines. Other
laboratory studies (Tessel et al., 1975a & b) have demonstrated that
the ability of a series of N-ethylamphetamines substituted at the
meta position of the phenyl ring either to increase locomotor
activity in mice or to increase isolated guinea-pig atria1 rate is
inversely related to the meta-substituted steric factor (size). In a
subsequent study (Tessel and goods, 19751, it has been demonstrated
that N-ethylamphetamine maintained self-injection performance in
rhesus- monkeys, whereas fenfluramine (meta-trifluoromethyl- N-
ethylamphetamine) failed to maintain self-injection performance.
These results indicate that the failure of fenfluramine to maintain
self-injection behavior is attributable to its meta-trifluoromethyl
group. The results obtained with the present series of
phenylethylamines extends these findings and suggests that ring
substitutions in general may decrease the potency of the
phenylethylamines in maintaining self-injection behavior. The seven
Figure 3. Chemical structures of the 14 phenylethylamines
tested to determine whether they maintained drug self-
administration.
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Figure 4. Average number of injections per day with 14
phenylethylamines. Intravenous injections were delivered
upon completion of 160 lever presses: a 3-hr timeout
followed each injection permitting a maximum of eight
injections per day. C indicates mean of all the 3-day
periods with cocaine which immediately preceded every
substitution of a phenylethylamine or saline. S indi-
cates mean of day 8-12 after substitution of saline (two
saline substitutions in each of 15 animals). Brackets
indicate ranges of individual animal's means. Drug data
points indicate mean of days 8-12 after substitution of
a drug for individual animals. Lines connect means at
indicated doses of drug.
compounds shown in the right columns of Figures 3 and 4 had
substitutions on the phenyl ring, and these compounds were generally
less potent (on a mg/kg basis) in maintaining self-injection than the
compounds in the left columns of Figures 3 and 4 which did not have
ring substitutions.
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Figures 5, 6 and 7 present additional results from testing a
range of other CNS stimulants (i.e., cocaine, caffeine, and nicotine)
and CNS depressants (i.e., various barbiturates and benzodiazepines)
using the substitution procedure.
The reinforcing
systematically evaluated
described above. Figure 8 shows the results of the progressive-ratio
efficacy of a series of CNS stimulant drugs was
using the progressive-ratio procedure
breaking point determinitions over a range of doses with
fenfluramine, chlorphentermine, diethylpropion, and cocaine. Doses
of fenfluramine (0.02, 0.1, 0.5 and 2.5 mg/kg) did not maintain
criterion self-injection performance in the two baboons tested, and
therefore were assigned breaking point scores of zero. As shown in
Figure 8, chlorphentermine maintained self-injection performance at
Figure 5. Average number of injections per day as a
function of dose of cocaine, caffeine, and nicotine.
Details of the experiments are presented in the legend
for Figure 4.
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some of the intermediate doses tested (1.0, 3.0, 5.6 mg/kg) in three
baboons. In all three animals, lower and higher doses failed to
maintain criterion self-injection performance. In the fourth baboon
tested (SA), chlorphentermine did not maintain self-injection
performance at the doses tested (1.0, 3.0 5.6 mg/kg). As shown in
Figure 8, 0.1 mg/kg diethylpropion did not maintain self-injection
performance, while at higher doses ranging between 1.0 and 10.0
mg/kg , the drug maintained behavior in all five baboons tested.
Therefore, the dose-breaking point function with diethylpropion was
an inverted U-shaped curve with a peak at 1.0 or 3.0 mg/kg. And
finally, Figure 8 shows that the 0.01 mg/kg cocaine dose did not
maintain performance; the 0.03 mg/kg dose maintained performance in
three of the four baboons tested; and doses of 0.1, 0.4 and 1.0 mg/kg
maintained self-injection behavior in all five baboons. Examination
of the figure reveals that for the four baboons which were exposed to
a number of intermediate doses of cocaine, the breaking point values
generally increased with increases in dose up to 0.1 or 0.4 mg/kg.
Figure 6. Average number of injections per day as a
function of dose of three barbiturates. Details of
the experiment are presented in the legend for Figure 4.
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Within-animal comparison of the maximum breaking points
maintained by the different drugs indicates that cocaine generally
maintained the highest breaking points, followed in order by
diethylpropion, chlorphentermine, and fenfluramine. More
specifically, within-animal comparisons of the data presented in
Figure 8 show that there were doses of cocaine which maintained
higher average breaking points than all the doses of diethylpropion,
chlorphentermine and fenfluramine tested. Similarly within-animal
comparison reveals that there were doses of diethylprooion which
maintained higher breaking points than all doses of chlorphentermine
and fenfluramine, and finally that there were doses of
chlorphentermine which maintained higher breaking points than all
doses of fenfluramine.
Utilizing information collected during the initial screening of
drugs, it has been possible to develop another potentially valuable
dimension for ranking the abuse liability of anorectic drugs. The
rationale for the dimension is similar to that for the Therapeutic
Index, which provides a measure of the toxicity of a drug in terms of
a ratio expressing the relationship between the therapeutic or
effective dose and a dose which produces a given toxic effect. In
the present case, the Anorectic-Reinforcement Ratio provides a
dimension for rank ordering drugs in terms of a ratio between two
doses: a dose which produces a specified anorectic effect
("therapeutic" effect), and a dose which produces a specified
reinforcing effect ("toxic" effect). Clearly, the most desirable
Figure 7. Average number of injections per day as a
function of dose of six benzodiazepines. Details of the
experiment are presented in the legend for Figure 4.
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anorectic drug would have potent anorectic properties but minimal
reinforcing properties. An undesirable anorectic drug would be a
weak anorectic but a powerful reinforcer. Undoubtedly, existing
anorectic drugs fall on a continuum between these extremes; a
quantitative measure of this continuum is provided by the
Anorectic-Reinforcement Ratio, and a number of substituted
phenylethylamines and cocaine were evaluated using this measure.
The analysis of the reinforcing properties of a drug required
examination of a substantial range of doses. Therefore, for many of
the drugs analyzed, the lowest reinforcing dose (dose which maintains
Figure 8. Breaking point values for doses of fenfluramine,
chlorphentermine, diethylpropion, and cocaine in five
baboons. Ordinates: breaking points; Abscissae: Dose
(mg/kg/inj,).Each point represents a single breaking
point observation. Lines connect the means of the breaking
point observations at different doses of drug. Filled
circles indicate data obtained during the first exposure
to a drug dose. Unfilled circles indicate data obtained
during a second exposure to a drug dose.
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self-injection performance at FR 160) had already been determined.
This dose provided the denominator of the Anorectic-Reinforcement
Ratio (Table 1, Column B). And in the course of evaluating the
reinforcing properties of the drugs under study, concurrent
assessments were made of the effects of these compounds on food
intake. Increasing doses of all drugs were associated with decreases
in the total number of food pellets taken each day. The dose which
suppressed food intake to 50 percent of saline control levels was
calculated individually for all compounds on the basis of a
regression line fitted to the raw data and these values are shown in
Table 1, Column C for each of the indicated drugs.
Column D, Table 1 and the filled bars of Figure 9 show the
resulting Anorectic-Reinforcement Ratios (based upon adjustment to an
arbitrarily assigned d-amphetamine value of 1.0) derived from the
relationship between- food suppression
numerator) and criterion reinforcing
dose (i.e., Column C,
dose (i.e., Column B,
denominator) for each of the drugs studied. The ratio values range
from a low of zero for fenfluramine and phenylpropanolamine to a high
of 14.81 for cocaine, and reflect the fact that compounds with high
ratio values are more potent reinforcers (relative to their anorectic
potency) than compounds with lower ratio values. But the measure of
Figure 9. Anorectic-Reinforcement Ratios for cocaine and
eight anorectic drugs. Filled bars show data derived
entirely from baboon experiments. Striped bars show data
derived from both human clinical information and baboon
experiments. Compounds with high ratio values are more
potent reinforcers (relative to their anorectic potency)
than compounds with lower ratio values.
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Table 1. Anorectic-Reinforcement Ratio - Fourteen anorectic drugs and cocaine. All doses are expressed on the basis
of the hydrochloride salts except for d-amphetamine and l-amphetamine which are expressed as the sulfates, and
phendimetrazine which is the tartrate. To facilitate comparison, ratios were adjusted to an arbitrarily assigned
d-amphetamine value of 1.0. Numbers in parentheses indicate the number of observations on which the reinforcing dose
and food suppression dose are based.
anorectic potency as determined with the baboon could be confounded
by non-specific psychopharmacological effects such a drug-induced
sensory or motor decrements. To provide more information about
anorectic potency of the drugs, an alternative set of values was
derived by utilizing the lowest recommended daily human anorectic
doses. These doses appear in Column E of Table 1, and provide the
numerator for computing a comparative set of ratio values (Column F).
Since cocaine is not used clinically as an anorectic, no entry
appears in Column E. Comparison of the values in Columns D and F
(also the striped bars vs. the filled bars of Figure 9) show the
correspondence between the ratios based upon these two independent
measures of anorectic potency.
Although the progressive-ratio procedure provides a useful
measure of the relative reinforcing efficacy of drugs, the procedure
is quite time consuming. An alternative procedure was therefore
examined to determine whether it might provide a more efficient
alternative to the progressive ratio procedure. Specifically, the
alternative procedure involved measuring stable response rates on a
drug maintained fixed-ratio schedule. A study was undertaken to
determine whether fixed-ratio schedules and progressive-ratio
schedules would provide similar information about the relative
reinforcing efficacy of different cocaine doses. The
progressive-ratio procedure was identical that previously
described. On the fixed-ratio schedule, 160 responses were required
for each injection. Each injection was followed by a timeout of
either 3 or 12 hours. Each dose of cocaine was examined for at least
15 days and until response rates showed no trends. Figure 10 shows
that with the 3-hour timeout, the dose-breaking point function on the
progressive ratio schedule (left-hand column) was similar to the
dose-response rate function on the fixed-ratio schedule (center
column). As shown, these dose-effect functions were inverted
U-shaped curves characterized by a graded ascending limb (0.01 - 0.32
mg/kg) and a downturn at the highest dose (3.0 - 4.0 mg/kg). On the
fixed-ratio schedule the downturn in the dose response rate function
was attributable to a cumulative drug effect as revealed by
manipulation of timeout duration, analysis of sequential
interresponse time distribution, and cumulative response records.
Overall the study showed that these fixed-ratio and progressive-ratio
schedules provide similar information about the relative reinforcing
efficacy of different cocaine doses, and that both schedules may be
useful in the assessment of drug reinforcing efficacy.
2. Methods and Results with Animal Psychophysical Procedures
for Evaluating the Sensory/Motor Effects of Drugs
The procedure for determining behavioral toxicity with a range
of drugs has previously been described in detail (Brady, Bradford,
and Hienz, 1979; Hienz and Brady, 1981; Hienz, Lukas, and Brady,
1981) and focuses upon a reaction time (RT) methodology with
laboratory baboons. This procedure has already been used extensively
with primates as an index of sensory function (Stebbins and Coombs,
1975). Briefly, in the RT procedure, an animal is required to press
and hold down a lever for a variable time, following which a signal
is presented (e.g., a light flash or tone burst). Release of the
lever within 1.5 sec. following the onset of the signal is then
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Figure 10. (Left-hand column) breaking point values for
cocaine in 5 baboons: Y-Axis = breaking point; X-Axis q
cocaine dose (mg/kg/inj.), log scale. Each point represents
a single breaking point observation. Lines connect means at
different doses of drug. (Right-hand column) Response
rates maintained by saline and various cocaine doses in
4 baboons on an FR 160 schedule with either a 3-hr or 12-hr
timeout following each injection: Y-Axis = response per
second; X-Axis = cocaine dose (mg/kg/inj.), log scale;
S = saline. Data points and brackets indicate mean
response rate ± SEM for the last 25 injections (the only
exceptions are the data points for SA at 0.32 and 0.1
mg/kg with the 12-hr timeout, which are based on the last
12 injections). Unfilled circles = data obtained during
first exposure to a drug dose; filled circles = data
obtained during second exposure to a drug dose.
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reinforced with food presentation (19O mg banana pellets). The
reaction time, which is the time elapsed between the onset of the
signal and the release of the lever, has been found to be inversely
related to stimulus intensity, and decreases as stimulus intensity
increases. This relation between reaction time and stimulus
intensity is a naturally occurring one, and needs no prior training.
This is a distinct advantage of using the RT procedure as a measure
of sensory function. In addition, the procedure is easily employed
with either auditory or visual stimuli, and can be used to obtain
stimulus detection thresholds. There is also an already existing
large data base on auditory reaction time with a number of primate
species, including the baboon, and the procedure can be easily
modified, when required, to extend research into other areas of
possible drug effects (e.g., auditory frequency and intensity
discrimination).
In terms of data analysis, the use of reaction time has allowed
for the separation of sensory deficits from extreme motor deficits by
requiring that an animal hold a lever down for a considerable period
of time prior to a stimulus presentation. Thus, for example, an
ataxic subject would produce a number of "premature releases" as
compared to a normal subject. Further, since variability of RTs in
primates is generally quite small, changes in RTs resulting from
administration of specific compounds are readily detected. The
measurement of the threshold levels for pure tones in primates,
however, has been demonstrated not to change greatly when different
reaction time criteria are used for estimating detection (Pfingst,
Hienz, and Miller, 1975). Thus, a compound which produced a motor
deficit resulting in longer reaction times would not necessarily
cause an increase in sensory threshold estimates unless the deficit
was debilitating enough to be detectable by the monitoring of
premature releases. Both small and large motor effects of specific
compounds can thus be separated from purely sensory effects.
The use of both auditory and visual stimuli in the reaction time
procedure has provided for the assessment of drug-related changes in
specific sensory systems. If drug-related changes occur in auditory
RTs but not for visual RTs, for example, the observed effects can be
attributed specifically to the auditory system. Further, when
drug-related changes produce consistently longer reaction times to
near-threshold auditory stimuli but not to high intensity auditory
stimuli, a laboratory primate analogue of the clinical phenomenon
which has been demonstrated to occur as a result of a brief exposure
to intense sounds (temporary threshold shifts), or as a result of the
use of ototoxic drugs, is provided.
Following initial shaping of lever pressing and discrimination
of the holding and release components of the response, all animals
were introduced to the discrete trial reaction time procedure. In
the presence of a flashing cue light (5/sec), a lever press changed
the flashing red light to a steady red light which remained instated
as feedback as long as the animal held the lever switch in the closed
position. At varying intervals (ranging 1.0 to 7.3 sec.) following
initiation of this maintained holding response, a test stimulus
(white light on the circular patch or tone burst through the speaker)
was presented for 1.5 sec. Release of the lever within the 1.5 sec
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test stimulus interval delivered a single banana pellet and initiated
a 1 sec. intertrial interval (ITI) during which no stimuli were
presented and lever responses re-initiated the ITI. Incorrect
responses (i.e., lever presses prior to test stimulus onset or after
the 1.5 sec test stimulus interval) reinstated the 1 sec. ITI without
reinforcement. Following the 1 sec. ITI, the flashing red cue light
signalled initiation of the next trial in the series of several
hundred which comprised each daily 2 to 3 hour experimental session.
Asymptotic levels of performance on this procedure typically required
2 to 3 months of such daily training sessions.
Auditory and visual thresholds were determined by randomly
varying (in accordance with the method of constant stimuli) the
intensity of the test stimuli, from trial to trial and examining
detection frequencies (i.e., correct lever releases) at each
intensity. For the auditory modality (where the baboon can
discriminate a range of frequencies extending to 40 kHz) four
intensity levels (10 dB apart) of a 16.0 kHz pure tone were used,
with the lowest level set just below the animal's estimated
threshold. Interspersed among the "test" trials were a series of
"catch" trials during which no tone was presented to measure the
false alarm (i.e., "guessing") rate. For the visual modality, four
intensity levels (0.5 log density units apart) of the white light
were used with the lowest level again set just below the animal's
estimated threshold. Again, "catch" trials with no light were
programmed to occur intermittently. In addition, sessions involving
visual threshold determinations were preceded by a 20-min dark
adaptation period in the light-proof chamber followed by a 10-min
"warm-up" with the various intensities of white light to be used in
the session.
For both the auditory and visual threshold determinations, each
test session was divided into four blocks of approximately 140 trials
with each of the 4 intensity levels (plus "catch" trials) presented
randomly approximately 28 times during each block. This provided 4
independent within-session estimates of the sensory thresholds and
functions relating reaction time to intensity. Sensory thresholds
were determined from percent correct detections at each intensity by
interpolating to the intensity which produced a detection score
halfway between the false alarm rate ("catch" trials) and 100%.
Stable auditory thresholds were based upon determinations from 3
successive test sessions with estimates which varied by no more than
4 dB. Stable visual thresholds were based upon determinations from 3
successive test sessions with estimates which varied by no more than
0.2 log density units. In both cases, such a determination of
threshold stability required a false alarm rate below 30% and no
systematic change trends in the data. With regard to the response
latency measure of reaction time (typically skewed due to the
physiological limits on lever release time), the measure of central
tendency employed for such distributions was the median, with
variability reported in terms of the interquartile range.
Following stabilization of the threshold and reaction time
measures, preliminary studies were undertaken to explore the
validity, reliability, sensitivity, and specificity of these
psychophysical methods with respect particularly to the evaluation of
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drugs of abuse. All drugs were administered intramuscularly at the
beginning of each experimental session, followed by a 30-minute delay
(dark adaptation and warm-up) before formal threshold determinations
were begun. Saline control sessions were conducted between each drug
session and return-to-baseline performances were required during
these intervening saline control sessions before further drug
administrations were programmed.
Figure 11 shows the orderly effects of increasing doses of
amobarbital sodium (i.e., 3.2, 10.0, 17.0 mg/kg, i.m.) upon reaction
time as a function of white light stimulus intensity in the baboon.
The latency-intensity functions were recorded 1 to 2 hours after drug
administration (i.e., at the peak action time) and show the sytematic
relationship between drug dose and response latency at all but the
lowest (i.e., threshold) intensity level. Even at the highest
intensity levels where response variability is minimal, the orderly
progression of increasing latencies with increasing doses is
apparent.
Figure 12 illustrates the dose-dependent effects of
pentobarbital upon absolute auditory and visual thresholds, and their
respective median reaction times for 2 animals. All data points are
the average of at least two determinations with each animal at each
dose, and represent the difference between those values at peak drug
action time and the corresponding saline values during the preceding
day's control session. Reaction time values are for auditory stimuli
presented at approximately 25 dB above the auditory thresholds, and'
Figure 11. Reaction time change as a function of in-
creasing visual stimulus intensity after saline or
three doses of amobarbital.
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for visual stimuli presented at approximately 1.25 log relative
density units above the visual thresholds. The 95% confidence limits
of the variability for all saline sessions preceding a drug session
are shown to the left in each graph for each animal. Consistent
elevations in the visual threshold and in both visual and auditory
reaction times were observed following doses of 10.0 and 17.0 mg/kg
with no change in auditory threshold over this same dose range.
Figure 12. Changes in absolute auditory and visual
thresholds and their respective median reaction times
for two animals (IK = , PE = ) as a function of
pentobarbital dose. The 95% confidence limits in
variability for all saline sessions preceding a drug
session are shown to the left in each graph for each
animal. Values obtained following vehicle administra-
tion are marked "V".
Figure 13 shows samples of individual auditory and visual
psychometric functions and their corresponding reaction time
functions during the peak time of effect for animal IK after
pentobarbital administration over the dose range 1.0 to 17.0 mg/kg.
Percent correct lever releases and reaction times for correct
releases are plotted as a function of stimulus intensity in dB sound
pressure level (SPL) for the auditory functions (top) and in log
relative density units for the visual functions (bottom). The saline
points were similarly derived from the control sessions conducted on
days preceding each drug session. At the highest dose (17.0 mg/kg),
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pentobarbital produced different effects upon auditory and visual
thresholds, though similar increases occurred in both auditory and
visual reaction times. The clear shift in the visual threshold
function shown in Figure 13 (bottom) at 17.0 mg/kg pentobarbital
occurred in the absence of any change in the auditory threshold
function (Figure 13, top) under identical drug conditions. Also, the
drug-induced reaction time increases were approximately parallel
shifts for both the auditory and visual curves.
Figure 13. Changes in individual auditory and visual
psychometric functions and their corresponding reaction
time functions during the peak time of drug effect for
animal IK over the dose range of 1.0 to 17.0 mg/kg
pentobarbital. Filled circles represent data from drug
sessions; open circles represent data similarly derived
from the preceding day's saline control session.
Figure 14 illustrates the effects of diazepam as a function of
dose (0.1, 0.32, 1.0, 3.2, 10.0 mg/kg) upon response latencies and
sensory thresholds in three baboons under the same stimulus
conditions and "peak drug action time" (i.e., 1-2 hours following
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Figure 14. Changes in absolute auditory and visual
thresholds and their respective median reaction times
for three animals (PE = , IK = , OL = ), as a function
of diazepam dose. The 95% confidence limits for all
saline sessions are shown to the left in each graph for
each animal. Values obtained following vehicle adminis-
tration are marked "V".
i.m. administration) relationships used with pentobarbital. The
range of saline control values is shown by the vertical lines on each
point. Clear effects upon reaction time and the visual threshold
were observed as a function of dose, and auditory thresholds were
similarly affected. For the most part, all three effects - increased
response latency, visual threshold elevations, and auditory threshold
increases - appeared in a dose-dependent manner with progressively
greater decrements through the range from 1.0 to 10.0 mg/kg. In
contrast, observations with chlordiazepoxide over approximately the
same dose range (1.0 to 32.0 mg/kg) used in the pentobarbital (Figure
12) and diazepan (Figure 14) experiments, revealed only modest
elevations in auditory threshold and reaction times at the highest
dose (32.0 mg/kg) and no effect on visual threshold at any of the
indicted doses.
Figure 15 illustrates the dose-dependent effects of
d-met-amphetamine upon changes in auditory and visual thresholds,
and their respective median reaction times. Consistent elevations in
visual threshold were observed only at the highest doses.
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Figure 15. Changes in absolute auditory and visual
thresholds and their respective median reaction times
for three animals as a function of d-methylamphetamine
dose. Other details are presented in the legend for
Figure 12.
Significantly, these elevated visual thresholds occurred in the
presence of a slight decrease in visual reaction time with one
animal. Dose-related decreases in auditory reaction times were also
observed with some animals during auditory testing, though auditory
thresholds were unaffected over the dose range 0.1 to 0.32 mg/kg d-
methylamphetamine. The effects of phencyclidine (PCP) over a range
of doses (0.0032, 0.01, 0.032, and 0.1 mg/kg) upon the auditory and
visual thresholds and their respective median reaction times were
also studied. Although frequent disruptions in performance occurred
at the highest dose, the auditory threshold and reaction time were
only minimally affected throughout this dose range. Visual
thresholds and reaction time were both significantly elevated at the
0.032 mg/kg dose level, however, though again frequent disruptions in
performance occurred at the highest dose (0.1 mg/kg).
3. Relationship Between Reinforcing Properties and
Behavioral Toxicity of Abused Drugs
The results obtained from an analysis of the relationship
between the measures of reinforcing efficacy (i.e., drug
self-administration) and behavioral toxicity (i.e., sensory/motor
decrements) with three barbiturates (amobarbital, secobarbital, and
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pentobarbitall and two dissociative anesthetics (phencyclidine and
ketamine) have been detailed in a report incorporated in the present
volume (Brady, Lukas, and Hienz, 1982). All five compounds
maintained drug self-administration rates as a function of dose level
and the dose of each compound which maintained criterion intravenous
self-injection was determined. Dose-dependent increases in reaction
time were also observed with all five drugs, and the dose of each
compound which produced a 10% change in this measure was determined.
The resulting Reinforcement/Reaction-Time-Toxicity Ratios derived
from the relationship between the criterion reinforcing dose and the
reaction time toxicity dose were determined for each of the five
drugs studied, the ratio values ranging from a low of 0.07 for
amobarbital to a high of 1.22 for phencyclidine.
Dose-dependent increases in sensory thresholds were also
observed with all five drugs, and the criterion dose of each compound
which produced a 50% change in either auditory or visual threshold
was determined. The resulting Reinforcement/Sensory-Threshold-
Toxicity Ratios derived from the relationship between criterion
reinforcing dose and the sensory threshold toxicity dose were
developed for each of the five drugs studied, the ratio values
ranging from a low of 0.04 for amobarbital to a high of 2.0 for
phencyclidine. The relationship between the criterion sensory and
motor change doses and the criterion self-administration dose for the
five compounds thus far studied revealed that with all three
barbiturates, the doses which produced disruptive sensory/motor
changes were generally higher than the doses required to maintain
self-administration of these compounds. Moreover, there was a
consistent relationship between the sensory and motor effects of
these three barbiturates, with the reaction time effects appearing at
lower doses than the sensory effects. In contrast, both ketamine and
phencyclidine were differentiated from the three barbiturates by the
appearance of sensory changes at doses below those which produced
reaction time effects. The phencyclidine values also showed that the
doses required to maintain self-administration were generally higher
than the doses which produce disruptive sensory/motor changes.
The ordering of compounds derived from analyzing the
relationship between reinforcing efficacy and behavioral toxicity
shows that there are wide ranging differences between drugs of abuse,
with the Reinforcement/Toxicity Ratios for phencyclidine being up to
10 times greater than those for amobarbital. The high ratio values
reflect the fact that such compounds have disruptive sensory/motor
effects at lower doses (relative to their reinforcing potency) than
compounds with lower ratios. And in the case of phencyclidine, these
behaviorally toxic effects can occur below the reinforcing dose: In
contrast, the low ratio values reflect the fact that a drug has
disruptive sensory/motor effects at higher doses (relative to its
reinforcing dose) than compounds with higher ratios. Amobarbital,
for example, maintained self-administration at doses below those
which produce behaviorally toxic effects.
The sensory toxicity dose values for the compounds included in
the present analysis were determined on the basis of criterion
changes in either auditory or visual thresholds as a first
approximation in analyzing their relationships to reinforcing
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potency. That these compounds can produce differential effects as a
function of sensory modality and drug dose, however, is illustrated
in Figures 12 and 13, and has as well been documented in recent
studies of the psychophysical profiles of drugs of abuse (Hienz and
Brady, 1981; Hienz, Lukas, and Brady, 1981). The results of these
experiments have shown, for example, that the barbiturates can
produce significant elevations in the visual threshold at doses which
produce no change in the auditory threshold. These findings suggest
that the relationships described in the present report can be
extended to provide a much more specific analysis of the nature and
degree of disruptive effects under various conditions of drug
self-administration.
Extending behavioral models for drug elevation to include
analysis of the relationship between a drug's reinforcing effects and
the effects of that compound from a behavioral toxicity perspective
adds a critical dimension to the assessment of pharmacological
activity and abuse liability.
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Development of Clinical
Procedures for Abuse Liability
Assessment:
Progress Report From the Behavioral
Pharmacology Research Unit of the Johns
Hopkins University School of Medicine
and Baltimore City Hospitals
George E. Bigelow, Roland R. Griffiths, Maxine L. Stitzer, and
Ira A. Liebson
For the past 15 years the Behavioral Pharmacology Research Unit
laboratory at Baltimore City Hospitals has been conducting a
variety of studies concerning the self-administration and effects
of drugs of abuse in human volunteers. The purpose of the present
progress report is to summarize work conducted during the last two
years with supplemental grant support from The Committee on
Problems of Drug Dependence.
In mid-1980 the Committee initiated a program to provide research
grant support to clinical research laboratories for the develop-
ment of clinical testing procedures to be used in the assessment
of drug abuse liability in humans. A major impetus for this
research grant program was the fact that the clinical laboratories
of the National Institute on Drug Abuse Addiction Research Center
in Lexington, Kentucky, had been disallowed, since 1970, from
conducting clinical studies with volunteer federal prisoners.
Prior to that time, the NIDA-ARC research program, conducted with
incarcerated former drug abusers at the Lexington prison facility,
had provided the major resource in this country for the clinical
testing of drug abuse liability. With the closing of the Lexing-
ton clinical facility and the subsequent transfer and reopening
of the ARC program in Baltimore in 1980 it was clear that there
would be major changes in the nature and magnitude of the
facilities available for the clinical assessment of drug abuse
liability. For example, the transfer of the Addiction Research
Center to Baltimore was accompanied by a dramatic reduction in
the size of its clinical resources -- from approximately 60 beds,
to approximately 10 beds. Also, with the loss of access to
federal prisoners as research volunteers it was clear that new
clinical resources and procedures needed to be developed for the
conduct of clinical abuse liability evaluations.
Several questions arose: 1) What clinical settings would be
appropriate for these studies? 2) What subject populations could
125
sensitively and appropriately differentiate compounds along the
dimension of abuse liability? 3) To what extent would there be
generality and transfer of the methods developed in the ARC
prison facility to other settings and subject populations? and
4) What alternative procedures might be feasible and/or necessary
to maximize the data yield from these new research contexts?
Since the purpose of our CPDD support was to promote procedural
development, this progress will provide primarily a descriptive
overview of our clinical abuse liability assessment resources and
procedures, with only brief illustrative results from individual
procedures.
Approach
In designing our clinical research program we have considered and
attempted to assess four aspects of abuse liability: 1) The ex-
tent of maintenance of drug self-administration behavior; 2) The
profile of acute subjective and physiological effects; 3) Altera-
tions produced in cognitive/psychomotor performance; and 4) Al-
terations produced in global clinical mood and behavior. These
dimensions are intended to assess the two crucial aspects of abuse
liability -- the likelihood of a compound's being self-administered,
and the likelihood of its producing disruptive effects following
its administration.
Clinical Resources
As summarized in Table 1, our laboratory has utilized both a wide
variety of subject populations and a wide variety of clinical
research settings for conducting abuse liability evaluations.
TABLE 1. Resources for clinical Drug Abuse
Liability Assessment
A. SUBJECT POPULATIONS
1. Non-dependent abusers
2. Addiction treatment patients
3. "Recreational" users
4. General community volunteers
5. Medical patients
B. RESEARCH SETTINGS
1. Residential laboratory
2. Intravenous laboratory
3. Methadone treatment clinic
4. Day-laboratory sessions
5. Weight control clinic
It is possible to recruit from the community volunteers for re-
search participation with extensive chronic abuse histories who
are not physically dependent; these individuals would presumably
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be most similar to the former addicts traditionally studied by
the Lexington Addiction Research Center. Patients enrolled in
addiction treatment also provide convenient access to volunteers
with extensive abuse histories; this population (i.e., methadone
maintenance patients) can also be appropriate for studies where
physiological dependence upon opiates is desirable. Another con-
venient and readily available population is that of “recreational”
drug users; these are individuals with extensive illicit drug use
experiences, for whom drugs function as reinforcers, but who are
not in treatment and whose patterns of use are not so intense or
destructive that one would necessarily recommend treatment.
General community volunteers without significant illicit drug use
histories, and medical patients who are exposed to potential
drugs of abuse for therapeutic reasons both provide alternative
populations in which the profile of drug effects can be readily
assessed; these populations can also provide a basis for assess-
ing whether similar abuse liability discriminations are made by
nonabuser versus experienced-abuser subjects.
Measures
Table 2 illustrates the range of measures which we attempt to in-
clude in our clinical drug abuse evaluations. These include a
range of behavioral, subjective and physiological variables. The
TABLE 2. Array of Measures Used in Clinical
Abuse Liability Assessments
BEHAVIORAL
Drug self-administration
Psychomotor/cognitive performance
Observer ratings of mood and behavior
SUBJECTIVE
Drug liking
Symptom ratings
Mood ratings
ARCI scales
PHYSIOLOGICAL
Vital signs
Pupil diameter
behavioral measures include indices of drug self-administration
behavior, psychomotor/cognitive performance, and observer ratings
of global clinical mood and behavior. The subjective measures
include evaluations of subjective drug liking, symptom rating
scales, mood rating scales and various scales of the Addiction
Research Center Inventory. The physiological measures include
periodic vital signs assessment and, for studies of opioids,
measures of pupillary diameter.
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One general method which we have used to assess relative drug
abuse liability involves a series of forced exposure trials to
the various test doses or test compounds followed by a choice
trial, in which the subject himself chooses which of the pre-
viously-experienced test conditions he will receive again. Ex-
periments proceed as a series of alternating forced exposure
trials and choice trials. The forced exposure trials permit
evaluation of the profile and time-course of subjective and be-
havioral effects in a manner similar to that traditionally used
by the NIDA Addiction Research Center. The added choice trials,
however, provide an objective behavioral measure of the relative
reinforcing efficacy of the test compounds.
Residential Laboratory
Within our residential laboratory we have used this alternating
forced-exposure/choice-trial procedure to compare diazepam
(50 - 400 mg) and pentobarbital (200 - 900 mg) in experienced
sedative abusers. In that previously-reported study (Griffiths
et al. 1980) the subjective liking data generally paralleled the
behavioral choice data -- with both active drugs being preferred
over placebo, and with higher doses of pentobarbital being pre-
ferred over lower doses, but with relatively little diazepam dose
preference over the range tested. Comparisons between the two
active drugs, using intermediate doses producing similar magni-
tudes of overall sedative effect, showed a uniform preference for
pentobarbital over diazepam.
Elsewhere in these proceedings Griffiths et al. report more re-
cent data from our residential laboratory indicating differential
effects of pentobarbital and diazepam upon global clinical mood
and behavior; disturbances in mood and behavior were seen follow-
ing diazepam (50 - 100 mg/day) which did not occur following
pentobarbital (200 - 400 mg/day).
At last year's CPDD meeting McLeod et al. (1982) presented data
illustrating use of the residential laboratory for assessing the
effects of pharmacological treatments upon the signs and symptoms
of the opioid abstinence syndrome and upon opioid drug-seeking
and self-administration behavior during methadone detoxification.
Intravenous Laboratory
One evaluation procedure developed specifically via our support
from the Committee on Problems of Drug Dependence is our intra-
venous laboratory. In this procedure subjects participate in
sessions of several hour duration 2 - 3 times per week while in-
tensive psychophysiological and subjective data are collected to
evaluate the profile and time course of effects of intravenously
administered drugs. An advantage of this intravenous procedure is
the speed of the drug effect onset and time course, which permits
intensive multifaceted assessment of changes over a relatively
brief period within a standardized laboratory setting.
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At last year’s CPDD meeting (McCaul et al. 1982) and also else-
where in these proceedings , McCaul et al. have presented data
describing the profile and time course of the subjective and
physiological effects of a range of hydromorphone doses in experi-
enced opioid abusers and describing the effects of methadone
maintenance treatment (i.e., opioid tolerance) on those effects.
These data have identified symptom ratings and overall drug “high”
ratings which appear to track the time course of opioid agonist
effects at least as sensitively as the subjective effect indices
traditionally used in opioid evaluations by the NIDA Addiction
Research Center.
Day-Laboratory
A second procedure developed specifically via our support from
CPDD is our day-laboratory procedure for evaluating drugs in
“recreational” users and in general nonabuser community volun-
teers. In these studies volunteers from the community partici-
pate in within-subject experimental designs in which they spend
a number of hours in the laboratory on several different days
while subjective and behavioral effect time-course data are col-
lected concerning each of several drug or dose test conditions.
In studies in this setting we have evaluated the ability of
“recreational” drug users to detect the effects and time course
of normal therapeutic dose levels of various benzodiazepines
versus placebo, and we have assessed the effects upon psycho-
motor/cognitive performance of these therapeutic dose levels both
when given alone and when combined with various doses of ethanol
(0.75 and 1.5 ml/kg). Benzodiazepine doses have been 5 mg diaze-
pam, 1 mg lorazepam, or 7.5 mg clorazepate, each given twice daily
at a 4-hr interval.; when ethanol was given it accompanied the
second of the daily drug doses. Results have shown that in this
subject population both subjective liking measures and psycho-
motor/cognitive performance measures were able sensitively to
differentiate among these benzodiazepines even at these modest
dosage levels and that it is possible in this setting to track
the time course of these drug effects and to assess their inter-
action with ethanol. Detailed data analysis is still in progress.
Weight Control Clinic
A final setting in which we have conducted comparative clinical
evaluations of drugs of potential abuse is a behavioral pharmaco-
logical weight control treatment research clinic (Bigelow et al.
1980). Here it is possible to evaluate the effects and self-ad-
ministration of drugs among nonabuser volunteer patients who are
exposed to the test drugs for therapeutic reasons. We have been
using this setting for comparative evaluations of the various
phenylethylamine CNS stimulant-anorectics which are marketed for
weight control. The general procedure is a within-subject ex-
perimental. design involving cycles of forced exposures to the
test compounds followed by choice trials, as described earlier.
Results have shown d-amphetamine (5 - 10 mg tid) to be preferred
over fenfluramine (20 - 40 mg tid) and diethylpropion (75 mg con-
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trolled release) to be preferred over chlorphentermine (65 mg).
The behavioral choice procedure has proven its value by detect-
ing differences between compounds which were not detected by
comparing the effects of forced exposures. While it is not
possible to know whether variations in drug self-administration
within this therapeutic context are related to variations in the
reinforcing efficacy or abuse liability characteristics of these
compounds, it is interesting that the between-drug differences
so far observed have all been in a direction congruent with both
animal and clinical data concerning relative abuse liability.
Conclusions
We have found that a variety of settings and subject populations
appear adaptable to providing orderly clinical data concerning
the relative reinforcing efficacies and abuse liability of drugs.
Specifically, we have found that such studies can be conducted
in nonresidential settings and with volunteer participants with-
out chronic drug abuse histories. Many of the general methods
developed by the NIDA-ARC for conducting these evaluations with
incarcerated postaddicts have proven adaptable to these other
settings and other populations -- especially the general approach
of examining the profile and time course of subjective drug ef-
fects and the use of liking measures and the Addiction Research
Center Inventory as assessment instruments. In addition to the
ARCI scales we have found that there are a variety of other self-
report measures which appear to provide sensitive indices of
relative drug effects -- at times even more sensitively than the
ARCI scales. Finally, we would emphasize the value of the be-
havioral measures in these procedures. Behavioral choice measures
of drug preference would appear to provide us with the most
straightforward and direct measure of the criterion we are trying
to predict in abuse liability testing -- the relative efficacy of
compounds in sustaining self-administration. In addition, be-
havioral measures of drug effects on skill performances and on
global clinical behavior provide useful complementary data con-
cerning the relative risks which might ensue consequent to the
use or abuse of these compounds.
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Comparative Assessment of
Potential Abuse Liability of
Natural and Synthetic
Cannabis Compounds
Jack H. Mendelson, Nancy K. Mello, Barbara Lex, Jon
Pehrson, and Samuel Bavli
INTRODUCTION
Laboratory and clinical investigations have indicated that canna-
bis compounds may have therapeutic applications as analgesics,
antiemetics, bronchodilators, antihypertensives and in the treat-
ment of glaucoma (Babor et al. 1975; Cohen and Stillman 1976).
Since cannabis compounds produce hypnosedative and psychoactive
effects in humans and are commonly used as recreational drugs,
the risk of illicit diversion may increase as cannabis is used
more widely in medicine. The situation is analogous to the prob-
lems associated with the development of new analgesics. The ra-
tionale for FDA scheduling of prescription opioid drugs is to re-
duce drug dependence liability through illicit distribution. Dur-
ing 1979, the Committee on Problems of Drug Dependence, Inc. ini-
tiated a program to develop methodologies to assess the abuse de-
pendence liability of non-opioid drugs which may have applications
in clinical medicine. This report describes a new behavioral
paradigm for the evaluation of potential abuse liability of a syn-
thetic cannabis compound in man.
Following anecdotal reports that marijuana smoking reduced nausea
and vomiting associated with cancer chemotherapy? more systematic
observations suggested that naturally occurring 9 tetrahydrocan-
nabinol was an effective antiemetic agent for patients receiving
chemotherapy (Herman et al. 1977). The active compound in mari-
juana 9 THC is delivered in unpredictable doses of varying
potency in marijuana cigarettes. Consequently, synthetic cannabis
derivatives were prepared for use as adjunctive agents in cancer
chemotherapy. Nabilone is a modified cannabinol derivative which
has been shown to be efficacious in suppressing severe nausea and
vomiting induced by cancer chemotherapy (Isbell et al. 1967).
Studies of the clinical pharmacology of Nabilone have been carried
out with normal healthy male volunteers and acute-administration of
1 and 2.5 mg doses produced relaxation and sedative effects
(Lemberger and Rowe 1975). A minimal degree of euphoria, dry
mouth, tachycardia and postural hypotension were observed after
1 and 2.5 mg dosage (Lemberger and Rowe 1975). Although euphoria
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was not significant at low dosage administration of Nabilone
(1 to 2.5 mg) (Lemberger and Rowe 1975)) illicit use of the drug
could occur. This report describes assessment of the reinforcing
properties of a single dose of Nabilone (2 mg) in comparison to
9 THC (17.5 mg) , a standardized marijuana cigarette containing
1.83 %. 9 THC, and placebo controls. Behavioral assessment of
reinforcing properties by a combination of self-reports and work-
contingent choice between these four substances provides an objec-
tive index of potential abuse liability.
METHODS
Subjects: Twenty-four healthy, adult, male volunteers recruited
through newspaper advertisements, provided informed consent for
participation in these studies. Prior to selection for the study
all subjects completed a standardized drug use questionnaire and
a Cornell medical index. All subjects received a complete medical
examination, an electrocardiogram, and blood and urine laboratory
studies.
No subject reported a history of drug use other than marijuana and
none had a history of drug dependence. No subject had a history
of alcohol abuse or alcohol dependence.
Subjects selected to participate in the study were divided into
three groups on the basis of their reported marijuana use. Regu-
lar users were subjects who smoked 1-3 marijuana cigarettes per
day and had engaged in this pattern of marijuana use for at least
one year. Eight subjects with a mean age of 26.8 years (range 23-
30) and a mean weight of 163.8 lbs (range 140-216 lbs.) were regu-
lar marijuana users. Intermittent users smoked 1-3 marijuana
cigarettes per week and had engaged in this pattern of marijuana
use for at least one year. Eight subjects with a mean age of 25.3
years (range 22-30) and a mean weight of 158.6 lbs. (range 131-181)
were intermittent (weekly) marijuana users. Occasional (monthly)
users smoked 1-3 marijuana cigarettes per month and had engaged in
this pattern of marijuana use for at least one year. Eight mari-
juana users with a mean age of 24.4 years (range 22-28) and a mean
weight of 164.1 lbs. (range 133-192) were occasional marijuana
users. Final data are reported on 23 subjects; one subject left
the study after the first experimental day because of anxiety
about his interaction with the other subjects.
Drugs: Each subject served as his own control over five consecu-
tive days during which Nabilone (2 mg), Nabilone placebo, a stan-
dardized marijuana cigarette (1 gram containing 1.83 percent THC),
a standardized marijuana placebo cigarette, 17.5 mg THC P.O.,
and a THC placebo were administered under double blind and double
dummy conditions to control for two routes of administration e.g.,
smoking and oral capsules.
Drug dosage for this study was selected on the basis of 2 mg of
Nabilone having equal potency of 17.5 mg of orally administered
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9 THC (Lemberger and Rowe 1975). Studies carried out by Isbell
and his associates (1967) have shown that the potency of9 THC
after smoking (as determined from changes in peak pulse rate) is
approximately 2.6 times that after oral ingestion. The marijuana
cigarettes used in the study contained 1.83 % of 9 THC in each
1 gram cigarette. However, subjects actually inhaled only 1/3 of
the total pyrolyzed material in any cigarette or approximately
6.1 mg of 9 THC.
Sequence of Procedures: During the first four days of the study
each subject received only one dose of the active compound (mari-
juana, Nabilone or THC) and placebos during each drug trial.
Drugs were administered according to a 4 x 4 Latin square design
to control for sequence effects. Each drug trial day (the first,
four consecutive days of study) was designated by a specific
color code (blue, red, yellow or green). During these four days
subjects remained on the research ward from 6:00 p.m. each eve-
ning until 7:00 a.m. the following morning when they were allowed
to depart for their usual school or job activities.
During the first four days of drug administration, subjects pro-
vided a urine sample for drug screening examination when they
reported to the laboratory. Questionnaire instruments adminis-
tered to assess the type and quality of subject drug effects in-
cluded a Profile of Mood States (POMS), the Adjective Check List
(ADCL) and a “High” scale to assess subjects’ levels of intoxica-
tion. These instruments have been successfully employed in pre-
vious studies to assess marijuana effects in humans (Mendelson
et al. 1976; 0rr and McKernan 1981; Rossi et al. 1978)). Sub-
jects were also asked to provide a placebo-drug report to indicate
whether they believed they had received an active drug or a place-
bo. Blood samples were obtained for determination of pituitary-
gonadal hormones prior to and following drug administration.
These data will be reported elsewhere.
On the fifth day of the study, subjects were given an operant
manipulandum and told that they could work for one dose of the
red, yellow, blue or green drug which they received during the
four previous consecutive days. In order to obtain one addition-
al dose of their drug of choice, subjects were instructed to
press the response key on the operant manipulandum to earn 3600
reinforcement points. Acquisition of the required number of
points for their drug of choice required 30 to 40 minutes of work.
Following drug administration, subjects could then work at an
identical operant task to earn money. They could earn $10.00 for
3600 responses or 30 to 40 minutes of sustained operant perform-
ance.
RESULTS
Drug Safety: Eight regular marijuana users, seven intermittent
users and eight occasional users completed all phases of the study.
No adverse physical side effects or changes in vital signs
occurred during the course of the study. No subject became ill
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or was unable to attend to work or school activities during the
five study days. All subjects were drug free during the study.
Daily urine drug screens did not reveal any psychoactive substan-
ces such as opiates, sedative hypnotics, stimulants, tranquilizers
or depressants for any subject.
Subjective Levels of Intoxication: The subjects were able to dis-
criminate placebo from active drugs with 98 percent accuracy.
Following marijuana smoking, all subjects reported "high" scale
scores which were significantly greater (p <.01) than after pla-
cebo administration. Subjects in the regular, intermittent and
occasional groups did not differ significantly in "high" ratings
following marijuana smoking. However, heavy and intermittent
users reported significantly lower "high" scores after THC than
after marijuana smoking (p <.05). Occasional users reported
equivalent "high" scores after marijuana smoking and oral THC ad-
ministration. Following Nabilone administration all subjects'
reports of "high" were significantly lower than after marijuana
smoking (p <.05). The degree of "high" following oral THC ad-
ministration and Nabilone did not differ significantly for any
group. Thus in terms of perceived high, the rank order from most
to least was smoked marijuana  >oral THC >Nabilone >placebo.
Following marijuana smoking, a statistically significant increment
in "stoned" scores was obtained for all three subject groups
(p <.05) and there were no statistically significant differences
between these groups. Following THC and Nabilone administration,
"stoned" scores were significantly lower than after marijuana
smoking for all three subject groups (p <.05). There were no
statistically significant differences in "stoned" scores between
THC and Nabilone administration for the three subject groups.
Changes in Mood States: Following placebo administration no sta-
tistically significant differences occurred for any of the sub-
ject groups in POMS elation factor scores. After marijuana smok-
ing, a small but statistically significant increment in elation
scores (p <.05) was reported by the regular users. No significant
changes in the POMS elation factor scores were observed for any of
the subject groups following THC or Nabilone administration. How-
ever, there was a small but consistent decrement in the POMS ela-
tion factor score at the end of each experimental session for each
subject group. The most parsimonious explanation for this obser-
vation was that subjects tended to become more fatigued toward the
end of each experimental day assessment period.
Changes in Pulse Rate: No significant changes in pulse rate were
observed for any subject group following placebo administration.
Pulse rates increased after marijuana smoking and administration
of THC and Nabilone. Statistically significant increases in pulse
rate were observed for the intermittent and occasional users fol-
lowing marijuana administration (p <.05) and for all subjects fol-
lowing THC and Nabilone administration (p <.05). Although pulse
rate increases following marijuana, THC or Nabilone administration
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achieved statistically significant levels, the biological signifi-
cance of these observations is questionable since the increment in
pulse rates were relatively small.
Operant Contingent Drug Choice: Eighteen subjects (7 regular
users, 6 intermittent users, and 5 casual users), worked to ob-
tain an active marijuana cigarette. Two subjects (1 regular and
1 intermittent user) worked to obtain 17.5 mg of oral THC. None
of the subjects worked for Nabilone and three subjects (all occa-
sional users) elected not to work for any drug on the fifth study
day. All twenty-three subjects worked to obtain the $10.00 mone-
tary reinforcement on the fifth study day and all earned the requi-
site 3600 reinforcement points within 30 to 40 minutes. There
were no significant differences in the time spent at operant work
or the efficiency of operant performance for money reinforcement
between the regular, intermittent and occasional users. There
were no significant differences in operant performance for mone-
tary reinforcement between those subjects who had elected to smoke
marijuana, ingested THC or who had not worked for any drug prior
to the opportunity to earn operant points for money.
DISCUSSION
The major findings obtained in this study were: subjects accu-
rately discriminated marijuana cigarettes, orally administered
THC and Nabilone from their placebos; marijuana smoking produced
the greatest change in subjective responses for the “high” and
“stoned” rating scales; marijuana was the drug of choice for
90 percent of the subjects (20 of 22) who elected to work at an
operant task for drug acquisition. Taken together these data
strongly suggest that marijuana smoking is the preferred mode of
cannabis self-administration by regular, intermittent and occa-
sional marijuana users and that orally administered THC compounds
are much less preferred (only two subjects who worked for a drug
of choice selected oral THC). Since no subject elected to work
for Nabilone and since Nabilone produced significantly less change
in self-rating scores than marijuana, we conclude that Nabilone
would have relatively low abuse potential liability for indivi-
duals who have a wide spectrum of past history of marijuana use.
This study also demonstrated that evaluation of new pharmacothera-
pies (with psychoactive properties) for safety and efficacy may
also be supplemented with procedures to determine potential abuse
liability in humans. The research design and procedures utilized
in this study may provide a useful model for assessing the rein-
forcing properties and potential abuse liability of psychoactive
drugs for selected populations who may be at risk for drug abuse.
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Synthesis and Analgesic Activity
of 5-Aryl-3-Azabicyclo [3.2.0.]
Heptan-6-One Dimethylacetals:
Compounds With Extraordinary
Morphine-Like Properties
J. W. Epstein, T. C. McKenzie, W. J. Fanshawe, A. C.
Osterberg, B. A. Regan, L. P. Wennogle, M. S. Abel, and
L. R. Meyerson
As a part of our studies of aryl azabicycloalkanes as analgesic
agents (Epstein et al. 1981, 1982), we undertook the synthesis of
5-aryl-3-azabicyclo[3.2.0]heptanes (McKenzie et al. 1982). We
employed a [2+2]photocycloaddition of 1,1-dimethoxyethylene to 2-
phenylmaleimides, 1, [prepared by the method of Izzo (1963)] to give
the cyclobutanedicarboximides 2, and subsequent reduction with
sodium bis(2-methoxyethoxy)aluminum hydride gave the desired 5-aryl-
3-azabicyclo[3.2.0]heptanes, 3a-3e. The structure of the photo-
products 2 was established by 1H NMR spectroscopy. The bridge-
head methine proton at 3.32 is coupled to the adjacent cis and
trans cyclobutane methylene protons with a coupling constant of
4.4 and 10.5 Hz, respectively. The ring juncture was assumed to
be cis. The N-methyl-m-methoxyphenyl analogue 3b was demethylated
(Epstein et al. 1981) with sodium ethyl mercaptide in N,N-dimethyl-
formamide to give phenol 4. The N-ally1 derivative 5 was obtained
from 3a by alkylation with allyl bromide in toluene-sodium carbonate.
Ketal 3b was hydrolyzed to the corresponding ketone 6 using hydro-
chloric acid.
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PHARMACOLOGY
The results of analgesic testing using the reversal of the 3-legged
gait in rats are presented in Table I, and an examination of the
data suggests that these compounds fall into the category of
narcotic-type compounds. The most potent members of the series are
the m-methoxyphenyl 3b and m-hydroxyphenyl-N-methyl 4 congeners,
while the absence of the N-methyl group in 3a significantly cur-
tails activity. The phenyl analogue 3c retains moderate activity,
while the p-chloro 3e compound is less active, and the p -methyl 3d
analogue is inactive. The significant aspect of this study is that
compound 3b shows considerable (ED50= mg/kg) oral activity, and
remarkable morphine-like effects (Table II). The hydrolysis product
of 3b, the ketone 5, is inactive, which suggests that the ketal re-
mains intact in vivo. The N-allyl derivative 6 is active, but the
ED50 was not determined.
Table I also shows the inhibition of 3H-naloxone binding by compounds
at 25 and 0.78 micromolar. It is interesting that compound 3b shows
inhibition in a range which is comparable to the less active,and
inactive compounds. The phenol 4, however, shows morphine-like
binding characteristics. Table III compares the IC50 values of 3b
and 4, as well as sodium-index values. Compound 3b has an IC50-
value around 10,000 nM with a sodium index (6.3) car that of
morphine (5.1), while the phenol 4 has an IC50 value (61 nM) equiv-
alent to morphine (74 nM). In addition, the sodium index of 4
(9.4) suggests that it is a pure agonist (Pert and Snyder 1973).
Compounds 3b and 4 show narcotic toxicity at relatively low doses
and these effects can be inhibited by naloxone. Table II summar-
izes these characteristics for 3b.
There are some geometric similarities between 3a and morphine that
are not obvious on casual inspection. The distances and orienta-
tion from the nitrogen atom to the other three atomic features
thought necessary for analgesic activity are similar to those of
morphine. These salient features are a benzene ring, a quaternary
carbon attached to the ring, and a hydroxyl group disposed meta
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to the quaternary carbon. In addition, the two oxygen atoms of the
ketal are in similar positions relative to the nitrogen as the re-
maining two oxygen atoms of morphine. The distance from nitrogen
to the allylic hydroxyl group of morphine is 6.5Å and from nitrogen
to the -methoxylgroupof 4 is 4.6Å.
of the five features discussed.
This is the largest discrepancy
PHARMACOLOGICAL METHODS
Inflamed Rat-Paw Reversal of Abnormal Gait. A modification
(Epstein et al. 1982) of the procedure of Atkinson and Cowan (1974)
was used as the primary assay.
Inhibition of 3H-Naloxone Binding. Inhibition of 3H naloxone
binding was conducted employing the procedure originally described
by Pert and Snyder (1973) and modified by Ong et al. (1980).
Mouse Hot Plate Method. An adaptation of the methods of Woolfe
and MacDonald (1944) and Eddy et al. (1950) was employed. Individual
mice were confined on a heated surface (Techni Lab Instruments,
Model 475) maintained at 55.0 ± 0.5°C and the time required to elicit
a response (licking of paws or-an attempt to jump from plate), was
recorded. A maximum (cut-off) time of 30 seconds was used. The
criterion for analgesia is a 100% increase in response time over that
of vehicle treated mice.
Rat Tail Flick - Radiant Heat Method. A modification of the
method of D'Amour and Smith (1941) was used. The tail of each rat
was exposed to high intensity radiant heat stimulus 90 minutes after
oral administration of the compound, and the time required to elicit
a threshold response (characteristic tail flick) was recorded. A
maximum exposure (cut-off time) of 15 seconds was employed for the
high intensity stimulus. The criterion for analgesia is a 100% in-
crease in response time over that of vehicle treated rats.
Statistics. ED50's and 95% confidence limits were calculated accord-
ing to the linear arc sine transformation method of Finney (1964).
140
Table II. Summary of Effects Induced by 3b in Mice and Rats
Procedure
Reversal of abnormal gait in rats.
Rat tail flick - high intensity
radiant heat stimulus
Mouse hot plate (55° C)
Induction of Straub tail in mice
Acute lethality in rats
Overt Effects
Rats
Interactions
Mice - naloxone (10 mg/kg i.p.)
Rats - naloxone (25 mg/kg i.p.)
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Results
ED50 = 4.0 (2.8-5.6) mg/kg p.o.
ED50 = 5.7 (4.5-7.3) mg/kg p.o.
significant increase in threshold
response at 20 mg/kg s.c.or p.o.
8/8 Straub tail (12.5, 25mg/kg
p.o.
Est. LD50 = 10 mg/kg i.p.,
20 mg/kg p.o.
Catatonia, exophthalamus, de-
creased respiration, decreased
motor activity (10 mg/kg i.p.)
Complete reversal of Straub
tail
Inhibition of overt effects
and lethality
Table III. IC50 Values in Competition Binding with 
3H-Naloxone
in the Presence and Absence of Na+ Ions
Compound IC50 (nM)
a Sodium Index
-NaCl +NaCl(100 mM)
IC50(+ Na+)
IC50(- Na+)
Naloxone 46 42 1.1
Morphine 74 380 5.1
Levallorphan 9 34 3.7
3b 9,924 62,531 6.3
4 61 579 9.4
a IC50 value is defined by the concentration of drug required to
inhibit by 50% the stereospecific binding of 3H naloxone (5 nM) to
homogenates of rat brain minus cerebellum in the presence or absence
of 100 mM NaCl. Each value represents the mean of three separate
experiments.
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Mr 2033 CL—A Novel
Non-Morphine-Like
Opioid Analgesic
K. Stockhaus, H. A. Ensinger, W. Gaida, H.-M. Jennewein,
and H. Merz
Compounds which are acting predominantly by means of the re-
ceptors are different from the morphine-like µ agonists with
regard to several unwanted side-effects and seem to be a new
group of potent analgesics (Martin et al. 1976). In various in
vitro and in vivo experiments, Mr 2033 CL was characterized as a
agonist (Lord et al. 1977; Woods et al. 1979). The action
profile of this compound has some remarkable features which will
be reported here.
Drugs used: Mr 2033 CL = (±)-(1R/S, 5R/S, 9R/S, 2"S/R)-5,9-
dimethyl-2'-hydroxy-2-tetrahydrofurfuryl-6,7-benzomorphan hydro-
chloride, morphine, pentazocine, (±)-ketazocine, nalorphine,
naloxone and naltrexone as hydroclorides, Mr 2266 CL = (-)-
2-(3-furylmethyl)-2'-hydroxy-5,9 -diethyl-6,7-benzomorphan hydro-
chloride synthezised in our laboratories, (±)-bremazocine hydro-
chloride (Sandoz, Basel), [3H]-dihydromorphine (35.5 Ci/mmol),
[3H]-naloxone (50 Ci/mmol), [3H]-Ethylketazocine (15 Ci/mmol) all
from New England Nuclear, and [3H]-D-Ala2-D-Leu5 enkephalin
(26 Ci/mmol; Amersham).
1. Analgesia
Mr 2033 CL is a very potent analgesic drug in different test
models and species (Fig. 1). After subcutaneous administration it
is about 20 times more potent than morphine. Its duration of
action is longer than that of pentazocine in different assays.
Like ketazocine it is active in the Haffner test, the hot-plate
test, and the tail-flick model in mice, while pentazocine and
bremazocine are inactive in these rigorous test models.
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Analgesic Activity of Mr2033-Cl, Morphine and
Pentazocine (ED50)
Figure 1. Analgesic activity of Mr 2033 CL, morphine and penta-
zocine (ED50) in different test models and species. Rb = rabbit.
According to Takemori (1976), the interactions of Mr 2033 CL,
bremazocine, and morphine with the selective µ antagonist na-
loxone and the putative antagonist Mr 2266 CL were analyzed by
means of the apparent pA2-values in the Haffner test and the
writhing assay in mice after subcutaneous administration (Tab. 1).
Table 1. Apparent pA2-values and potency ratios for the inter-
actions of morphine, Mr 2033 CL and bremazocine with naloxone
resp. Mr 2266 CL in two analgesic assays.
In the writhing test, naloxone is 4 times more potent than
Mr 2266 CL as an antagonist of morphine and twice as potent in
the case of Mr 2033 CL. Antagonizing bremazocine, both anta-
gonists are equipotent. These data indicate that different re-
ceptor populations are involved in the analgesic effects of the
three compounds in the writhing assay. The potency ratios charac-
terize naloxone as the most potent antagonist in the Haffner test
because Mr 2266 CL has a relatively low activity in this assay.
The similarity of some of the apparent pA2-values suggest that
- in part - similar receptor populations may be responsible for
the analgesic effects in both assays (Wüster et al. 1981).
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2. Binding studies
Receptor binding studies with the two agonists Mr 2033 CL and
bremazocine in membrane homogenates of rat brain resulted in
similar binding properties of these two drugs, comparing their
affinities to µ, a n d opioid receptor subtype (Tab. 2). In
contrast to morphine and naloxone, which act predominantly via
the µ receptor, Mr 2033 CL and bremazocine show high affinities
to both, µ and receptors (Kosterlitz et al. 1981). According
to the sodium shift, Mr 2033 CL should demonstrate some marked
morphine antagonistic properties.
Table 2. Binding properties (ki-values, [nM]) of morphine,
Mr 2033 CL, bremazocine, Mr 2266 CL, and naloxone. Radioligand:
µ receptor: 3H-dihydromorphine, receptor: 3H-ethylketazocine,
and receptor: 3H-D-Ala2-D-Leu5-enkephalin.
3. Morphine antagonistic effects
Morphine antagonistic effects of Mr 2033 CL have been found in
different assays. Stereotypic circling movements and the Straub
tail phenomenon induced by morphine were suppressed in mice. In
morphine-treated rats, catalepsy was antagonized and in rabbits
morphine-induced stupor was suppressed by Mr 2033 CL.
In morphine-dependent rats in the stage of withdrawal, exacerba-
tion of abstinence was observed after administration of
Mr 2033 CL. In non-withdrawn morphine-dependent dogs, Mr 2033 CL
precipitated abstinence (Gilbert et al. 1977). The antagonistic
potency of Mr 2033 CL ranged between that of nalorphine and that
of naloxone in these experiments.
4. Side-effects
The strong analgesic effects of Mr 2033 CL were not accompanied
by the Straub tail phenomenon or enhanced circling movements in
mice. Mr 2033 CL did not induce catatonia in rats and stupor in
rabbits in a morphine-like manner.
CNS-depressant effects of Mr 2033 CL were observed in different
assays. In mice, the dose range of analgesia does not overlap
with the dose range reducing aggression, exploration and loco-
motor activity.
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In conscious rabbits, respiratory depression was weaker and of
shorter duration than in animals treated with morphine. After
stimulation of respiration in anaesthetized dogs by increasing
arterial CO, tension, 1 mg/kg of Mr 2033 CL i.v. did not in-
fluence the respiratory minute volume, while 2 mg/kg of morphine
i.v. provoked a pronounced depression.
The influence of Mr 2033 CL on the intestinal transit and the
analgesic effects on the hot plate were tested in mice simulta-
neously. Mr 2033 CL reduced gut motility in a minor degree than
morphine because it was 3 times more potent than morphine in re-
ducing the intestinal transit, and 7 times more potent than mor-
phine in the hot-plate test. Thus the analgesic ED50 of
Mr 2033 CL did not inhibit gut motility completely, while the
analgesic ED50 of morphine induced a complete inhibition.
In contrast to µ agonists, which cause urine retention,
Mr 2033 CL and other agonists induce diuresis in unloaded rats
(Fig. 2). In waterloaded animals Mr 2033 CL had an antidiuretic
effect like morphine. The diuretic effect of Mr 2033 CL was not
antagonized by naltrexone and might be explained by inhibition of
ADH because the free water clearance increased significantly. The
antidiuretic effect was antagonized by naltrexone in a morphine-
like manner and might be a renal opioid effect. Concentration of
plasma electrolytes and plasma osmolarity were not influenced
with statistical significance.
Figure 2. Effects of 0.3 mg/kg Mr 2033 CL and 10 mg/kg morphine
on the urine excretion of rats, unloaded and water loaded with
5 ml/100 g body weight, and the antagonistic effects of naltre-
xone (= N). Mean values 2 hours after s.c. administration. C =
saline control.
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Dependence studies have been performed in rats, dogs and rhesus
monkeys. Mr 2033 CL did not substitute for morphine in morphine-
dependent animals of all three species. In the primary-dependence
experiments in rats and rhesus monkeys, symptoms of withdrawal
occurred, but these differed, both quantitatively and qualita-
tively, from those of morphine. Precipitation with nalorphine or
naloxone provoked also a mild abstinence syndrome in both
species. In self-administration studies in codeine-trained rhesus
monkeys, Mr 2033 CL was not self-injected at rates above saline
at any tested dose except one (Woods et al. 1979).
SUMMARY
Mr 2033 CL is a very potent non-morphine-like opioid analgesic as
shown in different test models and animal species. On a weight
for weight basis, it is about 20 times more potent than morphine.
The analgesic effects of Mr 2033 CL are supposed to be different
from those of morphine and bremazocine because of individual
sensitivity against selective antagonists like naloxone and
Mr 2266 CL. Mr 2033 CL does not induce the Straub tail phenomenon
and increased circling movements in mice, catatonia in rats, and
stupor in rabbits which are characteristic for µ agonists. More-
over, Mr 2033 CL does not have a morphine-like abuse potential in
rats, dogs and rhesus monkeys. CNS-depressive effects were ob-
served in different species. Respiratory depression and inhibi-
tion of intestinal transit seem to be of minor degree. In con-
trast to morphine, Mr 2033 CL provokes diuresis in rats. Binding
studies in rats as well as dependence studies in rats and rhesus
monkeys characterize Mr 2033 CL as a predominant agonist with
morphine antagonistic properties.
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Preclinical Pharmacology of
Metkephamid (LY127623), A
Met-Enkephalin Analogue
Robert C. A. Frederickson, C. John Parli, Gary W. DeVane,
and Martin D. Hynes
The structures of the two enkephalins, Met- and Leu-enkephalin, were
reported in 1975 (9). There is convincing evidence that these
peptides function in brain as neurotransmitters mediating or modu-
lating various physiological functions including reaction to pain
(5,8,14). These endogenous opioids could, therefore, provide the
basis for development of specialized therapeutic entities but have
no obvious clinical utility themselves. They are too rapidly
degraded enzymatically to have any useful activity after systemic
administration. Synthetic efforts, however, have produced analogues
of the enkephalins which are more resistant to enzymatic degradation
and which provide analgesic activity by the parenteral route. One
such compound, which has been demonstrated to be an efficacious
analgesic in the clinic is Metkephamid (LY127623). The preclinical
pharmacology studies with this compound are reported in this paper.
Preliminary accounts of some of this data have been reported
previously (6,7).
METHODS
In Vitro Assays of Opioid Activity
IC50 values for inhibition of the electrically-induced (O.l5hz,
lmsec, 40v) twitch of the mouse vas deferens preparation by
normorphine and metkephamid were determined as described previously
(6). IC50 values were determined also for inhibition of the
electrically-induced (0.8 hz, 0.7 msec, 40v) twitch of the guinea
pig ileum preparation. The comparative affinities of metkephamid
and morphine for µ and opioid receptors were determined by
measuring the displacement of 0.25 nM [3H]-naloxone and 0.75 µM
3H-D-Ala-D-Leu-enkephalin, respectively, from freshly prepared
homogenate of rat brain (10).
In Vivo Assays of Opioid Activity
The comparative ED5O's of metkephamid, meperidine and morphine for
producing analgesic activity in the mouse hot plate (6), mouse
writhing (4,12) and rat tail jerk (12,13) tests were determined as
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described previously (4,6,12,13). Mouse locomotor activity was
measured in circular wire mesh cages. A light beam passed through
the center of each cage and a count was registered each time a mouse
interrupted one of these beams (11).
Assessment of Cross-Tolerance
Mice were made tolerant by treatment with 4 daily doses of morphine
for 4 days as described previously (10). Control mice received
saline on the same schedule. On day five, 16 to 20 hours after the
last morphine injection, dose-response curves to morphine and
metkephamid were generated in the mouse writhing assays.
Measurement of Placental Transport
Maternal femoral arteries in pregnant ewes were catheterized and
fetal jugular veins and carotid arteries were also catheterized and
externalized. When the animals had stabilized, metkephamid was
given intramuscularly and maternal (10 ml) and fetal (7 ml) arterial
blood samples were taken at 0, 10, 20, 30 and 45 minutes for later
assay. Nineteen - twenty day pregnant female rats were decapitated
and their blood collected in glass tubes. The fetuses were removed
from the uterus and their blood was collected either after
decapitation or via heart puncture using glass capillary tubes.
For the assay of metkephamid, one ml serum samples containing 6.72
mg NaF and 8.0 mg EDTA were precipitated with 2 ml of acetone. The
supernatants were saturated with NaCl and extracted with ethyl
acetate. The dried extracts were then derivatized with a Fluram
solution and the resulting solution was subjected to reverse phase
HPLC and fluorescence detection. For assay of meperidine, one ml
serum samples containing 6.72 mg NaF and 8.0 mg EDTA were made
basic with 0.1 ml of 1.0 M NaOH and extracted with diethyl ether.
The dried extracts were dissolved in 0.3 ml of ethyl acetate and an
aliquot was injected into a gas chromatograph c
glass column packed with 3 percent OV-1 on lOO/12O mesh Gas Chrom
Q. The oven temperature was 165°C and the flame ionization
detector's temperature was 250°C.
Drugs
Metkephamid was synthesized in the Lilly Research Labs as described
previously (6).
RESULTS
Metkephamid produced potent naloxone-reversible depression of the
electrically-induced twitch of both the mouse vas deferens and the
guinea pig ileum. The IC5O's for these effects are given in Table
1 together with the IC50 values for normorphine. pA2 values for
naloxone versus normorphine, Met-enkephalin and metkephamid on the
mouse vas deferens preparation were determined to be 8.32 (9.06-
8.69), 1.54 (7.38-7.74) and 7.60 (7.43-7.80), respectively. Also
shown in Table 1 are the IC50 values for metkephamid and morphine
for inhibition of the binding of 3H-naloxone (3H-Nx) and
3H-D-Ala-D-Leu enkephalin (3H-DADL) to rat brain homogenates.
151
TABLE 1
In Vitro IC50 Values (nM)
Morphine Meperidine Metkephamid
(Normorphine*)
A. Isolated tissues
Mouse vas deferens (MVD) 390* 3900 5.4
Guinea pig ileum (GPI) 100* 1957 21.0
GPI/MVD 0.25 0.50 3.9
B. Inhibition of binding
3H-DADL 75 1814 4.4
3H-Naloxone 6.5 460 2.5
3H-Nx/3H-DADL 0.09 0.25 0.6
By the intraventricular route, the ED50 for metkephamid for
analgesia in the mouse hot plate test was 1.5 pmoles/mouse. For
comparison the ED5O's for morphine and meperidine were 103 and
48000 pmoles, respectively. Metkephamid was also analgesic by
systemic routes of administration. The ED5O's after subcutaneous
administration for metkephamid and several standards in the mouse
hot plate and mouse writhing tests for analgesia are given in Table
2. By the intravenous route the ED5O's for metkephamid and
meperidine in the hot plate jump response were 0.21 (0.03-0.57) and
3.1 (1.4-5.7) µmole/kg, respectively, and on the hot plate hind paw
lick response were 0.36 (0.08-0.05) and 1.7 (0.89-2.7) pmole/kg,
respectively.
TABLE 2
ED5O's* (µmoles/kg, s.c.) in Analgesic Tests
Mouse Hot Plate
Escape Jump Hind Paw Lick Mouse Writhing
Morphine 2.4 4.8 2.8
Meperidine 8.5 11.3 15.2
Metkephamid 0.2 1.5 5.5
*ED5O's were determined at times of peak effect (30 minutes for
morphine; 15 minutes for meperidine and metkephamid).
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Comparison of the stimulation of mouse locomotor activity produced
by metkephamid and morphine revealed marked differences. Morphine
produced far greater locomotor activity in the 4 hour-test period
than did metkephamid (Fig. 1).
FIGURE 1
The dose-response curve for morphine was shifted to the right after
chronic administration of morphine, resulting in a 3.5-fold increase
in the ED50 value for morphine (Fig. 2). A similar shift in the
dose response curve was not observed for metkephamid in morphine-
tolerant mice (Fig. 2).
FIGURE 2
The morphine dose-response curves were shifted to the right by 3 to
4-fold in the mouse hot plate hind paw lick and escape jump measures
in mice treated 20 hours earlier with naloxazone (50 mg/kg, i.p.)
compared to mice pretreated with saline. Such pretreatment with
naloxazone produced no shift to the right of the dose-response
curves to metkephamid.
The ability of metkephamid to cross the placental barrier was
assessed by measuring maternal and fetal serum levels in sheep and
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rats at various times after intramuscular injection of high doses
of metkephamid. The data are summarized in Table 3. In the sheep,
maternal serum levels of metkephamid after a dose of 5 mg/kg were
8-10 µg/ml at 10, 20 and 45 minutes after injection while fetal
levels were undetectable at all times measured. The limit of sensi-
tivity of the assay is 50 ng/ml so the ratio of fetal:maternal
levels must be <1:200. In the rat the fetal:maternal ratio at 1 hr
(time of peak blood levels) after metkephamid (50 mg/kg, s.c.) was
about 1:60. The fetal:maternal ratio for meperidine, by contrast,
was about 1:2.
TABLE 3
Maternal and fetal serum levels (µg/ml) of metkephamid and
meperidine at various times after administration to sheep
(intramuscular) and rats (subcutaneous).
1. The dose of metkephamid was 5 mg/kg. 2. The dose of metkephamid
was 50 mg/kg. 3. The dose of meperidine was 50 mg/kg.
DISCUSSION
Metkephamid (Tyr-D-Ala-Gly-Phe-N(Me)Met-NH2) is an analogue of
Met-enkephalin which has proved to be a very potent opioid ligand in
various in vitro and in vivo assay systems. pA2 analysis indicated
that metkephamid utilzed -receptors in the MVD and the ratio of
IC5O's on GPI versus MVD further supported a predominant, although
not exclusive, action on a-receptors. Surprisingly, however, this
s-selectivity was not seen in binding studies with brain homogenate.
Metkephamid was much better (16X) than morphine at displacing the
-ligand (3H-DADL) in these studies but appeared roughly equi-
effective at displacing a µ-ligand (3H-Nx). One explanation for
these apparently disparate findings might be that metkephamid has
much greater efficacy at the -receptor than at the p-receptor.
Analgesic data supports the concept that Metkephamid acts on a
different receptor (presumably the a-receptor) than does morphine.
On a molar basis metkephamid was at least 100X more potent than
morphine at producing analgesia after administration into the lateral
ventricles and was about 10X more potent than meperidine after
intravenous administration. After subcutaneous administration
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metkephamid was more potent than morphine and meperidine in the mouse
hot plate test for analgesia and was intermediate in potency between
morphine and meperidine in the mouse writhing test for analgesia.
Both metkephamid and meperidine were considerably less potent than
morphine, however, on the rat tail jerk test. ED5O's for
metkephamid and meperidine in this test were not calculated because
of the very shallow dose-response curves. Analgesic testing in
morphine-tolerant mice revealed a relative lack of cross-tolerance to
metkephamid. Similar findings have been reported for morphine-
tolerant rats and monkeys (15). These findings indicate a different
mechanism of action for Metkephamid which most likely involves
production of analgesia by an action on -receptors, as well as on
the u-receptors utilized by morphine. The latter mechanism appears
to become more prominent at higher doses. This concept is supported
also by the selective antagonism of morphine analgesia without effect
on metkephamid analgesia by pretreatment with the appropriate dose
(50 mg/kg, i.p.) of naloxazone.
It was reported previously that metkephamid produces much less
physical dependence relative to its analgesic activity than do
standard analgesics such as morphine, meperidine or pentazocine
(6,7). This is confirmed here by the relative inactivity of
metkephamid compared to morphine on locomotor activity in mice.
This measure is a reflection of physical dependence potential.
Studies on placental transport in sheep and rats have revealed a
dramatic advantage for metkephamid for potential use in obstetric
analgesia. Very little, if any, metkephamid appears to cross the
placental barrier compared to an almost 1:1 transport for meperidine.
Metkephamid has been tested in man also (6,7) and clinical studies
have demonstrated analgesic efficacy for this unique new compound
(see eg. 1,2,3,).
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Development of Orally
Active Cannabinoids for the
Treatment of Glaucoma
Raj K. Razdan, John F. Howes, and Harry G. Pars
Glaucoma is one of the major causes of blindness in the
world. It is a condition of the eye where higher than
normal intraocular pressure (IOP) progressively affects
the field of vision resulting in irreversible blindness.
Early observations by Hepler and Frank (1971) demon-
strated that smoking marijuana resulted in a decrease of
IOP in normal subjects. Several reports have since ap-
peared confirming the IOP-lowering effects of marijuana
or 9-THC in both normal subjects (Hepler et al. 1972;
Shapiro 1974; Perez-Reyes et al. 1976; Cooler and
Gregg 1977) and glaucoma patients (Hepler et al. 1976;
Lockhart et al. 1977) and are reviewed elsewhere (Razdan
and Howes 1980). Although 9-THC has been reported to
lower IOP in animals when administered topically, these
results have not been confirmed in glaucoma patients
(Merritt et al. 1981; Green and Roth 1982).
As part of an ongoing program in our laboratories to de-
velop new chemical entities derived from the cannabinoid
nucleus as potential drugs (Meltzer et al., 1981; Pars
et al. 1977), we describe in this paper two compounds,
Nabitan (SP-106) and Naboctate (SP-325), which reduce
IOP in animals and in man and are potential antiglaucoma
drugs.
Drugs from the cannabinoid class produce a number of
side effects such as tachycardia, orthostasis and sub-
jective CNS effects which could limit their therapeutic
use. The objective of our development program has been
to prepare a compound in which a good separation of
therapeutic and side effects exists. To achieve these
goals, we have looked for lowering of intra-ocular pres-
sure in animals, combined with a low incidence of tachy-
cardia. Identified candidates were then evaluated
clinically.
Our earliest evaluations were with Nabitan (Razdan et al.
1976). This has been studied by Weber et al. (1981)
and Tiedeman et al. (1981).
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Table 1 shows the decrease in intra-ocular pressure ob-
served in normotensive human volunteers (Weber et al.
1981). The falls in IOP are small but none of the sub-
jects in this study had a starting IOP of greater than
18.0mmHg.
Table 1. Changes in Intra-ocular Pressure Due to Nabitan*
*By the Mann-Whitney two-sample rank test, from Goldstein, A.:
Biostatistics, An Introductory Text. New York, Macmillan, 1964,
pp. 55-59.
ap 0.005 when compared to placebo controls
b p 0.01
c p 0.05
At high doses, Nabitan caused a mild tachycardia (Weber
et al. 1981). Subjects receiving 10mg or more reported
marijuana-like side effects.
In a further clinical study on ocular hypertensives,
Nabitan showed a lowering of IOP (Figures 1, 2 and 3).
This was a double masked study carried out over a period
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Fig. 1. Mean IOP Placebo Subgroup Nabitan (12 eyes)
of two days. On the first day, the subject received
only placebo; on the second day either a placebo or the
test drug. The results show that Nabitan caused a dose-
related fall of IOP. Mild tachycardia was observed and
some incidents of orthostasis occurred.
In an effort to reduce the cardiovascular side effects
a different compound, Naboctate (SP-325) was developed
(Razdan and Howes 1981).
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Fig. 2 MEAN IOP 8mg NABITAN (20 eyes)
Fig. 3 MEAN IOP 12mg NABITAN (6 eyes)
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Fig. 4 Mean fall in IOP vs time for normal
subjects.
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Naboctate (SP-325) lowered the intra-ocular pressure of
normotensive rabbits at doses of 5, 10 and 20mg/kg orally.
The peak effect was observed after 3 hours at which time
a dose-related response was observed. The duration of
action in these experiments was about 6 hours. SP-325
caused a slight increase in heart rate in conscious
rats given doses of 5, 10 and 20mg/kg orally. A small
non-dose-related hypotension was observed at 3 1/2 to
5 1/2 hours in these animals. In the anesthetized ani-
mal, no significant cardiovascular effects were ob-
served. SP-325 did not affect respiratory parameters
in any of these experiments. When challenges of neuro-
transmitters were used, SP-325 exerted a weak anti-
cholinergic effect.
The acute LD50 (p.o.) in the rat and the rabbit was
>1500 and >1000 mg/kg respectively. In a 30-day sub-
chronic study using rats and rabbits, SP-325 caused be-
havioral effects, which disappeared by the end of the
first week. These included ataxia and sedation. No
gross pathology was observed and microscopic analysis
of tissues revealed no drug-related pathological changes.
In normal volunteers Naboctate was well tolerated and
caused a dose-dependent decrease in IOP (Figure 4). In
this limited study there was a notable absence of cardio-
vascular and CNS side effects.
We conclude that marijuana and synthetic cannabinoids
appear to have a place in the therapy of glaucoma. The
two cannabinoids we have examined lower IOP when ad-
ministered orally. Naboctate is potent in normoten-
sive subjects and appears to be free of major side
effects. This drug is currently under development for
the treatment of glaucoma.
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Dependence Studies on Zopiclone
Tomoji Yanagita and Shin Kato
INTRODUCTION
Zopiclone is a nonbenzodiazepine hypnotic developed by Rhone-Poulenc
France, which is known to act through the benzodiazepine receptors
and shows a benzodiazepine-like pharmacodynamic profile. Its chemi-
cal name is 6-(5-chloro- 2-pyridyl)-7-((4-methyl-1-piperazinyl) car-
bonyloxy)-6,7-dihydro-(5H)-pyrrolo(3,4-b)pyrazine-5-one.
METHOD
Experiment 1. GROSS BEHAVIORAL OBSERVATION OF THE ACUTE CNS EFFECTS
OF ZOPICLONE AND DIAZEPAM IN NORMAL MONKEYS. Single doses of intra-
venous and intragastric zopiclone and intragastric diazepam were ad-
ministered to normal rhesus and crab-eating monkeys, and gross beha-
vior was observed until the drug effects disappeared.
Experiment 2. CROSS PHYSICAL DEPENDENCE TEST ON ZOPICLONE IN BARBI-
TAL-DEPENDENT AND WITHDRAWN MONKEYS. The suppressive effects of zo-
piclone and diazepam on the barbital withdrawal signs were' observed
in rhesus monkeys that had been made physically dependent on barbital
by twice daily intragastric doses of barbital 75 mg/kg for 3 months
or longer and withdrawn for 28-30 hrs. The severity of the with-
drawal signs was graded by our criteria (Yanagita & Takahashi 1970).
Experiment 3. PHYSICAL DEPENDENCE-PRODUCING TEST IN NORMAL MONKEYS.
Zopiclone 16 mg/kg was intragastically administered twice daily for 4
weeks to 4 normal crab-eating monkeys, followed by a withdrawal test
on week 5. Administration was thereafter immediately reinitiated at
the same dose as before for 2 weeks, and at 32 mg/kg twice daily for
2 more weeks, with a second withdrawal test during the next week.
Gross behavior, body temperature, and weight were observed regularly
during administration periods, and withdrawal signs were observed
several times daily during the withdrawal periods. Similar experi-
ments were conducted with diazepam in crab-eating monkeys and with
nitrazepam in rhesus monkeys, the doses being shown in table 1.
Experiment 4. CONTINUOUS INTRAVENOUS SELF-ADMINISTRATION OF ZOPI-
CLONE. This experiment was conducted in 4 rhesus monkeys. An intra-
venous catheter was connected through the restraint arm to an auto-
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matic injector, each lever-press activating the injector to deliver a
predetermined unit dose of zopiclone at infusion volume 0.25 ml/kg
and speed 24-26 sec/ml. Two monkeys had had previous experience with
self-administration of the reinforcing stimulant lefetamine and/or
other drugs and had been rested from any experiment for 1 month or
longer. The other 2 naive monkeys were first tested with saline
until the daily intake rate became low and stable, then with zopi-
clone. The unit doses and period observed are shown in table 2.
Experiment 5. CONTINUOUS INTRAGASTRIC SELF-ADMINISTRATION OF ZOPI-
CLONE AND DIAZEPAM. Intragastric self-administration of zopiclone
and diazepam was tested in 4 rhesus monkeys each as in Experiment 4 .
Here the unit volume was 1 ml/kg and infusion speed was 13-18 sec/ml.
The unit doses and period observed are shown in tables 3 and 4.
RESULTS
Experiment 1. By intravenous administration of zopiclone 0.25 mg/kg
1 out of 2 monkeys exhibited slow movements and diminished spontane-
ous motor activity. These signs disappeared in about 1 hr. At 1
mg/kg, marked motor impairment and hyporeactivity were noted. At 4
mg/kg the intensity of the above signs remained the same although the
duration of the effect was extended. With the crab-eating monkeys,
zopiclone 1 and 4 mg/kg produced practically the same results as with
the rhesus monkeys. With single intragastric administrations of zo-
piclone to rhesus monkeys, slowed movement was seen at 4 mg/kg from
30 min after administration, followed by motor impairment, diminished
spontaneous motor activity, and hyporeactivity. The intensity and
duration of the drug effects reached a plateau at 16 mg/kg. In
crab-eating monkeys single doses of 4 and 16 mg/kg produced slightly
less intense and shorter lasting signs than with rhesus monkeys.
Single intragastric doses of diazepam 1 mg/kg in crab-eating monkeys
produced hyporeactivity and slight slowing of movement. At 4 mg/kg,
hyporeactivity and motor impairment were seen.
Experiment 2. At 28.5 hr after the final administration of barbital
all monkeys showed such signs as apprehension, hyperirritability, pi-
loerection, tremor, abdominal muscular rigidity, and motor impair-
ment. Some monkeys additionally showed clonic convulsions. Single
doses of intragastric administration of zopiclone 4 mg/kg lessened
most of the withdrawal signs, and 8 mg/kg suppressed the signs nearly
completely. At 16 mg/kg the signs were completely suppressed at 0.5
hr after administration. With diazepam the suppression was incom-
plete at 4 mg/kg but complete at 8 mg/kg. The complete suppression
continued for 1 hr with zopiclone and for 3 hrs with diazepam.
Experiment 3. In repeated administration of zopiclone the monkeys
showed depressed signs as described in Experiment 1. On day 7, all
monkeys showed less pronounced signs than on the first day, but from
day 14 on there was no noteworthy change in severity. In the l-week
withdrawal test, monkeys showed apprehension, hyperirritability, tre-
mor, piloerection, and increased muscular rigidity of the limbs from
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the 2nd day, with the peak signs on day 3 or 4 and gradual lessening
thereafter. Extremely moderate body weight loss was noted in 3 out
of 4 monkeys during this period, and rise in body temperature was
confined to 1 C or less, so that the withdrawal signs were graded as
intermediate in all monkeys (table 1). The administration was re-
sumed thereafter for the 2nd test. On day 7, the severity was the
same as or less than that on the last day of the 1st administration
period. Due to further lessening on day 14, the doses were increased
to 32 mg/kg twice daily from day 15. On day 15 the severity incre-
ased in all monkeys, lessening again in a week to near that on day 14
and continuing at this level to the end of the second administration
period. The following 1 week of withdrawal observation showed signs
in all 4 monkeys to be nearly the same as before.
Table 1 DEVELOPMENT OF PHYSICAL DEPENDENCE IN MONKEYS
* : SEVEREST GRADE DURING 7-DAY WITHDRAWAL PERIOD.
"INTERMEDIATE" INCLUDES HYPERIRRITABILITY, RESTLESSNESS, TREMOR,
AND IMPAIRED MOTOR ACTIVITY, AND “SEVERE” INCLUDES CONVULSIONS.
With diazepam, depression less severe than on the 1st day was ob-
served on day 14 with shortened duration of effect in all monkeys.
Doubling the doses from day 15 produced somewhat severer depressive
signs and longer duration of effect, but the severity decreased again
on day 21 or 28. In the 1st withdrawal test, apprehension, hyperir-
ritability, tremor, and piloerection were observed in all monkeys,
with convulsions in 2 out of 4 monkeys on day 6. No body weight de-
crease exceeded 10 percent, and no body temperature increase exceeded
1 C. The withdrawal signs were thus graded as severe and intermedi-
ate in 2 monkeys each. In the 2nd administration period the effects
of the drug gradually weakened as observed on days 7, 14, 21, and 28.
During the 2nd withdrawal test convulsions occurred in 3 out of 4
monkeys on days 3, 6, and 7. The body weight of 1 monkey decreased
12 percent, but changes in the other 3 remained within 10 percent.
This time the grade was severe in 3 monkeys and intermediate in 1.
In the case of nitrazepam all monkeys showed gradual decrease in sev-
erity of the depressive signs throughout the 4-week administration
period, with a major decrease in the 1st week. In the withdrawal
test, all monkeys showed apprehension, muscular rigidity of the
limbs, hyperirritability, and/or tremor from the 2nd day, peaking on
day 4 in all monkeys, gradually lessening thereafter. Loss of body
weight did not exceed 10 percent and no body temperature rise was ob-
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served; thus the withdrawal signs were graded as intermediate in all
monkeys. On day 14 of the 2nd administration period the depressant
effects weakened beyond the level on the last day of the 1st period.
When doses were increased to 8 mg/kg from day 15, the intensity in-
creased in all monkeys, but it was still weaker on day 21 than on day
21 of the 1st period, and the intensity stayed at this level until
the end of-the administration period. The 2nd withdrawal test showed
results in all 4 monkeys similar to those observed in the 1st test.
Experiment 4. The 2 experienced monkeys (Nos. 742, 1026)
self-administered saline at low rates (table 2). In
self-administration of zopiclone 0.25 mg/kg/inj, the animals took
respective daily averages of 75.3 and 34.1 injections in the 1st 2
weeks, increasing in the next 2 weeks. Replacing with saline for 2
days, No. 742 intook 36 and 18 times on days 1 and 2. No. 1026 in-
took 154 times on day 1. Returning to zopiclone produced further in-
crease of daily intake rates in them. These monkeys initially exhi-
bited reduced responsiveness to the observers, decreased spontaneous
motor activity, and motor impairment, but the signs gradually weak-
ened from week 2. In the final l-week saline test intake reduced
markedly from day 2 and such mild withdrawal signs as hyperirritabil-
ity and tremor were observed. One of the naive monkeys (No. 1062)
maintained daily average intake at 32.0 with the unit dose of 0.25
mg/kg for the 2 weeks, while the other (No. 1063) did not. The unit
dose for No. 1063 was thus raised to 1.0 mg/kg, with a resulting in-
crease in the daily average over 2 weeks to 24.0, then to 34.8 in the
next 2 weeks. In 2 days of withdrawal with saline, both monkeys ex-
hibited a rapid decrease in intake on day 2. When zopiclone was re-
sumed at 0.25 mg/kg in both monkeys fairly stable intakes were ob-
served. During the final 1 week with saline, rapid decrease in in-
take was noted and the mild withdrawal signs were observed.
Table 2
CONTINUOUS INTRAVENOUS SELF-ADMINISTRATION OF ZOPICLONE IN RHESUS MONKEYS
Experiment 5. In intragastric self-administration of zopiclone at 1
mg/kg, 3 out of 4 monkeys self-administered the drug at higher daily
rates than for CMC; however, these rates were less than 10, although
different unit doses were tested (0.25, 0.5 and 2.0 mg/kg; table 3).
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No. 256 did not show any intake during the 12-week test period in
spite of programmed forced administration of the drug for 2 weeks.
In 3 days of withdrawal with CMC, No. 595 extinguished the
drug-taking behavior without any increase of intake, but Nos. 755
and 1000 showed obvious rate increase and mild withdrawal signs.
During active self-administration periods in the 3 monkeys, only mod-
erate depressive signs were observable. In a final 1 week of with-
drawal, a slight increase of CMC intake was observed in Nos. 595 and
1000, and some increase similar to the previous withdrawal was ob-
served in No. 755. Again only mild withdrawal signs were observed.
Table 3
CONTINUOUS INTRAGASTRIC SELF-ADMINISTRATION OF ZOPICLONE IN RHESUS MONKEYS
* : PROGRAMMED ADMINISTRATION ADDED (2 MG/KG EVERY 3 HRS)
Table 4
CONTINUOUS INTRAGASTRIC SELF-ADMINISTRATION OF DIAZEPAM IN RHESUS MONKEYS
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In the experiment on diazepam also, 3 out of 4 self-administered the
drug at relatively low rates at unit doses of 0.25 and 1.0 mg/kg
(table 4). The daily rates increased in Nos. 433 and 828 when the
unit dose was again increased to 1 mg/kg, but the rates gradually de-
creased thereafter. In 3 days of withdrawal, the daily rate of No.
828 increased but the rates of the other monkeys were low. During
the active self-administration periods the monkeys showed CNS depres-
sive signs that were not so prominent. In the final 1 week with CMC,
only No. 828 showed meaningful increase of intake rate and manifest-
ed mild withdrawal signs.
DISCUSSION
In the present study, crab-eating monkeys were used in some, and
rhesus monkeys in most of the studies. The reason for this was the
short supply of rhesus monkeys; however, in Exp. 1 not much species
difference was found between them regarding susceptibility to the CNS
effects of zopiclone. The acute CNS effects of zopiclone quite re-
semble those of diazepam in both rhesus and crab-eating monkeys. The
minimum effective doses from gross behavioral observation were less
than or roughly equal to 0.25 mg/kg i.v. and 4 mg/kg i.g. The i.g.
effect reached a plateau at 16 mg/kg, reflecting a characteristic
dose-response relationship of many benzodiazepines (Yanagita 1981).
Duration of effect was generally short in comparison to diazepam,
particularly at large doses. For reference, the respective minimum
effective doses of diazepam and nitrazepam in rhesus monkeys have
been reported as 1.0 and 0.2 mg/kg i.g. (Yanagita et al. 1975, Kato
& Yanagita 1981).
Zopiclone suppressed barbital withdrawal signs incompletely at 8
mg/kg and completely at 16 mg/kg. Diazepam 4 and 8 mg/kg were equi-
potent to zopiclone 8 and 16 mg/kg in this respect. The duration of
complete suppression by zopiclone was considerably shorter than with
diazepam. The cross physical dependence potentials of both drugs to
barbital appear to be nearly parallel to the potencies of the CNS de-
pressant effects. In physical dependence-producing tests, however,
diazepam showed higher potential to produce physical dependence than
zopiclone in crab-eating monkeys, since severer withdrawal signs were
found with diazepam in both withdrawal tests. With zopiclone, the
development of physical dependence appeared to have reached to a max-
imum level in the 1st 4-week period, since no increase of withdrawal
severity was observed in the 2nd test. The potential of zopiclone
appeared to be similar to nitrazepam. During repeated administration
of zopiclone, diazepam, and nitrazepam, obvious development of toler-
ance to the CNS depressant effects was observed in the monkeys' gross
behavior. With zopiclone, however, the tolerance development tended
to reach a maximal level relatively early.
It was quite evident that zopiclone possesses reinforcing effect,
especially when self-administered intravenously. The higher daily
response rate than for diazepam by this administration route may be
attributable to the shorter duration of effect. In contrast, with
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pentobarbital (Yanagita & Takahashi 1973), no marked depressive signs
such as severe motor impairment or light anesthesia were observed
during the active intravenous self-administration period with zopi-
clone, nor were severe withdrawal signs observed when the drug was
replaced with saline. In intragastric self-administration, however,
the daily rates were generally low regardless of unit dose, although
weak reinforcing effect has been demonstrated with the drug. These
results were very similar to the results with diazepam.
Thus the dependence potential of zopiclone was regarded to be weaker
than that of diazepam and nearly equal to that of nitrazepam physi-
cally, and comparable to that of diazepam psychologically.
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Dissociation of the Rewarding
and Physical Dependence-
Producing Properties of Morphine
Michael A. Bozarth and Roy A. Wise
Addiction to opiates is usually characterized by the repetitive
intake of large quantities of drug and the development of marked
physical dependence. Although recent definitions of drug addic-
tion emphasize the behavioral aspects of compulsive drug intake
(e.g., Eddy, 1973; Jaffe, 1975), several theories of opiate ad-
diction have postulated that the development of physical depen-
dence is essential for establishing compulsive drug use (e.g.,
Dole, 1980; Lindesmith, 1980; Spragg, 1940; Wickler & Pescor,
1967). Specifically, the withdrawal discomfort produced by the
discontinuance of opiate intake in physically dependent persons
has been postulated to provide the motivation to ingest opiates
by relieving the distress produced by abstinence. This negative
reinforcement model of addiction seems to fit with many of the
patterns of opiate intake, but it fails to account for the initial
acquisition of drug-taking habits. Nonetheless, the notion that
opiate addicts self-administer drugs to alleviate withdrawal dis-
tress remains a very popular view.
The self-administration of drugs by laboratory animals has sug-
gested that many of the substances abused by humans can serve as
positive reinforcers (Seiden & Dykstra, 1977; Woods & Schuster,
1968). Although some early studies of animal self-administration
used subjects that were made physically dependent on an opiate
prior to testing for self-administration (e.g., Weeks, 1962),
later studies have shown that naive subjects will also learn and
sustain self-administration of opiates at dose levels that do not
produce obvious physical dependence. On the other hand, it has
been shown that physically dependent animals will work to avoid
injections of narcotic antagonists that precipitate withdrawal
(Goldberg et al., 1972). Thus it seems that negative reinforce-
ment (i.e., the avoidance of withdrawal distress) is also capable
of maintaining behavior. This has led to controversy regarding
the relative importance of positive and negative reinforcement
mechanisms in maintaining opiate intake in human addicts. Even
studies reporting the absence of clear signs of physical depen-
dence in animals self-administering opiates cannot rule out the
possibility that the animals are experiencing some withdrawal dis-
comfort during periods of abstinence.
One approach to studying the relative contribution of the positive
and negative reinforcing properties of opiates to the maintenance
of drug intake is to identify the underlying neural substrate of
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each component and differentially manipulate them to assess their
impact on behavior. Usually, however, it is not possible to pro-
duce physical dependence without the concomitant positive rein-
forcing properties of opiate or to test for positive reinforce-
ment without the possibility that some degree of physical depen-
dence has developed as a consequence of drug intake. We report
here the results of two lines of investigation designed to deter-
mine the relationship between opiate reward and the development
of physical dependence. The first experiment was designed to
determine if the opiate receptor field responsible for positive
reinforcement is also involved in physical dependence and a sec-
ond experiment was designed to assess the rewarding properties of
a single injection of heroin. These studies should help to clari-
fy the importance of physical dependence in drug-taking behavior
by examining the degree to which positive reinforcement and physi-
cal dependence mechanisms can be dissociated.
EXPERIMENT I: Physical Dependence From Central Morphine Injections
Wei (1981) and Wei and Loh (1976) have reported that rats chroni-
cally infused with morphine into the periaqueductal gray-fourth
ventricle region show pronounced withdrawal signs when challenged
with the narcotic antagonist naloxone. In these studies, morphine
was infused chronically using an osmotic minipump (Alzet Corp.)
and various withdrawal signs were measured following a challenge
dose of naloxone. Although a variety of withdrawal signs are de-
monstrable after central morphine injections, the most clear
appear to be escape attempts from a cylindrical enclosure, teeth
chattering, and wet-dog shakes. We have used the procedure de-
scribed in Wei (1981) to study the ability of morphine injected
into the ventral tegmental area to produce physical dependence in
rats. This brain region has previously been shown to contain the
opiate receptor population that is critical for the rewarding
properties of morphine (Bozarth & Wise, 1980, 1981a, 1982; Britt
& Wise, 1981; Phillips & LePiane, 1980). The effects of chronic
morphine injections into other brain regions were also assessed to
determine the locus of the opiate receptor field mediating the
development of physical dependence.
Method
Male Long-Evans rats (weighing 300-375 g) were stereotaxically
implanted with 21 gauge cannulae aimed at the various brain re-
gions listed in Table 1. While the rats were anesthetized with
sodium pentobarbital (60 mg/kg), cannulae filled with morphine
were connected to osmotic minipumps and the cannula tips lowered
to the brain region under study. The minipumps delivered 1.0
ul/hr of 1.5 nmole/ul morphine sulfate dissolved in Ringer's solu-
tion. The minipumps were implanted subcutaneously between the
scapulae of the animals and polyethylene tubing was used to con-
nect the minipumps to the implanted cannulae (see Wei, 1981, for
details).
After 72 hours of continuous drug infusions, the rats were chal-
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lenged with an intraperitoneal injection of naloxone hydrochloride
(5.0 mg/kg) and placed in a Plexiglas cylinder (23 x 25 cm). The
presence of teeth chattering, wet-dog shakes, and the number of
escapes from the cylinder were scored in five minute segments for
the next 20 minutes. Other withdrawal signs were also observed
but no attempt was made to quantify them since they have been
shown to be more variable than the measures assessed in this study
(see Wei et al., 1973).
anterior-posterior1 lateral2 ventral3 animals tested
VTA -3.8 ±0.6 7.8 12
VTA -3.8 ±0.6 8.8 19
PVG-R -3.8 ±0.6 5.8 14
D3V -3.8 ±0.0 4.9 13
PVG-C -6.8 ±0.0 4.5 20
Table 1: Stereotaxic coordinates used for central morphine infu-
sions (adapted from Pellegrino et al., 1979). VTA: ventral
tegmental area; VTA30°: ventral tegmental area with cannulae
angled 20 to 30° from the midline to avoid the PVG; PVG-R: rostral
periventricular gray substance; D3V: central aspect of the dorsal
third-ventricle; PVG-C: caudal periventricular gray-Aqueduct of
Sylvius. 1mm from bregma; 2mm fro the midline; 3mm from dura.
(Pellegrino, L.J.; Pellegrino, A.S.; and Cushman, A.J. A Stereotaxic Atlas of the
Rat Brain, 2nd edition, 1979. New York, Plenum Press.)
Results and Discussion
Injections into either the rostra1 or caudal regions of the peri-
ventricular gray substance produced marked physical dependence as
reflected in escape behavior (see Figure 1). The animals with
cannulae in the ventral tegmental area also demonstrated signifi-
cant escape behavior, although at about one third the frequency
of subjects injected with morphine into the rostral periventricu-
lar gray region. When morphine was injected into the dorsal as-
pect of the third ventricle, few escapes were seen after the
naloxone challenge. Other signs of physical dependence were also
observed in the rats injected with morphine in the periventricular
gray regions: teeth chattering was seen with equal frequency in
these two sites (26.2% vs. 26.7%), but wet-dog shakes were pri-
marily observed following infusions into the caudal periventricu-
lar gray reqion (36.2% vs. 12.5%). This supports the notion that
different brain regions may be involved in the production of dif-
ferent signs of physical dependence (e.q., Wei et al., 1973) and
cautions against consideration of the withdrawal syndrome as a
unitary phenomenon generated by a single brain mechanism. The
fact that morphine infusions into the central aspect of the dorsal
third-ventricle did not produce physical dependence suggests that
the dependence resulting from rostral periventricular gray infu-
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sions was due to a local drug action and independent of ventricu-
lar diffusion.
Figure 1: Mean (±SEM) number of escapes in 20 minutes
following nalozone challenge. See Table 1 for abbre-
viations
The possibility that the ventral tegmental area might play a role
in the production of physical dependence is particularly important
because this region has been shown to be involved in the rewarding
action of opiates. Since the rostral periventricular gray site
associated with maximal escape behavior was just two mm dorsal to
the ventral tegmentum, we investigated the possibility that drug
injected into the ventral tegmental area may have been diffusing
up the cannula shaft and acting in the periventricular gray to
produce physical dependence. Such drug efflux up the cannula
shaft is a well-documented problem in intracranial injection
studies (see Routtenberg, 1972). To test this possibility, we
implanted another group of rats with cannulae aimed at the ventral
tegmentum but angled to avoid penetration of the cerebral ventri-
cal and lateral periventricular gray substance. As shown in
Figure 1, rats with cannulae angled to avoid the periventricular
gray region displayed little escape behavior during naloxone chal-
lenge.
Physical dependence as indexed by escape behavior thus seems to be
produced by an action of morphine localized to the periventricular
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gray region. The escape responding seen in animals receiving drug
in the ventral teqmentum probably results from drug diffusion up
the cannula shaft to the periventricular gray region. The results
of this experiment, considered with the earlier localization of
the reward-relevant opiate receptors in the ventral tegmentum
(Bozarth & Wise, 1980, 1981a, 1982; Britt & Wise, 1981; Phillips
& LePiane, 1980), suggest that the site of action for opiate
reward and that for the production of physical dependence are
anatomically dissociable. The demonstration that rats will work
for morphine injected into the ventral tegmental area but not for
morphine injected into the periventricular gray region (Bozarth &
Wise, 1980, 1982) supports the notion that opiates can be reward-
ing because of a positive reinforcing action. This study does
not, however, rule out the possibility that negative reinforcement
mechanisms also contribute to the net rewarding effect during
systemic delivery of opiates in which drug reaches both of these
brain regions (see Weeks & Collins, 1979).
EXPERIMENT II: Temporal Dissociation of Reward & Physical Dependence
The intravenous self-administration paradigm has been used exten-
sively to study the rewarding properties of abused drugs. Work
with opiates has shown that laboratory animals will reliably self-
administer opiates for prolonged periods of time and that physical
dependence frequently accompanies this self-administration. Other
self-administration studies have shown that animals will self-
administer opiates at what appear to be sub-dependence producing
doses (e.g., Woods & Schuster, 1968). Upon termination of testing,
these subjects do not show obvious signs of physical dependence.
Nonetheless, the failure to observe marked signs of abstinence
does not eliminate the possibility that some degree of physical
dependence has developed unnoticed in these subjects. The absti-
nence syndrome is accompanied by marked dysphoria in humans, and
it is not clear that the autonomic effects that are usually quanti-
fied in animals are necessary for the production of this dysphoric
response. It seems likely that some degree of withdrawal distress
is produced by the termination of chronic opiate intake in animals
and that this subjective state is not readily detectable with the
current methods used by these investigators. Therefore, the
relief of the withdrawal distress by subsequent opiate self-admin-
istration may not be ruled out as a factor in the control of
opiate intake in any paradigm involving repeated drug administra-
tion.
To avoid the potentially confounding influence of negative rein-
forcement produced by the relief of withdrawal distress, we have
assessed the rewarding impact of a single injection of heroin in
rats. In a previous report, it was shown that animals which re-
ceived a series of four heroin injections that were associated
with a novel environment returned to the place where they had pre-
viously experienced the effects of these injections (Bozarth &
Wise, 1981b). This conditioned place preference paradigm has been
used to show the rewarding effects of several drugs including mor-
phine (Rossi & Reid, 1976), heroin (Bozarth & Wise, 1981b), and
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amphetamine (Sherman et al., 1980), and it has been proposed as a
measure of the affective consequences of drug administration
(Rossi & Reid, 1976). The present study involved testing for a
conditioned place preference after only one injection of heroin,
and thus there was no opportunity for the animals to learn about
the effects of the drug injection on any opiate withdrawal discom-
fort.
Method
Naive rats were adapted to a shuttle box for five days and the
amount of time spent on each side of the chamber was automatically
recorded during 15 minute test sessions. One side of the test box
had a plain plywood floor while the other side had a plywood floor
covered with wire mesh. The amount of time spent on each of the
two sides on the fifth trial was used to determine the initial
place preference for each animal. On the sixth day, the rats were
subcutaneously injected with heroin (0.5 mq/kq) or saline (1 ml/kg)
immediately prior to being placed on their nonpreferred side of
the shuttle box. A partition was used to confine the animals to
their nonpreferred side for 30 minutes following the heroin injec-
tions. On the next day, the partition was removed and place pref-
erence was retested during a single 15-minute trial in the drug
free state.
Results and Discussion
The single injection of heroin resulted in a significant shift in
the animals' place preference suggesting that initial heroin ad-
ministration is rewarding in these animals (see Figure 2). Since
this study involved only one injection of drug, there was no op-
portunity for the drug injections to relieve withdrawal distress.
Thus, positive reinforcement mechanisms are sufficient to account
for the place preference of these animals.
Figure 2: Mean ±SEM)
percentage change in the
amount of time spent on
the non-preferred side
of the test chamber fol-
lowing a single condi-
tioning trial
(n=12/group).
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GENERAL DISCUSSION
Many theories of opiate addiction have focused on the physical
dependence-producing properties of this class of drugs. The pre-
sent studies show, however, that (i) the opiate receptor field
mediating the physical dependence-producing effects of morphine
is neuroanatomically dissociable from morphine's site of rewarding
action (Experiment I) and (ii) the rewarding properties of heroin
can be demonstrated at a time when there is no opportunity for the
subjects to have developed an association between the drug injec-
tion and relief from withdrawal distress (Experiment II). Thus
physical dependence is distinct from and not necessary for the
positive reinforcing action of opiates.
The fact that opiates can serve as powerful positive reinforcers
and that a state of physical dependence is not necessary for the
rewarding properties to occur does not mean that the tendency to
use the drug is independent of personality or psychosocial factors
nor does it mean that physical dependence is irrelevant to the
strength of the drug-taking habit. Indeed, it would seem likely
that both positive and negative reinforcing effects make important
contributions to governing the behavior of opiate addicts. The
reported dissociation does, however, leave open the possibility
that much of the rewarding impact of opiates is due to an action
on the neural substrate involved in psychomotor stimulant and
natural rewards (Wise & Bozarth, 1981)--an action which is inde-
pendent of the physical dependence usually associated with opiate
addiction.
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Buprenorphine Self-Administration
by the Baboon: Comparison
With Other Opioids
Scott E. Lukas, Roland R. Griffiths, and Joseph V. Brady
Animal drug self-administration procedures that have been developed
and refined over the last two decades provide a great deal of
information relevant to human drug-taking behavior. Numerous
investigators, for example, have shown that animals will
self-administer most drugs that are abused by humans (Griffiths et
1981).
al., 1980; Johanson and Balster, 1978; Johanson and Schuster,
In addition, a good correlation exists between the reported
subjective effects of opioids and animal self-administration
results (Griffiths and Balster, 1979).
The reinforcing properties of pure agonist opioids has been
previously studied (Schuster and Woods, 1967; Oeneau et al., 1969;
Woods, 1980), but the recent development of opioids that possess
both agonist and antagonist properties has provided a new and
interesting sub-class of compounds that need to be evaluated.
The present study was undertaken to provide information on the
relative reinforcing properties of a series of opioid mixed
agonist/antagonist analgesics using a substitution drug
self-administration procedure. Cocaine was used as the baseline
drug in order to obviate potential problems associated with
dependence development and, in addition, served as a reliable
standard upon which the comparisons between opioids were made.
METHODS
Sixteen adult male baboons (Papio anubis) weighing 15-31 kg were
subjects. Animals were adapted either to a standard restraint
chair (Findley et al. , 1971) or a harness-tether system (Lukas et
al., 1982) and invididually housed in a sound-attenuated chamber.
Extraneous sounds were further masked by continuous white noise.
Water via drinking tube was continuously available; animals also
had the opportunity to respond for food (1 g Noyes monkey pellets)
via a separate lever on a fixed ratio 30 schedule of reinforcement.
Animals also received fresh fruit on a daily basis.
Each animal was surgically prepared with a jugular, femoral or
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axillary venous catheter (inside diameter 0.79 mm, outside
diameter, 2.36 mm), using the procedure described by Lukas et al.
(1982). A detailed description of the drug injection system has
been reported previously (Findley et al., 1972).
SELF-ADMINISTRATION PARADIGM
The availability of an injection was indicated by a 5-s tone and
illumination of a light directly over a lever. Upon completion of
a 160-response fixed-ratio requirement, the light over the lever
was extinguished, the drug injection begun, and a 5 x 5 cm light
was illuminated in the upper left-hand corner of the intelligence
panel for a 1 hr period. A time-out period of 3 hr followed each
injection, permitting a maximum of 8 injections per day. There was
no time limit for completion of the fixed ratio response
requirement.
Self-injection performance was first established with cocaine at a
dose of 0.32 mg/kg. After three consecutive days of cocaine
availability during which six or more injections were taken each
day, a dose of test drug or vehicle was substituted for cocaine for
a period of either 12 or 15 days. Cocaine was then reinstated, and
when the criterion was met, another dose of a test drug was
substituted. Drugs tested included codeine (0.01-10.0 mg/kg),
butorphanol (0.00032-0.1 mg/kg), nalbuphine (0.001-0.1 mg/kg),
pentazocine (0.01-10.0 mg/kg), buprenorphine (0.00032-1.0 mg/kg),
d-,l- N-allyl normetazocine (SKF-10,047, 0.01-0.32 mg/kg), and
naloxone (0.01-3.2 mg/kg).
RESULTS
Figure 1 depicts the self-administration pattern for various doses
of codeine during the 15-day substitution period. When saline was
substituted the number of daily self-injections quickly dropped
from the 7-8 per day for cocaine (0.32 mg/kg/inj) to 1-2 per day.
A similar profile was observed for the lowest dose of codeine. As
the dose of codeine was increased, the number of daily
self-injections increased (to 4-5 per day at the 0.32 mg/kg/inj
dose, and to 7-8 per day at the 1.0 mg/kg/inj dose).
The results for the three mixed agonist/antagonist compounds
butorphanol, nalbuphine, and pentazocine were similar to those for
codeine. Butorphanol maintained self-injection behavior in the
dose range of 0.001-0.1 mg/kg/inj while the reinforcing dose ranges
for nalbuphine and pentazocine were 0.01-1.0 mg/kg/inj and
0.32-10.0 mg/kg/inj, respectively. In contrast, neither SKF-10,047
nor naloxone maintained performance above saline baseline levels
over the dose range studied.
Self-administration of buprenorphine was characterized by only
modest performance at the dose levels studied and appeared to reach
a plateau in the 0.1-1.0 mg/kg/inj range (i.e., only 4-5
self-injections per day).
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Figure 1. Self-injection of codeine during
the 15-day substitution period in one subject.
Open circles represent cocaine self-
injections at a dose of 0.32 mg/kg.
When an ABA substitution procedure was employed in one animal,
however, it was clear that buprenorphine did in fact serve as a
reinforcer (figure 2). The 1.0 mg/kg/inj dose of buprenorphine
maintained marginal self-injection behavior which quickly decreased
after saline substitution. By the fourth day of buprenorphine
re-substitution, the daily number of self-injections had returned
to the pre-saline level.
DISCUSSION
The results of this study demonstrate clear differences among the
seven compounds examined with respect to their maintenance of
self-injection behavior. These findings replicate and extend
previous studies of opioid self-administration in the non-human
primate (Balster et al., 1977; Woods, 1977). Four of the opioids
tested (codeine,- butorphanol, nalbuphine, and pentazocine)
maintained dose-related self-injection performance that was maximal
(e.g., 7-8 injections per day) at some doses. Neither the racemic
mixture of SKF-10,047 nor naloxone maintained performance above
vehicle control.
In the present report, buprenorphine maintained only marginal rates
of responding; although it clearly serves as a reinforcer as
demonstrated by the saline substitution-resubstitution experiment
(fig. 2). In addition, the dose-response curve appeared to reach a
plateau at doses above 0.1 mg/kg/inj. These findings are in
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Figure 2. Self-injection of buprenorphine
(1.0 mg/kg) after cocaine baseline and after
saline extinction in one subject.
agreement with other reports. Woods (1977) compared buprenorphine
with 32 other opioids using a substitution procedure (fixed ratio
30 schedule of reinforcement) and codeine as the baseline drug.
Ruprenorphine maintained response rates that were higher than
saline-reinforced rates, but were only 54% of the rate maintained
by codeine. No changes in the dose response curve were observed in
the 0.003-0.1 mg/kg/inj dose range. Similar findings were reported
by Mello et al. (1981) in which buprenorphine maintained responding
on a second order schedule of reinforcement when substituted from a
cocaine or a morphine baseline. The marginal reinforcing
properties of buprenorphine were evident by the fact that only 3 out
of 4 monkeys self-administered buprenorphine; only 1 of these 3
actually increased its intake with increasing doses. Finally,
Yanagita et al. (1981) also demonstrated that huprenorphine
possesses reinfircing properties that plateaued with higher doses
and that performance was only 34-43% of the baseline drug,
lefetamine (SPA).
In conclusion, the results of this study show that buprenorphine
injections will maintain lever responding in baboons. When
compared with other opioids, however, buprenorphine clearly
maintains lower rates of responding and fewer daily injections. On
the basis of the available data, no distinctions can be made
between the reinforcing properties of codeine, butorphanol,
nalbuphine and pentazocine, all of which maintained maximal
performance.
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Somatic and Neurobiological
Alterations in the Progeny of
Female Rats Treated With
Methadone Prior to Mating
Ian S. Zagon and Patricia J. McLaughlin
INTRODUCTION
Methadone, a synthetic narcotic analgesic, has received widespread
use in detoxification and maintenance programs for heroin addicts,
many of whom are females of childbearing age (Blinick et al. 1976).
Clinical reports suggest that infants maternally exposed to metha-
done may be considered at risk for growth retardation and neuro-
developmental dysfunction (Wilson et al. 1973, 1979). Laboratory
investigations support these clinical findings and demonstrate that
animals exposed perinatally to methadone may suffer numerous diffi-
culties including retarded somatic growth (McLaughlin et al. 1978;
Zagon and McLaughlin 1977), neuroanatomical and neurochemical abnor-
malities (Zagon and McLaughlin 1978), physiological dysfunction
(Rech et al. 1980; Slotkin et al. 1979; Thompson and Zagon 1981), al-
terations in nociception (Zagon and McLaughlin 1980), abnormal behav-
ioral ontogeny (Zagon and McLaughlin 1978) and impaired learning
ability (Zagon et al. 1979).
Given the problems in children of mothers treated with methadone,
and since methadone is known to persist long after cessation of drug
exposure (Harte et al. 1976), it is of great importance to determine
whether women discontinuing consumption are in danger of bearing
children who are physiologically and/or intellectually compromised.
The present study was designed to address this question in a labora-
tory setting by examining the offspring of rats delivered by mothers
who received daily injections of methadone for over 7 weeks and then
were removed from drug treatment at least 1 week prior to mating. In
addition to litter size and gestation time, infant mortality, birth-
weight, preweaning body, brain, and cerebellar growth, as well as noci-
ception at 21 days served as criteria in our evaluation.
METHOD
Female (180-200 g) and male (400-450 g) Sprague-Dawley rats (Charles
River Laboratories, Wilmington, MA) were used in this study. All ani-
mals were housed under controlled conditions (Zagon and McLaughlin
1978), with Purina Laboratory Chow and water available ad libitum.
Ten female rats were randomly divided into groups of 5 rats each
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and treated dailv with an intraperitoneal injection of either
5 mg/kg dl-methadone hydrochloride (Dolophine, Eli Lilly Company,
Indianapolis, IN) or 0.2 ml sterile saline. Animals were
weighed every week and dosage adjustments made.
Five days after the beginning of drug treatment, the nulliparous
females were placed with drug-free males for breeding. Females con-
tinued to receive drug injections daily throughout mating, gestation,
and lactation. At weaning, the litters of offspring were removed from
the female rats and used in other experiments. Drug treatment was
terminated at this time and females were housed 5 per cage; all females
were closely observed for signs of withdrawal (e.g., weight loss,
tremors, wet-dog shakes). One week later, females previously exposed
to methadone (M) or saline (C) were placed with drug-free males for
breeding; the presence of sperm in vaginal smears indicated day 1 of
pregnancy. On day 18 of gestation, females were placed in separate
cages. At birth, litter size was noted and litters were culled to
8 pups per mother with an equal distribution of males and females.
Animals were weighed on postnatal days 0, 10 and 21. At weaning
(day 21), pups were tested for analgesia using an Analgesia Meter
(Technilabs Instrument, Pequannock, NJ) at 55°C. latency times were
recorded (± 0.1 sec) for each animal; pups were removed if no response
occurred within 45 sec. Animals were then anesthetized with ether
and fixed by cardiac perfusion with 10% neutral buffered formalin at
an air pressure of 120 mm Hg. Brains were removed and placed in
buffered formalin for 3 days before weights and measurements were
made. Brain length was measured from a line extending from the rostral
edge of the olfactory bulbs to the obex of the fourth ventricle.
Cerebellar width was computed from a line extending parallel to the
long folial axis. The brains (excluding olfactory bulbs) with cere-
bella were weighed; cerebella were then removed from the brainstem
by transecting the peduncles as close to the cerebellum as possible,
and weighed.
Body and brain weights and measurements, litter size, and analgesia
scores were analyzed separately using analysis of variance; subse-
quent planned comparisons were made using Newman-Keuls procedure
(Winer, 1971).
RESULTS
Females exposed to methadone prior to mating exhibited no difficulties
in mating, conception, or parturition, and the length of gestation for
these females was comparable to controls. Moreover, litter size and
number of stillborns for animals in the M group ( = 14; n = 1, re-
spectively) were similar to those of the C group ( = 12.7; n = 0,
respectively). Examination of gross behavioral abnormalities associ-
ated with withdrawal were not recorded during mating, gestation or
lactation in females of the M group, and the body weights of these
animals during pregnancy resembled those of control females.
The birthweights (Table 1) of pups from mothers of the M group were
reduced 20% from offspring of the C females. Body weights of pups
in the M group were also lower than those from C females at 10
and 21 days, with reductions of 19% and 16%, respectively, noted.
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TABLE 1
Body weights of offspring from mothers treated with methadone prior
to mating
AGE (days)
0 10 21
Control 7.52 23.82 47.52
±.036 ±0.74 ±1.79
Methadone 6.02** 19.27 39.85**
±0.44 ±0.97 ±2.11
Values represent means ± S.E. for 12-33 pups per group
at different ages. Significantly different from controls
at p<0.05 (*) and p<0.01 (**).
TABLE 2
Brain and cerebellar weights and measurements of offspring from
mothers treated with methadone prior to mating
Brain Brain Cerebellar Cerebellar
Weight length Weight Weight
(g) (mm) (g) (mm)
Control 1.58 25.08 0.18 10.96
±0.13 ±0.65 ±0.00 ±0.28
Methadone 1.37* 23.87** 0.18 11.15
±0.12 ±0.11 ±0.01 ±0.09
Values represent means ± S.E. from 12-15 pups per group
at 21 days of age. Significantly different from controls
at p<0.05 (*) and p<0.01 (**).
Evaluation of brain weights and measurements (Table 2) at 21 days
revealed that the brain weights of M pups were 87% control pups and
the length of the brain was 95% of control rats. The cerebellum of
M rats was comparable to control animals in both weight and width.
At 21 days, animals in the M and C groups were tested for nociceptive
response. Pups in the M group were markedly (p<0.01) slower to
react to the hot-plate than animals in the C group, with latency
scores of the M pups (27.8 sec) being 2-fold greater than those for
control rats (14.1 sec).
DISCUSSION
The results of the present study show that female rats chronically
exposed to methadone prior to conception have offspring with alter-
ations in both somatic and neurobiological development. These off-
spring were lighter in weight than controls at birth and during
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the preweaning period, and had brains that were subnormal in weight
and length. Furthermore, rats delivered by mothers given a pre-
gestational exposure to methadone were not as responsive to thermal
stimuli in comparison to control animals. Interestingly, many of
these deficits resemble those observed in rat offspring of mothers
chronically receiving methadone during pregnancy and/or lactation
(Zagon and McLaughlin, 1977, 1978, 1980).
Our observations confirm and extend the findings in other studies
showing the effects of opioid consumption prior to mating. Friedler
and colleagues have carried out several studies demonstrating that
pregestational exposure of female rats (Friedler and Cochin, 1972)
and mice (Friedler, 1978) to morphine results in growth retardation
of offspring that can not be eliminated by cross-fostering. In some
cases, F2 generations were also affected in body weight and had pro-
nounced movement deficits, indicating a cross-generational character-
istic in effectiveness (Friedler, 1978). It also appears that opioid
injections to male mice prior to mating may also be detrimental to
subsequent progeny. Smith and Joffe (1975) have found an increased
neonatal mortality in offspring of male rats given acute methadone
or morphine treatments before mating, and Friedler and Wheeling
(1979) have reported that male mice exposed to morphine prior to
mating had offspring that exhibited behavioral alterations.
The mechanism underlying the disturbances in offspring of mothers
treated with methadone prior to conception can only be speculated
upon at this time. One possibility is that the process of drug
withdrawal following long-term administration may serve to influence
in utero development which may, in turn, have postnatal ramifications.
However, evidence gathered in our study does not support this hypo-
thesis. Overt signs of withdrawal such as tremors and wet-dog shakes
were not observed during the period immediately following drug expo-
sure nor during gestation or lactation. Moreover, body weight
losses often encountered in animals undergoing abstinence were not
found during the investigation. An alternative explanation may be
that genetic alterations/mutagenicity could be involved in the course
of methadone treatment, and that such factors could be imprinted on
subsequent progeny. Although we have no evidence that would reflect
on this hypothesis, it is known that opiates can damage chromosomes
(Falek and Hollingsworth, 1980). Finally, it has been reported that
methadone binds firmly to tissue proteins (Sung et al. 1953), and
persists in several organs for up to 10 weeks after administration
(Harte et al. 1976). In view of the absence of the blood-brain
barrier in fetal and preweaning rats, and since immature organisms
may not be able to cope with drugs as well as adults (Kandall, 1977),
it certainly may be envisioned that any remaining methadone in the
female rats could be effective in altering the course of fetal
development. Regardless of the mechanism responsible, it does appear
that the defects observed in offspring of mothers given methadone
prior to mating may be of prenatal origin since the cerebellum, a
part of the brain that undergoes extensive postnatal development,
is unaffected in our experiment.
Differences in pharmacokinetics and routes of administration certain-
ly make if difficult to make any direct comparisons between our
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laboratory findings and the human situation. However, a number of
parallels between laboratory and clinical studies, such as growth
retardation and neurobehavioral disturbances, do suggest biological
similarities in methadone's actions. In view of our findings and
those of other investigators, it would seem prudent to assess the
safety of bearing children following exposure to methadone or
other opiates.
FOOTNOTES
1This research was supported by NIDA Grant DA-01618.
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Differential Stereospecific Effects
of Mu, Kappa, and Sigma Opioid
Agonists on Cortical EEG Power
Spectra in the Rat
Gerald A. Young and Naim Khazan
INTRODUCTION
We have recently reported that mu, kappa, and sigma opioid agonists
produced differential effects on cortical EEG and EEG power spectra
in the rat (Young et al. 1981). Intravenously administered morphine
(mu agonist) produced high-voltage cortical EEG bursts associated
with dose-related increases in EEG spectral power in the zero to
10 Hz band. Ketocyclazocine (kappa agonist) produced high-voltage
cortical EEG bursts associated with dose-related increases in the
5 to 8 Hz band as a predominant spectral peak. N-allyl-notmetazo-
cine, SKF-10,047 (sigma agonist), produced desynchronized cortical
EEG along with frequent theta wave activity, the EEG power spectra
of which consisted of the minimal power peaking at about 7.5 Hz.
These data further support the multiple receptor theories (Gilbert
and Martin 1976; Lord et al. 1977; Martin et al. 1976) and
complement the wide range of studies on opioid-receptor inter-
actions (Chang et al. 1981; Wood et al. 1981). The pharmacological
specificity of the differential effects of mu, kappa, and sigma
opioid agonists on EEG and EEG spectra was further assessed
in the present study by delineating the effects of the enantimers
of each type of opioid agonist.
METHODS
Female Sprague-Dawley rats (250-300 g) were implanted with both
bipolar epidural frontoparietal EEG electrodes and electromyo-
graphic (EMG) temporalis muscle electrodes and with indwelling
jugular cannulae. For ipsilateral EEG recordings, stainless steel
screws were implanted over the frontal (2 mm anterior and 2 mm
lateral to bregma) and parietal (3 mm posterior and 2 mm lateral
to bregma) cortices. Surgical procedures have been previously
described (Khazan 1975). The intravenous cannulae were prepared
and implanted according to the method of Weeks (1972).
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During the experimental procedures, all rats were housed in individ-
ual chambers, 12" x 12" x 24". To permit unrestrained movement of
the rat during EEG and EMG recordings, each cage was equipped with a
swivel connector with concentric mercury pools which served as noise-
free sliding contacts. A  feed-through cannula for drug administra-
tion extended through the center of each swivel (Khazan et al. 1967).
All rats were allowed to acclimatize to the experimental cages for
two to threedays before experimentation. Lighting conditions
consisted of a tiner-regulated lights-off period (10 p.m. - 6 a.m.).
The enantiomers of methadone hydrochloride, ketocyclazocine methane-
sulfonate, and SKF-10,047 hydrochloride were administered in doses
of 1.0, 1.25, and 2.5 mg/kg to three groups of three rats each,
respectively. Both (-)- and (+)-methadone hydrochloride were
dissolved in isotonic saline at a concentration of 1 mg/kg, and both
(-)- and (+)-SKF-10,047 hydrochloride at a concentration of 10 mg/kg.
Both (-)- and (+)-ketocyclazocine methanesulfonate were dissolved in
a small amount of 0.5 N NaOH and brought up to a concentration of
2.5 q/kg with isotinic saline. Injections of the appropriate
vehicle on previous days served as the control.
For each rat, direct EEG and integrated EMG activities were continu-
ously recorded on Grass polygraphs. EEG activities were filtered to
pass frequencies between 1 and 35 Hz. EMG activities were filtered
to pass frequencies between 10 and 75 Hz and were integrated. EEG
activity was simultaneously recorded on FM tape using a Hewlett-
Packard model 3960-A recorder. Power spectral analysis of the EEG
was performed offline using a Nicolet MED-80 mini-computer system
(Khazan and Young, 1980; Young et al, 1978a). For each ra
opioid, EEG power spectra were derived from six separate 10-sec
epochs of EEG that were digitized at a sampling rate of 100/sec, and
power spectral densities were estimated at 0.05 Hz intervals from
zero to 50 Hz. Average EEG power spectra were then obtainedby
averaging each of these sets of six spectra.
RESULTS
Representative cortical EEG samples and associated EEG power spectra
following intravenous administration of (-)-methadone and (+)-
methadone (1 mg/kg) are shown in Figure 1. (-)-Methadone injection
produced high-voltage EEG bursts superimposed on a back ground of
desynchronized EEG activity. behaviorally, (-)-methadone-induced
high-voltage EEG bursts were associated with stupor or catalepsy,
exophthalmos, and respiratory depression. These EEG and behavioral
effects of (-)-methadone continued for one-half to one hour following
the injection of 1 mg/kg. Associated cortical EEG power spectra
consisted of predominant per in the zero to 10 Hz range. These
effects of the (-) enantiomer of methadone were similar to those
produced by the racemic mixture of either morphine or methadone. In
contrast, the (+) enantiomer of methadone did not induce behavioral
change; the EEG and EEG power spectra were analogous to those of
normal wakefulness.
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FIGURE 1
Cortical EEG recordings and related power spectra
after acute intravenous administration of (-) and
(+)-methadone (l.0 mg/kg) in an individual rat.
(-)-Ketocyclazocine injection also produced high-voltage EEG
bursts (Figure 2). However, the high voltage EEG bursts produced
by (-)-ketocyclazocine consisted of more regular, sinusoidal-like
waveforms than those produced by morphine. Additionally, the (-)-
ketocyclazocine-induced high-voltageEEG bursts occurred on a back-
ground of considerable theta wave activity, in contrast to a desyn-
chronized EEG background activity following methadone or morphine
administration. behaviorally, (-)-ketocyclazocine-induced high-
voltage EEG bursts were associated with stupor or catalepsy, exo-
phthalmos, and respiratory depression that were as a whole similar
to the behavioral effect produced by methadone or morphine. These
EEG and behavioral effects of (-)-ketocyclazocine lasted for one-
half to one hour after the 1.25 mg/kg dose. Associated EEG power
spectra had a prominent peak in the 5-8 Hz band. (-)-Ketocyclazocine
produced effects similar to those produced by the racemic mixture.
Conversely, (+)-ketocyclazocine induced neither EEG nor behavioral
changes. Both the EEG and EEG power spectra were those of normal
wakefulness.
192
FIGURE 2
Cortical EEG recordings and related power spectm
after acute intravenous administration of (-) and
(+)-ketocyclazocine (1.25 mg/kg) in an individual rat.
As shown in Figure 3, (+)-SKF-10,047 produced long EEG episodes of
theta wave activity. The associated power spectra had a prominent
peak in the 7-9 Hz band. Behaviorally, (+)-SKF-10,047 produced
circling, erect ears, moderate exophthalmos, episcdes of backing up
and "piano playing" with the front paws, abortive grooming, and mild
ataxia. These EEG and behavioral effects produced by 2.5 mg/kg of
(+)-SKF-10,047 continued for 10 to 20 minutes. A mixture of EEG
theta waves and desynchronized wavefoms were produced by (-)-
SKF-10,047. The associated EEG power spectra reflected aroused
wakefulness, similar to those produced by the racemic mixture.
Behaviorally, (-)-SKF-10,047 produced ataxia, crawling, or crouched
walking, frequent periods of stillness (rats were responsive to
stimulation), and moderate exophthalms. These EEG and behavioral
effects produced by (-)-SKF-10,047 continued for 20 to 40 minutes
following administration of 2.5 mg/kg. The racemic mixture of
SKF-10,047 produced desynchronized EEG waveform that were
associated with frequent occurrences of theta wave activity,
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similar to (-)-SKF-10,047. However, in contrast to either (+)- or
(-)-SKF-10,047, rats were behaviorally aroused with prolonged periods
of stereotypic activities such as chewing and licking. This EEG and
behavioral effect of the racemic mixture of SKF-10,047 persisted for
one-half to one hour following the 5 mg/kg dose.
FIGURE 3
Cortical EEG recordings and related power spectra
after acute intravenous administration of (+)- and
(-)-SKF-10,047 (2.5 mg/kg) in an individual rat.
DISCUSSION
Stereospecific effects of the enantiomers of methadone, keto-
cyclazocine, and SKF-10,047 were delineated. While both (-)
enantiomers of methadone and ketocyclazocine were active, the (+)
enantiomers were not. The (+) enantiomer of SKF-10,047 induced
behavioral changes that were reminiscent of the behavioral effects
produced by a psychomimetic agent like dimethyl- or diethyltrypta-
mine (Siegel et al. 1974). Thus, our findings lend further support
to the theories of multiple opioid receptors (Gilbert and Martin
1976; Lord et al. 1977; Martin et al. 1976) and complement the
recent biochemical findings (Chang et al. 1981; Wood et al. 1981).
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We have previously characterized qualitative and quantitative
differences incortical EEG power spectra associated with the
behavioral states of SWS, rapid eye movement (REM) sleep, and
wakefulness in the rat (Young et al. 1978a). When one compares
the EEG power spectra associatedwith opioid administration in the
present study with the EEG power spectra previously shown to be
associated with the above three behavioral states, it is apparent
that the EEG power spectra produced by morphine and ketocyclazocine
are several times higher in total density area than the EEG power
spectra associated with any of the behavioral states of either SWS,
RFM sleep, or wakefulness. The EEG power spectra associated with
SKF-10,047 administration (racemic mixture) represents an aroused
state of behavior.
Utilizing the EEG spectral analysis, we have previously studied
and reported on the CNS effects of several narcotic agonists,
antagonists, and mixed agonist-antagonists (Kareti et al. 1980;
Lukas et al. 1980; Steinfels et al. 1980. Young et al. 1978b,
1981), ethanol (Wolf et al. 1981), and 9-tetrahydrocannabinol
(Buonamici et al. 1982). The present study offers additional
characterization of the enantiomers of selective µ, , and opioid
agonists.
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Relationship Between Reinforcing
Properties and Sensory/Motor
Toxicity of CNS Depressants;
Implications for the Assessment of
Abuse Liability
Joseph V. Brady, Scott E. Lukas, and Robert D. Hienz
INTRODUCTION
Preclinical assessment procedures developed over the past two decades
for evaluating drug dependence potential and abuse liability have
demonstrated a good correspondence between the compounds
self-administered by laboratory animals and those abused by humans
(Deneau et al., 1969; Griffiths et al., 1976, 1980, 1981; Schuster
and Thompson, 1969). The proper evaluation of drugs from a broader
abuse liability perspective, however, would seem to require an
assessment of the relationship between these reinforcing effects and
the disruptive pharmacological/behavioral effects of such compounds.
Substances with only minimal (if any) disruptive behavioral or
pharmacological activity are not generally regarded as having
significant abuse liability even though self-administration may be
widespread (e.g., caffeine in tea or coffee). In contrast, compounds
used even sparingly which produce disruptive
pharmacological/behavioral changes are considered to have high abuse
liability (e.g., lysergic acid diethylamide). Drugs may fall
anywhere on the continua defined by these parameters, and the present
report describes a quantitative approach to the comparative
evaluation of drugs based upon this relationship.
More specifically, a "reinforcement/toxicity ratio" is proposed for
comparing the relative potency of a drug as a reinforcer maintaining
self-administration, on the one hand, with its relative potency as
regards disruptive effects upon sensory and motor functions, on the
other. A drug with potent reinforcing properties (i.e., maintains
self-injection at relatively low doses) but which produces disruptive
effects only at relatively high doses would have a low
reinforcement/toxicity ratio, whereas a drug which maintains
self-injection only at relatively high doses but produces disruptive
sensory/motor effects at relatively low doses would have a high
reinforcement/toxicity ratio. The measure thus provides a
potentially useful preclinical assessment of the extent to which
self-administration of a compound may disrupt basic sensory/motor
processes as well.
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METHODS AND PROCEDURES
The reinforcing properties of three barbiturates (amobarbital,
pentobarbital, secobarbital) and two dissociative anesthetics
(ketamine and phencyclidine) were evaluated with 10 laboratory
baboons to determine the dose of each compound which maintained
criterion self-administration. The procedure for determining
reinforcing properties has been previously described in detail
(Griffiths et al., 1976, 1981) and involved the initial establishment
of drug self-administration with cocaine (0.32 mg/kg/injectionl
followed by substitution of saline or another drug dose for cocaine.
Amobarbital (0.1-17.8 mg/kg), pentobarbital (0.1-17.8 mg/kg),
secobarbital (0.1-17.8 mg/kg), ketamine (0.01-1.0 mg/kg), and
phencyclidine (0.01-1.0 mg/kg) were studied under conditions which
required completion of a fixed number of responses on a lever (i.e.,
a 160-response fixed-ratio schedule) for intravenous injections. A
3-hour time-out period followed each injection, permitting a maximum
of eight injections per day. When saline or low doses of drugs were
substituted, the number of injections taken decreased over successive
days. When higher doses of the drugs were substituted for cocaine,
however, the self-injection rate was reliably maintained above saline
control levels. Figure 1, for example, shows the effects of dose on
the number of pentobarbital injections per day self-administered by
two of the baboon subjects in the study, and illustrates the
procedure used for determining the criterion reinforcing dose values.
All drugs were also evaluated to determine the criterion dose which
produced a 50% change in auditory and/or visual thresholds, and/or a
10% change in motor reaction time. The procedures for determining
such sensory/motor toxicity have been previously described in detail
(Brady et al., 1979; Hienz and Brady, 1981; Hienz et al., 1981) and
involved training baboons to press and hold a lever until
presentation of a sound burst or light flash signalled availability
of food reward contingent upon lever release (i.e., reaction time
paradigm). During auditory testing, 16.0 kHz pure tones were
delivered through an overhead wide-range acoustic speaker located '20
cm above ear level. During visual testing, a circular white patch at
eye level on the response panel was illuminated at different
intensities. Trials started with a dimly flashing red cue light that
became steady contiguous with a lever press, and thus served as
feedback for the lever holding response. At varying intervals (1.0
to 7.3 sec.) following initiation of the holding response, a test
stimulus (1.5 sec. duration) was presented. Release of the lever in
the presence of the test stimulus defined a correct detection of the
stimulus, and produced a food pellet reward, terminated the test
stimulus, and initiated a 1-sec intertrial interval (ITI). Lever
releases prior to test stimulus onset or following test stimulus
offset reinstated the ITI without food delivery. Reappearance of the
flashing red cue light following the 1-sec ITI signalled initiation
of the next trial. Daily 2 to 2.5 hour experimental sessions were
conducted in a double-walled sound-attenuating chamber, and included
approximately 700 such discrete reaction time trials.
Auditory and visual thresholds were determined in separate sessions
by randomly varying the intensity of the test stimuli from
trial-to-trial in accordance with the method of constant stimuli, and
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Figure 1. Daily pentobarbital self-injections as a function of
dose. The criterion dose for self-administration (dotted line)
was halfway between the performance maintained by saline (i.e.,
1-2 inj/day) and maximal performance on cocaine (i.e., 7-8 inj/day).
Figure 2. Visual threshold shift as a function of pentobarbital
dose. Values are the means of three baboons. The criterion
sensory threshold toxicity dose (dotted line) was halfway
between central and maximal change.
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examining detection frequencies at each intensity. For the auditory
modality, four intensity levels 10 dB apart of a 16.0 kHz tone were
used, with the lowest level set just below an animal's estimated
threshold. For the visual modality, four intensity levels of the
white light were used, 0.5 log density units apart, with the lowest
level set just below the animal's threshold. False-alarm rates were
also measured by occasionally presenting "no-stimulus" trials.
Reaction times were measured as elapsed time between signal onset and
lever release. Drugs were administered intramuscularly (i.m.)
immediately before each experimental session, followed by 15 minutes
of dark adaptation and 15 minutes of "warm-up" on the reaction time
task before threshold determinations were begun. Saline control
sessions requiring return-to-baseline performances occurred between
drug sessions. Figure 2 shows an example of the effects of
pentobarbital dose level upon visual threshold in three baboons and
illustrates the determination of toxic dose values.
RESULTS
All three barbiturates and both dissociative anesthetics (Table 1,
Column A) maintained drug self-administration rates as a function of
dose level, and the criterion dose of each compound which maintained
intravenous self-injection is shown in Table 1, Column B.
Dose-dependent increases in reaction time were also observed with
all five drugs, and the dose of each compound which produced the
criterion 10% change in this measure is shown in Table 1, Column C.
The resulting Reinforcement/Reaction-Time-Toxicity Ratios derived
from the relationship between the criterion reinforcing dose (i.e.,
Column B, numerator) and the reaction time toxicity dose (i.e.,
Column C, -denominator) are shown in Table 1, Column D for each of the
five drugs studied. The ratio values range from a low of 0.07 for
amobarbital to a high of 1.22 for phencyclidine.
Dose-dependent increases in sensory thresholds were also observed
with all five drugs, and the criterion dose of each compound which
produced a 50% change in either auditory or visual threshold is shown
in Table 1, Column E. The resulting Reinforcement/Sensory-
Threshold-Toxicity Ratios derived from the relationship between
criterion reinforcing dose (i.e., Column B, numerator) and the
sensory threshold toxicity dose (Column E, denominator) are shown in
Table 1, Column F for each of the five drugs studied. The ratio
values range from a low of 0.04 for amobarbital to a high of 2.0 for
phencyclidine.
Table 1: Reinforcement/Toxicity Ratios for three barbiturates and two dissociative anesthetics.
Determination of doses is described in text. The criterion reinforcing doses in Column B were
derived by multiplying the actual doses by a constant that corrects for differential absorption
rates and makes the I.V. self-administration doses more comparable to the I.M. toxicity doses.
A B C D E F
Drug Criterion Criterion Reinforcement/ Criterion Sensory- Reinforcement/
Reinforcing Reaction-Time Reaction-Tine Threshold-Toxicity Sensory Threshold
Dose (mg/kg) Toxicity Dose Toxicity Ratio Dose (mg/kg) Toxicity Ratio
(mg/kg) (B/C) (B/E)
Phencyclidine 0.05 0.041 1.22 0.025 2.00
Ketamine 0.39 1.20 0.33 0.40 0.98
Secobarbital 1.8O 3.30 0.55 6.60 0.27
Pentobarbltal 1.44 4.78 0.30 9.60 0.15
Amobarbital 0.44 5.90 0.07 11.60 0.04
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Figure 3 summarizes in graphic form the relationship between the
criterion sensory and motor change doses and the criterion
self-administration dose for the five compounds thus far studied.
With the broken diagonal line representing equality between the
reinforcing and the toxic doses, all three barbiturates are seen to
cluster above the diagonal (upper right corner), indicating that the
doses which produce disruptive sensory/motor changes are generally
higher than the doses required to maintain self-administration of
these compounds. Moreover, there is a consistent relationship
between the sensory and motor effects of these three barbiturates,
with the motor effects appearing at lower doses than the sensory
effects. In contrast, both ketamine and phencyclidine are readily
differentiated from the three barbiturates by the consistent
appearance of sensory changes at doses below those which produce
motor effects. The phencyclidine values can also be seen to fall
below the diagonal (lower left corner), indicating that the doses
required to maintain self-administration are generally higher than
the doses which produce disruptive sensory/motor changes.
Figure 3. Relationship between criterion sensory and motor
toxicity doses and criterion self-administration doses for three
barbiturates and two dissociative anesthetics. The broken
diagonal line represents equality between the reinforcing and
toxic doses.
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DISCUSSION
The ordering of compounds derived from analyzing the relationship
between reinforcing efficacy and behavioral toxicity shows that there
are wide ranging differences between drugs of abuse, with the
Reinforcement/Toxicity Ratios for phencyclidine being up to 20-50
times greater than those for amobarbital. The high ratio values
reflect the fact that such compounds have disruptive sensory/motor
effects at lower doses (relative to their reinforcing potency) than
compounds with lower ratios. And in the case of phencyclidine, these
behaviorally toxic effects can occur below the reinforcing dose (Fig.
3). In contrast, the low ratio values reflect the fact that a drug
has disruptive sensory/motor effects at higher doses (relative to its
reinforcing efficacy) than compounds with higher ratios.
Amobarbital, for example, maintained self-administration at doses
below those which produce behaviorally toxic effects (Fig. 3).
The sensory toxicity dose values for the compounds included in the
present report were determined on the basis of criterion changes in
either auditory or visual thresholds as a first approximation in
analyzing their relationships to reinforcing potency. That these
compounds can produce differential effects as a function of sensory
modality and drug dose has been convincingly documented in recent
studies of the psychophysical profiles of drugs of abuse (Brady et
al., 1979; Hienz and Brady, 1981; Hienz et al., 1981). The results
of these latter experiments have shown, for example, that the
barbiturates can produce significant elevations in the visual
threshold at doses which produce no change in the auditory threshold.
These findings suggest that the relationships described in the
present report can be extended to provide a much more specific
analysis of the nature and degree of disruptive effects under various
conditions of drug self-administration.
Drug self-administration procedures with laboratory animals have
provided an important conceptual and methodological focus for the
preclinical assessment of pharmacological agents. Extending drug
evaluations to include analysis of the relationship between these
reinforcing effects and the behavioral/pharmacological effects of a
compound adds a critical dimension to the assessment of its abuse
liability. Caution is required however when, as in the present
report, estimates of reinforcing efficacy and behavioral toxicity are
derived under circumstances which limit the range of species
variations, drug dosing schedules, routes of administration, as well
as a host of other historical influences both environmental and
pharmacological. The Reinforcement/Toxicity Ratio, based upon the
relationship between such determinations of reinforcing potency on
the one hand, and sensory/motor toxicity on the other, may
nonetheless add a useful and important quantitative dimension to the
preclinical assessment of drug abuse liability.
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Diazepam, Pentobarbital, and
Methaqualone Effects on Several
Behaviors in the Rat and
Antagonism by Ro 15-1788
David J. Mokler and Richard H. Rech
The sedative hypnotics may exert their effects through a number of
different mechanisms. Diazepam interacts with a specific receptor linked
to a GABA receptor and a Cl- ionophore (Skolnick and Paul, 1981) and
enhances the binding affinity of the GABA receptor for its ligand.
Barbiturates may act at an additional receptor linked to this complex
(Olsen, 1981). The sites of action of methaqualone have yet to be defined.
Recently Hunkeler et al. (1981) synthesized a new class of compounds, the
imidazodiazepines, the prototype being Ro 15-1788. They showed that
Ro 15-1788 inhibits 3H-diazepam binding to brain synaptosomes, reverses
diazepam-induced protection against metrazol seizures, and alleviates the
disruption induced by diazepam in a horizontal wire test. Ro 15-1788 does
not affect the depression induced by phenobarbital, meprobamate or
ethanol. In a standard conflict paradigm Ro 15-1788 prevents the
antipunishment effect of diazepam. Ro 15-1788 also antagonizes the
decrease in rat cerebellar cGMP by diazepam, but not that by barbitur-
ates, ethanol or meprobamate (Mohler et al., 1981), and reverses the
effects of 3-methylclonazepam in a number of tests in humans (Darragh
et al., 1981).
We have investigated the effects of diazepam (DZ), pentobarbital (PB) and
methaqualone (MQ) alone and in combination with Ro 15-1788 in a novel
conflict paradigm, conditioned suppression of drinking (CSD), as well as in
rotarod performance (RR) and motor activity (MA).
METHODS
Conditioned Suppression of Drinking (CSD). Female Sprague-Dawley rats
(150-200 g; Spartan Research Animals, Inc., Haslett, MI) were water-
deprived and -trained to drink in 10 min daily sessions from a tube
protruding through the wall of a 30x56x28 cm plexiglass cage with
stainless steel floor (Kilts et al., 1981). The drinking tube was attached to
a calibrated (±0.5 ml) polyethylene tube to monitor fluid consumption.
When drinking-had stabilized, 7-sec tones were presented on a variable
interval 21 sec schedule. During the last 5 sec of the tone the drinking
tube and cage floor were electrified (0.03 mA current, C.J. Applegate,
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Stimulator Model No. 250, Boulder, CO). Animals were tested six days a
week at the same time of day.
Drug treatments were administered every 3-4 days. DZ, PB and MQ were
administered 10 min and Ro 15-1788 immediately before the session. The
number of shocks received (punished responding) and the volume of water
consumed (unpunished responding) on drug-days’ were divided by these
measures for the day immediately prior to obtain percent of control
shocks taken and water consumed, respectively. Changes in water or
shocks were compared using a multi-factorial ANOVA with least signi-
ficant differences for multiple comparisons; p<0.05 was used as the
criterion for statistical significance.
Rotarod Performance (RR). Female Sprague-Dawley rats were trained to
walk on a rotating rod (RR, 8 rpm). Drugs were tested after animals had
reached criterion of walking 180 sec. for two consecutive trials on two
consecutive days. Thirty mg/kg DZ, 18 mg/kg PB, 18 mg/kg MQ, or saline
was administered 15 min before testing and 2.0 mg/kg Ro 15-1788 or
saline was administered 5 min before testing. Animals were then placed
on the RR for two consecutive trials; the longest walk was recorded.
Mean scores for each drug were compared using a one-way ANOVA with
least significant differences for multiple comparisons (p<0.05 = level of
significance).
Motor Activity (MA). Rats used previously in a RR experiment were
randomly divided into groups regardless of previous drug experience.
Animals were given 18 mg/kg DZ, 18 mg/kg PB, 18 mg/kg MQ or saline 15
min before and 2 mg/kg Ro 15-1788 or saline 5 min before being placed
into motor activity cages. Total counts over 15 minutes were recorded
using a Stoelting electromagnetic-field counter. Statistical analysis was
done as described for RR performance.
Drugs. All drugs were administered i.p. and doses were randomized. Ro
15-1788 and DZ were gifts from Hoffman-LaRoche, Inc (Nutley, NJ). PB
sodium was obtained from Sigma Chemical Co. (St. Louis, MO). MQ free
base was a gift from Wm. H. Rorer, Inc. (Fort Washington, PA).
Ro 15-1788, DZ and MQ were suspended in 0.5% methylcellulose with two
drops/10 ml Tween 80. PB sodium was dissolved in distilled water.
RESULTS
CSD. Baseline responding consisted of 15.5±0.5 (mean ± SEM., n = 20) ml
of ater consumed per session and 17±2 (mean ± S.E.M., n = 20) shocks
taken. Both measures were stable across control sessions. Ro 15-1788
(0.5, 1 or 2 mg/kg), administered alone immediately before the sessions,
did not alter shock or water scores (zero dose, Fig. 1). DZ (3, 5.6, 10, 18
and 30 mg/kg) caused a significant increase in punished responding
(shocks) and, at doses of 18 and 30 mg/kg, caused a decrease in unpunished
responding (water intake). Ro 15-1788 caused a dose-dependent at-
tenuation of the effects of DZ on punished responding (F(3, 182) = 21.4).
At a dose of 0.5 mg/kg, Ro 15-1788 in combination with DZ significantly
reduced the DZ anticonflict effect, although shocks taken were still above
baseline with several dose levels. Water intake, reduced by 18 mg/kg DZ
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was significantly different from DZ alone after the drug combination.
The 1.0 mg/kg dose of Ro 15-1788 nullified the DZ anticonflict effect for
all but the 18 mg/kg dose; the DZ-induced decrease in water intake was
reversed by the combination at the 30 mg/kg DZ dose level but not at 18
mg/kg DZ. At 2.0 mg/kg, Ro 15-1788 combined with DZ resulted in
complete attenuation of the DZ anticonflict effect. The reduction of
water intake bv DZ was not reversed by combination with 2.0 mg/kg Ro
15-1788.
FIG. 1. Effects of diazepam alone and in combination with Ro 15-1788 in
CSD. = significantly different from control, = significantly
different from diazepam alone, p<.05.
PB (3 to 18 mg/kg) also released punished responding (Fig. 2), being
maximal at 10 mg/kg. Water intake was significantly decreased at 10 and
18 mg/kg PB. Combination with 1 or 2 mg/kg Ro 15-1788 did not alter
the PB effect on the punished component of this behavior. Unpunished
behavior, however, was significantly potentiated at 18 mg/kg PB by
combination with 1 or 2 mg/kg Ro 15-1788. MQ (5.6 to 30 mg/kg) also
caused a release of punished responding, increasing shocks at 10, 18 and
30 mg/kg (Fig. 3). Unpunished responding was decreased by MQ alone at
doses of 18 and 30 mg/kg. Combination with Ro 15-1788 (1 mg/kg) did not
alter the effects of MQ on either punished or unpunished responding.
RR. The results of RR experiments are seen in Fig. 4. Ro 15-1788 (2
mg/kg) did not alter RR performance. DZ (30 mg/kg) caused a significant
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disruption of performance; this effect was reversed by Ro 15-1788 com-
bined with 30 mg/kg DZ. In contrast, the disruption by 18 mg/kg PB was
significantly potentiated by combining with Ro 15-1788. Ro 15-1788 had
no effect on the disruption of RR walking by 18 mg/kg MQ.
MA. When compared
an effect by itself on
to saline controls, 2 mg/kg Ro 15-1788 did not have
MA measured over 15 min (Fig. 5). DZ (18 mg/kg)
caused a significant reduction in MA which was almost completely
reversed by combination with Ro 15-1788. When Ro 15-1788 was given to
animals receiving either 18 mg/kg PB or 18 mg/kg MQ, their MA was not
significantly different from that of animals receiving the same dose of PB
or MQ alone.
FIG. 2. Effects of pentobarbital alone and in combination with Ro 15-
1788 in CSD. = significantly different from control, =significantly
different from pentobarbital alone, p<.0.05.
DISCUSSION
In agreement with Kilts et al. (1981) DZ caused a release of punished
responding in this conditioned suppression paradigm. Only at higher doses
(18 and 30 mg/kg) were depressant effects of DZ observed on water
intake. Since water intake is insignificant during tone periods, it serves
as a good measure of unpunished responding in the CSD. For example, 5.6
mg/kg DZ increased punished responding by 1400% without altering the
level of intake from control (Fig. 1).
Ro 15-1788 caused a dose-dependent attenuation of the release of
punished responding elicited by DZ. However, Ro 15-1788 may not
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FIG. 3. Effects of methaqualone alone and in combination with Ro 15-
1788 in CSD. = significantly different from control, p<0.05.
FIG. 4. Effects of diazepam, pentobarbital and methaqualone alone (open
bars) or in combination with 2.0 mg/kg Ro 1.5-1788 (filled bars) on rotarod
performance. * = significantly different from Ro 15-1788 alone, ** =
significantly different from diazepam alone, *** = significantly different
from pentobarbital alone, p<0.05.
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antagonize some depressant effects of DZ, as evidenced by the inability
of Ro 15-1788 to reverse in a clear dose-dependent manner the decrease
in unpunished responding after higher doses of DZ. This is in contrast to
the findings of Darragh et al. (1981) that Ro 15-1788 is capable of
reversing the depressant side effects of 3-methylclonazepam in humans.
It may be that higher doses of Ro 15-1788 would be capable of reversing
these depressant effects in the CSD.
FIG. 5. Effects of diazepam, pentobarbital and methaqualone alone (open
bars) or in combination with 2.0 mg/kg Ro 15-1788 (filled bars) on motor
activity. * = significantly different from saline alone, ** = significantly
different from diazepam alone, p<0.05.
The apparent lack of effect of Ro 15-1788 on the release of punishment-
suppressed behavior by PB would suggest that the anti-anxiety effects of
PB are not related to a specific benzodiazepine effect, in agreement with
other investigators, Barrett and Brady (1982), Brady (this volume), and
Gorodetzky (this volume). The potentiation by Ro 15-1788 of the depres-
sion in water consumption by higher doses of PB may indicate some
interaction between these two drugs, however. This has also been
suggested by Barrett and Brady (1982): Ro 15-1788 potentiated the
effects of PB in another conflict test. Ro 15-1788 also did not reverse
the anti-conflict effects of MQ, suggesting that this compound is similar
to PB in not interacting with the benzodiazepine receptor to produce its
effects.
Ro 15-1788 reversed the disruptive effects of DZ on RR and MA, a
paradox when contrasted with the lack of a clear-cut antagonism by
Ro 15-1788 of the DZ decrease in the unpunished component of the CSD.
This suggests that these depressant actions may be working through
different mechanisms. The potentiation by Ro 15-1788 of PB disruption
of RR further supports an interaction between these drugs. The current
study has not ruled out pharmacokinetic interaction. The lack of effect
of Ro 15-1788 on MQ disruption of RR and MA suggests that this drug
works by mechanisms that differ from both DZ and PB.
These experiments indicate that these examples of the sedative-hypnotic
class of drugs exert their effects through a number of different mecha-
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nisms. The anticonflict effects of DZ are clearly mediated through a
mechanism which is antagonized by Ro 15-1788. This may not be the case
for the decrease in water intake by DZ in the CSD paradigm. The anti-
conflict effects of PB and MQ, however, are clearly not mediated through
a Ro 15-1788-blockable mechanism. The effects of Ro 15-1788 on RR and
MA depressant actions of DZ, PB and MQ further separate these drugs as
to mechanisms. Obviously, further study of these interactions is desirable
to further define differences in the mechanisms of action of these
sedative-hypnotic agents.
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Alcohol Effects on Estradiol in
Female Macaque Monkey
N. K. Mello, J. Ellingboe, M. P. Bree, K. L. Harvey, and
J. H. Mendelson
The effects of alcohol on male reproductive function have been
studied extensively. Impotence, testicular atrophy, gynecomastia
and loss of sexual interest are often associated with alcoholism.
Both acute and chronic alcohol intoxication significantly sup-
press plasma testosterone levels in normal men (Gordon et al.
1976; Mendelson et al. 1977), alcoholics (Mendelson and Mello,
1974) and rodents (Badr and Bartke, 1974; Cicero and Badger,
1977). Testicular, prostatic and seminal vesicle atrophy have
been reported in rodents (cf. Cicero, 1980a b).
In alcoholic women, there is clinical evidence of menstrual and
procreative dysfunction including amenorrhea, infertility, men-
strual irregularities (Bourne and Light, 1979; Hugues et al,
1980), and spontaneous abortions (Harlap and Shiono, 1980). How-
ever, there has been a surprising lack of systematic studies of
the effects of alcohol on female reproductive hormones. It is
not known whether alcohol interferes with female reproductive
function at the level of the ovaries or the hypothalamic-pituitary
axis (cf. Cicero, 1980b).
This report describes the first evaluation of the acute effects
of alcohol on neuroendocsine hormones essential for reproductive
function in the female macaque monkey. Patterns of neuroendo-
crine hormone secretion during the menstrual cycle are similar
in rhesus monkey and women. The rhesus monkey has been the pre-
ferred model for reproductive physiologists for decades (Knobil,
1980).
M E T H O D S
The acute effects of alcohol on 17- estradiol, luteinizing hor-
mone and follicle stimulating hormone were studied at four phases
of the menstrual cycle (menstruation, ovulation, mid-luteal phase
and the pre-menstruum) . Progesterone was also studied at the mid-
luteal phase. Alcohol at doses of 1.5, 2.5, and 3.5 g/kg were
compared with equal volume isocaloric control solutions. This
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range of alcohol doses produced peak blood alcohol levels between
150 and 325 mg/dl. Data are reported for the primary female re-
productive hormone 17- estradiol, which is analogous to testos-
terone in the male. Analysis of the other hormones is still in
progress.
Sexually mature macaque monkeys (6 M. mulatta, 1 M. nemestrina)
(4.0 to 8.5 kg) were acquired from commercial suppliers, quaran-
tined and housed individually in a cage room with adult male
rhesus monkeys. All females were alcohol and drug naive except
one that had a brief history of alcohol self-administration, but
had been alcohol free for 95 days at the initiation of these
studies.
Monkeys were maintained on food and water ad lib. Monkey chow
was supplemented with fresh fruit, vegetables and multiple vita-
mins . Daily vaginal swabs were taken to determine the onset and
duration of menstruation. A 12-hour light-dark cycle (7 a.m. to
7 p.m.) was in effect.
When each monkey’s menstrual cycle became stable (after two to
six months), acute doses of alcohol were given to coincide with
menstruation and the predicted time of ovulation, the mid-luteal
period, and the pre-menstruum. The accuracy of predictions of
each menstrual cycle phase could not be established until the on-
set of the next menses. Ovulation was later confirmed by radio-
immunoassay of estradiol. It was seldom feasible to study the
acute effects of alcohol at each of the four menstrual cycle
phases during a single menstrual cycle. Consequently, it was
necessary to follow the monkeys over 1.2 to 18 consecutive men-
strual cycles in order to evaluate the effects of three doses of
alcohol and isocaloric control solutions at four verified men-
strual cycle phases.
Alcohol (1.5, 2.5, and 3.5 g/kg) was prepared in a 25% solution
(v/v) and administered through a pediatric grade nasogastric tube.
Monkeys were fasted for 18 hours to insure uniform absorption of
alcohol from the small intestine.
Since gonadal steroids and pituitary gonadotropins are secreted
episodically (Knobil, 1980; Yen, 1980), we devised a procedure for
integrated blood sample collections (Bree et al, 1982). Inte-
grated plasma samples were exfused continuously over four or five
hours and aliquots were collected every thirty minutes. Each
sample reflected the true mean level of each hormone measured for
that thirty-minute period, whereas a bolus sample might coincide
with the peak or nadir of episodic secretory activity. A full
description of the integrated plasma sample collection procedure
has been published (Bree et al. 1982).
Plasma levels of 17- estradiol were determined in duplicate by
radioimmunoassay using a modification of the procedure of Hotchkiss
et al. (1971). After diethyl ether extract-ion, estradiol was
measured directly without chromatography. Goat anti-rabbit
211
gamma-globulin, rather than dextran-coated charcoal, was used to
separate the bound from the free steroid. Antiserum to 17- es-
tradiol (No. 26-47, Endocrine Sciences, Tarzana, CA.) was essen-
tially free of cross reactivity to other estrogens and known
plasma steroids; the greatest cross reactivity (1.3%) was with
estrone. The labeled steroid used for the assay was the radio-
iodinated (125I). 7-succinyl tyrosine methyl ester derivitive of
17- estradiol (Cat. No. D-1240 Micromedics Systems, Horsham, PA.).
17- estradiol (2, 4, 6, 7, 16, 17-3H) (Cat. No. NET-517, New
England Nuclear, Boston, MA.) was used for extraction recovery
corrections. Intra- and inter-assay C.V.s were 6% and 19%.
Levels of alcohol in blood were measured in duplicate, in plasma
samples, by a colorometric, micromethod (Léric et al, 1970). This
method is based on oxidation of ethanol to acid aldehyde catalyzed
by yeast alcohol dehydrogenase, with nicotinamide adenine dinu-
cleotide (NAD) as co-factor. The NADH produced reacts with p-io-
donitrotetrazoliun violet (INT) and phenozine methylsulphate (PMS)
to form a formazan dye that absorbs at 500 nm.
RESULTS AND DISCUSSION
The time-course and range of blood alcohol levels achieved after
doses of 1.5, 2.5, and 3.5 g/kg are shown in Figure 1. At lower
alcohol doses, peak blood alcohol levels were above 125 mg/dl,
which is a high level of intoxication in a non-alcoholic person.
The legal limit of intoxication in most states ‘is 100 mg/dl. At
the highest alcohol dose (3.5 g/kg) peak blood alcohol levels ex-
ceeded 300 mg/dl, a level sometimes seen in chronic alcoholic in-.
dividuals. Monkeys appeared severely intoxicated at 2:5 and 3.5
g/kg alcohol doses. Since respiratory failure and death can occur
at blood alcohol levels of 450 to 600 mg/dl, we did not risk ad-
ministering higher doses of alcohol.
There was no correlation between plasma estradiol levels and the
ascending and peak blood alcohol levels. Moreover, es tradiol
levels did not decrease as a function of increasing doses of al-
cohol at any phase of the menstrual cycle. Comparison of each
post-alcohol sample with the pre-alcohol sample for the group of
monkeys showed no statistically significant differences. Compari-
son of each post-alcohol sample with the post-sucrose samples for
the group of monkeys also showed no statistically significant
differences.
Figure 2 shows the percent change in estradiol from the sucrose
control levels after each dose of alcohol. These findings illus-
trate the lack of alcohol dose-related changes in estradiol during
menstruation. Blood samples for hormone analysis were collected on
the first, second or third day of menstruation as determined by
vaginal swabs. Comparable findings were obtained during the pre-
menstruum (1, 2, or 3 days immediately before the onset of men-
struation).
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Fig. 1. Average blood alcohol levels during the ascending and
peak phase of the blood alcohol curve, after nasogastric intuba-
tion of 1.5, 2.5 and 3.5 g/kg alcohol.
Fig. 2. Acute alcohol effects on 17- estradiol. Each point
represents an average of six monkeys.
Fig. 3. Acute alcohol effects on 17- estradiol. Data following
1.5 and 2.5 g/kg alcohol represent an average of five monkeys.
Data following 3.5 g/kg alcohol represents an average of four
monkeys.
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Normally, estradiol levels are lowest during menstruation and the
pre-menstruum so that an alcohol-induced suppression might be dif-
ficult to detect. Estradiol levels are highest during ovulation
and therefore might be most sensitive’ to an alcohol-related sup-
pression. Unfortunately, accurate prediction of ovulation proved
to be extremely difficult. Estimates that appeared valid (15 to
17 days before the onset of menstruation) were not always con-
firmed by radioimmunoassay. Eighteen of twenty-five sample col-
lection days were not confirmed as ovulation using the criterion
that estradiol levels must exceed 200 pg/ml. There were no alco-
hol dose-related changes in estradiol during ovulation in the
seven valid sample days.
The only statistically significant changes in estradiol following
acute alcohol administration occurred during the mid-luteal phase
after 2.5 g/kg of alcohol. Figure 3 shows the percent change in
estradiol from sucrose control levels. Estradiol levels were sig-
nificantly elevated at 150, 180 and 210 minutes after alcohol
(p < .05 to .01). However, no significant changes in estradiol
followed administration of a higher dose of alcohol (3.5 g/kg).
It was anticipated that acute doses of alcohol would produce a
decrement in estradiol comparable to that seen in the male hormone,
testosterone. In human males, acute doses of alcohol sufficient
to produce peak blood alcohol levels of 109 mg/dl resulted in a
significant dose-dependent decrease in plasma testosterone
(Mendelson et al, 1977). Single doses of alcohol have consistent-
ly resulted in dose-dependent decreases in plasma testosterone in
rodents (see Cicero, 1980a b). It was surprising to find that
even very high doses of alcohol, sufficient to produce blood alco-
hol levels above 300 mg/dl, did not suppress estradiol in females,
since estradiol production requires essentially the same biosyn-
thetic pathways as testosterone production in males.
In order to insure that the absence of acute alcohol effects on
estradiol in rhesus monkey females did not reflect some heretofore
unrecognized species difference, control studies of the acute ef-
fects of alcohol (2.5 and 3.5 g/kg) were conducted in male macaque
monkeys. Preliminary findings. from on-going studies have shown a
highly significant alcohol dose-related decrement in male macaque
plasma testosterone levels. Pre-alcohol control values averaging
between 1000 and 1400 ng/dl fell to 200 to 300 ng/dl within 210
minutes after acute alcohol administration. These data suggest
that alcohol effects on testosterone in rhesus males are com-
parable to those consistently observed in other species (Cicero,
1980a b).
The lack of alcohol effects on estradiol in female macaque monkeys
is consistent with our recent study of the effects of a single low
dose of alcohol on estradiol, luteinizing hormone and prolactin
in human females (Mendelson et al, 1981). Low doses of alcohol
sufficient to produce peak blood alcohol levels of 88 mg/dl had
no significant effect on estradiol in comparison to isocaloric
sucrose solutions in six women. These women were studied at only
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one phase of their menstrual cycle, the mid-follicular phase, 8,
9 or 10 days following menstruation. These data suggest that
there may be a differential vulnerability to the acute effects of
alcohol on reproductive hormones in males and females.
However, most clinical reports of menstrual aberrations associated
with alcohol have occurred in chronic alcoholic women. We are
currently studying the effects of chronic high dose alcohol ad-
ministration on reproductive hormones and menstrual cycle regu-
larity in a behavioral (alcohol self-administration) paradigm and
a forced alcohol administration paradigm. Studies in progress
indicate that chronic alcohol administration at levels of 4 gm/
kg/day and above disrupt menstrual cycle regularity and suppress
ovulation. Parametric studies to determine the time-course and
alcohol dose range over which effects comparable to those ob-
served in alcoholic women may occur in monkey are in progress.
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Modulation of Phencyclidine
Receptor Sensitivity
Remi Quirion and Candace B. Pert
INTRODUCTION
In the past decade, phencyclidine (PCP) has become a major drug of
abuse in the United States (1). Because of its unique pharmaco-
logical profile which bears some resemblence to schizophrenia (2),
a great deal of research on possible mechanisms of action of PCP
have recently been published (1,2). One of the most interesting
possibilities is the existence of a specific receptor for PCP in
brain. Zukin and Zukin (3) and Vincent et al. (4) have provided
evidence for the presence of such PCP receptors in rat brain.
Using the brain slice technique, we have confirmed these results
(5,6), and showed that the autoradiographic distribution of PCP
binding sites in rat brain are unique (5,6), being mainly concen-
trated in the hippocampus and cortex. These PCP binding sites
appear to be stereoselective (7). Interestingly, benzomorphan,
which possesses " " pharmacological effects (8), are the only
class of opiates which interact with the PCP receptor (5,6,9,10).
In this paper, we provide further characterization of PCP binding
sites. First of all, we described the action of the two isomers
of N-Allylnormetazocine (SKF 10,047, a -opiate agonist) on these
binding sites. We also reported the effect of amantadine, an
antiviral compound with anti-Parkinsonian activity (11) on the
same sites. Finally, we reported the effect of a chronic PCP
treatment on various receptors such as PCP receptors, dopamine
receptors and opiate receptors. Because of the apparent plastici-
ty of PCP binding sites, these results strenghtened our hypothesis
that these sites represent the biological substrate on which PCP
acts to induce its multiple actions.
MATERIALS AND METHODS
Rat olfactory bulb slices were prepared as described before (5).
Frozen slide-mounted sections were preincubated for 15 min in 5.0
mM Tris-HCl, 50 mM sucrose, 20 mM NaCl, pH 7.4 at O°C, followed by
a 45-min incubation in the same buffer (without NaCl), pH 7.4 at
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O°C with 8.2 nM [3H]-PCP (48 Ci/mmol; New England Nuclear), in
the presence of various concentrations (+) SKF 10,047 or (-) SKF
10,047 and amantadine or its inactive analogue, rimantadine. At
the end of the incubation, the slides were transferred sequen-
tially through six rinses (30 sec in each) of 5.0 mM Tris-HCl
buffer plus 50 mM sucrose, pH 7.4 at O°C plus 1% bovine serum
albumin. Binding of [3H]-PCP to the tissue slice was quantita-
ted by counting the tissue-laden slide fragment in 10 ml Aquassure
scintillation cocktail (New England Nuclear). Specific binding
was calculated as the difference in counts bound in the presence
and absence of 0.1 mM PCP.
For chronic PCP treatment, male Sprague-Dawley rats weighing
250-310 g (from Zivic-Miller Laboratories, Inc., Allison Park, PA)
received a daily subcutaneous injection of 10 mg/kg PCP in saline
or saline alone (controls) for 14 consecutive days. Animals were
sacrificed on day 15 and their brains were rapidly immersed in
sopentane at -4O°C, mounted on cryostat chucks and olfactory bulbs
(for PCP binding) and striatum (for dopamine and opiate binding)
Were cut into 25 pm-thick coronal sections at -14°C. Sections
were thaw-mounted on gelatin-coated slides, air-dried on ice for 2
hr, and then stored at -14°C for at least 48 hr before use. For
PCP, frozen olfactory bulb slide-mounted sections were preincuba-
ted and incubated as described above, with various concentrations
of [3H]-PCP. For the opiate binding study, striatum slide-
mounted sections were incubated for 30 min in 50 mM Tris-HCl, 3 mM
Mn (OAc)2, pH 7.4 at 25°C with various concentrations of
[3H]-dihydromorphine (73 Ci/mmol; Amersham, OHM). For the dopa-
mine binding study, striatum slide-mounted sections were incubated
for 30 min in 50 mM Tris-HCl, 120 mM NaCl, 5 mM KCl, 2 mM CaCl2,
1 mM MgCl2, 3 mM Mn (OAc)2, 0.1% ascorbic acid, 50 nM ketan-
serin with pH 7.4 at 25°C, with various concentrations of [3H]-
spiperone (27.6 Ci/mmol; New England Nuclear). At the end of the
incubation period, th slides were washed in cold buffer as
described above for [5H]-PCP. For [3H]-DHM, the slides were
transferred se uentially through six rinses (20 sec in each of the
cold buffers) (12). For [3H]-spiperone, the slides were trans-
ferred through six rinses (1 min in each) of cold incubation
buffer and then dipped in and out of distilled water to remove
ions. Under these conditions, specific [3H]-spiperone binding
represents 70-75% of total bin ing
tion). Binding of [3H]-PCP,
(Quirion and Pert, in prepara-
[3H]-DHM and [3H]-spiperone to
the tissue slide were quantitated by assaying the tissue bearing
slide fragment in 10 ml of aquassure scintillation cocktail.
Specific binding was calculated as the difference in counts bound
in presence and absence of 0.1 mM PCP for [3H]-PCP binding, 1.0
µM etorphine for [3H]-DHM binding and 1.0 µM (+)- butaclamol for
[3H]-spiperone binding. Scatchard analysis of the binding data
was used for calculation of receptor concentration (Bmax) and
dissociation constant (KD). The means of the calculated values
(Bmax and KD) for control and treated rats were compared
for significant differences by the Student's t-test.
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RESULTS AND DISCUSSION
TABLE 1
RELATIVE POTENCIES OF STEREOISOMERS OF N-ALLYLNORMETAZOCINE
(SKF 10,047) on [3H]PCP BINDING
Table 1 shows that (+) SKF 10,047 is a least ten times more potent
than (-) SKF 10,047 in displacing [3H]-PCP from its binding
sites. In fact, since (+) SKF 10,047 is as potent as (±) SKF
10,047, it is likely that (+) SKF 10,047 represents the active
isomer of the mixture. Recently, Brady et al. (13) have also
reported that in monkeys trained to discriminate between saline
and PCP or PCP-like compounds, only (+) SKF 10,047 was recognized
as a PCP-like drug. (-) SKF 10,047 was totally inactive in the
same test. Thus, it appears that first the (+) isomer of -like
benzomorphans are able to interact with PCP, and the (-) isomer
being active on opiate receptors (13). These results may explain
some of the conflicting results obtained with a mixture of isomers
of various benzomorphans (e.g., cyclazocine).
TABLE 2
EFFECTS OF AMANTADINE OF [3H]-PCP BINDING
Numbers are mean ± SEM of three determinations each in
triplicate.
* p < 0.05
** p < 0.01
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Amantadine is an antiviral drug which has been shown, unexpec-
tedly, to improve the symptomatic condition of parkinsonian
patients (11). The mechanism of action related to this antipar-
kinsonism activity is not completely understood, but appears to be
due to the dopamine-releasing properties of amantadine (14-15).
As shown in Table 2, amantadine significantly increases the affin-
ity (Kd) of [3H]-PCP for its binding site in a dose dependent 3
manner. The number of sites (Bmax) does not appear to be
changed by the presence of amantadine in the incubation buffer.
Interestingly enough, rimantadine, an analogue of amantadine with
antiviral properties, but completely devoid of any central nervous
system effects, is also totally inactive on the [3H]-PCP binding
site.
It is tempting to speculate that maybe some of the CNS effects of
amantadine are related to an action of this drug on the PCP recep-
tor complex. It is well known that PCP is able to induce the
release of dopamine in various conditions (16) and acts as a
"non-amphetamine" stimulant of the dopaminergic system (17).
Since the mechanisms of action of amantadine appears to involve
the release of dopamine from the pre-synaptic areas (14-15), it is
possible that both amantadine and PCP act on the same substrate to
induce the release of dopamine in the brain. Also, this interac-
tion of amantadine on the PCP binding site may explain some of the
CNS effects of this antiviral drug. In fact, it had been reported
that both PCP (1) and amantadine (18) induced hallucinations in
humans.
TABLE 3
EFFECTS OF CHRONIC PCP TREATMENT ON PCP, OPIATE AND DOPAMINE
BINDING PARAMETERS IN RAT BRAIN SLICES
3 . No change in the affinity (KD) of the receptors for
[3H]-PCP and [3H]-spiperone were observed (Table 3). Also,
[3H]-DHM binding was not affected (Bmax and KD) by a
chronic PCP treatment (Table 3).
Finally, a chronic PCP treatment ca sed a significant decrease in
the number (Bmax) of [
3H]-PCP and [3H]-spiperone binding
sites in rat brain slices (Table 3). For [3H]-PCP, we observed
a 33% decrease in the number of sites and for [3H]-spiperone,
the Bmax is 31% lower in treated than in control rats (Table
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Our results show that a chronic PCP treatment induced a decrease
in number of [3H]-PCP binding sites in rat brain. Much evidence
suggest that there is an inverse relationship between the number
of receptors and the degree of receptor occupancy by agonists.
PCP receptors also appear to be regulated that way. This down-
regulation of the number of PCP sites induced by chronic PCP
treatment may explain the development of tolerance (19,20) and
dependence (21) to this drug observed in various species.
The diminution in the number of [3H]-spiperone binding sites, an
antagonist of the D-2 dopamine receptor (after chronic PCP treat-
ment is interesting, especially in regard to the "schizophrenic-
like" effects induced by PCP. Since a direct interaction of PCP
on dopamine binding sites in unlikely (22), the decrease in D-2
binding sites in rat striatum might be related to the various
effects of PCP on the dopaminergic system (23). Since it has been
shown that PCP can induce the release of dopamine in various
preparations (17), it is possible that some PCP binding sites
might be located on dopaminergic terminals and can stimulate the
release of dopamine, which in a chronic situation induces a down-
regulation of the number of D-2 dopamine binding sites. Another
explanation might be that PCP can block the uptake of dopamine
(16,17), thus inducing a decrease in the number of binding sites
because of the higher than normal concentration of dopamine in the
synaptic cleft. In any case, the diminution of D-2 dopamine
binding sites may contribute in some way to the development of
tolerance and dependence to PCP.
The absence of effect of chronic PCP treatment on opiate binding
sites indicates that there is little cross-reactivity between
opiates and PCP. It has already been shown that very high
concentrations of PCP are necessary to inhibit opiate binding in
vitro (24). However, some benzomorphans with a peculiar " "
opiate effects appear to be the only class of opiates which
possess strong interaction with PCP-like drugs (5,6,9,10).
In conclusion, our results demonstrate further that only opiate-
like compounds are able to interact with PCP receptors. Moreover,
amantadine, which represents a totally different class of drugs,
also interacts with the PCP binding site. Finally, a chronic PCP
treatment appears to decrease the number of PCP receptors in rat
brain, which may provide some explanation for the development of
tolerance and dependence to PCP. This plasticity of the PCP
receptor complex provides evidence that [3H]-PCP binding sites
represent the functional PCP receptor.
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Ciramadol (Wy-15,705) and Codeine
Analgesia After Episiotomy
S. S. Bloomfield, A. Sinkfield, J. Mitchell, G. Bichlmeir, and
T. P. Barden
Ciramadol (Fig 1) is one of a new series of analgesics known as
mixed narcotic agonist-antagonists. In animal models (unpub-
lished data) onset of analgesia was rapid, within 15 to 30
minutes, and duration was 3 to 5 hours. Effects on vital centers
were minimal, and ciramadol neither substituted for morphine in
acute studies nor produced direct dependence when administered
chronically to monkeys. These characteristics, combined with a
low incidence of side effects of a mild nature in humans (Camu,
1981; Staquet, 1980), give ciramadol the potential to fill a gap
in the spectrum of available drugs for the relief of pain. Early
studies in humans demonstrated single doses to be safe when ad-
ministered intramuscularly and orally at doses up to 20 and 60 mg,
respectively (unpublished data). Oral ciramadol is rapidly ab-
sorbed with peak plasma levels occurring within 1 to 2 hours, and
the half-life is 3 to 6 hours. Urinary excretion is the primary
Fig 1 Ciramadol (Wy- 15,705), 1-cis- 2 -
( -dimethylamino-m-hydroxybenzyl)
cyclohexanol-HCl
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elimination pathway for ciramadol and its major conjugated
metabolite (unpublished data). In previous double-blind and open
clinical studies the types of pain treated orally included post-
operative, postepisiotomy and pain due to malignancy. Postoper-
ative pain was also treated parenterally. In general, moderate
to severe pain responded to oral doses of 20 to 60 mg. However,
the minimum effective oral dose was not clearly demonstrated.
Adverse effects were infrequently encountered and consisted
primarily of nausea, vomiting and/or dizziness. In single doses,
sedation was not reported; however, in a multiple dose study,
mild sedation did occur (Cochrane, 1979). There were no abnormal
laboratory parameters or electrocardiographic findings due to the
drug reported after single doses of ciramadol (unpublished data).
The present report is of a late phase II investigation to clarify
minimum and optimum effective analgesic doses of ciramadol when
administered in single oral doses. It was performed in hospital-
ized women with moderate or severe pain after episiotomy (Bloom-
field et al. 1976).
METHODS
The experimental protocol was the usual one used for oral studies
in our clinical analgesic program. Subjects included in this
report were a homogeneous population of 157 consecutive healthy
consenting hospitalized postpartum women 18 years of age or older
complaining of moderate or severe postepisiotomy pain within 24
hours of an uncomplicated delivery. This study included only
episiotomy pain; afterbirth cramping pain was not measured. Also
excluded were patients who were breastfeeding their infants,
those given analgesics or other CNS drugs within the previous 3
hours, and those with a history of a known hypersensitivity to
narcotics or narcotic antagonists. On enrollment, patients were
stratified according to their initial pain intensity, moderate or
severe. Those with only mild pain were not included.
The design included a concurrent comparison of 5 experimental
treatments: 3 graded dose levels of ciramadol, 15 mg, 30 mg, and
60 mg, one dose level, 60 mg, of codeine sulfate, and placebo.
All experimental medications were in the form of identical coded
tablets, administered on demand as a single oral dose of one
tablet with 8 oz of water. Patients were instructed to lie on
their right sides for 2 hours after administration.
Treatment allocation involved parallel groups of patients with
each patient receiving, at random, only one of the 5 treatments.
Strict double-blind conditions prevailed. The randomized allo-
cation was stratified two ways: for moderate or severe initial
pain, and also for 3 nurse observers. Within each of these 6
strata separate randomized matched blocks of patients were assign-
ed to the 5 treatment groups. This insured that all groups were
evenly balanced with respect to initial levels of pain intensity,
and with respect to interobserver variation. It also
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insured that all treatment groups were approximately equal in
sample size, i.e., 29 to 33 patients each. The 157 cases included
92 with moderate pain and 65 with severe pain. After cross
validation of responses, the stratified data were pooled for
presentation of results.
Using subjective reports as indices of response, each patient
rated pain intensity, pain relief and side effects for 6 hours
and reported her ratings to one of the 3 trained nurse observers
at uniformly conducted interviews (Bloomfield et al. 1976). All
interviews for any one patient were performed by only one ob-
server. Patients were awakened if necessary. At each interview,
each patient's estimates of pain intensity (PI) and pain relief
(PR) were rated on a four-point verbal ordinal scale. Interviews
were done immediately before administration of medication, and 7
times thereafter at intervals of one-half or one hour.
From the original observations, pain intensity difference (PID),
summed pain intensity difference (SPID), and summed pain relief
(SPR) scores were derived. In addition, a 10 cm visual pain
analog scale was used to determine pain analog intensity dif-
ference (PAID) and summed pain analog intensity difference
(SPAID). The final efficacy variable was global evaluation which
was rated on a 0 to 10 verbal ordinal scale. These graded
measurements of analgesia were used to measure relative efficacy
including peak effects, and time course. Side effects were
elicited at the final interview, or earlier, with minimum use of
leading questions and without invoking a checklist of possible
side effects. Data were recorded on case report forms specifi-
cally designed for computer application and were statistically
analyzed for treatment group differences by standard parametric
and nonparametric statistical tests (Siegel 1956, Morrison 1976).
RESULTS
Three patients were disqualified when it was discovered they had
received a prescribed analgesic less than 3 hours before en-
rollment. Results are therefore based on 154 cases. Initial (0
hour) mean PI values were almost identical (2.37 to 2.45) in all
treatment groups (Table I). Subsequently, responses to the 3
Table I. Pain intensity scores (mean ± S.E.) after treatment with ciramadol,
codeine and placebo for episiotomy pain
Time Ciramadol Ciramadol Ciramadol Codeine Placebo
(hr) 60 mg
(n = 31)
30 mg 15 mg 60 mg (n = 29)
(n = 31) (n = 30) (n = 33)
0 2.42 ± 0.09 2.45 ± 0.03 2.37 ± 0.09 2.39 ± 0.09 2.41 ± 0.09
0.5 1.68 ± 0.14 1.64 ± 0.13 1.70 ± 0.15 1.70 ± 0.14 2.00 ± 0.13
1 1.29 ± 0.14 1.10 ± 0.14 1.17 ± 0.14 1.27 ± 0.13 1.83 ± 0.14
2 1.07 ± 0.13 0.84 ± 0.12 0.97 ± 0.12 1.09 ± 0.15 1.52 ± 0.14
3 1.03 ± 0.16 0.93 ± 0.14 1.00 ± 0.14 1.21 ± 0.17 1.52 ± 0.14
4 0.94 ± 0.17 1.03 ± 0.16 1.00 ± 0.14 1.33 ± 0.17 1.45 ± 0.16
5 1.03 ± 0.16 1.03 ± 0.15 1.17 ± 0.17 1.36 ± 0.17 1.59 ± 0.18
6 1.07 ± 0.15 1.16 ± 0.15 1.10 ± 0.16 1.39 ± 0.17 1.55 ± 0.20
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Table II. Relative analgesic efficacy of ciramadol, codeine and placebo after episiotomy
based on mean scores of summary variable!; (number of patients)
ciramadol doses and codeine tended to be better than responses to
placebo.
Table II shows relative efficacy based on six-hour mean scores of
all summary variables including derived variables and global
evaulation. It shows that all dose levels of ciramadol induced
higher mean scores than either codeine or placebo. Ciramadol 30
mg was invariably rated the most effective treatment, followed
in order by ciramadol 60 mg, ciramadol 15 mg, codeine 60 mg, and
placebo. All 3 dose levels of ciramadol showed significant
superiority over placebo, and ciramadol 15 mg and 30 mg, but not
60 mg, exhibited a positive dose-response slope. Codeine 60 mg
clearly did better than placebo, but its performance was signifi-
cant only at the 10 percent level (SPID and SPAID) Moreover
global ratings showed that codeine was significantly inferior to
the 30 mg dose of ciramadol.
Time-PID effects (Fig 2A) show that all 3 doses of ciramadol ap-
peared to have comparable analgesic time course patterns. Start-
Fig 2 Pain Intensity difference and pain relief versus time
with single oral doses of ciramadol, codeine and
placebo after episiotomy
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ing at one hour, separation from placebo seemed equally distinct
with each of the 3 doses of ciramadol. Peak effect of the 30 mg
dose tended to exceed that of the other 2 dose levels. The sepa-
ration from placebo seemed to remain intact until the 5th or 6th
hour, including a statistical advantage over placebo at several
time points with one or more of the dose levels. By contrast,
peak effect with codeine was lower than that of all the ciramadol
doses, and, while separation of codeine from placebo may have
been significant at the first and second hours, thereafter it
diminished rapidly indicating a different time-effect pattern
from that of the ciramadol doses.
These results are mirrored in the time-PR graph in Figure 2B which
shows further that significant responses to ciramadol persisted
almost to the end of the 6-hour observation period, despite a
suggested natural tendency toward return of pain as reflected in
the placebo curve.
Very similar results were also obtained with PAID scores versus
time (Fig 3) which, in addition to previously mentioned drug-
placebo differences, show that at the second hour the peak effect
of ciramadol 30 mg was significantly superior to'that of codeine.
Rescue analgesic was requested by a total of 13 patients: 5 in
the codeine group, 4 in the ciramadol 60 mg group, 3 in the
placebo group, and 1 in the ciramadol 15 mg group. There were
no such cases in the ciramadol 30 mg group.
Fig 3 Pain analog intensity difference versus
time with single oral doses of ciramadol,
codeine and placebo after epislotomy
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Table III. Incidence of side effects after treatment with ciramadol,
codeine and placebo for episiomy pain  
Taken together, these data demonstrate that ciramadol was an ef-
fective analgesic for postepisiotomy pain and, compared to co-
deine, was more effective and longer acting. However, dose-
dependent analgesia was absent with the 60 mg dose of ciramadol,
suggesting that a ceiling effect was reached at the 30 mg dose.
Of the 154 patients, 68 spontaneously reported one or more side
effects; drowsiness in the majority of cases (Table III). There
were 13 cases of drowsiness after ciramadol 30 mg, and 12 after
60 mg, compared to only 6 after 15 mg, 7 after codeine and 2
after placebo. The drowsiness induced by ciramadol seemed dose
related, and was statistically significant at the two higher dose
levels, but, as was the case with analgesia, a ceiling effect
seemed to be reached at the 30 mg dose,
DISCUSSION
These results suggest that in the postepisiotomy pain model single
15, 30 and 60 mg oral doses of ciramadol provide effective anal-
gesia for up to 5 or 6 hours. There is a positive dose-response
slope with an apparent ceiling effect reached at 30 mg for both
analgesia and side effects. Fifteen mg is near the minimum ef-
fective dose, and the optimum dose appears to lie between 15 mg
and 30 mg. Peak and summed analgesia with all 3 dose levels of
ciramadol tends to exceed that of codeine 60 mg, which appears to
have a shorter as well as a weaker effect.
Dose-dependent analgesia was observed with 15 mg and 30 mg of
ciramadol, but not with the 60 mg dose. We have interpreted these
findings as suggestive of a ceiling effect at the 30 mg dose.
Another explanation is possible and relates to the limitations of
the bioassay methodology. If responses to the 30 mg dose of
ciramadol had reached the limit of the upside sensitivity of the
method of measurement, then it would not have been possible to
demonstrate increased analgesia with the 60 mg dose even if it
were present. Examination of the results for each of the anal-
gesic variables reveals, however, that maximum analgesia (i.e., 90
229
percent response) was not achieved with the 30 mg dose. Mean
peak PID response was 1.6 compared to a theoretical maximum of
2.2. The corresponding values for PR were 2.2 and 2.7, respec-
tively, and for PAID, 45 and 90, respectively. Thus, lack of
dose-dependent responses to the 60 mg dose is not likely attrib-
utable to the limitation of the upside sensitivity of the methods
used to measure analgesia in this clinical trial, and is probably
due to a ceiling effect of ciramadol. The side-effect data re-
ported above tend to corroborate this assertion.
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Development of TR5379M
(Xorphanol Mesylate), an
Oral Analgesic
J. F. Howes and A. R. Bousquet
DEVELOPMENT OF TR5379M AS AN ANALGESIC
For the relief of pain, there still exists the need for
an analgesic drug which is active when administered
orally and free from the side effects associated with
the non-steroidal anti-inflammatory analgesics or the
psychotomimetic effects associated with the mixed
agonist antagonists. Several compounds of this latter
class are available commercially, but all have signi-
ficant drawbacks to their use. Pentazocine causes
psychotomimetic side effects at the upper dose levels
(Jasinski et al, 1975) and nalbuphine is poorly avail-
able by the oral route (Beaver et al, 1981). Currently
available drugs produce some degree of physical depen-
dence liability in rats (Howes, 1981), in monkeys
(Cowan, 1973, Villarreal and Seevers, 1971, and Woods
et al, 1980), and in humans (Jasinski and Mansky, 1972,
Jasinski et al, 1976). Self-administration also has
been demonstrated in monkeys with these drugs (Woods,
1977, Hoffmeister et al, 1972). This paper describes
the development of a new drug which appears to be free
of many of the undesirable effects described above.
In addition the compound appears to have an unique
pharmacological profile. Herrera et al, (1982) reported
that TR5379M is resistant to naloxone antagonism in the
guinea pig ileum and blocks the abstinence precipitated
by naloxone in morphine-dependent isolated guinea pig
ilea.
ANTINOCICEPTIVE AND NARCOTIC ANTAGONIST ACTIVITY IN
ANIMALS
In Table 1, antinociceptive and narcotic antagonist
data for TR5379M and some closely related derivatives
are presented. Antinociceptive effects were determined
using the mouse acetic acid writhing test (Whittle,
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1964), and narcotic antagonist activity was evaluated
versus morphine using the rat tail flick procedure
(Harris and Pierson, 1964). Dr. Jacobson has reported
an ED50 of 1.3 in the Nilsen Test.
Two compounds, I and TR5379, were selected for further
development.
Table 1
ANTINOCICEPTIVE ACTIVITY AND NARCOTIC ANTAGONIST
ACTIVITY OF TR5379 AND RELATED COMPOUNDS
PHYSICAL DEPENDENCE LIABILITY OF TR5379 AND (I)
Both compounds were studied using the rat infusion pro-
cedure (Howes, 1981). Compound (I) showed a weak pri-
mary dependence in this procedure, whereas TR5379 was
free of primary dependence (Figure 1).
In the morphine-dependent rat TR5379M did not substi-
tute for morphine, whereas compound I substituted par-
tially (Figure 2). In morphine-dependent rats TR5379
caused a precipitation of withdrawal (Table 2).
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Figure 1
Mean percent weight change of rats following the abrupt
termination of a six-day infusion of either saline ( )
or 40mg/kg/day TR5379 ( ). Points represent the means
of six animals and the vertical bars are standard errors.
*Statistically significant from control values.
In the monkey (Aceto et al, 1981) TR5379M did not sub-
stitute for morphine, and was active as an antagonist
causing the precipitation of withdrawal at doses down
to 0.125mg/kg s.c. (Table 3).
Figure 2
Mean percent weight change of ratsfollowing the termin-
ation of a six-day morphine infusion. For the first
24 hours, the rats were infused with a solution of the
test substance, which was terminated at 24 hours. The
test substances were compound I ( ), TR5379 ( ) and
saline ( ). Points represent the means of six animals,
and the vertical bars are standard errors.
*Statistically significant from control values (P<0.05)
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Table 2
The acute administration of TR5379, naloxone or saline
to rats made physically dependent on morphine. The data
are means and standard errors or ratios of animals
showing the effect to the total number in the group.
The quantitation of each symptom is described in the
methods. * Denotes significant differences (P<0.05) vs
controls; † Denotes significant differences (P<0.05)
vs naloxone.
TR5379
Symptom (3.0mg/kg s.c.)
Teeth chattering 3.25±0.85*
Tremors 4.25±1.25*
Chewing 4.00±1.23*
Wet Dog Shakes 23.25±4.06*†
Irritability 0/4†
Aggression 0/4
Vocalization 0/4
Diarrhea 3/4*
4hr weight loss (%) 10.59±1.69*
Naloxone
(2.0mg/kg i.p.) Saline
3.20±1.01* 0.00
7.20±1.61* 0.00
3.40±1.12* 0.00
8.20±2.67* 0.00
5/5* 1/5
1/5 0/5
1/5 1/5
3/5* 1/5
6.22±1.01* 2.14±0.71
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Table 3
PHYSICAL DEPENDENCE LIABILITY DATA FOR TR5379 IN MONKEY
Procedure Doses Used (mg/kg s.c.) Result
Single Dose 1.0, 2.0 & 4.0 No Substitution
Suppression
Precipitated 0.125, 0.25, 0.5, 2.0, Withdrawal signs
Withdrawal 4.0 & 8.0 observed at all
doses
STUDIES IN HUMAN VOLUNTEERS
TR5379M was studied in human volunteers at the Ohio
State University under the direction of Dr. J. R.
Bianchine. TR5379M is well tolerated in normal human
volunteers at doses up to and including 10 mg given
orally. Marked pupil constriction was observed in sub-
jects receiving 5.0 and 10.0 mg.
Several ongoing phase II studies with TR5379M are dem-
onstrating a high degree of analgesic efficacy with
this agent. Compared to codeine, TR5379M has a slower
onset of action but a long duration of action. Side
effects are minimal.
Table 4
Side
Effects P 0.5mg 1.0mg 2.0mg 5.0mg 10.0mg
Cold 1/3
Sweating 1/9 1/3
Dry Mouth 1/9 1/3
Nausea 1/3
Drowsiness 1/10 2/3 6/9 2/3
Dizziness 1/3 5/9 1/3
Depression 1/3
Lethargy 1/3
Anorexia 1/3
Weakness 1/3
Pallor 1/3
Confusion 1/3 1/9 1/3
Headache 3/10 1/9 1/3
Euphoria 1/3
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Table 4 (continued)
Side
Effects P 0.5mg 1.0mg 2.0mg 5.0mg 10.0mg
Light-
headed 1/10 1/9
Tinnitus 1/3
‘High’ 1/3
Abdominal
Pain 2/9
Insomnia 4/9
Blurred
Vision 1/9
Anxiety 2/9
Disoriented 1/9
W a r m 1/9
Frequent
Urination 1/9
No Effects 6/10 0/3 3/3 2/3 1/9 1/3
CONCLUSIONS
Data generated in experimental animals indicate that
TR5379 is active as an antinociceptive with a low in-
cidence of side effects. Preliminary studies in human
volunteers confirm the low incidence of side effects
at doses which are well absorbed orally.
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Intravenous Hydromorphone:
Effects in Opiate-Free and
Methadone Maintenance Subjects
Mary E. McCaul, Maxine L. Stitzer, George E. Bigelow, and
Ira A. Liebson
Methadone maintenance serves two functions: it prevents the on-
set of withdrawal signs and symptoms in opiate-dependent patients,
and it attenuates the euphoric effects of opiate administration
by establishing tolerance to opiate drugs. Two earlier studies
examined the euphoric response to opiate administration during
induction onto methadone. Dole, Nyswander and Kreek (1966)
demonstrated a progressive blockade of heroin’s euphoric effects
as a result of increasing time in treatment and increasing dose
of methadone during methadone induction. Jones and Prada (1975)
reported that self-administration of intravenous hydromorphone
decreased during induction onto 100 mg/day methadone; pupillary
constriction and liking scores following intravenous hydromor-
phone also gradually decreased to placebo levels during this in-
duction procedure.
Although these earlier reports suggest that there is little or no
effect of supplemental opiate administration following induction
onto high doses of methadone, methadone maintenance clinics fre-
quently report continued illicit opiate use by the maintenance
clients. In an effort to increase understanding of this continued
supplemental opiate use in methadone maintenance clients, the
present study examined the physiological and subjective effects
of intravenous hydromorphone in long-term methadone maintenance
patients. Drug effects were also assessed in a group of post-
addict subjects who were not currently dependent on or tolerant
to opiates; results from this group provided a standard against
which to compare the drug effects in methadone maintenance sub-
jects.
Methods
Subjects. The subjects were 10 males, ranging in age from 25 to
35 years of age. All subjects had extensive histories of intra-
venous opiate use; five subjects were currently opiate-free and
five were maintained on 50 - 60 mg/day methadone. The methadone
maintenance subjects had been receiving a stable dose of metha-
done for at least nine months at the time of the study. Partici-
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pants were fully informed of the experimental protocol and risks
at the start of the study and were reimbursed for their partici-
pation.
Procedure. Sessions were conducted two or three days per- week
with at least one nonstudy day separating sessions. For metha-
done maintenance subjects , sessions were conducted approximately
24 hours following their last dose of methadone.
A venous catheter was placed in the subject’s arm prior to the
start of each session. The vein was kept patent by a saline drip,
which was removed approximately a half-hour following the injec-
tion. Subjects were seated in a quiet room with the experimenter
throughout the three hour session.
A minimum of 30 minutes elapsed between the start of the session
and drug administration. Physiological measures stabilized dur-
ing the first 15 minutes. Baseline data for each session were
collected during the next ten minute period. Five more minutes
then elapsed before drug administration. At the end of this half-
hour period, the saline drip was clamped off and the injection
was given via the catheter. Data collection continued for two
hours following the injection.
All subjects were exposed to several different doses of hydro-
morphone and to placebo control injections. Four of the five
opiate- free subjects received 0, 2, 4 and 6 mg doses of hydro-
morphone; the other opiate-free subject only received doses of
0, 2 and 4 mg. All five methadone maintenance subjects received
0, 10, 14 and 18 mg doses of hydromorphone, Subjects received
each dose at least twice in a random sequence; doses were admin-
istered under a double-blind procedure.
The following measures were continuously recorded throughout each
session: 1) heart rate, using EKG leads on the chest; 2) skin
temperature, using a probe on the finger tip; 3) respiration,
using a mercury strain gauge stretched across the abdomen; and
4) blood pressure, using a cuff that automatically inflated and
recorded pressure once every minute (Roche Arteriosonde #1216).
In addition, a number of measures were intermittently recorded
during each session. A pupil photograph was taken approximately
15 minutes prior to the injection and six times following the in-
jection, using a Polaroid camera with 3X magnification. Four
subjective report forms were also administered approximately 15
minutes prior to the injection and four times following the in-
jection at half-hour intervals. Subjective report forms included:
1) an analogue high scale on which subjects were asked to rate
their current degree of “high” from 0 to 100; 2) the short form
of the Addiction Research Center’s MBG (Morphine-Benzedrine Group)
scale (Haertzen 1974); and 3) a 32-item adjective checklist, which
included the Fraser Single-Dose Opiate Questionnaire (Fraser
et al. 1961), as well as additional signs and symptoms character-
istic of opiate effects. Each time the self-report forms were
administered during the session, subjects were instructed to
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respond according to the way they felt at the present moment.
Data analysis. Physiological data are presented using “differ-
ence from control” scores. These were calculated by subtracting
the mean of the 10-minute baseline measures from the mean of the
2-hour postinjection measures for each session. These differ-
ence scores were averaged across replications at each dose for
each subject and were then summarized across subjects at each
dose. Responses to MBG and adjective checklist self-report
scales were also adjusted with respect to predrug data by calcu-
lating difference scores. Scores for the Fraser Single-Dose
Opiate Questionnaire were derived using the weighted scoring
system introduced by Martin and Fraser (1961). Dose-effect data
for each measure are presented graphically using the mean of the
2-hour postinjection period. Data are presented separately for
the postaddict subjects and the methadone maintenance subjects.
Results
None of the baseline physiological measures were significantly
different in the opiate-free subjects and in the methadone main-
tenance subjects 24 hours following their last dose of methadone;
for example, mean pupil diameter prior to the injection was 6.3 mm
in opiate-free subjects and 6.1 mm in methadone maintenance sub-
jects. For both methadone maintenance and opiate-free subjects,
intravenous hydromorphone produced changes in physiological and
subjective measures when compared with placebo administration.
However, the magnitude of the drug effect was generally smaller
in the methadone subjects than in the opiate-free subjects even
though the maximum drug dose employed was three times higher for
the methadone subjects.
Figure 1 summarizes the effects of intravenous hydromorphone on
pupil diameter in both opiate-free and methadone subjects. There
was little change in pupil diameter for either group following
the placebo injection. In opiate-free subjects, hydromorphone
produced a graded increase in pupillary constriction from 2.2 mm
following the 2 mg dose to 3.7 mm following the 6 mg dose. In
methadone maintenance subjects, there was little difference in
the amount of pupillary constriction following the range of test
doses; pupillary constriction averaged 1.9 to 2.3 mm, approxi-
mately the same constriction seen in opiate-free subjects follow-
ing administration of the lowest dose of drug.
Figure 2 summarizes the dose-dependent effects of hydromorphone
on respiration for the two groups of subjects. There was little
change from baseline respiration rates following placebo admin-
istration in either group. In contrast to the effects of hydro-
morphone on pupil diameter, hydromorphone produced similar de-
creases in respiration rates for both opiate-free and methadone
maintenance subjects; for both groups, respiration decreased an
average of 2 to 3 breaths per minute during the 2-hour postinjec-
tion period. While the magnitude of the effect was similar follow-
ing the highest dose in both groups, this effect was achieved at
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FIG. 1. The effects of intravenous hydromorphone
on pupil diameter in opiate-free subjects ( )
and methadone maintenance subjects ( ).
Unconnected symbols represent the results of
placebo administration. Error bars indicate
± SEM.
a dose three times greater in methadone maintenance subjects than
in opiate- free subjects (6 mg vs 18 mg).
In contrast to the similarity of the baseline physiological
measurements observed in the two groups of subjects, baseline
subjective scores for the two groups were significantly differ-
ent on three of the four self-report scales. Baseline scores
for the methadone maintenance subjects were significantly lower
than for opiate-free subjects on the adjective checklist, the
Fraser Single-Dose Opiate Questionnaire and the MBG scale.
Although methadone maintenance subjects did not appear to be ex-
periencing physical symptoms associated with withdrawal during
the baseline period, these differences could be related to the
24-hour lapse since ingestion of their last dose of methadone.
As shown in Figure 3, there was little or no change from baseline
on subjective report measures following placebo administration in
either group. For opiate-free subjects, there were marked, dose-
related increases on all subjective measures following 2 and 4 mg
of hydromorphone , with little or no further increase in scores
following 6 mg. In contrast, for methadone maintenance subjects,
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FIG. 2. The effects of intravenous hydromorphone
on respirationz in opiate-free subjects ( ) and
methadone maintenance subjects ( ). Unconnected
symbols represent the results of placebo adminis-
tration. Error bars indicate ± SEM.
scores on the Adjective Checklist and Analogue High scale in-
creased only slightly over the range of hydromorphone doses em-
ployed. Scores on the Fraser Single-Dose Opiate Questionnaire
and the MBG scale were increased in a dose-related manner follow-
ing administration of hydromorphone to methadone maintenance sub-
jects; however, the absolute magnitude of the increase on the
Single-Dose Questionnaire was less for methadone maintenance sub-
jects than for opiate-free subjects. The MBG scale was the only
self-report scale on which opiate-free and methadone maintenance
subjects showed comparable increases in score.
Discussion
For both methadone maintenance and opiate-free subjects, intra-
venous hydromorphone produced changes in physiological and sub-
jective measures as compared with placebo administration. How-
ever, the absolute magnitude of the drug effect was generally
smaller in the methadone maintained than in the opiate-free sub-
jects even though the maximum hydromorphone dose employed was
three times higher for the methadone subjects. Furthermore, in
contrast to the opiate-free subjects, there was little graded
242
FIG. 3. The effects of intravenous hydromorphone on four sub-
jective report measures in opiate-free subjects ( ) and
methadone maintenance subjects ( ). Unconnected symbols
represent the results of placebo administration. Error bars
indicate ± SEM.
effect of the range of test doses in methadone maintenance sub-
jects. Both the blunted magnitude of the drug effect and the
lack o-f clear dose-effect relationships suggest that there is
tolerance to the effects of intravenous hydromorphone on physio-
logical and subjective measures in methadone maintenance subjects
as compared with opiate-free subjects.
The results of this study differ from the results of previous
research on supplemental opiate effects during methadone induc-
tion. Those studies reported little or no difference between
opiate and saline administration following induction onto high
doses of methadone (Dole, Nyswander and Kreek 1966; Jones and
Prada 1975); however, in the present study, there were clear
differences between placebo and hydromorphone administration on
all measures in patients maintained on moderate doses of metha-
done. These findings suggest that the effects of opiate adminis-
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tration are diminished but not eliminated in methadone mainten-
ance clients, and that these patients continue to experience the
typical range of physiological and subjective responses to intra-
venous opiate use during long-term methadone maintenance. These
results may explain in part the observation that some methadone
maintenance patients continue to use supplemental opiate drugs
during treatment.
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The Effect of Morphine
on Symptoms of
Endogenous Depression
Michael Feinberg, Jean-Paul Pegeron, and Meir Steiner
INTRODUCTION
Opium has been used to relieve the troubled mind for countless
years, and has been remended for the treatment of a wide range
of mental illnesses for centuries. With the isolation of morphine
and the invention of the hypodermic syringe, subcutaneous
administration of morphine came to replace oral opium in the
treatment of seriously ill patients, although the use of opium
continued. Morphine was considered a sedative par excellence,
effective when a wide variety of drugs had failed. Indeed, some
physicians who remended it said that its effect was secondary
to the sleep it produced, especially in depressed patients
(McDiarmid, 1876: Russell, 1860). In the past 40 years, morphine
has been replaced by other somatic treatments which are thought to
be more specific and which do not have the addiction liability
associated with the narcotics. More recently, following the
discovery of the endorphins, a number of investigators have
suggested that they may be involved in the pathophysiology of
mental illness. Some have postulated a functional excess of
endorphins in, for example, schizophrenia (Bloom et al., 1976),
and have treated patients with narcotic antagonists (Berger et
al., 1981). others have suggested that there may be a functional
deficit of endorphins, and have administered beta-endorphin with
good results (Kline et al., 1977; Gerner et al., 1980). This
resurgence of interest in the association between narcotics and
mental illness suggests that a careful reading of the older
clinical literature may point the way toward fruitful experiments
which will shed light on the pathophysiology of some mental
illnesses and may suggest radically new treatments. Comfort
(1977) has briefly reviewed the literature written in English.
Recent clinical and laboratory data suggest that some patients
with melancholia (endogenous depression; ED) may have higher than
normal levels of beta-endorphin. Carroll et al. (1981) have
shown that 2/3 of patients with ED fail to suppress cortisol
secretion for 24 hours after oral dexamethasone. These patients
also have high cortisol levels throughout the day and lose the
normal diurnal rhythm of cortisol production. Other evidence
suggests that these high cortisol levels are secondary to high
ACTH levels (Reus et al., 1982) and also that the increase in
secretion of ACTH is accompanied by an increased secretion of
beta-endorphin (Guillemin et al., 1977). Thus it may be most
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fruitful to begin with the literature on the treatment of
affective disorders, particularly melancholia, with opiates.
We have reviewed the clinical literature on the treatment of
melancholia with morphine or opium, covering the years from 1850
to 1960, to address several questions:
1. Is morphine effective in relieving the symptoms of endogenous
depression?
2. If so, is this merely nonspecific sedation, or is there some
more specific treatment of symptoms?
3. Does the relief of symptoms persist after the administration
of morphine is stopped?
4. How do depressed patients respond to morphine? What dose is
needed for relief of symptoms, or for sedation? What is the
incidence of tolerance and dependence?
REVIEW OF THE LITERATURE
Our review concentrated on articles written in English and German,
and included a few written in French. The literature was
translated by the authors, who are psychiatrists practicing in
English. One author (M.S.) is a native speaker of German;
another (J-P.P.), of French. We will address the questions above
in the order given, and have included synopses and evaluations of
the literature reviewed in an Appendix. In order to compare
studies, it is necessary to assume that all the opium used
contained 10 percent morphine base as the sole active ingredient,
even though this may not be true. It is difficult to compare
reports about oral morphine or opium with those discussing the
effects of subcutaneous administration of morphine salts because
of the uncertainties of absorption after oral administration and
of first-pass hepatic metabolism. McDiarmid (1876) cites these
uncertainties as one reason for preferring parenteral
administration. The recommended daily dose of morphine ranges
from about 7 mg hs to 90 mg per day. In the discussion that
follows, morphine is assumed to include both morphium and opium
unless otherwise noted. Opium was given by mouth in all the
references cited; morphine itself was given by mouth in one
study, by Mickle (1874).
The interpretation of the literature cited is made more difficult
by the usual clinical course of endogenous depression
(melancholia). It is most only an episodic illness, with each
episode lasting some 4 to 12 months if untreated. The patient
usually remains well until the next episode, which not uncommonly
begins 12 months after the previous one began.
Nearly every author cited concluded that morphine provided
symptomatic relief in melancholia, and some suggested that
morphine cured the patient. Kielholz (1959) compared opium with
imipramine and concluded that opium produced symptomatic relief
but that the symptoms might return if treatment were stopped. (It
is interesting to note that this represents the current clinical
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wisdom about imipramine: the symptom may return if administra-
tion of the drug is stopped too early.) Tigges (1864) was the
only author who found opium useless in the treatment of melan-
cholia. He described the treatment of 39 patients, and provided a
good deal of information about each patient's history, symptoms,
and treatment. He concluded that the poor response may have been
caused by the patients' having chronic, rather than acute,
melancholia. It is equally likely that the lack of response was
due in part to the relatively low doses of opium used. Some older
textbooks of psychiatry recommend opium as a sedative-hypnotic in
endogenous depression (Bucknill & Tuke, 1858; Cramer et al.,
1907; Maudsley, 1867), while others found it useless (Henderson
and Gillespie, 1933). The latter did not comment on the doses
used, and the former only occasionally provided guidelines for its
use.
Every author found that morphine was an effective sedative if the
dose were high enough. Even Tigges (1864) found that morphine
(but not opium) was initially effective as a sedative, although
this effect was soon succeeded by excitation, suggesting the
development of tolerance. McDiarmid (1876) and Russell (1860)
believed that the relief of other symptoms was secondary to the
sleep produced by morphine. Kielholz (1959) and Marce (1857)
found, however, that patients improved clinically despite the
persistence of the sleep disturbance which is such a common
feature of melancholia.
Nearly all of the patients described were psychotic. Morphine had
an antipsychotic effect out of proportion to its effect on other
symptoms, such as depressed mood. Kielholz (1959), Mickle (1874),
and Marce (1857) were quite specific about this, and Ziehen (1889)
found that the presence of hallucinations predicted a good
response to opium. These reports are even more interesting in
light of the more recent finding that psychotically depressed
patients may not respond to treatment with tricyclic
antidepressants (Glassman et al., 1975).
Some of the papers cited describe psychotic patients who probably
did not have endogenous depression (Engelken, 1851; Knecht, 1872;
Voisin, 1881; 1891); in these cases the antipsychotic effect was
clearly separate from an antidepressant (or antimelancholic)
effect. The antipsychotic effect of morphine, found in a wide
variety of patients, is difficult to reconcile with the current
theory that psychosis may be due to a functional excess of
endorphins and be relieved by narcotic antagonists (Bloom et al.,
1976; Berger et al., 1981). Gold et al. (1977) have suggested
that morphine may have an antipsychotic effect, basedonthe
morphine-induced increase in plasm prolactin.
Only a few of the authors mentioned tolerance or physical
dependence. Mickle (1874) did not find that tolerance developed,
and believed that this was because of the low dose of morphine,
15-20 mg, tid. This is not, by most standards, a low dose, and it
is likely that tolerance does ordinarily develop to this dose.
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The French authors, Marce (1857) and Voisin (1881; 1891) clearly
described tolerance and physical dependence in their patients, the
latter at doses of morphine similar to those used by Mickle.
Voisin also described an increased sensitivity to morphine, which
occurred suddenly when patients became well. He could find no
reason for this, or for the wide range of sensitivity to morphine
in his patients: he said that he'd asked Claude Bernard, who was
similarly puzzled.
CONCLUSIONS
The available evidence clearly suggests that morphine produces
symptomatic relief in melancholic patients, and that this relief
is out of proportion to any sedative effects. These effects seem
to be dose related, as authors using lower doses (<60 mg of
morphine/day) reported fewer responses to treatment than did those
using higher doses. It is likely that rather than being a cure,
this is symptomatic relief similar to that provided by
antidepressant drugs, although most of the authors do not give
enough information to allow a clear decision. This finding
suggests that abnormal functioning of an endorphin "system" may be
responsible for sane of the symptoms of melancholia. It is
tempting, and may be fruitful, to speculate that this abnormal
functioning my underlie the illness itself. It is also possible
that morphine, an artificial endorphin, acts to remedy symptoms
caused by abnormal function elsewhere in the brain.
The evidence suggests that we should mount a double-blind
placebo-controlled study of morphine or other centrally acting
endorphin agonist in patients with melancholia. Such a study
should probably include a narcotic antagonist and one or more of
the partial agonists. The drugs used should be selected for their
differential effects on the several postulated endorphin receptors
in the brain.
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The Effects of Two Non-
Pharmacological Variables on
Drug Preference in Humans
H. deWit, C. E. Johanson, E. H. Uhlenhuth, and S. McCracken
The question of whether benzodiazepines, and in particular diazepam,
should be considered drugs of abuse has recently become a matter of
considerable controversy. On the one hand, there is concern over the
large number of prescriptions that are written for these drugs every
year. On the other hand, there is very little evidence that the
benzodiazepines are being used inappropriately, i.e., nontherapeutically,
by the vast majority of people exposed to them. Because of the
limitations of clinical surveys and case reports as a reliable source of
data, this issue has also become the subject of experimental research
in both animals and humans (Griffiths and Ator, 1980). Experimental
techniques have been developed in the laboratory to measure the
dependence potential of drugs by assessing their efficacy as positive
reinforcers of behavior. In these experiments, as well, there is little
evidence that diazepam is similar to other, clearly abused drugs. For
example, there are only isolated reports of animals self-administering
benzodiazepines, and results from our laboratory indicate that in normal
human volunteers, diazepam also does not act as an effective reinforcer
(Johanson and Uhlenhuth, 1980a). The present experiments further
explored the reinforcing properties of this drug in human volunteer
subjects.
These studies utilized a choice procedure in which a drug was compared
to placebo. The experiments consisted of two phases, a sampling phase
followed by a choice phase, in which subjects were allowed to ingest
the substance they preferred. The number of times that a drug was
chosen (compared to placebo) was considered an indication of its positive
reinforcing efficacy in this situation. In addition to this behavioral
measure of preference, the subjects also were asked to complete
subjective effects questionnaires before and at various times after
ingestion of the drug, providing a quantitative and temporal profile of
the drug’s effects on mood. It is important to be able to examine
the degree of concordance between the behavioral measure of positive
reinforcement (choice) and the subjective mood effects, particularly
since the subjective effects of drugs traditionally have been used as
indicators of dependence potential.
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In the previous study using this procedure (Johanson and Uhlenhuth
1980a), normal, healthy volunteer subjects preferred placebo over 5 and
10 mg diazepam. A dose of 2 mg diazepam was chosen equally as
often as placebo. At the two higher doses there were clear, dose-
dependent changes in subjective effects on several subscales of an
experimental version of the Profile of Mood States (POMS; McNair et
al, 1971) after drug ingestion, showing effects that were consistent
with the drug's known sedative properties (e.g., decreased Vigor and
Arousal, increased Fatigue). It is clear that the experimental paradigm
is sensitive to the reinforcing properties of drugs since in a comparison
between amphetamine, a highly abused drug, and placebo, these same
subjects showed a clear preference for amphetamine (Johanson and
Uhlenhuth, 1980a).
Despite the experimental evidence suggesting that diazepam is not an
effective positive reinforcer, there is one report that is not consistent
with this notion. Griffiths et al. (1980) have shown that inpatient
subjects do show a strong preference for diazepam over placebo.
However this study differed from studies in our laboratory in terms of
the subject population used, the doses of drug used, and the procedural
details of the experiments. While these differences make it difficult
to identify the variables that might account for the discrepancy between
their results and ours, it is clear that further research is needed to
explore the variables that influence the reinforcing properties of this
drug.
The present experiments explored this problem by manipulating two
nonpharmacological variables that might increase the ability of
diazepam to serve as a positive reinforcer. One of these was to
determine whether preference for the drug would be different for
people who are anxious. The oossibility existed that the therapeutic
value of the drug, its anxiolytic property, would make it a positive
reinforcer. Secondly, the absence of a preference for diazepam in the
earlier study may have been due to the drug’s mild sedative effects.
Since most of the subjects were university students and employees
whose work required a high level of activity and alertness, the sedative
effects of the drug might have been too disruptive. To test this
hypothesis, a group of normal nonanxious subjects ingested the drug
late in the day, when the demands on concentration and activity were
presumably less. In addition to these two groups of subjects, a group
of normal subjects who ingested the drug in the mornings was used for
purposes of comparison to the previous study.
M E T H O D
Subjects. Three groups of subjects, aged 21 to 35, were tested in each
of three experiments. On the basis of a complete psychiatric interview,
24 subjects were selected who were considered normal, and 12 subjects
(Anxious Group) were selected on the basis of having a DSM III (A.P.A.,
1980) Generalized Anxiety Disorder. Twelve normal subjects served as
the Control Group and the remainder were assigned to the Afternoon
Group, who reported to the laboratory in the late afternoon rather
than the morning. Subjects with a history of primary depression or
drug abuse were excluded from the study. All subjects signed an
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informed consent before participation that detailed the experimental
protocol and informed the subjects of any possible drug effects they
might experience.
Procedure. All subjects participated in three separate choice
experiments, each comparing a drug to placebo. Drug and placebo
were prepared in opaque gelatin capsules with dextrose powder used
as filler. The procedure for each experiment was identical except for
the drug used, which was either 5 or 10 mg diazepam, or 5 mg d,l-
amphetamine. The order of presentation of these experiments was
randomized across subjects.
Each experiment consisted of 9 sessions, of which the first four were
sampling days, and the following 5 were choice days. Subjects in the
Control and Anxious Groups reported to the laboratory between 9 and
10 am, and the subjects in Afternoon Group came between 4 and 5 pm
to ingest their capsule. When a subject arrived, she/he filled out mood
questionnaires (see below) and then received a distinctively colored
capsule containing either drug or placebo for immediate ingestion.
Approximately half the subjects received drug during sessions 1 and 3
and placebo on sessions 2 and 4, and the order was reversed for the
other half. For each subject, each drug was dispensed in a capsule of
a consistent and distinctive color in order to facilitate identification
during choice sessions. Capsule colors were assigned randomly across
subjects to minimize the influence of color preference. Subjects were
instructed during the initial four sessions (sampling) to note the capsule
colors, to try to associate each of the two colors with the effects of
the substances contained in them and to remember that the same drug
was always contained in a capsule of the same color. After ingesting
the capsule, subjects were free to leave the laboratory. They took
three additional sets of mood forms with them, to be completed 1, 3
and 6 hours later. During the last five sessions, the procedure was
identical in every respect except that the subjects were given a choice
of the two colored capsules to ingest.
The mood questionnaires to be completed were the Addiction Research
Center Inventory (ARCI) (Haertzen, 1974) and an experimental version
of the Profile of Mood States (POMS). The ARCI consists of 49
true/false questions separated into 5 clusters described as measuring
stimulant-like effects (two subscales), euphoria, sedation and dysphoria.
The POMS consists of 72 adjectives commonly used to describe
momentary mood states. Subjects indicate how they feel at the moment
in relation to each of the adjectives on a S-point scale, ranging from
‘not at all’ to ‘extremely.’ There are 8 clusters of items (Anxiety,
Depression, Anger, Vigor, Fatigue, Confusion, Friendliness and Elation)
and two additional derived subscales (Arousal and Positive Mood). The
results of the subjective effects rating scales reported here are based
only on data from the first four sessions (sampling sessions) of each
experiment.
RESULTS AND DISCUSSION
The number of subjects in the Control Group who chose each drug on
0-5 occasions is illustrated in figure 1. T-Tests for correlated measures
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were used to determine whether the mean number of drug choices
differed statistically from chance (2.5). Amphetamine at 5 mg was
Figure 1: Number of subjects choosing drug 0-5 times.
chosen over placebo on 80 percent of the occasions (p < .01); this
preference for racemic amphetamine is similar to that found for
d-amphetamine in previous studies (Johanson and Uhlenhuth, 1980a,b),
despite the fact that the racemic amphetamine may be less otent
than the d-isomer. Consistent with earlier findings, the Control Subjects
did not show a preference for diazepam at either dose. The 5 mg
dose was chosen about equally as often as placebo (41 percent drug
choice) while at the higher dose of diazepam (10 mg), subjects preferred
placebo to the drug (25 percent drug choices; p=.02). Subjects who
chose diazepam 4 or 5 times at the 5 mg dose were not usually the
same subjects who chose drug 4 or 5 times at the 10 mg dose.
The subjects in the Anxious Group did not choose diazepam over placebo
at either of the doses tested. They chose 5 mg diazepam about as
often as placebo (48 percent), and preferred placebo to the 10 mg dose
of diazepam (29 percent drug, choices). Unexpectedly, the Anxious
subjects chose amphetamine less often than the Control Group (58
percent - drug choice). These results are apparently inconsistent with
an earlier finding (Uhlenhuth, Johanson, Kilgore and Kobasa, 1981) that
normal subjects who chose amphetamine 5 out of 5 times had higher
pre-drug scores on the Anxiety subscale of the POMS than subjects
who did not choose the drug consistently.
For the group of subjects who ingested the drug late in the day, the
drug preferences in the three experiments were similar to those seen
in the Anxious Group. That is, amphetamine was chosen equally as
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often as placebo (53 percent), while placebo was preferred to both 5
and 10 mg dose of diazepam (32 percent drug choice in each case).
Amphetamine produced surprisingly little effect on the subjective
effects questionnaires for the Control Group despite these subjects’
clear preference for the drug. None of the subscales of the POMS
showed a significant drug x hour interaction. It is notable, however,
that the one scale that did show a significant effect for this group
was the MBG Scale of the ARCI, a scale that has been associated with
“euphorie" drug effects. These modest changes in subjective effects
after amphetamine are in contrast to previous studies with the d-
isomer, which have shown clear changes in subjective effects. This
difference may indicate that the dose of drug used approached the
threshold of discrimination. Nevertheless, this discrepancy across
measures suggests that preference is a more sensitive indicator of a
drug’s reinforcing properties than scores on these subjective effects
questionnaires.
For the Anxious Group, amphetamine increased scores on Vigor and
Arousal subscales of the POMS at hours 1 and 3, while for the Afternoon
Group, no significant drug effects were observed.
Diazepam produced clear dose-dependent effects on both the POMS
and the ARCI (figures 2 and 3). Increased scores on POMS subscales
Figure 2: POMS and ARCI scores for placebo (solid lines) and 5 mg
diazepam (broken lines). Asterisks show significant (p<.05) differences.
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Figure 3. POMS and ARCI scores for placebo (solid lines) and 10 mg
diazepam (broken lines). Asterisks show significant (p<.05) differences.
Confusion and Fatigue, and decreased scores on Arousal and Vigor have
been observed in previous studies with this drug (Johanson and
Uhlenhuth, 1980a), and are consistent with the drug’s known sedative
properties. Decreased scores on the Anxiety subscale have not
previously been observed, but are consistent with diazepam’s well-known
anxiolytic property. It is notable that the average baseline scores on
the Anxiety subscale for the Anxious Group were almost double those
for the Control Group. This difference is an independent confirmation
that the subject groups differed on this dimension, since the measures
used for subject selection were different. The fact that measures of
anxiety were elevated both at the recruitment interview and throughout
the period of the study (9-11 weeks), suggests that these subjects
exhibited the “trait” of anxiety rather than a more transient “state.”
Scores on the ARCI for all three groups also reflect diazepam’s sedative
properties: PCAG (“sedative” subscale) scores were elevated and BG
(“amphetamine” subscale) scores decreased.
Thus, the results from these experiments confirmed and extended earlier
findings of the absence of a positive reinforcing effect of diazepam
in normal human volunteers. Subjects who were anxious by DSM III
criteria showed no preference for diazepam over placebo at either of
the doses tested, despite this drug’s measurable anxiolytic effect on
the POMS. Even in a population of anxious subjects, the anti-anxiety
property of the drug does not appear to be a sufficient condition to
make it a positive reinforcer.
It was also shown that time of drug administration did not affect the
preference for diazepam, even when the drug’s presumed disruptive
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effects were minimized by giving it late in the day, a time more
probable for recreational drug use such as alcohol. These results
contribute to the growing body of literature suggesting that diazepam
is not an effective positive reinforcer in the majority of laboratory
animals or humans.
It was interesting to note that the preference for amphetamine was
attenuated in the two experimental groups, demonstrating that it is
possible to influence choice by such manipulations, and, more
importantly, that the experimental design is sensitive to alterations in
reinforcement efficacy.
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Differential Effects of Diazepam
and Pentobarbital on Mood
and Behavior in Subjects With
Histories of Sedative Drug Abuse
Roland R. Griffiths, George E. Bigelow, and Ira A. Liebson
The effects of administering moderate to high doses of diazepam
(placebo, 50 mg and 100 mg) and pentobarbital (placebo, 200 mg
and 400 mg) for five consecutive days to subjects with histories
of sedative drug abuse were examined. The two drugs produced
similar dose-related effects on psychomotor performance, daytime
sleeping, and staff and subject ratings of magnitude of drug
effects. Diazepam but not pentobarbital produced dose-related
decreases in staff ratings of subjects’ mood and social inter-
actions, and increases in staff ratings of subjects’ hostility,
complaining and unusual behavior. During the ten to fourteen day
placebo washout periods which followed drug administration,
diazepam but not pentobarbital was associated with carryover
effects on psychomotor performance, daytime sleeping and staff
ratings of drug effect, mood, social interactions, hostility and
confusion. The diazepam-produced deterioration in mood and social
behavior observed in this study is consistent with previous case
reports describing similar effects associated with chronic diaze-
pam use in therapeutic settings.
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Rapid Physiologic Effects of
Nicotine in Humans and Selective
Blockade of Behavioral Effects
by Mecamylamine
Jack E. Henningfield, Katsumasa Miyasato, Rolley E.
Johnson, and Donald R. Jasinski
Recent research in the area of tobacco dependence has focused on
characterizing the functional properties of nicotine in cigarette
smoking. These studies have shown that many of the effects of
cigarette smoking are due to the nicotine delivered via the smoke
(Griffiths and Henningfield, 1982; Gritz, 1980). A recently
completed study in our Laboratory indicated that some effects of
intravenous nicotine (e.g., cardiovascular and subjective re-
sponses) occurred very rapidly, onsetting within seconds and
offsetting within minutes of an injection (Henningfield, Miyasato
and Jasinski, 1981). That study also demonstrated that different
doses of nicotine could be tested at one-hour intervals within
subjects and produce reliable changes in physiologic and behav-
ioral responses with no apparent interaction of tolerance or dose
order effects.
The present report describes two experiments in which a new
preparation for the analysis of rapid drug effects was utilized.
In the first experiment, the temporal pattern of response to
intravenous nicotine was determined in measures of skin temper-
ature, pupil diameter, and two locations of electromyograph (EMG)
recording. Selected behavioral responses were also measured.
The second experiment was a replication of the first except that
prior to the sessions subjects were given a dose of the centrally
acting nicotinic antagonist, mecamylamine.
EXPERIMENT I. Effects of Nicotine on Physiologic and
Behavioral Measures
M E T H O D
Subjects. The subjects were four male Volunteer cigarette
smokers who resided on the Clinical Pharmacology Research Unit
for the approximate four-week duration of the study. Prior to
the study, they were medically and psychologically evaluated,
found healthy, and provided informed consent for the experimental
procedures. Two subjects had histories of alcoholism (SA and
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HE), one subject had taken sedatives and stimulants (BA), and one
was without a history of drug dependence other than cigarette
smoking (HO).
Drugs.
saline to provide unit doses of 0.75, 1.5 and 3.0 mg (expressed
Nicotine hydrogen tartrate was mixed with bacteriostatic
as the nicotine free base). Nicotine doses or saline were
delivered via an intravenous catheter placed in a forearm vein at
an injection rate of 1 ml (one unit dose) per ten seconds. All
drug doses were given double-blind.
Apparatus. A microcomputer-controlled physiological testing
system (Cyborg) was used to collect data. Four physiologic
measures collected using this system were: (1) skin temperature,
taken from the index finger on the arm not equipped with a
catheter; (2) two EMG measures, taken from the Lower Leg and the
opposite forearm of that which held the catheter; (3) pupil
diameter, which was measured by a closed circuit television
system (from Applied Science Laboratories) and interfaced to the
physiologic testing system.
Procedure.
following
Subjects were tested individually in the morning
at Least eight hours of tobacco deprivation. An
experimental session consisted of four ten-minute tests which
occurred at 60-minute intervals. During the ten-minute test, a
subject was seated in a chair with his arms resting on a table in
front of him. Every five seconds a two-second Long tone was
automatically turned on by the physiological testing system.
During the tone the subject relaxed and focused his eyes (without
blinking) on his own pupil, which was displayed on a video
monitor Located 150 cm in front of the subject. One second into
the tone, the physiological test system simultaneously recorded
the values at the EMG channels, the skin temperature channel, and
the pupilometer channel. Between tone signals (3 seconds), the
subject blinked his eyes 3 times. This sampling sequence
continued for 10 minutes, though for the purpose of data anal-
ysis, the first two minutes of data were discarded. The
intravenous dose was delivered three minutes after the start of
the test, without interruption of the data collection procedure.
Between these ten-minute tests, the subject was permitted to
relax in another room but was not permitted to eat, smoke cigar-
ettes or drink caffeinated beverages. Before and after tests,
the subject completed structured questionnaires which measured
various interoceptive (subjective) drug effects.
Experimental design. On the first test day, for each subject,
placebo plus the three nicotine doses were given in order of
increasing dose values. These data were not used for final
analysis but the session provided an opportunity for the subject
to Learn and adapt to the protocol, and for the safety of the
doses to be verified. Each subject was then tested for four more
sessions in which all four doses were presented each session,
according to a 4 x 4 Latin square design across sessions.
Sessions were scheduled one to three days apart.
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RESULTS
Nicotine produced dose-related changes in both physiologic and
behavioral measures. Figure 1 shows the bi-phasic effect of
nicotine on pupil diameter. Pupil diameter began to increase
during injections and further increased as a direct function of
the dose level. The maximum increase was about 30 seconds
post-injection and was followed by a precipitous dose-related
decrease in pupil diameter. Skin temperature was decreased in a
dose-related fashion in all subjects, reaching a maximum decrease
within about five minutes of the nicotine injections. These
decreased skin temperature levels did not recover within the 10-
minute sessions. Electromyographic responses from the Lower Leg
were weak and were not altered in a consistent fashion by nic-
otine. Electromyographic responses from the upper arm occurred
at much higher baseline levels and were increased by the 3.0 mg
Figure 1. Mean changes in pupil diameter, from
initial baseline values, are shown at three nico-
tine doses (n=16, 4 subjects x 4 observations).
Data from the 0.75 mg dose are omitted to increase
the clarity of the figure (these data were similar
to those obtained at placebo). Dose levels are in-
dicated by the label adjacent to each function.
dose of nicotine and not consistently altered by other doses of
nicotine. This effect corresponded to a visibly increased muscle
tension of the subjects facial and neck muscles at high nicotine
doses. The most reliable subjective measure was self-reported
drug dose strength which was directly increased by nicotine
doses. Other self-reported responses included dose-related
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increases in scores on the scale of "drug liking," and identifi-
cation of. the drug effects as those produced by amphetamine or
cocaine (Addiction Research Center, Single Dose Questionnaire).
EXPERIMENT II. Pharmacologic Antagonism of Nicotine's Effects
M E T H O D
Subjects and Apparatus. These were the same as described in
Experiment I.
Drugs.
Experiment I. Mecamylamine doses consisted of commercially
Nicotine doses and preparations were the same as for
available preparations (Inversine, from Merck, Sharp and Dohme)
in pill form, which were placed inside gelatin capsules with
Lactose filler. The doses were 2.5, 5.0 and 10.0 mg meca-
mylamine, and Lactose placebo. All drug doses were given double-
blind.
Experimental design. Each subject was tested in one four-hour
session at each mecamylamine dose. The nicotine dose sequence
was held constant for each subject but was varied across subjects
according to a 4 x 4 Latin square design. Mecamylamine doses
were also presented according to a 4 x 4 Latin square design
across subjects.
Procedure. The general procedure was the same as that described
for Experiment I. The mecamylamine dose was given 60 minutes
prior to the start of the four-hour nicotine session. Addition-
ally, 65 minutes prior to sessions, supine and standing pulse,
and blood pressure were measured, along with a brief symptom
check List given verbally to the subjects by the research staff
with items pertaining to possible anticholinergic effects. This
physical and symptomatic status evaluation was repeated at 30 and
5 minutes prior to the four-hour session, immediately following
each 10-minute nicotine test, and at 1-hour intervals for three
hours following the test session.
R E S U L T S
In the mecamylamine placebo condition, the effects of nicotine on
the behavioral and physiologic variables were the same as had
been measured in Experiment I. Active mecamylamine doses, how-
ever, attenuated all effects of nicotine. Figure 2 shows the
mecamylamine dose-related attenuation of nicotine's effects on
skin temperature. The bi-phasic effects of nicotine on pupil
diameter were also eliminated by mecamylamine. Mecamylamine also
attenuated the variability in EMG responses which were produced
by the high nicotine dose. Whereas mecamylamine produced a dose-
related attenuation of the physiological responses to nicotine,
subjective responses to nicotine were maximally attentuated by
the lowest mecamylamine dose. Figure 3 shows this effect most
clearly in scores on the drug dose strength scale which were
rated by the subjects following each 10-minute nicotine test. An
orthogonal polynomials analysis confirmed that (1) mecamylamine
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Figure 2. Mean changes in skin temperature from
initial baseline values are shown as a function
of nicotine dose under the four mecamylamine con-
ditions (n=4 subjects). The values shown are
those measured at each minute except for the two
values measured during the injection. The 0.75
mg nicotine dose function was similar to placebo
and is not shown. Open triangles indicate place-
bo injections; open circles indicate 1.5 mg injec-
tions; closed circles indicate 3.0 mg injections.
alone was not discriminated, (2) the slopes of the dose-
strength functions were not different under the three active
mecamylamine dose conditions, (3) these slopes were different
from that obtained in the placebo condition, and (4) each
active dose of mecamylamine produced a reliable decrease in the
response to nicotine. Other subjective effects of nicotine
which were observed in Experiment I and in the mecamylamine
placebo condition were completely eliminated by all meca-
mylamine doses. These included (1) elevated drug liking
scores, (2) drug identifications given as "amphetamine" and (3)
the weak nicotine dose-related decreases in desire to smoke.
Mecamylamine did not produce reliable changes in supine or
standing blood pressure and heart rate, as determined by the
physical and behavioral status examinations.
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Figure 3. Post-session ratings of drug dose
strength are shown as a function of nicotine
dose under the four mecamylamine conditions
(n4 subjects).
DISCUSSION
This study demonstrates the utility of a new behavioral-
pharmacologic preparation for the analysis of the effects of
the rapid and complex activity of nicotine. Such changes in
pupil diameter in response to nicotine have not been previously
reported and perhaps best illustrate the sensitivity of this
preparation to rapid drug effects. The pupillary response also
reveals the complexity of nicotine's activity, which is a
combination of sympathetic activation resulting from
catecholamine release by nicotine (the nicotinic potentiation
of the initial mydriasis), direct nicotinic stimulation of
ganglia (the subsequent miosis), and its own self-antagonism
(resulting in transient nature of the responses). The effects
of nicotine on EMC responses were variable and not in the
expected direction of a decrease, which would have been con-
sistent with earlier findings by Domino that nicotine inhibited
the patellar reflex (Domino, 1969). The EMG findings were,
however, consistent with more recent analyses of nicotine
effects on skeletal muscle activity in which it has been
concluded that the effects are dependent on variables such as
the measure used, the nicotine dose, and the particular muscle
group under study (Domino, 1979).
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The mecamylamine findings ranged from the predictable effects
of apparent competitive antagonism of the nicotinic skin
temperature response, to the more exciting effects of selective
blockade of behavioral responses to nicotine. Specifically,
the observation that mecamylamine produces a substantial
blockade of subjective responses at physiologically insig-
nificant dose levels raises the possibility that mecamylamine
may provide a useful adjunct for the treatment of tobacco
dependence in a similar fashion as naltrexone is used to treat
opioid dependence.
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The Specificity of the Thyrotropin-
Releasing Hormone (TRH) Test and
Dexamethasone Suppression Test
(DST) for Major Depressive Illness
in Alcoholics
Charles A. Dackis, A. L. C. Pottash, Joyce Bailey, Robert F.
Stuckey, Irl L. Extein, and Mark S. Gold
It is estimated that in this country 10 million people suffer from alcoholism
(I), and that the incidence of major depression in the alcoholic population
ranges from 28% (2) to 59% (3). Major depression is difficult to diagnose
in the presence of alcoholism because the two disorders share many signs
and symptoms in common, such as sleep disorder, fatigue, anorexia,
decreased libido, and apathy. Neuroendocrine abnormalities have been
consistently and reproducibly demonstrated in major depression (4). The
thyrotropin-releasing hormone (TRH) test and dexamethasone suppression
test (DST) have a high degree of diagnostic predictive value with respect
to major depression (5,6), and could aid in the diagnosis of depressed
alcoholics. However, since chronic alcohol abuse also causes endocrine
abnormalities directly (7), and indirectly due to coexistent hepatic
dysfunction (8), the TRH test and DST abnormalities in alcoholics, when
present, may be due to alcoholism per se and may not be sufficiently
specific for confirming the diagnosis of major depression in this group of
patients.
The effect of alcohol on the hypothalamic-pituitary-adrenal (HPA) axis is
most dramatically represented by the alcohol-induced Cushingoid syndrome
reported in the endocrine literature (9,10,11,12). The elevated plasma
and urinary corticosteroids, abnormal circadian rhythm of plasma cortisol,
and abnormal DST associated with this condition may result from alcohol-
induced corticotropin release (13). Contradictory reports regarding DST
testing in alcoholics include one study of 12 abstinent alcoholics showing
significant non-suppression of cortisol (14) and another study of 10
alcoholics with no DST abnormalities (15). Neither studies adequately
screened the alcoholics for affective disease, and the presence or absence
of alcohol withdrawal was not clarified. The TRH test has been given to
a small number of alcoholic patients. Loosen studied 16 chronic alcoholic
men free of liver disease but with secondary depression (16). Six of 12
had a blunted TSH response to TRH during alcohol withdrawal, and 3 of
10 showed this abnormality during postwithdrawal. A more recent report
showed a blunted TSH response to TRH in 3 of 15 alcoholics abstinent
from alcohol for at least 2 years (17). Van Thiel studied 40 chronic
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alcoholics with alcohol-induced liver disease and found the TSH responses
to TRH significantly blunted when compared to normal controls (18).
Alcohol administration to normals failed to produce abnormal TSH
responses, and the abnormal TSH responses seen in alcoholics persisted
over a 10-day period (19). Additional studies testing the TSH response
to TRH have shown a delayed peak response in cirrhotic alcoholics (20)
and a blunted response in alcoholics presenting with clinical signs of
hyperthyroidism (21) and cirrhosis (22). It is not clear whether thyroidal
abnormalities result from chronic, toxic effects of alcohol or from
elements of the alcoholic life style such as poor diet or related illnesses.
In summary, relatively few studies have been reported regarding DST and
TRH testing in alcoholics. None of the studies reported have tested
alcoholics carefully screened for the absence of depression, liver disease,
and other medical illnesses. In addition, the influence of alcohol
withdrawal on the TRH test and DST has not been adequately tested by
comparing pre-detoxification and post-detoxification results for these
procedures. To investigate the reliability of the DST and TRH tests as
confirmatory diagnostic tests for major depression in alcoholic patients,
30 consecutive admissions without liver disease, endocrine illness, or other
significant medical diseases were tested with the DST and TRH test. All
patients were carefully screened with a SADS-C interview (23) in order
to select only patients free of RDC (24) major and minor depression,
mania and hypomania. We hypothesized that we would not find
abnormalities in the DST and TRH test in this group of alcoholics presenting
without major depressive illness, and that this finding would indicate that
these two tests are specific for major depressive illness in alcoholics. In
addition, the effect of alcoholism and the alcohol withdrawal syndrome
on these tests is described in order to assess the specificity of the TRH
test and DST for major depression in alcoholics.
Subjects and Methods
Twenty-one male and nine female alcoholics, aged 25-57 years (38.7 ±
1.7, mean ± SEM) were studied. All patients were admitted to Fair
Oaks Hospital and diagnosed as having definite alcoholism according to
RDC criteria (23). None had a history of polysubstance abuse, major
psychiatric illness, or previous dependence on substances other than
alcohol. All patients received antibody-based testing for barbiturates,
cocaine, amphetamine, opiates, marijuana and benzodiazepines in their
urine at admission and none had evidence of these drugs of abuse. Patients
with body weight greater than 20% over their ideal weight were excluded
as were patients presenting with a present or past history of cirrhosis
or hepatitis, or with a total bilirubin greater than 2.0 mg % or albumin
less than 3.5 gm%. No patients were taking dilantin, coumadin, L-DOPA,
bromocriptene or steroids, and none had present or past endocrine disease.
Patients with anemia (Hgb < 11 gm% in females, Hgb < 13gm% in males)
were excluded. Of those patients diagnosed with alcohol withdrawal
syndrome, all met specific SSA criteria according to Gross, Lewis and
Hasley upon admission (25). During the fourth week after admission, all
patients received a SADS-C structured interview to rule out the diagnosis
of RDC major or minor depressive illness, hypomanic, or manic disorder.
Patients fulfilling these criteria (4 of 34 tested) were excluded from this
study.
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Thirteen patients fulfilling criteria for alcohol withdrawal were detoxified
with chlordiazepoxide and received a TRH test and DST during the first
week of admission. These tests were repeated in each of these 13 patients
during the fourth week. Seventeen alcoholic patients not fulfilling criteria
for alcohol withdrawal syndrome were tested only during the fourth week
of hospitalization with a TRH test and a DST. Twenty normal men and
woman aged 19-47 years (30.0 ± 1.9, mean ± SEM) received the TRH test.
There were nine men and eleven women in this group and none had current
or past major psychiatric illness. All patients and normals received the
TRH test (500 mcg TRH IV) with blood drawn at 0, 15, 30, 60 and 90
minutes according to methods previously described (26). Baseline
determinations of TRH, T3 uptake, T3 RIA and T4 were made. All
patients with a delta TSH (peak minus baseline TSH) greater than 20
ulU/ml received testing for antithyroid antibodies (27). Within three days
of the TRH test, dexamethasone (1.0 mg) was administered by mouth at
12 midnight and sequential blood samples were drawn the next day at 8
a.m., 4 p.m., and midnight. The determinations of plasma cortisol levels
were done in duplicate, by radioimmunoassay.
Results
In 13 of 30 alcoholics studied, thyroid parameters were measured during
the withdrawal state and during the fourth week, or postwithdrawal state.
These parameters, including T3 RIA, T4 RIA, T3 uptake, baseline TSH
and delta TSH (peak TSH minus baseline TSH) were each compared during
withdrawal and postwithdrawal using a paired two-tailed Student’s t-test.
There were no significant differences with respect to the T3 RIA, T4
RIA, T3 uptake, and baseline TSH, although there was a trend (p < 0.10)
in T3 RIA comparisons with greater values seen during the withdrawal
state (146.5 ± 7.9, mean ± SEM) than at postwithdrawal (127.8 ± 9.0, mean
± SEM). Statistical significance (p < 0.05) was found comparing the delta
TSH during withdrawal (7.45 ± 1.1, mean ± SEM) with the delta TSH at
postwithdrawal (9.82 ± 1.9, Mean ± SEM).
The thyroid measurements at week 4 in those patients showing withdrawal
(N=13) were then compared using a two-tailed Student’s t-test with thyroid
measurements at week 4 in alcoholics not presenting with an alcohol
withdrawal syndrome upon admission (N=17). There were no significant
differences with respect to the T3 RIA, T3 uptake, baseline TSH and
delta TSH. However, in alcoholics with alcohol withdrawal, the T4 RIA
at week 4 (6.85 ± 0.41, mean ± SEM) was significantly greater (p < 0.05)
than the T4 RIA found in alcoholics who presented with no withdrawal
syndrome (5.53 ± 0.34, mean ± SEM). Since this parameter was significantly
different in the two groups, the T4 RIA values were analyzed separately
with respect to normal values, whereas the fourth week values for T3
RIA, T3 uptake, baseline and delta TSH were combined for the two groups
of alcoholics.
When the normals (N=20) were compared to the total alcoholics (N=30),
a two-tailed Student’s t-test showed no significant differences with respect
to the T3 RIA, T3 uptake, baseline TSH and delta TSH. There was a
large standard deviation in the alcoholics (11.74 ± 7.93, mean ± SD)
compared to the normals (13.36 ± 4.36, mean ± SD) with respect to the
delta TSH scores. This resulted from a bimodal distribution of delta
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TSH values in the alcoholic group, in which 5 of 30 were elevated above
20 uIU/ml. In the alcoholics who presented with a withdrawal syndrome,
the T4 RIA at the fourth week (6.85 ± 0.41, mean ± SEM) was significantly
less (t=3.30, p < .01) than the T4 RIA seen in normals (8.7 ± 0.35, mean
± SEM). The alcoholics with no alcohol withdrawal had the smallest T4
RIA values (5.53 ± 0.34, mean ± SEM) which were significantly less than
the normal T4 values (t=6.34, p < 0.001).
The delta TSH scores for the alcoholics and norrnals were compared with
a Chi-Square test to evaluate the percentage of blunted scores (See Table
1). When a cut-off point of less than 5 uIU/ml was used to define
blunting, 0 of 20 normals and 4 of 30 alcoholics at week 4 had blunted
values (X2=2.79, p < 0.1, NS). When a cut-off point of 7 uIU/ml was used,
8 of 30 alcoholics and 0 of 20 normals had a blunted delta TSH (X2=6.34,
p < 0.02), which was statistically significant. The 13 alcoholics studied
during alcohol withdrawal showed 5 of 13 (38%) blunting using a cut-off
of 5 uIU/ml, and 7 of 13 (54%) with a cut-off of 7 uIU/ml. Both of these
findings were highly significant when compared to the normals (X2=11.64,
p < .001 and X2 =7.52, p < .01 respectively). We have defined augmented
responses as a delta TSH greater than 20 uIU/ml. Five of 30 alcoholics
(17%) and 1 of 20 normals (5%) showed a delta TSH greater than 20 IU/ml.
This finding was not statistically significant.
Toxic Detoxified
Normals Alcoholics Alcoholics
(N=20) (N=13) (N=30)
Percent Blunted
delta TSH scores
(cut-off = 5uIU/ml)
Percent Blunted
delta TSH score
(cut-off = 7uIU/ml)
0% 38%(p < 0.001)
0% 54%(p< 0.01)
13%(NS)
27%(p< 0.02)
Table 1. Percent of blunted delta TSH responses in normals, toxic
alcoholics, and detoxified alcoholics according to defined cut-off points
of 5uIU/mI and 7uIU/ml.
With the DST, cortisol values were analyzed at 8 a.m., 4 p.m., and 12
midnight as described. Since Carroll’s work has defined normal values
for this test (6), a control group was not obtained. An abnormal DST
was defined as any cortisol value after 1.0 mg dexamethasone greater
than 5 ug/dL. At 4 weeks, none of the 30 alcoholics had an abnormal
DST. The alcoholics studied during alcohol withdrawal showed
abnormalities on the DST in 2 of 13 cases. There were no baseline
cortisol differences in the alcoholics during withdrawal as compared to
baseline cortisol during the fourth week.
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Discussion
The data presented here indicate that, in alcoholics screened for the
absence of affective disease, hepatic dysfunction and other medical
illnesses, there are neuroendocrine abnormalities relevent to the use of
current confirmatory laboratory tests for major depression. With respect
to the TRH test, this refutes our hypothesis that no abnormalities would
be present in this group of alcoholics devoid of major depression. Our
hypothesis was supported by the DST data showing no abnormalities in
detoxified non-depressed alcoholics. The test re-test data indicate that
the neuroendocrine effects of alcoholism tend to be most pronounced
during the alcohol withdrawal state, especially in the thyroid axis. This
finding is largely in agreement with previous reports (16,18) but with
these data it has now been shown to be more clearly related to alcoholism
than concomitant depression or liver disease. The degree of blunting
with the TRH test implies that it is an unsuitable test for depression in
alcoholics, particularly if administered during a period of alcohol
withdrawal. Even during the fourth week after detoxification there was
an unusually high frequency of inadequate responses, both by the stringent
criterion of 5 uIU/ml and the more sensitive criterion of 7 ulU/ml as a
cut-off point for a blunted delta TSH response. This has implications
regarding the significance of a blunted delta TSH in a clinical situation.
The diagnosis of alcoholism is often missed because of the strong denial
associated with the disease. The presence of a blunted TRH test, in the
absence of a clinical picture of depression, should alert the physician to
the possibility of alcoholism and indicate the desirability of contacting a
family or close friend informant in order to explore this possibility.
Our findings demonstrate significantly higher T4 values during withdrawal
than at postwithdrawal. This has been reported previously (28) and
attributed to relatively increased thyroidal activation during alcohol
withdrawal, in which certain clinical signs and symptoms resemble
hyperthyroidism (21). The finding that T4 levels are lower in both toxic
and postwithdrawal alcoholics than in normals has also been reported (7),
although not universally (16). This finding may represent a direct toxic
effect of alcohol on the thyroid gland and is supported by our finding that
5 of 30 alcoholics actually had augmented TSH responses to TRH, perhaps
compensating for a mildly hypoactive thyroid gland. None of these 5
patients had antithyroid antibodies in their blood which might have
explained their augmented TSH responses. Perhaps alcohol exerts toxic
effects, depending on dose and duration, on both the thyroid gland (leading
to decreased thyroxin and an increased TSH response to TRH) and on the
hypothalamic-pituitary segment of the thyroid axis, leading to blunted
TSH responses. The degree of thyroid abnormalities in alcoholics seen
during the first few weeks after cessation of drinking indicates that
assessment of their thyroid status with the TRH test may be an important
adjunct in their evaluation and treatment. This possibility requires further
study.
The DST data is very encouraging from a diagnostic point of view.
Negative findings for all 30 of 30 alcoholics during the fourth week offer
strong support for the hypothesis that the DST is specific for major
depression and devoid of false positives related to alcoholism in detoxified
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alcoholics. Our finding that 2 of 13 alcoholics in acute withdrawal had
an abnormal DST result implies that the clinician should conduct the DST
during the alcohol withdrawal state with caution and repeat any positive
findings at a later time. These data with the DST support the efficacy
of more widespread use of this excellent and practical laboratory test
for depression in the high risk alcoholic population. Further research is
currently underway at Fair Oaks Hospital to test the predictive value of
the DST in identifying alcoholics meeting KDC criteria for major
depression.
In conclusion, the DST appears to be an excellent diagnostic test for
confirming the diagnosis of major depression in the alcoholic population.
This easily administered test might serve as an effective screen for
depression in certain alcoholic patients who are at considerable risk for
this psychiatric disorder. Neuroendocrine testing with the DST may
identify patients who are self-medicating their psychiatric illness with
alcohol, or who prefer the diagnosis of alcoholism to that of major
depressive illness. The TRH test, however, lacks specificity for depression
in alcoholics, and is especially abnormal during acute alcohol withdrawal.
In fact, a blunted TSH response to TRH in an individual lacking a clinical
picture of depression should raise the clinician’s index of suspicion for
alcoholism. Further use of appropriate neuroendocrine tests for the
diagnosis of psychiatric disorders should enable alcoholic patients requiring
psychiatric treatment to be more easily identified and treated.
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The Symptoms of Alcohol
Withdrawal as Predictors of
Behavioral and Physiological
Responses to an Ethanol Stimulus
Richard F. Kaplan, Roger E. Meyer, and Charles F. Stroebel
INTRODUCTION
Behavioral and psychophysiological studies of alcoholism
have tended to "lump" alcoholics into a specific group, despite
the fact that behavioral theory would suggest that individuals
will differ in their operant and physiological response to
ethanol as a function of prior reinforcement history. Edwards
and Gross (1976) sought to describe the elements of a
"behavioral syndrome" which could be differentiated from
alcohol-related disabilities. They attempted to define
criteria which emphasized the elements of "dependence" that
could be quantified across a continuum of severity. When
Hershon (1977) examined two elements of Edwards' dependence
syndrome, withdrawal symptoms and drinking to relieve these
symptoms, he found a positive correlation between withdrawal
symptomatology and drinking behavior in 100 alcoholic
patients. More recently, Hesselbrock et al. (1981) positively
correlated withdrawal symptomatology in the last 30 days and
frequency of alcohol consumption in 114 alcoholic patients.
These studies in two different samples of alcoholics strongly
suggest the utility of examining elements of alcohol dependence
along a continuum of severity.
For behavioral researchers, the definition of a behavioral
syndrome which can be studied in the laboratory should permit
comparison of the stimulus control of psychophysiological and
behavioral responses to ethanol (and stimuli associated with
ethanol) between subjects. Since a history of ethanol
dependence can affect the respondent, discriminative, and
reinforcing stimulus properties of ethanol within the subject,
an examination of the syndrome in the laboratory should include
the assessment of physiological, subjective, and operant
responses in subjects who differ in the severity of the alcohol
dependence syndrome.
The present study is an attempt to investigate the
contributions of subclinical withdrawal symptomatology
occurring in the previous 30 days to psychophysiological
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arousal, desire to drink, and operant behavior associated with
alcohol within the clinical laboratory. The methodology
incorporates the monitoring of psychophysiological responding
and subjective desire to drink with the opportunity to work for
a drink reward.
MATERIALS AND METHODS
Subjects
The subjects were 16 alcoholic patients (mean age 33.67)
recruited from the inpatient Alcohol Treatment Unit at the
University of Connecticut Health Center and 16 control subjects
(mean age 28.0) selected from responses to posted
advertisements. All alcoholic subjects had a history of heavy
drinking of at least five years (mean years = 15.1 years). All
controls rated themselves as social drinkers who drank beer.
Questionnaires
The present report focuses on a self-report instrument
called the "Last 30 Days of Drinking Questionnaire," which
concentrates on withdrawal symptoms and drinking behavior
during the month just prior to hospital admission. Items in
the first part of this questionnaire were developed by Hershon
(1977) to measure withdrawal symptomatology, particularly in
the areas of physiological discomfort and affective
disturbance. Each item was rated on a four-point Likert-type
scale representing frequency of occurrence in the last month of
drinking. The response categories ranged from "never" to
"everyday." The second part of the survey presented a series
of items measuring the quantity and frequency of wine, beer,
and liquor consumption.
Procedure
Subjects in both the alcoholic and control groups were
randomly assigned on a double blind basis to either an ethanol
or placebo condition at the start of the experiment.
The sequence of events is summarized in Table 1. All
subjects were studied individually. At the outset of the
experimental period, each subject was seated in a comfortable
chair. Sensors for measuring heart rate, skin conductance, and
finger temperature were connected. Each subject was then given
a variety of questionnaires to complete; which also allowed
time for stabilization of physiological responses.
TABLE 1
The beer or non-ethanol containing malt beverage was
presented to the subjects in a frosted mug on a tray which also
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held an empty can of a commercially available alcoholic brand
of beer. The subjects were asked to hold, smell, and think
about the drink for one minute while physiological measurements
were being taken. At the end of the minute each subject was
asked to record (1) his desire for a beer (no desire to
greatest desire), (2) his belief whether the beer actually
contained alcohol (definitely contains alcohol to definitely
does not contain alcohol), and (3) his subjective response to
the beer (non-intoxicated to intoxicated). After the minute of
psychophysiological assessment and subjective report, each
subject was given five minutes to consume the drink. After
consumption of the first drink, a second drink identical to the
first was presented and consumed following this same
procedure. Subjects were then instructed that they had an
opportunity to work for a third drink identical to the first
two, or a Connecticut state lottery ticket (whichever they
chose). The procedure for obtaining the reward consisted of a
progressive-ratio operant task as described by Funderburk and
Allen (1977). When sufficient points had been accumulated to
secure the reinforcer, subjects were again told that they could
have a third drink or the lottery ticket.
R E S U L T S
Alcohol Dependence Syndrome
The mean scores on the Last 30 Days of Drinking
Questionnaire for the groups: alcoholics receiving alcohol
(AA), alcoholics receiving placebo (AP), controls receiving
alcohol (CA), and controls receiving placebo (CP) were 57.75,
65.24, 38.75 and 40.29 respectively. A one-way ANOVA indicated
significant group differences (F=9.32, df=3.28, p<.001); and
the Newman-Keuls comparison showed that both alcoholic groups
were significantly more dependent than either control group;
alcoholic groups did not differ from each other and neither did
control groups differ from each other.
Desire to Drink
The desire to drink scores were analyzed using a
split-plot analysis of variance with groups as the between
subjects factor, and time point in the experiment as the within
subjects factor. Where significant main effects were found,
mean comparisons were computed using the Newman-Keuls test for
multiple comparisons.
All groups increased their desire to drink level upon
presentation and before the consumption of the first drink.
The alcoholic group receiving alcohol (AA group) showed a
significantly higher desire to drink level following
consumption of the first drink than all other groups (p<.05).
The AA group maintained this difference (Figure 1) throughout
the experimental period. Both the AP and CA groups manifested
significantly greater desire to drink than the CP group (p<.05).
275
FIGURE 1
It is of special interest that 6 of 8 alcoholics (after 2
drinks) who received placebo thought that they had received
real beer; whereas only 2 of 8 control subjects receiving
placebo thought that the placebo drink was real beer. These
data which can be seen in Table 2 were analyzed using the 2
statistic and were significant at p<.05. Moreover, there was a
positive
was real
TABLE 2
correlation between the assumption that the placebo
beer and the alcoholics' increase in desire to drink
following consumption of the first beer (rho=0.63, p<.045).
This correlation was also significant for the AA group
(rho=0.73, p<.01); but not for either control group. Finally,
the correlation between severity of alcohol dependence in the
alcoholic subjects and the rating of placebo as real beer
approached statistical significance (rho=0.41, p<.056).
Physiological Responses
SCL scores were transformed using Lacey's (1966) autonomic
lability score (ALS) formula to compensate for baseline
differences and the law of initial values. As can be seen in
Figure 2 both alcoholic groups showed a greater SCL response
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to the presentation of the first drink. This was statistically
significant only for the alcoholic group that received alcohol
(p<.05).
FIGURE 2
There was also a significant correlation between SCL (ALS)
to the initial presentation of the beverage (before
consumption) and increased desire to drink in the combined
group of alcoholic subjects (r=.46, p<.04) (AA and AP); but not
in control subjects. There was a positive correlation between
SCL response to the drink prior to consumption and severity of
alcohol dependence in the AA group (rho=.58, p<.06) suggesting
some effect of alcohol dependence on psychophysiological
arousal to stimuli associated with drinking. This was not,
however, seen in our other alcohol group or either control
group. The two groups of alcoholic subjects and the control
subjects who received real beer also manifested a small
increase in heart rate with the presentation of the first
drink. Following consumption of this drink, heart rate dropped
in all groups. It increased in the AA group following
presentation of the second drink and remained elevated in this
group through the remainder of the experiment.
There were no significant differences between group means
for skin temperature and there were no differences across the
time points in the experiment for this variable.
Operant Responding and Reward Choice
There was no significant differences between groups in
accumulated operant points. All but one subject earned
sufficient points to receive either the drink or the lottery
ticket by at least the end of the second operant period. This
one alcoholic subject in the AP group refused to press the
operant button and was not included in this analysis.
Although the operant task did not discriminate among our
groups, reward choice of beer or lottery ticket did. Within
the AA and AP groups half of the subjects chose the drink
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reward and half chose the lottery ticket. Five of the subjects
in CA group chose the drink but only 2 of 8 subjects in the CP
group picked the drink. Among the alcoholic subjects (but not
among the controls) there was a significant correlation between
thinking that a drink contained real beer and the decision to
choose the drink reward (rho=.46, p<.04).
In an attempt to examine those variables affecting the
choice of the drink reward within each population (alcoholics
and controls) we computed a forward stepwise multiple
regression with alcohol dependence, increase in desire to
drink, whether or not the subject received beer or placebo, and
our psychophysiological measures as predictor variables. Table
TABLE 3
3 shows that for our alcoholic population, an increase in
desire to drink, a higher degree of alcohol dependence and an
increase in cardiac rate to the presentation of the drink all
contributed significantly in predicting choice of drink
reward. These three variables accounted for over 57% of the
total variance. It is important to point out that whether the
alcoholic received real beer or placebo did not significantly
predict choice of reward. For our control non-alcoholic beer
drinking subjects, only desire to drink significantly
contributed as a predictor of reward choice.
DISCUSSION
The major finding in the present study is that for
alcoholic subjects severity of alcohol dependence, increased
desire to drink, and increased heart rate in response to
alcohol-associated stimuli all significantly contributed to the
probability that a subject would select and consume an optional
drink. This did not occur within the control population for
whom only an increased desire to drink significantly predicted
choice and consumption of the drink reward. Also, an increase
in desire to drink among alcoholic subjects was significantly
related to their belief that they were actually drinking real
beer in both the beer and placebo groups. This is consistent
with the data of Meyer and Mirin that describes craving in the
heroin addict as greatest in situations in which he expects to
consume heroin (Meyer & Mirin, 1979). It is also consistent
with the data of Marlatt and Rohsenow who demonstrated that the
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expectation that alcohol is being consumed is more important
than actual alcohol content in predicting drinking behavior in
the alcoholic (Marlatt & Rohsenow, 1980). We believe that the
placebo response in our alcohol group, which was not apparent
in control subjects, is evidence of conditioned discriminative
effects in the alcoholic. That this also predicted the choice
of reinforcer (the placebo beverage in preference to the
lottery ticket) in the alcoholic subjects is suggestive
evidence of conditioned reinforcement in individuals with a
history of alcohol dependence. Since the correlation between
severity of alcohol dependence and our physiological variable
of SCL only approached significance in one of our alcoholic
groups (AA), we suspect this relationship is more complex. It
is possible that respondent conditioning may be manifested more
clearly with other physiological or neuroendocrine measures
that we did not measure. It is also likely that severity of
alcohol dependence in the last 30 days of drinking does not
account for all aspects of reinforcement history.
Finally, the data confirm the caveat of Hodgson, Rankin,
and Stockwell (1979) that studies of "craving" in the alcoholic
in the laboratory should view it as a multidimentional
phenomenon. Our findings suggest that severity of alcohol
dependence, increased arousal (as manifested by increased heart
rate) and increased desire to drink in response to ethanol
independently increased our ability to predict the choice of a
third drink. We thus believe that physiological and subjective
data add an important dimension which is critical to studying
the three conditioned alcohol stimulus properties consequent to
prior ethanol consumption. Further work is needed to establish
the validity of the alcohol dependence syndrome in the
laboratory in order to establish its usefulness in
differentiating among alcoholics in clinical settings.
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Initial Opiate Use and
Treatment Outcome in Methadone
Detoxification Patients
Mary E. McCaul, Maxine L. Stitzer, George E. Bigelow, and
Ira A. Liebson
Overall rates of illicit opiate use are frequently quite high
among opiate-dependent patients during outpatient methadone de-
toxification treatment (Fulwiler et al. 1979; Hall et al. 1979;
Sorensen et al. 1982; Wilson et al. 1974). We have noticed,
however, that individual street addict patients may differ
markedly in rate of opiate-positive urinalysis results during the
initial weeks of their enrollment in a 90-day outpatient metha-
done detoxification program. Some patients show continuous
opiate positive tests after enrolling in treatment, while others
are virtually opiate free early in treatment. These different
patterns of drug use suggest a higher degree of treatment moti-
vation among patients with very low initial rates of urine
positives.
The present paper compares two groups of detoxification patients
who differed on initial levels of opiate use, as revealed in
urinalysis test results. The first purpose of this comparison
was to identify any additional demographic or behavioral charac-
teristics which might differentiate patients who exhibit very
different levels of involvement with opiate use early in out-
patient detoxification treatment. The second purpose was to
determine whether treatment prognosis was any better for patients
who showed little or no opiate use early in detoxification treat-
ment compared to patients who showed persistent opiate use at the
beginning of treatment.
Methods
This paper reports data for 20 of the 55 male patients who
entered 90-day outpatient detoxification treatment at the Be-
havioral Pharmacology Research Unit of Baltimore City Hospitals
during a 12-month period of time. Eligibility for treatment was
based upon urinalysis evidence of recent opiate use obtained at
the initial contact with the program. All detoxification
enrollees were classified into two groups on the basis of the
number of morphine-positive tests observed in four urine samples
collected during the second and third weeks of enrollment.
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Patients with three or more morphine-positive tests were classi-
fied as high frequency opiate users (32.7 percent of enrollees)
while patients with two or fewer morphine-positive urine samples
were classified as low frequency opiate users (67.3 percent of
enrollees). Patients of each type were randomly assigned either
to a behavioral intervention condition (data to be reported else-
where) or to a control condition. The present paper reports com-
parative data for the first ten consecutive enrollees classified
into the high and low frequency opiate positive groups and
assigned to control detoxification treatment.
Baseline measures. Demographic data were obtained Prom patient
self-report during a clinical. intake interview conducted prior to
treatment enrollment . Demographic variables reported are shown
in Table 1. Four behavioral measures were examined during weeks
2 and 3 of treatment enrollment; when all patients were maintained
on 30 mg/day of methadone: 1) Morphine-positive urine tests.
Urine samples were collected twice weekly on Mondays and Fridays.
Samples were tested for presence of morphine using an onsite EMIT
system (Syva Corp.). 2) Clinic attendance. Missed clinic ap-
pointments (“no shows”) were calculated as the percent of oppor-
tunities to attend based upon the number of patients enrolled in
treatment. 3) Sedative positives. One of the two urine samples
collected each week was randomly selected for testing at an out-
side laboratory by thin layer chromatography analysis. Data re-
ported for sedative drugs include benzodiazepines, unspecified
barbiturates, phenobarbital, methaqualone, amitriptyl ine and
phenothiazines. Each urine sample could contribute only a single
sedative positive result to the weekly percent of positive speci-
mens even if multiple sedative drugs were identified. Missing
urine samples did not contribute to this analysis. 4) Symptom
reports. Subjects completed a 60-item symptomatology checklist
twice weekly (Mondays and Fridays) on which they reported any
symptoms experienced during the previous 24 hours and rated
severity of the symptoms on a scale of 0 - 4. The checklist con-
tained a variety of symptoms specific to opiate withdrawal as well
as a wide range of miscellaneous complaints. A total score was
calculated by adding together the severity score for each item
marked by the patient.
Detoxification procedures. All patients were stabilized for 21
days on a dose of 30 mg/day methadone. Both groups also were de-
toxified according to a blind gradual 6-week dose reduction
schedule followed by maintenance on cherry syrup vehicle. How-
ever, for the high frequency opiate group, stabilization at 30 mg
was -followed by an increase to a 50 mg dose for 14 days then a
return to 30 mg for an additional week prior to dose reduction.
The rationale for this dose increase was to improve the prognosis
for this group by allowing subjects additional time to reduce
their supplemental opiate use prior to initiating the dose re-
duction procedure. As a consequence, the high frequency opiate
group received their dose reductions three weeks later in the
detoxification protocol than did the low frequency opiate group
and received placebo methadone (vehicle only) for a shorter time
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(one week as compared to three weeks).
Detoxification outcome comparison. The outcome measure used for
comwarison between the two groups was percent of opiate (morphine)
positive urinalysis tests observed during the 90 day detoxifica-
tion program. Urine samples were collected and analyzed twice
weekly. Missing samples were counted as morphine-positive as
long as the patient remained in treatment. Once a patient termi-
nated treatment he no longer contributed to urinalysis results.
Because the groups were exposed to different dosage schedules,
data are reported for the two groups at comparable dose levels
rather than at comparable times during the detoxification
protocol. Data for the high frequency opiate group are shown for
the entire 90-day period, while data for the low frequency group
include only the first week of placebo methadone treatment.
Results
Baseline Characteristics
Demographic variables. As shown in Table 1, demographic charac-
teristics of the high and low frequency opiate users were quite
similar in terms of age, racial group and history of opiate use.
The high frequency opiate group had more patients who were cur-
rently involved with the criminal justice system, a somewhat
higher rate of currently unemployed patients and fewer high school
graduates than the low frequency opiate group. However, these
differences were not statistically significant.
Behavioral variables. During baseline stabilization, 92.5 per-
cent of urine samples were morphine-positive for the high fre-
quency opiate group while 7.5 percent of samples were morphine-
positive for the low frequency opiate group. Regularity of
clinic attendance also differed for the two groups of patients
during the baseline stabilization period. During this time, the
low frequency opiate users never missed any scheduled clinic ap-
pointments, while the high frequency users missed about 10 per-
cent of scheduled appointments. The two groups did not differ
either on their use of sedative drugs or on reported levels of
symptomatology during the baseline portion of the study. Both
groups showed about 22 percent of tests positive for sedative
drugs, these being primarily benzodiazepine-positive tests.
Detoxification outcome. As shown in Figure 1, opiate positive
samples for the low frequency group increased steadily during the
detoxification, reaching 60 percent positive samples during the
period when dosage was between 8 mg and 0 mg (study weeks 9 - 11).
One patient remained opiate-free throughout the dose reduction
period; all the rest showed a substantial number of opiate posi-
tive specimens. Despite this gradual increase in urine-positive
results, the low frequency group did maintain superiority over
the high -frequency opiate group throughout the detoxification
program. For the high frequency opiate group, the percent of
urine positive tests was lowest during the time that their dose
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TABLE 1. Characteristics of Detoxification
Patients
Demographic Variables
Average age (yrs) 29.4 30.6
(± SD) (3.5) (5.7)
Race (%)
black
white
50
50
50
5 0
Average years of
continuous opiate use
(range)
8 - 1 10 - 1
(2 - 12) (2 - 18)
Legal status (%)
free
free pending trial
parole/probation
Currently employed (%)
70
-
30
30
50
30
20
60
Education
average years
completed (± SD)
10.8 10.1
(2.4) (2.7)
Percent of patients
completing
no high school
some high school.
high school graduate
or more
40
-
60
30
50
20
Behavioral Variables
Low Frequency
Opiate Group
(N=10)
High Frequency
Opiate Croup
(N=10)
Morphine-positive urines (%) 7.5 92.5
Sedative-positive urines (%) 22.2 21.4
Missed clinic appointments (%) 0.0 10.0
Average symptomatology score 20.5 24.0
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FIG. 1. Percent morphine-positive urine samples during methadone
detoxification for subjects with high (open circles) and low
(closed circles) rates of opiate-positive urine samples during
all initial two week period of dosage stabilization (B). Shown
in parentheses are the number of patients remaining in treatment
at each dosage reduction level.
increased to 50 mg methadone, with 62.5 percent of samples
morphine-positive. By the end of treatment, the opiate positive
rate for this group had returned to initial baseline levels, with
87.5 percent positive samples.
Discussion
Although there was a clear and dramatic difference in rates of
opiate-positive urine results observed between two groups of
patients during the initial baseline stabilization portion of a
90-day outpatient methadone detoxification treatment program, the
data presented in this paper generally support the conclusion
that these two groups of patients did not differ either in their
pretreatment demographic characteristics or in other relevant pre-
treatment behaviors including use of sedative drugs. Some inter-
esting trends were noted in the demographic data including more
criminal involvement among the high frequency opiate users and
more formal education in the low frequency opiate users. The
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fact that employment rate was higher among subjects who used
supplemental opiate drugs runs counter to the popular belief that
excessive drug use is associated with unemployment.
Regularity of clinic attendance did differentiate the two groups.
The groups which used more opiate drugs had more irregular clinic
attendance, although the absolute rate of missed appointments was
relatively low (10 percent). The nature of the relationship be-
tween these two behavioral measures is not clear. Patients may
have been using more opiates to relieve withdrawal symptoms re-
sulting from missed methadone doses. Alternatively, patients may
have missed methadone doses in order to enhance the effects of
supplemental opiates which they planned on taking. Finally, the
two measures may have no causal relationship but both may reflect
a common underlying lack of treatment motivation. Additional
evidence for a relative lack of treatment motivation among
patients in the high frequency opiate group may be reflected in
the fact that three of these patients were terminated from treat-
ment by clinic staff prior to the end of their 90 day enrollment
for failure to complay with various clinic regulations.
The dose increase manipulation appeared to have a beneficial im-
pact on supplemental drug use in the high frequency opiate users.
Opiate-positive samples were reduced by about 30 percent during
the dose increase manipulation compared to rates observed during
the previous two-week baseline dose stabilization period. These
effects were only temporary, of course, since drug use again in-
creased during gradual dose reduction and detoxification.
The fact that some patients stop or drastically curtail their
street use of opiates and adhere strictly to the prescribed
treatment regimen during the early stages of methadone detoxifi-
cation treatment suggests that these patients are initially well
motivated for treatment. These patients continued to maintain
superior rates of opiate-free urines during the detoxification
compared to patients who initially showed a high rate of illicit
opiate use. However, the present comparison study suggests that
the ultimate prognosis in terms of continued illicit opiate use
is equally poor both for patients who do and do not give up their
supplemental opiate use during the initial portions of detoxifi-
cation treatment.
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Motoric and Attentional Behavior
in Infants of Methadone-
Maintained Women
Sydney L. Hans and Joseph Marcus
The effects of in utero exposure to opiates on the neonate have been
well documented in the research literature (Finnegan et al. 1975,
Kron et al. 1975, Lodge et al. 1975, Rosen and Pippenger 1976, Strauss
et al. 1975). Neuro-behavioral. manifestations of neonatal narcotic
abstinence syndrome include hypertonicity, tremulousness, jerky motor
movements, weak sucking, frantic hand-to-mouth movements, and high-
pitched crying. In particular, the neonatal effects of exposure to
drugs seem to be most pronounced and long lasting in the area of
motoric functioning (Marcus et al.. 1982a b).
There are few reports on the behavior of offspring of drug-using
women past the neonatal period. These studies have generally used
standardized tests o-f infant skill acquisition that are summarized
by developmental quotients analogous to adult IQ scores. In vir-
tually all studies, these measures have failed to show differences
between drug-exposed and control infants (Strauss et al. 1976,
Chasnoff et al. 1980, Wilson et al. 1973, Strauss et al. 1979, Ramer
and Lodge 1975, Kaltenback et al. 1979; Johnson and Rosen 1981, Wilson
et al. 1981).
The few findings of post-neonatal differences between opiate-exposed
and other infants have been from those studies employing clinical
measures or scales that rate qualitative aspects of behavior rather
than rate of skill acquisition-scales that measure how a skill is
performed rather than whether it is performed. Lodge (1978) observed
that methadone toddlers were highly energetic, active, reactive to
stimuli, and easily distractible; their overall persistence, atten-
tion span and goal-directedness were brief. Wilson et al. (1981)
described them as less attentive and more active than comparison
infants. Strauss et al. (1979) reported that methadone group 5-
year-olds showed higher gross bodily movement, higher energy level,
poorer fine-motor coordination, and more irrelevant minor movements
than other children. Wilson et al. (1979) reported that at preschool
and school age, a group of narcotic-exposed children showed deficits
in perception, quantitative skills, and memory. Their parents de-
scribed them as impulsive, difficult, aggressive, and lacking self-
control.
The particular symptoms that are emerging from different studies as
characteristics of drug-exposed children are not a random set of
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behaviors. They are typical of the symptoms of Attention Deficit
Disorder (ADD). As described by the most recent Diagnostic and
Statistical Manual of the American Psychiatric Association (APA
1980), the essential features of ADD (also referred to as minimal
brain dysfunction and the hyperkinetic child syndrome) are short
attention span and poor concentration. Associated with the syndrome
in some cases are impulsivity, excessive motor activity, negativism,
impaired academic performance and neurological soft signs such as
clumsiness. Little is known about the early etiology of ADD since
it is generally not observed until a child is placedinthe con-
straints of a classroom setting, although parents have reported that
their ADD children began showing symptoms even during infancy
(Stewart et al. 1966, Werry et al. 1964).
The purpose of the present paper is to report on longitudinal assess-
ments made of 4- and 12-month-old infants of methadone-maintained
women using the Bayley Scales of Infant Development. Analyses will
look for differences in developmental quotients and also differences
in qualitative aspects of behavior as assessed by the Infant Behavior
Record (IBR) part of the Bayley Scales. The IBR will be analyzed
to look for differences in ADD-type behaviors between individual
methadone and comparison children and to examine temporal patterns
in the development of such behaviors.
METHOD
Subjects
Infants were the first cohort (N=45) of subjects in a longitudinal
study on the effects of in utero methadone exposure on child develop-
ment. The sample was composed of a group of black infants whose
mothers were being treated in methadone maintenance programs on the
south side of Chicago and a comparison group whose mothers were of
similar age and socioeconomic background, but had no history of drug-
use or alcohol abuse. In previous papers, we have reported on the
behavior of these infants during the first month of life as assessed
by the Brazelton Neonatal Assessment Scale (Brazelton 1973, Horowitz
et al. 1978). During this period the offspring of the methadone
mothers showed marked abnormalities in motor functioning including
hypertonicity, tremulousness, and poor motor maturity. There was
a subgroup of the methadone infants who also showed poor state
functioning; specifically, poor alertness and high irritability
(Marcus et al. 1982a).
The present paper reports data on the 39 infants in this cohort who
were assessed at both 4- and 12-months of age: 16 from the methadone
group and 23 from the comparison group. Six infants from the original
cohort were not included due to sudden infant death (1 methadone
group female), serious brain damage from a stroke (1 methadone group
male), unavailability for testing at the 4-month age only (1 methadone
group female and 1 comparison group male), unavailability for testing
at the 12-month age only (1 methadone group female), and mother's
withdrawal of consent after the neonatal period (1 comparison group
female).
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Procedures
Mothers and infants were brought for assessment to laboratories at
the University of Chicago. Following a 25-minute videotaping
session, infants were seated in the mothers’ laps and administered
the Bayley Scales of Infant Development (Bayley 1969) by a trained
female examiner. Examiners did not know whether infants were part of
the methadone or comparison group, and they did not have access to
information about infants’ behavior at earlier ages.
DATA ANALYSIS
The Baylcy IBR consists of 35 items rated on 2-, 5-, and 9- Point
scales by the examiner at completion of the examination. Items On
the IBR measure at least three of the symptoms observed in ADD: poor
attention span, high activity level, and poor motor coordination.
Three psychologists were asked to nominate items from the IBR that
they thought were examples of these types of functioning. From this
item pool, items representing the three symptoms were selected accord-
to the following criteria: that all items within a category were
monotonically related to one another both within the methadone and
comparison groups and at both 4- and 12-months. On this basis the
following items were selected to represent each category: ATTENTION--
Responsiveness to Objects (#8), Goal Directedness (#11) , Attention
Span (#12), and Reactivity (#15); ACTIVITY LEVEL--Activity (#14)
and Energy (#25); and MOTOR COORDINATION--Cross Motor Coordination
(#26) and Fine Motor Coordination (#27).
In order to look at the structural relationships of these variables,
Partial Order Scalogram Analysis with Base Coordinates (POSAC) (Shye
1980) was performed in two dimensions using an input profile for
each child of these eight IBR variables as assessed at 4-months of
age. In this analysis, the energy iterns showed no clear regional ity
and the POSAC was recomputed using an input profile of only the four
attention and two motor coordination items. The resulting two
dimensional space is displayed in Figure 1. The POSAC arranges sub-
jects in space along a joint direction with the most poorly function-
ing infants at the lower left and the best functioning infants at the
upper right. The base axes in this POSAC represented the attention
items (on the horizontal axis) and the motor coordination items (on
the vertical axis). In this figure, methadone group infants are
indicated by circles; comparison group infants by squares. The POSAC
space reveals strong discrimination between the methadone and com-
parison groups, with those showing poorest motor coordination being
almost exclusively methadone infants. A dotted line on the figure
highlights this subgroup of poorer functioning infants. It consists
of 7 methadone group infants and only one comparison group infant.
A similar POSAC was computed on the attention and motor coordination
profiles at 12 months of age. Again, in the resulting space, the
two axes represented attention and motor coordination. See Figure
2. The resulting configuration shows sharp discrimination between
methadone and comparison group infants. At this age, however, the
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FIGURE 1. POSAC of 4-Month IBR Items. FIGURE 2, POSAC of 12-Month IBR Items.
= Methadone. = Comparison. = Methadone. = Comparison.
attentional variables were the better discriminators of the two
groups. The infants functioning most poorly on the attentional
variables (at the left of the figure) were predominantly from the
methadone group (9 versus 3) . The best functioning infants (at the
right of the figure) were all from the comparison group (11 versus
0).
Figure 3 plots the joint directionsofthe 4- and 12-month POSAC’s
against each other. The abscissa represents 4-month motor and at-
tentional functioning; the ordinate, 12-month functioning. There
is a moderate degree of continuity in functioning across the two
ages. For the control group the Pearson correlation between the
two ages is +0.38; for the methadone group, near zero. The lack of
an association between the two ages for the methadone group is due
primarily to the performance of two individuals: one who
showed a marked increase in performance across age and one
who showed a marked decrease in performance across age. The figure
indicates the regions of children who showed clinically poor func-
tioning and good functioning at both ages. The ten consistently
poor functioning infants included seven from the methadone group;
the nine consistently well functioning infants included only two from
the methadone group.
FIGURE 3. Scatterplot of 4- by 12-Month IBR Items.
= Methadone . = Comparison.
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In order to be comparable to other at-risk studies in the drug field,
a univariate repeated measures analysis of variance was computed using
drug group as a between subjects factor and 4- and 12-month Mental
Development Index (MDI) scores as repeated measures. There were no
significant differences between groups, ages, or an interaction of
the two. At four months, both groups had mean MDI scores of between
110 and 115; at twelve months, both had scores of 108. A similar
analysis of Psychomotor Development Index (PDI) scores also revealed
no significant differences for group or age by group. There was,
however, a significant age effect with both methadone and comparison
groups showing a decline in PDI from 4- to 12-months, dropping for
both groups from means of approximately 117, to 107. Similar
repeated measures ANOVA’s were computed on the 8 IBR items represent-
ing attention, motor coordination, and activity level. On all items
there was a statistically significant effect for age with 12-month-
olds showing higher mean levels of attention. motor coordination.
and activity. On two of the items there were group by age effects
statistically significant at the .05 level. with 4-month-old
methadone group infants having poor motor coordination and higher
activity level than comparison group infants.
DISCUSSION
Poor attention, sometimes accompanied by poor motor coordination and
hyperactivity, are characteristics of childhood attention deficit
disorders. It is possible that these same behaviors in infancy
represent the early stages of ADD. Our results indicate that a sub-
group of infants exposed in utero to methadone showed deficits in both
attention and motor coordination that often co-occurred. High
activity level was also characteristic of some methadone group
infants but did not co-occur with deficits in attention and motor
coordination. The deficits in these areas show different patterns
of emergence. Attention deficits in the methadone group infants
emerge clearly at 12 months, while differences in motor coordination
are disappearing at 12 months. It is possible that the motoric
symptoms in some methadone-exposed infants at 4 months are merely
indications of delayed or prolonged narcotic. withdrawal, while the
strong attentional deficits in a subgroup of methadone infants at
12 months are indicators of anew, morepermanent neuro-behavioral
syndrome. Further longitudinal follow-up is necessary to determine
the stability of these attentional deficits into the toddler years.
In addition, we are also investigating the effects of type of maternal
drug use, infant perinatal problems, and parental neuropsychological
functioning in determining infant behavior.
Measures of infant behavior do not generally show a high degree of
continuity from one age to another. The relative stability in at-
tentional and motor functioning across age in our comparison group
infants serves to highlight the fluctuations in patterning of be-
havior in some of the methadone infants across this time period. One
explanation for the lack of stability between 4 and 12 months in
this group is the effect of narcotic withdrawal. Many of the
symptoms of narcotic withdrawal in infants are similar to those
behaviors used to assess central nervous system dysfunction. In the
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methadone group infants at 4 months, the residual effects of nar-
cotics in the system or symptoms of withdrawal may in some children
mask their underlying level of CNS functioning.
In this sample, as in other reported research, there were no dif-
ferences between drug-exposed and comparison infants on standardized
tests of infant skill acquisition. There were, however, differences
between the groups on scales that rated qualitative aspects of the
infants’ behavior made during the same time period. Standardized
tests of ability are known to have poor predictive validity, and
because they report global scores, they can offer no suggestions
of the specific underlying physiological or anatomical deficits
that may affect a group of children. Ratings of more qualitative
aspects of behaviors, on the other hand, have already paid off
in the field of behavioral teratology. During the neonatal period,
drug-exposed infants differ in the quality of their motor behaviors
(e.g., smoothness of movement, tenseness of limbs, strength of
reflexes) rather than the presence or absence of behaviors in their
repertoire. Likewise, we have now confirmed that post-natally
such infants continue to differ in qualitative aspects of their
motoric and cognitive functioning. We strongly advocate that future
research with this population continue to explore such qualitative
aspects of behavioral development.
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Predictors of Favorable Outcome
Following Naltrexone Treatment
Robert A. Greenstein, Bradley D. Evans, A. Thomas
McLellan, and Charles P. O’Brien
INTRODUCTION
Naltrexone is an opiate antagonist which has been used in the
treatment of opiate addiction at our clinic during the past
eight years. Naltrexone is an effective opiate blocker and
appears to produce few unwanted side effects (Resnick et al.
1973). In addition several studies have indicated that
patients show significant reductions in both opiate and
non-opiate drug use and appear to improve in social and work
adiustments (O'Brien et al. 1975; O'Brien and Greenstein 1976)
during naltrexone treatment.
However, despite the safety and apparent effectiveness of
naltrexone; the drug has not been well accepted by the patient
population and therefore has not enjoyed wide use. Early
investigators noted from the start that drop-out was high and
that the average length of treatment was less than 30 days.
For example, Hass et al. (op. cit.) and Hurzeler et al. (op.
cit.) observed that more than half of their naltrexone patients
returned to methadone maintenance after less than two months.
Several workers in the field have suggested potential reasons
for the unpopularity of naltrexone and have attempted to
pranote better patient acceptance through lengthening the
detoxification period (Greenstein et al. op. cit.), offering
monetary incentives (Grabowski et al. 1979), providing
extensive patient education (Goldstein op. cit.) and even
combining it with psychotherapy. While all of these
suggestions show promise, prior results suggest that it is
unlikely that any of these interventions alone will increase
the general acceptance of the drug significantly.
In the present paper, we have attempted to apply a different
strategy to the naltrexone effectiveness question. We have
completed a series of predictive analyses utilizing
multivariate statistical procedures to define and describe the
type of patient for what naltrexone has had the most
significant impact. Results of these analyses may make it
possible to direct and promote naltrexone treatment to those
patients who are potentially best suited for it.
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STAGE I - PREDICTION OF ONE-MONTH OUTCOME
Previous work with naltrexone in our population (O'Brien et al.
1975; O'Brien and Greenstein 1976) showed that significant
improvements in opiate and nonopiate drug use, employment, and
several subjective ratings of physical and emotional status
were seen at one month postnaltrexone followup. Thus, as a
first step in identifyingthe patients most likely to benefit
from naltrexone we used a range of patient demographic and
pretreatment status measures as well as during-treatment
performance treasures in a multivariate regression analysis to
predict patient status at one month following treatment.
METHOD
Subjects - Subjects were 89 naltrexone patients who canpleted
induction (greater than six days) during their first treatment
episode; sixty-nine (73 percent) of these subjects were
interviewed one month following naltrexone tennination by an
independent technician. Urine samples for subsequent
urinalysis were collected at the followup interview and
"drug-free" status was strictly defined as subjective denial of
drug use and confirmation by a negative urinalysis.
Procedure - A canplete range of predictor variables were
included in the BMDP step-wise regression analysis and these
were divided into three categories. Demographic items included
age; race; years of education, years of technical training, and
number of prior drug abuse treatments. Pretreatment status
measures included years of opiate and nonopiate drug use, hours
worked, criminal activity and earnings in the month prior to
naltrexone induction, lifetime arrests, months spent in prison,
and self-reported ratings of family problems, health, leisure
activity, anxiety, depression and thought confusion.
During-treatment variables included days of naltrexone
treatment, type of termination and a self-rating of
satisfaction with naltrexone.
Four variahles were used as outcome measures in the regression
analyses and were measured for the month prior to the followup
interview. Days of opiate use; days of nonopiate use,
employment earnings; and self-reported criminal activity were
each used as dependent variables. In each of these analyses,
the predictor variables were sequentially entered into a
regression equation and the procedure indicated the extent to
which each of these variables was related to the outcome
(dependent) measure. Only variables which were significantly
(p < .01) related to outcome were selected by the regression
equation.
RESULTS
The results of all regression analyses were essentially the
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same. Only two predictor variables were significantly related
to any of the outcome measures at the p < .01 level.
Pretreatment employment earnings was significantly and
positively related to better one-month outcome status on two
measures (opiate use, posttreatment earnings), and this measure
accounted for an average of 17 percent of variance across these
two outcome measures. However, days of naltrexone treatment
was significantly and positively related to better one-month
outcome status, on all four outcome measures and explained an
average of 30 percent of the outcome variance across these
measures.
STAGE II - OPTIMUM LENGTH OF TREATMENT
The Stage I analyses indicated that the duration of naltrexone
treatment (in lays) was the best general predictor of one month
posttreatment outcome. Thus, it became important to determine
whether there was a minimum period of naltrexone treatment,
below which posttreatment outcome was clearly poor.
METHOD
Subjects - Subjects were the same 69 naltrexone patients used
in the
Stage I analysis.
Procedure - The patient sample was divided into subgroups based
upon their treatment duration; less than 11 days, 11-20 days,
21-30 days, 31-50 days, 51-70 days, 71-100 days and greater
than 100 days. Then, the relationship between naltrexone
treatment duration and outcome was examined by charting the
mean scores for each of our one-month followup criteria for
each subgroup.
RESULTS
The results for two (Opiate Use, Earnings) of the four Charts
are presented in figures 1-2. The results are quite similar
for all four criteria and two points were evident. First,
patients who remained on naltrexone less than ten days had
clearly worse outcomes. Opiate and nonopiate drug use was
greater, and employment earnings were lower for those patients
who canpleted 10 days or less of naltrexone treatment following
induction.
A second aspect of the relationship between days of naltrexone
treatment and one-month followup status is seen in the
asymptotic nature of the charts at approximately one month
(postinduction) of treatment. From one to approximately 30
days there is a clear and direct relationship between treatment
duration and posttreatment status. That is, patients who
stayed in treatment longer had better one-month posttreatment
criterion scores on all four measures. However, at
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approximately 30 days of naltrexone treatment the relationship
becomes less pronounced and the performance equalizes,
suggesting that post-treatment outcomes are not significantly
better following treatments greater than one month. This
aspect of the relationship was seen on all charts at
approximately the same treatment duration point. It must be
stressed that relatively fewer data points are available at
treatment durations beyond 30 days and that patients who
remained in treatment longer derived more prolonged benefit
while they were on naltrexone, even though their followup
results may be similar to those who stopped treatment at the
end of the first month.
STAGE III - PREDICTION OF LFNGTH IN TPFATMENT
Although the duration of naltrexone treatment was positively
related to one-month outcome as shown in Stages I and II, this
measure was obviously of little value in predicting whether new
patients would do well on naltrexone. However, we reasoned
that if this variable were the best predictor of posttreatment
outcome, then it might be possihle to perform a second analysis
to determine the patient variables which predicted longer
durations of naltrexone treatment.
M E T H O D
Subjects - Subjects were 139 naltrexone patients who had
completed induction on their first naltrexone treatment. This
sample included all subjects from the Stage I study plus the
remaining patients who had completed induction but had not been
scheduled for followup.
Procedure - The same demographic and pretreatment status
variables which were used as predictors in the Stage I analysis
were again used in a multiple regression analysis, with days of
naltrexone treatment as the outcome measure.
RESULTS
The multiple regression analysis indicated that two patient
variables were significantly associated with length of
naltrexone treatment at the p<.01 level. The marital status
variable explained 17 percent of the variation. Patients who
were married had significantly longer treatment durations than
patients who were not married. Employment during the month
preceeding naltrexone treatment was also significantly related
to treatment duration and explained 11 percent of outcome
variance. Together, these two predictor variables explained 26
percent of the variability in the duration of naltrexone
treatment.
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DISCUSSION
In an attempt to determine the type of patient most likely to
benefit from opiate antagonist therapy, we performed a series
of multivariate regression analyses on a sample of male
veterans who completed induction on the opiate antagonist
naltrexone during their drug abuse treatment. A range of
patient background characteristics, demographic factors and
during-treatment variables were used to predict outcome on four
criteria measured at followup, one month after termination of
naltrexone therapy. Only two measures-employment at the start
of naltrexone and length of naltrexone therapy - were
significantly related to better outcome at one-month
follow-up. Of these; treatment duration was clearly the best
outcome predictor. The finding that at least thirty days of
naltrexone therapy was necessary for significant improvement at
one-month followup but that longer periods of treatment were
not necessarily associated with greater gains suggests that
treatment can be limited and still be relatively successful.
Perhaps a minimum period of treatment is necessary to overcome
the conditioning factors that can lead to readdiction. In
fact, much of the rationale for antagonist therapy is based on
the premise that drug-taking behavior can be extinguished by
eliminating the reinforcement produced by opiates. The
necessity for a minimal treatment duration can also be
consistent with a purely biological explanation. For example,
chronic opiate dependence may significantly affect central
nervous system neurophysiology, and some minimal period or
"recovery time" may be necessary to return to the preaddiction
physiological state.
In a second set of analyses in which we attempted to discover
patient characteristics predictive of longer treatment
duration, it was shown that patients who were employed and/or
married at the start of naltrexone therapy were more likely to
stay in treatment longer.
others.
Similar results were obtained by
Lewis et al. (1978) for example; showed that 66
percent of his patients who stayed on naltrexone more than two
months were married as compared with only 13 percent of those
who left treatment prior to the two-month point. Resnick et
al. (op. cit.) also found that employed patients spend more
time on naltrexone, and were more likely to be opiate free at
one year follow-up. Further, studies by Myers et al. (1975)
showed that chronically unemployed patients were most likely to
drop out of inpatient naltrexone therapy prior to the
recommended one to two months of therapy. One obvious direct
explanation for these results would be that these patients have
the best family and social supports to sustain a positive
treatment outcome. In addition; they may also be more
"motivated" since they have the most to lose personally and
financially by readdiction.
Another possible indirect explanation for these results relates
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to our prior work attempting to predict outcome from
therapeutic comunity and methadone maintenance treatments
(McLellan et al. in press). In these studies we found that a
global estimate of the seriousness of a patient's psychiatric
symptomatology-- their "psychiatric severity"-- was the best
"psychiatric severity" was not available in the present patient
general predictor of outcome. A suitable measure of overall
sample, but there is suggestive clinical evidence that this
factor may also be important in predicting treatment outcome
for naltrexone therapy. For example, we have observed that
sane patients who drop out of treatment early do so because of
excessive anxiety and dysphoria during the induction period.
Others have made similar observations. Lewis et al. (1978)
observed that patients who stayed in treatment less than eight
weeks were more depressed and angry at baseline in addition to
being more anxious and tense at three weeks than those who
stayed in treatment longer than eight weeks.
present results in this light,
Considering the
it may be that those patients
who were working and/or married were more psychologically
"stable" than their unemployed, single counter parts, and
better able to tolerate the stresses of drug-free living. It
might be useful for a future study of naltrexone treatment to
determine whether or not psychiatric severity predicts
posttreatment outcome and if so, what effect adequate
psychotropic medication for anxiety and depression would have
on retention and outcome. Historically, our psychiatrically
heterogeneous population was treated "drug free" with
naltrexone only; and a patient simply made it or not pretty
much on his own. Theoretically, the extended use of
appropriate anxiolytic and antidepressant medications during
the induction period and during the critical first month of
treatment should help the most dysphoric patients stay in
treatment longer and therefore have a better chance for a
positive outcome. We are presently reviewing 26 consecutive
naltrexone patients; sane of whom were prescribed additional
psychotropic medications during their naltrexone induction and
maintenance treatment. The results from these and additional
pat-ients treated in this manner will be the subject of a future
report.
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Addressing the Diversion of Take-
Home Methadone: LAAM as the
Sole Treatment Choice for Patients
Seeking Maintenance Therapy
Gordon Hough, Arnold M. Washton, and Richard B. Resnick
I N T R O D U C T I O N
In a series of papers published between 1969 and 1972, Jaffe
et al. (1969, 1970a, 1970b, 1972), showed that supervised admin-
istration of LAAM three times a week in the clinic allows
maintenance of the opioid-dependent patient without take-home
doses. Subsequent studies have established a record of safety
for LAAM maintenance (Ling, et al., 1976, 1978, Blaine, et al.,
1976, 1978, 1981). During the last ten years, moreover,
widespread diversion of take-home methadone doses has become
a public health problem of major concern (Goldstein and Judson,
1974).
An approach to curtailing methadone diversion might include
restricting or eliminating take-home methadone and offering
LAAM as the only alternative for patients who desire reduced
clinic visits, an approach offered first by Goldstein (1976).
In 1981 we reported a clinical trial which tested the feasibility
of conducting a maintenance program where patients chose either
LAAM, requiring three clinic visits per week, or daily methadone
requiring six clinic visits per week. (Resnick, et al., 1981.)
That study indicated that such a choice was acceptable as long
as patients were not eligible under FDA rules for take-home
methadone. It appeared to us that availability of methadone at
all complicated evaluation of LAAM's acceptability. We began
a protocol in which only LAAM was offered to maintenance patients
in hope of providing a clearer trial of LAAM's acceptability as
a maintenance treatment.
PATIENTS AND METHODS
During an 11-month period from the beginning of February through
December, 1981, patients requesting methadone maintenance treat-
ment were told on their first contact before an appointment was
set for an intake interview that we offered maintenance using
LAAM only. Potentially eligible patients included those
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enrolled in methadone maintenance treatment and persons addicted
to illicit opiates.
Patients who elected to enter LAAM maintenance had to meet the
following requirements for acceptance onto the program: FDA
and New York State requirements for methadone maintenance; absence
of serious medical or psychiatric illness; no abuse of non-opiate
drugs or alcohol. In addition, women of child-bearing potential
could not be pregnant. During the first three weeks on LAAM,
patients wuld come to the clinic on alternate (non-LAAM) days
for a supplemental dose of methadone (usually 10-15 mgs).
RESULTS
Seventy-four patients entered LAAM treatment during the 11-month
period. Twenty-six switched to LAAM from methadone maintenance
treatment and 48 entered LAAM from addiction to illicit opiates
(heroin and/or methadone). Forty-eight patients were males and
16 were females. At the end of the 11-month period (as of
January 31, 1982), 72% of the patients who entered LAAM
maintenance were still in treatment and 28% had discontinued
LAAM. Table 1 lists the reported reasons for discontinuing
LAAM for the 21 subjects who terminated LAAM treatment during
the study period. As can be seen, 15 patients terminated for
reasons unrelated to LAAM itself and only 6 terminated because
of reported dissatisfaction with LAAM.
The most common LAAM-related complaint concerned problems
experienced during the 72-hour weekend period beginning with the
Friday dose. Patients complained that the Friday LAAM dose,
which was usually at least 10 mgs higher than the Monday and
Wednesday dose, resulted in their feeling over-medicated on
Friday and feeling under-medicated on Sunday.
It is of interest to note that patients who discontinued LAAM
treatment tended to do so early in treatment. Among those
who discontinued LAAM the average retention in treatment was 7.6
weeks (range 1 to 26 weeks) as compared to an average of 27 weeks
(range 4 to 52 weeks) for patients who continued on LAAM.
Table 2 presents LAAM retention data for the methadone maintenance
patients as compared to the illicit opiate users. Table 3 presents
the data for male vs. female patients. As shown in the tables,
retention in LAAM treatment did not differ significantly between
methadone patients and illicit opiate users, nor did it differ
significantly between males and females. No reaction to LAAM was
peculiar or distinctive to females as opposed to males.
Additional information was obtained on the acceptability of
LAAM when our clinic was closed for two consecutive days on
holidays. Patients could choose to remain on LAAM and change
their medication days, or to switch to methadone, e.g., because
of travel plans. Each alternative produced no complaints, with
one exception: patients not yet stabilized on LAAM experienced
withdrawal symptoms when switched to methadone and again when
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returned to LAAM.
DISCUSSION
This study suggests that LAAM is a clinically viable treatment
drug in a setting where take-home methadone is available in
nearby clinics to patients who meet necessary eligibility
requirements. Six other clinics are within twelve blocks of ours.
Patients continued to enroll in our program and remained in treat-
ment past the time when they wuld have applied to transfer to
another clinic after they became eligible for take-home methadone.
Acceptance and retention in treatment were regarded as satisfactory.
The majority of drug-related drop-outs - four of six - were
patients who felt over-medicated on Friday and under-medicated
the Sunday following. Probably a reduction in LAAM dose and
an increase in supplement would address this problem. However,
it should be noted that one of the four drop-outs for this reason
had had a previous treatment episode on methadone in our clinic.
She was a demanding patient with very low frustration tolerance:
we have some reason to doubt whether she was ready or able to
deal with every other day medication, because, among other things,
she had received considerable attention from the staff on virtually
every clinic visit when maintained on methadone. Our experience
in the past has suggested that patients with poor psychosocial
functioning may have difficulty with LAAM treatment (Resnick, et
al., 1976).
In this study we were motivated by concern about methadone
diversion and wished to explore the feasibility of discontinuing
take-home methadone without penalizing working patients by
requiring daily clinic visits. Methadone diversion is rife in
the East Harlem neighborhood of our clinic. Should the FDA
act favorably on an NDA for LAAM, this drug should offer a
viable, non-punitive alternative to daily clinic visits in
communities where methadone diversion is a hazard to public
health.
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TABLE 1
REASONS FOR DISCONTINUING LAAM MAINTENANCE
(N = 21)
# SUBJECTS
1. RELATED TO LAAM (N=6)
a. Felt overmedicated Friday 4
and undermedicated Sunday
b. Insomnia & bad dreams 2
II. UNRELATED TO LAAM (N = 15)
a. Pregnancy 1
b. Administrative detox due to
non-payment of fees 2
C. Hospitalization unrelated to LAAM 1
d. Voluntary detoxification 7
e. Miscellaneous others 4
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TABLE 2
RETENTION IN LAAM TREATMENT FOR METHADONE MAINTENANCE PATIENTS VS. ILLICIT OPIATE USERS
SUBJECTS STARTING LAAM N
(%)
SUBJECTS STILL ON LAAM N
AS OF 1/31/82
(%)
SUBJECTS WHO DISCONTINUED
LAAM N
(%)
METHADONE
MAINTENANCE
PATIENTS
26
(100%)
17
(65%)
9
(35%)
ILLICIT
OPIATE
USERS
48
(100%)
36
(75%)
12
(25%)
TOTAL
74
(100%)
53
(72%)
21
(28%)
TABLE 3
SUBJECTS STARTING LAAM
ACCEPTABILITY OF LAAM IN MALES VS. FEMALES
STILL ON LAAM
DISCONTINUED ON LAAM
MALES FEMALES TOTAL
N 58 16 74
(%) (100%) (100%) (100%)
N 42 11 53
(%) (72%) (6%) (72%)
N 16 5 21
(%) (2%) (31%) (28%)
Efficacy of Psychotherapeutic
Counselling During 21-Day
Ambulatory Heroin Detoxification
R. A. Rawson, A. J. Mann, F. S. Tennant, Jr.,
and D. Clabough
ABSTRACT
Structured, psychotherapeutic counselling during 21-day heroin
detoxification was evaluated by randomly assigning a group of 25
heroin addicts to a detoxification treatment regimen with manda-
tory counselling by a therapist and 25 to a control group who
received only standard detoxification without counselling. There
was no significant difference between groups in the number who
successfully detoxified as measured by conversion of morphine
positive urine to morphine negative urine. The counselling
intervention group did, however, improve the attendance of sub-
jects while in detoxification treatment, and significantly more
patients entered long-term treatment following detoxification.
Maximal use of a counselor during 21-day heroin detoxification
may best be realized by directing therapy toward engaging
patients in long-term care.
INTRODUCTION
The contribution of psychotherapeutic counselling in combination
with pharmacotherapy for the treatment of heroin addiction has
received little critical evaluation. (Kuncel, 1981; Brown,
Jackson, and Bass, 1973: Ramer, Zaslone, and Langan, 1971)
Experienced clinicians suggest that counselling is a necessary
adjunct to methadone treatment, but little data exists to justify
the expense incurred by the use of counselling during medical
detoxification. In addition, if counselling is useful as an ad-
junct to detoxification, the specific aims and goals of the
counselling intervention need to be clearly defined. The purpose
of this study was to evaluate the efficacy of psychotherapeutic
counselling as an adjunct to the widely used 21-day ambulatory
methadone detoxification program.
METHODS
Fifty (50) heroin-dependent patients seeking admission to a 21-
day methadone detoxification program served as subjects. There
were 33 male and 17 female subjects, who ranged in age from 18 to
54 years (X = 30.0 years). Subjects reported mean heroin
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dependency of 8.8 years and had previously attempted detoxifica-
tion a mean of 4.0 times. No significant difference between
treatment groups was demonstrated on any demographic or drug-use
variable.
Subjects were assigned according to a random numbers table to one
of two treatment groups; a group receiving detoxification with
counselling (C), or no counselling (NC). Detoxification was am-
bulatory and the dosage began at 35 mg on the first day and de-
creased systematically to zero over 21 days. This technique is
standard in the United States. (6) The NC group was allowed to
progress normally through the standard 21-day detoxification
regimen with no attempts made to engage patients in a counselling
relationship. These subjects were provided with referrals for
counselling to local agencies and given information on long-term
treatment modalities by the dispensing nurse only when the
patient inguired about them. Subjects in the C group were re-
guired to participate in a mandatory counselling session on the
second dosing day. Subsequent non-mandatory sessions were
scheduled during the second and third weeks of treatment. Coun-
selling sessions averaged approximately 15 to 20 minutes in
length. Sessions followed a format similar to that proposed by
Wolberg (7) and utilized by Woody (8) in their investigations of
the efficacy of psychotherapy techniques in methadone treatment.
This form of drug counselling entails the assessment of indivi-
dual patient's needs and the provision of services to meet these
needs. Discussion of the problems surrounding relapse and the
availability of long-term treatment to addicts was included.
Treatment options that were available and which the patient was
educated about included methadone, naltrexone, and propoxyphene
napsylate maintenance; drug-free psychotherapy; and residential
therapy. No attempt was made to mediate intrapsychic processes
or engage in any specific form of psychotherapeutic techniques.
All counselling sessions were conducted by one counselor with a
master's degree of psychology who was experienced in drug abuse
treatment.
A urine specimen was collected at admission and during each sub-
sequent week. It was analyzed for morphine in order to determine
if heroin abuse ceased during detoxification. Futher evaluation
was done by determining drop-outs during the 21-day program and
the number who entered long-term treatment following 21-day
detoxification. Long-term effects of counselling were assessed
by contacting all subjects and doing oral interviews with sub-
jects six months after detoxification was completed.
RESULTS
Table I presents a comparison of outcome in the two groups.
Counselling intervention had no impact on the number of subjects
who completed the full 21-day detoxification program, or the num-
ber who converted urine from morphine-positive on admission to
morphine-negative. The C group had significantly fewer drop-outs
and an increased rate of transfer to a long-term treatment
311
modality. In addition, the C group had increased compliance in
attending scheduled medication visits during the detoxification
treatment.
Another indication that counselling intervention increased reten-
tion in treatment is that, of those subjects who attended one or
more of the non-mandatory counselling sessions, 82% (9 of 11)
continued in long-term treatment, while only 43% (6 of 14) of
those who did not attend a non-mandatory counselling session re-
tained in long-term treatment (X2 = 3.8: P< .05). Although it
was impossible to contact 19 of 50 subjects at six months follow-
up, there was the suggestion that counselling intervention may
have resulted in retaining more subjects in long-term treatment.
(Table II)
DISCUSSION
The results of this study suggest that counselling may have a
significant impact on the efficacy of the 21-day methadone de-
toxification program which is widely used in the United States.
(6) Data in this study shows that conselling during ambulatory
21-day methadone detoxification primarily results in a higher
rate of patient transfer to long-term treatment.
Several studies indicate that a heroin addict best benefits from
long-term treatment. (6,9,10) Simpson (9) surveyed major drug
treatment modalities and found that on virtually all psycho-
social, medical and drug use indices, an addict in treatment is
benefited more than an addict out of treatment. Others have de-
monstrated that addicts in treatment are much more productive to
society and require less social cost than those not in the
treatment. (1,10)
Although various investigators have argued for the addition of
counselling to methadone treatment, there has been little data to
support this belief. (3) Data from this study suggests that a
counselor should best direct intervention toward the goal of en-
gaging the patient in long-term treatment rather than short-term
benefits. To implement such a strategy, the counselor must be
skilled in developing rapport, have knowledge of long-term treat-
ment, and have available the necessary treatments to provide
long-term treatment.
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TABLE I
OUTCOME OF TWO DETOXIFICATION TREATMENTS
No
Counselling Counselling
Group Group
N=25 N=25
Completion of a 21-day program.
(16%) (12%)
Subjects with a morphine-
negative urine sample during
treatment.
(2%) (53%)
Wan days in detoxification
treatment. 14.0 12.8
Subjects who dropped out of
treatment
(36%) (68%)
Subjects who transferred to
long-term treatment 12
(48%) (20%)
Scheduled medication visits
attended while on detoxifi-
cation program 377/460 313/482
(82%) (65%)
TABLE II
SIX-MONTH FOLLOW-UP STATUS
No
Statistical
Significance
NS
NS
NS
P <.025
P <.05
P <.01
Counselling Counselling Statistical
Group Group Sigfnificance
N=25 N=25
In continued treatment for
six months. 8
(32%)
7
(28%)
Re-addicted to illicit drugs
or incarcerated. 12
(48%)
Unable to contact at six
months.
4
(l6%)
NS
NS
10 9
(40%) (36%) NS
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Outpatient Treatment of
Prescription Opioid Dependence:
Comparison of Two Methods
F. S. Tennant, Jr., R. A. Rawson, L. Miranda, and J. Obert
ABSTRACT
Outpatient treatment of 42 patients who presented with dependence
upon prescription opioids was attempted by two different methods.
The first group of 21 patients was treated by 21-day detoxifica-
tion followed by psychotherapeutic counseling (D/C), and the next
21 patients were offered 21-day detoxification to be followed
by opioid maintenance if detoxification was unsuccessful (D/M).
Only 5 of 21 (23.8%) patients in the D/C group compared to 20 of
21 (95.2%) in the D/M group completed three weeks of treatment
(P <.001). On admission, no patient perceived that chronic
pain due to a medical condition would be an impediment to with-
drawal from opioids, but pain which was masked by opioid depen-
dency and which emerged during detoxification proved to be an
insurmountable barrier to total withdrawal in the majority of
patients. Treatment of outpatients who presented with dependence
upon prescription opioids was best provided in the study by
opioid maintenance and adjunctive pain therapy.
INTRODUCTION
Although there is voluminous data on the treatment of heroin
dependence, treatment of outpatients who present with dependence
on prescription opioids has not been systematically studied.
(1,2) Reported here is a series of 42 consecutive patients who
voluntarily sought outpatient withdrawal from prescription opioid
dependence. Patients were treated by one of two methods. The
first 21 patients were treated by a three-week detoxification
schedule with post-withdrawal psychotherapy, and the second 21
patients were offered three-week detoxification to be followed
by opioid maintenance if withdrawal was not successful. The
primary opioid of dependence, precipitating cause of opioid use,
medical regimens used in the treatment, and outcome of treatment
are described.
METHODS
Forty-two (42) patients volunteered for outpatient treatment bet-
ween January, 1979 and September, 1981. All patients obtained
opioids fran one or more physicians. On admission, patients
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completed a written medical and drug history, received a complete
physical examination and submitted a urine for drug analysis.
The daily dosage of opioid and reason the patient began taking
the drug was determined. The first 21 patients in the study
entered a three-week detoxification program which administered
standard doses of methadone, propoxyphene napsylate, clonidine,
or symtematic relief with diphenoxylate and sedative-hypnotics.
(3-6) Patients attended the clinic each day. Detoxification was
to be followed by weekly psychotherapeutic counseling with a
psychologist (D/C). The next 21 patients admitted to the study
entered one of the above detoxification regimens, and they were
informed on day one of treatment that they could be maintained
with an opioid if detoxification was unsuccessful (D/M) as judged
by the patient's inability to refrain from opioid use.
Maintenance regimens offered were methadone or propoxyphene nap-
sylate unless the patient was found to have significant cause of
chronic pain which would qualify the patient to receive other
opioids and be registered as a medical addict with the California
Attorney General. (6-8)
Patients who chose maintenance attended the clinic for psycho-
therapy and medical treatments two tines per week for the first
month; weekly the second month, and bi-monthly thereafter. The
initial maintenance dose was gradually reduced over tine as any
associated painful condition was successfully treated. The
treatment team consisted of a physician, nurse practitioner, and
two psychologists. Psychotherapeutic counseling sessions lasted
approximately 30 minutes and often included family members. Pain
treatments included anti-depressants, physical therapy, non-
opioid analgesics, localized steroid injections, and electrical
stimulation. (9) Naltrexone was available for patients who
could gradually withdraw and achieve a drug-free state. (10)
RESULTS
Table One shows demographic and drug-use data for both study
groups. The statistically significant difference between groups
was in mean age. The majority of patients began their prescrip-
tion opioid dependence due to a painful medical problem (Table
Two). Accident or injury, headaches, post-surgical pain, or back
or spine disorder were the major initiating causes of opioid use.
Nine (9;21.4%) patients could not give a reason for beginning
opioid use. Although a total of 13 of 21 (61.9%) in the D/C
group, and 15 of 21 (71.4%) in the D/M group claimed to have
chronic, persistent pain at the tin-e of admission, no patient in
either group initially perceived that their pain was severe
enough to interfere with total withdrawal from opioids. This
belief proved false since significant pain emerged during the
detoxification phase in the majority of patients. The most com-
mon opioids of dependence were codeine, propoxyphene, and oxyco-
done (Table Three). Codeine accounted for 24 of 42 (57.1%) sub-
jects. Mean daily dosage ranges were compatible with a signifi-
cant degree of physical dependence. (8) Table Four shows the
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detoxification agent attempted in both groups. Twenty of 21
(95.2%) subjects in the D/M group requested maintenance at some
point during detoxification. Following are the opioids used for
maintenance, the number of patients administered each drug, and
the approximate average daily dosage used for maintenance: pro-
poxyphene napsylate (9; 1200 mg); codeine (5; 700 mg); hydro-
morphone (3; 40 mg); oxycodone (2; 55 mg); and levorphanol (1;
20 mg). All the patients maintained with opioids other than
propoxyphene napsylate were found to have such pain secondary to
medical problems that they qualified to be a legally registered
medical addict. (8)
Only 5 of 21 (23.8%) patients in the D/C group compared to 20 of
21 (95.2%) patients in the D/M group retained in treatment pest
three weeks (P <.001) (Table Five). After 90 days past admis-
sion, two patients in each group were opioid abstinent at this
time point as judged by history, a urine test negative for mor-
phine and other opiates, and no further requests for opioid pres-
criptians. Two additional D/M patients achieved abstinence with-
in 180 days by gradually reducing the daily maintenance dose.
One of those patients entered naltrexone maintenance in order to
remain abstinent. Sixteen (16; D/M) patients remained in main-
tenance treatment for periods ranging from 3 to 18 months (mean,
12 months). After 15 months, one codeine-dependent patient was
able to totally cease codeine use and maintain on the non-ste-
roidal, non-opioid, benoxaprofen.
DISCUSSION
Patients in this study exhibited several common characteristics.
The majority began opioid dependence following the occurrence of
accident or injury, surgery, headaches, back, or spine disorder,
or arthritis. None appeared to develop dependence accidentally,
but developed dependence by taking opioids over a considerable
period of time, (11) Most common opioids of dependence were
codeine, propoxyphene, and oxycodone. In contrast to patients
who obtain opioids, such as heroin, on the illegal market, these
patients were predominantly white, older, middle-class, and 50%
were female. (1) The difference in outcome between D/C and D/M
groups appears significant. Since 16 of 21 (76.2%) patients in
the D/C group, compared to 1 of 21 (4.8%) in the D/M group, drop-
ped out of treatment during the first three weeks, it appears
that retention is best achieved by assuring the patient that opi-
oid maintenance will be provided for at least a temporary period.
This finding supports those of Senay and Showalter who have re-
cently shown that 84-day detoxification from methadone produces
far better results than 21-day detoxification.
It is possible that outcome with these patients could have been
improved if the patients had been hospitalized, although publish-
ed studies comparing inpatient and outpatient outcomes of drug-
dependent persons do not show any advantage of one treatment over
the other. (13,14) Recently, inpatient opioid detoxification
with clonidine and inpatient pain treatment have been highly
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touted, so it is possible that inpatient treatment could have
produced batter long-term outcomes than observed in this study,
(15-16) Clonidine was used to detoxify 7 patients in this study,
but it did not produce results superior to other detoxification
agents. At this time, there is no evidence to indicate that
persons dependent on prescription opiods could be batter
treated on an inpatient basis, and until such evidence is
available, the extra cost of inpatient treatment should be a
factor in selection of treatment site.
Outcome in the D/C group was similar to that found with out-
patient heroin detoxification. (17) The inability to withdraw
patients in this study provides additional data to considerable
animal and human evidence that opioid dependence may be a chronic
intractable problem that may last years, and possibly a lifetime.
(18-19) Opiates should, therefore, only be prescribed as a last
resort in patients with chronic pain. (21) The role of chronic
pain secondary to a medical condition in these patients proved
to be very important. Even though 28 of 42 (66.5%) stated at
admission they had chronic, persistent pain, none initially be-
lieved it to be an impediment to complete withdrawal from opi-
oids. As withdrawal began, however, the majority of patients be-
gan to experience unmasking of significant pain which probably
caused many patients in the D/C group to drop out of treatment,
and the majority in the D/M group to request opioid maintenance.
It was necessary to provide adjunctive pain treatment as well as
opioid maintenance to retain patients in treatment.
Retention of the D/M group in long-term treatment appeared to be
related to informing the patient that opioid maintenance would be
available if 21-day detoxification was unsuccessful. Even though
this assurance may make some patients less motivated to totally
withdraw from opioids, the extremely high drop-out rate in the
D/C group does not support a simple withdrawal and counseling
technique. Long-term treatment has been shown to be more effect-
ive than short-term treatment for several types of drug problems.
(12,22) Outpatient opioid maintenance with adjunctive pain
treatment produced more opioid-abstinent patients, although not
a statistically significant number, at the end of 180 days.
TABLE ONE
CHARACTERISTICS OF 42 PATIENTS DEPENDENT
ON PRESCRIPTION OPIOIDS
Detox/ Detox/
Counseling Maintenance
N=21 N=21
Age Range 21 - 67
Mean Age+
(years) 26 - 73
33.4 44.1
Male (no. of patients) 11 (52.4%) 10 (47.6%)
Female (no. of patients) 10 (47.6%) 11 (52.4%)
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Employed (no. of patients)
Length of Narcotic Use
(range in years)
Mean Length Opioid Use
White
Hispanic
Black
9 (42.9%)
3 - 16
7.2 yrs.
17 (80.9%)
2 (9.5%)
2 (9.5%)
8 (38.1%)
2 - 34
9.2 yrs.
18 (85.7%)
2 (9.5%)
1 (4.8%)
+ Is statistically significant at the P < .05 level
TABLE TWO
REASONS FOR INITIATION
OF PRESCRIPTION OPIOID USE
Detox/ Detox/
Counseling Maintenance
N=21 N=21
Accident or Injury
Headaches
Post-Surgery
Back/Spine Disorder
Arthritis
unknown
Trigeminal Neuralgia
2 (9.5%)
3 (14.3%)
4 (19.0%)
5 (23.8%)
2 (9.5%)
5 (23.8%)
0
1 (4.8%)
5 (23.8%)
5 (23.8%)
4 (19.0%)
0
4 (19.0%)
2 (9.5%)
TABLE THREE
PRIMARY OPIOIDS OF DEPENDENCE
No. in No. in
Range of Approx. Mean Detox/ Detox/
Daily Dose Daily Dose Counseling Maintenance
(MG) (MG) N=21 N=21
Codeine 240 - 2400 800 14 (66.7%) 10 (47.6%)
Propoxyphene 975 - 1950 1400 2 (9.5%) 5 (23.8%)
O x y c o d o 30 - 60 40 3 (14.3%) 2 (9.5%)
Hydromorphone 48 - 72 65 1 (4.8%) 1 (4.8%)
Pentazocine 500 - 800 600 1 (4.8%) 1 (4.8%)
Morphine 75 - 105 90 0 1 (4.8%)
Meperidine 100 - 300 190 0 1 (4.8%)
TABLE FOUR
DETOXIFICATION AGENT USED TO DETOXIFY
42 PRESCRIPTION OPIOID ADDICTS
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Propoxyphene Napsylate
Detox/
Counseling
N=21
11 (52.4%)
Detox/
Maintenance
N=21
11 (52.4%)
Methadone 4 (19.0%) 5 (23.8%)
Clonidine 4 (19.0%) 3 (14.3%)
Symptomatic 2 (9.5%) 2 (9.5%)
TABLE FIVE
OUTCOME OF TREATMENT
Detox/
Counseling
N=21
Detox/
Maintenance
N=21
Did not return for a
second clinic visit+
Dropped out in first
3 weeks of treatment+
In treatment 90 days
after admission
Abstinent on the 90th day
following admission
Completed detoxification, but
relapsed within 90 days
Abstinent on the 180th day
following admission
5 (23.8%)
11 (52.4%)
NA
2 (9.5%)
3 (14.3%)
2 (9.5%)
0
1 (4.8%)
18 (85.7%)
2 (9.5%)
NA
4 (19.0%)
+ Is statistically significant at the P < .05 level
* One patient achieved opioid abstinence by use of naltrexone
maintenance
REFERENCES
1. Simpson, D.D., Savage, J.L., Lloyd, M.R.: Follow-Up Evalua-
tion of Drug Abuse During 1969 to 1972. Arch Gen Psych-
iatry 1979: 36: 772-780.
2. Tennant, F.S., Jr. Outpatient Treatment and Outcome of Pre-
scription Drug Abuse. Arch Intern Med 1979: 239: 154-
156.
3. Tennant, F.S., Jr., Russell, B.A., Casas, S.K., et. al.:
Heroin Detoxification: A Comparison of Propoxyphene and
Methadone. JAMA 1975, 232: 1019-1022.
4. Kleber, H.D., Gold, M.S., Riordan, C.W.: The Use of Cloni-
dine in Detoxification From Opiates. Bull on Narcotics
1980; 22: 1-10.
320
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
Goodman, A.: Use of Diphenoxylate Hydrochloride in the With-
drawal of Narcotic Addiction: A Preliminary Report.
South Med J 1968: 61: 313-316.
Goldsteien, A.: Heroin Addiction and the Role of Methadone
in Its Treatment. Arch Gen Psychiat 1972: 26: 291-297.
Tennant, F.S., Jr., Rawson, R.A.: Propoxyphene Napsylate
Maintenance Treatment for Narcotic Dependence: A Non-
Methadone Model. Drug and Alcohol Depend 1981; 8: 79-83.
Tennant, F.S., Jr.: The California Registration System for
Habitues to Schedule II Drugs, in Harris LS (ed): Pro-
blems of Drug Dependence, 1980. Rockville, Maryland,
National Institute of Drug Abuse, 1981, pp. 193-198.
Reuber, J.B., Girard, D.E., Nardona, D.A.: The Chronic Pain
Syndrome: Misconceptions and Mismanagement. Ann Intern
Med 1980; 93: 588-596.
Resnick, R.B., Volavka, F., Freedman, A.M., et. al.: Studies
of EN-1639A (Naltrexone): A New Narcotic Antagonist. Am
J Psychiatry 1974; 131: 646-650.
Porter, J., Jick, H.: Addiction Rare in Patients Treated
With Narcotics, N Engl J Med 1980; 302-123.
Senay, E.D., Showalter, D.V.: Short-Term Detoxification With
Methadone. Am NY Acad Sci 1981: 362: 203-216.
Wilson, B.K., Elms, R.R., Thompson, C.P.: Outpatient Versus
Hospital Methadone Detoxification: An Experimental Com-
parison. Int J Addiction 1975: 10: 13-21.
Cole, S.G., Lehmon, W.E., Cole, E.A., et. al.: Inpatient
Versus Outpatient Treatment of Alcohol and Drug Abuse.
Am J Drug Alcohol Abuse 1981; 8: 329-345.
Gold, M.S., Pottash, A.C., Sweeney, D.R., et. al.: Opiate
Withdrawal Using Clonidine: A Safe, Effective, and Rapid
Nonopiate Treatment. JAMA 1980: 243: 343-346.
Tyre, T.E., Anderson, D.L.: Inpatient Management of the
Chronic Pain Patient: A One-Year Follow-Up Study. J of
Family Pract 1981; 12: 819-827.
Maddux, J.F., Desmond, D.P., Esguiver, M.: Outpatient Metha-
done Withdrawal for Heroin Dependence. Am J Drug Alcohol
Abuse 1980: 7: 323-333.
Dole, V.P.: Narcotic Addiction. Physical Dependence and Re-
lapse. N Engl J Med 1972: 286: 988-992.
Maddux, J.F., Desmond, D.P.: New Light on the Maturing Out
Hypothesis in Gpioid Dependence. Bull on Narcotics
1980; 22: 15-25.
Vaillant, F.E.: A 20-year Follow-Up of New York Narcotic
Addicts. Arch Gen Psychiatry 1973: 29: 237-241.
Lewis, J.R.: Misprescribing Analgesics. JAMA 1974: 228:
1155-1156.
22. McLellan, A.T., Luborsky, L., O'Brien, C.P., et. al.: Is
Treatment for Substance Abuse Effective. JAMA 1982:
247: 1423-1428.
AUTHORS: F.S. Tennant, Jr., R.A. Rawson, L. Miranda, J. Obert
Community Health Projects, Inc. Administrative Offices
336 ½ South Glendora Avenue
West Covina, CA 91790
321
Prevalence and Implications of
Multi-Drug Abuse in a Population
of Methadone-Maintained Women
Elizabeth D. Leifer, Joan Goldman, and Loretta P. Finnegan
The Family Center Program in Philadelphia is a multi-focal program
encompassing medical and psychosocial services for drug-dependent
pregnant women. On admission to our out-patient program, patients
are stabilized on a methadone dose adequate to prevent withdrawal
symptoms, with the average patient receiving a daily dose of 40 mg.
It is not uncommon for our patients to need an increase in their
methadone dose as their requirements for stabilization of withdrawal
symptoms increase with the normal course of pregnancy. However, al-
though requests for increases in methadone are rarely refused by our
clinic physicians, we still see 74 percent of our patients using
heroin. In addition, non-opiate drug abuse is a problem in our pop-
ulation. Knowledge of multi-drug abuse, as ascertained by urine
toxicology reports, has a number of uses in addition to the legal
requirements. Weekly urine toxicology reports are used by the
Family Center staff as a clinical tool to measure treatment efficacy,
to evaluate whether the patient is on an adequate dose of methadone,
and as a possible indication that the patient may be self-medicating
symptoms of anxiety or depression. Knowledge of the specific agents
of abuse are also pertinent to the appropriate treatment of the in-
fants prenatally exposed to drugs.
Many programs (Kornblith, 1981; Budd, 1979; Budd, 1980; Kokoski,
et al. 1973; Senay, et al., 1977, Langrod, 1970; Kokoski, et al.;
1974) have reported on the frequency with which multi-drug abuse
occurs among methadone maintained patients. However, the methodology
does not always present an accurate representation of the extent of
this problem. The extent of multi-drug use has often been calculated
by the percent of urine samples positive for the specified agent
(Kornblith, 1981; Budd, 1979; Budd, 1980; Kokoski, et al., 1973;
Senay, et al., 1977). This methodology does not accurately reflect
the prevalence of illicit drug use in the population under study.
The urine samples are not independent measures since more than one
sample per patient is obtained. Repeated measures are involved and
mathematical analysis must be appropriate for this situation. Re-
porting on the proportion of patients ever using specified drugs -
for program evaluation purposes - or the percent of urines per
patient positive for specified drugs - for patient care - will re-
sult in a far more realistic measure of multi-drug use.
Methods
In order to determine the extent of multi-drug use among our patients,
we studied a population of 100 women who had been admitted to the
Family Center Program between 1978 and 1981, were maintained on
methadone, and remained on the program long enough for us to have
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obtained a minimum of 20 urine samples per woman (about four
months). This population cannot be considered as a representa-
tive sample of methadone patients on all other programs because
they are: female, pregnant, and stayed on the program for at least
four months. The period of time during which the urine samples were
collected included both the pregnant and postpartum states for each
woman. The average number of urine samples collected per patient
was about 40, for a total of 3,980 toxicology reports. Urine samples
are collected by the medicating pharmacist at the initial clinic
visit and/or hospitalization, once a week on a random schedule
during the time the patient is on methadone maintenance, and at ad-
mission for delivery. In addition, any time a patient misses one
or more consecutive doses of methadone, she is required to provide
a urine sample before being medicated again. The urine samples are
sent daily to our hospital laboratory where they are analyzed using
the thin-layer chromatography technique which screens qualitatively
for:
Laboratory Analysis, Thin-Layer chromatography (TLC)
Methadone Amphetamine Dilantin
Phenobarbital Mlethamphetamine Demerol
Secobarbital Morphine Codeine
Other Barbiturates Quinine Phenypropanolamine
Doriden Dilaudid Pentazocine
Cocaine Propoxyphene Phencyclidine
In addition, the enzyme monitored immunoassay test is utilized to
detect the presence of benzodiazepines, which, along with their
metabolites. are all reported as “diazepam” for which we also get a
quantitative report. The range of values reported is 1) more than
zero to 0.5 micrograms/ml, 2) more than 0.5 to 5 micrograms/ml, and
3) more than 5 micrograms/ml.
The variables studied include specific drugs of abuse, frequency of
abuse and association of levels of abuse with methadone dose. The
data was analyzed utilizing Pearsons Correlations, Analysis of
Variance, Chi-square and Student-T tests of significance.
Results
In total, 98% of the study population were multi-drug users. There
were three drugs of abuse which occurred with sufficient frequency
to cause concern: heroin, diazepam and amphetamines. Correlational
analysis did result in a highly significant (p<.001) degree of
association between drugs within classes. Patients using one type
of depressant were highly likely to be using another and not to be
taking stimulants. Patients, when abusing drugs other than narco-
tics, tended to stay within specific drug classes. In Table I the
frequency of use of heroin, diazepam and amphetamines is presented
first as results of the urine toxicology reports from the population
of 100 women calculated as percent of the total, i.e., percent of the
3,980 urines that were positive for the drug specified; secondly as
results of calculating percent of the population of 100 Family Center
patients who had one or more urines positive for the specified agent;
and lastly as percent of population who had urines positive for the
individual drugs 10% or more of the time, so as to eliminate those
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who were occasional users. It is evident that use of drugs, when
reported according to percent of patients ever using, shows a far
graver picture. Although 28 percent of the urines were positive
for heroin, 74 percent of the patients had a urine sample positive
for heroin at least once and 58 percent had a positive report 10%
or more of the time. Similar patterns are also found for diazepam
and amphetamines.
Table I
Pharmacologic Agents Detected in
How Calculated: Addition to Methadone
Heroin Diazepam Amphetamines
Percent of urines positive
for specified agent. 2 8 % 4 5 % 1 0 %
Percent of women who had urines
positive at least once. 7 4 % 9 0 % 6 7 %
Percent of women who had urines
positive 10% of the time. 58% 8 1 % 3 1 %
Analysis of the results with regard to level of use of heroin, dia-
zepam and amphetamines is presented in Table II. The patterns of
level of use differ between the drug categories. Those using dia-
zepam tended to use it frequently, with 68 percent of the women
having 20 percent or more of their urines positive for the drug.
Those using amphetamines are more often occasional users, with only
18 percent of the patients having 20 percent or more of their urines
positive for this drug. Patients using heroin are more evenly dis-
tributed across the level of use categories.
Table II
Percent of Urines Positive for Percent of women according to
specified drug (usage level) usage levels
Heroin Diazepam Amphetamines
None 2 6 % 10% 3 3 %
1 to 9% 17% 9 % 1 6 %
10 to 19% 1 4 % 1 3 % 1 3 %
20 to 49% 16% 2 9 % 15%
50-79% 2 0 % 2 1 % 2 %
80%+ 7 % 1 8 % 1 %
Because methadone is a treatment for opiate-dependent persons, it
would seem likely that there should be a relationship between
methadone dose and heroin use. In Table III the percent of urines
positive for heroin is presented according to category of daily
methadone dose, i.e., those 19 patients who were receiving 30 to 35
mg/day of methadone had, on the average, 31.2% of their urines posi-
tive for heroin. As can be seen from the data, there is no direct
linear relationship of methadone dose with respect to heroin use.
Indeed the correlation coefficient was -.017. However, there does
seem to be a blocking dose pattern established at the upper end of
the dosage scale. Those women receiving 70+ mg/day are more likely
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not to be using heroin. In spite of the small number involved, it
is highly unlikely that this happened by chance (p < .001).
Methadone Dose (mg)
Table III
Average percent of urines
Number of per patient positive for
Patients heroin
10-15 9 27.0
20-25 22 31.3
30-35 19 31.2
40-45 18 24.1
50-55 17 34.7
60-65 7 25.4
70+ 8 1.8
A totally unexpected finding, presented in Table IV, is the high
degree of linear association between the use of diazepam and the
daily dose of methadone. Patients receiving 10 to 15 mg/day of
methadone had, on the average, 33.9 percent of their urines positive
for diazepam. Whereas for those women at the top of the methadone
dosage scale, an average of 67 percent of their urines were positive
for diazepam. The Pearson Correlation between the two drugs is
r = .84 (p < .01).
Table IV
Average percent of urines
Number of per patient positive for
Methadone Dose (mg) Patients diazepam
10-15 9 33.9
20-25 22 36.7
30-35 1 9 20.6
40-45 18 44.7
50-55 17 52.6
60-65 7 54.1
70+ 8 67.3
Discussion
The high level of multi-drug use detected in our population of
methadone-maintained women is consistent with that of Chambers
(1972) who found, in a one-month study in 1970, that 97% of
methadone-maintained patients at Philadelphia General Hospital were
using other drugs. This has serious implications of both a phycho-
social and biochemical nature. In following the Dole-Nyswander
(1965) approach to methadone therapy, once an adequately high metha-
done dose is given to achieve stabilization, “narcotic hunger” is
blocked. Our data, initially, appears to support this blocking dose
theory; however, patients on the higher doses of methadone, while not
using heroin, are abusing drugs in other categories. It has been
suggested (McClellan et. al, 1979) that many patients attempt to
induce a particular effect from their multi-drug use. Brill and
Chambers (1973) report evidence of an increased level of anxiety in
methadone-maintained versus control populations. Perhaps we are
seeing diazepam self-medication to alleviate this problem. This
would be consistent with our finding of a positive relationship
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between methadone dose and diazepam use. There has also been evi-
dence (McLellan et al., 1979) that methadone patients are more de-
pressed than controls. Therefore, we could be seeing amphetamines
used as antidepressants. A second factor to consider is the grow-
ing number of studies regarding drug interactions between these non-
opiate drugs of abuse and methadone. There are two types of inter-
actions to consider. In the first we see an increased level of
methadone, or its active metabolites, available at the opiate recep-
tor . In the second, there is a change in the functional response
to methadone at its receptor site (Kreek, 1978).
Studies indicate that an interaction of the first type may be occur-
ing with methadone and diazepam wherein we see an increased amount
of drug available at the receptor site due to interference in metha-
done metabolism. Shah and associates (1979) have studied the effect
of diazepam on methadone metabolism in mice. They found that dia-
zepam produced significant increases in methadone concentrations in
the brain at one hour and in the liver at one and three hours. The
enhanced hepatic levels of methadone may indicate an interference
in methadone metabolism by diazepam. A number of other studies
(Spaulding et al., 1974; Downs, 1979) have corroborated these find-
ings . Although no studies have been done in humans to look at this
methadone-diazepam interaction, it is supportive of subjective re-
ports by abusers of the combination. In a self-report study by
Bigelow and Liebson (1981) of methadone-maintained women who report
diazepam abuse, patients said they generally took their daily dose,
all at once, usually within an hour of the time they ingested their
methadone. Another report, by Dewey (1972), states that the primary
response of patients using diazepam and methadone simultaneously is
an increase in the subjective response to the effects of methadone,
or a sense of euphoria that was not experienced on methadone alone.
These subjective reports are supportive of a biochemical interaction
occurring between diazepam and methadone.
The other class of drugs we see frequently abused by our patients
is stimulants, most often represented by amphetamines. A drug in-
teraction between opiates and amphetamines was first reported as
early as 1944 by Ivy et al. They studied the effect of morphine/
dextro-amphetamine combination on pain threshold and sedation in
medical students. They found that dextroamphetamines enhanced the
analgesic effect of morphine and counteracted, in part, some of its
undesirable side effects (nausea and sedation). It was more than
20 years before Evans (1967) followed by Forrest (1977) did suppor-
tive work. In 1978, Sprague and Takemari compared analgesic effect
of methadone alone and in combination with methamphetamine on mice.
They found an enhanced effect when the combination was used. They
attempted to further characterize the interaction by measuring brain
levels to levels of analgesia. They found that methadone brain
levels were not enhanced with methamphetamine pretreatment. There-
fore, they suggested that methamphetamine induced changes in neuro-
chemical function which resulted in the enhanced analgesic effect.
Richards (1975) studied another aspect of the opiate-amphetamine
interaction. His results supported those of other investigators
with respect to an increase in methadone’s analgesic effect when
given in combination with d-amphetamine and are most probably of the
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second type: a function of neurochemical events at the receptor
level. The conclusions were that amphetamines enhance methadone’s
analgesic effect and decrease its undesirable side effects.
Summary
Within our study population of 100 women for whom 3,980 urine toxi-
cology reports were accomplished, 98 percent were multi-drug users.
This proportion is far greater than would have been calculated from
the percent of urines that were positive for the drugs of abuse and
is a more realistic estimate of the extent of the problem than is
often reported. Despite this high percentage of multi-drug use, due
to the uniqueness of our patient population (pregnant women), it is
not possible to deny them pharmacologic therapy for their addiction.
Therefore, the use of urine toxicology reports in our clinical set-
ting has broader implications than adherence to the methadone
regulations. These reports serve as excellent devices to assess
newborn abstinence symptomatology , in addition to helping us monitor
the physical and psychological status of our patients. The implica-
tions are that self-medication may be used to achieve a particular
effect concomitant with methadone therapy. The effects are generally
to enhance the action of methadone and to decrease undesirable side
effects.
Conclusions
Clinicians in the field of drug addiction rehabilitation should take
advantage of the requirement of urine toxicology reports for metha-
done-maintained patients. Particular attention should be paid to
those patients who are female, especially during pregnancy or the
postpartum period, when psychological issues may be so overwhelming
that self-medication appears to be used as adjunct therapy. To
assist the clinician in treating such patients, more investigation
is necessary to elucidate the psychosocial and biochemical interac-
tions involved with the use of opiate and non-opiate drug abuse
concomitant with methadone maintenance.
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How Specific Are the Early
Predictors of Teenage Drug Use?
Sheppard G. Kellam, David L. Stevenson, and
Barnett R. Rubin
Early predictors of teenage substance use have now been described
in a number of studies. Several of these early predictors have
been found across studies that have used different methods,
different populations, and different theoretical frameworks.* In
the Woodlawn Project we have found several early predictors of
substance use. Teacher ratings of early aggressiveness in first
grade males (i.e. fighting, breaking rules) was found to be an
important predictor of drug, alcohol, and (cigarette use, in
contrast to shyness (i.e. sitting alone, not speaking up), which
was associated in males with later inhibition of substance use.
However, shyness in combination with aggressiveness markedly
increased the risk of substance use ten years later (Kellam,
Brown, Rubin, and Ensminger, In Press 1983; Kellam, Simon &
Ensminger, In Press 1983; Kellam, et al. 1980; Ensminger, et al.
1982).
Test performance on readiness-for-school and IQ tests in first
grade were also predictive of later drug and alcohol use. Higher
scoring first grade children used marijuana and alcohol earlier
and had a higher lifetime frequency by age 16 or 17 in the case
of both males and females (Fleming et al. 1982; Kellam et al.
In Press, 1983: 1980).
This paper addresses the question of how specific these early
predictors are to teenage substance use. Other teenage outcomes
we have examined thus far include psychiatric symptoms and
delinquency. Great importance must be placed on whether these
early antecedents are specific to drug use alone, other
substances, or whether they are more generally predictive of
several, or all of these outcomes. The answers will help us
design plausible hypotheses as to the function of these
predictors in the developmental paths leading to teenage
outcomes.
We have viewed mental health as two dimensional. The first is a
domain including affect, self-esteem, and measures of thought
disorder. The second dimension is social adaptational status and
refers to the adequacy of social role performance by individuals
in those particular social fields that are important in
particular stages of life (Kellam et al. 1975). For example,
the teacher in the early elemantary school classroom defines
social tasks and rates the behavioral responses of the children
to those task demands, just as the foreman does in the work
place, parents at home, and significant others in the peer group.
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The periodic measures of adequacy by the teacher or other
natural raters (as we termed such people) we have called social
adaptational status.
Social adaptation is a highly interactive demand/response
process. Social adaptational status refers to the level of
success attributed to an individual's performance in a particular
social field. To review, the predictors we have found in
Woodlawn for later substance use all fall into the domain of
social adaptational status measures in the first grade classroom.
We will discuss the implications of this later in this paper.
Woodlawn is a black, poor, urban community on the South Side of
Chicago. Between 1964 and 1968 we made periodic assessments of
the classroom social adaptational status and psychological
well-being of all first graders in four consecutive cohorts.
These assessments were coupled with service and research programs
(Kellam et al. 1975) and were supported by a community board
composed of leaders from the community's larger citizen
organizations (Kellam and Branch, 1971; Kellam et al. 1972).
In 1963, the first year of the Woodlawn project, fifty-seven
first grade teachers in the 12 Woodlawn elementary schools were
asked to define those behaviors that they thought would indicate
that the child was having difficulty accomplishing the tasks of
the classroom. Figure 1** contains the social tasks we inferred
from the teachers' responses and a representative set of
behaviors that the teachers reported to us.
A four point global scale was made for each category of task,
ranging from adapting within minimal limits, to mild, moderate,
and severe maladapting. Ratings were obtained for each child in
the classroom on each task three times in first grade, and again
in third grade (Kellam et al. 1975). The Metropolitan Readiness
Test was administered early in first grade and an IQ test toward
the end of first grade. We consider the tests quasi-social
adaptational status measures, since they are schcol task demands
made on the students by the school and are administered to large
groups of children with minimal standardization. The reliability
and validity of both the test scores and the teacher ratings have
been extensively described in earlier publications (Kellam et al.
1975).
In this paper, we examine the long term outcomes predicted by the
teacher ratings and those predicted by the test scores. Our
study population is the 1966-1967 total first grade population
(N=l242), who were followed-up in 1975-1976 when we located and
reinterviewed 75% of the mothers of the original students and
then reinterviewed, with the parents' permission, 705 of the
original children. The children had been 6 or 7 in first grade
and were age 16 or 17 at the time of follow-up. Comparisons of
the populations of children lost compared to those reinterviewed
revealed no differences on any of the measures we are concerned
about in this paper.
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FIGURE 1: REPRESENTATIVE MALADAPTIVE BEHAVIORS AND SOCIAL TASKS
MALADAPTIVE BEHAVIORS CATEGORIES OF SOCIAL TASKS
SHYNESS: SHY, TIMID, ALONE TOO 
MUCH, FRIENDLESS, ALOOF.
AGGRESSIVENESS: FIGHTS TOO MUCH,
LIES, RESISTS AUTHORITY, IS
DESTRUCTIVE TO OTHERS, DISOBEDIENT.
IMMATURITY: ACTS TOO YOUNG, CRIES
TOO MUCH, HAS TANTRUMS, SEEKS TOO
MUCH ATTENTION.
UNDERACHIEVEMENT: DOES NOT LEARN
AS WELL AS HE IS ABLE, LAZY, DOES
NOT COME PREPARED FOR WORK,
UNDERACHIEVES, LACKS EFFORT.
COGNITIVE ACHIEVEMENT
CONCENTRATION PROBLEMS: FIDGETS,
IS UNABLE TO SIT STILL IN
CLASSROOM, RESTLESS, DOES NOT
PAY ATTENTION.
SOCIAL CONTACT
AUTHORITY ACCEPTANCE
MATURATION
CONCENTRATION
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RESULTS
We will report on outcomes ten years after first grade in three
general areas: delinquency: drug, alcohol, and cigarette use:
and psychiatric symptoms. All of these data are self-reports by
the teenagers. We have reported on the psychometric work
dealing with the validity and reliability of the follow-up data
elsewhere (Kellam et al. 1980; Kellam, In press, 1983).
The results of the outcome studies generally show that, despite
fairly strong correlations among the first grade teacher ratings,
the scales have specific and well-defined patterns of outcomes.
The following findings are from log linear analyses in which
data from all five scales and the test scores were introduced in
a sequence of equations testing for 2-, 3-, 4-, and 5-way effects.
Shyness. Shyness among males in first grade has different
outcomes depending on whether it is combined with aggressiveness.
Among males, shyness without aggressiveness inhibits the later
use of marijuana, hard liquor, and cigarettes (Kellam et al.
1980; Kellam, In press, 1983: Ensminger et al. 1982).
Similarly, it inhibits later delinquency (Ensminger et al. In
press 1983). Shyness in first grade is also associated, however,
with a higher level of anxiety in adolescence among males.
Among females shyness is much less significant for later outcomes
than for males. The only significant relationship we have found
is that early shyness in females inhibits the initiation of use
of hard liquor in adolescence (Fleming et al. 1982; Ensminger-
et al. 1982).
Aggressiveness. For males aggressiveness in first grade leads to
increased levels of use of beer or wine, marijuana, hard liquor,
and cigarettes, but also a higher level of antisocial behavior
ten years later. Those males that are both moderately or
severely aggressive and shy tend to have even higher levels of
substance use and to some extent delinquency.
For females the outcome of aggressiveness and shy-aggressiveness
is quite different. Aggressiveness in first grade does not lead
to overt substance use and delinquency in adolescence as in the
case of males. However it leads to paranoid symptoms, possibly a
form of unexpressed aggressiveness.
Underachievement. Underachievemnt in first grade predicts clear
outcomes ten years later, but not in substance use. We discuss
this predictor because of its close and important relationship to
first grade shyness and aggressiveness and the test scores.
This very common form of maladaptation leads to higher levels of
depressive symptoms but not substance use ten years later among
males. Progressively higher levels of first-grade
underachievement lead to progressively higher proportion of the
sample reporting a high level of depressed feelings ten years
later (Kellam et al. In press 1983).
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Readiness-for-school and IQ. The two first-grade tests of
readiness and IQ are clearly related to drug and alcohol (but not
cigarette) use for both males and females (Kellam, Simon, and
Ensminger, 1983; Kellam, Brown, Rubin & Ensminger, In Press
1983; Kellam et al. 1980). The higher the children's scores on
each test, the higher the lifetime frequency of use. Survival
table analyses reveal that the brighter performers start using
drugs and alcohol earlier (Fleming et al. 1982).
Among females both IQ and readiness in first grade also had
strong relations to psychiatric symptoms 10 year later: lower
scores on the first grade tests were associated with higher
self-reports of specific symptoms ten years later. Overall
distress among females, however, showed a more complex relation:
the intensity of teenage distress was highest among the lowest
scoring first graders and decreased from the most immature
first-graders to the low normal and average group. But the above
average group showed considerably n-ore distress than the average.
Among males the picture was similar: depression was lower among
teenagers who had been more ready for first grade ten years
earlier, while anxiety was higher among the above average than
the average. It appears that while good performance on first
grade readiness and IQ tests may lead to less intense symptoms
ten years later, the very highest levels of early performance may
lead to later distress.
DISCUSSION
These results show that specific early predictors of drug use
also predict the use of other kinds of substances by teenagers as
well as certain other kinds of teenage outcomes. These specific
maladaptive behavioral responses to first grade tasks have
specific and apparently important relationships to outcomes.
Aggressiveness in first grade males, for example, predicts heavy
drug, alcohol, and cigarette use as well as delinquency. It does
not predict these outcomes for females, nor does it predict
psychiatric symptoms ten years later for males. Shyness predicts
an inhibition of both substance use and delinquency, but also
predicts higher anxiety levels in adolescence. Specific patterns
also occur for the first grade children's performance on
readiness-for-school and IQ tests. Higher first grade scorers
use more drugs and alcohol, while low scorers report more
symptoms of distress as teenagers, but for the highest first
grade scorers the risk of teenage distress increases again.
All of these predictors are behavioral responses rated by the
teachers or scored on tests to specific classroom task demands
the teacher sets for her children. We have shown in other papers
that the maladaptive behavioral responses in first grade operate
mainly separately, not as clusters or syndromes (Kellam et al.,
In press). The single exception is the combination of shyness
and aggressiveness, which exaggerates the effects of
aggressiveness in predicting substance use and delinquency ten
years later among males.
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Theoretically, the results suggest that later drug use evolves
along developmental paths leading through the specific social
task demands and behavioral responses in the first grade
classroom or earlier. How children react behaviorally to these
demands appears to have long-lasting predictive importance in
spite of the great span of time, events, and conditions which
intervene between first grade and mid-adolescence.
From the point of view of prevention research, one lesson seems
to be that early predictors are an important part of any effort
to design specific preventive intervention trials. The kinds of
prevention efforts that might reduce the risk for aggressive
first, graders might very well be counterproductive for the
brighter performing children. A second lesson is that sex
differences in the development a paths leading to later outcomes
are profoundly important. A third lesson is that the paths
leading to drug use in adolescence must be studied side by side
with other adolescent behavioral outcomes. Self-reports of
psychiatric symptoms, drugs, alcohol, and cigarette use,
delinquency, and probably other outcomes, including school
achievement and adolescent sexual behavior represent an important
profile of outcomes to examine. Studying one outcome in
isolation from others loses much information about the meaning
and function of the predictors. Indeed, the design of research
on development and on preventive intervention should take into
account early social adaptational responses, sex differences,
and a profile of adolescent behavioral outcomes.
A broad prevention research strategy can be built on a base of
life span developmental epidemiological research, the
biobehavioral laboratory, and prevention trial research. Models
can be constructed as to the functions of early antecedents
through epidemiological life span data examined more
systematically in the laboratory and prevention trials designed
based on the results. Such a strategy would represent a major
advance in the next stage of our efforts to understand the
origins of child, adolescent, and adult behavior as well as to
design and test methods of prevention.
FOOTNOTES
* See Kellam, Brown, Rubin and Ensminger, In press, 1983,
for a review.
** Tables have been left out because of space consideration.
Full manuscript and bibliography is available from:
Social Psychiatry Study Center
Department of Psychiatry, University of Chicago
5811 S. Kenwood
Chicago, Illinois 60637
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Increased Effectiveness of Drug
Abuse Treatment From Patient-
Program Matching
A. Thomas McLellan, George E. Woody, Lester Luborsky,
Charles P. O’Brien, and Keith A. Druley
INTRODUCTION
Like many others in the field; our group has attempted to find
the patient characteristics that are most related to favorable
outcome and then use this information to assign patients to the
most appropriate treatments. Initial reports described the
design of our matching study (McLellan et al. 1980a), and the
evaluation instrument which we developed to provide the
admission and six-month followup data for this project
(McLellan et al. 1980b). Subsequent studies reported a
six-month followup evaluation of 742 alcohol-and drug-dependent
patients treated in our six-program network (McLellan et al.
1982), and detailed the patient characteristics which were
found to be most predictive of outcome in these programs, based
upon retrospective analyses (McLellan et al. in press). In
this report, we discuss the results of a prospective
patient-treatment matching study that has been employed with a
new sample of 476 male, veteran., alcohol and drug abuse
patients assigned to treatment in our six rehabilitation
programs using these predictors.
RETROSPECTIVE STUDY - Predictors of Patient-Program "Matches"
The retrospective portion of this work involved a sample of 742
male veterans (460 alcohol-dependent, 282 drug-dependent)
treated in the six-program Veterans Administration treatment
network during 1978. All patients were evaluated at the start
of treatment and again at followup six months later, using the
Addiction Severity Index (ASI). These data were analyzed to
determine if there were any patient-program matches which
produced particularly favorable or unfavorable results.
Our initial analyses indicated that a ten-point, global rating
of patients' psychiatric severity; estimated at admission, was
the single best predictor of most outcome measures for both
alcohol- and drug-dependent samples (McLellan et al. 1980b;
McLellan et al. in press). This finding prompted us to divide
each of the alcohol and drug abuse samples into LOW, MID, and
HIGH psychiatric severity groups and perform the predictive
analyses again on each of these 6 groups. It is important to
note that the psychiatric severity rating is not diagnostic or
symptom-specific. It has been shown to provide a reliable and
valid general estimate of overall psychiatric/psychological
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impairment and is derived from a highly structured interview
(McLellan et al. 1980b; McLellan et al. in press). Patients in
the LOW psychiatric severity groups (scale values 0-2) were
generally asymptomatic with no of
problems.
history psychiatric
MID severity patients (scale values 3-6) generally
reported significant symptoms of anxiety, depression and/or
confusion but no recurrent history of such problems. HIGH
severity patients (scale values 7-9) usually reported
pronounced symptoms such as suicidal ideation, paranoia and/or
serious confusion/disorientation, and usually had a history of
recurring symptoms (LaPorte et al. 1981; McLellan et al. 1981).
Results of this second round of predictive analyses revealed
significant relationships which had been masked in the
unstratified samples. Alcohol or drug-dependent patients with
LOW psychiatric severity at admission showed significant
improvement and the best outcomes regardless of which treatment
program they entered. Conversely,
with HIGH psychiatric severity
patients in both samples
at admission showed little
improvement and uniformly poor outcomes regardless of which
program they entered. Thus, for very different reasons, there
was no evidence of differential effectiveness from patient-
program matching in these groups. Results in the MID severity
groups (60 percent of the population) did show evidence for
significantly better outcome from patient-program matching, and
different, specific factors were predictive in each program.
PROSPECTIVE STUDY - Matched (M) versus Mismatched (MM) Patients
Treatment Matching Strategy - In general, patients in the LOW
psychiatric severity groups were recommended for outpatient
treatment because this was considerably less expensive and
because the retrospective data indicated that approximately
equal outcomes would result. The one exception to this
strategy was LOW severity patients with significant family
and/or employment problems. The original data had suggested
that these problems might impair the effectiveness of
outpatient treatment; thus an inpatient program was
recommended. Patients in the HIGH psychiatric severity groups
were recommended for psychiatric treatment at either our
inpatient wards or an associated community clinic. The
retrospective data had suggested that these patients received
relatively little benefit from any of the programs, generally
at great expense of staff time and effort (LaPorte et al. 1981;
McLellan et al. 1981). However, these patients were treated
within the network if no appropriate referral could be made.
Patients in the MID psychiatric severity groups were assigned
to particular treatment programs based upon the pattern and
severity of their other treatment problems at the time of
admission.
Patients who were referred or self-admitted to inpatient
treatment were screened and assigned to one of the four
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specific programs by one author (Druley) using the criteria
described. No patient was refused treatment. Only 55 percent
of the patients were "matched' to the appropriate treatments.
Reasons for not matching included lack of bed availability or
treatment slot at the appropriate program (approximately 25
percent); patients' refusal or inability to accept assignment
(approximately 13 percent), and simple assignment errors or
clinical overriding of the decision strategy (approximately 7
percent). It is important to note that staff members in each
of the programs were unaware of which patients were "matched"
(M) and which were "mismatched' (MM).
Subjects - Subjects were all male veterans who applied for
substance abuse rehabilitation treatment at either the
Philadelphia or Coatesville VA Medical Centers during the first
nine months of 1980. As in the retrospective study, all
patients who completed a minimum of five inpatient days or five
outpatient visits were considered eligible. We initially
irterviewd 649 patients (238 alcohol-and 411 drug-dependent).
Approximately 20 percent of each group dropped out of treatment
prior to the eligibility criterion. Followup efforts were
successful with 94 percent of eligible subjects, leaving 476
patients (178 alcohol-, 298 drug-dependent) with complete data.
Treatment Programs -The substance abuse treatment network of
the Veterans Administration in Philadelphia consists of four
inpatient (two alcohol; one drug, one combined) therapeutic
community programs at the Coatesville VA Medical Center, plus
outpatient alcohol and drug abuse clinics at the Philadelphia
VA Medical Center.
1978 and 1980.
These same programs were studied both in
There were changes in personnel during this
period with three of the six programs changing their
directors. Further, due to construction at Coatesville, there
was a move to different quarters for three programs. However,
no program changed its treatment orientation or its program
length. Space limitations prevent a complete description of
these programs; see Gottheil et al. (1979).
RESULTS
Our initial analyses compared the during-treatment performance
and six-month follow-up outcomes of the matched and mismatched
patients in both the alcohol and drug-dependent samples. The
during-treatment comparisons for both samples indicated that
the M patients were rated as significantly (p=.05 or less) more
motivated for treatment, stayed in treatment longer, and had
fewer irregular discharges than the MM patients treated in the'
same programs. Analyses of covariance on the six-month outcome
measures, adjusting the groups for admission differences in
age, race, prior treatments and the admission criterion score,
indicated better outcomes for M patients on 17 of the 19
outcome variables and 10 of these comparisons were
significant. In fact, when all followup measures were
averaged; the M patients showed 27 percent better outcome than
the MM patients.
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Excluding High Severity Patients - Although the initial
analyses were quite encouraging in both patient samples, it was
possible that the results might be accounted for by the greater
proportion of patients with serious psychiatric problems in the
mismatched group. The results of our retrospective analyses
suggested that these HIGH severity patients responded poorly to
all of the available alcohol or drug abuse treatments (LaPorte
et al. 1981; McLellan et al. 1981). Thus, in our 1980
treatment assignment strategy; we considered the HIGH
subsamples to be mismatched in all programs. It was therefore
possible that the canparatively poorer performance of the
mismatched patients was due largely to the HIGH severity
subgroup. We therefore eliminated all HIGH psychiatric
severity patients and reanalyzed the data.
Results of these second-level analyses in both the alcohol and
drug-dependent samples indicated better adjustment to treatment
and better six-month outcomes (adjusted for differences in pre-
treatment status) in the matched patients than mismatched
patients who were treated in the same programs (see table 1).
In the alcohol abuse sample 17 of 19 outcome comparisons were
better in the M patients and eight were significant (p<.05).
In the drug abuse sample all 19 comparisons were better for the
M patients and 10 were significant (p <.05). Therefore, even
without the HIGH psychiatric severity patients, there was
considerable evidence for significantly better during-treatment
performance and post-treatment outcome (19 percent averaged,
across criteria) in the matched patients than in their
mismatched counterparts.
Effects of Matching in Four Treatment Programs - Despite the
results from the previous two stages of analysis it remained
possible that the more favorable results among-matched patients
might be due to only one or two programs, with less than
satisfactory results possible from the other programs. We
therefore analyzed during-treatment performance, and adjusted
follow-up outcomes for M and MM subjects from each of four
programs.
The during-treatment analyses showed that M patients were
significantly (p<.05) more likely to be rated as appropriate
for their assigned treatment in three of the four programs.
Further, staff from all four programs rated a larger proportion
of matched patients as motivated for treatment.
Analyses of adjusted six-month outcomes indicated considerable
evidence of improvement in several areas for both matched and
mismatched patients in all four programs. However; comparisons
of six-month outcomes between the matched and mismatched groups
showed pervasive evidence of better status in the matched
patients from all four programs. Only 10 of the 76 comparisons
(19 criteria x 4 programs) showed better outcomes for the
mismatched patients and only three of these were significant
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(p <.05). Tn contrast, 66 of the 76 comparisons in the four
treatment programs showed better outcomes for the matched
patients and 79 of these were significant. Therefore, we
conclude that the better during-treatment performance and
six-month outcomes seen by the matched patients in the
unstratified samples were largely consistent across all the
treatment programs examined.
DISCUSSION
Two major findings resulted from the present study. First, the
data from both the 1978 and 1980 patient cohorts and for both
the alcohol-and drug-dependent samples clearly indicated that
substance abuse rehabilitation was effective even without
modification of treatment assignment procedures. The impact of
this finding was given added weight by the consistency in type,
magnitude and distribution of improvements shown by these
cohorts in 1978 and 1980 (see McLellan et al. 1382).
A second major finding was that the effectiveness of treatment
was improved by matching patients to the most appropriate
program within the treatment network. Patients who were
assigned and admitted to an appropriate program, based upon the
1978 predictive factors; had significantly better adjustment
during treatment, showed more significant improvements and had
generally better six-month outcomes than patients who were
treated in the same programs but were predicted to have a
different optimum treatment assignment (Mismatched patients).
In fact; the overall outcome of the matched patients (averaged
across all criteria) was 19 percent better than that of the
mismatched patients; even when HIGH severity patients were
excluded. This "matching" effect was shown in both the alcohol-
and drug-dependent samples, in both LOW and MID severity groups
and in all of the treatment programs sampled. Thus, the effect
was not isolated to a particular type of patient or treatment.
This finding indicates that the same factors which were
predictive of patient outcome in 1978 were again predictive in
1980. This is noteworthy in view of the poor history of
replicated results in treatment outcome evaluations and in view
of the changes in the patient population and the treatment
program personnel which took place during those years.
Implications - We feel certain that a key reason for the
success of the present matching attempt has been the inclusion
of a global estimate of admission psychiatric severity as an
outcome predictor. In the present study; LOW severity patients
shed the best outcomes
assignment.
regardless of their treatment
Because of this, these patients were usually most
suited to the less expensive outpatient programs at a savings
of more than $53 per patient; per day; or an average of more
than $3,700 per patient over the normal course of treatment.
Conversely, both the 1978 and 1980 data indicated that HIGH
psychiatric severity patients, both alcohol and drug-dependent,
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had the poorest outcomes, regardless of the program in which
they were treated. In fact, these high-severity patients were
more than twice as likely to return to hospitalization (often
via the emergency room) than the other patients, during the
six-month follow-up interval.
The finding that the substance abuse patients in this
population who had more severe employment and/or family
problems were less suited to outpatient treatment is logical
and consistent with clinical experience. We feel that an
extended inpatient rehabilitation program for these patients
extricates them from a damaging environment, allows them to
concentrate upon the rehabilitation process, and permits the
families to objectively re-evaluate their contribution to the
patient's condition.
The more specific factors which were associated with favorable
outcomes in this study (e.g., medical condition, drug history,
etc.) may be peculiar to the particular programs evaluated. We
do not contend. that these factors are the outcome predictors
for other patient samples; only that they were effective in
this population, within these programs and at this time. We
anticipate that as the programs and/or the patient samples
evolve, these more specific predictors may also change.
However, we feel that the present methodology will be effective
in detecting these changes and that our ongoing "matching"
strategy will continue to be helpful in optimizing outcome.
REFERENCES
In the interests of space limitations all references can be
obtained from the senior author.
ACKNOWLEDGEMENTS
Supported by HSR D Projects #254 and #525 from the Veterans Ad-
ministration and by NIDA Project DA02554. The cooperation of
Dr. Anna Rose Childress, Dr. George Ainslie, Mr. Jeff Griffith,
and Mrs. Diane Hery in collection and interpretation of these
data is gratefully acknowledged.
AUTHORS
A. Thomas McLellan, Ph.D., Director, Clinical Research, Drug
Dependence Treatment Unit, VA Medical Center, Philadelphia, PA
19104 and Assistant Professor of Psychiatry, University of
Pennsylvania, Philadelphia, PA 19104
George E. Woody, M.D., Chief, Drug Dependence Treatment Unit,
VA Medical Center, Philadelphia, PA 19104 and Clinical
Associate Professor of Psychiatry, University of Pennsylvania,
Philadelphia, PA 19104
Lester Luborsky, Ph.D., Professor of Psychology in Psychiatry,
University of Pennsylvania, Philadelphia, PA 19104.
340
Charles P. O'Brien, M.D., Ph.D., Chief, Psychiatry Service, VA
Medical Center, Philadelphia, PA 19104 and Professor of
Psychiatry, University of Pennsylvania, Philadelphia, PA 19104
Keith A. Druley, Ph.D., Chief, Substance Abuse Treatment Unit,
VA Medical Center, Coatesville, PA 19320.
341
TABLE 1
SIX-MONTH FOLLOWUP PERFORMANCE OF MATCHED AND MISMATCHED SUBSTANCE
ABUSE PATIENTS, EXCLUDING THOSE WITH SEVERE PSYCHIATRIC PROBLEMS
ALCOHOLICS DRUG ADDICTS
Matched Mismatched Matched Mismatched
CRITERIA1 N= 80
MEDICAL FACTOR
Days Med. Probs.
275 * 350 202
9 8 6
EMPLOYMENT FACTOR
Days Worked
Money Earned
Welfare Income
357 ** 437
1 0 8
350 172
19 26
ALCOHOL FACTOR
Days Drinking
Days Intoxicated
217
7
3
DRUG FACTOR 11 *
0Days Opiate Use
Days Non-Opiate Use 2  *
LEGAL FACTOR 24      * *
Oays of Crime 1
Illegal Income 6 * *
FAMILY FACTOR 210    *
Days Fam. Probs. 2
PSYCHIATRIC FACTOR 121
Days of Psych. Probs. 5
50 114 142
186
7
4
5
33
2
101
2
32
263 205
4 2
134 125
6 5
300
12
469
38
72
5
1
129
5
5
75
3
64
*
**
*
**
*
*
*
*
*
*
248
7
471
7
235
64
80
6
2
153
7
6
86
3
132
251
4
156
6
1All criteria were measured during the 30 day periods preceding admission and preceding
six month followup. Higher factor scores indicate greater problem severity.
* = p < .05  * = p < .Ol by analysis of covariance. Covariates were age, race,
prior treatments and the admission criterion score.
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A Clinical Profile of 136
Cocaine Abusers
Antoinette Anker Helfrich, Thomas J. Crowley, Carol A.
Atkinson, and Robin Dee Post
ABSTRACT
Our examination of 136 cocaine-abusing patients who sought treatment
revealed impairment in the following areas: Psychological (99 percent of
patients); Interpersonal (87.5 percent); Financial (83 percent); Physical (81
percent); and Vocational (68 percent). Daily dose did, but route of
administration did not, contribute to degree of impairment. From these
data, we conclude that cocaine’s deleterious effects are both physiological
and psychological. It appeared to us that maintenance of a cocaine habit is
frequently at great expense to the user, regardless of whether the use is
intranasal, intravenous, or free-base smoking. In our opinion, it is the
multiplicity of psycho-social factors which drives patients to treatment.
These factors also define most accurately the extent of consequences
associated with cocaine use.
INTRODUCTION
Cocaine use results in significantly impaired functioning for many
individuals. Available literature in the area of cocaine abuse focuses on
limited aspects of possible impairment. For example, laboratory studies
have described cocaine’s physical and psychological effects as reported by
non-dysfunctional volunteer subjects who are administered doses of cocaine
within the prescribed maximal safe dose limits, on controlled schedules,
and in controlled settings. Our patients’ patterns of cocaine use do not
tend to replicate this type of controlled regimen, nor are the effects of
their drug administration confined to the actual state of intoxication.
Similarly, several studies have solicited subjects who have used cocaine to
interview them about cocaine’s effects. It is likely that these volunteers
were drawn largely from a population of non-dysfunctional, “social-
recreational” users . Finally, case studies typically do address the many
facets of cocaine abuse, but they report on small samples of users and may
focus on atypical cases.
A drawback to what is available in the cocaine literature is that the
characteristics and problems of dysfunctional users may not be adequately
represented. In fact, conclusions drawn from some of the existing studies
may be misleading to individuals who are using the drug as well as to
clinicians who are called upon to treat dysfunctional users. An example of
misleading information is related to the assessment of severity of cocaine
problems based solely on route of administration, i.e., that only intravenous
or free-base users become significantly impaired. Risks and losses
associated with intranasal administration have been minimized. Van Dyke
343
and Byck (1982) concluded that intranasal use of cocaine may produce "a
pattern of behavior . . . comparable to that experienced by many people with
peanuts and potato chips.” Similarly, Seigel (1977) maintained that
intranasal cocaine use “did not tend to escalate to more individually
oriented patterns of uncontrollable use.” In this study, we investigated
characteristics of 136 dysfunctional cocaine users who sought treatment
for problems associated with their use. We examined socio-demographic
data, patterns of drug use and psychological factors (including symptom
presentation) in this group of patients in an attempt to describe the
impairment of functioning associated with their cocaine use. We were
especially interested in testing the hypothesis that route of administration
is correlated with nature, extent and severity of problems. Given a 500
percent increase in the number of individuals seeking treatment for
cocaine abuse between 1975 and 1980 (NIDA 1980), it is timely and
relevant to examine characteristics of a large sample of cocaine abusers
who have sought treatment.
METHODS
The report is based on data obtained from 136 consecutive admissions to
specialized cocaine clinics in Denver and Aspen. All patients presented for
treatment voluntarily as described in Anker and Crowley (1982). Anyone
18 years or older with a DSM III (American Psychiatric Association 1980)
diagnosis of cocaine abuse (pathological use with impairment of social or
occupational functioning for at least 1 month) was eligible for admission.
Three of the authors (Helfrich, Crowley, Atkinson) treated all patients.
Socio-demographic data, drug use information, history of presenting illness,
medical and social history were collected at admission. Within two weeks
of admission, patients were asked to complete the Minnesota Multiphasic
Personality Inventory (Hathaway and McKinley 1967).
The clinicians retrospectively analyzed patient records to compile a
checklist with 8 symptom clusters: 1) Major Physical: hepatitis, endo-
carditis, infections, abcesses, nasal bleeding or ulceration, fainting (loss of
consciousness), seizures, respiratory depression and/or failure; 2) Minor
Physical: weight loss of 7 or more pounds, insomnia, dizziness, headaches,
nausea, tremor; 3) Major Psychological: hallucinations, delusions, serious
suicidal ideation; 4) Minor Psychological: depressed, anxious, irritable,
guarded, suspicious; 5) Vocational: job loss, impaired functioning at work or
school, absenteeism, reprimand or pressure from a supervisor, probation/
suspension/revocation of professional license or certification; 6) Inter-
personal and Family: spouse or significant other separates or threatens to
separate, increased discord; 7) Legal: drug-related investigation, arrest,
probation, parole; 8) Financial: diminished or exhausted resources,
accumulation of debts.
The Minnesota Multiphasic Personality Inventory (MMPI) is a general
survey of psychopathology (Hathaway and McKinley 1967). Scores on three
validity scales and ten clinical scales are converted to standard measures
(T-scores) for comparison with a normal population. Elevated scale scores
(T score > 70) have consistently been associated with behaviorally
observable psychopathology.
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Because the familiar MMPI scales are highly intercorrelated, we also
scored the factor pure measures suggested by Overall et al. (1973). These
factor scales are Somatization, Low Morale, Depression, Psychotic
Distortion and Acting Out. The Somatization factor correlates most highly
with neurotic profiles. Low Morale indicates anxiety discomfort.
Depression is self-explanatory. Psychotic Distortion suggests major
psychotic disturbance. Finally, psychopathy is indicated by the Acting Out
factor.
Hollingshead’s two-factor index of social position was calculated for each
patient (Hollingshead and Redlich 1958). This index integrates factors of
occupation and education. Social class is defined with I being the highest
and V the lowest.
RESULTS
The two cocaine clinics admitted 136 patients between March, 1980 and
March, 1982. Thirty females (22 percent) and 106 males (78 percent) had a
mean age of 29 years (range 19-57). Forty-two percent were single, 28
percent married, 7 percent separated and 23 percent divorced. Fifty-three
percent of patients fell within the top three Social Class continua (median
= III). The mean level of education for all patients was 14 years (bi-modal
at 12 and 16 years).
Favored routes of administration were: intranasal, 57 percent of patients;
intravenous, 33 percent; free-base smokers, 10 percent. We converted
average doses estimated by patients at the time of admission to grams-per-
week. The mean dose for the total group was 8 grams per week (range .25
to 45 grams per week). The mean dose for the nasal group was 7.2, for the
IV group it was 8.5 and for the free-base group, 10.3; these differences
were not significant by analysis of variance (F = 1.52). Seven percent of
patients reported using cocaine less than twice per week, 30 percent used
two or more times per week, 15 percent used two to three times daily, 27
percent used more than three times daily and 18 percent reported binge
use. Patients averaged 5 years between first use and admission to
treatment (range = 1-20).
Of these patients, 40 percent reported dysfunctional use of no other drugs,
34 percent were concurrently abusing alcohol, 8 percent reported
problematic marijuana abuse, 5 percent reported amphetamine abuse and 5
percent abused tranquilizers. Only 4 patients were using opiates (including
synthetic opiates).
Clinically, a pattern of significant psychological distress emerged.
Analysis of the symptom checklist revealed that 85 percent of patients
presented four or more of the eight symptom groups. The mean number of
symptom clusters presented was 5. The number of symptom clusters
reported by each patient did vary significantly (ANOVA, p > 0.02) with
route of administration, but the difference was small (mean number of
symptom groups presented per patient in nasal users, 4.7; in IV/FB users,
5.3) and of questionable clinical importance. The percentage of patients
representing each symptom complex are listed below: 1) Minor Psycho-
logical - 99%; 2) Interpersonal - 87.5%; 3) Financial - 85%; 4) Minor
Physical - 81%; 5) Vocational - 68%; 6) Major Psychological - 43%; 7) Major
Physical - 22%; 8) Legal - 15%. (See Figure 1). Figure 1 illustrates that
route has little effect on specific symptom clusters; chi square tests of
these differences were not significant.
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FIGURE 1
Frequency of symptom clusters reported by patients at admission
0 = Frequency for the IV and free-base group
x = Frequency for the Nasal group
Patients’ dose estimates correlated significantly (r = .34; p = .00003) with
number of symptom clusters per patient at admission. As dosage
increased, so did the number (range) of symptom clusters reported.
However, the presence or absence of Major Physical symptoms was the
only cluster that was significantly related to dose estimates (F = 7.85, p >
.01). It is interesting to note that symptom clusters correlated with dose
for the nasal group (r = .49), but there was not a significant correlation
between dose and symptom clusters in the IV/FB group.
Seventy-six patients completed MMPI’s; others left treatment early or
refused to complete the test. The generally elevated mean T-scores
corroborate the symptom information presented above documenting that
psychological turmoil is clearly evidenced by this group. (See Figure 2). A
comparison of mean MMPI factor scores (Overall et al. 1973) between this
group of cocaine abusers and normals also suggests considerable psycho-
logical turmoil. The Acting Out factor was especially elevated with a
mean for the cocaine group that was greater than one standard deviation
above the mean reported by Overall et al. for normals.
We found no significant relationships between elevated MMPI scale scores
and route of administration. In other words, it did not appear that IV/free-
base users differed from nasal users along MMPI dimensions. ANOVA F
ratios for each MMPI scale by route of administration were uniformly
insignificant.
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FIGURE 2
We correlated each patient’s dose estimates with each scale of the MMPI.
Considering all subjects from whom MMPI’s were available (N = 76), only
two significant correlations appeared (scales F and Pd). F scale elevations
are associated with rebellion, unconventional thinking and severity of
illness in a clinical population. Pd scale elevations suggest social alien-
ation, rebellion and resentment (Carson 1969) and has been correlated
highly with substance abuse (Caldwell and O’Hare 1975). The inter-
pretation of increased probability of substance abuse is corroborated by a
mean MacAndrew’s scale score of 25; the cutoff used to predict alcohol
abuse is 24 (MacAndrew 1965). While statistically significant, the
correlations are modest (r = .22 and r = .21, respectively). They tentatively
suggest that increased dose may be associated with greater rebelliousness,
social alienation, anger and psychiatric dysfunction.
DISCUSSION
This sample of 136 cocaine patients exhibited significant and serious
psychological distress regardless of the route of cocaine administration. A
general inventory of psychopathology (MMPI) revealed mean scale scores
that are clinically elevated ( > one standard deviation above the norm) on 9
of 13 scales. In terms of symptom presentation at admission, the range and
severity of reported dysfunction challenge reports of cocaine’s benign
effects. Given that over half of our sample were intranasal users, we were
especially interested in examining the hypothesis that intranasal use is
relatively safe compared to intravenous use or free-base smoking (Van
Dyke and Byck 1982; Wesson and Smith 1977). Additionally, we questioned
whether classifications of patterns of cocaine use (i.e., dose regimes) might
be a misleading distinction. For example, every patient in this sample
began with experimental use; some only months before admission. Using
Seigel’s (1977) method of classifying intranasal cocaine users, many of our
sample would be considered “social-recreational” users. However, unlike
Seigel’s sample of interview subjects for whom “psychometric instruments
failed to detect the presence of dysphoria or psychosis,” our patients clearly
demonstrated adverse consequences even with doses as small as gram per
week.
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We investigated characteristics of 136 patients for whom dysfunctional use
of cocaine was self-diagnosed by their voluntary admission to treatment.
The socio-demographic profile differs from NIDA’s characteristics of
cocaine abusers admitted to treatment programs (1977) in several respects.
Our patients were older ( = 29); more educated ( = 14 years); employed
(80 percent); predominantly white (90 percent); and had fewer legal
complications (15 percent). We had fewer intranasal users (57 percent vs.
69 percent) and our patients used cocaine more frequently (7 percent vs.
NIDA’s 54 percent used cocaine once per week or less).
Maintaining distinctions among routes of cocaine administration in terms
of adverse. consequences may be somewhat deceiving in the assessment of
the overall clinical profile. It is true that greater blood plasma concen-
trations of cocaine result in more noticeable physiological and psycho-
logical effects during intoxication and that intravenous or free-base
smoking lead to peak concentrations more quickly. Due to these factors,
abuse potential and threat of overdose are more likely. Based on this
observation, however, much of cocaine research to date assumes that
impairment, extent of adverse effects and dangerously frequent use are
mainly a function of the route of administration (Van Dyke and Byck 1982).
The percentage of nasal users in the general population whose functioning
is impaired may be much lower than the percentage of impaired IV/FB
users. It is important to emphasize, however, that in our experience,
intranasal users do present clinical syndromes. In fact, there was no
significant relationship between MMPI scale elevations and route of
administration in an analysis of variance. Dose also was not significantly
correlated with route. Finally, chi square computations for each symptom
cluster by route were not significant, even though route was marginally
associated with the total number of symptoms reported. In summary, route
of administration did not appear to affect dose, MMPI scores, or specific
types of symptoms in this clinical population. Nasal and IV/FB groups of
patients were clinically indistinguishable.
Dose, on the other hand, is related to the number of symptom clusters
reported by each patient at admission and to elevations on the MMPI F and
Pd scales. With increasing doses, patients are more likely to report Major
Physical symptoms. The MMPI findings suggest that dose does correlate
with overall severity of illness and -are consistent with Post’s (1975)
assertion that "increasing the dose and/or chronicity of cocaine admin-
istration is associated with increasingly severe affective and cognitive
alteration”.
Besides the direct (primarily pharmacological) effects of cocaine use, there
are numerous, more insidious, and presumably more pervasive consequences
that are not adequately addressed in laboratory research. Because of the
potency of cocaine’s reinforcing effects, animals will work, even to the
point of death, to receive injections (Deneau et al. 1969). The possible
parallel for human beings is of considerable clinical concern. Cocaine
drives behavior toward continued and exaggerated patterns of use. Our
patients report being drawn into a compelling cycle of obtaining, using and
recuperating from cocaine use. They maintain that cycle despite serious
risks (physical and psychological) and losses (spouse, job, finances, etc.). It
is this series of risks and losses which eventually leads patients into
treatment because they are experiencing serious psychological distress.
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Many factors could have contributed to the psychological turmoil in this
sample of cocaine abusers (as evidenced by reported symptoms and
elevated MMPI scales). It may be that these patients were predisposed to
psychopathology and cocaine use triggered a more intense reaction, but
their progress in treatment and history of pre-morbid adjustment argue
against this hypothesis. Perhaps the psychological turmoil is directly
related to the pharmacological action of cocaine. However, given the
short duration of cocaine’s effects and the time lapse between dosing and
admission, it is unlikely that direct effects would have contributed, for
example, to elevated MMPI scores. In addition, we found no relationship
betwen route of administration and either dose or clinical data (symptoms,
MMPI). Finally, it may be that the social and psychological consequences
of increasing cocaine use create and maintain serious psychological
stresses. Eventually the individual’s overall level of functioning is signi-
ficantly impaired. None of these possible explanations can be discounted;
however, we feel that the third is the most plausible and of the greatest
clinical importance.
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Cocaine and Amphetamine
Dependence Treated With
Desipramine
Forest S. Tennant, Jr., and Richard A. Rawson
ABSTRACT
Desipramine was administered to 8 amphetamine- and 14 cocaine-
dependent persons to assist withdrawal. Nineteen of 22 (86.4%)
reported discontinuation of drug use within two to seven days,
of which 15 (68.2%) gave urine samples negative for amhetamines
or cocaine. Recent primate studies show that chronic methamphet-
amine administration markedly depletes brain norepinephrine,
which suggests that desipramine is probably effective in treating
amphetamine and cocaine dependency because it selectively blocks
norepinephrine uptake.
INTRODUCTION
No specific treatment has been identified for amphetamine and
cocaine dependenCe. (1,2) Consequently, attempts to treat these
conditions have met with dismal outcome. (3,4) For example,
Anderson, et. al. offered 18 amphetamine users psychotherapeutic
treatment, but no patient returned for even a single, scheduled
visit. (3)
Animal studies suggest a possible treatment for amphetamine and
cocaine dependence. (5,6) Although Axelrod (7) demonstrated in
1961 that amphetamines and cocaine block the uptake of norepi-
nephrine, Seiden, et. al. have only recently shown that chronic
methamphetamine administration depletes appoximately 30 to 50
percent of whole brain norepinephrine in primates. (5) Therefore,
the chronic cocaine and amphetamine user may be in a condition of
severe norepinephrine depletion.
The tricyclic anti-depressant desipramine produces a greater de-
gree of selective blockage of norepinephrine uptake than any
other tricyclic anti-depressant. (8) Based on this, we hypo-
thesized that humans dependent on amphetamines and cocaine could
be treated by administering desipramine. Reported here are our
initial findings with 14 cocaine- and 8 amphetamine-dependent
patients.
METHODS
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During 1981-1982, subjects sought treatment at four outpatient
clinics located in East Los Angeles County. All stated they com-
pulsively used amphetamines or cocaine multiple times each day
for at least three months and that they were unable to cease use
without some form of medical intervention. Although some
patients used alcohol or marijuana occasionally, none considered
any drug a problem except amhetamines or cocaine. The treatment
team consisted of a physician, nurse, and psychologist. Each
subject completed a written questionaire which inquired about
length and amount of drug use, source of drugs, health problems,
previous attempts to cease drug use, and symptoms which pre-
cluded cessation of drug use. A complete physical examination
and urine analysis for amphetamines or cocaine were done. The
first day's dose of desipramine was 25 mg. given two to four
separate times for a 24-hour total of 50 to 100 mg. Subsequent
days' dosage was dependent on withdrawal symptoms. Patients were
informed they could take desipramine for as many days as it
proved helpful in achieving amphetamine or cocaine abstinence.
They were instructed to return to the clinic daily for the first
five days and after this period to attend one to two times weekly
for up to one month.
A daily drug diary was kept by each patient which listed the time
of day and amount of desipramine, amphetamine, cocaine, or other
drug used. On each visit, patients were asked about continued
amphetamine or cocaine use and whether desipramine helped than
cease drug use: reduced drug craving: prevented depression and
apathy: and reduced insonmia, since these symptom are well-
recognized as part of amphetamine and cocaine withdrawal. (1,2)
A repeat urine test for amphetamine or cocaine was taken in the
second week of treatment. When the patient chose to discontinue
desipramine, the option for weekly counseling sessions with the
psychologist was offered.. Patients who left treatment were
interviewed by telephone approximately 30 to 45 days after
leaving treatment to help determine if relapse had occurred.
RESULTS
The majority of amphetamine users were white, unmarried, employed,
and female, while cocaine users were predominantly employed
males. (See Table 1) Duration of amphetamine dependence ranged
up to 15 years and cocaine dependence up to 8 years. All
patients except one cocaine user returned to the clinics for
multiple visits. Seven of eight (87.5%) amphetamine and 12 of 14
(85.7%) cocaine users reported they ceased drug use within two
to seven days after beginning desipramine administration. Other
than one amphetamine user who stated that desipramine wasn't
helpful and took it only for two days, the remaining amphetamine
users chose to take it for period ranging from four to 120 days
(mean of 35.5). One amphetamine patient has chosen to maintain
on desipramine for a period that now exceeds 120 days, and an-
other took it intermittently for 105 days. Cocaine users tended
to take desipramine for shorter periods. Only three cocaine
patients elected to take desipramine for longer than 7 days with
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the longest period being 52 days. Eleven took desipramine for
2 to 7 days, and 9 of these patients stated they ceased cocaine
use and declined further treatment. Urine test analysis for
documentation of cocaine cessation could only be obtained in
eight cocaine users due to the claims that further treatment was
unnecessary and failure to attend the clinic for more than one
week.
Subjects variously reported that desipramine helped reduce drug
craving, prevent depression and aid sleep. (See Table 1) Daily
doses of desipramine ranged from 50 to 125 n-g. per day. Patients
reported it to be most effective when taken in multiple doses of
25 mg. two or three times during the day and a dose of 25 to 50
mg. at bedtime. The side-effect reported was mild sedation in
two patients. One amphetamine and two cocaine users reported
that desipramine suppressed amphetamine or cocaine effects when
they attempted to use them.
DISCUSSION
Although this study was conducted on a non--blind basis with a
relatively small number of subjects, the results are impressive
compared to previously published reports by us and others who
have attempted to treat amphetamine-dependent patients on an
outpatient basis. (3,4) We cannot identify any published re-
ports of systematic attempts to treat and assess outcome of
cocaine-dependent persons. (1) The major difficulty in treating
amphetamine users has been the inability to retain patients in
treatment beyond the first clinic visit. In this study, all 22
patients were retained beyond the first clinic visit. Nineteen
of the 22 (86.4%) reported cessation of amphetamine or cocaine
dependence within two to seven days, and it was possible to
document conversion of urine from amphetamine or cocaine positive
to negative in 15 of these subjects.
Use of desipramine to treat amphetamine and cocaine-dependent
persons represents a significant departure from conventional
drug withdrawal therapy. (4) In addition, it uses a tricyclic
anti-depressant in a way not previously utilized. (8) Until now,
pharmacologic assistance has normally only been used for drugs
such as opiates, barbiturates, and alcohol that produce physical
dependence. (4) In this preliminary study, desipramine was uti-
lized for withdrawal from drugs which do not produce typical
physical dependence. (1,2) The basis for the use of desipramine
was to enhance norepinephrine activity, since recent studies in
primates show that chronic methamphetamine administration signi-
ficantly depletes whole brain norepinephrine. (5,6) Normally,
desipramine and other tricyclic anti-depressants require approxi-
mately three weeks to show clinical improvement of endogenous
depression which has led to the belief that they act to relieve
depression by a mechanism not totally related to neurotransmitter
blockage. (8,9) Subjects in this study reported immediate
effects of desipramine which were most likely related to its
ability to selectively block norepinephrine uptake and potentiate
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norepinephrine activity.
The animal studies by Seiden et. al. showed that norepinephrine
depletion may be irreversible following long-term methamphetamine
administration. (5) If this is the case in some humans who abuse
amphetamines chronically, it provides an explanation for the in-
tractable nature of amphetamine dependence as well as an explana-
tion why some subjects in this study voluntarily chose main-
tenance with desipramine. Unfortunately, there is no reliable
method at this time to directly measure whole-brain norepine-
phrine in man.
This study must not be over-interpreted due to its non-blind
nature, the possibility of placebo effect, and the inherent
difficulty to control drug-dependent research subjects. Further
clarification of the role of desipramine in the treatment of
amphetamine and cocaine dependence must await double-blind
trials.
TABLE ONE
CHARACTERISTICS AND OUTCOME OF
AMPHETAMINE AND COCAINE SUBJECTS
Amphetamine Cocaine
N=8 N=14
Age Range 19 - 39 years 22 - 36 years
Mean Age 29.0 years 26.9 years
Females 6 (75.0%) 4 (28.6%)
White 8 (100.0%) 14 (100.0%)
Employed 7 (87.5%) 10 (71.4%)
Married 1 (12.5%) 8 (57.1%)
Range Drug Consuned Each Day 3 to 40 tabs/ 1/2 to 3 gms
caps
Total Length of Drug Use (Mean) 8.4 years 3.4 years
Length of Time Desipramine
Administered (Range) 2 - 120 days 2 - 52 days
Length of Time Desipramine
Administered (Mean) 35.5 days 11.9 days
No. Reported Cessation of Drug Use 7 (87.5%) 12 (85.7%)
No. With Two or More Clinic Visits 8 (100.0%) 13 (92.9%)
No. Converted Urine From Positive
to Negative 7 (87.5%) 8 (57.1%)
No. Reported Desipramine Did Following:
Helped Cease Drug Use
Reduced Craving
7 (87.5%) 12 (85.7%)
2 (25.0%) 8 (57.1%)
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Prevented Depression 5 (62.5%) 6 (42.9%)
Helped Sleep 5 (62.5%) 2 (14.3%)
Patient Status 30 - 45 Days After Admission:
Desipramine Maintenance
Reports Total Abstinence
Relapse to Drug Use
Unknown
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Recreational Opiate Addiction in a
Dentist and a Nurse
William E. McAuliffe
This article presents case studies-of a new from of opiate abuse
in medical professionals that appears to be on the rise in the
united states. Medical professionals have long had high addict-
ion rates because of their easy access to drugs (Terry and
Pellens 1970). Until recently these addictions have almost al-
ways been therapeutic (iatrogenic) or quasi-therapeutic in origin
(Clark, 1962; Winick, 1961; Green et al., 1978; Modlin and
Montes, 1964; Wall, 1958; Pescor, 1942; Poplar, 1969). Therapeu-
tic addictions originate from treatment with opiate medications
for pain; quasi-therapeutic addictions stem from opiate self-
treatment of depression, anxiety, fatigue, stress, hangover, and
so on; nontherapeutic addictions result from recreational
euphoria-seeking. The reasons physician and nurse addicts have
given most often for their opiate abuse are physical pain,
marital problems, stress, alcoholism, insomnia, and fatigue from
overwork (Winick, 1961; Green et al., 1978; Modlin and Montes,
1964; Wall, 1958; Jones, 1958; Pescor, 1942; Poplar, 1969).
Modlin and Montes (1964) found that 10 of 25 physician addicts
were initially prescribed opiates by a physician or surgeon, and
then continued by self-prescription. There is little evidence
that in the past medical professionals used opiate drugs for
kicks. Winick (1961; 1974) found that 98 physician addicts men-
tioned euphoria sixth in order of frequency as a reason for cur-
rent use of opiates, whereas 195 nurse addicts did not mention
euphoria at all. In other studies physician addicts did not men-
tion euphoria-seeking as a reason for drug use (Green et al.,
1978; Jones, 1958; Wall, 1958; Modlin and Montes, 1964).
However, the incidence of nontherapeutic addiction among medical
professionals may soon increase substantially. Unlike previous
decades, today many young medical professionals have been exposed
to and have used drugs recreationally. My colleagues and I
recently surveyed samples of premedical students, medical stu-
dents, nursing students, and young physicians in New England to
find that between 56 percent and 71 percent have used marijuana
and that significant proportions have progressed to recreational
experimentation with higher-risk drugs, especially cocaine
NOTE: This paper was presented at the 1981 scientific Meeting.
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(between 15 percent and 26 percent) (McAuliffe et al., 1982). It
is not surprising therefore that impaired physician committees
have begun to see a new type of physician addict, one who is ad-
dicted to recreational drugs , such as marijuana and cocaine (U.S.
Journal, 1981, p.10; Warmkessel, 1981; Buys, 1982, p. 10;
Grosswirth, 1982). Of 52 physicians recently referred to Cali-
fornia's impaired physician program, 28 percent had problems with
cocaine and 13 percent with marijuana (Buys, 1982). The present
author recently surveyed eight specialists who treat impaired
physicians, and they reported that a median of 10 percent of the
230 addicted physicians they have collectively treated were
nontherapeutically addicted.
The present article describes two case examples from a sample of
eight the author has interviewed over the past three years. Al-
though numerous case histories of therapeutically or guasi-ther-
apeutically addicted health professionals have been published,
the author know of no published case histories which purport to
describe nontherapeutically addicted health professionals. Since
there appear to be important differences between the types,
these case examples should be valuable for both clinicians and
researchers.
METHODS
The case studies stern from tape recorded, structured interviews
with an addicted dentist and nurse. Both subjects were receiving
treatment for drug addiction, one in a therapeutic community
(drug free, in-patient program) and the other on an out-patient
methadone maintenance program. The interviews covered family
background, drug use history, and consequences of addiction.
RESULTS
Case #1, The Dentist
This 29-year-old dentist began experimenting with opiates and
other drugs while taking a pharmacology course during his second
year in dental school. Fascinated with the drugs he was learning
about, he and two classmates, who were more experienced recrea-
tional drug users than he, would try the drugs (alium, metha-
qualone, barbiturates, Demerol, and codeine) they discussed in
class. Up to then, the subject had smoked marijuana daily while
in college, tried mescaline a few times, and cocaine and amphet-
mines just once each. After six months of experimentation, he
tried Percodan and immediately strongly preferred its effects
over the other drugs he had tried. By his last month of dental
school, he was taking codeine or Percodan orally (8 to 16 tablets
at a time) twice a week. On graduation, he stopped completely
until the next fall when he took a job in a very remote area
where dispensing of psychoactive medicines was not closely regu-
lated. During that winter and spring his solitary use of codeine
became more and more frequent so that he was psychologically ad-
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dicted by May and experienced physiological withdrawal symptoms
during his summer vacation. Euphoria-seeking was a major reason
for his use of opiate drugs, his drug use patterns, and his‘
drug preferences.
He remained addicted, mainly to Percodan, for the next three
years. During that period, his usual mild manner gave way to
bouts of rage in which he frequently yelled at assistants and
even abused his wife, both physically and psychologically. His
dosage escalated to as many as 25 Percodan tablets per episode.
He overdosed once, had a major automobile accident when drug in-
toxicated, and twice "nodded out" while treating patients.
He finally sought long-term treatment after pressures began to
build from all sides. At first he and his wife tried unsuccess-
fully to cope with his addiction by moving, his changing jobs
several times, seeking private psychiatric care, and then detoxi-
fying briefly in a private substance abuse hospital. On relapse,
his drug use and prescription writing became more frequent, and
soon he began having to travel long distances to obtain drugs
because local pharmacists refused to fill his prescriptions. He
also collaborated for several weeks with a street addict who had
approached him for a prescription: each day the addict would
pick up a prescription, get it filled, and return half of it to
the dentist. This episode was his only contact with street
addicts except through treatment programs; he never adopted sub-
cultural drug use patterns but admitted contemplating intravenous
injections after talking to street addicts who were fellow
patients at the drug programs. His wife left him, and his family
refused to see him. The Drug Enforcement Administration removed
his narcotics prescribing privileges, and at the urging of a
dental society representative, he entered a 28-day detoxification
Program. He quickly relapsed on release, was arrested for trying
to fill a prescription, and entered a therapeutic community
(inpatient, drug free facility) on the advice of his probation
officer. At last report he had successfully completed a year's
residence, had returned to dentistry part-time, and "graduated"
from his drug treatment program.
Case #2, The Nurse
This 30-year-old nurse began heavy recreational use of drugs
(marijuana, hallucinogens and amphetamines) as a teenager in a
lower-middle-class family. She became addicted to amphetamines.
She tried heroin and other opiates with friends at age 17, and
within two years was addicted. After several years of opiate
addiction, duringwhich she became a drug dealer and then a pro-
stitute, she was arrested for selling narcotics and was placed on
probation. Despite continued occasional (mainly weekends) opiate
use, she enrolled in a junior college, achieved top grades, and
then entered nursing school. Her opiate use increased in
frequency during her last year in nursing school (she frequently
took examinations while under the effects of heroin), so that her
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grades declined from "A'S" to "C's". As a registered nurse, she
began intravenously injecting the narcotics available to her (re-
placing opiates taken from vials with saline solution) and within
a year was addicted to Dilaudid. She would occasionally buy
street drugs from close friends. Her dosage had escalated to as
much as 36 mgs. of Dilaudid in one injection. She overdosed (in-
jecting 1,000 mg. of Demerol) in the bathroom at work, sustained
minor head injuries, and lost her job, although the director of
nursing offered to help the subject and did not report the
subject's addiction to authorities. For several weeks, the sub-
ject depended on street drugs exclusively (up to then she had
used them only on weekends when professional supplies were not
available), and then was accepted into a methadone-maintenance
program. During the last five years she worked as a nurse in
nursing homes and in a general hospital, while on methadone. She
has used illicit opiates (obtained from work or the street) only
on rare occasions when she missed her methadone dose. Recently,
she detoxified from methadone, but soon relapsed to using drugs
available at work and on the street. She is now back on
methadone.
The nurse was asked about the reasons for her opiate use:
Interviewer: Would you say that your opiate use was more a
form of recreation, or a form of self-treat-
ment for son-e sort of problem?
Subject: Recreation
Int:
Sub:
Int:
Sub:
Int:
Sub:
Int:
Were there times when you felt that you. . .
It became a self-treatment for withdrawal symptom, but
I don't really think that's what the question is
saying.
No, We're looking more for physical pain or some sort
of emotional problem--taking the drug to bring your-
self back up to some sort of par. You're talking
about taking the drug to move yourself away from some
sort of par towards more of a euphoric effect.
Yes.
Were there ever tines that you remember taking drugs
principally because you were so down you took the drug
to bring yourself back up to just a tolerable level?
There may have been times when I thought like that,
but I can't really see it being that way.
It was more of a recreational use straight through?
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Sub: Yeah.
Int: And would that have been true, that particular pattern
of recreational use, as opposed to a therapeutic use?
Did that pattern maintain from early drug taking then
moving on into when you were in a more medical pro-
fession?
Sub: Uh-huh (yes).
Int: So it was always . .
Sub: Even when I didn't have a habit I would like to go out
on a weekend and get high first. Stuff like that. We
were always into getting or obtaining drugs before
concerts or going to a club or doing something in par-
ticular. Y'know?
DISCUSSION
Interviews with these two subjects revealed several important
differences between them and opiate-addicted health professionals
described in previous studies. These subjects began using opiate
drugs recreationally with friends, after several years' heavy use
of marijuana and other nonopiate drugs. The usual addicted
health professionals began opiate use latter in life, by them-
selves, with little or no prior drug-use history, and as a means
of self-treatment rather than recreation. The dentist began
using in dental school, and the nurse had already been addicted
before entering nursing school. These patterns of initiation
were observed in other nontherapeutically addicted health pro-
fessionals, but contrast sharply with patterns described by ther-
apeutically addicted physicians and nurses who began use after
years in their professions.
Addiction adversely affected the careers of the dentist and
nurse, and almost took their lives. Despite their medical know-
ledge of dosages and the use of pure drugs, both subjects over-
dosed and had occasions in which they "nodded out" while caring
for patients. Both subjects also exparienced accidental injuries
due to being intoxicated on opiates. They explained their large
doses by their desire for deep euphoria.
Finally, the dentistandnursewere unique because they obtained
forms of drug treatment, methadone maintenance and therapeutic
community, that are popular for nontherapeutic street addicts but
not for therapeutically addicted health professionals. Perhaps
because most addicted health professionals begin opiate use as
self-treatment for medical or psychiatric problems, it is
reasonable that they seek and respond to medical detoxification
and psychiatric treatment for their drug problems. By contrast,
nontherapeutically addicted health professionals may instinctively
recognize their similarity to street addicts and therefore seek
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long-term drug treatment such as therapeutic communities,
designed to change values and lifestyles. If so, impaired health
professionals committees, who refer addicted professionals for
treatment and oversee their progress, should nowadays pay close
attention to whether the health professional was therapeutically
or nontherapeutically addicted.
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Frequency of Reinforced Practice
in the Development of Tolerance
to Alcohol
D. J. Beirness and M. Vogel-Sprott
Recent investigations have demonstrated that practice of a task
in the drug state facilitates the development of alcohol
tolerance. The present study explored the development and sub-
sequent display of tolerance as a function of the frequency of
reinforced practice under alcohol in social drinkers.
Three groups of four males each learned a complex psychomotor
task to a stable level of performance. They subsequently per-
formed either 4, 8 or 12 task trials under a moderate dose of
alcohol during each of five separate drinking sessions. During
the first four drinking sessions, Ss were reinforced for task
performance which equalled the S’s drug-free level of achieve-
ment. All Ss performed without reinforcement on the fifth
drinking session.
All groups developed tolerance, evidenced as a significant
decrease in drug-induced impairment of performance over the
first four drinking sessions. The final level of tolerance
displayed was greatest for Ss who performed 12 task trials on
each session under alcohol and least for Ss who performed only
four trials. When reinforcement was withdrawn, the amount of
impairment returned to that observed on the initial drinking
session.
These findings indicate that more frequent reinforced practice
under alcohol facilitates the rate of acquisition of tolerant
behaviour. In addition, the potent effect of reinforcement in
the display of tolerance is illustrated by the “extinction” of
tolerance when the reinforcement was withdrawn. Taken together,
the results are consistent with a learning interpretation of
tolerance.
AUTHORS' AFFILIATION: Department of Psychology, University of Waterloo,
Waterloo, Ontario, Canada
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Urinary Homovanillic Acid
Methadone Withdrawal
Frank A. DeLeon-Jones, John M. Davis, Edet E. Inwang; and
Haroutune DeKirmenjian
Homovanillic acid (HVA), the main metabolite of dopamine, was
determined in urine of long-term methadone-dependent subjects.
Two separate studies were performed. The first study was de-
signed to assess the effects of gradual methadone discontinuation
in eight subjects who received stable methadone doses ranging from
40 to 60 mgs daily per subject for a two-week stabilization period
followed by a stepwise decrease of 10 mg/week until zero dose was
reached. Ratings of withdrawal symptoms were done twice daily and
24-hour urines were collected throughout the study. The second
study was designed to assess the effects of abrupt methadone with-
drawal in fifteen long-term methadone-dependent subjects. Each
subject was stabilized on a 40 to 60 mg daily dose of methadone for
two weeks following which methadone was abruptly discontinued.
Withdrawal ratings and 24-hour urine collections were done during
the entire study period. Urine samples were also obtained from a
healthy control group. HVA levels during the stable methadone
period were not significantly different from those of healthy
controls. The gradual withdrawal study as well as the abrupt
withdrawal study showed a significant decrease in urinary levels
of HVA during withdrawal relative to the stable methadone period
and to the HVA excretion by normal controls. These data will be
discussed in comparison to the urinary excretion of MHPG, nor-
metanephrine, metanephrine and cyclic AMP by the same subjects as
well as platelet adenylate cyclase activity during stable methadone
and withdrawal by some of these subjects. Also these findings
will be discussed in relation to animal work which relates to the
role of dopamine and norepinephrine in tolerance and physical
dependence.
AUTHORS: Frank A. DeLeon-Jones, M.D., John M. Davis, M.D., Edet E.
Inwang, Ph.D., and Haroutune DeKirmenjian, Ph.D.
Veterans Administration, Medical Center, P.O. Box 8195,
Chicago, Illinois 60680
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Brain Growth and Cerebral
Ventricular Development in
Newborn Infants of Drug-
Dependent Mothers
Matthew E. Pasto, Pamela M. Foy, Leonard J. Graziani, Barry
B. Goldberg, Elizabeth D. Leifer, and Loretta P. Finnegan
Various investigators have been concerned about the incidence and
severity of neonatal abstinence. Clinical symptomatology and its
management have been evaluated. However, despite concerns and con-
tinued queries about the pathophysiology of the syndrome, few
studies have evaluated the effects of maternal prenatal drug in-
take on the developing brain. One investigator (Tenner, 1976) has
documented abnormalities in the ventricular systems of children of
drug-dependent women. Tenner reported compression of the cerebral
lateral ventricles in an a-mode ultrasound study of passively
addicted and symptomatic neonates. However, no control subjects
were evaluated. Left ventricular compression, with the third ven-
tricle shifted to the right, was found more commonly than right or
bilateral compression. In a limited followup study, the ventricles
remained small in some infants for as long as 2 to 14 weeks. The
cause of the compressed ventricles was undetermined, but the
authors conjectured that cerebral edema might be responsible.
Few investigators of perinatal addiction have utilized objective
measures, particularly due to the lack of methodology and the nature
of the subjects. Therefore, ultrasound methodology was considered
and chosen with attention to the relative risks and benefits to the
newborn. The American Institute of Ultrasound Medicine has cate-
gorically stated that there have been no independently proven harmful
effects of ultrasound intensities of 100 mW/CM2. The high resolu-
tion 5 megahertz scanner in use in the present study has an inten-
sity rating of 16 mW/CM2. The only contact with the infant is the
transducer and ultrasonic coupling gel or mineral oil applied to
the baby’s head. There is no need to exert pressure on the head
nor restrain the infant. Many times the scanning can take place
while the infant is feeding or sleeping. Because the equipment is
portable and the transducer is hand held, the examination can be
performed in the nursery without removing the infant from the crib
or isolette. Therefore, benefits obtained by the study are derived
at minimal risk.
The ATL Mark 100 sector scanner is a high resolution real-time
scanner that enables us to scan through the fontanel and sutures
and obtain detailed visualization of the brain. Since we are able
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to scan through the fontanels we can see the lateral ventricles
in the coronel scanning plane as well as the parasaggital scanning
plane by turning the transducer 90 degrees to the coronal plane.
The only limitation to scanning is the naturally occurring closure
of the anterior fontanel in the mid to late first year of life. The
brain is imaged through the anterior fontanel with a 90 degree sector
field of view. Ultrasound visualizes changes in tissue texture and
tissue boundaries. Hence, the cerebral sulci are very well seen in
the interhemispheric fissure. The margin of the lateral ventricles
and the superior margin of the corpus callosum are well defined.
The Sylvian fissures can be seen laterally on either side. Also,
because the examination is real time, arterial pulsations can be
visualized in both branches of the anterior cerebral arteries in
the interhemispheric fissure. Figure 1 is a parasagittal scan
of a lateral ventricle, demonstrating the frontal horn and the
body and atrial regions. The choroid plexus can be seen lying
on the floor of the body of the lateral ventricle and extending
along the posterior aspect of the thalamus within the atrium.
Figure 2 demonstrates a normal coronal scan through the region of the
ventricular atria. Cerebrospinal fluid (CSF) is seen as very black
areas surrounding the choroid plexus, which is draped around the
posterior margins of the thalami.
The infants studied were born to women maintained on methadone and
enrolled in the Family Center Program in Philadelphia, a multi-
modality program encompassing medical and psychosocial services for
pregnant and post-partum drug-dependent women and their children.
In addition, a group of infants born to drug-free mothers, of simi-
lar medical and socioeconomic status, are included in our evaluation
as a comparison group.
An initial group of 24 study infants and 22 controls have been
evaluated. Study and control infants were comparable for birth
weight, gestational age, apgar scores, sex, race and socioeconomic
status. All infants were full-term and healthy, except for absti-
nence for which 19 of the 24 study infants were treated.
Symptoms of abstinence manifested in our study population included:
tremors, increased muscle tone, hyperactive moro reflex, fever,
excoriation, nasal stuffiness and high pitched cry. Although
mothers of the study infants were on methadone maintenance, with
an average daily dose of 44 mg, almost all of the mothers utilized
various quantities of heroin, diazepam or amphetamines at least
once during their pregnancies. To date, 136 ultrasound studies
have been accomplished on the 46 infants, with examinations sched-
uled for 24 and 72 hours, with followups at 1, 2 and 6 months of age.
Results
In the study and control infants, the ultrasound examinations demon-
strated no evidence of hemorrhage or congenital abnormalities of the
brain structure and pulsations were normal. The echo-texture of the
white matter in the basal ganglia appeared normal in comparison to
controls. The interesting finding, in the drug-exposed infants,
was the very small size of the lateral ventricles at 24 and 72 hours
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of age. Specifically, the finding is lack of visualization of fluid
space within the lateral ventricles, or, at most, a very small amount
of fluid near the choroid plexus, giving the appearance of slit-like
ventricles. Figure 3 shows a parasagittal scan through the lateral
ventricles of another study infant. The lateral-ventricles, how-
ever, are poorly identified due to the lack of fluid within as con-
trasted to Figure 2 in which the ventricles are clearly identified
in a control infant, Figure 4 shows the coronal scanning in the
region of the atria in a study infant. The choroid plexes are well
seen, but there is no fluid space around them (compared to Figure 1
where a fluid space can be clearly seen).
This occurrence of slit-like ventricles (Table 1) was visualized at
24 hours in seventeen out of nineteen infants prenatally exposed to
drugs, whereas only 3 out of 21 control infants had any indication
of decreased ventricular size. The pattern follows through for the
scans accomplished at 72 hours and 1 month. By 2 months, however,
half of the drug-exposed infants studied at that age had ventricles
of normal size, and by 6 months of age only 3 out of 11 infants seen
still had smaller than normal ventricles. There was no association
between these findings and treatment status or dose of methadone.
In summary, ultrasound studies have revealed very small to slit-like
ventricles in almost all of the passively addicted neonates evalua-
ted, up to one month of age, with resolution to normal size, usually
by six months of age.
Table 1
Ventricular configuration of infants born to drug-dependent women
vs control infants
Age Ventricles Drug-Exposed Control
24 hours Slit-like 17 3
Normal 2 18
(p < .001)
72 hours
1 month
Slit-like
Normal
Slit-like
Norma1
20
--
13
3
--
18 (p < .001)
--
(p < .001)11
2 months Slit-like 6 *
Normal 7** *
6 months Slit-like 3 --
Normal 9 6
*Ultrasound studies were not accomplished at 2 months on controls,
**One of these infants had “normal” size ventricles but exhibited
evidence of brain atrophy.
Discussion
Slit-like ventricles may be secondary to diffuse compression of the
ventricles bilaterally, as may occur with generalized cerebral
edema. However, the pathogenesis remains in question. One might
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expect to see some dampening of the arterial pulsations within
the cranium if increased intracranial pressure is indeed present,
However, there has not yet been any consistent evidence of de-
creased pulsations. The possibility of edema localized to the
periventricular regions cannot be excluded. A localized process
adjacent to the ependymal surface, or involving the ependyma,
might produce the ultrasound images noted in this study. The peri
ventricular brain substance and ependymal lining do not contain
pain receptors so that intracranial discomfort is unlikely in the
absence of generalized increased pressure. Developmental abnor-
malities of the ventricular system and ependymal adhesions are not
indicated since the size of the lateral ventricles returns to normal
generally by six months of age. Decreased cerebrospinal fluid
production in the study infants, although a possible cause of slit-
like ventricles, should not result in a decreased volume unless
bulk absorption of CSF is inexplicably increased or unless CSF pro-
duction is virtually absent. Thus further studies, including
measurements of brain pressure and cerebrospinal fluid production,
are indicated. In addition, animal studies could provide infor-
mation on the pathophysiology of the ventricular findings, parti-
cularly related to CSF fluid balance.
It has been reported in many studies (Finnegan, 1978) that symptoms
of neonatal abstinence can appear shortly after birth and
usually within 2 days after birth in infants born to drug-dependent
women. It has also been noted that symptoms, including signs of
central nervous system irritability, are frequently manifested for
as long as four to six months after birth, even after extended
treatment in a hospital setting. In addition to the finding of
slit-like ventricles in almost all of the drug-exposed infants, we
have been able to obtain an ultrasound scan of a fetal brain (Fig. 5)
two weeks prepartally, for one of our subjects. The lateral ventri-
cles appeared to be completely normal. This same study infant mani-
fested slit-like ventricles by 24 hours of age. Therefore, ventri-
cular size seems to correlate with the onset and remission of the
neonatal abstinence syndrome. In conclusion, the slit-like
ventricles identified in infants born to drug dependent women
appear to be a manifestation of the neonatal abstinence syndrome.
The present study does not reveal an increased incidence of brain
abnormalities in these infants when compared to control infants.
References
Finnegan, L.P. (ed.) Drug dependence in pregnancy: Clinical manage-
ment of mother and child. A manual for medical professionals and
paraprofessionals prepared for the National Institute on Drug Abuse,
Services Research Branch, Rockville, Maryland, 1978. U.S. Govern-
ment Printing Office, Washington, DC.
Tenner M, Wodraska G, Montesineos C, Ultrasonic Evaluation of the
lateral ventricles in addicts, their children and neonates: Preli-
minary findings, in Ford DH, Clonet DH: Tissue Responses to Addic-
tive Drugs. Spectrum Pub., Inc.; New York 1976, pp. 641-651.
368
FIGURE 1. This is a parasagittal long axis view of the lateral
ventricles in a normal child. The arrows denote the extension of
the lateral cerebral ventricle. T represents the thalamus and C
represents the choroid plexus.
FIGURE 2. This is a coronal scan through the atria1 regions of the
lateral ventricles in a normal child. The arrows outline the ex-
tent of the fluid within the atria of the lateral ventricles. C
represents the choroid plexus.
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FIGURE 3. Parasagittal scan in a study infant. X’s mark the
position of the lateral ventricle, which cannot be identified.
T represents the thalamus and C represents the choroid plexus.
FIGURE 4. This is a coronal scan through the atria of a study
infant. X’s mark the position of the lateral ventricle, which
cannot be identified because of a lack of fluid within it. C
represents the choroid plexus.
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FIGURE 5. This is a parasagittal scan of a fetal head. B repre-
sents the mother's bladder, T represents the thalamus. The arrows
outline the lateral cerebral ventricle.
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Nicotine as a Punisher: Effects of
Chlordiazepoxide and
Mecamylamine on Responding
Suppressed by Intravenous
Nicotine Injections or by
Electric Shocks
Steven R. Goldberg and Roger D. Spealman
ABSTRACT
Squirrel monkeys responded under a two-component
fixed-ratio schedule of food presentation with both
nonpunishment and punishment components. In both com-
ponents of the multiple schedule, every 30th key-
pressing response resulted in food presentation. In
the punishment component, the first response in each
30-response fixed ratio also produced either an i.v.
injection of nicotine (10 TO 30 µG/KG) or an electric
shock (1 to 5 ma). Response-produced nicotine in-
jections or electric shocks functioned similarly to
suppress responding by over 70% in the punishment com-
ponent. Presession treatment with chlordiazepoxide
(5.6 to 10 mg/kg, i.m.) markedly increased responding
that had been suppressed by either nicotine injection
or electric shock. In contrast, presession treatment
with the nicotinic antagonist, mecamylamine (0.1 to
0.3 mg/kg i.m.) increased responding that had been
suppressed by nicotine injection but did not increase
responding that had been suppressed by electric shock.
Thus, chlordiazepoxide appeared to have general rate-
increasing effects on suppressed responding, regardless
of the nature of the event suppressing responding,
while mecamylamine appeared to selectively antagonize
the suppressant effects of nicotine. Doses of chlor-
diazepoxide and mecamylamine that increased suppressed
responding in punishment components, generally had
little effect on responding in nonpunishment components
These results show that under suitable environmental
conditions response-produced i.v. injection of nicotine
can function effectively as a punisher.
AUTHORS: Steven R. Goldberg, Ph.D., National Institute on Drug Abuse,
Addiction Research Center. Baltimore, Maryland
Roger D. Spealman, Ph.D., Harvard Medicai-School, New England
Regional Primate Research Center, Southborough, Massachusetts
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A Comparison of Bupropion and
Amphetamine for Abuse Liability
John D. Griffith, Jose Carranza, C. Griffith, and Loren Miller
ABSTRACT:
Bupropion (± -tert-meta-chloro-propiophenone; Wellbatrin;
Burroughs Wellcome Company), is a substituted
phenethylamine which has been shown in clinical trials to
be an effective antidepressant. That bupropion might have
amphetamine-like abuse potential was suggested by
pharmacological studies (drug discrimination in the rat;
monkey self - administration) as well as the structural
similarity of bupriopion to amphetamine and certain
hallucinogenic substances. For this reason, bupropion was
examined for abuse potential among 13 healthy informed
male inpatient volunteers with histories of psychostimulant
abuse. Subjects were given bupropion (100, 200 and 400
mg), d-amphetamine (15 and 30 mg) or placebo at intervals
of not less than 4 days according to a double-blind,
randomly assigned, crossover design. Drugs were
administered orally at 8:00 a.m. Subjects fasted 8 hours
before drug administration and 5 hours afterwards.
Bupropion, unlike amphetamine, had no significant effect
on supine blood pressure, pulse rate, respiration rate,
temperature, appetite, caloric intake or sleep. "Liking"
scores for bupropion did not differ from placebo, and
bupropion was most often identified as "Blank" (Single
Dose Questionnaire). ARCI Subscales (A, BG, MBG, PCAG,
LSD) for bupropion resembled those produced by the
placebo condition whereas amphetamine was typically
amphetamine-like. These findings suggest that bupropion is
unlikely to become an amphetamine-like abuse substance.
AUTHORS: John D. Griffith, M.D.; Jose Carranza, M.D.: C. Griffith, LL.B.
Department of Psychiatry, Taylor College of Medicine, Houston, TX
Loren Miller, Ph.D., Burroughs Wellcome
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The Role of Feedback in the
Development of Alcohol Tolerance
in Psychomotor Performance
J. V. Hill-Flewelling and M. Vogel-Sprott
Twelve male social drinkers, aged 20 to 25, were trained on the
Stressalyser, a complex psychomotor task, until a stable level
of performance was attained. Half of the subjects were trained
with feedback in the form of knowledge of results; the other half
did not receive any information regarding their performance.
Subjects receiving feedback attained a stable level of perfor-
mance more quickly, and became more skilled on the Stressalyser,
with respect to speed of performance, than subjects who were not
given feedback.
Subjects were then tested on the task under a low dose of alcohol
(0.88 ml 94.6 percent alcohol/kg), repeated over four separate
sessions. Alcohol impaired performance, but the degree of im-
pairment in the two groups did not differ on any of the drinking
sessions, and did not change over sessions.
Although there was no significant development of tolerance (i.e.,
diminished impairment) over drinking sessions as a function of
feedback, half of the subjects in the Feedback group actually
displayed less impairment by the final drinking session. This
suggests that feedback may have some effect on the development of
tolerance to alcohol on this psychomotor task, but it may have
been too “weak”, or may need to be supplemented with some incen-
tive.
AUTHORS: J. V. Hill-Flewelling, M.A.Sc., and M. Vogel-Sprott, Ph.D.
Department of Psychology, University of Waterloo
Waterloo, Ontario, Canada N2L 3G1
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Kinetics of Erythrocyte Rosette
Formation With T Lymphocytes
From Drug-Addicted Subjects
J. J. Madden, R. M. Donahoe, I. E. Smith,, D. C. Eltzroth,
F. Hollingsworth, A. Falek, P. J. Bokos, and D. Shafer
Heroin addicts prior to any involvement in methadone therapy
(McDonough et al., 1980 & 1981) have a significant decrease
in their percent of circulating T lymphocytes as judged by the
sheep erythrocyte (E) rosette assay. This E-rosette depression
becomes on average n-ore severe the longer the addict uses street
opiates (Fig. 1). Addicts in a methadone therapy program
(Interventions) generally recover E-rosette capacity within a
few months of the start of therapy (Fig. 2).,. although a few
clients still show a significant T lymphocyte depression after
several years of methadone use. These results are consistent
with the findings that heroin addiction decreases mitogen-
stimulated lymphocyte division. Patterns of mitogen stimulation
in lymphocytes from ten methadone clients produced inconsistent
results compared to pre-methadone, mitogen-stimulated
replication (Brown et al., 1974).
The rates of E-rosette formation by lymphocytes from street
opiate addicts, methadone clients, pregnant Women who use
alcohol, and matched controls for each group were analyzed
(Fig. 3 and 4). In controls, the rate of E-rosette formation is
best represented by a biphasic curve including a rapid initial
rate period of 2-60 minutes in which up to 90% of the rosettes
formed, and a slow overnight phase during which rosette formation
reached the value reported as total rosettes (Fig. 3). On the
other hand, heroin addicts have lower mean percents in both the
initial and slow phases of rosette formation. (Fig. 3) However,
the kinetic initial rates for addicts and controls were identical
after normalization to equalize the differences in the number of
lymphocytes with available receptors for sheep erythrocytes
present at the start of the assay (Fig. 5). In the case of the
methadone clients, the initial rate is briefly slower than
control but at 32 min catches up and mimics the control values
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Figure 1. Effect of length of street opiate use on
% circulating E-rosette forming lymphocytes. E-rosette
capacity of 58 opiate addicts was determined as in
McDonough et al. (1980). The control matched group
has a mean % E-rosette of 72.7 ± 9.6.
thereafter (Fig. 3). From the initial rate measurements, it
would appear that one effect of opiate use is a reduction in
the number of T lymphocytes and not an alteration of their
avidity for sheep erythrocytes.
We also found that lymphocytes from pregnant ethanol users formed
rosettes very rapidly, reaching total rosette formation in as
little as 10-15 minutes as compared to the hours required by
lymphocytes from matched pregnant controls (Fig. 4). In fact,
the non-pregnant control group (all ethanol users) and heroin
addict group (11 of 13 drank) had initial rates of rosette
formation identical to that of the pregnant ethanol users. The
methadone group was somewhat slower (only 4 of 10 patients drank),
while the non-drinking pregnant controls were slowest of all
(Fig 5).
In conclusion, heroin addicts had a reduced percent of
T lymphocytes as defined by the capacitytorosette sheep
erythrocytes. The avidity of their T lymphocytes for sheep
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Figure 2. effect of methadone therapy on % circulating
E-rosette forming lymphocytes. Lymphocytes from 34
methadone clients were tested for E-rosette capacity
Figure 3. Rate of E-rosette formation by lymphocytes from
13 heroin addicts, 10 methadone clients and 6 matched
controls. Lymphocytes and sheep erythrocytes (1:50 ratio)
were mixed. incubated at 37°C for 5 min. and centrifuged
for 20 sec. at 2000 x g. The rosetting process was stopped
by resuspension of the pellet at specific times measured
from the start of centrifugation. Rosettes and free
lymphocytes were stained with methylene blue and counted at
400 x. each time point was prepared in triplicate and 100
lymphocytes were evaluated per replicate.
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Figure 4. Rate of E-rosette formation by lymphocytes
from 11 pregnant women who drink ethanol and 10 matched,
pregnant, non-drinking controls.
erythrocytes was comparable to that of control T lymphocytes
as judged by kinetic initial rate measurerments. This finding
suggests that heroin may affect the quantity rather than the
quality of the T lymphocytes. Ethanol, on the other hand,
appears to increase the initial rate of E-rosette formation in
all populations studied, implying a qualitative alteration of
the lymphocyte surface. Interestingly, methionine-enkephalin
has also been shmown to increase formation of "active" rosettes
Wybran et al. 1979). In view of the findings of Hiller
et al. (1981), that ethanol inhibits the binding of
D-Ala2-D-Leu5-enkephalin to the rat brain delta receptor, we
speculate that ethanol and enkephalin act at similar sites on
the T lymphocyte, increasing lymphocyte rosette capacity.
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Figure 5. The initial rate of E-rosette formation
(as a function of the decrease in free E-rosette positive
cells) for controls, heroin addicts, methadone clients,
pregnant alcohol users, and pregnant non-drinkers was
plotted versus reaction time. The % non-rosetted (free)
E-rosette positive cells was calculated from the formula:
100% - (Normalized % E-rosettes). The Normalized
% E-rosettes was obtained by normalizing the % E-rosettes
for each time point to the overnight value (total) which
was set equal to 100%.
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Analgetic Potentiation by
Nalbuphine/Acetaminophen and
Nalbuphine/Aspirin Combinations
W. K. Schmidt, W. Galbraith, and V. G. Vernier
ABSTRACT
Oral combinations of nalbuphine with aspirin or acetaminophen
demonstrate a significant analgetic potentiation in mice, but
only acetaminophen potentiates nalbuphine’s narcotic antagonist
activity. Using Loewe’s isobolographic method, nalbuphine/
acetaminophen combinations demonstrate as much as 115% greater than
expected analgetic activity in the mouse antiphenylquinone writhing
test. The greatest potentiation occurs at 5 min after oral co-
administration, corresponding to the analgetic peak-effect times
for each drug alone. Less, but still significant potentiation is
observed at 10 and 40 min. In contrast, nalbuphine and aspirin
demonstrate peak potentiating activity (62-80%) at 20-80 min after
oral co-administration, corresponding to the peak effect time of
the aspirin component.
Since nalbuphine, acetaminophen, and aspirin share several common
metabolic pathways, we hypothesized that a pharmacokinetic/metabolic
alteration could explain a portion of the observed potentiation.
However, administration of nalbuphine by the s.c. route to avoid
its first-pass metabolism reduces its potentiation with acetamin-
ophen (given orally) only slightly. In the mouse anti-Straub tail
test, a measure of narcotic antagonist activity where aspirin and
acetaminophen are inactive at doses as high as 800 mg/kg p.o.,
acetaminophen potentiates nalbuphine’s oral narcotic antagonist
activity up to 2.4X. In support of the pharmacokinetic/metabolic
hypothesis, oral acetaminophen does not potentiate s.c. nalbuphine’s
antagonist activity. A quantitative comparison indicates that a
metabolic effect may account for 30% of the observed 115% maximum
oral analgetic potentiation, but none of the 90% analgetic poten-
tiation when nalbuphine is administered parenterally. In contrast,
aspirin does not potentiate nalbuphine’s oral narcotic antagonist
activity and oral nalbuphine does not potentiate aspirin’s
arachidonate lethality protection activity (an in vivo measure of
aspirin’s prostaglandin synthetase inhibitory activity). Thus a
pharmacokinetic/metabolic interaction is not likely to be
important in the nalbuphine/aspirin analgetic potentiation.
We conclude that pharmacodynamic factors involving independent/
covergent analgetic pathways are of a greater importance than
pharmacokinetic/metabolic factors in nalbuphine’s analgetic
potentiation with aspirin and acetaminophen.
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FIG. 1. Isobologram for the interaction of oral nalbuphine and
acetaminophen. Using Loewe's isobolographic method, oral combina-
tions of nalbuphine and acetaminophen demonstrate analgetic
potentiation in the mouse antiphenylquinone writhing (PQW) test.
Analgetic potentiation is indicated by a significant difference
(P< 0.05) between the ED50 Addition Line and the ED50 Regression
Line. Data are obtained at 5 min, corresponding to the individ-
ual oral analgetic peak effect times for nalbuphine and acetamin-
ophen. Similar data are obtained with s.c. nalbuphine and oral
acetaminophen.
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FIG. 2. Dose ration/potentiation analysis: nalbuphine and
acetaminophen. Using the data in Fig. 1, oral combinations of
nalbuphine and acetaminophen demonstrate as much as 115% analgetic
potentiation at 5 min after oral dosing. Significant but lower
potentiation is observed at 10 and 40 min.
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FIG. 3. Isobologram for the interaction of oral nalbuphine and
aspirin. Oral combinations of nalbuphine and aspirin demonstrate
significant (P< 0.05) analgetic potentiation in the mouse PQW
test. Data are obtained at 20 min, which is intermediate between
the individual peak effect times for oral nalbuphine (5 min) and
aspirin (40-80 min).
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FIG. 4. Dose ratio/potentiation analysis: nalbuphine and
aspirin. Using the data in Fig. 3, and similar data at other
time periods, oral combinations of nalbuphine and aspirin
demonstrate as much as 60-80% analgetic potentiation in the
mouse PQW test. Peak potentiation is observed at 20-80 min,
corresponding to the peak effect time for aspirin alone.
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FIG. 5. Mouse anti-Straub tail test: nalbuphine and
acetaminophen. Co-administration of oral acetaminophen and oral
nalbuphine potentiates nalbuphine's narcotic antagonist activity
as much as 2.4X in the mouse anti-Straub tail (AST) test.
Acetaminophen alone is inactive in this test. However, a 1:31.4
ratio of nalbuphine:acetaminophen produces only 30% narcotic
antagonist potentiation, in contrast to the peak 115% analgetic
potentiation-demonstrated by the same ratio in the mouse PQW
test. No antagonist potentiation is observed when nalbuphine is
administered s.c.
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FIG. 6. Mouse anti-Straub tail test: nalbuphine and aspirin.
In contrast to acetaminophen, similar doses of aspirin do not
potentiate nalbuphine’s oral narcotic antagonist activity.
FIG. 7. Mouse arachidonate lethality protection test: nalbuphine
and aspirin. The arachidonate lethality protection test is an
in vivo measure of prostaglandin synthetase inhibitory activity.
Mice dosed i.v. with 70 mg/kg sodium arachidonate, pH 8.5, die
in respiratroy arrest within 2-5 min in the absence of aspirin
or other prostaglandin synthetase inhibitors. Oral nalbuphine
does not potentiate aspirin’s in vivo prostaglandin synthetase
inhibitory activity; nalbuphine alone is inactive.
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CONCLUSIONS
Oral combinations of nalbuphine with acetaminophen or aspirin
demonstrate a suprising degree of analgetic potentiation in
the mouse. The time course for this potentiation is evidently
dependent on the peak analgetic effect time of the non-narcotic
analgesic in the mixture.
Pharmacodynamic factors involving independent/convergent analgetic
pathways are of a greater importance than pharmacokinetic/
metabolic factors in nalbuphine's analgetic potentiation with
aspirin or acetaminophen, resulting in significantly enhanced
analgetic effects without enhanced side effects.
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Biological Evaluation of
Compounds for Their
Dependence LiabiIity
\/I. Drug Testing Program of the
Committee on Problems of Drug
Dependence, Inc. (1982)
A. E. Jacobson
The individual Annual Reports from the Medical College of Virginia
(MCV) by Drs. Aceto, Harris and May (Aceto et al. 1982), and from
the University of Michigan (UM) by Drs. Woods, Katz, Medzihradsky,
Smith, and Winger (Woods et al. 1982) to the Committee on Problems
of Drug Dependence (CPDD) are somewhat larger than usual due to the
record number of compounds submitted and examined in 1980-1981, and
released this year. The Committee is indebted to the groups led by
Drs. Harris and Woods for their work which presently represents a
considerable part of the utility of the Committee and its public
recognition.
The biological testing groups, UM, MCV and NIH, held a few joint
meetings last year. One notable meeting was held in the Parklawn
Building, where NIDA representatives joined us in considerable
number. Dr. Brady’s group, from Johns Hopkins, also joined with us
on that occasion, and all groups presented an overview of their work.
Collaboration between MCV, UM and NIH has, also, resulted in the
publication of our first joint paper, on Zomepirac (Woods et al.
1982). Other papers are being scheduled for publication.
COMPOUNDS RECEIVED UNDER THE AUSPICES OF THE CPDD
The same “evaluation year”, from May 1 to April 30, was utilized in
this report as in my previous reports (Jacobson 1982). In table 1 I
have compared data from four years. Thus, it can be seen that the
nunber of compounds sent to MCV/UM ranged between 54 in 1978-1979 and
148 in 1980-1981. The present “evaluation year”, 1981-1982, saw
about the same number of compounds submitted to our testing groups as
in 1979-1980. However, a higher proportion of compounds were
submitted in 1981-1982 for examination in tests other than single
dose suppression (SDS). About the same number of compounds were
submitted for SDS in 1981-1982 as in 1978-1979, down considerably
from the nunber submitted in the intervening two years. The only new
record set this year was in the number of reports included in the
individual Annual Reports from MCV/UM.
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SOURCES OF NEW COMPOUNDS
Comparison of the sources of submitted compounds over the past four
“evaluation years” illustrates the inconsistency of these sources.
U. S. industry submitted 41% of our samples in 1979-1980, and 8% this
year. We can see, in table 1, a considerable reduction in the number
of compounds submitted by U. S. industry over the past three years.
Spectacularly, foreign industrial sources have reached zero. We will
receive at least some of our samples from foreign industries next
year, however. The largest number of compounds came from U. S.
universities and the National Institutes of Health (NIH). We
received 75% of our compounds from the latter two sources in
1981-1982. The number of samples from U. S. universities, on the
decline over the past few years, has seen a resurgence this year.
TABLE 1 - DRUG STATISTICS
TYPES OF COMPOUNDS EXAMINED
In tables 2 through 12 I have compiled the structures of the
compounds reported on this year, in a classical medicinal chemistry
manner. Thus, there are seventeen epoxymorphinans in tables 2 and 3,
twenty morphinans in tables 4 and 5, nine benzomorphans in table 6,
ten C-homobenzomorphans in table 7, thirteen phenylmorphans in table
8, five phenylpiperidines in table 9, and five peptides in table 10.
Tables 11 and 12 contain fifteen miscellaneous compounds which are
not easily classified. All of the compounds which showed
antinociceptive activity have at least one aromatic ring and a
nitrogen atom. The nitrogen atom can be observed to be either
primary, secondary or tertiary in nature, although tertiary amines
still predominate. Perhaps one day in the future a better
classification scheme will be promulgated based on a compound’s
primary activity on mu, delta, kappa, or sigma (et al.) opiate
receptors, or on a profile based on the ability of specific
390
antagonists to antagonize the compound’s xtions in the electrically
stimulated guinea pig ileum and mouse vas deferens preparations. The
ability of a classical narcotic antagonist, like naltrexone, to
antagonize the action of some of these compounds in the guinea pig
ileum, but not in the vas deferens, or vice versa, and occasionally
the inability of naltrexone to antagonize a compound’s action in
either preparation is worthy of further study and correlation with
other biological parameters (via self-administration and rat infusion
studies). It might be worthwhile to examine some of the compounds in
man which have interesting profiles from our classical tests and
which also show unusual patterns of biochemical behavior in order to
try to relate these biochemical differences to analgesia, dependence
liability, etc.
It can be noted, in the various tables, that we tested compounds with
some unusual structures and compounds with familiar structures which
had unusual substituents. As examples of the latter, epoxymorphinans
9651, 9939, 9787, and 9874, in table 2, are structurally classical
antagonists which are C-6 fluorinated. Some of them show potent
antinociceptive activity in the phenylquinone (PPQ) assay, but not in
other antinociceptive assays. The tailflick antagonist assay vs.
morphine (TFA) indicates their narcotic antagonist nature, which is
corroborated by their precipitation of abstinence in non-withdrawn
rhesus monkeys (PW) . NIH 9651 is efficacious in the guinea pig ileum
(gpi) preparation, but its effect is not antagonized by naltrexone.
Others of these fluorinated compounds have little or no effect in the
vas deferens (vd) preparation.
Benzomorphan 9807, which has a phenoxypropyl side-chain on nitrogen,
did not substitute for morphine in SDS and precipitated withdrawal in
non-withdrawn monkeys (table 6). It binds quite well to opiate
receptors from rat cerebrum membrane preparations and interacts less
well with receptors in the gpi and the vd. The antagonism of its
actions by naltrexone in smooth muscle would indicate that it is
morphine-like. Indeed, NIH 9807 completely suppressed morphine’s
action in rat infusion (RI) studies, in agreement with the data from
smooth muscle.
The homobenzomorphans, in table 7, generally failed to interact with
the opiate receptors from rat cerebrum membrane or smooth muscle
preparations. Some had limited antinociceptive activity in the hot
plate (HP) and tailflick (TF) assays, but almost all had reasonable
activity in the PPQ assay. However, their predominant
pharmacological effect in the monkey seemed to be ataxia.
A considerable number of phenylmorphans were examined this year
(table 8). Rat infusion studies and smooth muscle data were in
agreement about the morphine-like character of NIH 9889. Some of the
phenylmorphans were active in the TFA assay and precipitated
withdrawal in PW in monkeys.
All of the peptides which were examined (table 10) were essentially
morphine-like as antinociceptives, and all completely suppressed
withdrawal in SDS. The effects of NIH 9791 on smooth muscle
preparations were antagonized by naltrexone, and it was found to be
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morphine-like by RI, also. However, that compound, and perhaps other
peptides, had reduced reinforcing efficacy in self-injection (SA)
studies, as compared with codeine.
Lastly, another extremely potent narcotic was examined at the DEA’s
request, p-fluorofentanyl (NIH 10022). This compound was,
presumably, synthesized in clandestine California laboratories.
Detailed information on all of the compounds listed in these tables
is given in the MCV - UM Annual Reports.
ABBREVIATIONS USED IN TABLES
Antinociceptive ED50 values - HP = hot plate assay, sc injection,
mice; N = Nilsen assay, sc, mice; PPQ = phenylquinone assay, sc,
mice; TF = tail flick assay, sc, mice; TFA = tail-flick antagonism
vs. morphine, sc, mice. I = inactive, without a reasonable
dose-response relationship, or insufficiently active for statistical
analysis; TOX = toxicity precludes assay.
Receptor binding affinities: RBH = binding affinity, without sodium,
to rat cerebrum membrane preparations, in nM (parenthesized number is
ratio of +Na/-Na) [NOTE: binding affinity of morphine = 60.2 (2.36)
except where starred (*). Starred values should be compared with
more recent value of binding affinity of morphine = 14.0 (1.69)]. NE
= no effect. Smooth muscle preparations: GPI = electrically
stimulated guinea pig ileum EC50 values. E = x10; parenthesized
numbers are maximum percent inhibition at EC50; bracketed letters: A
= antagonized by naltrexone, NA = not antagonized by naltrexone. NE
= no inhibition of twitch. VD = electrically stimulated vas deferens
EC50 values. Parenthesized numbers and bracketed letters are as
listed under GPI.
SDS = single dose suppression, rhesus monkeys: NS = no suppression,
CS = complete suppression, PS = partial suppression. Parenthesized
numbers = dose range studied. Potency comparison with morphine [M]
may be stated, in brackets.
NW = studies in non-withdrawn monkeys: PW = precipitated withdrawal
at dose levels indicated in parentheses &/or potency comparison with
naloxone [N], in brackets; NE = no effect.
O T H E R : RI = rat infusion; NS = no suppression, CS = complete
suppression, Little SUBS = little substitution, PS = partial
suppression. PPD = primary physical dependence. SA =
self-administration; NE = no effect, HIGH = codeine-like.
The numbers used in the tables are rounded. For precise values, and
details of the procedures, see the Annual Reports of MCV (Aceto et
al. 1982) and UM (Woods et al. 1982).
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TABLE 2 - EPOXYMORPHINANSa,b
TABLE 3 - EPOXYMORPHINANS (CONTINUED)a,b
393
TABLE 4 - MORPHINANSa,b
TABLE 5 - MORPHINANS (CONTINUED)a,b
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TABLE 6 - BENZOMORPHANSa
TABLE 7 - C-HOMOBENZOMORPHANS
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TABLE 8 - PHENYLMORPHANS
TABLE 9 - 4-PHENYLPIPERIDINES
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TABLE 10 - PEPTIDES
TABLE 11 - MISCELLANEOUS
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TABLE 12 - MISCELLANEOUS (CONTINUED)
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Dependence Studies of New
Compounds in the Rhesus
Monkey, Rat, and Mouse (1982)
M. D. Aceto, L. S. Harris, and E. L. May
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All the test drugs were supplied by Dr. Arthur Jacobson, Medici-
nal Chemistry Section, NIADDK under the auspices of the Commit-
tee on Problems of Drug Dependence, Inc. The chemical struc-
tures of the test compounds excluding SKF 10,047 and (+)-Nicotine
were unknown to us when they were originally submitted.
For the most part, the procedures described by Seevers and his
colleagues (1936, 1963) and Deneau (1956) regarding the facili-
ties and training of the monkeys were used and a brief descrip-
tion follows. The monkeys were injected with 3 mg/kg/sc of
morphine sulfate every 6 hours for at least 90 days before being
used. This dose schedule was reported by Seevers and Deneau
(1963) to produce maximal physical dependence.
Modified procedures for the precipitated withdrawal (PPt-W) and
single dose suppression (SDS) tests were reported by Aceto and
co-workers (1977 and 1978). The PPt-W test was initiated by the
*This study was supported by a contract (#271-81-3830) from the
National Institute on Drug Abuse, Dr. Heinz Sorer, Contract
Officer.
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injection of a test drug 2% hours after an injection of morphine,
and the animals were observed for signs of withdrawal. The SDS
test was started approximately 15 hours after the last dose of
morphine at which time the animals were showing withdrawal signs.
The onset and duration of action of the test drug were noted.
In both tests, a vehicle control and an appropriate positive con-
trol [naloxone 0.05 mg/kg or morphine sulfate 3.0 (mg/kg)] along
with 3 different treatments (doses) of a test compound were ran-
domly allocated to the 5 monkeys of a group. Occasionally 4 mon-
keys comprised a group and 2 doses of test compound were studied.
Usually, 3 or 4 groups per compound were used. All drugs were
given subcutaneously or intravenously (1 ml/kg) and the vehicle
used is indicated for each compound. The observer was "blind"
with regard to the treatment given. A minimum 2-week washout
and recuperation period between tests was allowed. In the pri-
mary physical dependence (PPD) test, the animals of a group re-
ceived the drug every 4-6 hours for 30-50 days. They were placed
in abrupt withdrawal and challenged with naloxone periodically,
and were observed for signs of physical dependence. All potency
estimates are rough approximations only.
The rat-infusion method was reported by Teiger (1974) and certain
modifications are indicated below. Semi-restrained male, Sprague-
Dawley rats were medicated by continuous infusion through in-
dwelling, intraperitoneal cannula for 6 days with the drugs.
Rats were anesthetized and each was fitted with a specially pre-
pared cannula which was passed subcutaneously from the nape of
the neck to the lateral side of the lower abdomen and then in-
serted in the peritoneal cavity. The cannula was anchored at
both ends with silk sutures and attached to a flow-through;
swivel mechanism which allowed the animal to move about in the
cage and eat and drink normally. The swivel was connected to a
syringe which was attached to a syringe pump. The animals re-
ceived 7 to 10 ml of solution every 24 hours.
In the substitution for morphine (SM) test, the rats first re-
ceived morphine (50 mg/kg/24 hrs on the first day, 100 mg/kg/24
hr on the second day, and 200 mg/kg/24 hr from days 3-6). Then,
a test drug was substituted for 2 days. The morphine controls
received an infusion of water. The animals were observed for
changes in body weight and for behavioral-withdrawal signs for 4
hour at 6,24,48,72 and/or 96 hours after stopping the infusion of
morphine.
In the primary physical dependence (PPD) study, the rats received
test compound for 6 days and then were placed in abrupt withdrawal
and observed as above.
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Table 1
Comparative Data-ED50 mg/kg/sc (95% C.L.) of Selected
Standards in 3 Mouse Agonist-Antagonist Tests
Drug Tail Flick Tail-Flick An- Phenylquinone
Test tagonism Test Test
Pentazocine 15% at 10.0 18 (12.4-26) 1.65 (1.0-2.5)
Cyclazocine 17% at 1.Oa 0.03 (0.02-.78) 0.011 (0.0046-
0.03)
Nalorphine None at 10.0 2.6 (0.69-9.75) 0.6 (0.25-1.44)
.HCL
Naloxone
.HCL
None at 10.0 0.035 (0.010-0.093) No Activity
Naltrexone None at 10.0 0.007 (0.002-0.02) No Activity
.HCL
Morphine 5.8 (5.7-5.9) ----- 0.23 (0.20-
Sulfate 0.25)
aMice were ataxic at 3.0 and 10.0 mg/kg but no further increase
in reaction time was seen.
Three mouse tests were used in our laboratory at the Medical
College of Virginia to provide a preliminary estimate of the
potency and profile of activity of each test compound. The
tests were the tail-flick agonist (TF) and the morphine
antagonist (TF vs M) tests and the phenylquinone (PPQ) test
(Dewey et al., 1970; Dewey and Harris, 1971). Reference-
standard data for these tests are shown in table 1. In
addition, Dr. Jacobson provided us with estimated starting
doses. These doses were based on results obtained from the
mouse hot plate (HP) (Eddy and Leimbach, 1953; Jacobson and
May, 1965; Atwell and Jacobson, 1978) and Nilsen (N) (Perrine
et al., 1972) tests from his laboratory. Reference data for
these tests are shown in table 2.
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Table 2
Comparative Data (ED50 mg/kg/sc) [95% S.E.] from the Hot Plate
and Nilsen Test
Compound
Morphine Sulfate
Codeine Phosphate
Levorphanol Tartrate 0.2(0.16-0.3)
2.5(1.7-3.7)
Meperidine .HCL --
(-)-Metazocine .HBr 0.5(0.3-0.7)
26.0(21.0-33.0)
Dihydromorphinone
.HCL
Nalorphine .HCL
Cyclazocine
Pentazocine
Chlorpromazine .HCL
Hot Plate Test
Subcutaneous
Oral
0.98(0.83-1.1)
6.3(4.7-8.3)
6.8(4.5-10.2)
13.5(9.7-18.7)
0.2(0.1-0.3)
-
5.3(4.0-7.1)
-
0.6(0.5-0.9)
10.6(8.0-14.1)
0.19(0.15-0.25)
0.9(0.7-1.2)
9.9(5.7-17.1)
-
1.5(1.1-2.1)
-
9.3(6.7-12.8)
-
1.1(0.9-1.5)
-
Nilsen Test
Subcutaneous
Oral
1.3(1.0-1.7)
8.3(6.0-11.4)
7.4(4.9-11.0)
14.7(9.2-23.3)
0.2(0.15-0.3)
1.8(1.5-2.1)
23.0(16.2-32.7)
-
0.1(0.07-0.16)
-
6.5(4.4-8.8)
-
-
-
Naloxone .HCL and Naltrexone HCL No dose-response
Phenobarbital, Amobarbital, Valium, Oxazepam, Flurazepam,
Meprobamate and Mescaline are inactive on the hot plate test.
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SUMMARY OF COMPOUNDS TESTEDa
COMPOUND # CHEMICAL CLASS
MCV NIH UM
4142 9508 1325
4169 9614 1269
4175 9624 1258
4178 9651 1234
4186 9721 1216
4200 9739 1227
4206 8834 927
4209 9790 1241
4211
4214
4215 9807 1248
4216 9808 1249
4224 8893 1009
9803
9806
1244
1247
Dihydrocodeinone
C-Homobenzomorphan
6,7-Benzomorphan
3-Hydroxymorphinan
1-Phenylcyclopentanol
14-Hydroxymorphinone
Benzocyclodecenol
Ketobimidone
(4-Phenylpiperidine)
14-Hydroxymorphinone
Ketobemidone
(4-Phenylpiperidine)
6,7-Benzomorphan
6,7-Benzomorphan
Benzylprrole
TF, TFvsM, PPQ, HP, N
+
+
+
+
+
+
+
MOUSE RAT MONKEY
SM, PPD SDS PPt-W PPD
+
+
+
+
+
+
+
+ +
+ +
+ +
+ +
+ +
+ +
+
+
+
+
+
+
+
+
+
+
+
+
+
+ + +
+ + + + +
+ +
+ + +
+ +
+ +
+ + +
+ +
+ +
+
+ + +
+ + +
+ +
SUMMARY OF COMPOUNDS TESTED
COMPOUND # CHEMICAL CLASS MOUSE RAT MONKEY
MCV NIH UM TF, TFvsM, PPQ, HP, N SM, PPO SDS PPt-W PPO
4230 9874 1322
4231 9882 809
4232 8509 810
4234 9887 -
4236 9896 1291
4237 9899 1292
4238 9900 1293
4239 9881 1282
4240 9882 1283
4243 9888 -
4244 9889 1288
4245 9890 1289
4246 9891 1275
4248 9897 1279
3-Aetoxymorphinan
Phenylmorphan
Phenylmorphan
Phenylmorphan
1H-4-Benzazonine
1H-4-Benzazonine
1H-4-Benzazonine
Phenylmorphan
See MCV 4231
Phenylmorphan
Phenylmorphan
Phenylmorphan
Phenylmorphan
1H-4-Benzazonine
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+
+
+
+
+
+
+
+
+
+
+
+
+
+ + +
+ +
+ +
+ + +
+ + +
+ + +
+ + +
+
+
+
+
+
+
SUMMARY OF COMPOUNDS TESTED
COMPOUND #
MCV NIH U M
4252 9904 1278
4253 9921 -
4254 9903 1315
4259 9922 -
4260 9929 1311
4261 9930 1312
4264 9905 1308
4265 9906 1309
4266 9926 1310
4267 4912 902
4269 9938 -
CHEMICAL CLASS
1H-4-Benzazonine
(C-Homobenzomorphan)
Uronic acid glycoside
1H-4-Benzazonine
(C-Homobenzomorphan)
4-Phenylpiperidine
Morphine
14-Hydroxymorphinone
(Naltrexone)
1H-4-Benzazonine
(C-Homobenzomorphan)
1H-4-Benzazonine
(C-Homobenzomorphan)
Morphinan-6-one
6,7-Benzomorphan
6,7-Benzomorphan
MOUSE RAT MONKEY
TF, TFvsM, PPQ, HP, N SM, PPD SDS PPt-W PPO
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ +
+
+
+
+
+ +
+
+
+
+
+ +
SUMMARY OF COMPOUNDS TESTED
COMPOUND # CHEMICAL CLASS
MCV NIH UM
4270 9939 1330
4271 9947 -
4272 9948 -
4273 9949 -
4274 9950 -
4275 9955 -
4276 9450 1305
4279 9926 1310
4280 9931 1313
4281 9932 1314
4282 9940 -
4283 9941 -
4284 9942 -
4285 9943 -
3-Hydroxymorphinan
Pentapeptide
Pentapeptide
Pentapeptide
Pentapeptide
Phenylmorphan
6,7-Benzomorphan
See MCV 4266
Morphinan-6-one
Morphinan-6-one
Tetrahydronaphthylamine
Tetrahydronaphthylamine
Tetrahydronaphthylamine
Tetrahydronaphthylamine
TF, TFvsM, PPQ, HP, N SM, PPD
+
+
+
+
+
+
+
+
+
+
+
+
+
MOUSE RAT MONKEY
SDS PPt-W PPD
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ + +
+ +
+ +
+ +
+ +
+ + +
+ +
+ +
+ +
+
+
+
+
SUMMARY OF COMPOUNDS TESTED
COMPOUND # CHEMICAL CLASS MOUSE RAT MONKEY
MCV NIH UM TF, TFvsM, PPQ, HP, N SM, PPO SDS PPt-W PPD
4286 9945 1327
4288 9454 1146
4289 9927 -
4293 9971 -
4294 9972 -
4295 9974 -
4296 9975 1347
4297 9976 -
4298 9977 -
4299 9989 -
4305 9959 1340
4308 10,001 -
4309 10,002 -
4310 10,003 -
Phenylmorphan +
6,7-Benzomorphan +
Morphinan-6-one +
Phenylmorphan +
Phenylmorphan +
Morphinan-6-one +
Morphinan-6-one +
Epoxymorphinan-6-one +
14-Hydroxymorphinan-6-one +
Morphinan +
14-Hydroxymorphinan-6-one +
14-Hydroxymorphinone +
14-Hydroxymorphinone +
14-Hydroxymorphinone +
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ +
+ +
+ +
+ +
+
+
+ +
+ +
+ +
+
+ +
+ +
+ +
+
+ +
+ +
COMPOUND #
M C V NIH UM
4311 10,004 -
4312 10,005 -
4313 10,007 -
4314 10,008 -
4315 10,009 -
4316 10,010 -
4317 10,015
4318 10,016 -
4322 10,020 -
4323 10,022 -
4324 10,024 -
4325 9801 -
SUMMARY OF COMPOUNDS TESTED
CHEMICAL CLASS MOUSE RAT MONKEY
TF, TFvsM, PPQ, HP, N SDS, PPD SDS PPt-W PPD
14-Hydroxymorphinone +
14-Hydroxymorphinone +
14-Hydroxymorphinone +
14-Hydroxymorphinone +
14-Hydroxymorphinone-6-one +
Morphinan-6-one +
Morphinan-6-one +
Morphinan-6-one +
Hydroxyphenyl-1H-indole +
4-Anilinopiperidine
(Fentanyl) +
6,7-Benzomorphan +
Pyrindylpyrrolidine
(+)-(Nicotine) +
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ +
+ +
+ +
+ +
+ +
+ +
+
+
+
+
+ +
+ +
+ +
+
+ +
+
A "+" indicates compound tested as shown.
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MCV 4142, NIH 9508, UM 1325. N-Cyclopropylemthyl-8 -ethyl-N-
nordihydrocodeinone hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0,
3.0 and 30.0
2) TF vs M - 0.2 (0.03 -
1.5)
3) PPQ - 18.0 (7.5 - 43.6)
4) HP - 16.8 (10.5 - 26.9)
5) N - no dose-responses,
4/8 at 50.0 and 100.0
MONKEY DATA
(PPD)
Five drug naive
H2O every 6 hr.
mately one half
Day Dose
mg/kg/sc
1 2.0
2 4.0
3 6.0
4 9.0
5
6
12.0
15.0
7 18.0
8 21.0
9 18.0
10 19.0
11 20.0
12 21.0
13-14 19.0
rhesus monkeys were given MCV 4142 dissolved in
The animals were observed for 15 min, approxi-
hour after receiving drug.
Comments
During the first 2 days, the only drug-induced
behavioral effect noted was wet-dog shakes. By
day 3, some showed drowsiness and by the end of
day 4, all were drowsy. Some salivation occurred
on day 5 and all were drowsy. Wet-dog shakes
seemed not to occur as often when drowsiness was
present. On day 6, wet-dog shakes was the main
effect noted. After the last injection on day 8,
one animal convulsed and the other appeared to be
in a preconvulsive state; salivation and tremors
were also seen in all the animals. After the dose
was reduced and from days 9 - 14, the principal
signs noted were: drowsiness, wet-dog shakes,
salivation and jaw sag.
15 PPT-Withdrawal - After a challenge dose of 1.0 mg/kg of
naloxone, the principal withdrawal signs noted were: lying
on side or abdomen, fighting, avoiding contact, restless-
ness, wet-dog shakes, yawning and retching. The onset was
prompt and the effects lasted less than 90 minutes.
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15 20.0 Resumed study at noon. Restlessness, drowsiness,
16
18
-17 19.0 wet-dog shakes, jaw sag and salivation were the
-21 20.0 main drug effects seen. Two of the animals de-
22-23 21.0 veloped skin ulcers. It was noted that these
24 22.0 animals positioned themselves so that they were
25-28 23.0 being injected in the same area. From that time
29
30
30
31
24.0 onwagd, the animals were held and the site of in-
jection was rotated. The ulcers healed without
incident.
25.0 Abrupt Withdrawal. Virtually no signs were seen
12-15 hours after the last dose.
PPT-Withdrawal - A 2.0-mg/kg dose of naloxone at 16 hours
elicited the following signs. Lying on side or abdomen,
fighting, pacing, drowsiness, wet-dog shakes, retching,
coughing, yawning and vocalizing when abdomen palpated.
25.0 MCV 4142 injections were resumed at noon.
Drowsiness, tremors, wet-dog shakes, salivation
and jaw sag were noted. One monkey had convul-
sions. The dose was reduced to 20.0 mg/kg.
21.0 During the period 31-44 days the principal drug
32-34 22.0 effects noted were drowsiness, wet-dog shakes,
35 23.0 salivation  and jaw sag. On day 39, one monkey
36 24.0 developed convulsions.
37 25.0
38 26.0
39 27.0
40-44 27.0
45 Abrupt Withdrawal. During the observation period of 12-18
hr, the only withdrawal signs noted were avoiding contact,
restlessness, and wet-dog shakes.
PPt-Withdrawal. A. 2.0-mg/kg dose of naloxone elicited the
following signs: lying on side or abdomen, fighting, avoid-
ing contact, yawning restlessness, drowsiness, retching, and
vocalizing when abdomen palpated.
Conclusion. In the dose schedule tested, MCV 4142 produced few
withdrawal sign during abrupt withdrawal. A withdrawal syndrome
was precipitated by a high dose of naloxone. Convulsions may
have limited the degree of physical dependence. All the animals
but one gained weight throughout the study.
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MCV 4169, NIH 9614, UM 1269. (-)-9-Hydroxy-4,7-dimethyl-
C-homobenzomorphan hydrobromide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - a. Inactive at 3.0,
6.0, 10.0 and 30.0
b. Inactive at 3.0,
10.0 and 30.0
2) TF vs M - a. 13.4 (5.7 -
31.3)
b. 5.5 (1.2 -
25.9)
3) PPQ - a. 0.5 (0.2 - 1.7)
b. 0.4 (0.1 - 1.3)
4) HP - a. 1.8 (1.3 - 2.4)
b. 2.5 (1.9 - 3.3)
5) N - 13.0 (9.6 - 17.7)
MONKEY DATA # ANIMALS
(PPt-W) Doses (mg/kg/sc)
3  , 3 , 3 ,
12.0 6.0 3.0
Vehicle - H2O
Certain signs designated as lying on side or abdomen, drowsiness,
ataxia, restlessness and tremors were seen. However, only one
animal retched, one salivated and two vocalized when the abdomen
was palpated. This drug appeared to have very weak antagonist and/
or strong depressant properties.
MONKEY DATA # ANIMALS
(PPD) Doses (mg/kg/sc)
A group of 5 monkeys which had not received any drug for at least
3 months was given MCV 4169 as indicated below and observed for
behavioral signs for approximately 15 min 4 hr after drug was ad-
ministered or as indicated below. The drug was dissolved in H2O
and the volume given was ¼ - 1.0 ml/kg.
Day Dose mg/kg/sc (Times/Day) Comments
1 1.0 (4x8) The principal signs noted were
2 2.0 (4xd) vocalization, ataxia (at times
3 4.0 (4xd) severe). Drowsiness and slow-
4 6.0 (4xd) ing were also seen on occasion.
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Day
5-8
9
10
11
12
13-14
Dose mg/kg/sc (Times/Day) Comments
8.0 (4xd) Few signs were seen at the 2
9.0 (4xd) and lower doses.
4.5 (2xd)
9.0 (6xd)
9.0 (5xd) and
4.5 (1xd)
9.0 (4xd) and
4.5 (2xd)
9.0 (4xd) The following withdrawal signs
were noted: 5/5 rigid abdomen,
3/5 fighting, restless drowsy
fighting, retching, and vocal-
ized when abdomens palpated;
2/5 avoids contact, wet-dog
shakes; 1/5 vocalizing and,
coughing.
15 at PPT-W
8:30 AM Naloxone 2.0
mg/kg
15 Resumed 9.0 (4xd) and
study at 4.5 (1xd)
noon
16 9.0 (5xd) and
4.5 (1xa)
17-21 9.0 (6xd)
22-25 10.0 (6xd)
26-28 11.0 (6xd)
29-30 12.0 (5xd)
31 at PPT-W
8:35 AM Naloxone 0.5
mg/kg
31 at 12.0 (5xd)
noon
33-36 12.0 (6xd)
37-38 13.0 (6xd)
39-40 14.0 (6xd)
41-44 15.0 (6xd)
During precipitated withdrawal
the following signs were seen:
5/5 drowsy; 4/5 restless 3/5
rigid abdominal muscles and re-
tching; 2/5 vocalized when ab-
domens palpated; 1/5 wet dogs.
(Cont'd next page)
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MCV 4169, NIH 9614, UM 1269 (Cont'd)
45 Abrupt Withdrawal. The abrupt withdrawal syndrome peaked 10-
12 hour after the last injection and was recorded as follows:
5/5 rigid abdomen; 4/5 vocalized when abdomens palpated; 2/5
lying on side; 1/5 fighting, avoids contact, vocalized and
masturbation. By 18 hours no obvious signs were noted.
Conclusions. The drug definitely produced signs of opiate-like
physical dependence. Tolerance also developed to its effects.
All the animals lost body weight but by the end of the study 3/5
had either regained or exceeded the original starting weights.
The physical dependence liability is judged to be intermediate to
high.
Rat Infusion (PPD): According to the data shown in the
figure and table, MCV 4169 produces an opiate-type
primary physical dependence in the rat. The results
are dose-related regarding weight loss and behavioral
withdrawal signs.
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Table
Mean Number of Withdrawal Signs 1 Noted During a 1/2 Hr Observa-
tion Period at Specified Intervals and Calculated Probability
Values2 for Comparisons Between H2O Only Group and MCV 4169 and
Morphine Control.
Hr in withdrawal
6 24 48 72 96
H2O Controls x = 0 x = 1.8 x = 1.3 x = 0.5 x = 1.5
N=4
Morphine x = 4.3 x = 14.8 x = 18.5 x = 21.0 x = 13.3
Infusion
H2O Sub- p = 0.01 p = 0.01 p = 0.01 p = 0.02 p = 0.05
stitution
N=4
MCV 4169 x = 3.2 x = 6.6 x = 9.2 x = 12.0 x = 10.0
Infusion
50, 100, p = 0.05 p = 0.45 p = 0.05 p = 0.05 p = 0.14
200x4 mg/kg
N=5
MCV 4169 x = 4.2 x = 0.8 x = 1.4 x = 3.0 x = 2.2
25, 50, p = 0.05 p = 0.36 p = 0.45 p = 0.05 p = 0.36
100x4 mg/kg
H2O Substitution
1) Hypersensitivity, squealing, aggression, wet dog shakes,
rubbing and chewing.
2) One-tailed test (Mann Whitney U-Test).
MCV 4175, NIH 9624, UM 1258. 1-[2 ,6 ,11S)-(±)-1-(1,2,3,4,5,6-
Hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-
yl)]-3-octanone methanesulfonate.
(mg/kg/sc)
MOUSE DATA-ED50 (95% C.L.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs M - 0.03 (0.01 - 0.7)
3) PPQ - 0.2 (0.08 - 0.6)
4) HP - 2.4 (1.7 - 3.3)
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MCV 4175, NIH 9624, UM 1258 (Cont'd)
RAT INFUSION (PPD)
When given at doses comparable to those administered to the mor-
phine controls, little weight loss (Fig.) and few withdrawal signs
(Tables 1 and 2) were noted. An unexpected but non-significant
spurt in the number of withdrawal signs did occur 96 hours after
MCV 4175 was abruptly withdrawn. Whether or not this was a spuri-
ous event or may represent delayed emerging withdrawal cannot be
ascertained from this study. Additional studies are recommended
if indicated.
Table 1
Mean Number of Withdrawal Signs1 Noted During a 1/2 Hr Observa-
tion Period at Specified Intervals and Calculated Probability
Values2 for Comparisons Between MCV 4175 and Morphine Control.
24
Hr in Withdrawal
48 72 96
Morphine Controls x = 13.4 x = 19.2 x = 16.0 x = 14.0
N = 5
MCV 4175 Infusion
(50 mg/kg-day 1, x = 2.8 x = 1.4 x = 4.8 x = 10.6
100 mg/kg-day 2, p = 0.008 p = 0.004 p = 0.016 p = 0.274
200 mg/kg-days (3-6)
N=5
1) Hypersensitivity, squealing, aggression, wet dog shakes,
rubbing and chewing.
2) One-tailed test (Mann Whitney U-Test).
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Table 2
Mean Number of Withdrawal Signs1 Noted During a 1/2 Hr Observa-
tion Period as Specified Intervals and Calculated Probability
Values2 for Comparisons Between H2O Only Group and MCV 4175.
Hr in Withdrawal
24 48 72 96
H2O Controls x = 1.5 x = 4.8 x = 3.0 x = 4.0
N = 4
MCV 4175 Infusion
(50 mg/kg-day 1, x = 2.8 x = 1.4 x = 4.8 x = 10.6
100 mg/kg-day 2, p = 0.452 p = 0.056 p = 0.143 p = 0.278
200 mg/kg - days
3-6), N = 5
1) Hypersensitivity, squealing, aggression, wet dog shakes,
rubbing and chewing.
2) One-tailed test (Mann Whitney U-Test).
MCV 4178, NIH 9651, UM 1234. 17-Cyclopropylmethyl-4,5 -epoxy-6,6-
difluoro-3-hydroxymorphinan hydrochloride.
MONKEY DATA # ANIMALS
A) (SDS) Doses (mg/kg/sc)
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 3.0, 10.0
or 30.0
2) TF vs M - 0.001 (0.003 -
0.005)
3) PPQ - 0.5 (0.05 - 4.3)
4) HP - 17.2 (7.3 - 40.4)
2 , 2 ,
0.2 0.1
2 ,
0.05
Vehicle - H2O
In the dose range tested, MCV 4178 did not substitute for morphine.
MONKEY DATA # ANIMALS 1 , 1 ,
B) (PPT-W) boses (mg/kg/sc) 0.25 0.125
2 , 2 , 1 , 2 , 1 , 1 ,
0.062 0.031 0.015 0.008 0.004 0.002
Vehicle - H2O
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MCV 4178, NIH 9651, UM 1234 (Cont'd)
MCV 4178 was active at all doses but the lowest in precipitating
withdrawal signs. The drug acted promptly and the duration of
action is longer than that of naloxone. Approximately 10 x as
potent as naloxone.
MCV 4186, NIH 9721, UM 1216. 2 -Methylamino-1-phenylcyclo-pentanol
propanoate ester, hydrogen maleate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 0% at 1.0, 18% at
10.0, and 22% at 30.0
2) TF vs M - a) Inactive at
1.0, 10.0, 50.0, and 100.0,
b) 0% at 1.0 and 30.0
3) PPQ - 25.0 (14.8 - 43.9)
4) HP - Incompletely active
at 100.0
MONKEY DATA # ANIMALS 1 , 2 , 3 , 2 , 1 ,
(PPt-Withdrawal) Doses (mg/kg/sc) 40.0 20.0 10.0 5.0 2.5
Vehicle - H2O
In the dose range studies, MCV 4186 did not precipitate withdrawal
signs in morphine-dependent monkeys.
MCV 4200, NIH 9739, UM 1227. 2-Nitronaloxone
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 0% at 1.0, 17% at
10.0 5/6 died at 30.0
2) TF vs M - 3.6 (0.8 - 16.8)
3) PPQ - 3.5 (1.8 - 6.8)
4) HP - 3.5 (2.8 - 4.3)
5) N - 6.0 (4.5 - 8.0)
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MCV 4206, NIH 8834, UM 972. (-)-13 -Amino-5,6,7,8,9,10,11,12-
octahydro-5 -methyl-5,11-methanobenzocyclodecen-3-ol hydrobromide.
MOUSE DATA-ED5O (95% C.L.)
(mg/kg/sc)
1) TF - 2.6 (0.8 - 8.1)
2) TF vs M - 16% at 1.0, 18%
at 10.0 and 6% at 30.0
RAT INFUSION (PPD)
3) PPQ - 0.3 (0.07 - 1.0)
4) HP - 0.7 (0.5 - 0.9)
5) N - 0.9 (0.7 - 1.1)
MCV 4206 given chronically produces weight loss when abruptly
withdrawn (See Fig.). The weight loss is not as precipitous
during the first 24 hr as is that shown by the morphine-infused
controls. Furthermore, the animals were still losing weight at
96 hours whereas the morphine controls appeared to be regaining
weight. The same pattern was noted regarding withdrawal signs.
A significant difference was not noted until the 72-hr observation
period (see table). The withdrawal reaction seems to be delayed.
The drug appears to produce physical dependence in rats although
the degree of dependence may not be as intense as that shown for
morphine.
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Table
Mean Number of Withdrawal Signs1 Noted During 1/2 Hr Observa-
tion Period at Specified Intervals and Calculated Probability
Values2 for Comparisons Between H2O Only Group and MCV 4206 and
Morphine Control.
Hr in Withdrawal
24 48 72 96
H2O only
N = 5 x = 2.0 x = 1.0 x = 0.4 x = 1.2
Morphine Controls x = 10.4 x = 11.0 x = 13.8 x = 10.2
N = 5 p = 0.004 p = 0.008 p = 0.004 p = 0.004
MCV 4206 Infusion
(50 mg/kg-day 1, x = 3.0 x = 5.5 x = 8.2 x = 6.0
100 mg/kg-day 2, p = 0.535 p = 0.106 p = 0.007 p = 0.089
200 mg/kg-days 3-6).
N = 6
1)Hypersensitivity, squealing, aggression, wet dog shakes,
rubbing and chewing.
2)One-tailed test (Mann Whitney U-Test).
MCV 4209, NIH 9790, UM 1241. 3-Methylpentyl-N-norketobemidone
hydrobromide.
MOUSE DATA-ED50 (955 C.L.)
(mg/kg/sc)
1) TF - 4% at 11.0 and 13%
at 30.0
2) TF vs M - 0% at 1.0 and
27% at 30.0
3) PPQ - 12.9 (3.0 - 55.7)
4) HP - 16.6 (12.5 - 22.1)
MONKEY DATA # ANIMALS
(SDS) Doses (mg/kg/sc)
2 , 2 , 2
10.0 5.0 2.5
Vehicle-Lactic Acid
and H2O
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MCV 4209, NIH 9790, UM 1241 (Cont'd)
The drug did not substitute for morphine. It may have exacerbated
withdrawal. Severe tremors were noted in two monkeys. Drug supply
was exhausted.
MCV 4211, NIH 9803, UM 1244. (-)-N-(2-Methoxyethyl)noroxy-
morphone hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 17.9 (13.8 - 23.2)
2) TF vs M - 10% at 1.0 and
30.0
3) PPQ - 0.09 (0.01 - 0.95)
4) HP - 7.7 (5.9 - 10.0)
5) N - 20.1 (15.9 - 25.4)
MCV 4214, NIH 9806, UM 1247. N-[3-(N,N-Dimethylcarbamoyl)-3,3-
diphenylpropyl]-norketobetnidone hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 1% at 1.0, 33% at
10.0, 36% at 30.0, 72% at
60.0
4) HP - 20.5 (13.6 - 30.9)
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MCV 4215, NIH 9807, UM 1248. (-)-(1R,5R,9R)-5,9-Dimethyl-2'-
hydroxy-2-(3-phenoxypropyl)-6,7-benzomorphan hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 0.8 (0.2 - 2.6)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.1 (0.06 - 0.4)
4) HP - 0.3 (0.2 - 0.4)
MONKEY DATA # ANIMALS 1 , 2 , 3 , 2 , 3 ,
A) (SOS) Doses (mg/kg/sc) 38.4 19.2 19.6 2.4 1.2
Vehicle - H2O
MCV 4215 did not substitute for morphine in the dose range of 1.2-
38.4 mg/kg. At the higher doses, convulsions were noted in 2 mon-
keys which were terminated by morphine and pentobarbital injections.
Much less retching was seen in the animals receiving MCV 4215 com-
pared to those receiving vehicle.
MONKEY DATA # ANIMALS 3 , 3 , 3 ,
B) (PPt-W) Doses (mg/kg/sc) 16.0 8.0 4.0
Vehicle - H2O
MCV 4215 elicted some withdrawal signs at all doses tested. How-
ever, no retching, vomiting, and coughing were noted and little
vocalization was observed when the abdomens were palpated. At the
highest dose, one animal developed convulsions 20 min after re-
ceiving drug. Pentobarbital (60 mg/ip) was used to terminate those
convulsions. This drug may be regarded as being a weak antagonist.
RAT INFUSION (SM)
Dose-related substitution for morphine was observed regarding weight
loss and withdrawal signs (see figure and table).
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Table
Mean Number of Withdrawal Signs1 Noted During a 1/2 Hr Observa-
tion Period at Specific Intervals and Calculated Probability
Values2 for Comparisons Between H2O Only Group and MCV 4215
and Morphine Controls.
Hr in Withdrawal
24 48 72 96
H2O only Group x = 0.6 x = 1.6 x = 1.0 x = 1.4
N = 5
Morphine Infusion x = 15.2 x = 16.4 x = 11.4 x = 10.0
H2O Substitution p = 0.004 p = 0.004 p = 0.004 p = 0.004
N = 5
Morphine Infusion x = 0.2 x = 0.6 x = 18.0 x = 14.0
MCV 4215 Substitution p = 0.5 p = 0.5 p = 0.004 p = 0.009
64 mg/kg/day
N = 5
Morphine Infusion x = 0.8 x = 1.0 x = 7.0 x = 9.2
MCV 4215 Substitution p = 0.39 p = 0.3 p = 0.06 p = 0.009
128 mg/kg/day
Morphine Infusion x = 0.3 x = 0.7 x = 0.7 x = 5.0
MCV 4215 Substitution p = 0.14 p = 0.6 p = 0.6 p = 0.04
256 mg/kg/day, 2 of 5
rats died during infusion
1) Hypersensitivity, squealing, aggression, wet dog shakes,
rubbing and chewing.
2) One-tailed test (Mann Whitney U-Test).
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MCV 4216, NIH 9808, UM 1249. (+)-(1R,5R,9R)-5,9-Dimethyl-2'-
hydroxy-2-(3-phenoxypropyl)-6,7-benzomorphan hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 59.6 (8.4 - 421.1)
2) TF vs M - Inactive at 10.0
and 30.0
3) PPQ - 0.5 (0.2 - 1.5)
4) HP - 8.7 (6.3 - 12.0)
5) N - 11.7 (8.0 - 17.3)
MONKEY DATA # ANIMALS 3 , 3 , 3,
(SDS) Doses (mg/kg/sc) 24.0 12.0 3.0
Vehicle - H2O
In the dose range studied, the drug did not substitute for mor-
phine. Some body sag was seen in one monkey at the highest dose
and in another at the lowest dose.
MCV 4224, NIH 8893, UM 1009. (-)-o-Chlorobenzyl-2-(2-di- sec-
butylamino-1-hydroxyethyl)pyrrole p-hydroxybenzoate (Viminol R2).
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1)
2)
3)
TF - 12.8 (2.6 - 62.4)
TF vs M - Inactive at 1.0,
3.0, 10.0 and 30.0
PPQ - 2.7 (0.9 - 7.6)
HP - 1.2 (1.0 - 1.5)
N - 0.7 (0.5 - 0.9)
4)
5)
A) MONKEY DATA # ANIMALS
(SDS) Doses (mg/kg/sc)
2 , 3 , 3 , 1 ,
tion
36.0 24.0 12.0 6.0
(Vehicle)-Carboxymethyl-
cellulose aqueous solu-
Given subcutaneously, MCV 4224 did not substitute for morphine in
the dose range of 6.0 to 36.0 mg/kg.
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MCV 4224, NIH 8893, UM 1009 (Cont'd)
B) MONKEY DATA # ANIMALS 3 , 3 , 3 , - Vehicle
(SDS) Doses (mg/kg/iv) 2.0 1.0 0.5
Kollidon 17 in saline, ½ ml/kg
Given intravenously, MCV 4224 substituted completely for morphine.
Overall, the drug acted promptly and its duration of action was ap-
proximately 1 hr. With regard to the suppression of the important
withdrawal sign designated, "vocalizes when abdomen palpated", this
compound acted in a dose-related manner, i.e., at the high dose none
of the monkeys vocalized, at the intermediate dose 2 of 3 did not
vocalize and at the low dose 1 of 3 did not vocalize. This effect
lasted for about 1 hr and by 90 min all but one of the 9 animals
receiving MCV 4224 vocalized. On the other hand, morphine sulfate
at 1.0 mg/kg i.v. was ineffective in suppressing vocalization during
the first 30 min but was effective in 2 of 3 animals at 60 and 90
min. Retching, another withdrawal sign, was suppressed throughout
the entire 2½ hr observation period at the highest dose of MCV 4224.
At the 2 lower doses, retching was suppressed for the first 90 min.
Morphine was effective in this respect during the entire observa-
tion period.
MCV 4230, NIH 9874, UM 1322. 3-Acetoxy-17-cyclopropylmethyl-4,5
epoxy-6,6-dlfluoromorphinan.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 0.0008 (0.0002 -
0.0028)
3) PPQ - 0.1 (0.02 - 0.9)
4) HP - 30% at 20.0, 10% at
50.0 and 20% at 100.0
5) N - 19.8 (12.9 - 30.2)
MONKEY DATA # ANIMALS 2 , 2 , 1 , 1 ,
(PPt-W) Doses (mg/kg/sc) 0.1 0.05 0.01 0.008
Vehicle - H2O
This drug precipiated withdrawal at the 3 higher doses. The onset
of action was prompt and the duration about 2 1/2 hr compared to
1 1/2 hr for naloxone. The potency is approximately equal to that
of naloxone.
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MCV 4231, 4240 NIH 9882 and 8508, UM 809, 1283. (-)-5-(m-Hydroxy-
phenyl)-2-methylmorphan hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - a) 5.4 (2.1 - 13.9),
b) 6.1 (1.9 - 19.3), c) 21% at 1.0,
23% at 3.0, 34% at 10.0 and 53%
at 30.0
2) TF vs M - a) 0% at 1.0 and 30.0,
b) 27% at 1.0 and 21% at 30.0,
c) Inactive at 1.0 and 30.0
3) PPQ - a) 0.9 (0.03 - 2.4),
b) 0.9 (0.4 - 2.0), c) 1.3
(0.3 - 6.0)
4) HP - a) 1.7 (1.2 - 2.4),
b) 2.0 (1.4 - 2.8)
RAT INFUSION (SM, HBr Salt)
As shown in the Figure, at 200 and 400 mg/kg/24 hours, MCV 4231
did not suppress weight loss during the abrupt withdrawal of mor-
phine in morphine-dependent rats. Regarding behavioral withdrawal
signs, when the MCV 4231 groups are compared to the group receiv-
ing H2O only (Table 1) significant differences were calculated.
However; when the groups receiving MCV 4321 are compared to the mor-
phine control groups (Table 2) significant differences can also be
shown. We interpret these data to mean that MCV 4231 produced a
partial suppression of behavioral withdrawal signs. MCV 4231 does
not readily substitute for morphine in dependent rats.
426
Table 1
Mean Number of Withdrawal Signs1 Noted During the 1/2 Hr Observa-
tion Period at Specified Intervals and Calculated Probability
Values2 for Comparisons Between H2O Only Group and MCV 4231 Group
and Morphine Control.
H2O only
N = 5
Morphine Controls
N = 5
Morphine Infusion
MCV 4231 Subst.
(400 mg/kg) N = 5
Morphine Infusion
MCV 4231 Subst.
(200 mg/kg) N = 4
Hr in Withdrawal
x = 7.5 x = 7.5 x = 9.0 x = 5.5
p = 0.347 p = 0.032 p = 0.008 p = 0.024
96
x = 1.2
24 48 72
x = 2.0 x = 1.0 x = 0.4
x = 10.2
p = 0.004
x = 6.8
p = 0.028
x = 10.4 x = 11.0 x = 13.8
p = 0.004 p = 0.008 p = 0.004
x = 5.2 x = 17.6 x = 8.6
p - 0.111 p = 0.004 p = 0.004
Table 2
Mean Number of Withdrawal Signs1 Noted During 1/2 Hr Observa-
tion Period at Specified Intervals and Calculated Probability
Values2 for Comparisons Between MSO4 Group and MCV 4231 Group.
Hr in Withdrawal
24 48 72 96
Morphine Control x = 10.4 x = 11.0 x = 13.8 x = 10.2
N = 5
MCV 4231 Subst. x = 7.5 x = 7.5 x = 9.0 x = 5.5
(200 mg/kg) p = 0.175 p = 0.278 p = 0.075 p = 0.048
N = 4
MCV 4231 Subst. x = 5.2 x = 17.6 x = 8.6 x = 6.8
(400 mg/kg) p = 0.028 p = 0.111 p = 0.016 p = 0.274
N = 5
1) Hypersensitivity, squealing, aggression, wet dog shakes,
rubbing and chewing.
2) One-tailed test (Mann Whitney U-Test).
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MCV 4232, NIH 8509, UM 810 - (+)-5-(m-Hyproxyphenyl-2-methyl-
morphan Hydrochloride.
See MCV 4231
Optical isomer
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 4.8 (1.5 - 15.1)
2) TF vs M - 0% at 1.0, 18%
at 30.0
Rat Infusion (SM, HBr Salt)
3) PPQ - 0.5 (0.3 - 0.9)
4) HP - 0.35
At 200 mg/kg/24 hr, MCV 4232 suppressed withdrawal signs (table)
and when the drug was discontinued a typical opiate withdrawal
syndrome was seen. The drug was partially effective in supress-
ing weight loss (See figure). When the drug was discontinued,
weight loss again accelerated. MCV 4232 appears to substitute
for morphine.
Table 1
Mean Number of Withdrawal Signs Noted During a 1/2 Hour Obser-
vation Period at Specified Intervals and Calculated Probability
Values for Comparisons Between H2O Only Group and MCV 4232 and
Morphine Control.
Hours
24 48 72 96
H2O only Group x = 1.8 x = 1.3 x = 0.5 x = 1.5
Morphine Infusion x = 14.8 x=18.5 x = 21.0 x = 13.8
H20 Substitute p = 0.014 p = 0.014 p = 0.029 p = 0.057
Morphine Infusion x = 2.0 x = 0.8 x = 7.8 x = 11.0
MCV 4232 Substitution p = 0.548 p = 0.452 p = 0.008 p = 0.014
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MCV 4.234, NIH 9887. (-)-N-Hexyl-5-( m-hydroxyphenyl)morphan hydro-
chloride.
10.0 and 30.0
3) PPQ - 20.2 (4.7 - 88.2)
4) HP - Inactive; toxic at
50.0
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0, 3.0,
2) TF vs M - 2.1 (0.9 - 4.7)
MONKEY DATA # ANIMALS 2 , 2 , 1 ,
A) (SDS) Doses (mg/kg/sc) 0.08 0.31 1.25
Vehicle-alcohol; Tween 80
and H2O
The compound did not substitute for morphine and may have exacer-
bated withdrawal at the two higher doses. In the preliminary
study after 2.5 mg/kg, the monkey developed severe retching and
was given morphine to alleviate this distressing symptom.
MONKEY DATA # ANIMALS 2 , 2 , 1 ,
Doses (mg/kg/sc) 0.31 1.25B) (PPt-W) 0.08
Vehicle-alcohol; Tween
80 and H2O
MCV 4234 precipitated withdrawal in a dose-related manner. The
onset and duration of action were similar to naloxone. The po-
tency is about 1/6 that of naloxone.
MCV 4236, NIH 9896, UM 1291. (-)-4-Allyl-10-hydroxy-1-methyl-2,3,
4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA-ED50 (95% C.L.)
2) TF vs M - 6.7 (3.2 - 13.7)
3) PPQ - 4.3 (1.4 - 13.1)
10.0 and 30.0
(mg/kg/sc)
1) TF - Inactive at 0.3, 1.0
429
MCV, 4236, NIH 9896, UM 1291 (Cont'd)
4) HP - 0% at 20.0, 40% at
50.0, convulsions
5) N - Inactive at 5.0
MONKEY DATA # ANIMALS 3 , 3 , 3 ,
(PPt-W) Doses (mg/kg/sc) 4.0 1.0 0.25
Vehicle - H2O
The compound did not precipitate withdrawal in morphine-dependent
monkeys. Dose-related drowsiness, ataxia and tremor were noted.
One monkey receiving the highest dose was not able to sit and
appeared unconscious 10 min after receiving the drug. The animal
was given naloxone and appeared to recover within 15 min.
MCV 4237, NIH 9899, UM 1292. (+)-4-Cycylopropylmethyl-10-hydroxyl-
1-methyl-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA-ED50  (95% C.L.)
(mg/kg/sc)
1) TF - 0% at 3.0, 3.0, 10.0
and 30.0
2) TF vs M. - 1.5 (0.5 - 4.2)
3) PPQ - 4.7 (1.9 - 11.0)
4) HP - No dose-response
MONKEY DATA # ANIMALS
Doses (mg/kg/sc)
3 , 2 , 3
A) (SDS) 1.0 0.25 0.06
Vehicle-dil HCl and H2O
The drug substituted partially for morphine at all doses. Severe
ataxia, slowing, incoordination, and staring were noted at the
highest dose. In the preliminary study, in one monkey given 1.0
mg/kg the following signs were noted: ataxia, catalepsy, lying on
side, unable to walk. The animal was able to move about after 1 hr.
MONKEY DATA
B) (PPt-W)
# ANIMALS 1 , 2 , 1 , Vehicle-dil HCl
Doses (mg/kg/sc) 1.0 0.5 0.25
The drug did not precipitate withdrawal. Severe ataxia was noted
at the highest dose; the animal could not sit on the perch. Drow-
siness, body sag, and initially some restlessness were also noted.
At the intermediate doses, drowsiness, ataxia and body sag were
seen at the lowest dose, drowsiness was still evident.
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MCV 4238, NIH 9900, UM 1293. (-)-4-Cycylopropylmethyl-10-hydroxy-
1-methyl-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
See MCV 4237
(Optical isomer)
1) TF - 25% at 1.0, 0% at 30.0
2) TF vs M - 0% at 1.0, 17% at
10.0, 29% at 30.0
3) PPQ - 0.02 (0.007 - 0.08)
4) HP - 10% at 20.0 and 20%
at 50.0
5) N - Insufficient activity
at 50.0, 0% at 20.0, 25%
at 50.0
MONKEY DATA # ANIMALS 2 , 2 , 1 , Vehicle-dil HCl
(PPt-W) Doses (mg/kg/sc) 5.0 1.25 0.3
In the dose range tested, MCV 4238 did not precipitate withdrawal.
Tremor, ataxia, drowsiness, body sag and slowing were noted as was
drowsiness.
MCV 4239, NIH 9881, UM 1282. (-)-5-( m-Hydroxyphenyl)morphan hydro-
chloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 0% at 1.0 and 30.0
2) TF vs M - 0% at 1.0 and
12% at 30.0
3) PPQ - 0% at 1.0, 3.0, 10.0
and 30.0
4) HP - No dose-response
MCV 4240 and 4231, NIH 9882 and 8508, UM 1283 and 809.
Hydroxyphenyl)-2-methylmorphan hydrochloride.
(-)-5-(m-
MCV 4240 is identical with MCV 4231.
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MCV 4243, NIH 9888. (+)-5-(m-Hydroxyphenyl)morphan hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
See MCV 4239
(Optical isomer) 2)
TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0% at 1.0, 8% at 10.0
and 57% at 30.0
4) HP - No dose-response
MCV 4244, NIH 9889, UM 1288. (+)-5-(m-Hydroxyphenyl)-2-methyl-
morphan hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
See MCV 4231
(Optical isomer)
1) TF - 0.4 (0.1 -1.4)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.2 (0.03 - 1.6)
4) HP - 0.6 (0.5 - 0.7)
MCV 4245, NIH 9890, UM 1289. (+)-2-Ethyl-5-( m-hydroxyphenyl)
morphan hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
10.0
2) TF vs M - 27% at 0.3, 40%
at 0.1, 43% at 0.3, 10% at
10.0, 10% at 10.0 and 0%
at 30.0
3) PPQ - Approximately 28.0
4) HP - 15.8 (12.1 - 20.5)
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MCV 4246, NIH 9891, UM 1275.
morphan hydrochloride.
(+)-5-(m-Hydroxyphenyl)-2-n-propyl-
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 2O% at 1.0 and
17% at 30.0
3) PPQ - 2.5 (0.9 - 7.6)
4) HP - 9.2 (6.4 - 13.0)
MCV 4248, NIH 9897, UM 1279. (+)-1-Methyl-4-allyl-10-hydroxy-2,3,
4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 1.1 (0.3 - 3.9)
4) HP = 40% at 10.0, 60% at
20% Toxic at 20.0
3) PPQ - 0.4 (0.1 - 1.2)
MCV 4252, NIH 9904, UM 1278. (-)-1-Methyl-4-isopentenyl-10-
hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 17.3 (7.1 - 42.3)
4) HP - 20% at 2.0, 30% at
50.0 - Convulsions
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MCV 4253, NIH 9921. -Phenethyl-glucopyranosiduronic acid,
Potassium salt.
TF - Inactive at 1.0 and
30.0
at 1.0, 20% at 3.0 and 0%
at 30.0
3) PPQ - 2.5 (1.0 - 6.6)
4) HP - 10% at 20.0, 0% at
50.0 and 100.0
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1)
2) TF vs M - 17% at 0.3, 33%
MCV 4254, NIH 9903, UM 1315. (+)-1-Methyl-4-isopentenyl-10-
hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA -ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
See MCV 4252 2) TF vs M - 27% at 1.0, 45%
(Optical isomer) at 10.0, 55% at 30.0
3) PPQ - 1.8 (0.6 - 5.4)
4) HP - 10.1 (7.1 - 14.4)
MONKEY DATA # ANIMALS 1 , 3 , 3 ,
(SDS) Doses (mg/kg/sc) 1.0 5.0 1 . 0
Vehicle-dil HCl and H20
MCV 4254 did not substitute for morphine in the dose range tested
However, the drug reduced the incidence of the withdrawal signs
retching and vomiting. At the highest dose, ataxia, nystagmus,
myoclonic jerks and miosis were noted. In the preliminary study
at a cummulative dose of 15 mg/kg in 30 min, the animal was se-
verely uncoordinated and could not climb to the perch.
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MCV 4259, NIH 9922. 3-(1,2 ,4 ,5 -Tetramethyl-4 -piperidinyl)-
m-phenol, z-2-butenedioic acid salt.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 2.9 (0.8 - 10.6)
2) TF vs M - 18% at 1.0, 15%
at 3.0, 5% at 10.0 and 0%
at 30.0
3) PPQ - 0.5 (0.2 - 1.4)
4) HP - 2.4 (1.7 - 8.3)
MONKEY DATA # ANIMALS
(SDS)
3 , 3 , 2 , Vehicle-H2O
Doses (mg/kg/sc) 1.5 3.0 6.0
MCV 4259 substituted completely and briefly for morphine in all the
animals at the highest dose. The onset of action was rapid. At
the intermediate dose, the drug substituted as above in 2 of 3 mon-
keys. The drug is estimated to be 1/4 - 1/2 as potent as morphine.
MCV 4260, NIH 9929 and 0001, UM 1311 and 114. Morphine.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 5.0 (2.9 - 8.9)
2) TF vs M - Inactive 1.0
and 30.0
3) PPQ - (3.1 (0.03 - 0.3)
4) HP - 0.9 (0.6 - 1.2)
5) N - 1.3 (1.0 - 1.9)
MONKEY DATA # ANIMALS 1 , 1 ,
2.5 5.0
2 , 1 ,
(SDS) Doses (mg/kg/sc) 10.0 20.0
Vehicle-dil HCL and H2O
At the 2 higher doses, MCV 4260 substituted completely for morphine.
The drug has a quick onset and a long duration of action (> 5 hr).
Some drowsiness noted at the 10.0 mg/kg dose. Drug supply was ex-
hausted.
435
MCV 4261 and 4002, NIH 9930 and 8503, UM 1312 and 792. Naltrexone
hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive 1.0 and 30.0
2) TF vs M - 0.001 (0.0004 -
0.004)
3) PPQ - Inactive at 1.0 and
30.0
4) HP - 10% at 20.0, 40% 
50.0
MONKEY DATA # ANIMALS 1 , 3 , 3 ,
A) (SDS) Doses (mg/kg/sc) 0.00015 0.006 0.0025
Vehicle-H2O
MCV 4261 did not substitute for morphine.
acerbated withdrawal at the highest dose.
The drug may have ex-
1 ,
0.00125
2 , 3 ,
0.005
2 ,
0.015
Vehicle-H2O
MONKEY DATA # ANIMALS
B) (PPt-W) Doses (mg/kg/sc) 0.0003
MCV 4261 precipitated dose-related withdrawal signs in morphine-
dependent monkeys. The drug has a quick onset of action. The
duration of action is approximately 1 hr longer than that of
naloxone and its potency is approximate 10 x that of the re-
ference compound (Naloxone).
MCV 4264, NIH 9905, UM 1308. (±)-1-Methyl-4-isopentenyl-10-hydroxy-
2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
See MCV 4252 2) TF vs M - 24% at 1.0, 16%
at 30.0
3) PPQ - 6.9 (4.0 - 11.8)
4) HP - 20% at 20, 70% at
50.0
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MCV 4265, NIH 9906 UM 1309. 1,12 -Dimethyl-4-isopentenyl-10-
hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 12.2 (4.3 - 34.9)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 2.1 (0.7 - 6.2)
4) HP - 11.5 (8.9 - 15.0)
MCV 4266 and 4279, NIH 9926, UM 1310. (-)-N-Allyl-4-methoxy-
morphinan-6-one.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 4.7 (1.8 - 12.7)
2) TF vs M - 0% at 1.0 and
30.0
3) PPQ - 1.0 (0.3 - 2.9)
4) HP - 20% at 20.0, 30% at
50.0
MCV 4267, NIH 7912, UM 902. (±)-2-Allyl-2'-hydroxy-5,9 -dimethyl-
6,7-benzomorphan hydrochloride (SKF-10,047).
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 0.1 (0.004 - 0.4)
3) PPQ - 1.6 (0.6 - 4.6)
4) HP - Inactive
5) N - 16.1 (10.9 - 23.7)
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MCV 4269, NIH 9938. 5,9 -Dimethyl-2'-hydroxy-2-(4-methyl-pentyl)-
6,7-benzomorphan hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 3.3 (1.5 - 7.3)
2) TF vs M - 0% at 1.0 and
30.0
3) PPQ - 2.6 (1.0 - 7.9)
4) HP - 8.3 (6.0 - 11.4)
MCV 4270, NIH 9939, UM 1330. 6,7-Didehydro-4,5 -epoxy-6-fluoro-3-
hydroxy-17-n-propylmorphinan.
MOUSE DATA-ED5O (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 0.4 (0.1 - 1.4)
3) PPQ - 13% at 3.0, 38% at
10.0 and 49% at 30.0
4) HP - Insufficient activity,
toxic at 100.0
MONKEY DATA # ANIMALS 1 , 2 , 1 ,
A) (SDS) Doses (mg/kg/sc) 1.25 0.3 0.08
Vehicle - alcohol,
Tween 80, H2O
In the preliminary study, the monkey developed severe tremors after
receiving 5.0 mg/kg. The animal was given morphine twice to al-
leviate severe withdrawal in the regular SDS study, MCV 4270 did
not substitute for morphine in the dose range tested and appeared
to exacerbate withdrawal.
MONKEY DATA # ANIMALS 1 , 3 , 2 , 1 ,
B) (PPt-W) Doses (mg/kg/sc) 1.25 0.3
Vehicle - alcohol, Tween 80,
0.08 0.02
H2O
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MCV 4270, NIH 9939, UM 1330, (Cont'd)
MCV 4270 precipitated withdrawal signs at the 3 higher doses. Its
action was prompt and lasted 30-60 min longer than that of naloxone.
The drug is estimated to be about 2/3 as active as naloxone.
MCV 4271, NIH 9947. L-Tyrosyl-D-alanylglycyl-L-4-fluoro-
phenylalanyl-L-phenylglycinamide acetate.
MOUSE DATA-ED5O (95% C.L.)
(mg/kg/sc)
1) TF - 15.4 (5.3 - 44.8)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.06 (0.03 - 0.09)
4) HP - 2.1 (7.5 - 3.0)
MONKEY DATA # ANIMALS
(SDS) Doses (mg/kg/sc)
3 , 5 , 5 , 2 ,
8.0 4.0 2.0 1.0
Vehicle - H2O
At the 8.0 mg/kg dose, MCV 4271 substituted completely for morphine.
Drowsiness was also observed in one monkey at this dose. The onset
of action was delayed for 1/2 hr and the duration of action was
brief (60-90 min). At 4.0 and 2.0 mg/kg the drug substituted
briefly for morphine in 2 monkeys at each dose and drowsiness was
noted in all the animals. This compound is about 1/3 as active as
morphine.
MCV 4272, NIH 9948. L-Tyrosyl-D-alanylglycyl-N- -ethyl-L-m-bromo-
phenylalanine amide acetate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 11.3 (3.1 - 40.8)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.5 (0.2 - 1.6)
4) HP - 3.3 (2.3 - 4.9)
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MCV 4272, NIH 9948 (Cont'd)
MONKEY DATA # ANIMALS
(SDS) Doses (mg/kg/sc)
2 , 3 , 3 , 1 ,
8.0 4.0 1.0 0.25
Vehicle - H2O
At 8.0 mg/kg, the drug substituted completely in one of two monkeys
for about 2 hr. At 4.0 mg/kg; the drug substituted completely in
1 of 3 monkeys for the same length of time. Some drowsiness was
observed at all doses but the lowest. Exhaustion of drug supply
precluded a full evaluation of the compound.
MCV 4273, NIH 9949. N- -Methyl-L-tyrosyl-D-alanylglycyl-N- -ethyl-
L-p-fluorophenylalanine amide acetate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 2.5 (1.1 - 5.7)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ 0.06 (0.02 - 0.2)
4) HP - 0.7 (0.5 - 1.0)
MONKEY DATA # ANIMALS 3, 3 , 2 ,
(SDS)
Vehicle-H2O
Doses (mg/kg/sc) 3.0 1.5 0.75
At the highest dose, MCV 4273 briefly suppressed all withdrawal
signs; however, drowsiness was evident in 2/3 animals. The onset
of action was < 30 min and the duration of action was approximately
2 hr. At lower doses, the drug partially suppressed withdrawal.
Retching was the main sign suppressed. Approximately equipotent
with morphine.
MCV 4274, NIH 9950. N- -Methyl-L-tyrosyl-D-alanylglycyl-N- -cyclo-
propylmethyl-L- m-bromophenylalanine amide acetate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 11.8 (5.5 0 25.3)
2) TF vs M - Inactive at 1.0
and 30.0
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MCV 4274, NIH 9950 (Cont'd)
MONKEY DATA # ANIMALS
(SDS) Doses (mg/kg/sc)
3) PPQ - 0.02 (0.002 - 0.16)
4) HP - 2.1 (1.1 - 4.2)
2 , 2 , 1 , 1 ,
10.0 5.0 2.5 1.25
Vehicle - H2O
MCV 4274 substituted completely but briefly (1 to 2 hr) for mor-
phine at the 3 higher doses. Drowsiness was noted in many of the
animals at these doses. Approximately equipotent with morphine.
MCV 4275, NIH 9955. (±)-2,9 -Dimethyl-5-(m-hydroxyphenyl)morphan
hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 5.0 (2.0 - 12.8)
3) PPQ - 19% at 1.0 and 28%
at 30.0
4) HP - 9.3 (6.4 - 13.5)
MONKEY DATA # ANIMALS 1 , 2 , 1 , Vehicle-H2O
A) (SDS) Doses (mg/kg/sc) 4.0 1.0 0.25
In the dose range tested, the compound did not substitute for
morphine.
MONKEY DATA # ANIMALS 2 , 2 , 2 ,
B) (PPt-W) Doses (mg/kg/sc)
Vehicle-H2O
4.0 1.0 0.25
At the highest dose, MCV 4275 precipitated withdrawal. The onset
of action was prompt and the duration like that of naloxone. The
drug is about 1/80 as active as naloxone.
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MCV 4276, NIH 9450, UM 1305. 2,5-Dimethyl-2'-hydroxy-9 -isopentyl-
6,7-benzomorphan methanesulfonate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 13.8 (4.6 - 41.4)
4) HP - 14.1 (11.7 - 17.0)
5) N - 19.7 (13.4 - 29.0)
MCV 4279 (See MCV 4266) - Note MCV 4266 is identical with MCV 4279.
MCV 4280, NIH 9931, UM 1313. (-)-N-Cyclopropylmethyl-4-methoxy-
morphinan-6-one.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 16% at 1.0 and 14% at
30.0
2) TF vs M - 0.4 (0.1 - 1.6)
3) PPQ - 1.2 (0.3 - 4.1)
4) HP - 21.7 (17.9 - 26.3)
5) N - 0% at 10.0, 40% at 20.0
MCV 4281, NIH 9932, UM 1314. (-)-N-Cyclobutylmethyl-4-methoxy-
morphlnan-6-one hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 10.0 (2.5 - 40.1)
3) PPQ - 0.7 (0.3 - 1.8)
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MCV 4281, NIH 9932, UM 1314 (Cont'd)
4) HP - 50% at 20.0 6/10
convulsions at 50.0
5) N - 3.6 (2.5 - 5.4)
MCV 4282, NIH 9940. (+)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-
methyl-4-phenyl-2-naphthylamine hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - Inactive 1.0 and
30.0
3) PPQ - 4.4 (1.4 - 14.3)
4) HP - 0% at 20.0, 20% at
50.0 and 60% at 100.0
MCV 4283, NIH 9941. (-)-trans-N,N-Dimethyl-1,2,3,4-tetra-hydro-4-
methyl-4-phenyl-2-naphthylamine hydrochloride.
MOUSE DATA-ED 5 0 (95% C.L.)
(mg/kg/sc)
See MCV 4282
(Optical isomer)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 3.0 (1.2 - 7.6)
4) HP - 13.1 (9.9 - 17.3)
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MCV 4284, NIH 9942. (+)-trans-N,N-Dimethyl-1,2,3,4-tetra-
hydro-4-methyl-4-phenyl-2-naphthylamine hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
See MCV 4282
(Optical isomer)
1) TF - Inactive at 1.0 and
and 30.0
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 2.3 (0.9 - 6.1)
4) HP - 0% at 20.0, 40% at
50.0 and 30% at 100.0
MCV 4285, NIH 9943. (-)-cis-N,N-Dimethyl-1,2,3,4-tetra-hydro-4-
methyl-4-phenyl-2-naphthylamine hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
See MCV 4282
(Geometric isomer)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 1.9 (0.5 - 7.3)
4) HP - 5.6 (3.8 - 8.1)
MCV 4286, NIH 9945, UM 1327. (±)-2,9 -Dimethyl-5-(m-methoxyphenyl)
morphan hydrobromide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 0% at 1.0, 30%
at 30.0
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MCV 4286, NIH 9945, UM 1327 (Cont'd)
3) PPQ - 2% at 10.0 and 42%
at 30.0
4) HP - 10% at 20.0, 50% at
50.0
MCV 4288, NIH 9454, UM 1146.
phenethyl-6,7-benzomorphan.
9 -Ethyl-2'-hydroxy-5-methyl-2-
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 6.3 (0.2 - 239.9)
2) TF vs M - 4% at 1.0, 0% at
10.0, 58% at 30.0
RAT INFUSION (SM)
3) PPQ - 0.1 (0.006 - 0.3)
4) HP - 0.7 (0.6 - 0.9)
Although MCV 4288 did not completely suppress weight loss in
abruptly withdrawn morphine-dependent rats, it completely sup-
pressed behavioral withdrawal signs. When the drug was discon-
tinued weight loss was more precipitous and behavioral signs of
withdrawal were evident. The drug substitutes for morphine but
additional doses should be tested. Weight loss shown in Fig. and
withdrawal sign evaluation in table.
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Table
Mean Number of Withdrawal Signs1 Noted During 1/2 Hr Observa-
vation Period at Specified Intervals and Calculated Probability
Values2 for Comparisons Between H2O Only Group and MCV 4288
Group and Morphine Control.
Hr in Withdrawal
24 48 72 96
H2O only x = 2.0 x = 1.0 x = 0.4 x = 1.2
N = 5
Morphine Controls x = 10.4 x = 11.0 x = 13.8 x = 10.2
N = 5 p = 0.004 p = 0.008 p = 0.004 p = 0.004
Morphine Infusion x = 2.8 x = 3.8 x = 7.5 x = 5.5
MCV 4288 Subst. p = 0.409 p = 0.044 p = 0.076 p = 0.119
(200 mg/kg)
N = 4
(1 out of 5 died)
Morphine Infusion x = 3.8 x = 7.8 x = 13.0 x = 11.4
MCV 4288 Subst. p = 0.345 p = 0.155 p = 0.004 p = 0.012
(100 mg/kg)
N = 5
1) Hypersensitivity, squealing, aggression, wet dog shakes,
rubbing and chewing.
2) One-tailed tested (Mann Whitney U-Test).
MCV 4289, NIH 9927. (-)-3-Methoxy-N-methylmorphinan-6-one.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1)
2)
3)
4)
5)
TF - 0.3 (0.1 - 0.6)
TF vs M - Inactive at 1.0
and 30.0
PPQ - 0.005 (0.001 - 0.160)
HP - 1.1 (0.9 - 1.4)
N - 0.4 (0.3 - 0.6)
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MCV 4289, NIH 9927 (Cont'd)
MONKEY DATA # ANIMALS 1 , 2 , 1 , 2 , 1 ,
(SDS) Doses (mg/kg/sc) 2.0 1.0 0.5 0.25 0.06
Vehicle-DMSO and H2O
At all doses but the lowest dose, MCV 4289 substituted completely
for morphine. The onset of action was prompt. In one monkey re-
ceiving 1.0 mg/kg, the duration of action was about 7 1/2 hr. The
duration of action of the two active lower doses was about 1 hr.
Drowsiness was seen at all the active doses, except at the highest
dose. In one non-dependent animal receiving the compound, all
drug-induced signs such as sagging, drowsiness, slowing, ataxia
were reversed by 1.0 mg/kg of naloxone. Approximately 10 times
more potent than morphine.
MCV 4293, NIH 9971.
hydrochloride).
(-)-2,9 -Dimethyl-5-( m-hydroxyphenyl)morphan
MOUSE DATA-ED5O (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 1.9 (0.4 - 8.5)
4) HP - 40% at 20.0, 60% at
50.0
5) N - 0% at 20.0 and 25% at
50.0
MONKEY DATA # ANIMALS 2 , 2 , 2 ,
Doses (mg/kg/sc)
Vehicle-H2O
A) (SDS) 10.0 5.0 2.5
This compound did not substitute for morphine. At the highest
dose, both animals showed severe tremors; at lower doses tremors
were evident in all but one animal.
MONKEY DATA # ANIMALS 2 , 2 , Vehicle-H2O
B) (PPt-W) Doses (mg/kg/sc) 10.0 2.5
MCV 4293 precipitated withdrawal in the dose range of 2.5-10.0
mg/kg. The drug acted promptly and its duration of action was
30-60 min. longer than that of naloxone (duration 90 min). The
potency was estimated to be 1/200 that of naloxone. Drug supply
was exhausted.
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MCV 4294, NIH 9972. (+)-2,9 -Dimethyl-5-(m-hydroxyphenyl)morphan
hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
See MCV 4293
(Optical isomer)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 4.5 (1.7 - 11.8)
3) PPQ - Inactive at 1.0 and
30.0
4) HP - 10% at 20.0 and 50.0
5) N - Inactive at 20.0
MONKEY DATA # ANIMALS 2 , 2 , Vehicle-dil
A) (SDS) Doses (mg/kg/sc) 8.0 4.0 HCl and H2O
At the highest dose, the drug seemed to exacerbate withdrawal.
Tremors were especially evident at this dose. The drug did
not substitute for morphine.
MONKEY DATA # ANIMALS 2 , 2 , 2 , Vehicle-H2O
B) (PPt-W) Doses (mg/kg/sc) 12.0 6.0 3.0
MCV 4294 precipitated withdrawal at all three doses. At the
highest dose, one monkey was given pentobarbital 50 min after
receiving the compound to terminate severe tremors. At the
lowest dose, one animal showed withdrawal. The onset of action
was prompt; the duration was 30-60 min longer than that of
naloxone. The potency is approximately 1/100 that of naloxone.
MCV 4295, NIH 9974. (-)-N-Allyl-4-hydroxymorphinan-6-one.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 0.7 (0.3 - 1.6)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.1 (0.04 - 0.3)
4) HP - 1.8 (1.5 - 3.2)
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MCV 4296, NIH 9975, UM 1347. (-)-N-Allyl-14-hydroxy-4-methoxy-
morphinan-6-one.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 3.3 (1.3 - 8.8)
3) PPQ - 8.7 (1.8 - 42.6)
4) HP - 0% at 20 and 20%
at 50
MCV 4297, NIH 9976. (-)-N-Allyl-4,5-epoxymorphinan-6-one.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - Inactive at 1.0
and 10.0
3) PPQ - 2.3 (1.1 - 5.0)
4) HP - 6.4 (4.4 - 9.5)
5) N - 8.3 (6.0 - 11.4)
MCV 4298, NIH 9977. (-)-N-Cyclopropylmethyl-14-hydroxy-4-methoxy
morphlnan-6-one.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 0.9 (0.4 - 2.0)
3) PPQ - 2% at 1.0 and 23% at
30.0
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MCV 4298, NIH 9977 (Cont'd)
4) HP - 10% at 20.0 and 25%
at 50.0
5) N - 0% at 20.0 and 25%
at 50.0
MCV 4299, NIH 9989. (-)-N-Methylmorphinan d-tartrate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 3.9 (2.1 - 7.2)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 2.4 (1.3 - 4.3)
4) HP - 2.3 (1.7 - 3.2)
5) N - 2.5 (1.7 - 3.7)
MCV 4305, NIH 9959, UM 1340. (-)-14-Hydroxy-4-methoxy-N-methyl-
morphinan-6-one.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - a. 3.3 (1.1 - 9.6)
b. 0.6 (0.2 - 2.1)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.04 (0.01 - 0.14)
4) HP - 0.16 (0.12 - 0.21)
MCV 4308, NIH 10,001. 6-Desoxy-6,6-hydrazinaloxone.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
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MCV 4308, NIH 10,001 (Cont'd)
2) TF vs M - 0.06 (0.04 - 0.1)
3) PPQ - Inactive at 1.0 and
30.0
4) HP - 20% at 20.0, 0% at
50.0 and 100.0
5) N - Inactive at 100.0
MCV 4309, NIH 10,002. 6-Desoxy-6-isonitrosonaloxone.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 0.06 (0.02 - 0.1)
3) PPQ - Inactive at 1.0 and
10.0
4) HP - 20% at 20.0, 50.0 and
100.0
5) N - Inactive at 100.0
MCV 4310, NIH 10,003. 6-Desoxy-6,6-hydrazinaltrexone
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 0.02 (0.01 - 0.03)
3) PPQ - Inactive at 10.0 and
30.0
4) HP - 0% at 20.0 and 100.0
5) N - Inactive at 100.0
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MCV 4311, NIH 10,004. 6-Desoxy-6-isonitrosonaltrexone.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
2) TF vs M - 0.08 (0.03 - 0.2)
3) PPQ - Inactive at 1.0 and
3.0
4) HP - 20% at 20.0, 50.0 and
100.0
5) N - Inactive at 100.0
MCV 4312, NIH 10,005. 6-Desoxy-6,6-hydrazioxymorphone.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 2.2 (1.4 - 3.6)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.1 (0.03 - 0.4)
4) HP - 0.6 (0.4 - 0.8)
5) N- 0.5 (0.3 - 0.7)
MCV 4313, NIH 10,007. (-)-14-Hydroxy-N-methylmorphinan.
MOUSE DATA-ED5O (95% C.L.)
(mg/kg/sc)
1) TF - 4.7 (2.0 - 10.7)
2) TF vs M - Inactive 1.0 and
30.0
3) PPQ - 1.0 (0.4 - 2.3)
4) HP - 3.6 (2.7 - 4.8)
5) N - 4.2 (3.0 - 6.0)
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MCV 4314, NIH 10,008. 6-Desoxy-6-isonitrosooxymorphone hydrobromide.
MCV 4315, NIH 10,009. (-)- 14-Hydroxy-N-methylmorphinan-6-one.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 0.7 (0.3 - 1.7)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.05 (0.01 - 0.2)
4) HP - 0.8 (0.7 - 1.0)
5) N - 2.0 (1.4 - 2.4)
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/scJ
1) TF - 0.4 (0.2 - 0.8)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.3 (0.1 - 0.8)
4) HP - 0.5 (0.4 - 0.7)
5) N - 0.5 (0.4 - 0.7)
MCV 4316, NIH 10,010. (-)-N-Allylmorphinan-6-one.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 6.3 (3.5 - 11.4)
2) TF vs M - Inactive at 1.0
and 10.0
3) PPQ - 0.5 (0.2 - 1.4)
4) HP - 2.9 (2.1 - 3.9)
5) N - 1.8 (1.3 - 2.7)
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MCV 4317, NIH 10,015. (-)-3,4-Dimethoxy-5,17-dimethyl-morphinan-6-
one hydrobromide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 2.2 (0.7 - 6.8)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.3 (0.08 - 0.81)
4) HP - 0.8 (0.6 -1.1)
MCV 4318, NIH 10,016. (-)-N-Allyl-3,4-dimethoxymorphinan-6-one.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 21% at 3.0, 39% at
10.0 and 46% at 30.0
2) TF vs M - 4.6 (1.3 - 16.1)
3) PPQ - 1.5 (0.4 - 5.0)
4) HP - 10.6 (8.0 - 14.1)
MCV 4322, NIH 10,020. 1,3a -Dimethyl-2,3,3a,6,7,7a -hexahydro-
4-m-hydroxyphenyl-1H-indole.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF -Inactive at 1.0 and
30.0
2) TF vs M - 1.7 (0.5 - 6.6)
3) PPQ - Inactive at 1.0 and
30.0
4) HP - 40% at 20.0 and 50.0,
50% at 100.0
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MCV 4322, NIH 10,020 (Cont'd)
MONKEY DATA # ANIMALS 2 , 1 , 1 ,
A) (SDS) Doses (mg/kg/sc) 4.0 2.0 1.0
Vehicle-dil HCl and H2O
The drug did not substitute for morphine and appeared to exacer-
bate withdrawal. One of the monkeys at the highest dose and
one receiving vehicle were given morphine to alleviate severe
tremors.
MONKEY DATA # ANIMALS 2 , 3 , 2 ,
B) (PPt-W) Doses (mg/kg/sc) 8.0 4.0 1.0
Vehicle dil-HCl and H2O
This compound promptly precipitated withdrawal at the 2 higher
doses. The duration of action was similar to that of naloxone.
The potency is estimated at 1/80 that of naloxone.
MCV 4323, NIH 10,022. p-Fluorofentanyl hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
2) TF - 0.03 (0.01 - 0.08)
3) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.0006 (0.00007 -
0.005)
4) HP - 0.015 (0.011 - 0.020)
MONKEY DATA # ANIMALS 2 , 2 , 2 , Vehicle-H2O
(SDS) Doses (mg/kg/sc) 0.04 0.01 0.003
This compound substituted completely for morphine at the 2 higher
doses. However, the onset of action was slightly delayed (< 30
min) and the duration was about 90 min. Some drowiness was obvious
at that dose. The drug is estimated to be about 100 X as potent as
morphine.
MCV 4324, NIH 10,024. -(-)-N-Propynyl-N-normetazocine hydrobromide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - Inactive at 1.0 and
30.0
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MCV 4324, NIH 10,024 (Cont'd)
2) TF vs M - 0.3 (0.1 - 0.7)
3) PPQ - 0.2 (0.01 - 0.4)
4) HP - 50% at 20.0, 20% at
50.0 Toxic at 50.0
5) N - 0% at 20.0, 12% at
50.0
MONKEY DATA # ANIMALS 2 , 2 , 2 , Vehicle-H2O
A) (SDS) Doses (mg/kg/sc) 0.25 0.06 0.015
MCV 4324 did not substitute for morphine. The drug exacerbated
withdrawal at the 2 higher doses.
MONKEY DATA # ANIMALS 1 , 2 ,
Doses (mg/kg/sc)
2 , Vehicle-H2O
B) (PPt-W) 0.5 0.125 0.03
The compound precipitated withdrawal at all doses but the lowest.
The onset of action is rapid. The duration of action is about
30 min longer than that of naloxone. Naloxone is approximately
25 X more potent.
MCV 4325, NIH 9801. (+)-Nicotine di-d-tartrate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF - 3% at 1.0 and 21% at
30.0
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 22% at 27.0, 44% at
90.0 and 76% at 180.0
4) HP - 23.3 (16.7 - 32.1)
5) N - 38.2 (26.2 - 55.8)
MONKEY DATA # ANIMALS 2 , 3 , 1 , Vehicle-H2O
(SDS) Doses (mg/kg/sc) 4 . 02 . 00 . 5
Produced abdominal muscle relaxation and suppressed vocalization
when abdomens were palpated in approximately 1/2 the animals
tested at the 2 higher doses. The withdrawal sign retching was
also suppressed at the highest dose. This isomer did not substitute
completely for morphine. It is 1/4 to 1/5 as potent as its natural
isomer. More studies are recommended.
456
Evaluation of New Compounds
for Opioid Activity: 1982
Annual Report
James H. Woods, Jonathan L. Katz, Fedor Medzihradsky,
Charles B. Smith, and Gail D. Winger
The evaluation of new compounds by the programs at the University
of Michigan and the Medical College of Virginia is coordinated by
Dr. Arthur E. Jacobson, Medicinal Chemistry Section, NIADDKD,
National Institutes of Health, Bethesda, MD. The drugs, which come
originally from pharmaceutical companies, universities, and govern-
ment laboratories, are submitted to Dr. Jacobson, who performs the
MOUSE ANALGESIA tests. Values obtained in these tests for some
representative opioid drugs are given in Table I.
At the UM and MCV laboratories, drug samples arrive from Dr.
Jacobson with only the following information: (1) an identifying
NIH number, (2) molecular weight, (3) solubility information, (4) a
recommended starting dose, and (5) mouse analgesia data. Only
after the evaluation is completed and the report sent by Dr.
Jacobson to the submitter is the chemical structure released to the
evaluating laboratory.
DEPENDENCE EVALUATION IN RHESUS MONKEYS
The single-dose suppression test (SDS) determines the ability of a
drug to suppress the signs of withdrawal in monkeys which have been
made dependent by the chronic administration of morphine (3 mg/kg
every six hours). Compounds suspected of having morphine-
antagonist properties are tested for their ability to precipitate
the withdrawal syndrome in nonwithdrawn (NW) morphine-dependent
monkeys. Nondependent monkeys (Normals) are used to determine
whether the acute effects of the test drug are reversible by nalor-
phine or naloxone. In a primary dependence study (PDS), non-
dependent monkeys receive the test drug every six hours for 30 days
to determine whether withdrawal signs will appear when the animals
are challenged with an antagonist or when drug administration is
discontinued.
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Details of these techniques have been presented in the ANNUAL
REPORT to the Committee in 1963 (Minutes of the 25th Meeting) by
Deneau and Seevers (1963) and by Villarreal (1973).
SELF-ADMINISTRATION BY MONKEYS
Tests of self-administration determine the ability of the drug to
maintain responding in monkeys trained to self-inject codeine.
Each of at least three monkeys was studied with saline as a nega-
tive control and a number of doses of the test compound until a
maximum rate of responding was obtained or until, in the absence of
evidence of a reinforcing effect, directly observable changes in
behavior were produced by the compound.
The schedule of intravenous drug delivery was a-fixed-ratio 30;
when a light above a lever was illuminated, the 30th response pro-
duced a five-second intravenous drug injection accompanied by a-
nother light that was illuminated during drug delivery. After each
injection, a ten-minute timeout condition was in effect during
which responses had no scheduled consequence and neither light was
illuminated. Each of the two daily sessions consisted of 13 injec-
tions or 130 minutes, whichever occurred first. Other details of
the procedure and initial findings with a variety of narcotics are
given in previous reports (Woods, 1977; 1980).
Doses of the drugs are typically described in terms of moles/kg/-
injection (inj), to facilitate direct comparisons among drugs.
Duplicate, observations of codeine (7.5 x 10 mol/kg/inj; 0.32
mg/kg/inj) and of saline were obtained for each monkey. A saline
substitution was conducted before and after the series of observe-
tions on a test drug; the control rates of codeine-reinforced re-
sponding were obtained by a random sampling of two sessions inter-
polated between the drug-substitution sessions. These data are
represented in the following graphs with individual symbols for
each of the monkeys; each symbol is the mean of duplicate observa-
tions for a given dose in each monkey. There are two additional
types of averaged data presented. The closed circles indicate the
averaged data for observations on the subset of monkeys used to
study each drug under each of the experimental conditions. The
open circles indicate the codeine and saline rates of responding of
20 monkeys studied under the same conditions. The brackets indi-
cate ± 3 standard errors of the codeine mean, and + 3 standard
errors of the saline mean for the group of 20 monkeys. In all
cases, the rates of responding given are those calculated during
only the fixed-ratio portion of each session.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
Details of the binding assay were described in the 1978 ANNUAL
REPORT (Swain et al., 1978). Briefly, aliquots of a membrane prep-
aration from rat cerebrum were incubated with 3H-etorphine in the
absence and presence of 150 mM NaCl, and in the presence of dif-
ferent concentrations of the drug under investigation. Stereo-
specific, i.e., opiate receptor related, interaction of 3H-etor-
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TABLE I
MOUSE ANALGESIA. Before submission to The University of Michigan, all compounds are evaluated
for analgesic activity by Dr. Arthur E. Jacobson. Shown below are comparative data (ED 50mg/kg)
(95% Confidence Interval) from Hot Platea-c and Nilsend assays. mol/kg
TABLE I Continued
No antinociceptive activity in hot plate assay: Phenobarbital, amobarbital, diazepam,
meprobamate, mescaline, oxazepam, flurazepam.
Chlorpromazine.HCl 1.1 (0.9-1.5)
--------------
3.2 (2.4-4.2)
a) Eddy and Leimbach (1953); b) Jacobson and May (1965); c) Atwell and Jacobson (1978); d)
Perrine, Atwell, Tice, Jacobson and May (1972).
phine was determined as the difference in binding obtained in the
presence of an appropriate excess of dextrorphan and levorphanol,
respectively. The potency of the drugs in inhibiting the stereo-
specific binding of 3H-etorphine was determined from log-probit
plots of the day. It should be noted that since April 1982 the
concentration of 3H-etorphine in the binding assay was reduced from
3.0 nM to 0.5 nM, a concentration approaching the KD of the radio-
labeled opiate. This change was implemented in order to let the 74
determined EC50 approximate the true Ki of a given drug. However,
due to the different concentration of the radiolabeled ligand, the
EC50's determined since April, 1982 are lower than those obtained
previously. For the purpose of reference, Table II contains EC50
values of representative opiates determined in binding assays using
0.5 nM 3H-etorphine. Unless specifically noted in the Report, it
should be assumed that 3.0 nM etorphine was used in the binding
assays.
INHIBITION OF TWITCH IN ELECTRICALLY-DRIVEN GUINEA PIG ILEUM AND
MOUSE WAS DEFERENS PREPARATIONS.
Submitted drugs are evaluated on two smooth muscle preparations,
the details of which were described in the 1978 ANNUAL REPORT
(Swain et al, 1978). Showwn in the following pages are the EC50's
for the tested drug alone, for the drug in the presence of nal-
trexone (a pure opioid antagonist which is more effective against
so-called "mu" agonists than against so-called "kappa" agonists),
and for the drug in the presence of UM 979 (an antagonist which
appears to be n-ore effective against "kappa" than against "mu"
drugs) (Smith, 1978). The maximum depression of the electrically
induced twitch in each of the preparations is also indicated. The
concentrations of both naltrexone and UM 979 used in tests of
antagonism are for the guinea pig ileum always 10-7 M and for the
mouse vas deferens always 10-8 M.
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TABLE II
EC50 of representative opiates in displacing
0.5 nM 3H-etorphine in a membrane preparation
from rat cerebrum
Compound
UM 911
Morphine
Dextrorphan
UM 1071R
Ketazocine
Ethylketazocine
(-)SKF 10047
Etorphine
(-)Cyclazocine
Naltrexone
EC50 (nM)
-NaCl +NaCl
14.6 28.3
14.0 23.6
6180 9820
1.14 1.55
10.7 14.1
5.22 6.60
4.09 3.93
0.47 0.37
0.85 0.53
1.43 0.63
+Na/-Na
1.94
1.69
1.59
1.36
1.32
1.26
0.96
0.79
0.63
0.44
NOTE: Binding data for these and other compounds, determined in
binding assays using 3.0 nM 3H-etorphihe, are included in the 1978
and 1981 ANNUAL REPORTS.
SUMMARY OF TESTS PERFORMED
The compounds which were evaluated at the University of Michigan
during the past year and the individual tests which were performed
are shown in Table III. Also shown are dates of Annual Reports in
which results are reported of earlier tests on those compounds con-
ducted at Michigan.
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TABLE III
SUMMARY OF TESTS PEFORMED
UM NIH
1216 9721
1222 9742
1227 9739
1232 9769
1234 9651
1236 9771
1238 9791
1239 9788
1240 9787
1241 9790
1244 9803
1247 9806
1248 9807
1249 9808
1250 9809
1251 9810
1256 9827
CHEMICAL CLASS AND/OR
MCV GENERIC NAME SDS N W
- - -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
+ + - -
+
N SA GPI MVD BIND PDS
+ + + + -
- + -I- + -
- - - + -
- + + 1980 1980
- + + + -
- + + - -
+ 1981 1981 1981 -
+ - -- -
- - - + -
- - - + -
+ + + -
+ - - + + + -
- - - - + -I- + -
- - - - + + + -
- + - - + + + -
- - - - + + + -
- - - - + + + -
4186
4200
4178
4205
4210
4208
4209
4211
4265
4215
4216
4217
4218
4223
1-allylpiperidine
2-nitronaloxone
norketobemidone
methylpiperidine
peptide
acetoxymorphinan
norketobemidone
noroxymorphone
norketobemidone
6,7-benzomorphan
6,7-benzomorphan
6,7-benzomorphan
Flurazepam
TABLE III Continued
UM
1269
1275
1278
1279
1282
1283
1284
1288
1289
1290
1292
1293
1305
1308
1309
1310
1311
1312
NIH
9614
9891
9904
9897
9881
9882
9883
9889
9890
9895
9899
9900
9450
9905
9906
9926
9929
9930
CHEMICAL CLASS AND/OR
MCV GENERIC NAME
4169 homobenzomorphan
4246 n-propylmorphan
4252 benzazonine
4248 benzazonine
4239 morphan
4240 methhylmorphan
4244
4245
4235
4237
4238
4276
4264
4265
morphan
methylmorphan
morphan
benzazonine
benzazonine
benzazonine
benzomorphan
benzazonine
benzazonine
4266 methoxymophinan
4260 morphine
4261 naltrexone
SDS NW N
- - - -
- + - - + -
+ - - - + -
+ - - - + -
- - - +- -
- - - - + -
- - - - + -
- - - - + -
- - - - + -
- - - - + -
- - - - + -
- - - - + -
+ + - - - - - -
+ - - - + -
+ - - - + -
+ - - - - - -
- - - - - - -
+
SA
+
GPI MVD BIND PDS
1981 1981 1981
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ - - - - - -
TABLE III Continued
U N
1313
1314
1315
1325
1327
1330
1338
1339
1340
1344
1347
1381
1384
1385
1388
1401
NIH
9931
9932
9903
9508
9945
9939
9957
9958
9959
9960
9975
10015
10017
10018
10021
9615a
CHEMICAL CLASS AND/OR
MCV GENERIC NAME
4280 methoxymorphinan
4281 methoxynmophinan
4254 benzazonine
4142 nordihydrocodeinone
4286 morphan
4270 propylmorphinan
methylmorphinan
methylmorphinan
4305 mehylmorphinan
methylmorphinan
4296 methoxymorphinan
4317 dimethylmorphinan
dimethoxymorphinan
dimethoxymorphinan
morphan
4176 benzazcxine
SDS MVD BIND PDS
- - - - - - -
+ - - - - - - -
- - - - + + -
- - - + - - -
+
N W
+
+ - - - - - -
- - - - + + + -
- - - + + + -
- - + + + + -
- - - + + + -
- - - - - - -
- - - - - - -
- - - + + + -
- - - - - - -
+
N SA
+
GPI
-
-
-
-
+
+
+
+
+ - - - - - -
+ - - - - - - -
- - - - - - +
UM 1216 NIH 9721 MCV 4186
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Incompletely
active at 100
2-beta-Methylamino-1-phenylcyclopentanol propanoate ester, hydrogen
maleate
DRUG SELF-ADMINISTRATION RHESUS MONKEYS
UM 1216 maintained. over a wide range of doses, rates of responding
that were no different than those maintained by saline.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
The EC50 of UM 1216 in displacing tritiated etorphine, in the
presence and absence of NaCl, was higher than 20 UM.
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INHIBITION OF TWITCH TO ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
In concentrations which ranged from 10-9M to 3 x 10-4M UM 1216 had
no activity except for a slight decrease in the magnitude of the
twitch at the highest concentration. Increases in baseline tension
were observed at concentrations 3 x 20-6 M to 3 x 10-4 M Neither
naltrexone nor UM 979 altered responses to UM 1216.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Concentrations between 10-9 M to 3 x 10-5 M DM 1216 had no effect.
At concentrations between 3 x 10-5 M and 3 x 10-4 M, there was a
marked increase in the magnitude of the twitch. This drug did not
increase the baseline tension. UM 1216 did not directly contract
the vas deferens. Naltrexohe and UM 979 did not alter responses to
this drug.
SUMMARY
UM 1216 appears to be devoid of morphine-like activity. It has a
very low potency in displacing tritiated etorphine. Its actions
upon the two smooth muscle preparations resemble those of the
withdrawal-inducing benzazocines, UM 1037 and UM 1046.
UM 1222 NIH 9742
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 30% @ 20, 60% @
50
Spiro[(l,l-dimethyl-3-ethyl-7-hydroxy-1H-2-benzopyran)-4,4'-
(l-allylpiperidine)] hydrobromide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
The EC50 of UM 1222 in displacing tritiated etorphine, in the
presence and absence of NaCl, was higher than 20uM.
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INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN-PIG ILEUM
At concentrations which ranged from 10-9 M to 10-4M this drug did
not inhibif the twitch except at highest concentrations (3 x 10-5
M) and 10-4 M) . The maximum inhibition ranged between and 42%.
EC50's could not be determined.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
At none of the concentrations studied (10-9 to 10-4M) did this drug
decrease the twitch. High concentrations (3 x 10-5 and 10-4 M)
caused a two-fold increase in the magnitude of the twitch. Neither
naltrexone nor UM 979 altered responses to UM 1222.
SUMMARY
UM 1222 is devoid of opiate activity in the binding assay and upon
the guinea pig ileum and mouse vas deferens.
UM 1227 NIH 9739 MCV 4200
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 3.5 (2.8-4.3)
Nilsen: 6.0 (4.5-8.0)
2-Nitronaloxone
DISPLACEMENT OF STEPEOCSPECIFIC 3H-ETORPHINE BINDING
The EC50 of UM 1227 in displacing tritiated etorphine, in the
presence or absence of NaCl, was higher than 20 UM.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
At concentrations used for this preparation the compound was not
soluble.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFEPENS
At concentrations used for this preparation the compound was not
soluble.
468
UM 1232 NIH 9769
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 23.6 (17.7-31.5)
N-Pentylacetate-N-norketobemidone
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 2200 nM in absence of NaCl
EC50 of 1957 nM in presence of NaCl
Sodium ratio = 0.89
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug Alone
After naltrexone
After UM 979
2.29 x 10-6 M 43.6
no response
no response
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
UM 1232 did not decrease the magnitude of the twitch, but caused
large increases in the magnitude of the twitch at the highest
concentrations studied.
OBSERVATIONS IN MORPHINE-DEPENDENT MONKEYS
UM 1232 increased the severity of morphine withdrawal in the
morphine-dependent monkey but was not very potent in doing so.
SUMMARY
UM 1232 appears to have some morphine-like activity upon the guinea
pig ileal preparation although it is about 100-fold less potent and
about two-thirds as efficacious as morphine. It is devoid of
opiate activity on the mouse vas deferens.
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UM 1234 NIH 9651 MCV 4178
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 17.2 (7.3-40.4)
N-Cyclopropylmethyl-6,6-difluorodihydromorphine hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 0.54 nM in absence of NaCl
EC50 of 0.31 nM in presence of NaCl
Sodium ratio = 0.57
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 6.05 x 10-9 M 66.1
After naltrexone 9.79 x 10-9 M
After UM 979 7.36 x 10-9 M
65.9
62.8
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Only at the highest concentration (10-4 M) did UM 1234 inhibit the
twitch.
effect of
Neither naltrexone or UM 979 affected inhibitory
UM 1234. Concentrations between 3 x 10-6 and 10-4 M
caused large increases in the magnitude of the twitch.
SUMMARY
UM 1234 has a high affinity in the opiate receptor binding assay
with a sodium response ratio that suggests antagonist activity.
Its inhibitory actions on the smooth muscle preparations were not
reversed by narcotic antagonist nor were the increases in twitch
height produced at higher concentrations altered by narcotic
antagonist. Thus, this compound may have antagonist actions in vivo
at low doses and non-narcotic actions at much higher doses.
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UM 1236 NIH 9771 MCV 4205
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0% @ 20, 80% @
50, 40% @ 100
4-(1-Hydroxypropyl)-4- m -hydroxyphenyl-1-methylpiperidine
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
Drug alone
After naltrexone
After UM 979
EC50 Maximum Response (%)
3.44 x 10-6 M
9.53 x 10-6 M
91.5
6.32 x 10-6 M
unchanged
unchanged
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response (%)
Drug alone
After naltrexone
After UM 979
7.52 x 10-7 M
2.62 x 10-6 M
83.0
unchanged
6.71 x 10-6 M unchanged
SUMMARY
On both smooth muscle preparations UM 1236 had effects similar to
morphine which were antagonized slightly by naltrexone, but not by
UM 979. It was considerably less potent than morphine on both
preparations.
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UM 1238 NIH 9791 MCV 4210
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 1.4 (1.1-1.8)
Nilsen: 1.5 (1.1-2.1)
N-Methyl-L-tyrosyl-D-serylglycyl-N-methyl-L-phenylalanyl-D-
serinamide monoacetate
DRUG-SELF ADMINISTRATION IN RHESUS MONKEYS
At doses of 1.55 x 10-6 and 4.95 x 10-6, rates of responding were
slightly higher than those maintained by saline. At doses of 1.55
x 10-7, 4.95 x 10-7 and 1.55 x l0-5 rates were no higher than those
maintained by saline.
472
UM 1239 NIH 9788
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Incompletely
active at 100
mg/kg
Nilsen: 25.8 (17.4-38.5)
1-(3-Chlorophenyl)2-(1,1-dimethylamino)propan-1-one
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS
UM 1239 maintained rates higher than the average codeine rates in
all 3 monkeys tested (134% of the codeine rate). 3.62 x 10-6
mol/kg (3.0 mg/kg) maintained an average rate 102% of that
maintained by codeine. Lower and higher UM 1239 injection doses
maintained rates not higher than those maintained by saline. Like
other stimulants of the amphetamine-like substituted
phenylethylamine class and cocaine, this drug produced high rates
of drug-maintained responding.
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UM 1240 NIH 9787 MCV 4208
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 20% @ 20, 0% @
50, 40% @ 100
Nilsen: 0% @ 5, 25% @ 10
& 40, 50% @ 20
17-Cyclopropylmethyl-6,7-dehydro-4,5-alpha-epoxy-6-fluoro-3-
acetoxymorphinan
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 3.92 nM in absence of NaCl
EC50 of 2.29 nM in presence of NaCl
Sodium response ratio = 0.58
UM 1241 NIH 9790 MCV 4209
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: 16.6 (12.5-22.1)
Nilsen:
3-Methylpentyl-N-norketobemidone hydrobromide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 515 mM in absence of NaCl
EC50 of 515 mM in presence of NaCl
Sodium response ratio = 1.00
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UM 1244 NIH 9803 MCV 4211
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 7.7 (5.9-10.0)
Nilsen: 20.1 (15.9-25.4)
(-)-N-(2-Methoxyethyl)noroxymorphone hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 4.97 nM in absence of NaCl
EC50 of 2.99 nM in presence of NaCl
Sodium response ratio = 0.60
Maximum Response (%)
33.4
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINFA-PIG ILEUM
EC50
Drug alone 1.5 x 10-9 M
After naltrexone Completely antagonized
After UM 979 Completely antagonized
Maximum Response (%)
37.0
EC50
Drug alone 7.13 x 10-6 M
After naltrexone Completely antagonized
After UM 979 Completely antagonized
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1244 precipitated signs of narcotic withdrawal in the morphine-
dependent monkey. The signs were elicited promptly and at higher
doses were long lasting. UM 1244 is about 6 to 10 times as potent
as nalorphine and comparable to naloxone or naltrexone.
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SUMMARY
The compound posesses both narcotic agonist and antagonist actions
with the latter occurring at quite low doses. It may also be a
partial agonist in both smooth muscle preparations.
UM 1247 NIH 9806 MCV 4214
MOUSE ANATLGESIA, ED50 (mg/kg)
Hot Plate: 20.5 (13.6-30.9)
N-[3-(N,N-Dimethylcarbamoyl)-3,3-diphenylpropyl]-norketobemidone
hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 85.9 nM in absence of NaCl
EC50 of 94.8 nM in presence of NaCl
Sodium response ratio = 1.10
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINFA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 1.16 x 10
-7 M 53.7
After naltrexone
After UM 979
Completely antagonized
2.11 x 10-6 M 33.1
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response (%)
Drug alone 4.29 x 10-8 M 91.3
After naltrexone 2.24 x 10
-7 M 58.4
After UM 979 1.95 x 10
-7 M unchanged
476
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEYS
At doses of 3 to 10 mg/kg, UM 1247 was without effect but abscesses
at injection sites that did not occur after vehicle alone suggest
that the drug may not have been absorbed.
SUMMARY
The effects of UM 1247 in the binding assay and the muse vas
deferens agree and suggest a potency comparable to morphine.
However, its lack of action in the dependent rhesus monkey at 3 to
10 q/kg doses; (doses that should be active based on the in vitro
potency) suggests that the compound may be poorly absorbed when
administered subcutaneously. It has morphine-like activity on the
mouse vas deferens and the guinea pig ileum preparations. It is
unusual that upon both preparations, naltrexone reduces or
abolishes responses to UM 1247. On the guinea pig ileum UM 979
also reduces the maximum response to UM 1247 but on the mouse vaS
deferens it seems to act as if it were a competitive antagonist of
UM 1247.
UM 1248 NIH 9807 MCV 4215
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.33 (0.24-0.44)
(-)-(1R,5R,9R)-5,9-Dimathyl-2'-hydroxy-2-(3-phenoxypro-
pyl)-6,7-benzomorphan hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 29.6 nM in absence of NaCl
EC50 of 90.6 nM in presence of NaCl
Sodium response ratio = 3.06
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 1.40 x 10-6 M 67.5
After naltrexone 3.22 x 10-5 M unchanged
After UM 979 1.42 x 10-4 M unchanged
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INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response (%)
Drug alone 6.11 x 10-7 M
After naltrexone 1.97 x 10-6 M
99.5
unchanged
After UM 979 1.50 x 10-6 M unchanged
SUMMARY
See UM 1249.
UM 1249 NIH 9808 MCV 4216
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 8.7 (6.3-12.1)
Nilsen: 11.7 (8.0-17.3)
(+)-(1R,5R,9R)-5,9-Dimethyl-2'-hydroxy-2-(3-phenoxypropyl)-6,7-
benzomorphan hydrochloride
DISPLACEMENT OF STERESPECIFIC 3H-ETORPHINE BINDING
UM 1249 failed to displace tritiated etorphine in presence or
absence of NaCl up to concentration of 2 uM.
INHIBITION OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
No response until a concentration of 10-5 M. Maximum responsewas
33-59% inhibition of the twitch. Concentrations of 10-4 M caused
spontaneous activity of the preparation and an increase in baseline
tension. Therefore, EC50 could not be calculated. Neither
naltrexone nor UM 979 altered responses to UM 1249.
INHIBITION OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
At no concentration did UM 1249 inhibit the twitch. At
concentrations of 3 x 10-6 M and higher there was an increase in
the magnitude of the twitch. The maximum increase was
approximately two-fold and occurred at a concentration of 10-5 M.
Neither naltrexone nor UM 979 altered responses to UM 1249.
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SUMMARY
In the binding assay UM 1248 was twice as potent as morphine in the
absence of sodium chloride. On both the muse vas deferens and
guinea pig ileum preparations, UM 1248 appears to be morphine-like
in its activity. It is about one-tenth the potency of morphine on
the mouse vas deferens preparation and one-hundredth the potency of
morphine on the guinea pig ileum. UM 1249, the (+)-isomer of UM
1248, is devoid of significant opiate activity on these
preparations although it produces analgesia with low potency.
UM 1250 NIH 9809 MCV 4217
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.008
(0.006-0.01)
(-)-[(1R,5R,2'')-5,9-Dimethyl-hydroxy-2-(2-methoxypropyl-6,7-
benzomorphan hydrobromide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 7.1 nM in absence of NaCl
EC50 of 15.1 nM in presence of NaCl
Sodium response ratio = 2.14
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 3.18 x 10-10 M 60.9
After naltrexone 7.99 x 10-8 M
After UM 979 2.96 x 10-9 M
63.7
52.8
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response (%)
Drug alone 2.44 x 10 -9 M 100
After naltrexone 4.75 x 10-9 M 99.4
After UM 979 4.14 x 10-9 M 100
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OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1250 produced sedation, ptosis, mydriasis, and ataxia at low
doses (0.003 to 0.03 mg/kg]. At doses of 0.0056 and 0.01 mg/kg the
drug also reversed withdrawal signs; however, complete reversal of
withdrawal was not obtained since marked sedation at higher doses
precluded the grading of withdrawal. The sedative effects of the
drug resembled those seen with ethylketazocine.
SUMMARY
Upon the guinea pig ileum UM 1250 appears to be morphine-like in
that it is antagonized by both naltrexone and UM 979. In contrast,
on the mouse vas deferens, although UM 1250 is 10 tines more potent
than morphine, it does not appear to be morphine-like since neither
naltrexone nor UM 979 caused large shifts to the right in the
concentration effect curve for UM 1250. The size of the sodium
response ratio obtained from the binding assay is consistent with
the agonist actions of the compound and the compound was
consistently more potent than morphine in each of the preparations.
The observations in morphine-dependent rhesus monkeys suggest that
UM 1250 may have mixed morphine-like and ethylketazocine-like
effects.
UM 1251 NIH 9810 MCV 4218
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 40% @ 20 & 50,
50% @ 100
Nilsen: 28.9 (18.9-44.3)
2,3-Dihydro-2-ethyl-3-[2-(dimethylamino)propyl]-3-phenyl-1H-indol-
1-carboxaldehyde methanesulfonate
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
UM 1251 failed to displace tritiated etorphine in the presence or
absence of NaCl up to concentrations of 10 uM.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 6.69 x 10-7 M 92.9
After naltrexone 8.67 x 10-7 M
After 979 7.24 x 10-7 M
93.9
91.0
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INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
UM 1251 did not inhibit the twitch of this preparation at any
concentration until 10-4 M at which there was a 100% inhibition of
the twitch. Neither naltrexone nor UM 979 has any effect upon
this response to UM 1251.
SUMMARY
UM 1251 is devoid of morphine-like activity.
UM 1256 NIH 9827 MCV 4223
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0% @ 20 & 100,
10% @ 50
Flurazepam hydrochloride
DISPLACEMENT OF STEREOPECIFIC 3H-ETORPHINE BINDING
UM 1256 failed to displace significantly tritiated etorphine in the
presence or absence of NaCl up to concentrations of 20 uM.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 1.57 x 10-5M
After naltrexone 3.26 x 10-5M
94.3
After UM 979 3.06 x 10-5M
95.2
94.2
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
After UM 979
EC50 Maximum Response (%}
1.73 x 10-9 M 59.8
1.01 x 10-9 M 78.1
7.84 x 10-10 M 48.3
481
SUMMARY
UM 1256 has two inhibitory effects upon the guinea pig ileal prep-
aration. At low concentrations it causes a slight inhibition. At
higher concentrations it causes a further inhibition. This latter
inhibition of the twitch is antagonized slightly by both naltrexone
and UM 979. On the mouse vas deferens, UM 1256 is devoid of
opiate-like activity.
UM 1269 NIH 9614 MCV 4169
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 2.5 (1.9-3.3)
Nilsen: 13.0 (9.6-17.7)
(-)-9-Hydroxy-4,7-dimethyl-C-homobenzbezomoprphan hydrobromide
DRUG SELF-INJECTION IN THE RHESUS MONKEY
UM 1269 maintained self-injection rates of responding slightly
above those of saline only at a dose of 1.03 x 10-6 Mol/kg/inj (0.3
mg/kg/inj). In only one of the three monkeys did UM 1269 maintain
rates of responding higher than those of saline. The maximum
percent of the codeine response rates was 26 at 1.03 x 10-5
ml/kg/inj. A  s i n g l e  o b s e r v a t i o n  w a s  m a d e  a t  3 . 2 1
ml/kg/inj. Following a single injection (10 mg/kg) the monkey was
sedated and ataxic. Following a second injection, he became
unresponsive. Naltrexone (0.32 mg/kg) did not alter the effect.
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UM 1275 NIH 9891 MCV 4246
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 9.2 (6.4-13.0)
(+)-5-(m-Hydroxyphenyl)2- n-propylmorphan hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 1970 nM in absence of NaCl
EC50 of 1760 nM in presence of NaCl
Sodium response ratio = 0.89
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 2.16 x 10-5 M 89.8
After naltrexone 7.64 x 10-5 M
After UM 979 1.56 x 10-4 M
92.2
85.3
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
At no concentration did UM 1275 inhibit the twitch of this
preparation. At concentrations of 3 x 10-6 M and higher there were
increases in the magnitude of the twitch. The maximum increase was
1.5-fold and occurred at a concentration of 3 x 10-5 M. Neither
naltrexone nor UM 979 altered this response to UM 1275.
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1275 failed to produce any effects over a range of doses from 1
to 5.6 mg/kg.
SUMMARY
UM 1275 might have some morphine-like activity upon the guinea pig
ileum preparation. Upon the ileum it is approximately 1000-fold
less potent than morphine although it is more efficacious in
suppressing the twitch. Both naltrexone and UM 979 slightly
antagonized responses to UM 1275. On the mouse vas deferens UM
1275 is devoid of morphine-like activity. Over the dose range
studied, UM 1275 was inactive in the morphine-dependent monkey;
however, the compound should be studied in vivo at higher doses
based on the in vitro findings.
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UM 1278 NIH 9904 MCV 4252
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 20% @ 20, 30% @
50
Nilsen: 25% @ 50
(-)-1-Methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-
methano-1H-4-benzazonine
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
UM 1278 failed to displace tritiated etorphine significantly either
in the presence or the absence of NaCl up to concentrations of 10
UM.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
At no concentration did UM 1278 inhibit the twitch of this
preparation. At concentrations of 10-5 M and higher UM 1278 caused
marked increases in the baseline tension of the preparation.
Neither naltrexone nor UM 979 altered responses to this compound.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
At no concentration did UM 1278 inhibit the twitch of this
preparation. At concentrations of 10-6 M and greater UM 1278
increased the magnitude of the twitch with the maximum response
being a two-fold increase which occurred at a concentration of 10-4
M. Neither naltrexone nor UM 979 altered responses of the
preparation to UM 1278.
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
There was a slight exacerbation of withdrawal signs at the 10 mg/kg
dose.
SUMMARY
Upon both the mouse vas deferens and guinea pig ileal preparations
UM 1278 is devoid of morphine-like activity. There was an
indication that withdrawal severity was enhanced by M 1278. This
general pattern of pharmcological effects resembles that of other
compounds evaluated previously (UM 1037 and UM 1046). See also the
racemate (UM 1308) and (+)-isomer (UM 1315) of this compound.
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UM 1279 NIH 9897 MCV 4248
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 80% @ 20 (50%
convulse), 40% @
10
Nilsen: inactive @ 5
±-1-methyl-4-allyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-
1H-4-benzazonine
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 6010 nM in the absence of NaCl
EC50 of 9810 nM in the presence of NaCl
Sodium response ratio = 1.63
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE GUINEA-PIG ILEUM
At no concentration did UM 1279 inhibit the twitch of this
preparation. At high concentrations UM 1279 caused increases in
the baseline tension. Neither naltrexone nor UM 979 altered
responses of this preparation to UM 1279.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Only at a concentration of 10-6 M did UM 1279 inhibit the twitch of
this preparation. Higher concentrations increased the magnitude of
the twitch. The maximum response was a 2-fold increase in twitch
height which occurred at a concentration of 10-4 M. Neither
naltrexone nor UM 979 altered responses of this preparation to UM
1279.
OBSERVATIONS IN NORMAL AND MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1279 produced a set of behavioral signs of ataxia,
unresponsiveness, incoordination, increased pupil size, and
increased respiration in both normal and morphine-dependent
monkeys. These signs resemble those of phencyclidine. UM 1279 was
slightly less potent than phencyclidine in producing these effects.
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SUMMARY
UM 1279 was devoid of morphine-like activity upon both smooth
muscle preparations, and at high concentrations the compound
resembled UM 1046 and UM 1037. UM 1279 displaced tritiatated
etorphine only at high concentrations. In the rhesus monkey, UM
1279 resembled phencyclidine. This compound resembles UM 1267,
1268, 1269, 1277, 1280 and 1281 in produced phencyclidine-like
actions while having little, if any, affinity in the opiate binding
assay. See also the (+)-isomer of this compound (Um 1290).
UM 1282 NIH 9881 MCV 4239
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0% @ 20, 30% @
50, 10% @ 100
(-)-5-(m-Hydroxyphenyl)morphan hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 3360 nM in the absence of NaCl
EC50 of 1810 nM in the presence of NaCl
Sodium response ratio = 0.53
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 9.50 x 10-9 M 15.3
After naltrexone abolished response
After UM 979 abolished response
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
UM 1282 was devoid of activity except at concentrations of 10-4 M
and higher at which it caused a marked suppression of the twitch.
SUMMARY
UM 1282 may have antagonist properties as suggested by its low
sodium ratio. The drug might also have a very slight morphine-like
effect upon the guinea pig ileum which is completely blocked by
both antagonists. In the mouse vas deferens, it appears to be
devoid of morphine-like activity and only at very high doses does
it suppress the twitch.
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UM 1283, 809 NIH 9882,8508 MCV 4240,4231
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 2.0 (1.4-2.8)
(-)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 487 nM in absence of NaCl
EC50 of 443 nM in presence of NaCl
Sodium response ratio =0.94
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 4.49 x 10-9 M 31.3
After naltrexone complete antagonism
After UM 979 complete antagonism
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response (%)
Drug alone 1.28 x 10-6 M 62.6
After naltrexone 2.09 x 10-6 M
After UM 979 1.50 x 10-6 M
42.8
54.8
SUMMARY
UM 1283 displaced etorphine with lower potency than morphine with
an intermediate value of the sodium response ratio. The potency
estimates are not closely matched between the binding and either of
the smooth muscle preparations. UM 1283 might have slight
morphine-like activity on the guinea pig ileum which is completely
blocked by both antagonists. On the muse vas deferens, UM 1283 is
an agonist of low potency and the effect of the antagonist is
somewhat unusual in that naltrexone alone decreases the magnitude
of the maximum response without changing the EC50 for DM 1283. The
(+)-isomer of this compound has greater narcotic activity (see UM
1288).
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UM 1284 NIH 9883
Hot Plate: 50% @ 20, 60% @
MOUSE ANALGESIA, ED50 (mg/kg)
50 (toxic @ 100)
12% @ 50
(-)-2-Ethyl-5-( m-hydroxyphenyl)morphan hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 3650 nM in absence of NaCl
EC50 of 1780 nM in the presence of NaCl
Sodium response ratio = 0.49
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 1.53 x 10-7 M 44.3
After naltrexone unchanged
After UM 979 unchanged
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
At no concentration did UM 1284 suppress the twitch of this
preparation,
although at concentrations of 10-5 and higher there were increases
in the magnitude of the elicited twitch. Neither naltrexone nor UM
979 altered the response of this compound.
SUMMARY
See UM 1289.
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UM 1258 NIH 9889 MCV 4244
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.63 (0.53-0.75)
(+)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING (0.5 nM)
EC50 of 56.6 nM in absence of NaCl
EC50 of 85.7 nM in presencse of NaCl
Sodium response ratio = 1.51
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 1.81 x 10-7 M 94.6
After naltrexone 1.23 x 10-5 M 78.7
After UM 979 4.31 x  10-6 M 86.9
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response (%)
Drug alone 9.96 x 10-7 M 100
After naltrexone 2.60 x 10-6 M 88.1
After UM 979 2.67 x 10-6 M 91.8
SUMMARY
Upon each of the preparations UM 1288 resembled morphine but was
somewhat less potent. See the (-)-isomer of this compound (UM
1283).
489
UM 1289 NIH 9890 MCV 4245
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 15.8 (12.1-20.5)
(+)-2-Ethyl-5-( m-hydroxyphenyl)morphan hydrochloride
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING (0.5 nM)
EC50 of 1462 nM in absence of NaCl
EC50 of 1593 nM in presence of NaCl
Sodium response ratio = 1.09
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 1.86 x 10-5 M 91.5
After naltrexone 2.07 x 10-5 M 85.2
After UM 979 9.67 x 10-6 M 80.9
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DFERENS
EC50 Maximum Response (%)
Drug alone 1.01 x 10-6 M 48.6
After naltrexone 2.89 x 10-6  M
After UM 979 1.39 x 10-6 M
39.2
32.8
SUMMARY
In the binding assay, both isomers (UM 1284 and UM 1289) have very
low potency. Additionally, they fail to have opiate-like agonist
activity upon either smooth muscle preparation.
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UM 1290 NIH 9895 MCV 4235
MOUSE ANALGESIA, ED50 (mg/kg)
Hot plate: 90% @ 5, 20% @ 2,
0% @ 1 (90%
convulsed @ 2)
Nilsen: 0% @ 5 & 1
(+)4-Allyl-10-hydroxy-1-methyl-2,3,4,5,6,7-hexahydro-1,6-methano-
1 H - 4 - b e n z a z o n i n e
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING (0.5 nM)
EC50 of 845 in absence of NaCl
EC50 of 1348 in presence of NaCl
Sodium response ratio = 1.59
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 7.42 x 10-7 M 42.3
After naltrexone slight decrease
After UM 979 no decrease
Both naltrexone and UM 979 markedly inhibited the response to UM
magnitude of the twitch increased.
1290. At concentrations of 1 x 10-6 M and higher, in the presence
of naltrexone , the magnitude of the twitch was increased. At
concentrations of 10-6 M and higher, in the presence of UM 979, the
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response (%)
Drug alone 1.81 x 10-7 M 69.8
After naltrexone 6.60 x 10-8 M
After UM 979 1.02 x 10-7 M
64.5
74.7
SUMMARY
Upon the guinea pig ileum, UM 1290 appears to have some opiate-like
actions although these are not pronounced. Upon the muse vas
deferens, UM 1290 appears to be devoid of opiate-like activity.
See also the racemate (UM 1279).
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UM 1292 NIH 9899 MCV 4237
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 30% @ 20, 50% @ 5
Nilsen: 0% @ 5 & 1
(+)-4-Cyclopropylmethyl-10-hydroxy-1-methyl-2,3,4,5,6,7-hexahydro-
1,6-methano-1H-4-benzazonine
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING (0.5 nM)
EC50 of 1223 in the absence of NaCl
EC50 of 1463 in the presence of NaCl
Sodium response ratio = 1.20
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 1.16 x 10-5 M 39.6
After naltrexone markedly antagonized
After UM 979 markedly antagonized
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEPERENS
Only at a concentration of 3 x 10-6 M did UM 1292 produce a slight
decrease in the magnitude of the twitch (less than 10%). At
concentrations of 10-5 M and higher UM 1292 increased the magnitude
of the twitch. This increase was twice the baseline at a
concentration of 10-4 M. Neither naltrexone nor UM 979 altered
responses of this preparation to UM 1292.
SUMMARY
UM 1292 may have slight opiate-like activity at high concentrations
on the guinea pig ileum; however, on the muse vas deferens
preparation this drug seems to be completely devoid of opiate
activity. See also UM 1293, the (-)-isomer.
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UM 1293 NIH 9900 MCV 4238
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 10% @ 20, 20% @
50
Nilsen: 0% @ 20, 25% @ 50
(-)-4-Cycylopropylmethyl-10-hydroxy-1-methyl-2,3,4,5,6,7-
hexahydro-1,6-methano-1H-4-benzazonine
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
The EC50 of UM 1293 in displacing tritiated etorphine (0.5 nM) in
the absence or presence of NaCl was higher than 6 uM.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
At no concentration did UM 1293 decrease the magnitude of the
twitch of this preparation. At concentrations of 10-6 M and
greater this drug increased the magnitude of the twitch, and at a
concentration of 10-5 M and greater UM 1293 caused a baseline
contraction. Neither naltrexone nor UM 979 altered responses of UM
1293 on this preparation.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
UM 1293 did not inhibit the twitch of this preparation at any
concentration studied.
SUMMARY
UM 1293 does not have opiate activity. See the (+)-isomer (UM
1292).
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UM 1305 NIH 9450 MCV 4276
MOUSE ANALGESIA, ED50 (mg/kg)
Hot plate: 14.1 (11.7-17.0)
Nilsen: 19.7 (13.4-29.0)
2,5-Dimethyl-2'-hydroxy-9 alpha-isopentyl-6,7-benzomorphan methane-
sulfonate
OBSERVATIONS IN NORMAL AND MORPHINE-DEPENDENT RHESUS MONKEYS
Doses of 5.6, 10.0 and 17.0 mg/kg were tested in withdrawn and
non-withdrawn subjects. At the lower doses there were no clear
effects. The highest dose was preconvulsive. In normal subjects
10.0 mg/kg produced pupil dilation, tremor, some ataxia, and
convulsions in one monkey. The effects in the monkey that did not
convulse were not reversed by naloxone. In normal subjects 5.6
mg/kg did not reverse effects of 10.0 mg/kg morphine.
UM 1308 NIH 9905 MCV 4264
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 20% @ 20, 70% @
50
±-1-methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-
methano-1H-4-benzazonine
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING (0.5 nM)
EC50 of 793 in absence of NaCl
EC50 of 1315 in presence of NaCl
Sodium response ratio = 1.66
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INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
In control experiments, UM 1308 caused very slight inhibition of
the twitch (less than 10%) at a concentration of 10-5 M. Higher
concentrations caused increases in the magnitude the twitch and
a baseline contraction at a concentration of 10-4 M. The slight
inhibitory effect of UM 1308 was completely antagonized by both
naltrexone and UM 979.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
In control experiments, UM 1308 caused very slight inhibition of
the twitch (less than 15%) at a concentration of 3 x 10-6 M.
Higher concentrations increased the magnitude of the twitch. Both
naltrexone and UM 979 antagonized this slight inhibitory effect.
OBSERVATIONS IN NORMAL AND MORPHINE-DEPENDENT MONKEYS
UM 1308 failed to suppress withdrawal at 1 to 5.6 mg/kg. At 10
mg/kg it appeared to increase signs of withdrawal; however, at this
dose it produced convulsions in nonwithdrawn rhesus monkeys. In
normal monkeys UM 1308 failed to antagonize effects of 10.0 mg/kg
morphine.
SUMMARY
It is unlikely that the slight exacerbation of withdrawal signs at
10 mg/kg was mediated by narcotic mechanisms, due to the lack of
narcotic activity upon any of the in vitro preparations. On the
smooth muscle preparations it resembles UM 1046 and 1037. See also
the isomers of this compound (UM 1278 and UM 1315).
UM 1309 NIH 9906 MCV 4265
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 11.5 (8.9-15.0)
1,12 alpha-Dimethyl-4-isopentenyl-l0-hydroxy-2,3,4,5,6,7-
hexahydro-1,6-methano-1H-4-benzazonine
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING (0.5 nM)
EC50 of 364 nM in absence of NaCl
EC50 of 611 nM in presence of NaCl
Sodium response ratio = 1.68
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INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 2.20 x 10-6 M
After naltrexone
After UM 979
2.50 x 10-6 M
63.3
23.2
2.80 x 10-6 M 31.7
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
At no concentration did UM 1309 decrease the magnitude of the
twitch. At high concentrations this drug increased the magnitude
of the twitch.
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1309 suppressed the withdrawal syndrome produced by morphine
deprivation. Due to the small amount of the drug supplied, its
potency could not be estimated.
SUMMARY
The binding assay and the observations in dependent monkeys suggest
that this compound has morphine-like agonist The smooth
muscle preparations suggest a different mode of action in these
preparations.
UM 1310 NIH 9926 MCV 4266,4279
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 20% @ 20, 30% @
50
(-)-N-Allyl-4-methoxymorphinan-6-one
OBSERVATIONS OF MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1310 precipitated withdrawal with a potency of one-thirtieth
to one-one hundredth that of naloxone.
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UM 1311, 114 NIH 9929,0001 MCV 4260
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.87 (0.63-1.2)
Nilsen: 1.3 (0.97-1.9)
Morphine
OBSERVATIONS OF MORPHINE-DEPENDENT RHESUS MONKEYS
When evaluated blind, morphine was observed to suppress withdrawal
signs in the  monkey with an estimate of potency to be about half
that of our archival morphine standards.
UM 1312, 792 NIH 9930, 8503 MCV 4261,4002
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 10% @ 20, 40% @
50, 10% @ 100
Nilsen: 0% @ 20 & 40
Naltrexone hydrochloride
OBSERVATIONS OF MORPHINE-DEPENDENT RHESUS MONKEYS
When evaluated blind, naltrexone was observed to precipitate
withdrawal with an estimated potency equal to our archival
naltrexone standards.
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UM 1313 NIH 9931 MCV 4280
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 21.7 (17.9-26.3)
Nilsen: 0% @ 10, 40% @ 20
(-)-N-Cyclopropylmethyl-4-methoxymorphinan-6-one
OBSERVATIONS OF MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1313 precipitated withdrawal with a potency of 0.03 times
that of naltrexone.
UM 1314 NIH 9932 MCV 4281
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 50% @ 20, 60% @
50
Nilsen: 3.6 (2.5-5.4)
(-)-N-Cyclobutylmethyl-4-methoxynmorphinan-6-one hydrochloride
OBSERVATIONS OF MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1314 suppressed withdrawal with a potency about the same as that
of morphine.
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UM 1315 NIH 9903 MCV 4254
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 10.1 (7.1-14.4)
(+)-1-Methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-
methano-1H-4-banzazonine
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
UM 1315 failed to displace significantly tritiated etorphine up to
a concentration of 2 x 10-6 M.
INHIBITION OF TWITCH OF ELECTRICALLY DPIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 4.61 x 10-6 M 48.7
After naltrexone 71
After UM 979 56.6
In the presence of naltrexone in a concentration of UM 1315 of 10-5
M and greater a 71% inhibition of the twitch resulted. In the
presence of UM 979, in concentrations of UM 1315 of 10
-5 and
greater, a 56.5% inhibition of the twitch resulted. EC50'S in the
presence of the antagonists could not be calculated.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFEPENS
EC50 Maximum Response (%)
Drug alone 1.51 x 10-6 M 69.5
After naltrexone 2.10 x 10-6 M 58.4
After UM 979 3.12 x 10-6 M 47.1
SUMMARY
On the smooth muscle preparations UM 1315 appears to have some
opiate activity although on both preparations this drug is of
extremely low potency. See also the racemate (UM 1308) and
(-)-isomer (UM 1278) of this compound.
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UM 1325 NIH 9508 MCV 4142
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 16.8 (10.5-26.9)
Nilsen: 0% @ 20, 50% @ 50 &
100
N-Cyclopropylmethyl-8
hydrochloride
DRUG SELF-ADMINISTRATION IN RHESUS
beta-ethyl-N-nordihydrocodeinone
MONKEYS
Rates of responding maintained by UM 1325 were only slightly higher
than those maintained by saline at doses of 7.44 x 10-9 , 2.48 x
10-9 and 7.44  x 10-8 mol/kg/inj.
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UM 1327 NIH 9945 MCV 4286
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 10% @ 20, 50% @
50 (90% dead @
100)
(±)-2,9-beta-Dimethyl-5-( m-methoxypheny1)morphan hydrobromide
OBSERVATIONS OF MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1327 did not reverse withdrawal but rather produced sedation,
ptosis and mydriasis at doses of 17.0 and 30.0 q/kg. The compound
did not precipitate withdrawal at a dose of 17.0 mg/kg.
UM 1330 NIH 9939 MCV 4270
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 10% @ 20, 30% @
50
Nilsen: Inactive @ 100
6,7-Didehydro-4,5 alpha-epoxy-6-fluoro-3-hydroxy-17-n-
propylmorphinan
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING (0.5 nM)
EC50 of 66 nM in absence of NaCl
EC50 of 30.8 nM in presence of NaCl
Sodium response ratio = 0.47
501
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 3.73 x 10-9 M 57.4
After naltrexone 3.44 x 10-7 M 43.0
After UM 979 completely antagonized
In the presence of both naltrexone and UM 979, UM 1330 increased
the baseline tension at concentrations of 3 x 10-5 M and higher.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response (%)
Drug alone
After naltrexone
After UM 979
1.42 x 10-9 M 57.9
2.82 x 10-9 M
1.15 x 10-8 M
46.2
48.6
SUMMARY
UM 1330 has potent narcotic actions on each of the preparations.
It has opiate activity upon the isolated ileal preparation which is
completely abolished by UM 979 and antagonized by naltrexone.
Similarly, it has opiate activity upon the vas deferens preparation
which is antagonized only by UM 979. It may, in addition, have
antagonist activity as suggested by the findings from the binding
assay.
UM 1338 NIH 9957
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.46 (0.38-0.54)
(-)-4,5-Epoxy-14-hydroxy-N-methylmorphinan-6-one
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING (0.5 nM)
EC50 of 259 nM in absence of NaCl
EC50 of 492 nM in presence of NaCl
Sodim response ratio = 1.90
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INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone
titer naltrexone
After UM 979
1.13 x 10-6 M 43.2
no response
4.49 x 10-6 M 20.2
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response (%)
Drug alone 1.79 x 10-6 M
After naltrexone 1.27 x 1O-5 M
100
100
After UM 979 5.20 x 10-6 M 100
SUMMARY
UM 1338 had significant opiate action in each of the preparations
though it was less potent than morphine in each. Since the
compound was reversed by both antagonists on both smooth muscle
preparations, it may have morphine-like actions in vivo.
UM 1339 NIH 9958
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.57 (0.49-0.67)
(-)-4,14-Dihydroxy-N-methylmorphinan-6-one
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING (0.5 nM)
EC50 of 27.6 nM in absence of NaCl
EC50 of 38.9 nM in presence of NaCl
Sodium response ratio = 1.41
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INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 1.91 x 10-7 M
After naltrexone 2.85 x 10-5 M
51.0
46.5
After UM 979 1.59 x 10-6 M 46.0
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response (%)
Drug alone 21.7 x 1O-7 14 100
After naltrexone 3.42 x 10-6 M 100
After UM 979 1.12 x 1O-6 M 100
SUMMARY
Upon each of the preparations, UM 1339 had significant opiate
activity, approaching, in some cases, the potency of morphine. It
may have morphine-like activity in vivo based on the fact that both
antagonists reverse the actions of UM 1339 on both smooth muscle
preparations.
UM 1340 NIH 9959 MCV 4305
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.16 (0.12-0.21)
(-)-14-Hydroxy-4-methoxy-N-methylmorphinan-6-one
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING (0.5 nM)
EC50 of 70.7 nM in absence of NaCl
EC50 of 101 nM in presence of NaCl
Sodium response ratio = 1.43
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INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
Drug alone
After naltrexone
After UM 979
EC50
1.12 x 10-7 M
2.66 x 10-6 M
Maximum Response (%)
55.0
completely blocked
45.5
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response (%)
Drug alone
After naltrexone
After UM 979
2.53 x 10-7 M 98.0
1.14 x 10-5 M 96.7
1.10 x 10-6 M 95.7
SUMMARY
UM 1340 had significant opiate actions upon each of the
preparations. It was somewhat less potent than morphine, but may
share its in vivo actions since UM 1340 was antagonized by both
antagonists on both smooth muscle preparations.
UM 1344 NIH 9960
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.33 (0.27-0.40)
Nilsen: 0.21 (0.15-0.28)
(-)-N-Methylmorphinan-6-one
OBSERVATIONS OF MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1344 suppressed withdrawal with a potency about ten times that
of morphine.
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UM 1347 NIH 9975 MCV 4296
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0% @ 20, 20% @ 50
(-)-N-Allyl-14-hydroxy-4-methoxymorphinan-6-one
OBSERVATIONS OF MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1347 precipitated withdrawal with a potency of about one
thirtieth that of naloxone.
UM 1381 NIH 10015 MCV 4317
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.81 (0.62-1.1)
(-)-3,4-Dimethoxy-5,17-dimethylmorphinan-6-one hydrobromide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING (0.5 nM)
EC50 of 105 nM in absence of NaCl
EC50 of 116 nM in presence of NaCl
Sodium response ratio = 1.11
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 Maximum Response (%)
Drug alone 3.65 x 10
-8 M
9.06 x 10-6 M
63.7
After naltrexone 46.6
After UM 979 1.95 x 10-6 M 44.2
In all preparations, concentrations of UM 1381 of 10-5 M and higher
increased the magnitude of the twitch. No concentration of this
drug caused a baseline contraction.
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INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
After UM 979
EC50 Maximum Response (%)
9.50 x 10-8 M 98.9
2.86 x 10-6 M 100
3.70 x 10-7 M 99.1
OBSERVATIONS OF MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1381 suppressed withdrawal with a potency of about that of
morphine.
SUMMARY
UM 1381 appears to be a morphine-like agonist upon both smooth
muscle preparations. These data agree with the previous report
that this compound suppresses morphine abstinence completely at
doses comparable to morphine.
UM 1384 NIH 10017
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 3.9 (2.8-5.5)
Nilsen: 11.1 (6.2-19.6)
(-)-N-Cyclopropylmethyl-3,4-dimethoxymrphinan-6-one hydrobromide
OBSERVATIONS OF MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1384 was without appreciable effects in doses from 1.0 to 10.0
mg/kg. Higher doses were not tested since the supply of the
compound was depleted.
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UM 1385 NIH 10018
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.14 (0.10-0.181
(-)-3,4-Dimethoxy-N-(2-phenethyl)morphinan-6-one hydrobtide
OBSERVATIONS IN NORMAL AND MORPHINE-DEPENDENT RHESUS MONKEYS
UM 1385 reversed withdrawal with a potency comparable to that of
morphine. Its effects in normal subjects, except pupil dilation,
were reversed by naloxone (1.7 mg/kg, s.c.).
UM 1388 NIH 10021
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 2.0 (1.4-2.8)
9 beta-Acetoxy-2-methyl-5-( m-acetoxyphenyl)morphan hydrabromide
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS
At doses from 1.0 to 10.0 mg/kg UM 1388 was without effect. Higher
doses were not tested as the supply was exhausted.
508
UM 1401 NIH 9625 MCV 4176
MOUSE ANALGESIA, ED50 mg/kg)
Hot Plate: 1.1 (0.8-1.3)
1-[2-alpha,6-alpa,11S)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-
3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)]-6-methyl-3-
hepatanone methanesulfonate
PRIMARY DEPENDENCE STUDY
In studies in withdrawn morphine-dependent monkeys conducted at The
Medical College of Virginia, this drug neither suppressed nor
exacerbated withdrawal. A primary dependence study was terminated
prematurely as subjects were unconscious after injections. The
present study initially increased dose very slowly in an attempt to
allow more tolerance to develop to the sedative effects of the
drug.
Subjects. Three rhesus monkeys weighing from 4.4. to 5.5 kg were
used. Each monkey lost about 1.0 kg over the 32 days of chronic
drug administration.
Dosage Schedule.
The drug was dissolved in water Day Dose (mg/kg/6 hr, s.c.)
1 1.0
2 3.0
5 5.6
12 10.0
23 17.0
35 Abrupt withdrawal
Subjects were tested for precipitation of withdrawal with
nalorphine on days 15 and 29, and with naloxone on days 18 and 32.
Acute Effects. There were no obvious effects of 1.0 mg/kg. With
the increase in dose to 3.0 mg/kg, there was some pupil dilation,
scratching, and decreases in activity and eating.
Chronic Effects. Apparent tolerance developed to effects at 3.0
mg/kg by the third day so the dose was increased to 5.6 mg/kg with
little increase in effects. Since the subjects were losing weight,
that dose was maintained until the 12th day of the study when it
was increased to 10.0 mg/kg. At this dose one monkey (FQ-35) was
observed to assume peculiar postures with little muscle tone but
could be aroused by observers. All three monkeys lost weight at
this dose. Additionally, abscesses developed at injection sites.
At 17.0 n-g/kg a second monkey showed a loss of muscle tone and was
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lying on the cage floor. This subject also could be aroused by
observers. On the fifth day at 17.0 mg/kg, monkey FQ-35 was found
dead one hour after an observation indicating no obvious effects.
Dependence. Nalorphine administered on days 15 and 30 produced
very mild, if any, signs of withdrawal.
effects than nalorphine.
Naloxone had greater
Subjects were observed to be lying on
their sides, vocalizing, and restless after naloxone administration
on day 33. With the abrupt discontinuation of drug administration,
only very mild signs of withdrawal were observed in the two
surviving monkeys.
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depression of smooth muscle twitch, 491
displacement of stereospecific 3H-etorphine binding,
491
mouse analgesia, 491
(-)-N-Allyl-4-hydroxymorphinan-6-one (NIH 9974, MCV 4295)
biological evaluation for dependence liability, 394
mouse analgesia, 448
(-)-N-Allyl-4-methoxymorphinan-6-one (NIH 9926, MCV 4266,
MCV 4279, UM 1310)
biological evaluation for dependence liability, 394
dependence studies in monkeys, 496
mouse analgesia, 437, 496
(-)-N-Allylmorphinan-6-one (NIH 10,010, MCV 4316)
biological evaluation for dependence liability, 394
mouse analgesia, 453
N-Allylnormetazocine (SKF 10,047, NIH 7912, MCV 4267, UM
902)
agonist activity, 81
antagonist activity, 82, 437
biological evaluation for dependence liability, 394
displacement of stereospecific 3H-etorphine binding,
462
effect on 3H-PCP binding, 219
evaluation in the chronic spinal dog, 87-88
self-administration in the baboon, 179-181
sigma agonists: progress report, Medical College of
Virginia, 79-84
similarities between PCP and the sigma agonist (±)-
N-allylnormetazocine (SKF 10,047), 80
stereospecific effects on cortical EEG power spectra
in the rat, 190-195
(-)-N-Allylnormetazocine
effect on 3H-PCP binding, 219
(+)-N-Allylnormetazocine
effect on 3H-PCP binding, 219
Amantadine
effect on 3H-PCP binding, 219
(-)-13 -Amino-5,6,7,8,9,10,11,12-octahydro-5 -methy1-5,11-
methanobenzocyclodecen-3-ol hydrobromide (NIH 8834, MCV,
4206, UM 972)
dependence studies in rats, 419
mouse analgesia, 419
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Amobarbital
reaction time to visual stimulus intensity in animals,
116
reinforcement/toxicity ratio in the baboon, 197-202
self-administration in the baboon, 106-108
Amphetamine
abuse liability, 373
anorectic/reinforcement ratio in the baboon, 108-112
dependence treated with desipramine, 351-355
drug preference in humans, 251-257
laboratory analysis, 323-325
self-administration in animals, 103-105
weight control clinic, 129-130
Antagonists
benzodiazepine antagonists: RO 15-1788 and CGS,
8216, 89-91
opioid antagonists: role in treatment programs, 71-
78
5-Aryl-3-Azabicyclo [3.2.0] heptan-6-one-dimethylacetal
analgesic activity, 139-141
inhibition of 3H-naloxone binding, 142
synthesis of, 138
Barbiturates
use among high school students in Ontario, 34
Benzphetamine
anorectic/reinforcement ratio in the baboon, 108-112
self-administration in animals, 103-105
(+)-Bremazocine hydrochloride
analgesic activity, 144-146
receptor binding studies, 146
Buprenorphine
role in treatment programs, 75
self-administration in the baboon 178-183, 179-181
treatment agent in narcotic addiction, 95-97
Bupropion ((+)- -tert-m-chloropropiophenone; Wellbatrin)
abuse liability, 573
Butorphanol
self-administration in the baboon, 179-181
Caffeine
self-administration in animals, 106-108
Cannabinoids
development of orally active cannabinoids for the
treatment of glaucoma, 157-163
Cannabis
potential abuse liability of natural and synthetic
compounds, 132-137
use among high school students in Ontario, 34
CGS 8216
benzodiazepine antagonist, 89-91
Chlordiazepoxide
effects on responding suppressed by nicotine or by
electric shocks, 372
evaluation for pentobarbital-like effects, 92-93
(-)-o-Chlorobenzyl-2-(2-di- sec-butylamino-1-hydroxyethyl)
pyrrole p-hydroxybenzoate (NIH 8893, MCV 4224, UM 1009)
biological evaluation for dependence liability, 397
cont'd
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dependence studies in monkeys, 424-425
mouse analgesia, 424
1-(3-Chlorophenyl)-2-(1,1-dimethylamino)propan-1-one (NIH
9788, UM 1239)
biological evaluation for dependence liability, 397
mouse analgesia, 473
self-administration in monkeys, 473
(+)- -tert-m-Chloropropiophenone
see Bupropion
6,5-(Chloro-2-pyridyl)-7-((4-methyl-1-piperazinyl)car-
bonyloxy)-6,7-dihydro-(5H)-pyrrolo(3,4-b)pyrazine-5-one
see Zopiclone
Chlorphentermine
anorectic-reinforcement ratio in the baboon, 108-112
self-administration in animals, 103-105
weight control clinic, 129-130
Chlorpromazine
mouse analgesia, 402, 460
Ciramadol (Wy-15,705)
analgesia after episiotomy, 224-230
side effects after treatment for episiotomy pain, 229
Clonazepam
self-administration in the baboon, 106-108
Clonidine
recent advances in opiate detoxification, 44-50
Clorazepate
clinical assessment of abuse lability, 129
self-administration in the baboon, 106-108
Clortermine
anorectic-reinforcement ratio in the baboon, 108-112
self-administration in animals, 103-105
Cocaine
anorectic-reinforcement ratio in the baboon, 108-112
clinical profile of abusers, 343-350
dependence treated with desipramine, 351-355
evaluation of behavioral toxicity, 112-113
laboratory analysis, 323-325
self-administration in the baboon, 102, 106-108, 179
self-administration in the dog, 88-89
use among high school students in Ontario, 34
analgesia after episiotomy, 224-230
laboratory analysis, 323-325
Codeine (NIH 0002)
mouse analgesia, 402, 459
self-administration in the baboon, 179-181
Cyclazocine (NIH 7981)
mouse analgesia, 401-402, 460
displacement of stereospecific 3H-etorphine binding,
462
(-)-N-Cyclobutylmethyl-4-methoxymorphinan-6-one hydro-
chloride (NIH 9932, MCV 4281, UM 1314)
biological evaluation for dependence liability, 394
dependence studies in monkeys, 498
mouse analgesia, 442-443, 498
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17-Cyclopropylmethyl-6,7-dehydro-4,5 -epoxy-6-fluoro-3-
acetoxymorphinan (NIH 9787, MCV 4208, UM 1240)
biological evaluation for dependence liability, 393
displacement of stereospecific 3H-etorphine binding,
474
mouse analgesia, 474
(-)-N-Cyclopropylmethyl-3,4-dimethoxyoxymorphinan-6-one
hydrobromide (NIH 10,017, UM 1384)
biological evaluation for dependence liability, 394
dependence studies in monkeys, 507
mouse analgesia, 507
17-Cyclopropylmethyl-4,5 -epoxy-6,6-difluoro-3-hydroxy-
morphinan hydrochloride (NIH 9651, MCV 4178, UM 1234)
biological evaluation for dependence liability, 393
dependence studies in monkeys, 417
depression of smooth muscle twitch, 470
displacement of stereospecific 3H-etorphine binding,
470
mouse analgesia, 417, 470
N-Cyclopropylmethyl-8 -ethyl-N-nordihydrocodeinone hydro-
chloride (NIH 9508, MCV 4142, UM 1235)
biological evaluation for dependence liability, 393
dependence studies in monkeys, 410-411
mouse analgesia, 410, 500
self-administration in monkeys, 500
(-)-N-Cyclopropylmethyl-14-hydroxy-4-methoxymorphinan-6-
one (NIH 9977, MCV 4298)
biological evaluation for dependence liability, 394
mouse analgesia, 449-450
(-)-4-Cyclopropylmethyl-10-hydroxy-1-methyl-2,3,4,5,6,7-
hexahydro-1,6-methano-1H-4-benzazonine (NIH 9900, MCV
4238, UM 1293)
biological evaluation for dependence liability, 395
dependence studies in monkeys, 431
depression of smooth muscle twitch, 493
displacement of stereospecific 3H-etorphine binding,
493
mouse analgesia, 431, 493
(+)-4-Cyclopropylmethyl-l0-hydroxy-1-methyl-2,3,4,5,6,7-
hexahydro-1,6-methano-1H-4-benzazonine (NIH 9899, MCV
4237, UM 1292)
biological evaluation for dependence liability, 395
dependence studies in monkeys, 430
depression of smooth muscle twitch, 492
displacement of stereospecific 3H-etorphine binding,
492
mouse analgesia, 430, 492
(-)-N-Cyclopropylmethyl-4-methoxymorphinan-6-one (NIH 9931,
MCV 4280, UM 1313)
biological evaluation for dependence liability, 394
dependence studies in monkeys, 498
mouse analgesia, 442, 498
Dependence
brain growth and cerebral ventricular development in
newborn infants of drug dependent mothers, 365-371
cont'd
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chemical dependence in Canada. "A view from the
Hill", 10-20
Cocaine and amphetamine dependence treated with de-
sipramine, 351-355
outpatient treatment of prescription opioid depend-
ence, 315-321
Depressants
relationship between reinforcing properties and sen-
sory/motor toxicity, 196-202
Desipramine
treatment of cocaine and amphetamine dependence, 351-
355
6-Desoxy-6,6-hydrazinaloxone (NIH 10,001, MCV 4308)
biological evaluation for dependence liability, 393
mouse analgesia, 450-451
6-Desoxy-6,6-hydrazinaltrexone (NIH 10,003, MCV 4310)
biological evaluation for dependence liability, 393
mouse analgesia, 451
6-Desoxy-6,6-hydrazioxymorphone (NIH 10,005, MCV 4312)
biological evaluation for dependence liability, 393
mouse analgesia, 452
6-Desoxy-6-isonitrosonaloxone (NIH 10,002, MCV 4309)
biological evaluation for dependence liability, 393
mouse analgesia, 451
6-Desoxy-6-isonitrosonaltrexone (NIH 10,004, MCV 4311)
biological evaluation for dependence liability, 393
mouse analgesia, 452
6-Desoxy-6-isonitrosooxymorphine hydrobromide (NIH 10,008,
MCV 4314)
biological evaluation for dependence liability, 393
mouse analgesia, 453
Detoxification
ambulatory heroin detoxification: efficacy of psy-
chotherapeutic counselling, 310-314
opiate use and treatment outcome in methadone de-
toxification patients, 280-286
outpatient treatment of prescription opioid depend-
ence, 315-321
Dexamethasone
specificity of the dexamethasone suppression test
for major depressive illness in alcoholics, 266-272
Dextrorphan
displacement of stereospecific 3H-etorphine binding,
462
Diazepam
behavioral effects in the rat and antagonism by Ro
15-1788, 203-209
clinical assessment of abuse liability, 128
continuous intragastric self-administration in mon-
keys, 168
effects on auditory and visual thresholds in animals,
118-119
effects on mood and behavior in subjects with his-
tories of sedative drug abuse, 258
drug preference in humans, 251-259
physical dependence in monkeys, 166
self-administration in the baboon, 106-108
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6,7-Didehydro-4,5 -epoxy-6-fluoro-3-hydroxy-17- n-propyl-
morphinan (NIH 9939, MCV 4270, UM 1330)
biological evaluation for dependence liability, 393
dependence studies in monkeys, 438-439
depression of smooth muscle twitch, 502
displacement of stereospecific 3H-etorphine binding,
501
mouse analgesia, 438, 501
Diethylpropion
anorectic/reinforcement ratio in the baboon, 108-112
self-administration in animals, 103-105
weight control clinic, 129-130
2,3-Dihydro-2-methyl-3-[2-(dimethylamino)propyl)]-3-phenyl-
1H-indol-1-carboxaldehyde methanesulfonate (NIH 9810, MCV
4218, UM 1251)
biological evaluation for dependence liability, 397
depression of smooth muscle twitch, 480-481
displacement of stereospecific 3H-etorphine binding,
480
mouse analgesia, 480
Dihydromorphine (DHM)
effects of chronic PCP treatment on DHM binding, 220
Dihydromorphinone (NIH 0123)
mouse analgesia, 402, 460
(-)-4,14-Dihydroxy-N-methylmorphinan-6-one (NIH 9958, UM
1339)
biological evaluation for dependence liability, 394
depression of smooth muscle twitch, 504
displacement of stereospecific 3H-etorphine binding,
503
mouse analgesia, 503
Dilantin
laboratory analysis, 323-325
Dilaudid
laboratory analysis, 323-325
(-)-3,4-Dimethoxy-5,17-dimethylmorphinan-6-one hydrobromide
(NIH 10,015, MCV 4317, UM 1381)
biological evaluation for dependence liability, 394
dependence studies in monkeys, 507
depression of smooth muscle twitch, 506-507
displacement of stereospecific 3H-etorphine binding,
506
mouse analgesia, 454, 506
2,5-Dimethoxy-4-ethylamphetamine
self-administration in animals, 103-104
2,5-Dimethoxy-4-methylamphetamine
self-administration in animals, 103-105
(-)-3,4-Dimethoxy-N-(2-phenethyl)morphinan-6-one hydrobromide
(NIH 10,018, UM 1385)
biological evaluation for dependence liability, 394
dependence studies in monkeys, 508
mouse analgesia, 508
1-cis-2-( -Dimethylamino-m-hydroxybenzyl)cyclohexanol
H C l
see Ciramadol (Wy-15,705)
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N-[3-(N,N-Dimethylcarbamoyl)-3,3-diphenylpropyl]-norketo-
bemidone hydrochloride (NIH 9806, MCV 4214, UM 1247)
biological evaluation for dependence liability, 396
dependence studies in monkeys, 477
depression of smooth muscle twitch, 476
displacement of stereospecific 3H-etorphine binding,
476
mouse analgesia, 421, 476
1,3a -Dimethyl-.2,3,3a,6,7,7a -hexahydro-4-m-hydroxyphenyl-
1H-indole (NIH 10,020, MCV 4322)
biological evaluation for dependence liability, 398
mouse analgesia, 454
2,5-Dimethyl-2'-hydroxy-9 --isopentyl-6,7-benzomorphan
methanesulfonate (NIH 9450, MCV 4276, UM 1305)
biological evaluation for dependence liability, 395
dependence studies in monkeys, 494
mouse analgesia, 442, 494
(-)-[(1R,5R,2"S)-5,9-Dimethyl-2'-hydroxy-2-(2-methoxy-
propyl)-6,7-benzomorphan hydrobromide (NIH 9809, MCV
4217, UM 1250)
biological evaluation for dependence liability, 395
dependence studies in monkeys, 480
depression of smooth muscle twitch, 479
displacement of stereospecific 3H-etorphine binding,
479
mouse analgesia, 479
5,9 -Dimethyl-2'-hydroxy-2-(4-methylpentyl)-6,7-benzo-
morphan hydrochloride (NIH 9938, MCV 4269)
biological evaluation for dependence liability, 395
mouse analgesia, 438
(-)-(1R,5R,9R)-5,9-Dimethyl-2'-hydroxy-2-(3-phenoxypropyl)-
6,7-benzomorphan hydrochloride (NIH 9807, MCV 4215, UM 1248)
biological evaluation for dependence liability, 395
dependence studies in monkeys, 422
dependence studies in rats, 422-423
depression of smooth muscle twitch, 477-478
displacement of stereospecific 3H-etorphine binding,
477
mouse analgesia, 422, 477
(+)-(1R,5R,9R)-5,9-Dimethyl-2'-hydroxy-2-(3-phenoxypropyl)-
6,7-benzomorphan hydrochloride (NIH 9808, MCV 4216, UM 1249)
biological evaluation for dependence liability, 395
dependence studies in monkeys, 424
depression of smooth muscle twitch, 478
displacement of stereospecific 3H-etorphine binding,
478
mouse analgesia, 424, 478
(-)-2,9 -Dimethyl-5-(m-hydroxyphenyl)morphan hydrochloride
(NIH 9971, MCV 4293)
biological evaluation for dependence liability, 396
dependence studies in monkeys, 447
mouse analgesia, 447
(+)-2,9 -Dimethyl-5-(m-hydroxyphenyl)morphan hydrochloride
(NIH 9972, MCV 4294)
biological evaluation for dependence liability, 396
cont'd
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dependence studies in monkeys, 448
mouse analgesia, 448
(+)-2,9 -Dimethyl-5-(m-hydroxyphenyl)morphan hydrochloride
(NIH 9955, MCV 4275)
biological evaluation for dependence liability, 396
dependence studies in monkeys, 441
mouse analgesia, 441
(±)-(1R/S, 5R/S, 9R/S, 2"S/R)-5,9-Dimethyl-2'-hydroxy-2-
tetrahydrofurfuryl-6,7-benzomorphan hydrochloride (Mr 2033
CL)
analgesia, 144-145
binding studies, 146
morphine antagonist effects, 146
side effects, 146-148
1,12 -Dimethyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine (NIH 9906, MCV 4265,
UM 1309)
biological evaluation for dependence liability, 395
dependence studies in monkeys, 495
depression of smooth muscle twitch, 495
displacement of stereospecific 3H-etorphine binding,
495
mouse analgesia, 437, 495
(±)-2,9 -Dimethyl-5-(F-methoxyphenyl)morphan hydrobromide
(NIH 9945, MCV 4286, UM 1327)
biological evaluation for dependence liability, 396
dependence studies in monkeys, 501
mouse analgesia, 444-445, 501
(-)-cis-N,N-Dimethyl-l,2,3,4-tetrahydro-4-methyl-4-phenyl-
2-naphthylamine hydrochloride (NIH 9943, MCV 4285)
biological evaluation for dependence liability, 398
mouse analgesia, 444
(-)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-4-phenyl-
2-naphthylamine hydrochloride (NIH 9941, MCV 4283)
biological evaluation for dependence liability, 398
mouse analgesia, 443
(±)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-4-phenyl-
2-naphthylamine hydrochloride (NIH 9942, MCV 4284)
biological evaluation for dependence liability, 398
mouse analgesia, 444
(±)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-4-phenyl-
2-naphthylamine hydrochloride (NIH 9940, MCV 4282)
biological evaluation for dependence liability, 398
mouse analgesia, 443
Doriden
laboratory analysis, 323-325
Drugs
drug preference in humans: effects of two non-phar-
macological variables, 251-257
predictors of teenage drug use, 329-334
self-administration procedures in animals, 100-112
Drug abuse
clinical procedures for abuse liability assessment,
125-131
clinical profile of cocaine abusers, 343-350
increased effectiveness of treatment from patient-
cont'd
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program matching, 335-342
prevalence and implications of multi-drug abuse in
methadone-maintained women, 322-328
problems of drug abuse in Canada, 27-35
reinforcement/toxicity ratio: implications for the
assessment of abuse liability, 196-202
testing drugs for abuse ability in animals, 99-124
treatment needs of, 15-18
EEG
stereospecific effects of mu, kappa and sigma agonists
on cortical EEG power spectra in the rat, 190-195
Electric shock
effects of chlordiazepoxide and mecamylamine on res-
ponding suppressed by, 372
Endogenous depression
effect of morphine on symptoms, 245-250
-Endorphin
levels in patients with endogenous depression, 245
-Ephedrine
self-administration in animals, 103-105
(-)-4,5-Epoxy-14-hydroxy-N-methylmorphinan-6-one (NIH
9957, UM 1338)
biological evaluation for dependence liability, 393
displacement of stereospecific 3H-etorphine binding,
502
mouse analgesia, 501
Erythrocyte
kinetics of erythrocyte rosette formation with T
lympocytes from drug-addicted subjects, 375-380
17 -Estradiol
effects of alcohol on levels in the monkey, 210-216
Ethanol
chemical dependence in Canada, 10-20
9 -Ethyl-2'-hydroxy-5-methyl-2-phenethyl-6,7-benzomorphan
(NIH 9434, MCV 4288, UM 1146)
biological evaluation for dependence liability, 395
dependence studies in rats, 445
mouse anaaesia. 445
(-)-2-Ethyl-5-(m-hydroxyphenyl)morphan hydrochloride (NIH
9883, UM 1284)
biological evaluation for dependence liability, 396
depression of smooth muscle twitch, 488
displacement of stereospecific 3H-etorphine binding,
488
mouse analgesia, 488
(+)-2-Ethyl-5-(m-hydroxyphenyl)morphan hydrochloride (NIH
9890, MCV 4245, UM 1289)
biological evaluation for dependence liability, 396
depression of smooth muscle twitch, 490
displacement of stereospecific 3H-etorphine binding,
490
mouse analgesia, 432, 490
Ethylketazocine
displacement of stereospecific 3H-etorphine binding,
462
521
Fenfluramine
anorectic/reinforcement ratio in the baboon, 108-112
self-administration in animals, 103-105
weight control clinic, 129-130
Flurazepam hydrochloride (NIH 9827, MCV 4223, UM 1256)
biological evaluation for dependence liability, 397
depression of smooth muscle twitch, 481
displacement of stereospecific 3H-etorphine binding,
481
mouse analgesia, 481
self-administration in the baboon, 106-108
p-Fluorofentanyl hydrochloride
biological evaluation for dependence liability, 398
dependence studies in monkeys, 455
mouse analgesia, 455
Follicle stimulating hormone
effects of alcohol on levels in the monkey, 210-216
(-)-2-(3-Furylmethyl)-2'-hydroxy-5,9 -diethyl-6,7-benzo-
morphan hydrochloride (Mr 2266 CL)
antagonistic effects, 145
binding studies, 146
Glaucoma
orally active cannabinoids for the treatment of, 157-
163
Glue
use among high school students in Ontario, 34
Hallucinogens
use among high school students in Ontario, 34
Health
jurisdiction in Canada with regard to health, 13-15
Heroin
efficacy of psychotherapeutic counseling during
ambulatory detoxification, 310-314
use among high school students in Ontario, 34
1-[2 ,6 ,11S)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-3,6,
11-trimethyl-2,6-methano-3-benzazocin-ll-yl)]-6-methyl-
3-hepatanone methanesulfonate (NIH 9625, MCV 4176, UM 1401)
dependence studies in monkeys, 509-510
mouse analgesia, 509
1-[2 ,6 ,11S)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-3,6,
11-trimethyl-2,6-methano-3-benzazocin-11-yl)]-3-octanone
methanesulfonate (NIH 9624, MCV 4175, UM 1258)
biological evaluation for dependence liability, 395
dependence studies in rats, 416
mouse analaesia. 415
(-)-N-Hexyl-5-( m-hydroxyphenyl)morphan hydrochloride (NIH
9887, MCV 4234)
biological evaluation for dependence liability, 396
dependence studies in monkeys, 429
mouse analgesia, 429
Hydromorphine
effect on pupil diameter, 241
effects on respiration, 242
Hydromorphone
effects in opiate-free and methadone-maintenance
subjects, 238-244
effects on subjective scores, 243
522
(-)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan hydrobromide
(NIH 9614, MCV 4169, UM 1269)
biological evaluation for dependence liability, 395
dependence studies in monkeys, 412-414
dependence studies in rats, 414
mouse analgesia, 412,482
self-administration in monkeys, 482
(-)-14-Hydroxy-4-methoxy-N-methylmorphinan-6-one (NIH 9959,
MCV 4305, UM 1340)
biological evaluation for dependence liability, 394
depression of smooth muscle twitch, 504
displacement of stereospecific 3H-etorphine binding,
504
mouse analgesia, 450, 504
(-)-14-Hydroxy-N-methylmorphinan (NIH 10,007, MCV 4313)
biological evaluation for dependence liability, 394
mouse analgesia, 452
(-)-14-Hydroxy-N-methylmorphinan-6-one (NIH 10,009, MCV
4315)
biological evaluation for dependence liability, 394
mouse analgesia, 453
(-)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride (NIH
8505, NIH 9882, MCV 4231, MCV 4240, UM 809, UM 1283)
biological evaluation for dependence liability, 396
dependence studies in rats, 426-427
depression of smooth muscle twitch, 487
displacement of stereospecific 3H-etorphine binding,
487
mouse analgesia, 426, 487
(+)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride (NIH
8509, NIH 9889, MCV 4232, MCV 4244, UM 810, UM 1288)
biological evaluation for dependence liability, 396
dependence studies in rats, 428
depression of smooth muscle twitch, 489
displacement of stereospecific 3H-etorphine binding,
489
mouse analgesia, 428, 432, 489
(-)-5-(m-Hydroxyphenyl)morphan hydrochloride (NIH 9881,
MCV 4239, UM 1282)
biological evaluation for dependence liability, 396
depression of smooth muscle twitch, 486
displacement of stereospecific 3H-etorphine binding,
4 8 6
mouse analgesia, 431, 486
(+)-5-(m-Hydroxyphenyl)morphan hydrochloride (NIH 9888,
MCV 4243)
biological evaluation for dependence liability, 396
mouse analgesia, 432
(+)-5-(m-Hydroxyphenyl)-2-n-propylmorphan hydrochloride
(NIH 9891, MCV 4246, UM 1275)
biological evaluation for dependence liability, 396
dependence studies in monkeys, 483
depression of smooth muscle twitch, 483
displacement of stereospecific 3H-etorphine binding,
483
mouse analgesia, 433, 483
523
4-(1-Hydroxypropyl)-4- m-hydroxyphenyl-1-methylpiperidine
(NIH 9771, UM 1236)
biological evaluation for dependence liability, 396
depression of smooth muscle twitch, 471
mouse analgesia, 471
Ketamine
reinforcement/toxicity ratio in the baboon, 197-202
Ketazocine
displacement of stereospecific 3H-etorphine binding,
462
(+)-Ketazocine
analgesic activity in mice, 144
Ketocyclazocine
stereospecific effects on cortical EEG power specta
in the rat, 190-195
LAAM
see -Acetylmethadol
Levallorphan
competition binding with 3H-naloxone, 142
Lofexidine
recent advances in opiate detoxification, 44-50
Lorazepam
clinical assessment of abuse liability, 129
Levorphanol (NIH 4590)
mouse analgesia, 402, 459
Luteinizing hormone
effects of alcohol on levels in the monkey, 210-216
LY127623
see Metkephamid
Marihuana
potential abuse liability of marihuana cigarettes,
132-137
Mazindol
anorectic-reinforcement ratio in the baboon, 108-112
MCV 4002 (NIH 8503, NIH 9930, MCV 4261, UM 792, UM 1312)
see Naltrexone
MCV 4142 (NIH 9508, UM 1325)
see N-Cyclopropylmethyl-8 -ethyl-N-nordihydrocodeinone
hydrochloride
MCV 4169 (NIH 9614, UM 1269)
see (-)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan
hydrobromide
MCV 4175 (NIH 9624, UM 1258)
see 1-[2 ,6 ,11S)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-
hydroxy-3,6,ll-trimethyl-2,6-methano-3-benzazocin-
11-yl)]-3-octanone methanesulfonate
MCV 4176 (NIH 9625, UM 1401)
see 1-[2 ,6 ,11S)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-
hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-
yl)]-6-methyl-3-hepatanone methanesulfonate
MCV 4178 (NIH 9651, UM 1234)
see 17-Cyclopropylmethyl-4,5 -epoxy-6,6-difluoro-3-
hydroxymorphinan hydrochloride
MCV 4186 (NIH 9721, UM 1216)
see 2 -Methylamino-1-phenylcyclopentanol propanoate
ester, hydrogen maleate
524
MCV
MCV
MCV
MCV
MCV
MCV
MCV
MCV
MCV
MCV
MCV
MCV
MCV
MCV
MCV
4200 (NIH 9739, UM 1227)
see 2-Nitronaloxone
4206 (NIH 8834, UM 972)
see (-)-13 -Amino-5,6,7,8,9,10,11,12-octahydro-5
methyl-5,11-methanobenzocyclodecen-3-ol hydrobromide
4208 (NIH 9787, UM 1240)
see 17-Cyclopropylmethyl-6,7-dehydro-4,5 -epoxy-6-
fluoro-3-acetoxymorphinan
4209 (NIH 9790, UM 1241)
see 3-Methylpentyl-N-norketobemidone hydrobromide
4210 (NIH 9791, UM 1238)
see N-Methyl-L-tyrosyl-D-serylglycyl-N-methyl-L-
phenylalanyl-D-serinamide monoacetate
4211 (NIH 9803, UM 1244)
see (-)-N-(2-Methoxyethyl)noroxymorphone hydrochlo-
ride
4214 (NIH 9806, UM 1247)
see N-[3-(N,N-Dimethylcarbamoyl)-3,3-diphenylpropyl]-
norketobemidone hydrochloride
4215 (NIH 9807, UM 1248)
see (-)-(1R,5R,9R)-5,9-Dimethyl-2'-hydroxy-2-(3-phe-
noxypropyl)-6,7-benzomorphan hydrochloride
4216 (NIH 9808, UM 1249)
see (+)-(1R,5R,9R)-5,9-Dimethyl-2'-hydroxy-2-(3-phen-
oxypropyl)-6,7-benzomorphan hydrochloride
4217 (NIH 9809, UM 1250)
see (-)-[(1R,5R,2"S)-5,9-Dimethyl-,2'-hydroxy-2-(2-
methoxypropyl)-6,7-benzomorphan hydrobromide
4218 (NIH 9810, UM 1251)
see 2,3-Dihydro-2-methyl-3-[2-(dimethylamino)propyl]-
fihenyl-1H-indol-1-carboxaldehyde methanesulfonate
4223 (NIH 9827, UM 1256)
see Flurazepam hydrochloride
4224 (NIH 8893, UM 1009)
see (-)-o-Chlorobenzyl-2-(2-di- sec-butylamino-1-hy-
droxyethyl) pyrrole p-hydroxybenzoate
4230 (NIH 9874, UM 1322)
see 3-Acetoxy-17-cyclopropymethyl-4,5 -epoxy-6,6-di-
fluoromorphinan
4231 (NIH 8508, NIH 9882, MCV 4231, MCV 4240, UM 809,
UM 1283)
MCV
MCV
MCV
MCV
MCV
see (-)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride
4232 (NIH 8569, UM 810)
see (+)-5-(m-Hydroxyphenyl-2-methylmorphan hydrochloride
4234 (NIH 9887)
see (-)-N-Hexyl-5-(m-hydroxyphenyl)morphan hydrochloride
4235 (NIH 9895, UM 1290)
see (+)-4-Allyl-10-hydroxy-1-methyl-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine
4236 (NIH 9896, UM 1291)
see (-)-4-Allyl-10-hyd~oxy-1-methyl-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine
4237 (NIH 9899, UM 1292)
see (+)-4-Cyclopropylmethyl-10-hydroxyl-1-methyl-2,
3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine
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MCV 4238 (NIH 9900, UM 1293)
see (-)-4-Cyclopropylmethyl-10-hydroxy-1-methyl-2,
3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine
MCV 4239 (NIH 9881, UM 1282)
see (-)-5-(m-Hydroxyphenyl)morphan hydrochloride
MCV 4240 (NIH 8508, NIH 9882, MCV 4231, UM 809, UM 1283)
see (-)-5-(m-Hydroxyphenyl)-2-methylmorphan hydro-
cloride
MCV 4243 (NIH 9888)
see (+)-5-(m-Hydroxyphenyl)morphan hydrochloride
MCV 4244 (NIH 9889, UM 1288)
see (+)-5-(m-Hydroxyphenyl)-2-methylmorphan hydro-
chloride
MCV 4245 (NIH 9890, UM 1289)
see (+)-2-Ethyl-5-(m-hydroxyphenyl)morphan hydro-
chloride
MCV 4246 (NIH 9891, UM 1275)
see (+)-5-(m-Hydroxyphenyl)-2-n-propylmorphan hydro-
chloride
MCV 4248 (NIH 9897. UM 1279)
see (+)-1-Methyl-4-allyl-10-hydroxy-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine
MCV 4252 (NIH 9904, UM 1278)
see (-)-1-Methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,
mexahydro-1,6-methano-1H-4-benzazonine
MCV 4253 (NIH 9921)
see -Phenethylglucopyranosiduronic acid, potassium
salt
MCV 4254 (NIH 9903, UM 1315)
see (+)-1-Methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,
nexahydro-1,6-methano-1H-4-benzazonine
MCV 4259 (NIH 9922)
see 3-(1,2 ,4 ,5 -Tetramethyl-4 -piperidinyl)-m-phenol,
z-2-butenedioic acid salt
MCV 4260 (NIH 0001, NIH 9929, UM 114, UM 1311)
see Morphine
MCV 4261 (NIH 8503, NIH 9930, MCV 4002, UM 792, UM 1312)
see Naltrexone
MCV 4264 (NIH 9905, UM 1308)
see (±)-1-Methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,
mexahydro-1,6-methano-1H-4-benzazonine
MCV 4265 (NIH 9906, UM 1309)
see 1,12 -Dimethyl-4-isopentenyl-10-hydroxy-2,3,4,5,
6,7-hexahydro-1,6-methano-1H-4-benzazonine
MCV 4266 (NIH 9926, MCV 4279, UM 1310)
see (-)-N-Allyl-4-methoxymorphinan-6-one
MCV 4267 (SKF 10,047, NIH 7912, UM 902)
see N-Allylnormetazocine
MCV 4269 (NIH 9938)
see 5,9 -Dimethyl-2'-hydroxy-2(4-methyl-pentyl)-6,
7-benzomorphan hydrochloride
MCV 4270 (NIH 9939, UM 1330)
see 6,7-Didehydro-4,5 -epoxy-6-fluoro-3-hydroxy-17-
n-propylmorphinan
MCV 4271 (NIH 9947)
see L-Tyrosyl-D-alanylglycyl-L-4-fluoro-phenylalanyl-
L-phenylglycinamide acetate
526
MCV 4272 (NIH 9948)
see L-Tyrosyl-D-alanylglycyl-N- -ethyl-L-m-bromophenyl-
alanine amide acetate
MCV 4273 (NIH 9949)
see N- -Methyl-L-tyrosyl-D-alanylglycyl-N- -ethyl-L-
p -fluorophenylalanine amide acetate
MCV 4274 (NIH 9950)
see N- -Methyl-L-tyrosyl-D-alanylglycyl-N- -cyclopro-
pylmethyl-L- m-bromophenylalanine amide acetate.
MCV 4275 (NIH 9953)
see (+)-2,9 -Dimethyl-5-( m-hydroxyphenyl)morphan
hydrochloride
MCV 4276 (NIH 9450, UM 1305)
see 2,5-Dimethyl-2'-hydroxy-9 -isopentyl-6,7-benzo-
morphan methanesulfonate
MCV 4279 (NIH 9926, MCV 4266, UM 1310)
see (-)-N-Allyl-4-methoxymorphinan-6-one
MCV 4280 (NIH 9931, UM 1313)
see (-)-N-Cyclopropylmethyl-4-methoxymorphinan-6-one
MCV 4281 (NIH 9932, UM 1314)
see (-)-N-Cyclobutylmethyl-4-methoxy morphinan-6-one
hydrochloride
MCV 4282 (NIH 9940)
see ( ± ) -trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-
4-phenyl-2-naphthylamine hydrochloride
MCV 4283 (NIH 9941)
see (-)- trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-
4-phenyl-2-naphthylamine hydrochloride
MCV 4284 (NIH 9942)
see ( + ) - trans-N,N-Dimethyl-1,2,3,4,-tetrahydro-4-methyl-
4-phenyl-2-naphthylamine hydrochloride
MCV 4285 (NIH 9943)
see (-)-cis-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-
4-phenyl-2-naphtylamine hydrochloride
MCV 4286 (NIH 9945, UM 1327)
see (+)-2,9 -Dimethyl-5-(m-methoxyphenyl)morphan hy-
drobromide
MCV 4288 (NIH 9454, UM 1146)
see 9 -Ethyl-2'-hydroxy-5-methyl-2-phenethyl-6,7-
bezomorphan
MCV 4289 (NIH 9927)
see (-)-3-Methoxy-N-methylmorphinan-6-one
MCV 4293 (NIH 9971)
see (-)-2,9 -Dimethyl-5-(m-hydroxyphenyl)morphan hy-
drochloride
MCV 4294 (NIH 9972)
see (+)-2,9 -Dimethyl-5-(m-hydroxyphenyl)morphan hy-
drochloride
MCV 4295 (NIH 9974)
see (-)-N-Allyl-4-hydroxymorphinan-6-one
MCV 4296 (NIH 9975, UM 1347)
see (-)-N-Allyl-14-hydroxy-4-methoxymorphinan-6-one
MCV 4297 (NIH 9976)
see (-)-N-Allyl-4,5-epoxymorphinan-6-one
MCV 4298 (NIH 9977)
see (-)-N-Cyclopropylmethyl-14-hydroxy-4-methoxy-
morphinan-6-one
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MCV 4299
MCV 4305
MCV 4308
MCV 4309
MCV 4310
MCV 4311
MCV 4312
MCV 4313
MCV 4314
MCV 4315
MCV 4316
MCV 4317
see
see
see
see
see
see
see
see
see
see
see
MCV 4318 (NIH 10,016)
MCV 4322 (NIH 10,020)
MCV 4323 (NIH 10,022)
MCV 4324 (NIH 10,024)
MCV 4325 (NIH 9801)
see
hydrobromide
see (-)-N-Allyl-3,4-dimethoxymorphinan-6-one
see 1,3a -Dimethyl-2,3,3a,6,7a -hexahydro-4-m-hydro-
xyphenyl-1H-indole
see p-Fluorofentanyl hydrochloride
see -(-)-N-Propynyl-N-normetazocine hydrobromide
.
(NIH 9989)
(-)-N-Methylmorphinan d-tartrate
(NIH 9959, UM 1340)
(-)-14-Hydroxy-4-methoxy-N-methylmorphinan-6-one
(NIH 10,001)
6-Desoxy-6,6-hydrazinaloxone
(NIH 10,002)
6-Desoxy-6-isonitrosonaloxone
(NIH 10,003)
6-Desoxy-6,6-hydrazinaltrexone
(NIH 10,004)
6-Desoxy-6-isonitrosonaltrexone
(NIH 10,005)
6-Desoxy-6,6-hydrazioxymorphone
(NIH 10,007)
(-)-14-Hydroxy-N-methylmorphinan
(NIH 10,008)
6-Desoxy-6-isonitrosooxymorphone hydrobromide
(NIH 10,009)
(-)-14-Hydroxy-N-methylmorphinan-6-one
(NIH 10,OIO)
(-)-N-Allylmorphinan-6-one
(NIH 10,015, UM 1381)
(-)-3,4-Dimethoxy-5,17-dimethylmorphinan-6-one
see (+)-Nicotine di-d-tartrate
Mecamylamine
effects on responding suppressed by nicotine or by
electric shocks, 372
selective blockade of behavioral effect of nicotine,
259-265
Medazepam
self-administration in the baboon, 106-108
Meperidine (NIH 5221)
maternal and fetal levels, 154
mouse anlagesia, 152, 402, 459
(-)-Metazocine (NIH 7569)
mouse analgesia, 402, 459
Methadone
alterations in the progeny of female rats treated
with methadone prior to mating, 184-189
LAAM as the sole treatment choice for patients seek-
ing maintenance therapy, 302-309
laboratory analysis, 323-325
maintenance programs: an update, 51-58
maintenance programs in Canada, 18-20
cont'd
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maintenance subjects: effects of intravenous hydro-
morphone on, 238-244
motoric and attentional behavior in infants of metha-
done maintained women, 287-293
multi-drug abuse in methadone maintained women, 322-
328
naloxone and buprenorphine-induced withdrawal in
methadone maintenance patients, 95-96
opiate use and treatment outcome in methadone detoxi-
fication patients, 280-286
somatic and neurobiological'alterations in the pro-
geny of female rats treated prior to mating, 184-189
stereospecific effects on cortical EEG power spectra
in the rat, 190-195
urine homovanillic acid during withdrawal, 364
Methamphetamine
laboratory analysis, 323-325
Methaqualone
behavioral effects in the rat and antagonism by Ro
15-1788, 203-209
4-Methoxyamphetamine
self-administration in animals, 103-105
(-)-N-(2-Methoxyethyl)noroxymorphone hydrochloride (NIH
9803, MCV 4211, UM 1244)
biological evaluation for dependence liability, 393
dependence studies in monkeys, 475
depression of smooth muscle twitch, 475
displacement of stereospecific 3H-etorphine binding,
475
mouse analgesia, 421, 475
(-)-3-Methoxy-N-methylmorphinan-6-one (NIH 9927, MCV 4289)
biological evaluation for dependence liability, 394
dependence studies in monkeys, 447
mouse analgesia, 446
(+)-1-Methyl-4-allyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,
6-methano-1H-4-benzazonine (NIH 9897, MCV 4248, UM 1279)
biological evaluation for dependence liability, 395
dependence studies in monkeys, 485
depression of smooth muscle twitch, 485
displacement of stereospecific 3H-etorphine binding,
485
mouse anlagesia, 433, 485
2 -Methylamino-1-phenylcyclopentanol propanoate ester,
hydrogen maleate (NIH 9721, MCV 4186, UM 1216)
biological evaluation for dependence liability, 397
dependence studies in monkeys, 418
depression of smooth muscle twitch, 467
displacement of stereospecific 3H-etorphine binding,
466
mouse analgesia, 418, 466
self-administration in monkeys, 466
d-Methylamphetamine
anorectic/reinforcement ratio in the baboon, 108-112
effect on auditory and visual thersholds in animals,
120
-Methylamphetamine
anorectic/reinforcement ratio in the baboon, 108-112
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-3,4-Methylenedioxyamphetamine (MDA)
self-administration in animals, 103-105
(-)-1-Methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine (NIH 9904, MCV 4252,
UM, 1278)
biological evaluation for dependence liability, 395
dependence studies in monkeys, 484
depression of smooth muscle twitch, 484
displacement of stereospecific 3H-etorphine binding,
484
mouse analgesia, 433, 484
(+)-1-Methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine (NIH 9903, MCV 4254,
UM 1315)
biological evaluation for dependence liability, 395
dependence studies in monkeys, 434
depression of smooth muscle twitch, 499
displacement of stereospecific 3H-etorphine binding,
499
mouse analgesia, 434, 499
(+)-1-Methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine (NIH 9905, MCV 4264,
UM 1308)
biological evaluation for dependence liability, 395
dependence studies in monkeys, 495
depression of smooth muscle twitch, 495
displacement of stereospecific 3H-etorphine binding,
494
mouse analgesia, 436, 494
(-)-N-Methylmorphinan (NIH 9989, MCV 4299)
biological evaluation for dependence liability, 394
mouse analgesia, 450
(-)-N-Methylmorphinan-6-one (NIH 9960, UM 1344)
biological evaluation for dependence liability, 394
dependence studies in monkeys, 505
mouse analgesia, 505
3-Methylpentyl-N-norketobemidone hydrobromide (NIH 9790,
MCV 4209, UM 1241)
biological evaluation for dependence liability, 396
dependence studies in monkeys, 420-421
displacement of stereospecific 3H-etorphine binding, 474
mouse analgesia, 420
self-administration in monkeys, 474
N- -Methyl-L-tyrosyl-D-alanylglycyl-N-a-cyclopropylmethyl-
L-m-bromophenylalanine amide acetate (NIH 9950, MCV 4274)
biological evaluation for dependence liability, 397
dependence studies in monkeys, 441
mouse analgesia, 440-441
N- -Methyl-L-tyrosyl-D-alanylglycyl-N- -ethyl-L-p-fluoro-
phenylalanine amide acetate (NIH 9949, MCV 4273)
biological evaluation for dependence liability, 397
dependence studies in monkeys, 440
mouse analgesia, 440
N-Methyl-L-tyrosyl-D-serylglycyl-N-methyl-L-phenylalanyl-
D-serinamide monoacetate (NIH 9791, MCV 4210, UM 1238)
biological evaluation for dependence liability, 397
cont'd
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mouse analgesia, 472
self-administration in monkeys, 472
Metkephamid (Ly 127623)
inhibition of binding, 152
maternal and fetal serum levels, 154
met-enkephalin analogue: preclinical pharmacology,
150-156
mouse analgesic tests, 152
mouse locomotor activity, 153
Michael J. Morrison Award
1-4
Midazolan
self-administration in the baboon, 106-108
Morphine (NIH 0001, NIH 9929, MCV 4260, UM 114, UM 1311)
analgesic activity in animals, 144-145, 152, 401-402,
435, 459, 497
biological evaluation for dependence liability, 393
competition binding with 3H-naloxone, 142
dependence studies in monkeys, 435
displacement of stereospecific 3H-etorphine binding,
462
dissociation of the rewarding and physical dependence,
171-177
effect on intestinal transit in mice, 147
effect on symptoms of endogenous depression, 245-250
effect on urinary flow in rats, 147
laboratory analysis, 323-325
mouse locomotor activity, 153
physical dependence from central injections, 172-175
receptor binding studies, 146
respiratory depression in rabbits, 147
Mr 2033 CL
see (±)-(1R/S, 5R/S, 9R/S, 2"S/R)-5,9-Dimethyl-2'-
hydroxy-2-tetrahydrofurfuryl-6,7-benzomorphan hydro-
chloride
Mr 2266 CL
see (-)-2-(3 Furylmethyl)-2'-hydroxy-5,9 -diethyl-6,
7-benzomorphan hydrochloride
Nabilone
potential abuse liability, 93, 132-137
Nabitan (SP-106)
cardiovascular effects, 158
effects on intraocular pressure, 158-161
Naboctate (SP-325)
acute LD50 in the rat and rabbit, 162
cardiovascular effects, 162
effect on intraocular pressure, 162
Nalbuphine
analgesic potentiation by acetaminophen and aspirin,
381-388
self-administration in the baboon, 179-181
Nalorphine
antagonistic potency, 146
mouse analgesia, 401-402, 460
Naloxone (NIH 7890)
antagonistic effects, 145-146, 401-402, 460
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Naloxone
competition binding with 3H-naloxone, 142
self-administration in the baboon, 179-181
receptor binding studies, 146
withdrawal in methadone maintenance patients, 95
Naltrexone (NIH 8503, NIH 9930, MCV 4002, MCV 4261, UM 792,
UM 1312)
biological evaluation for dependence liability, 393
clinical efficacy, 73-75
dependence studies in monkeys, 436, 497
displacement of stereospecific 3H-etorphine binding,
462
mouse analgesia, 401, 436, 460, 497
pharmacological efficacy, 73
predictors of favorable outcome following naltrexone
treatment, 294-301
role in treatment programs, 71-78
safety, 71-73
Narcotics
chemical dependence in Canada, 10-20
Nathan 8. Eddy Memorial Award
pharmacological treatment of narcotic addiction, 5-9
Neonatal studies
brain growth and cerebral ventricular development in
newborn infants of drug dependent mothers, 365-371
motoric and attentional behavior in infants of metha-
done-maintained women, 287-293
somatic and neurolobiological alterations in the pro-
geny of female rats treated with methadone prior to
mating, 184-189
Nicotine
as a punisher: effects of chlordiazepoxide and mec-
amylamine on responding suppressed by nicotine in-
jections, 372
physiological and behavioral effects, 259-265
self-administration in addicts, 94
self-administration in the baboon, 106-108
self-administration in the dog, 88-89
(+)-Nicotine di-d-tartrate (NIH 9801, MCV 4325)
biological evaluation for dependence liability, 397
dependence studies in monkeys, 456
mouse analgesia, 456
NIDA Addiction Research Center
progress reports, 85-91, 92-98
NIH 0001 (NIH 9929, MCV 4260, UM 114, UM 1311)
see Morphine
NIH 0002
see Codeine phosphate
NIH 0123
see Dihydromorphinone
NIH 4590
see Levorphanol
NIH 5221
see Meperidine
NIH 7569
see (-)-Metazocine
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NIH 7890
see Naloxone
NIH 7912 (SKF 10,047, MCV 4267, UM 902)
see N-Allylnormetazocine
NIH 7958
see Pentazocine
NIH 7981
see Cyclazocine
NIH 8503 (NIH 9930, MCV 4002, MCV 4261, UM 792, UM 1312)
see Naltrexone
NIH 8508 (NIH 9882, MCV 4231, MCV 4240, UM 809, UM 1283)
(-)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride
NIH 8509 (MCV 4232, UM 810)
see (+)-5-(m-Hydroxyphenyl-2-methylmorphan hydro-
chloride
NIH 8834 (MCV 4206, UM 972)
see (-)-13 -Amino-5,6,7,8,9,10,11,12-octahydro-5
methyl-5,11-methanobenzocyclodecen-3-ol hydrobromide
NIH 8893 (MCV 4224, UM 009)
see (-)-o-Chlorobenzyl-2-(2-di- sec-butylamino-l-hy-
droxyethyl)pyrrole p-hydroxybenzoate
NIH 9450 (MCV 4276, UM 1305)
see 2,5-Dimethyl-2'-hydroxy-9 -isopentyl-6,7-benzo-
morphan methanesulfonate
NIH 9454 (MCV 4288, UM 1146)
see 9-Ethyl-2'-hydroxy-5-methyl-2-phenethyl-6,7-ben-
zomorphan
NIH 9508 (MCV 4142, UM 1325)
see N-Cyclopropylmethyl-8 -ethyl-N-nordihydrocodeinone
hydrochloride
NIH 9614 (MCV 4169, UM 1269)
see (-)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan
hydrobromide
NIH 9624 (MCV 4175, UM 1258)
see 1-[(2 ,6 ,11S)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-
hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-
11-yl)]-3-octanone methanesulfonate
NIH 9625 (MCV 4176, UM 1401)
see 1-[(2 ,6 ,11S)-(±)-1-)1,2,3,4,5,6-Hexahydro-8-
hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-
11-yl)]-6-methyl-3-hepatanone methanesulfonate
NIH 9651 (MCV 4178, UM 1234)
see 17-Cyclopropylmethyl-4,5 -epoxy-6,6-difluoro-3-
hydroxymorphinan hydrochloride
NIH 9721 (MCV 4186, UM 1216)
see 2 -Methylamino-1-phenylcyclopentanol propanoate
ester, hydrogen maleate
NIH 9739 (MCV 4200, UM 1227)
see 2-Nitronaloxone
NIH 9742 (UM 1222)
see Spiro[(1,1-dimethyl-3-ethyl-7-hydroxy-1H-2-benzo-
pyran)-4,4'-(1-allylpiperidine)] hydrobromide
NIH 9769 (UM 1232)
see N-Pentylacetate-N-norketobemidone
NIH 9771 (UM 1236)
see 4-(1-Hydroxypropyl)-4-m-hydroxyphenyl-1-methyl-
piperidine
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NIH 9787 (MCV 4208. UM 1240)
NIH 9788 (UM 1239)
NIH 9790 (MCV 4209, UM 1241)
NIH 9791 (MCV 4210, UM 1238)
NIH 9801 (MCV 4325)
NIH 9803 (MCV 4211, UM 1244)
NIH 9806 (MCV 4214, UM 1247)
NIH 9807 (MCV 4215, UM 1248)
NIH 9808 (MCV 4216, UM 1249)
NIH 9809 (MCV 4217, UM 1250)
NIH 9810 (MCV 4218, UM 1251)
NIH 9827 (MCV 4223, UM 1256)
NIH 9874 (MCV 4230, UM 1322)
NIH 9881 (MCV 4239, UM 1282)
NIH 9882 (NIH 8505, MCV 4231, MCV 4240, UM 809, UM 1283)
NIH 9883 (UM 1284)
NIH 9887 (MCV 4234)
NIH 9888 (MCV 4243)
NIH 9889 (MCV 4234, UM 1288)
NIH 9890 (MCV 4245, UM 1289)
see 17-Cyclopropylmethyl-6,7-dehydro-4,5 -epoxy-6-
fluoro-3-acetoxymorphinan
see 1-(3-Chlorophenyl)2-(1,1-dimethylamino)propan-1-
one
see 3-Methylpentyl-N-norketobemidone hydrobromide
see N-Methyl-L-tyrosyl-D-serylglycyl-N-methyl-L-
phenylalanyl-D-serinamide monoacetate
see (+)-Nicotine di-d-tartrate
see (-)-N-(2-Methoxyethyl)noroxymorphone hydrochloride
see N-[3-(N,N-Dimethylcarbamoyl)-3,3-diphenylpropyl]-
norketobemidone hydrochloride
see (-)-(1R,5R,9R)-5,9-Dimethyl-2'-hydroxy-2-(3-phen-
oxypropyl)-6,7-benzomorphan hydrochloride
see (+)-(1R,5R,9R)-5,9-Dimethyl-2'-hydroxy-2-(3-phen-
oxypropyl)-6,7-benzomorphan hydrochloride
see (-)-[(1R,5R,2"S)-5,9-Dimethyl-2'-hydroxy-2-(2-
methoxypropyl)-6,7-benzomorphan hydrobromide
see 2,3-Dihydro-2-methyl-3-[2-(dimethylamino)propyl]-
3-phenyl-1H-indol-1-carboxaldehyde methanesulfonate
see Flurazepam hydrochloride
see 3-Acetoxy-17-cyclopropylmethyl-4,5 -epoxy-6,6-
difluoromorphinan
see (-)-5-(m-Hydroxyphenyl)morphan hydrochloride
(-)-5-(m-Hydroxyphenyl)-2-methylmorphan hydrochloride
see (-)-2-Ethyl-5-(m-hydroxyphenyl)morphan hydro-
chloride
see (-)-N-Hexyl-5-(m-hydroxyphenyl)morphan hydro-
chloride
see (+)-5-(m-Hydroxyphenyl)morphan hydrochloride
see (+)-5-(m-Hydroxyphenyl)-2-methylmorphan hydro-
chloride
see (+)-2-Ethyl-5-(m-hydroxyphenyl)morphan hydro-
chloride
NIH 9891 (MCV 4246, UM 1275)
see (+)-5-(m-Hydroxyphenyl)-2- n-propylmorphan hydro-
chloride
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NIH 9895 (MCV 4235, UM 1290)
NIH 9896 (MCV 4236, UM 1291)
NIH 9897 (MCV 4248, UM 1279)
NIH 9899 (MCV 4237, UM 1292)
NIH 9900 (MCV 4238, UM 1293)
NIH 9903 (MCV 4254, UM 1315)
NIH 9904 (MCV 4252, UM 1278)
NIH 9905 (MCV 4264; UM 1308)
NIH 9906 (MCV 4265, UM 1309)
NIH 9921 (MCV 4253)
NIH 9922 (MCV 4259)
NIH 9926 (MCV 4266. MCV 4279. UM 1310)
NIH 9927 (MCV 4289)
NIH 9929 (NIH 0001, MCV 4260, UM 114, UM 1311)
NIH 9930 (NIH 8503, MCV 4002, MCV 4261, UM 792, UM 1312)
NIH 9931 (MCV 4280, UM 1313)
NIH 9932 (MCV 4281, UM 1314)
NIH 9938 (MCV 4269)
NIH 9939 (MCV 4270, UM 1330)
NIH 9340 (MCV 4282)
see (+)-4-Allyl-10-hydroxy-1-methyl-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine
see (-)-4-Allyl-10-hydroxy-1-methyl-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine
see (+)-1-Methyl-4-allyl-10-hydroxy-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine
see (+)-4-Cycylopropylmethyl-10-hydroxyl-1-methyl-2,
3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine
see (-)-4-Cycylopropylmethyl-10-hydroxy-1-methyl-2,
3,4,5,6,7-hexahydro-1,6-methano-1H-4-benazaonine
see (+)-1-Methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,
7-hexahydro-1,6-methano-1H-4-benzazonine
see (-)-1-Methyl-4-isoientenyl-10-hydroxy-2,3,4,5,6,
7-hexahydro-1,6-methano-lH-4-benazonine
see (+)-1-Methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,
7-hexahydro-1,6-methano-1H-4-benzazonine
see 1,12 -Dimethyl-4-isopentenyl-10-hydroxy-2,3,4,5,
6,7-hexahydro-1,6-methano-1H-4-benzazonine
see -Phenethylglucopyranosiduronic acid, potassium
salt
see 3-(1,2 ,4 ,5 -Tetramethyl-4 -piperidinyl)-m-phenol,
z-2-butenedioic acid salt
see
see
see
see
see
see
(-)-N-Allil-4-methoxymorphink-6-one
(-)-3-Methoxy-N-methylmorphinan-6-one
Morphine
Naltrexone
(-)-N-Cyclopropylmethyl-4-methoxymorphinan-6-one
(-)-N-Cyclobutylmethyl-4-methoxymorphinan-6-one
nyarocnloride
see 5,9 -Dimethyl-2'-hydroxy-2-(4-methylpentyl)-6,7-
benzomorphan hydrochloride
see 6,7-Didehydro-4,5 -epoxy-6-fluoro-3-hydroxy-17-
n -propylmorphinan
see (±)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-
methyl-4-phenyl-2-naphthylamine hydrochloride
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NIH 9941 (MCV 4283)
see (-)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-
methyl-4-phenyl-2-naphthylamine hydrochloride
NIH 9942 (MCV 4284)
see (+)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-
methyl-4-phenyl-2-naphthylamine hydrochloride
NIH 9943 (MCV 4285)
see (-)-cis-N,N-Dimethyl-1,2,3,4-tetrahydro-4-
methyl-4-phenyl-2-naphthylamine hydrochloride
NIH 9945 (MCV 4286, UM 1327)
see (±)-2,9 -Dimethyl-5-( m-methoxyphenyl)morphan
hydrobromide
NIH 9947 (MCV 4271)
see L-Tyrosyl-D-alanylglycyl-L-4-fluoro-phenylalanyl-
L-phenylglycinamide acetate
NIH 9948 (MCV-4272)
see L-Tyrosyl-D-alanylglycyl-N- -ethyl-L- m-bromo-
phenylalanine amide acetate
NIH 9949 (MCV 4273)
see N- -Methyl-L-tyrosyl-D-alanylglycl-N- -ethyl-L-
p -fluorophenylalanine amide acetate
NIH 9950 (MCV 4274)
see N- -Methyl-L-tyrosyl-D-alanylglycl-N- -cyclo-
propylmethyl-L- m-bromophenylalanine amide acetate
NIH 9955 (MCV 4275)
see (+)-2,9 -Dimethyl-5-(m-hydroxyphenyl)morphan
hydrochloride
NIH 9957 (UM 1338)
see (-)-4,5-Epoxy-14-hydroxy-N-methylmorphinan-6-one
NIH 9958 (UM 1339)
see (-)-4,14-Dihydroxy-N-methylmorphinan-6-one
NIH 9959 (MCV 4305, UM 1340)
see (-)-14-Hydroxy-4-methoxy-N-methylmorphinan-6-one
NIH 9960 (UM 1344)
see (-)-N-Methylmorphinan-6-one
NIH 9971 (MCV 4293)
see (-)-2,9 -Dimethyl-5-(m-hydroxyphenyl)morphan
hydrochloride
NIH 9972 (MCV 4294)
see (+)-2,9 -Dimethyl-5-(m-hydroxyphenyl)morphan
hydrochloride
NIH 9974 (MCV 4295)
see (-)-N-Allyl-4-hydroxymorphinan-6-one
NIH 9975 (MCV 4296, UM 1347)
see (-)-N-Allyl-14-hydroxy-4-methoxymorphinan-6-one
NIH 9976 (MCV 4297)
see (-)-N-Allyl-4,5-epoxymorphinan-6-one
NIH 9977 (MCV 4298)
see (-)-N-Cyclopropylmethyl-14-hydroxy-4-methoxy-
morphinan-6-one
NIH 9989 (MCV 4299)
see (-)-N-Methylmorphinan d-tartrate
NIH 10,001 (MCV 4308)
see 6-Desoxy-6,6-hydrazinaloxone
NIH 10,002 (MCV 4309)
see 6-Desoxy-6-isonitrosonaloxone
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NIH 10,003 (MCV 4310)
see 6-Desoxy-6,6-hydrazinaltrexone
NIH 10,004 (MCV 4311)
see 6-Desoxy-6-isonitrosonaltrexone
NIH 10,005 (MCV 4312)
see 6-Desoxy-6,6-hydrazioxymorphone
NIH 10,007 (MCV 4313)
see (-)-14-Hydroxy-N-methylmorphinan
NIH 10,008 (MCV 4314)
see 6-Desoxy-6-isonitrosooxymorphone hydrobromide
NIH 10,009 (MCV 4315)
see (-)-14-Hydroxy-N-methylmorphinan-6-one
NIH 10,010 (MCV 4316)
see (-)-N-Allylmorphinan-6-one
NIH 10,015 (MCV 4317, UM 1381)
see (-)-3,4-Dimethoxy-5,17-dimethylmorphinan-6-one
hydrobromide
NIH 10,016 (MCV 4318)
see (-)-N-Allyl-3,4-dimethoxyrnorphinan-6-one
NIH 10,017 (UM 1384)
see (-)-N-Cyclopropylmethyl-3,4-dimethoxyoxymorphinan-
6-one hydrobromide
NIH 10,018 (MCV 1385)
see (-)-3,4-Dimethoxy-N-(2-phenethyl)morphinan-6-one
hydrabromide
NIH 10,020 (MCV 4322)
see 1,3a -Dimethyl-2,3,3a,6,7,7a -hexahydro-4- m-
hydroxyphenyl-1H-indole
NIH 10,021 (MCV 1388)
see 9 -Acetoxy-2-methyl-5-( m-acetoxyphenyl)morphan
hydrobromide
NIH 10,022 (MCV 4323)
see p-Fluorofentanyl hydrochloride
NIH 10,024 (MCV 4324)
see -(-)-N-Propynyl-N-normetazocine hydrobromide
Nitrazepam
physical dependence in monkeys, 166
2-Nitronaloxone (NIH 9739, MCV 4200, UM 1227)
biological evaluation for dependence liability, 393
depression of smooth muscle twitch, 468
displacement of stereospecific 3H-etorphine binding,
468
mouse analgesia, 418, 468
Opiates
use in methadone detoxification patients, 280-286
Opiate addiction
in medical professionals, 356-362
Opiate addicts
psychotherapy for, 59-70
rate of erythrocyte rosette formation, 375-380
Opiate dependence
methadone maintenance: an update, 51-58
Opiate detoxification
recent advances: clonidine and lofexidine, 44-50
Opioids
outpatient treatment of prescription opioid depend-
cont'd
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ence, 315-321
self-administration in the baboon, 178-183
stereospecific effects of mu, kappa, and sigma
agonists on cortical EEG in the rat, 190-195
Opioid antagonists
role in treatment programs, 71-78
Oxymorphone
metabolism of, 85-87
Pentazocine (NIH 7958)
analgesic activity in animals, 144-145, 401-402, 460
laboratory analysis, 323-325
self-administration in the baboon, 179-181
Pentobarbital
behavioral effects in the rat and antagonism by Ro
15-1788, 203-209
clinical assessment of abuse liability, 128
effect on auditory and visual thresholds in animals,
effects on mood and behavior in subjects with his-
tories of sedative, 258
116-118
reinforcement/toxicity ratio in the baboon, 197-202
self-administration in the baboon, 106-108
N-Pentylacetate-N-norketobemidone (NIH 9769, UM 1232)
biological evaluation for dependence liability, 396
dependence studies in monkeys, 469
depression of smooth muscle twitch, 469
displacement of stereospecific 3H-etorphine binding,
469
mouse analgesia, 469
Phencyclidine (PCP)
effect of chronic PCP treatment on PCP, opiate and
dopamine binding, 220
reinforcement/toxicity ratio in the baboon, 197-202
similarities between PCP and the sigma agonist (±)-
N-allylnormetazocine (SKF 10,047), 80
laboratory analysis, 323-325
receptor sensitivity, 217-223
Phendimetrazine
anorectic-reinforcement. ratio in the baboon, 108-112
self-administration in animals, 103-105
-Phenethylglucopyranosiduronic acid, potassium salt (NIH
9921, MCV 4253)
biological evaluation for dependence liability, 398
displacement of stereospecific 3H-etorphine binding,
mouse analgesia, 434
Phenmetrazine
anorectic-reinforcement ratio in the baboon, 108-112
self-administration in animals, 103-105
Phenobarbital
laboratory analysis, 323-325
Phentermine
anorectic-reinforcement ratio in the baboon, 108-112
self-administration in animals, 103-105
Phenylpropanolamine
anorectic-reinforcement ratio in the baboon, 108-112
laboratory analysis, 323-325
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Progesterone
effects of alcohol on levels in the monkey, 210-216
Propoxyphene
laboratory analysis, 323-325
-(-)-N-Propynyl-N-normetazocine hydrobromide (NIH 10,024,
MCV 4324
biological evaluation for dependence liability, 395
dependence studies in monkeys, 456
mouse analgesia, 455-456
Psychotropic drugs
chemical dependence in Canada, 10-20
Quinine
laboratory analysis, 323-325
Reinforcement/toxicity ratio
implications for the assessment of abuse liability,
196-202
Rimantadine
effect on 3H-PCP binding, 219
Ro 15-1788
antagonism of diazepam, pentobarbital and methaqualone
behavioral effects in the rat, 203-209
benzodiazepine antagonist, 89-91
Saline
self-administration in animals, 102-103
Secobarbital
laboratory analysis, 323-325
reinforcement/toxicity ratio in the baboon, 197-202
self-administration in the baboon, 106-108
Sedatives
use among high school students in Ontario, 34
Self-administration
substitution procedure in animals, 101-112
SKF 10,047 (NIH 7912, MCV 4267, UM 902)
see N-Allylnormetazocine
Solvents
use among high school students in Ontario, 34
SP-106
see Nabitan
SP-325
see Naboctate
Spiperone
effect of chronic PCP treatment on binding, 220
Spiro[(1,1-dimethyl-3-ethyl-7-hydroxy-1H-2-benzopyran)-4,
4'-(1-allylpiperidine)] hydrobromide (NIH 9742, UM 1222)
biological evaluation for dependence liability, 397
depression of smooth muscle twitch, 468
displacement of stereospecific 3H-etorphine binding,
467
mouse analgesia, 467
Stimulants
use among high school students in Ontario, 34
g-Tetrahydrocannabinol
potential abuse liability of, 93, 132-137
3-(1,2 ,4 , 5 -Tetramethyl-4 -piperidinyl)-m-phenol, z-2-
butenedioic acid salt (NIH 9922, MCV 4259)
biological evaluation for dependence liability, 396
cont'd
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dependence studies in monkeys, 435
mouse analgesia, 435
Thyrotropin-releasing hormone (TRH)
specificity of the TRH test for major depressive
illness in alcoholics, 266-272
Tobacco
use among high school students in Ontario, 34
Tolerance
alcohol tolerance in psychomotor performance, 374
Toxicity
assessment of behavioral toxicity of drugs with abuse
potential, 99-124
TR 5379M
see xorphanol mesylate
L-Tyrosyl-D-alanylglycyl-N- -ethyl-L-m-bromophenylalanine
amide acetate (NIH 9948, MCV 4272
biological evaluation for dependence liability, 397
dependence studies in monkeys, 440
mouse analgesia, 439
L-Tyrosyl-D-alanylglycyl-L-4-fluoro-phenylalanyl-L-phenyl-
glycinamide acetate (NIH 9947, MCV 4271)
biological evaluation for dependence liability, 397
dependence studies in monkeys, 439
mouse analgesia, 439
UM 114 (NIH 0001, NIH 9929, MCV 4260, UM 1311)
see Morphine
UM 792 NIH 8503, NIH 9930, MCV 4002, MCV 4261, UM 1312)
see Naltrexone
UM 809 NIH 8508, NIH 9882, MCV 4231, MCV 4240, UM 1283)
see (-)-5-(m-Hydroxyphenyl)-2-methylmorphan hydro-
chloride
UM 810 (NIH 8509, MCV 4232)
see (+)-5-(m-Hydroxyphenyl-2-methylmorphan hydro-
chloride
UM 902 (SKF 10,047, NIH 7912, MCV 4267)
see (±)-2-Allyl-2'-hydroxy-5,9 -dimethyl-6,7-benzo-
morphan hydrochloride
UM 911
displacement of stereospecific 3H-etorphine binding,
462
UM 972 (NIH 8834, MCV 4206)
see (-)-13 -Amino-5,6,7,8,9,10,11,12-octahydro-5
methyl-5,11-methanobenzocyclodecen-3-ol hydrobromide
UM 1009 (NIH 8893, MCV 4224)
see (-)- o -Chlorobenzyl-2-(2-di- sec-butylamino-1-
hydroxyethyl)pyrrole p-hydroxybenzoate
UM 1071R
displacement of stereospecific 3H-etorphine binding,
462
UM 1146 (NIH 9454, MCV 4288)
see (9 -Ethyl-2'-hydroxy-5-methyl-2-phenethyl-6,7-
benzomorphan
UM 1216 (NIH 9721, MCV 4186)
see 2 -Methylamino-1-phenylcyclopentanol propanoate
ester, hydrogen maleate
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UM 1222 (NIH 9742)
see Spiro[(1,1-dimethyl-3-ethyl-7-hydroxy-1H-2-benzo-
pyran)-4,4'-(1-allylpiperidine)] hydrobromide
UM 1227 (NIH 9739, MCV 4200)
see 2-Nitronaloxone
UM 1232 (NIH 9769)
see N-Pentylacetate-N-norketobemidone
UM 1234 (NIH 9651, MCV 4178)
see 17-Cyclopropylmethyl-4,5 -epoxy-6,6-difluoro-3-
hydroxymorphinan hydrochloride
UM 1236 (NIH 9771)
see 4-(1-Hydroxypropyl)-4-m-hydroxyphenyl-1-methyl-
piperidine
UM 1238 (NIH 9791, MCV 4210)
see N-Methyl-L-tyrosyl-D-serylglycyl-N-methyl-L-
phenylalanyl-D-serinamide monoacetate
UM 1239 (NIH 9788)
see 1-(3-Chlorophenyl)-2-(1,1-dimethylamino)propan-1-
one
UM 1240 (NIH 9787, MCV 4208)
see 17-Cyclopropylmethyl-6,7-dehydro-4,5 -epoxy-6-
fluoro-3-acetoxymorphinan
UM 1241 (NIH 9790, MCV 4209)
see 3-Methylpentyl-N-norketobemidone hydrobromide
UM 1244 (NIH 9803, MCV 4211)
see (-)-N-(2-Methoxyethyl)noroxymorphone hydrochloride
UM 1247 (NIH 9806, MCV 4214)
see N-[3-(N,N-Dimethylcarbamoy)-3,3-diphenylpropyl]-
norketobemidone hydrochloride
UM 1248 (NIH 9807, MCV 4215)
see (-)-(1R,5R,9R)-5,9-Dimethyl-2'-hydroxy-2-(3-
phenoxypropyl)-6,7-benzomorphan hydrochloride
UM 1249 (NIH 9808, MCV 4216)
see (+)-(1R,5R,9R)-5,9-Dimethyl-2'-hydroxy-2-(3-
phenoxypropyl)-6,7-benzomorphan hydrochloride
UM 1250 (NIH 9809, MCV 4217)
see (-)-[1R,5R,2"S)-5,9-Dimethyl-2'-hydroxy-2-(2-
methoxypropyl)-6,7-benzomorphan hydrobromide
UM 1251 (NIH 9810, MCV 4218)
see 2,3-Dihydro-2-methyl-3-[2-(dimethylamino)propyl]-
chenyl-1H-indol-1-carboxaldehyde methanesulfonate
UM 1256 (NIH 9827, MCV 4223)
see Flurazepam hydrochloride
UM 1258 (NIH 9624, MCV 4175)
see 1-[(2 ,6 ,11S)-(+)-1-(1,2,3,4,5,6-Hexahydro-8-
hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-
11-yl)]-3-octanone methanesulfonate
UM 1269 (NIH 9614, MCV 4169)
see (-)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan
hydrobromide
UM 1275 (NIH 9891, MCV 4246)
see (+)-5-( m -Hydroxyphenyl)-2- n-propylmorphan
hydrochloride
UM 1278 (NIH 9904, MCV 4252)
see (-)-1-Methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,
mexahydro-1,6-methano-1H-4-benzazonine
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UM 1279 (NIH 9897, MCV 4248)
see (+)-1-Methyl-4-allyl-10-hydroxy-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine
UM 1282 (NIH 9881, MCV 4239)
see (-)-5-(m-Hydroxyphenyl)morphan hydrochloride
UM 1283 (NIH 8508, NIH 9882, MCV 4231, MCV 4240, UM 809)
see (-)-5-(m-Hydroxyphenyl)-2-methylmorphan hydro-
chloride
UM 1284 (NIH 9883)
see (-)-2-Ethyl-5-(m-hydroxyphenyl)morphan hydro-
chloride
UM 1288 (NIH 9889, MCV 4244)
see (+)-5-(m-Hydroxyphenyl)-2-methylmorphan hydro-
chloride
UM 1289 (NIH 9890, MCV 4245)
see (+)-2-Ethyl-5-(m-hydroxyphenyl)morphan hydro-
chloride
UM 1290 (NIH 9895. MCV 4235)
see (+)-4-Allyl-10-hydroxy-1-methyl-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine
UM 1291 (NIH 9896. MCV 4236)
see (-)-4-Aliyl-10-hydroxy-1-methyl-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine
UM 1292 (NIH.9899, MCV 4237)
see (+)-4-Cycylopropylmethyl-10-hydroxyl-1-methyl-2,
3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine
UM 1293 (NIH 9900, MCV 4238)
see (-)-4-Cycylopropylmethyl-10-hydroxy-1-methyl-2,
3,4,5,6,7-hexahydro-1,6-methano-1H-4-benazaonine
UM 1305 (NIH 9450, MCV 4276)
see 2,5-Dimethyl-2'-hydroxy-9 -isopentyl-6,7-benzo-
morphan methanesulfonate
UM 1308 (NIH 9905, MCV 4264)
see (±)-1-Methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,
7-hexahydro-1,6-methano-1H-4-benzazonine
UM 1309 (NIH 9906, MCV 4265)
see 1,12 -Dimethyl-4-isopentenyl-10-hydroxy-2,3,4,5,
6,7-hexahydro-1,6-methano-1H-4-benzazonine
UM 1310 (NIH 9926, MCV 4266, MCV 4279)
see (-)-N-Allyl-4-methoxymorphinan-6-one
UM 1311 (NIH 0001, NIH 9929, MCV 4260, UM 114)
see Morphine
UM 1312 (NIH 8503, NIH 9930, MCV 4002, MCV 4261, UM 792)
see Naltrexone
UM 1313 (NIH 9931, MCV 4280)
see (-)-N-Cyclopropylmethyl-4-methoxymorphinan-6-one
UM 1314 (NIH 9932, MCV 4281)
see (-)-N-Cyclobutylmethyl-4-methoxymorphinan-6-one
hydrochloride
UM 1315 (NIH 9903, MCV 4254)
see (+)-1-Methyl-4-isopentenyl-10-hydroxy-2,3,4,5,6,
7-hexahydro-1,6-methano-1H-4-benzazonine
UM 1322 (NIH 9874, MCV 4230)
see 3-Acetoxy-17-cyclopropymethyl-4,5 -epoxy-6,6-
difluoromorphinan
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UM 1325 (NIH 9508, MCV 4142)
see N-Cyclopropylmethyl-8 -ethyl-N-nordihydrocodeinone
hydrochloride
UM 1327 (NIH 9945, MCV 4286)
see (±)-2,9 -Dimethyl-5-(m-methoxyphenyl)morphan
hydrobromide
UM 1330 (NIH 9939, MCV 4270)
see 6,7-Didehydro-4,5 -epoxy-6-fluoro-3-hydroxy-l7-
n-propylmorphinan
UM 1338 (NIH 9957)
see (-)-4,5-Epoxy-14-hydroxy-N-methylmorphinan-6-one
UM 1339 (NIH 9958)
see (-)-4,14-Dihydroxy-N-methylmorphinan-6-one
UM 1340 (NIH 9959, MCV 4305)
see (-)-14-Hydroxy-4-methoxy-N-methylmorphinan-6-one
UM 1344 (NIH 9960)
see (-)-N-Methylmorphinan-6-one
UM 1347 (NIH 9975, MCV 4296)
see (-)-N-Allyl-14-hydroxy-4-methoxymorphinan-6-one
UM 1381 (NIH 10,015, MCV 4317)
see (-)-3,4-Dimethoxy-5,17-dimethylmorphinan-6-one
hydrobromide
UM 1384 (NIH 10,017)
see (-)-N-Cyclopropylmethyl-3,4-dimethoxyoxymorphinan-
6-one hydrobromide
UM 1385 (NIH 10,018)
see (-)-3,4-Dimethoxy-N-(2-phenethyl)morphinan-6-one
hydrobromide
UM 1388 (NIH 10,021)
see 9 -Acetoxy-2-methyl-5-(m-acetoxyphenyl)morphan
hydrobromide
UM 1401 (NIH 9625, MCV 4176)
see 1-[(2 ,6 ,11S)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-
hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-
11-yl)]-6-methyl-3-hepatanone methanesulfonate
Wellbatrin
see Bupropion
Wy-15,705
see Ciramadol
Xorphanol mesylate (TR5379M)
antagonist activity in rodents, 232
antinociceptive activity in rodents, 232
oral analgesic, 231-237
physical dependence liability in animals, 232-235
studies in human volunteers, 235-236
Zopiclone
continuous intragastric self-administration in
monkeys, 168
continuous intravenous self-administration in
monkeys, 167
physical dependence in monkeys, 166
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